0000919956-14-000029.txt : 20140807 0000919956-14-000029.hdr.sgml : 20140807 20140807161011 ACCESSION NUMBER: 0000919956-14-000029 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20140630 FILED AS OF DATE: 20140807 DATE AS OF CHANGE: 20140807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Diversicare Healthcare Services, Inc. CENTRAL INDEX KEY: 0000919956 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 621559667 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12996 FILM NUMBER: 141023967 BUSINESS ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 BUSINESS PHONE: 6157717575 MAIL ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 FORMER COMPANY: FORMER CONFORMED NAME: ADVOCAT INC DATE OF NAME CHANGE: 19940309 10-Q 1 dvcr-20140630x10q.htm 10-Q DVCR-2014.06.30-10Q


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________ 
FORM 10-Q
________________________________ 
CHECK ONE:
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended: June 30, 2014
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             .

Commission file No.: 1-12996
________________________________ 
Diversicare Healthcare Services, Inc.
(exact name of registrant as specified in its charter)
 ________________________________
Delaware
 
62-1559667
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
1621 Galleria Boulevard, Brentwood, TN 37027
(Address of principal executive offices) (Zip Code)
(615) 771-7575
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and a “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
 
¨
Accelerated filer
 
¨
 
 
 
 
Non-accelerated filer
 
¨
Smaller reporting Company
 
ý
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  ý
6,156,428
(Outstanding shares of the issuer’s common stock as of July 31, 2014)
 




Part I. FINANCIAL INFORMATION
ITEM 1 – FINANCIAL STATEMENTS
DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands)
 
 
June 30,
2014
 
December 31,
2013
 
(Unaudited)
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
4,071

 
$
3,781

Receivables, less allowance for doubtful accounts of $4,582 and $3,879, respectively
42,678

 
32,658

Other receivables
1,187

 
1,118

Prepaid expenses and other current assets
1,925

 
2,442

Income tax refundable
747

 
763

Current assets of discontinued operations
2,913

 
2,870

Deferred income taxes
6,666

 
6,579

Total current assets
60,187

 
50,211

PROPERTY AND EQUIPMENT, at cost
95,310

 
93,572

Less accumulated depreciation and amortization
(51,678
)
 
(48,516
)
Discontinued operations, net
8,502

 
8,987

Property and equipment, net
52,134

 
54,043

OTHER ASSETS:
 
 
 
Deferred income taxes
15,804

 
15,912

Deferred financing and other costs, net
1,860

 
1,914

Investment in unconsolidated affiliate
428

 
487

Other noncurrent assets
6,217

 
5,698

Acquired leasehold interest, net
8,036

 
8,228

Noncurrent assets of discontinued operations
969

 
1,251

Total other assets
33,314

 
33,490

 
$
145,635

 
$
137,744

The accompanying notes are an integral part of these interim consolidated financial statements.

2



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(continued)
 
 
June 30,
2014
 
December 31,
2013
 
(Unaudited)
 
 
CURRENT LIABILITIES:
 
 
 
Current portion of long-term debt and capitalized lease obligations
$
10,334

 
$
4,549

Trade accounts payable
9,356

 
7,177

Current liabilities of discontinued operations
8,823

 
1,359

Accrued expenses:
 
 
 
Payroll and employee benefits
13,203

 
12,255

Self-insurance reserves, current portion
12,777

 
11,711

Other current liabilities
4,829

 
5,116

Total current liabilities
59,322

 
42,167

NONCURRENT LIABILITIES:
 
 
 
Long-term debt and capitalized lease obligations, less current portion
43,120

 
43,552

Self-insurance reserves, noncurrent portion
16,146

 
16,375

Noncurrent liabilities of discontinued operations

 
5,952

Other noncurrent liabilities
14,484

 
15,214

Total noncurrent liabilities
73,750

 
81,093

COMMITMENTS AND CONTINGENCIES

 

SERIES C REDEEMABLE PREFERRED STOCK
 
 
 
$.10 par value, 5,000 shares authorized, issued and outstanding
4,918

 
4,918

SHAREHOLDERS’ EQUITY:
 
 
 
Series A preferred stock, authorized 200,000 shares, $.10 par value, none issued and outstanding

 

Common stock, authorized 20,000,000 shares, $.01 par value, 6,388,000 and 6,307,000 shares issued, and 6,156,000 and 6,075,000 shares outstanding, respectively
63

 
63

Treasury stock at cost, 232,000 shares of common stock
(2,500
)
 
(2,500
)
Paid-in capital
19,883

 
19,570

Accumulated deficit
(9,207
)
 
(8,435
)
Accumulated other comprehensive loss
(594
)
 
(569
)
Total shareholders’ equity of Diversicare Healthcare Services, Inc.
7,645

 
8,129

Noncontrolling interest

 
1,437

Total shareholders’ equity
7,645

 
9,566

 
$
145,635

 
$
137,744

The accompanying notes are an integral part of these interim consolidated financial statements.

3



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
Three Months Ended
June 30,
 
2014
 
2013
PATIENT REVENUES, net
$
82,313

 
$
61,488

EXPENSES:
 
 
 
Operating
64,687

 
50,316

Lease and rent expense
6,251

 
4,804

Professional liability
1,556

 
1,758

General and administrative
5,381

 
5,779

Depreciation and amortization
1,705

 
1,496

Total expenses
79,580

 
64,153

OPERATING INCOME (LOSS)
2,733

 
(2,665
)
OTHER INCOME (EXPENSE):
 
 
 
Equity in net income (loss) of unconsolidated affiliate
(56
)
 
22

Interest expense, net
(949
)
 
(745
)
Debt retirement costs

 
(320
)
Total other expense
(1,005
)
 
(1,043
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
1,728

 
(3,708
)
BENEFIT (PROVISION) FOR INCOME TAXES
(755
)
 
1,287

INCOME (LOSS) FROM CONTINUING OPERATIONS
973

 
(2,421
)
INCOME FROM DISCONTINUED OPERATIONS:
 
 
 
Operating income, net of tax of $419 and $142, respectively
128

 
242

Income from discontinued operations
128

 
242

NET INCOME (LOSS)
1,101

 
(2,179
)
Less: (income) loss attributable to noncontrolling interests

 
(16
)
NET INCOME (LOSS) ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC.
1,101

 
(2,195
)
PREFERRED STOCK DIVIDENDS
(86
)
 
(86
)
NET INCOME (LOSS) FOR DIVERSICARE HEALTHCARE SERVICES, INC. COMMON SHAREHOLDERS
$
1,015

 
$
(2,281
)
NET INCOME (LOSS) PER COMMON SHARE FOR DIVERSICARE HEALTHCARE SERVICES, INC. SHAREHOLDERS:
 
 
 
Per common share – basic
 
 
 
Continuing operations
$
0.15

 
$
(0.43
)
Discontinued operations
0.02

 
0.04

 
$
0.17

 
$
(0.39
)
Per common share – diluted
 
 
 
Continuing operations
$
0.14

 
$
(0.43
)
Discontinued operations
0.02

 
0.04

 
$
0.16

 
$
(0.39
)
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$
0.055

 
$
0.055

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic
6,015,000

 
5,874,000

Diluted
6,181,000

 
5,874,000

                              
The accompanying notes are an integral part of these interim consolidated financial statements.

4



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands and unaudited)
 
 
Three Months Ended
June 30,
 
2014
 
2013
NET INCOME (LOSS)
$
1,101

 
$
(2,179
)
OTHER COMPREHENSIVE INCOME (LOSS):
 
 
 
Change in fair value of cash flow hedge, net of tax
84

 
110

Less: reclassification adjustment for amounts recognized in net income
(129
)
 
(78
)
Total other comprehensive income (loss)
(45
)
 
32

COMPREHENSIVE INCOME (LOSS)
1,056

 
(2,147
)
Less: comprehensive (income) loss attributable to noncontrolling interest

 
(16
)
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC.
$
1,056

 
$
(2,163
)

The accompanying notes are an integral part of these interim consolidated financial statements.

5



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
 
Six Months Ended
June 30,
 
2014
 
2013
PATIENT REVENUES, net
$
160,112

 
$
119,927

EXPENSES:
 
 
 
Operating
127,511

 
97,828

Lease and rent expense
12,218

 
9,581

Professional liability
3,617

 
3,265

General and administrative
10,495

 
10,763

Depreciation and amortization
3,440

 
2,938

Total expenses
157,281

 
124,375

OPERATING INCOME (LOSS)
2,831

 
(4,448
)
OTHER INCOME (EXPENSE):
 
 
 
Equity in net loss of unconsolidated affiliate
(59
)
 
(215
)
Interest expense, net
(1,841
)
 
(1,285
)
Debt retirement costs

 
(320
)
Total other income (expense)
(1,900
)
 
(1,820
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
931

 
(6,268
)
BENEFIT (PROVISION) FOR INCOME TAXES
(391
)
 
2,573

INCOME (LOSS) FROM CONTINUING OPERATIONS
540

 
(3,695
)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS:
 
 
 
Operating income (loss), net of tax of $348 and $(334), respectively
(484
)
 
569

Income (loss) from discontinued operations
(484
)
 
569

NET INCOME (LOSS)
56

 
(3,126
)
Less: (income) loss attributable to noncontrolling interests
25

 
(34
)
NET INCOME (LOSS) ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC.
81

 
(3,160
)
PREFERRED STOCK DIVIDENDS
(172
)
 
(172
)
NET INCOME (LOSS) FOR DIVERSICARE HEALTHCARE SERVICES, INC. COMMON SHAREHOLDERS
$
(91
)
 
$
(3,332
)
NET INCOME (LOSS) PER COMMON SHARE FOR DIVERSICARE HEALTHCARE SERVICES, INC. SHAREHOLDERS:
 
 
 
Per common share – basic
 
 
 
Continuing operations
$
0.07

 
$
(0.67
)
Discontinued operations
(0.08
)
 
0.10

 
$
(0.01
)
 
$
(0.57
)
Per common share – diluted
 
 
 
Continuing operations
$
0.07

 
$
(0.67
)
Discontinued operations
(0.08
)
 
0.10

 
$
(0.01
)
 
$
(0.57
)
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$
0.11

 
$
0.11

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic
5,995,000

 
5,861,000

Diluted
5,995,000

 
5,861,000


The accompanying notes are an integral part of these interim consolidated financial statements.

6






DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands and unaudited)
 
 
Six Months Ended
June 30,
 
2014
 
2013
NET INCOME (LOSS)
56

 
(3,126
)
OTHER COMPREHENSIVE INCOME (LOSS):
 
 
 
Change in fair value of cash flow hedge, net of tax
224

 
110

Less: reclassification adjustment for amounts recognized in net income
(248
)
 
(78
)
Total other comprehensive income (loss)
(24
)
 
32

COMPREHENSIVE INCOME (LOSS)
32

 
(3,094
)
Less: comprehensive (income) loss attributable to noncontrolling interest
25

 
(34
)
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC.
$
57

 
$
(3,128
)

The accompanying notes are an integral part of these interim consolidated financial statements.



7



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
 
 
Six Months Ended
June 30,
 
2014
 
2013
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net income (loss)
56

 
(3,126
)
Discontinued operations
(484
)
 
569

Income (loss) from continuing operations
540

 
(3,695
)
Adjustments to reconcile loss from continuing operations to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
3,440

 
2,938

Provision for doubtful accounts
2,780

 
1,830

Deferred income tax benefit
36

 
(4,214
)
Provision for self-insured professional liability, net of cash payments
827

 
771

Stock-based compensation
295

 
357

Equity in net losses of unconsolidated affiliate, net of investment
59

 
(36
)
Debt retirement costs

 
320

Other
(315
)
 
(124
)
Changes in assets and liabilities affecting operating activities:
 
 
 
Receivables, net
(13,166
)
 
(5,640
)
Prepaid expenses and other assets
(146
)
 
1,929

Trade accounts payable and accrued expenses
3,447

 
974

Net cash provided by (used in) continuing operations
(2,203
)
 
(4,590
)
Discontinued operations
(491
)
 
5,056

Net cash provided by operating activities
(2,694
)
 
466

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(1,826
)
 
(2,416
)
Acquisition of property and equipment through business combination

 
(14,742
)
Change in restricted cash
35

 
(4,641
)
Deposits and other deferred balances
(43
)
 

Net cash used in continuing operations
(1,834
)
 
(21,799
)
Discontinued operations
(5
)
 
(546
)
Net cash used in investing activities
(1,839
)
 
(22,345
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Repayment of debt obligations
(4,412
)
 
(22,805
)
Proceeds from issuance of debt
9,765

 
45,000

Financing costs
(114
)
 
(1,341
)
Issuance and redemption of employee equity awards
78

 
33

Payment of common stock dividends
(662
)
 
(323
)
Payment of preferred stock dividends
(172
)
 
(172
)
Distributions to noncontrolling interest
(1,410
)
 
(104
)
Payment for preferred stock restructuring
(298
)
 
(288
)
Net cash provided by continuing operations
$
2,775

 
$
20,000

Discontinued operations
2,048

 
(100
)
Net cash provided by (used in) investing activities
4,823

 
19,900


8



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
(continued)
 
 
Six Months Ended
June 30,
 
2014
 
2013
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
$
290

 
$
(1,979
)
CASH AND CASH EQUIVALENTS, beginning of period
3,781

 
5,928

CASH AND CASH EQUIVALENTS, end of period
$
4,071

 
$
3,949

SUPPLEMENTAL INFORMATION:
 
 
 
Cash payments of interest, net of amounts capitalized
$
1,652

 
$
1,076

Cash payments of income taxes
$
33

 
$
45

The accompanying notes are an integral part of these interim consolidated financial statements.

9



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2014 AND 2013

1.
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare Healthcare Services” or the “Company”) provides long-term care services to nursing center patients in eight states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. In addition to the nursing, personal care and social services usually provided in long-term care centers, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Ohio, Tennessee, and Texas. The Company's operating results also include the results of certain discontinued operations that have been reclassified on the face of the financial statements to reflect the discontinued status of these operations.
As of June 30, 2014, the Company’s continuing operations consist of 46 nursing centers with 5,282 licensed nursing beds. The Company owns 13 and leases 33 of its nursing centers. The nursing center and licensed bed count includes the following recent business development activity:
The 73-bed facility in Nicholasville, Kentucky, for which the Company entered into a lease agreement and assumed operations effective June 1, 2014. The Medicaid and Medicare certification processes for this facility are currently underway, and are expected to be completed in the fourth quarter of 2014.
The 135-bed facility in Huntsville, Alabama, for which the Company entered into a lease agreement and assumed operations effective March 1, 2014. The Medicaid and Medicare certification processes for this facility are currently underway, and are expected to be completed in the third quarter of 2014.
The 442 licensed nursing beds at the four recently leased skilled nursing centers, three in Ohio and one in Indiana, which we have operated since October 1, 2013. The Medicaid and Medicare certification processes were completed for these four leased facilities in the first quarter of 2014. In addition to the licensed nursing beds, these four centers also include 270 licensed assisted living beds which are not included in the licensed nursing bed count.
The 107-bed facility in Louisville, Kentucky, for which the Company entered into a lease agreement in August 2013. The Medicare certification processes for this facility was completed in the first quarter of 2014. The Medicaid certification process was completed in the second quarter of 2014.
The Kansas centers acquired in May 2013, which comprise five skilled nursing centers and 418 licensed beds. The Medicaid certification process was completed for these facilities during the second quarter of 2013, and the Medicare certification process was completed for these facilities during the third quarter of 2013.

2.
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. Any variable interest entities (“VIEs”) in which the Company has an interest are consolidated when the Company identifies that it is the primary beneficiary. The Company had one variable interest entity related to a nursing center in West Virginia that was dissolved in the first quarter of 2014 as a result of the asset purchase of the Rose Terrace nursing center as further described in Note 8, and is no longer consolidated into the interim consolidated financial statements of the Company. The investment in an unconsolidated affiliate (a 50 percent-owned joint venture partnership) is accounted for using the equity method and is described in Note 9.
The interim consolidated financial statements for the three and six month periods ended June 30, 2014 and 2013, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at June 30, 2014, and the results of operations for the three month and six month periods ended June 30, 2014 and 2013, and cash flows for the six month periods ended June 30, 2014 and 2013. The Company’s balance sheet information at December 31, 2013, was derived from its audited consolidated financial statements as of December 31, 2013.
The results of operations for the periods ended June 30, 2014 and 2013 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the

10



audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

3.
RECENT ACCOUNTING GUIDANCE
In February 2013, the FASB issued Accounting Standards Update ("ASU") 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. The amendments in this update require an entity to provide information about the amounts reclassified from accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the income statement or in the notes, significant amounts reclassified from accumulated other comprehensive income by the net income line item. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.
In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity changing the criteria for reporting discontinued operations. The ASU states that only those disposed components (or components held-for-sale) representing a strategic shift that have a significant effect on operations and financial results will be reported in discontinued operations. The ASU also required expanded disclosures about discontinued operations in the financial statement notes. The ASU is effective for disposals (or classifications as held-for-sale) that occur within annual periods beginning on or after December 15, 2014 and interim periods within those annual periods. Early application is permitted, but only for those disposals that have not been reported in financial statements previously issued or available for issuance. We have chosen to early adopt this ASU and have applied the new criteria in determining the accounting treatment for the nursing centers exited during 2014. The adoption of this guidance did not have a material impact on the Company's consolidated financial results.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.


4.
LONG-TERM DEBT AND INTEREST RATE SWAP
The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On May 1, 2013, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated February 28, 2011. The Credit Agreement increases the Company's borrowing capacity to $65,000,000 allocated between a $45,000,000 Mortgage Loan ("Amended Mortgage Loan") and a $20,000,000 Revolver ("Amended Revolver"). Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $1,341,000 and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of $45,000,000 with a five-year maturity through April 30, 2018, and a $20,000,000 Amended Revolver through April 30, 2018. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest is based on LIBOR plus 4.5%. A portion of the Amended Mortgage Loan is effectively fixed at 6.87% pursuant to an interest rate swap with a notional amount of $21,973,000. As of June 30, 2014, the interest rate related to the Amended Mortgage Loan was 4.65%. The Amended Mortgage Loan is secured by thirteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.5% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective March 31, 2014, the Company entered into the Second Amendment to the Amended and Restated Revolver ("Second Amendment"). The Second Amendment temporarily increased the Amended Revolver capacity from the $20,000,000 in the original Amended Revolver to $27,500,000 through September 30, 2014, as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process. The Second Amendment also provided for a permanent increase in the Amended Revolver capacity to $22,500,000 beginning October 1, 2014 through the original maturity date of April 30, 2018, to reflect the expansion of the Company's business through new facility acquisitions.
As of June 30, 2014, the Company had $9,000,000 borrowings outstanding under the revolving credit facility compared to $3,000,000 outstanding as of December 31, 2013. The outstanding borrowings on the revolver primarily reflect the Company's approach to accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through

11



the change in ownership process with CMS. Annual fees for letters of credit issued under this Revolver are 3.00% of the amount outstanding. The Company has eight letters of credit with a total value of $7,712,000 outstanding as of June 30, 2014. Considering the balance of eligible accounts receivable, the letter of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $27,500,000, the balance available for borrowing under the revolving credit center is $10,524,000 at June 30, 2014.
Effective March 27, 2014, the Company executed its purchase option to acquire all assets associated with the Rose Terrace nursing center in Culloden, West Virginia from Milton Holdings, LLC which was considered a variable interest entity ("VIE") by the Company and consolidated prior to the date of this transaction. See Note 8 for further information on the VIE considerations. In conjunction with the purchase of the assets, the Company entered into an interest-only $8,000,000 term loan ("Rose Terrace Note") with a maturity date of March 27, 2015. The structure of the Rose Terrace Note reflected the Company's intent to sell the property and transfer operations to an unrelated third-party operator as further disclosed in Note 12. This transaction closed on July 1, 2014. As such, the Rose Terrace Note is classified as a Current Liability of Discontinued Operations on the Interim Consolidated Balance Sheet.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relate to minimum cash deposits, cash flow and debt service coverage ratios. The Company is in compliance with all such covenants at June 30, 2014.
Interest Rate Swap Transaction
As part of the debt agreements entered into in March 2011, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the amendment to the credit facility, the Company retained the previously agreed upon interest rate swap terms, and redesignated the interest rate swap as a cash flow hedge. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount of $21,973,000 at an annual fixed rate of 6.87% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amounts.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at June 30, 2014, the Company determined that the interest rate swap was effective. The interest rate swap valuation model indicated a net liability of $959,000 at June 30, 2014. The fair value of the interest rate swap is included in “other noncurrent liabilities” on the Company’s interim consolidated balance sheet. The balance of accumulated other comprehensive loss at June 30, 2014 is $594,000 and reflects the liability related to the interest rate swap, net of the income tax benefit of $364,000. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.

5.
INSURANCE MATTERS
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, consolidated offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”) which has issued a policy insuring claims made against all of the Company's nursing centers in Florida, Tennessee, and West Virginia as well as the Company’s formerly operated Arkansas facilities. Several of the Company’s nursing centers in Alabama, Kentucky, Ohio, and Texas are also covered under this policy. The SHC policy provides coverage limits of either $500,000 or $1,000,000 per medical incident with a sublimit per center of $1,000,000 and total annual aggregate policy limits of $5,000,000. The remaining nursing centers are covered by one of three claims made professional liability insurance policies purchased from entities unaffiliated with the Company. These policies provide coverage limits of $1,000,000 per claim and have sublimits of $3,000,000 per center, with varying aggregate policy limits. 
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $27,695,000 as of June 30, 2014. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.

12



The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of the current portion of this reserve. Merlinos & Associates, Inc. (“Merlinos”) assisted management in the preparation of an estimate of the appropriate accrual for the current claims period and for incurred, but not reported, general and professional liability claims based on data furnished as of May 31, 2014.  The Company used this estimate from Merlinos in the preparation of its estimate of liability for incurred, but unreported professional liability claims as of as of June 30, 2014.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of June 30, 2014, the Company is engaged in 53 professional liability lawsuits. Nine lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $2,225,000 and $2,134,000 for the six months ended June 30, 2014 and 2013, respectively.
The Company follows current accounting guidance set forth in FASB ASU 2010-24, “Presentation of Insurance Claims and Related Insurance Recoveries,” that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim, and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the Company has recorded assets and equal liabilities of $70,000 at June 30, 2014 and $440,000 at December 31, 2013, respectively.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.
Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either an indemnity insurance plan or state-sponsored programs in May 1997. The Company is completely self-insured for workers’ compensation exposures prior to May 1997. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2008 through June 30, 2014, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500,000 per claim, subject to an aggregate maximum of $3,000,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $328,000 at June 30, 2014. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,130,000 as of June 30, 2014. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of June 30, 2014, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $175,000 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $900,000 at June 30, 2014. The differences between actual settlements and reserves are included in expense in the period finalized.

6.
STOCK-BASED COMPENSATION

Overview of Plans

13



In December 2005, the Compensation Committee of the Board of Directors adopted the 2005 Long-Term Incentive Plan (“2005 Plan”). The 2005 Plan allows the Company to issue stock options and other share and cash based awards. Under the 2005 Plan, 700,000 shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted thereunder. All grants under this plan expire 10 years from the date the grants were authorized by the Board of Directors.
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers and 150,000 shares of the Company's common stock has been reserved for issuance under the Stock Purchase Plan. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. No grants can be made under the Stock Purchase Plan after April 25, 2018.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. Under the 2010 Plan, 380,000 shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted.

Equity Grants and Valuations
During 2014 and 2013, the Compensation Committee of the Board of Directors approved grants totaling approximately 68,000 and 69,000 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares are determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed. In addition to the shares of restricted common stock granted in 2013, the Compensation Committee of the Board of Directors also approved grants of approximately 55,000 unrestricted shares of common stock to certain employees. These shares were granted without restrictions and considered fully vested upon the date of the grant.
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
 
 
Average
 
Shares
 
Exercise Price
Outstanding, December 31, 2013
333,000

 
$
6.64

Granted

 

Exercised
(1,000
)
 
2.37

Expired or cancelled
(27,000
)
 
7.49

Outstanding, June 30, 2014
305,000

 
$
6.58

 
 
 
 
Exercisable, June 30, 2014
262,000

 
$
6.71



14



 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2013
118,000

 
$
5.41

Granted
68,000

 
5.51

Dividend Equivalents
2,000

 
6.86

Vested
(40,000
)
 
5.47

Cancelled
(1,000
)
 
5.42

Outstanding June 30, 2014
147,000

 
$
5.45


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2013
41,000

 
$
5.35

Granted
25,000

 
5.51

Dividend Equivalents
1,000

 
6.86

Vested
(21,000
)
 
5.70

Cancelled

 

Outstanding June 30, 2014
46,000

 
$
5.30



Prior to 2013, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date. The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation using the Black-Scholes-Merton equity grant valuation model.

In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.

While no SOSARs or Options were granted during 2014 and 2013, previously granted SOSARs and Options remain outstanding as of June 30, 2014. The following table summarizes information regarding stock options and SOSAR grants outstanding as of June 30, 2014:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$10.40 to $11.59
 
11.13

 
63,000

 

 
63,000

 

$2.37 to $6.21
 
5.32

 
243,000

 
529,000

 
199,000

 
450,000

 
 
 
 
306,000

 
 
 
262,000

 
 
Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded

15



total stock-based compensation expense of $295,000 and $357,000 in the six month periods ended June 30, 2014 and 2013, respectively.

7.
EARNINGS (LOSS) PER COMMON SHARE
Information with respect to basic and diluted net earnings (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
 
 
 
 
 
 
2014
 
2013
 
2014
 
2013
Numerator: Income (loss) amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
973

 
$
(2,421
)
 
$
540

 
$
(3,695
)
Less: income (loss) attributable to noncontrolling interests

 
(16
)
 
25

 
(34
)
Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc.
973

 
(2,437
)
 
565

 
(3,729
)
Preferred stock dividends
(86
)
 
(86
)
 
(172
)
 
(172
)
Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders
887

 
(2,523
)
 
393

 
(3,901
)
Income (loss) from discontinued operations, net of income taxes
128

 
242

 
(484
)
 
569

Net income (loss) attributable to Diversicare Healthcare Services, Inc. common shareholders
$
1,015

 
$
(2,281
)
 
$
(91
)
 
$
(3,332
)
 
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2014
 
2013
 
2014
 
2013
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.15

 
$
(0.43
)
 
$
0.07

 
$
(0.67
)
Income (loss) from discontinued operations
 
 
 
 
 
 
 
Operating income (loss), net of taxes
0.02

 
0.04

 
(0.08
)
 
0.10

Discontinued operations, net of taxes
0.02

 
0.04

 
(0.08
)
 
0.10

Net income (loss) per common share – basic
$
0.17

 
$
(0.39
)
 
$
(0.01
)
 
$
(0.57
)
Per common share – diluted
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.14

 
$
(0.43
)
 
$
0.07

 
$
(0.67
)
Income (loss) from discontinued operations
 
 
 
 
 
 
 
Operating income (loss), net of taxes
0.02

 
0.04

 
(0.08
)
 
0.10

Discontinued operations, net of taxes
0.02

 
0.04

 
(0.08
)
 
0.10

Net income (loss) per common share - diluted
$
0.16

 
$
(0.39
)
 
$
(0.01
)
 
$
(0.57
)
Denominator: Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,015

 
5,874

 
5,995

 
5,861

Diluted
6,181

 
5,874

 
5,995

 
5,861

The effects of 326,000 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share for the three-month and six-month periods ended June 30, 2013, because these securities would have been anti-dilutive

16



due to the net loss. The weighted average common shares for basic and diluted earnings for common shares were the same due to the year-to-date loss in these periods.

8.
VARIABLE INTEREST ENTITY
Accounting guidance requires that a variable interest entity (“VIE”) must be consolidated by the primary beneficiary in accordance with the provisions set forth in FASB ASC 810, Consolidation, as mentioned in Note 2 above. The primary beneficiary is the party that has both the power to direct activities of a VIE that most significantly impact the entity's economic performance and the obligation to absorb losses of the entity or the right to receive benefits from the entity that could potentially be significant to the VIE. We perform an ongoing qualitative analysis to determine if we are the primary beneficiary of a VIE. The Company had one variable interest entity related to a nursing center in West Virginia that was dissolved in the first quarter of 2014 as a result of the asset purchase of the Rose Terrace nursing center, and is no longer consolidated into the interim consolidated financial statements of the Company.
Rose Terrace Health and Rehabilitation Center
On December 28, 2011, the Company completed construction of Rose Terrace Health and Rehabilitation Center (“Rose Terrace”), its third health care center in West Virginia. The 90-bed skilled nursing center is located in Culloden, West Virginia, along the Huntington-Charleston corridor, and offers 24-hour skilled nursing care designed to meet the care needs of both short and long-term nursing patients. The Rose Terrace nursing center utilizes a Certificate of Need the Company obtained in June 2009, when the Company completed the acquisition of certain assets of a skilled nursing center in West Virginia.
The Company initially entered into a lease agreement with the real estate developer that constructed, furnished, and equipped Rose Terrace. The agreement included the right to purchase the center and all associated assets beginning at the end of the first year of the initial term of the lease and continuing through the fifth year for a purchase price ranging from 110% to 120% of the total project cost. On March 27, 2014, the Company exercised this purchase option and acquired the land, building, and all other assets of the Rose Terrace nursing center from the real estate developer for the contractually agreed upon price of $7,693,000.
Prior to the exercise of the purchase option, the Company had determined it was the primary beneficiary of the VIE based on the ownership of the Certificate of Need, the fixed price purchase option described above, the Company’s ability to direct the activities that most significantly impact the economic performance of the VIE, and the right to receive potentially significant benefits from the VIE. Accordingly, as the primary beneficiary, the Company consolidated the balance sheet and results of operations of the VIE for periods prior to the exercise of the purchase option. However, after the exercise of the purchase option, the previous owners paid the outstanding debt related to the entity in full. Subsequently, as further disclosed in Note 11, the Company sold the Rose Terrace facility and all assets associated with the facility. As a result of these events, the entity is no longer considered a VIE as of June 30, 2014.

9. EQUITY METHOD INVESTMENT
The investment in unconsolidated affiliate reflected on the interim consolidated balance sheet relates to a pharmacy joint venture partnership in which the Company owns 50%. The joint venture was initially funded by the Company and its partner and began operations during 2012. This investment in unconsolidated affiliate is accounted for using the equity method as the Company exerts significant influence, but does not control or otherwise consolidate the entity. The investment in unconsolidated affiliate balance at June 30, 2014, was $428,000 as compared to $487,000 at December 31, 2013. Additionally, the Company's share of the net profits and losses of the unconsolidated affiliate are reported in equity in net earnings or losses of unconsolidated affiliate in our statement of operations. The Company's equity in the net losses of unconsolidated affiliate for the six month period ended June 30, 2014, was $59,000 as compared to $215,000 for the six month period ended June 30, 2013.

10.
BUSINESS DEVELOPMENT
Acquisitions
On March 6, 2013, the Company entered into an asset purchase agreement ("the Agreement") with Cumberland & Ohio Co. of Texas, as receiver of the assets of SeniorTrust of Florida, Inc. to acquire certain land, improvements, furniture, fixtures and equipment, and personal property of five facilities, all located in Kansas, for an aggregate purchase price of $15,500,000. The purchase of the Kansas facilities was completed on May 1, 2013. The Company also incurred $338,000 in acquisition-related expenses associated with this transaction. The five facilities acquired under the Agreement include the following:

77-bed skilled nursing facility known as Chanute HealthCare Center
119-bed skilled nursing facility known as Haysville HealthCare Center

17



80-bed skilled nursing facility known as Larned HealthCare Center
62-bed skilled nursing facility known as Sedgwick HealthCare Center
80-bed skilled nursing facility known as Council Grove HealthCare Center

As a result of the consummation of the Agreement, the Company allocated the purchase price of $15,500,000 between the assets associated with the transaction based on the fair value of the acquired net assets. In addition to the assets acquired in the transaction, the Company also assumed liabilities of $758,000 which resulted in total cash outlay of $14,742,000. The allocation of the purchase price was determined with the assistance of HealthTrust LLC, a third-party real estate valuation firm. The allocation for the net assets acquired is as follows:

 
As of May 1, 2013
Purchase Price
$
15,500,000

 
 
Land
$
2,130,000

Buildings
12,127,000

Furniture, fixtures, and equipment
1,200,000

Inventory
43,000

 
 
Less: Liabilities assumed
$
758,000

 
 
Total cash paid
$
14,742,000


Lease Agreements
On June 1, 2014, the Company assumed operations at Diversicare of Nicholasville, an existing 73-bed facility in Nicholasville, Kentucky. The nursing center is owned by a real estate investment trust ("REIT"), and the lease provides for an initial 15-year lease term with a 5-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
On March 1, 2014, the Company assumed operations at Diversicare of Big Springs, an existing 135-bed facility in Huntsville, Alabama. The nursing center is owned by an unrelated third-party and the lease provides for an initial 10-year lease term with two additional 5-year renewal options. The additional skilled nursing center increases the Company's footprint in Alabama to seven centers, and the third center in the Huntsville market. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
On October 1, 2013, the Company assumed operations at four existing nursing centers, three in Ohio and one in Indiana. The nursing centers are owned by a REIT and the lease of these centers provides for an initial 15-year lease term with a 5-year renewal option. This transaction represents an increase in the Company's footprint in the Midwest, expanding into one new state, Indiana, and increasing our presence in Ohio to four nursing centers. All four of the centers were operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers.
On August 1, 2013, the Company assumed operations at Seneca Place, an existing 107-bed facility in Louisville, Kentucky.  The nursing center is owned by a REIT, and the lease provides for an initial 15-year lease term with a 5-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.


11.
DISCONTINUED OPERATIONS
West Virginia Disposition
Effective April 3, 2014, the Company entered into an asset purchase agreement with Rose Terrace Acq., LLC (“Purchaser”) to sell its skilled nursing facility in Culloden, West Virginia. The original asset purchase agreement was subject to a number of conditions including an amendment to the Master Lease with Omega Health Investors, Inc. ("Omega") to terminate the lease only with respect to two other skilled nursing facilities in West Virginia, state licensure and regulatory approval. The Company concurrently entered into an operations transfer agreement with respect to the two other skilled nursing facilities located in

18



Danville and Ivydale, West Virginia. Effective May 31, 2014, the Company determined that these three centers, based on the progress of the underlying contingencies and conditions associated with the asset purchase agreement, met the requirements for classification as discontinued operations. As a result, the three facilities are reflected as discontinued operations for all periods in the accompanying financial statements. The Company finalized the transaction on July 1, 2014, and is disclosed as a subsequent event in Note 12.
These centers contributed revenues of $10,989,000 and $10,222,000 and net income of $660,000 and $906,000 during the six months ended June 30, 2014 and 2013, respectively.  The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense or any allocation of corporate interest expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations.
Arkansas Lease Termination
Effective September 1, 2013, the Company entered into an agreement with Omega Healthcare Investors, Inc. ("Omega") to terminate its lease with respect to eleven nursing centers and 1,181 licensed beds located in Arkansas and concurrently entered into operation transfer agreements to transfer the operations of each of those eleven centers to an operator selected by Omega. Upon the completion of the transaction, the Company no longer operates any skilled nursing centers in the State of Arkansas. In connection with the closing of this transaction, the Company and Omega entered into the Thirteenth Amendment to Consolidated Amended and Restated Master Lease ("Master Lease") most recently amended on January 22, 2013. This amendment effectively modifies the terms of the Master Lease to terminate the terms surrounding the eleven nursing centers in Arkansas, and only as to those eleven centers, and effectively reduces the annual rent payable under the Master Lease by $5,000,000.
As a result of this transaction, the Company has reclassified the operations of these centers as discontinued operations for all periods presented in the accompanying interim consolidated financial statements. These centers contributed revenues of $0 and $31,880,000 and net loss of $739,000 and $87,000 during the six months ended June 30, 2014 and 2013, respectively.  The net loss in 2014 primarily relates to professional liability expense incurred during the first quarter of 2014. The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense or any allocation of corporate interest expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations.
The discontinued assets and liabilities of the disposed skilled nursing centers have been reclassified and are segregated in the interim consolidated balance sheets as assets and liabilities of discontinued operations. The current asset amounts, which are primarily composed of net accounts receivable of $2,913,000 and $2,870,000 at June 30, 2014 and December 31, 2013, respectively. The current liabilities are primarily composed of outstanding short-term debt on the Rose Terrace facility, trade payables, and various accrued expenses of $8,823,000 and $1,359,000 at June 30, 2014 and December 31, 2013, respectively. The Company expects to collect the balance of the accounts receivable and pay the remaining trade payables and accrued expenses in the ordinary course of business. The short-term debt related to the Rose Terrace facility was paid in full in conjunction with the sale of the facility on July 1, 2014. The Company did not transfer the accounts receivable or liabilities to the new owners or operators of the facilities. Further, in accordance with Company accounting policy, the reserve for professional liability and workers' compensation will remain in the consolidated liability accounts as future payment of these liabilities will be paid through the Company's future operating cash flows.


12.
SUBSEQUENT EVENTS
Effective July 1, 2014, subsequent to the end of the second quarter, the Company completed the transaction with Rose Terrace Acq., LLC to sell Rose Terrace, a 90-bed skilled nursing facility in Culloden, West Virginia for a sales price of $16.5 million. The Company also agreed to an amendment to the Master Lease with Omega Health Investors, Inc. to terminate the lease only with respect to two other skilled nursing facilities in West Virginia, and concurrently entered into an operations transfer agreement with American Health Care Management, LLC, an affiliate of the purchaser with respect to two other skilled nursing facilities located in Danville and Ivydale, West Virginia. Upon completion of the transaction, Diversicare no longer operates any skilled nursing centers in the state of West Virginia. In conjunction with the closing of the sale, the Company paid the balance of the $8,000,000 mortgage loan outstanding on the Rose Terrace facility.
In a separate and unrelated transaction, the Company also completed a transaction to enter the state of Missouri through the assumption of operations of three facilities totaling 339 skilled nursing beds effective July 1, 2014. This portfolio is expected to contribute in excess of $17 million in annual revenues with initial lease terms of 15 years.
Also effective July 1, 2014, the Company entered into the Third Amendment to the Amended and Restated Revolver ("Third Amendment"). The Third Amendment makes the previously temporary increase to the Amended Revolver capacity from the

19



$20,000,000 in the original Amended Revolver to $27,500,000 as defined in the Second Amendment, a permanent change to the borrowing capacity as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process.
Effective August 1, 2014, the Company completed a transaction to assume operations of two facilities in Ohio. The facilities included in this transaction are Avon Place, a 142-bed skilled nursing facility, and Ontario Commons, a 42-bed assisted living facility. The assumption of operations at Ontario Commons represents the Company's first and only all-assisted living facility in the current portfolio. These facilities are expected to contribute in excess of $9 million in annual revenues with initial lease terms of 10 years.



20




ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
Diversicare Healthcare Services, Inc. provides long-term care services to nursing center patients in eight states, primarily in the Southeast, Midwest and Southwest. Our centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. In addition to the services usually provided in long-term care centers, we also offer a variety of comprehensive rehabilitation services as well as nutritional support services. As of June 30, 2014, the Company’s continuing operations consist of 46 nursing centers with 5,282 licensed nursing beds. The Company owns 13 and leases 33 of its nursing centers. The nursing center and licensed bed count includes the following recent business development activity:
The 73-bed facility in Nicholasville, Kentucky, for which the Company entered into a lease agreement and assumed operations effective June 1, 2014. The Medicaid and Medicare certification processes for this facility are currently underway, and are expected to be completed in the fourth quarter of 2014.
The 135-bed facility in Huntsville, Alabama, for which the Company entered into a lease agreement and assumed operations effective March 1, 2014. The Medicaid and Medicare certification processes for this facility are currently underway, and are expected to be completed in the third quarter of 2014.
The 442 licensed nursing beds at the four recently leased skilled nursing centers, three in Ohio and one in Indiana, which we have operated since October 1, 2013. The Medicaid and Medicare certification processes were completed for these four leased facilities in the first quarter of 2014. In addition to the licensed nursing beds, these four centers also include 270 licensed assisted living beds which are not included in the licensed nursing bed count.
The 107-bed facility in Louisville, Kentucky, for which the Company entered into a lease agreement in August 2013. The Medicare certification processes for this facility was completed in the first quarter of 2014. The Medicaid certification process was completed in the second quarter of 2014.
The Kansas centers acquired in May 2013, which comprise five skilled nursing centers and 418 licensed beds. The Medicaid certification process was completed for these facilities during the second quarter of 2013, and the Medicare certification process was completed for these facilities during the third quarter of 2013.
Our continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Ohio, Tennessee, and Texas.
Discontinued Operations
Effective April 3, 2014, the Company entered into an asset purchase agreement with Rose Terrace Acq., LLC (“Purchaser”) to sell its skilled nursing facility in Culloden, West Virginia. The original asset purchase agreement was subject to a number of conditions including an amendment to the Master Lease with Omega Health Investors, Inc. ("Omega") to terminate the lease only with respect to two other skilled nursing facilities in West Virginia, state licensure and regulatory approval. The Company concurrently entered into an operations transfer agreement with respect to the two other skilled nursing facilities located in Danville and Ivydale, West Virginia. Effective May 31, 2014, the Company determined that these three centers, based on the progress of the underlying conditions associated with the asset purchase agreement, met the requirements for classification as discontinued operations. As a result, the three facilities with 240 licensed beds are reflected as discontinued operations for all periods in the accompanying financial statements. The Company finalized the transaction on July 1, 2014, and is disclosed in the accompanying financial statements as a subsequent event to the second quarter ended June 30, 2014.
Effective September 1, 2013, the Company finalized an agreement with Omega Healthcare Investors, Inc. to terminate its lease with respect only to eleven nursing centers with 1,181 licensed beds located in Arkansas and to concurrently transfer operations to an operator selected by Omega. The completion of this transaction represents disposal of all of the Company's operations in the state of Arkansas.
The net income for the nursing centers included in discontinued operations does not reflect any allocation of regional or corporate general and administrative expense or any allocation of corporate interest expense. We considered these additional costs along with the future prospects of these nursing centers when determining the contribution of the skilled nursing centers to our operations.
The assets and liabilities of the disposed skilled nursing centers have been reclassified and are segregated in the interim consolidated balance sheets as assets and liabilities of discontinued operations. The current asset amounts are primarily composed of net accounts receivable and the current liabilities consist primarily of accounts payable. The Company expects to collect the balance of the accounts receivable and pay the remaining trade payables and taxes in the ordinary course of business. The Company did not transfer the accounts receivable or liabilities to the new operators of these centers. Further, in

21



accordance with Company accounting policy, the reserve for professional liability and workers' compensation will remain in the consolidated liability accounts as future payment of these liabilities will be paid through the Company's future operating cash flows.
Strategic Operating Initiatives
During the third quarter of 2010, we identified several key strategic objectives to increase shareholder value through improved operations and business development. These strategic operating initiatives included: improving skilled mix in our nursing centers, improving our average Medicare rate, implementing Electronic Medical Records (“EMR”), and completing strategic acquisitions. We have experienced success in these initiatives and expect to continue to build on these improvements. We describe each of these below as well as provide metrics for our most recent quarter versus the third quarter of 2010, the quarter before we embarked on our strategic operating initiatives.
Improving skilled mix and average Medicare rate:
Our strategic operating initiatives of improving our skilled mix and our average Medicare rate by accurately capturing the delivery of care required investing in nursing and clinical care to treat more acute patients along with nursing center based sales representatives to attract these patients. These initiatives developed referral and Managed Care relationships that have attracted and are expected to continue to attract patients whose stay in the centers is covered by Medicare and Managed Care. A comparison of our most recent quarter versus the third quarter of 2010, the quarter before we embarked on our strategic operating initiatives, reflects our success with these strategic operating initiatives: 
 
Three Months Ended
 
June 30, 2014
 
September 30,
2010
As a percent of total census:
 
 
 
Medicare census
13.8
%
 
12.3
%
Managed Care census
3.4
%
 
1.3
%
Total skilled mix census
17.2
%
 
13.6
%
As a percent of total revenues:
 
 
 
Medicare revenues
31.3
%
 
29.3
%
Managed Care revenues
6.4
%
 
2.8
%
Total skilled mix revenues
37.7
%
 
32.1
%
Medicare average rate per day:
$
438.46

 
$
394.23

The initiatives have developed positive results in growing our skilled patient population, increasing the Managed Care census to 3.4% of total census in the second quarter of 2014, as compared to 1.3% in the third quarter of 2010, and total skilled mix census from 13.6% to 17.2% over the same period.
Implementing Electronic Medical Records:
As another part of our strategic operating initiative, we implemented EMR to improve documentation of the delivery of care. We completed the implementation of EMR in all our nursing centers in December 2011, on time and under budget. A comparison of our most recent quarter versus the third quarter of 2010 reflects the increase in our average Medicaid rate per day:
 
Three Months Ended
 
June 30, 2014
 
September 30,
2010
Medicaid average rate per day:
$
158.47

 
$
147.93


Completing strategic acquisitions:
Our strategic operating initiatives include a renewed focus on completing strategic acquisitions. We continue to pursue and investigate opportunities to acquire, lease or develop new centers, focusing primarily on opportunities within our existing areas of operation. We expect to announce additional development projects in the near future. Since September 30, 2010, the

22



Company has added four skilled nursing centers in Kentucky, three in Ohio, one in Indiana, one in Alabama, and five in Kansas.
As part of our strategic efforts, we have also performed a thorough analysis on our existing centers in order to determine whether continuing operations within certain markets or regions was in line with the short-term and long-term strategy of the business. As a result, we disposed of an owned building in Arkansas in 2012, and reached an agreement to terminate our lease for eleven other facilities in Arkansas in 2013. Additionally, we reached an agreement to dispose of the owned Rose Terrace facility in West Virginia and transfer operations of the other two facilities we operated in West Virginia. This transaction was effective July 1, 2014, subsequent to the end of the current period. As a result of these transactions, we no longer operate within the states of Arkansas or West Virginia.
Basis of Financial Statements
Our patient revenues consist of the fees charged for the care of patients in the nursing centers we own and lease. Our operating expenses include the costs, other than lease, professional liability, depreciation and amortization expenses, incurred in the operation of the nursing centers we own and lease. Our general and administrative expenses consist of the costs of the corporate office and regional support functions. Our interest, depreciation and amortization expenses include all such expenses across the range of our operations.

Critical Accounting Policies and Judgments
A “critical accounting policy” is one which is both important to the understanding of our financial condition and results of operations and requires management’s most difficult, subjective or complex judgments often involving estimates of the effect of matters that are inherently uncertain. Actual results could differ from those estimates and cause our reported net income or loss to vary significantly from period to period. Our critical accounting policies are more fully described in our 2013 Annual Report on Form 10-K.

Revenue Sources
We classify our revenues from patients and residents into four major categories: Medicaid, Medicare, Managed Care, and Private Pay and other. Medicaid revenues are composed of the traditional Medicaid program established to provide benefits to those in need of financial assistance in the securing of medical services. Medicare revenues include revenues received under both Part A and Part B of the Medicare program. Managed Care revenues include payments for patients who are insured by a third-party entity, typically called a Health Maintenance Organization, often referred to as an HMO plan, or are Medicare beneficiaries who assign their Medicare benefits to a Managed Care replacement plan often referred to as Medicare replacement products. The Private Pay and other revenues are composed primarily of individuals or parties who directly pay for their services. Included in the Private Pay and other are patients who are hospice beneficiaries as well as the recipients of Veterans Administration benefits. Veterans Administration payments are made pursuant to renewable contracts negotiated with these payors.
The following table sets forth net patient and resident revenues related to our continuing operations by payor source for the periods presented (dollar amounts in thousands):
 
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2014
 
2013
 
2014
 
2013
Medicaid
$
39,201

 
47.6
%
 
$
32,889

 
53.5
%
 
$77,510
 
48.4%
 
$63,376
 
52.8%
Medicare
25,691

 
31.3

 
17,109

 
27.8

 
48,039
 
30.0
 
34,060
 
28.4
Managed Care
5,287

 
6.4

 
3,444

 
5.6

 
10,717
 
6.7
 
7,411
 
6.2
Private Pay and other
12,134

 
14.7

 
8,046

 
13.1

 
23,846
 
14.9
 
15,080
 
12.6
Total
$
82,313

 
100.0
%
 
$
61,488

 
100.0
%
 
$160,112
 
100.0%
 
$119,927
 
100.0%
The following table sets forth average daily skilled nursing census by payor source for our continuing operations for the periods presented: 

23



 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2014
2013
 
2014
 
2013
Medicaid
2,727

 
66.7
%
 
2,297

 
69.8
%
 
2,718

 
67.3
%
 
2,231

 
69.7
%
Medicare
563

 
13.8

 
382

 
11.6

 
531

 
13.2

 
383

 
12.0

Managed Care
138

 
3.4

 
89

 
2.7

 
144

 
3.6

 
100

 
3.1

Private Pay and other
662

 
16.1

 
524

 
15.9

 
645

 
15.9

 
488

 
15.2

Total
4,090

 
100.0
%
 
3,292

 
100.0
%
 
4,038

 
100.0
%
 
3,202

 
100.0
%
Consistent with the nursing home industry in general, changes in the mix of a facility’s patient population among Medicaid, Medicare, Managed Care, and Private Pay and other can significantly affect the profitability of the facility’s operations.

Health Care Industry
The health care industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, quality of resident care and Medicare and Medicaid fraud and abuse. Over the last several years, government activity has increased with respect to investigations and allegations concerning possible violations by health care providers of fraud and abuse laws and regulations as well as laws and regulations governing quality of care issues in the skilled nursing profession in general. Violations of these laws and regulations could result in exclusion from government health care programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Compliance with such laws and regulations is subject to ongoing government review and interpretation, as well as regulatory actions in which government agencies seek to impose fines and penalties. The Company is involved in regulatory actions of this type from time to time.
In March 2010, significant legislation concerning health care and health insurance was passed, including the “Patient Protection and Affordable Care Act,” (“Affordable Care Act”) along with the “Health Care and Education Reconciliation Act of 2010” (“Reconciliation Act”) collectively defined as the “Legislation.” We expect this Legislation to impact our Company, our employees and our patients and residents in a variety of ways. This Legislation significantly changes the future responsibility of employers with respect to providing health care coverage to employees in the United States. Two of the main provisions of the Legislation become effective in 2014 whereby most individuals will be required to either have health insurance or pay a fine and employers with 50 or more employees will either have to provide minimum essential coverage or will be subject to additional taxes. On July 2, 2013, the United States Treasury Department announced that it will delay the employer reporting mandate, which was to be effective for 2014, until 2015 to allow additional time for process improvement and system integration. We have not estimated the financial impact of the Legislation and the costs associated with complying with the increased levels of health insurance we will be required to provide our employees and their dependents in future years. We expect the Legislation will result in increased operating expenses.
We also expect for this Legislation to continue to impact our Medicaid and Medicare reimbursement as well, though the exact timing and level of that impact is currently unknown. The Legislation expands the role of home-based and community services, which may place downward pressure on our ability to maintain our population of Medicaid residents.
On June 28, 2012, the United States Supreme Court ruled that the enactment of the Affordable Care Act did not violate the Constitution of the United States. This ruling permits the implementation of most of the provisions of the Affordable Care Act to proceed. The provisions of the Affordable Care Act discussed above are only examples of federal health reform provisions that we believe may have a material impact on the long-term care industry and on our business. We anticipate that many of the provisions of the Legislation may be subject to further clarification and modification through the rule making process and could have a material adverse impact on our results of operations.
Medicare and Medicaid Reimbursement
A significant portion of our revenues are derived from government-sponsored health insurance programs. Our nursing centers derive revenues under Medicaid, Medicare, Managed Care, Private Pay and other third party sources. We employ third-party specialists in reimbursement and also use these services to monitor regulatory developments to comply with reporting requirements and to ensure that proper payments are made to our operated nursing centers. It is generally recognized that all government-funded programs have been and will continue to be under cost containment pressures, but the extent to which these pressures will affect our future reimbursement is unknown.
Medicare

24



Effective October 1, 2011, Medicare rates were reduced by a nationwide average of 11.1%, the net effect of a reduction to restore overall payments to their intended levels on a prospective basis and the application of a 2.7% market basket increase and a negative 1.0% productivity adjustment required by the Affordable Care Act. The final Centers for Medicare and Medicaid Services (“CMS”) rule also adjusts the method by which group therapy is counted for reimbursement purposes and, for patients receiving therapy, changes the timing of reassessment for purposes of determining patient RUG categories. These October 2011 Medicare reimbursement changes decreased our Medicare revenue and our Medicare rate per patient day. The new regulations also resulted in an increase in costs to provide therapy services to our patients.
The Budget Control Act of 2011 (“BCA”), enacted on August 2, 2011, increased the United States debt ceiling and linked the debt ceiling increase to corresponding deficit reductions through 2021. The BCA also established a 12 member joint committee of Congress known as the Joint Select Committee on Deficit Reduction (“Super Committee”). The Super Committee’s objective was to create proposed legislation to reduce the United States federal budget deficit by $1.5 trillion for fiscal years 2012 through 2021. Part of the BCA required this legislation to be enacted by December 23, 2011, or approximately $1.2 trillion in spending reductions would automatically begin through sequestration on January 1, 2013, split between domestic and defense spending. As no legislation was passed that would achieve the targeted savings outlined in the BCA, payments to Medicare providers have been reduced by 2% from planned levels effective April 1, 2013.
In July 2013, CMS issued Medicare payment rates, effective October 1, 2013, that increased reimbursement to skilled nursing centers by approximately 0.6% compared to the fiscal year ending September 30, 2013. The increase is the net effect of a 2.5% inflation increase as measured by the SNF market basket, offset by a 0.7% negative productivity adjustment required by the Affordable Care Act, and a 1.2% budget neutrality adjustment. This adjustment is further offset by the ongoing sequestration from the BCA as mentioned above. The 2% sequestration is not applied to the payment rate, but rather it is applied to Medicare claims after determining coinsurance, any applicable deductibles, and any applicable Medicare secondary payment adjustments.
Therapy Services. There are annual Medicare Part B reimbursement limits on therapy services that can be provided to an individual. The limits impose a $1,920 per patient annual ceiling on physical and speech therapy services, and a separate $1,920 per patient annual ceiling on occupational therapy services. CMS established an exception process to permit therapy services in certain situations and we provide services that are reimbursed under the exceptions process. The exceptions process has been extended several times, most recently by the Protecting Access to Medicare Act of 2014, which extended this exception process through March 31, 2015.
Related to the exceptions process discussed above, for services provided with dates of service between January 1, 2014, through March 31, 2015, providers are required to submit a request for an exception for therapy services above the threshold of $3,700 which will then be manually medically reviewed, consistent with the treatment of these services historically. Similar to the therapy cap exceptions process, the threshold process will have a $3,700 per patient threshold on physical and speech therapy services, and a separate $3,700 per patient threshold on occupational therapy services. The exception reviews were conducted by Medicare Administrative Contractors during this period.
It is unknown if any further extension of the therapy cap exceptions or the new threshold process will be included in future legislation or CMS policy decisions. If the exception process is discontinued or if the manual review process for therapy in excess of $3,700 negatively impacts our Medicare Part B reimbursement, we would likely see a reduction in our therapy revenues which would negatively impact our operating results and cash flows.
On November 2, 2010, CMS released a final proposed rule as part of the Medicare Physician Fee Schedule (“MPFS”) that was effective January 1, 2011. The policy impacts the reimbursement we receive for Medicare Part B therapy services in our facilities. The policy provides that Medicare Part B pay the full rate for the therapy unit of service that has the highest Practice Expense ("PE") component for each patient on each day they receive multiple therapy treatments. Reimbursement for the second and subsequent therapy units for each patient each day they receive multiple therapy treatments was reimbursed at a rate equal to 75% of the applicable PE component through March 31, 2013. Effective April 1, 2013, the rate at which these services are reimbursed was reduced to 50% of the applicable PE component.
Medicare Part B therapy services in our centers are determined according to MPFS. Annually since 1997, the MPFS has been subject to a Sustainable Growth Rate Adjustment (“SGR”) intended to keep spending growth in line with allowable spending. Each year since the SGR was enacted, this adjustment produced a scheduled negative update to payment for physicians, therapists and other healthcare providers paid under the MPFS. Congress has stepped in with so-called “doc fix” legislation numerous times to stop payment cuts to physicians, most recently by the Protecting Access to Medicare Act of 2014, which stopped these payment cuts through March 31, 2015.

25



The Protecting Access to Medicare Act of 2014 also extended several other elements of the Middle Class Tax Relief and Job Creation Act of 2012, including the reduction of bad debt treated as an allowable cost. Prior to this act, Medicare reimbursed providers for beneficiaries’ unpaid coinsurance and deductible amounts after reasonable collection efforts at a rate between 70 and 100 percent of beneficiary bad debt. This provision reduced bad debt reimbursement exposure for all providers to 65 percent.
Medicaid
Several states in which we operate face budget shortfalls, which could result in reductions in Medicaid funding for nursing centers. The federal government made an effort to address the financial challenges state Medicaid programs are facing by increasing the amount of Medicaid funding available to states. Pressures on state budgets are expected to continue in the future and are expected to result in Medicaid rate reductions.
We receive the majority of our annual Medicaid rate increases during the third quarter of each year. The rate changes received in the third quarter of 2013 and the third quarter of 2012, along with increased Medicaid acuity in our acuity based states, was the primary contributor to our 1.3% increase in average rate per day for Medicaid patients in 2014 compared to 2013. Based on the rate changes received during the third quarter of 2013, we expect downward pressure on our rate per day for Medicaid patients as we move into 2014 due to modest rate decreases in many of the states within which we operate.
We are unable to predict what, if any, reform proposals or reimbursement limitations will be implemented in the future, or the effect such changes would have on our operations. For the six months ended June 30, 2014, we derived 31.3% and 47.6% of our total patient revenues related to continuing operations from the Medicare and Medicaid programs, respectively. Any health care reforms that significantly limit rates of reimbursement under these programs could, therefore, have a material adverse effect on our profitability.
We will attempt to increase revenues from non-governmental sources to the extent capital is available to do so. However, private payors, including Managed Care payors, are increasingly demanding that providers accept discounted fees or assume all or a portion of the financial risk for the delivery of health care services. Such measures may include capitated payments, which can result in significant losses to health care providers if patients require expensive treatment not adequately covered by the capitated rate.
Licensure and Other Health Care Laws
All of our nursing centers must be licensed by the state in which they are located in order to accept patients, regardless of payor source. In most states, nursing centers are subject to certificate of need laws, which require us to obtain government approval for the construction of new nursing centers or the addition of new licensed beds to existing centers. Our nursing centers must comply with detailed statutory and regulatory requirements on an ongoing basis in order to qualify for licensure, as well as for certification as a provider eligible to receive payments from the Medicare and Medicaid programs. Generally, the requirements for licensure and Medicare/Medicaid certification are similar and relate to quality and adequacy of personnel, quality of medical care, record keeping, dietary services, patient rights, and the physical condition of the center and the adequacy of the equipment used therein. Each center is subject to periodic inspections, known as “surveys” by health care regulators, to determine compliance with all applicable licensure and certification standards. Such requirements are both subjective and subject to change. If the survey concludes that there are deficiencies in compliance, the center is subject to various sanctions, including, but not limited to, monetary fines and penalties, suspension of new admissions, non-payment for new admissions and loss of licensure or certification. Generally, however, once a center receives written notice of any compliance deficiencies, it may submit a written plan of correction and is given a reasonable opportunity to correct the deficiencies. There can be no assurance that, in the future, we will be able to maintain such licenses and certifications for our facilities or that we will not be required to expend significant sums in order to comply with regulatory requirements.

Contractual Obligations and Commercial Commitments
We have certain contractual obligations of continuing operations as of June 30, 2014, summarized by the period in which payment is due, as follows (dollar amounts in thousands):

26



Contractual Obligations
Total
 
Less than
1  year
 
1 to 3
Years
 
3 to 5
Years
 
After
5 Years
Long-term debt obligations (1)
$
72,134

 
$
21,002

 
$
7,953

 
$
43,179

 
$

Settlement obligations (2)
5,470

 
5,470

 

 

 

Series C Preferred Stock (3)
4,918

 
4,918

 

 

 

Elimination of Preferred Stock Conversion feature (4)
2,920

 
687

 
1,374

 
859

 

Operating leases (5)
585,122

 
28,958

 
59,509

 
61,428

 
435,227

Required capital expenditures under operating leases (6)
6,738

 
244

 
488

 
488

 
5,518

Total
$
677,302

 
$
61,279

 
$
69,324

 
$
105,954

 
$
440,745

 
(1)
Long-term debt obligations include scheduled future payments of principal and interest of long-term debt and amounts outstanding on our capital lease obligations.
(2)
Settlement obligations relate to professional liability cases that the Company is obligated to pay within the next twelve months. The professional liabilities are included in our current portion of self-insurance reserves.
(3)
Series C Preferred Stock equals the redemption value at the preferred shareholder’s earliest redemption date.
(4)
Payments to Omega Health Investors ("Omega"), from which we lease 23 nursing centers, for the elimination of the preferred stock conversion feature in connection with restructuring the preferred stock and master lease agreements. Monthly payments of approximately $57,000 will be made through the end of the initial lease period that ends in September 2018.
(5)
Represents lease payments under our operating lease agreements. Assumes all renewal periods are enacted.
(6)
Includes annual expenditure requirements under operating leases.
We have employment agreements with certain members of management that provide for the payment to these members of amounts up to two times their annual salary in the event of a termination without cause, a constructive discharge (as defined therein), or upon a change of control of the Company (as defined therein). The maximum contingent liability under these agreements is approximately $1,610,000 as of June 30, 2014. The terms of such agreements are for one year and automatically renew for one year if not terminated by us or the employee. In addition, upon the occurrence of any triggering event, those certain members of management may elect to require that we purchase equity awards granted to them for a purchase price equal to the difference in the fair market value of our common stock at the date of termination versus the stated equity award exercise price. Based on the closing price of our common stock on June 30, 2014, the potential contingent liability for the repurchase of the equity grants is $179,000.

Results of Operations
The results of operations presented have been reclassified to present the effects of certain divestitures discussed in the overview to "Management's Discussion and Analysis of Financial Condition and Results of Operations."
The following tables present the unaudited interim statements of operations and related data for the three and six month periods ended June 30, 2014 and 2013:
 

27



(in thousands)
Three Months Ended
June 30,
 
2014
 
2013
 
Change
 
%
PATIENT REVENUES, net
$
82,313

 
$
61,488

 
$
20,825

 
33.9
 %
EXPENSES:
 
 
 
 
 
 
 
Operating
64,687

 
50,316

 
14,371

 
28.6
 %
Lease and rent expense
6,251

 
4,804

 
1,447

 
30.1
 %
Professional liability
1,556

 
1,758

 
(202
)
 
(11.5
)%
General and administrative
5,381

 
5,779

 
(398
)
 
(6.9
)%
Depreciation and amortization
1,705

 
1,496

 
209

 
14.0
 %
Total expenses
79,580

 
64,153

 
15,427

 
24.0
 %
OPERATING INCOME (LOSS)
2,733

 
(2,665
)
 
5,398

 
202.6
 %
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Equity in net income (loss) of unconsolidated affiliate
(56
)
 
22

 
(78
)
 
354.5
 %
Interest expense, net
(949
)
 
(745
)
 
(204
)
 
27.4
 %
Debt retirement costs

 
(320
)
 
320

 
 %
 
(1,005
)
 
(1,043
)
 
38

 
(3.6
)%
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
1,728

 
(3,708
)
 
5,436

 
(146.6
)%
BENEFIT (PROVISION) FOR INCOME TAXES
(755
)
 
1,287

 
(2,042
)
 
(158.7
)%
INCOME (LOSS) FROM CONTINUING OPERATIONS
$
973

 
$
(2,421
)
 
$
3,394

 
(140.2
)%
 
(in thousands)
Six Months Ended
June 30,
 
2014
 
2013
 
Change
 
%
PATIENT REVENUES, net
$
160,112

 
$
119,927

 
40,185

 
33.5
 %
EXPENSES:
 
 
 
 
 
 
 
Operating
127,511

 
97,828

 
29,683

 
30.3
 %
Lease and rent expense
12,218

 
9,581

 
2,637

 
27.5
 %
Professional liability
3,617

 
3,265

 
352

 
10.8
 %
General and administrative
10,495

 
10,763

 
(268
)
 
(2.5
)%
Depreciation and amortization
3,440

 
2,938

 
502

 
17.1
 %
Total expenses
157,281

 
124,375

 
32,906

 
26.5
 %
OPERATING INCOME (LOSS)
2,831

 
(4,448
)
 
7,279

 
163.6
 %
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Equity in net income (loss) of unconsolidated affiliate
(59
)
 
(215
)
 
156

 
72.6
 %
Interest expense, net
(1,841
)
 
(1,285
)
 
(556
)
 
43.3
 %
Debt retirement costs

 
(320
)
 
320

 
100.0
 %
 
(1,900
)
 
(1,820
)
 
(80
)
 
4.4
 %
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
931

 
(6,268
)
 
7,199

 
114.9
 %
BENEFIT (PROVISION) FOR INCOME TAXES
(391
)
 
2,573

 
(2,964
)
 
(115.2
)%
INCOME (LOSS) FROM CONTINUING OPERATIONS
$
540

 
$
(3,695
)
 
$
4,235

 
114.6
 %


28



Percentage of Net Revenues
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2014
 
2013
 
2014
 
2013
PATIENT REVENUES, net
100.0
%
 
100.0
 %
 
100.0
 %
 
100.0
 %
EXPENSES:
 
 
 
 
 
 
 
Operating
78.6

 
81.8

 
79.6
 %
 
81.6
 %
Lease and rent expense
7.6

 
7.8

 
7.6
 %
 
8.0
 %
Professional liability
1.9

 
2.9

 
2.3
 %
 
2.7
 %
General and administrative
6.5

 
9.4

 
6.6
 %
 
9.0
 %
Depreciation and amortization
2.1

 
2.4

 
2.1
 %
 
2.4
 %
Total expenses
96.7

 
104.3

 
98.2

 
103.7

OPERATING INCOME (LOSS)
3.3

 
(4.3
)
 
1.8

 
(3.7
)
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Equity in net losses of unconsolidated affiliate
(0.1
)
 

 
 %
 
(0.2
)%
Interest expense, net
(1.2
)
 
(1.2
)
 
(1.1
)%
 
(1.1
)%
Debt retirement costs

 
(0.5
)
 
 %
 
(0.3
)%
 
(1.3
)
 
(1.7
)
 
(1.1
)
 
(1.6
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
2.0

 
(6.0
)
 
0.7

 
(5.3
)
BENEFIT (PROVISION) FOR INCOME TAXES
(0.9
)
 
2.1

 
(0.2
)%
 
2.1
 %
INCOME (LOSS) FROM CONTINUING OPERATIONS
1.1
%
 
(3.9
)%
 
0.5
 %
 
(3.2
)%

29



Three Months Ended June 30, 2014 Compared With Three Months Ended June 30, 2013
Patient Revenues
Patient revenues were $82.3 million for the three months ended June 30, 2014, as compared to $61.5 million in the three months ended June 30, 2013. This increase is primarily attributable to the acquisition of new facilities during the period. The following table summarizes the revenue increases attributable to our portfolio growth (in thousands):
 
Three Months Ended
June 30,
 
2014
 
2013
 
Change
Same-store revenue
$
60,443

 
$
57,593

 
$
2,850

2013 acquisition revenue
18,619

 
3,895

 
14,724

2014 acquisition revenue
3,251

 

 
3,251

Total revenue
$
82,313

 
$
61,488

 
$
20,825

The overall increase in revenue of $20.8 million is primarily attributable to revenue contributions from acquisition activity in 2013 of $14.7 million, as well as the $3.3 million contribution from the two newly leased nursing centers in 2014.
The same-store revenues increased by $2.9 million in 2014 compared to the same period in 2013 primarily attributable to improved census. The largest driver for the increase in same-store revenues is the increase in Medicare census which increased 11.9% resulting in a $1.7 million increase in revenues for the three months ended June 30, 2014, as compared to the same period in 2013. Managed Care average daily census increased 14.7% resulting in a revenue increase at our same-store nursing centers of $0.4 million. Additionally, Medicaid census increased 2.1% in 2014 compared to the same period in 2013, resulting in an increase of $0.6 million to revenues. These increases were offset by a decline in private pay census during the period which resulted in a decrease of $0.8 million for the three months ended June 30, 2014 compared to the same period in 2013.
The average Medicare rate per patient day at same-store nursing centers for the three months ended June 30, 2014 increased 1.8% compared to the same period in 2013, resulting in an increase in revenue of $0.3 million. This average rate per day for Medicaid patients also increased during the period by 0.6% resulting in an increase in revenue of $0.2 million.
The following table summarizes key revenue and census statistics for continuing operations for each period:
 
 
Three Months Ended
June 30,
 
 
2014
 
 
 
2013
 
Skilled nursing occupancy
78.2
%
 

 
74.9
%
 
As a percent of total census:
 
 
 
 
 
 
Medicare census
13.8
%
 
 
 
11.6
%
 
Managed Care census
3.4
%
 
 
 
2.7
%
 
As a percent of total revenues:
 
 
 
 
 
 
Medicare revenues
31.3
%
 
 
 
27.8
%
 
Medicaid revenues
47.6
%
 
 
 
53.5
%
 
Managed Care revenues
6.4
%
 
 
 
5.6
%
 
Average rate per day:
 
 
 
 
 
 
Medicare
$
438.46

 
  
 
$
426.14

 
Medicaid
$
158.47

 
  
 
$
156.45

 
Managed Care
$
378.53

 
  
 
$
384.55

 
Operating Expense
Operating expense increased in the second quarter of 2014 to $64.7 million as compared to $50.3 million in the second quarter of 2013, driven primarily by the $11.8 million increase in operating costs attributable to the nursing center operations acquired in 2013, as well as $2.3 million of operating expense associated with the nursing center operations assumed in 2014. The following table summarizes the expense increases attributable to our portfolio growth (in thousands):

30



 
Three Months Ended
June 30,
 
2014
 
2013
 
Change
Same-store operating expense
$
47,077

 
$
46,836

 
$
241

2013 acquisition expense
15,301

 
3,480

 
11,821

2014 acquisition expense
2,309

 

 
2,309

Total expense
$
64,687

 
$
50,316

 
$
14,371

Operating expense decreased as a percentage of revenue at 78.6% for the second quarter of 2014 as compared to 81.8% for the second quarter of 2013. The largest component of operating expenses is wages. Considering the aforementioned addition of the new centers, we experienced an increase to $37.9 million in the second quarter of 2014 as compared to $29.6 million in the second quarter of 2013, an increase of $8.3 million, or 28.0%. While wages increased overall, wages as a percentage of revenue decreased in the second quarter of 2014 to 46.1% as compared to 48.2% in the second quarter of 2013, a decrease of 2.1%.
Lease Expense
Lease expense increased in the second quarter of 2014 to $6.3 million as compared to $4.8 million in the second quarter of 2013. The increase in lease expense was primarily attributable to $1.1 million in combined lease expense for the five newly leased nursing centers in 2013. Additionally, the two nursing centers leased in 2014 contributed $0.4 million in expense during the period.
Professional Liability
Professional liability expense was $1.6 million in the second quarter of 2014 compared to $1.8 million in the second quarter of 2013, a decrease of $0.2 million. We were engaged in 53 professional liability lawsuits as of June 30, 2014, compared to 54 as of December 31, 2013. Our quarterly cash expenditures for professional liability costs of continuing operations were $1.1 million and $0.1 million for 2014 and 2013, respectively. Professional liability expense and cash expenditures fluctuate from year to year based respectively on the results of our third-party professional liability actuarial studies and on the costs incurred in defending and settling existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.

General and Administrative Expense
General and administrative expense was $5.4 million in the second quarter of 2014 as compared to $5.8 million in the second quarter of 2013, a decrease of $0.4 million, and also decreased as a percentage of revenue from 9.4% in 2013 to 6.5% in 2014. The decrease in general and administrative expense is primarily attributable to a decrease in non-recurring, acquisition-related expenses of $0.2 million in the second quarter of 2013.
Depreciation and Amortization
Depreciation and amortization expense was approximately $1.7 million in the second quarter of 2014 as compared to $1.5 million in 2013. The increase in depreciation expense relates to fixed assets at the newly leased and acquired centers.
Interest Expense, Net
Interest expense was $0.9 million in the second quarter of 2014 and $0.7 million in the second quarter of 2013, an increase of $0.2 million. The increase was primarily attributable to higher debt balances in 2014 as a result of the amended Mortgage Loan, which increased the balance of outstanding debt as a result of the acquisition of the Kansas centers, as well as the outstanding balance of the amended Revolver as a result of the on-going CHOW process at newly leased facilities.
Income (Loss) from Continuing Operations before Income Taxes; Income (Loss) from Continuing Operations per Common Share
As a result of the above, continuing operations reported income before income taxes of $1.7 million for the second quarter of 2014 as compared to a loss of $3.7 million for the second quarter of 2013. The provision for income taxes was $0.8 million in the second quarter of 2014 as compared to a benefit for income taxes of $1.3 million in the second quarter of 2013. The basic income per common share from continuing operations was $0.15 and the diluted income per common share was $0.14 for the second quarter of 2014, as compared to a loss per common share from continuing operations of $0.43 in the second quarter of 2013.

31



Six Months Ended June 30, 2014 Compared With Six Months Ended June 30, 2013
Patient Revenues
Patient revenues were $160.1 million for the six months ended June 30, 2014, as compared to $119.9 million in the six months ended June 30, 2013. This increase is primarily attributable to the acquisition of new facilities during the period. The following table summarizes the revenue increases attributable to our portfolio growth (in thousands):
 
Six Months Ended
June 30,
 
2014
 
2013
 
Change
Same-store revenue
$
119,586

 
$
116,032

 
$
3,554

2013 acquisition revenue
36,301

 
3,895

 
32,406

2014 acquisition revenue
4,225

 

 
4,225

Total revenue
$
160,112

 
$
119,927

 
$
40,185

The overall increase in revenue of $40.2 million is primarily attributable to increased revenue contributions from acquisition activity in 2013 of $32.4 million, as well as the $4.2 million contribution from the two newly leased nursing centers in 2014.
The same-store revenues increased by $3.6 million in the six months ended June 30, 2014 compared to the same period in 2013 primarily attributable to improved census. The largest driver for the increase in same-store revenues is the increase in Medicaid census which increased 2.6% resulting in a $1.6 million increase in revenues for the six months ended June 30, 2014, as compared to the same period in 2013. Medicare census also increased by 3.7% resulting in a $1.1 million increase in revenues in 2014 as compared to 2013. Additionally, Managed Care average daily census increased 8.6% resulting in a revenue increase at our same-store nursing centers of $0.6 million. These increases were offset by a decline in private pay census during the period which resulted in a decrease of $1.1 million in 2014 compared to the same period in 2013.
The average Medicare rate per patient day at same-store nursing centers for the six months ended June 30, 2014 increased 1.3% compared to the same period in 2013, resulting in an increase in revenue of $0.4 million. This average rate per day for Medicaid patients also increased during the period by 0.9% resulting in increased revenue of $0.6 million.
The following table summarizes key revenue and census statistics for continuing operations for each period:
 
 
Six Months Ended
June 30,
 
 
2014
 
 
 
2013
 
Skilled nursing occupancy
78.0
%
 
 
 
75.2
%
 
As a percent of total census:
 
 
 
 
 
 
Medicare census
13.2
%
 
 
 
12.0
%
 
Managed Care census
3.6
%
 
 
 
3.1
%
 
As a percent of total revenues:
 
 
 
 
 
 
Medicare revenues
30.0
%
 
 
 
28.4
%
 
Medicaid revenues
48.4
%
 
 
 
52.8
%
 
Managed Care revenues
6.7
%
 
 
 
6.2
%
 
Average rate per day:
 
 
 
 
 
 
Medicare
$
438.08

 
  
 
$
431.38

 
Medicaid
$
158.16

 
  
 
$
156.32

 
Managed Care
$
378.14

 
  
 
$
381.18

 
Operating Expense
Operating expense increased in 2014 to $127.5 million as compared to $97.8 million in 2013, driven primarily by the $26.7 million increase in operating costs attributable to the nursing center operations acquired in 2013, as well as $3.0 million of operating expense associated with the nursing center operations assumed in 2014. The following table summarizes the expense increases attributable to our portfolio growth (in thousands):

32



 
Six Months Ended
June 30,
 
2014
 
2013
 
Change
Same-store operating expense
$
94,410

 
$
94,336

 
$
74

2013 acquisition expense
30,151

 
3,492

 
26,659

2014 acquisition expense
2,950

 

 
2,950

Total expense
$
127,511

 
$
97,828

 
$
29,683

Operating expense decreased as a percentage of revenue at 79.6% for 2014 as compared to 81.6% for 2013. The largest component of operating expenses is wages. Considering the aforementioned addition of the new centers, we experienced an increase to $73.9 million in 2014 as compared to $58.6 million in 2013, an increase of $15.3 million, or 26.1%. While wages increased overall, wages as a percentage of revenue decreased in 2014 to 46.2% as compared to 48.9% in 2013, a decrease of 2.7%.
Lease Expense
Lease expense increased in 2014 to $12.2 million as compared to $9.6 million in 2013. The increase in lease expense was primarily attributable to $2.3 million in combined lease expense for the five newly leased nursing centers in 2013. Additionally, the two nursing centers leased in 2014 contributed $0.5 million in expense during the period.
Professional Liability
Professional liability expense was $3.6 million in 2014 compared to $3.3 million in 2013, a increase of $0.3 million. We were engaged in 53 professional liability lawsuits as of June 30, 2014, compared to 54 as of December 31, 2013. Our cash expenditures for professional liability costs of continuing operations were $2.2 million and $2.1 million for 2014 and 2013, respectively. Professional liability expense and cash expenditures fluctuate from year to year based respectively on the results of our third-party professional liability actuarial studies and on the costs incurred in defending and settling existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.

General and Administrative Expense
General and administrative expense was $10.5 million in 2014 as compared to $10.8 million in 2013, a decrease of $0.3 million, and also decreased as a percentage of revenue from 9.0% in 2013 to 6.6% in 2014. The decrease in general and administrative expense is primarily attributable to a decrease in non-recurring, acquisition-related expenses of $0.2 million in the second quarter of 2013 related to the acquisition of the Kansas portfolio.
Depreciation and Amortization
Depreciation and amortization expense was approximately $3.4 million in 2014 as compared to $2.9 million in 2013. The increase in depreciation expense relates to fixed assets at the newly leased and acquired centers, an primarily driven by an increase of $0.3 million in depreciation expense for the Kansas portfolio.
Interest Expense, Net
Interest expense was $1.8 million in 2014 and $1.3 million in 2013, an increase of $0.5 million. The increase was primarily attributable to higher debt balances in 2014 as a result of the amended Mortgage Loan, which increased the balance of outstanding debt as a result of the acquisition of the Kansas centers, as well as the outstanding balance of the amended Revolver as a result of the on-going CHOW process at newly leased facilities.
Income (Loss) from Continuing Operations before Income Taxes; Income (Loss) from Continuing Operations per Common Share
As a result of the above, continuing operations reported income before income taxes of $0.9 million for the six months ended June 30, 2014, as compared to a loss of $6.3 million for the same period in 2013. The provision for income taxes was $0.4 million for the six months ended June 30, 2014, as compared to a benefit for income taxes of $2.6 million for the six months ended June 30, 2013. The basic and diluted income per common share from continuing operations were both $0.07 for the six months ended June 30, 2014, as compared to a loss per common share from continuing operations of $0.67 for the same period in 2013.
Liquidity and Capital Resources

33



Liquidity
Our primary source of liquidity is the net cash flow provided by the operating activities of our centers. We believe that these internally generated cash flows will be adequate to service existing debt obligations, fund required capital expenditures as well as provide cash flows for investing opportunities. In determining priorities for our cash flow, we evaluate alternatives available to us and select the ones that we believe will most benefit us over the long-term. Options for our cash include, but are not limited to, capital improvements, dividends, purchase of additional shares of our common stock, acquisitions, payment of existing debt obligations, preferred stock redemptions as well as initiatives to improve nursing center performance. We review these potential uses and align them to our cash flows with a goal of achieving long-term success.
Net cash used by operating activities of continuing operations totaled $2.2 million in the six months ended June 30, 2014, as compared to $4.6 million in the same period of 2013.
Our cash expenditures related to professional liability claims of continuing operations were $2.2 million and $2.1 million for six months ended June 30, 2014 and 2013, respectively. We will also have on-going cash expenditures related to professional liability claims remaining against our discontinued operations. Although we work diligently to limit the cash required to settle and defend professional liability claims, a significant judgment entered against us in one or more legal actions could have a material adverse impact on our cash flows and could result in our being unable to meet all of our cash needs as they become due.
Investing activities of continuing operations used cash of $1.8 million and $21.8 million in 2014 and 2013, respectively. The decrease is a result of the Kansas asset purchase that occurred in the second quarter of 2013.
Financing activities of continuing operations provided cash of $2.8 million in 2014 as compared to cash provided of $20.0 million in 2013 primarily due to the Company's debt restructuring associated with the Kansas acquisition in the second quarter of 2013, as compared primarily to normal debt repayments and draws on the Company's revolving credit facility in 2014.

Dividends
On August 6, 2014, the Board of Directors declared a quarterly dividend of $0.055 per common share payable to shareholders of record as of September 30, 2014, to be paid on October 14, 2014. While the Board of Directors intends to pay quarterly dividends, the Board will make the determination of the amount of future cash dividends, if any, to be declared and paid based on, among other things, the Company’s financial condition, funds from operations, the level of its capital expenditures and its future business prospects and opportunities.
Redeemable Preferred Stock
At June 30, 2014, we have outstanding 5,000 shares of Series C Redeemable Preferred Stock (“Preferred Stock”) that has a stated value of approximately $4.9 million which pays an annual dividend rate of 7% of its stated value. Dividends on the Preferred Stock are paid quarterly in cash. The Preferred Stock was issued to Omega in 2006 and is not convertible, but has been redeemable at its stated value at Omega’s option since September 30, 2010, and since September 30, 2007, has been redeemable at its stated value at our option. Redemption under our option or Omega’s is subject to certain limitations. We believe we have adequate resources to redeem the Preferred Stock if Omega were to elect to redeem it.
Professional Liability
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. On a per claim basis, coverage for losses in excess of those covered by SHC are maintained through unaffiliated commercial reinsurance carriers. All of the Company's nursing centers in Florida, Tennessee, and West Virginia are now covered under the captive insurance policies along with most of the nursing centers in Alabama, Kentucky, Ohio, and Texas. The insurance coverage provided for these centers under the SHC policy include coverage limits of $500,000 per medical incident with a sublimit per center of $1,000,000 and total annual aggregate policy limits of $5,000,000. All other centers within the Company’s portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. 
As of June 30, 2014, we have recorded total liabilities for reported and settled professional liability claims and estimates for incurred, but unreported claims of $27.7 million. Our calculation of this estimated liability is based on an assumption that the Company will not incur a severely adverse judgment with respect to any asserted claim; however, a significant judgment could

34



be entered against us in one or more of these legal actions, and such a judgment could have a material adverse impact on our financial position and cash flows.
Capital Resources
As of June 30, 2014, we had $61.5 million of outstanding long-term debt and capital lease obligations. The $61.5 million total includes $0.5 million in capital lease obligations, $9.0 million currently outstanding on the revolving credit facility, and $8.0 million in a note payable for the asset purchase of the Rose Terrace nursing center in West Virginia. The balance of the long-term debt is comprised of $43.9 million owed on our mortgage loan.
On May 1, 2013, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated February 28, 2011. The Credit Agreement increases the Company's borrowing capacity to $65,000,000 allocated between a $45,000,000 Mortgage Loan ("Amended Mortgage Loan") and a $20,000,000 Revolver ("Amended Revolver"). Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $1,341,000 and are being amortized over the five-year term of the agreements. Loan acquisition costs of $320,000 associated with the Original Mortgage Loan were written off in conjunction with this restructuring and are recorded in Debt Retirement Costs in the Interim Consolidated Statement of Operations for the six-month period ended June 30, 2013.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of $45.0 million with a five-year maturity through April 30, 2018, and a $20.0 million Amended Revolver through April 30, 2018. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest is based on LIBOR plus 4.5%, which was 4.65% at June 30, 2014, but a portion of the outstanding principal balance under the Amended Mortgage Loan is effectively fixed at 6.87% as a result of the interest rate swap described below. The Amended Mortgage Loan is secured by thirteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.5%, which resulted in an interest rate of 4.65% as of June 30, 2014.
Effective March 31, 2014, the Company entered into the Second Amendment to the Amended and Restated Revolver ("Second Amendment"). The Second Amendment temporarily increased the Amended Revolver capacity from the $20.0 million in the original Amended Revolver to $27.5 million through September 30, 2014, as a result of the increase in receivables related to new facilities that continue to progress in the change in ownership process. The Second Amendment also provided for a permanent increase in the Amended Revolver capacity to $22.5 million beginning October 1, 2014 through the original maturity date of April 30, 2018, to reflect the expansion of the Company's business through new facility acquisitions. Effective July 1, 2014, subsequent to the end of the second quarter, the Company entered into the Third Amendment to the Amended and Restated Revolver ("Third Amendment"). The Third Amendment makes the previously temporary increase to the Amended Revolver capacity from the $20,000,000 in the original Amended Revolver to $27,500,000 as defined in the Second Amendment, a permanent change to the borrowing capacity as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process.
As of June 30, 2014, the Company had $9.0 million borrowings outstanding under the revolving credit facility. The outstanding borrowings on the revolver primarily reflect the Company's approach to accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under this Revolver are 3.00% of the amount outstanding. The Company has eight letters of credit with a total value of $7.7 million outstanding as of June 30, 2014. Considering the balance of eligible accounts receivable, the letter of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $27.5 million, the balance available for borrowing under the revolving credit center is $10.5 million at June 30, 2014.
Effective March 27, 2014, the Company executed its purchase option to acquire all assets associated with the Rose Terrace nursing center in Culloden, West Virginia from Milton Holdings, LLC which was considered a variable interest entity ("VIE") by the Company and consolidated prior to the date of this transaction. See Note 8 to the Interim Consolidated Financial Statements under Item 1 above (the "Financial Statements") for further information on the VIE considerations. In conjunction with the purchase of the assets, the Company entered into an interest-only $8.0 million term loan ("Rose Terrace Note") with a maturity date of March 27, 2015. The structure of the Rose Terrace Note reflected the Company's intent to sell the property and transfer operations to an unrelated third-party operator. Effective July 1, 2014, subsequent to the end of the second quarter, the Company completed the transaction with Rose Terrace Acq., LLC to sell Rose Terrace, a 90-bed skilled nursing facility in Culloden, West Virginia for a sales price of $16.5 million. The Company also agreed to an amendment to the Master Lease with Omega Health Investors, Inc. to terminate the lease only with respect to two other skilled nursing facilities in West Virginia, and concurrently entered into an operations transfer agreement with American Health Care Management, LLC, an affiliate of the purchaser with respect to these two other skilled nursing facilities located in Danville and Ivydale, West Virginia. Upon completion of the transaction, Diversicare no longer operates any skilled nursing centers in the state of West Virginia. In

35



conjunction with the closing of the sale, the Company paid the balance of the $8,000,000 mortgage loan outstanding on the Rose Terrace facility. As such, the Rose Terrace Note is classified as a Current Liability of Discontinued Operations on the Interim Consolidated Balance Sheet.
Our lending agreements contain various financial covenants, the most restrictive of which relate to minimum cash deposits, cash flow and debt service coverage ratios. We are in compliance with all such covenants at June 30, 2014.
Our calculated compliance with financial covenants is presented below:
 
 
Requirement
  
Level at
June 30, 2014
Minimum fixed charge coverage ratio
1.10:1.00
 
1.27:1.00
Minimum adjusted EBITDA
$10.00 million
 
$18.05 million
EBITDAR (mortgaged centers)
$5.875 million
 
$9.683 million
As part of the debt agreements entered into in March 2011, we entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and carries a notional equivalent to half of the outstanding principal on the Amended Mortgage Loan. The interest rate swap agreement requires us to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 6.87% while the bank is obligated to make payments to us based on LIBOR on the same notional amounts. We entered into the interest rate swap agreement to mitigate the variable interest rate risk on our outstanding mortgage borrowings.
Receivables
Our operations could be adversely affected if we experience significant delays in reimbursement from Medicare, Medicaid or other third-party revenue sources. Our future liquidity will continue to be dependent upon the relative amounts of current assets (principally cash, accounts receivable and inventories) and current liabilities (principally accounts payable and accrued expenses). In that regard, accounts receivable can have a significant impact on our liquidity. Continued efforts by governmental and third-party payors to contain or reduce the acceleration of costs by monitoring reimbursement rates, by increasing medical review of bills for services, or by negotiating reduced contract rates, as well as any delay by us in the processing of our invoices, could adversely affect our liquidity and results of operations.
Accounts receivable attributable to patient services of continuing operations totaled $47.5 million at June 30, 2014 compared to $36.6 million at December 31, 2013, representing approximately 45 days and 43 days revenue in accounts receivable, respectively. The increase in accounts receivable is due to increases in payor sources with longer payment cycles, including Managed Care payors, as well as an increase in Medicaid patients undergoing the initial qualification process.
Our accounts receivable included approximately $6.8 million and $5.1 million at June 30, 2014 and December 31, 2013, respectively of unbilled accounts, primarily attributable to newly acquired facilities.  During the change of ownership process, we were required to hold these accounts while waiting for final Medicare and Medicaid approvals.
The allowance for bad debt was $4.6 million at June 30, 2014 as compared to $3.9 million at December 31, 2013. We continually evaluate the adequacy of our bad debt reserves based on patient mix trends, aging of older balances, payment terms and delays with regard to third-party payors, collateral and deposit resources, as well as other factors. We continue to evaluate and implement additional procedures to strengthen our collection efforts and reduce the incidence of uncollectible accounts.
Off-Balance Sheet Arrangements
We have eight letters of credit outstanding with an aggregate value of approximately $7.7 million as of June 30, 2014, the first of which serves as a security deposit for our facility lease with Omega in the amount of $4.6 million. The second letter of credit serves our initial funding of insurance policies with a captive insurance company in the amount of $1.0 million. The balance of the outstanding letters of credit relate to deposits at various leased facilities where the Company opted to issue letters of credit as a deposit in lieu of cash. These letters of credit were issued under our revolving credit facility. Our accounts receivable serve as the collateral for this revolving credit facility.


36



Forward-Looking Statements
The foregoing discussion and analysis provides information deemed by management to be relevant to an assessment and understanding of our consolidated results of operations and financial condition. This discussion and analysis should be read in conjunction with our consolidated financial statements included herein. Certain statements made by or on behalf of us, including those contained in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere, are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those contemplated by the forward-looking statements made herein. In addition to any assumptions and other factors referred to specifically in connection with such statements, other factors, many of which are beyond our ability to control or predict, could cause our actual results to differ materially from the results expressed or implied in any forward-looking statements including, but not limited to, our ability to successfully operate the new nursing centers in Alabama, Kansas, Kentucky, Missouri, Ohio, and Indiana, our ability to increase census at our renovated centers, changes in governmental reimbursement, including the impact of the CMS final rule that has resulted in a reduction in Medicare reimbursement as of October 2012 and our ability to mitigate the impact of the revenue reduction, government regulation, the impact of the recently adopted federal health care reform or any future health care reform, any increases in the cost of borrowing under our credit agreements, our ability to comply with covenants contained in those credit agreements, the outcome of professional liability lawsuits and claims, our ability to control ultimate professional liability costs, the accuracy of our estimate of our anticipated professional liability expense, the impact of future licensing surveys, the outcome of proceedings alleging violations of state or Federal False Claims Acts, laws and regulations governing quality of care or other laws and regulations applicable to our business including laws governing reimbursement from government payors, impacts associated with the implementation of our electronic medical records plan, the costs of investing in our business initiatives and development, our ability to control costs, changes to our valuation of deferred tax assets, changes in occupancy rates in our centers, changing economic and competitive conditions, changes in anticipated revenue and cost growth, changes in the anticipated results of operations, the effect of changes in accounting policies as well as others. Investors also should refer to the risks identified in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as risks identified in “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2013, for a discussion of various risk factors of the Company and that are inherent in the health care industry. Given these risks and uncertainties, we can give no assurances that these forward-looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from anticipated results. These risks and uncertainties also may result in changes to the Company’s business plans and prospects. Such cautionary statements identify important factors that could cause our actual results to materially differ from those projected in forward-looking statements. In addition, we disclaim any intent or obligation to update these forward-looking statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The chief market risk factor affecting our financial condition and operating results is interest rate risk. As of June 30, 2014, we had outstanding borrowings of approximately $60.9 million, $31.0 million of which was subject to variable interest rates. In connection with our May 2013 financing agreement, we entered into an interest rate swap with respect to one half of the Amended Mortgage Loan to mitigate the floating interest rate risk of such borrowing. In the event that interest rates were to change 1%, the impact on future pre-tax cash flows would be approximately $310,000 annually, representing the impact of increased or decreased interest expense on variable rate debt.

ITEM 4. CONTROLS AND PROCEDURES
As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), our management, including our chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of June 30, 2014. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is properly recorded, processed, summarized and reported within the time periods required by the Securities and Exchange Commission’s rules and forms. Management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures that, by their nature, can provide only reasonable assurance regarding management’s control objectives. Management does not expect that its disclosure controls and procedures will prevent all errors and fraud. A control system, irrespective of how well it is designed and operated, can only provide reasonable assurance, and cannot guarantee that it will succeed in its stated objectives.
Based on an evaluation of the effectiveness of the design and operation of disclosure controls and procedures, our chief executive officer and chief financial officer concluded that, as of June 30, 2014, our disclosure controls and procedures were effective in reaching a reasonable level of assurance that information required to be disclosed by us in the reports that we file or

37



submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission’s rules and forms.

PART II — OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
The provision of health care services entails an inherent risk of liability. Participants in the health care industry are subject to lawsuits alleging malpractice, product liability, or related legal theories, many of which involve large claims and significant defense costs. Like many other companies engaged in the long-term care profession in the United States, we have numerous pending liability claims, disputes and legal actions for professional liability and other related issues. It is expected that we will continue to be subject to such suits as a result of the nature of our business. Further, as with all health care providers, we are periodically subject to regulatory actions seeking fines and penalties for alleged violations of health care laws and are potentially subject to the increased scrutiny of regulators for issues related to compliance with health care reimbursement and fraud and abuse laws and with respect to the quality of care provided to residents of our facility. Like other health care providers, in the ordinary course of our business, we are also subject to claims made by employees and other disputes and litigation arising from the conduct of our business.
As of June 30, 2014, we are engaged in 53 professional liability lawsuits. Nine lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The ultimate results of any of our professional liability claims and disputes cannot be predicted with certainty. A significant judgment entered against us in one or more of these legal actions could have a material adverse impact on our financial position and cash flows.
In November 2012, a purported stockholder class action complaint was filed in the Chancery Court for Williamson County, Tennessee (21st Judicial District) against the Company's Board of Directors. This action alleges that the Board of Directors breached its fiduciary duties to stockholders related to its response to certain expressions of interest in a potential strategic transaction from Covington Investments, LLC (“Covington”). The complaint asserts that the Board failed to negotiate or otherwise appropriately consider Covington's proposals. Plaintiff has filed a motion seeking to certify the action as a class action, which is not currently set for hearing. On May 23, 2014, the plaintiff and defendants entered into a memorandum of understanding outlining the terms of a settlement subject to the execution of definitive documentation and court approval. The agreement provides that the Company will adopt and maintain certain corporate governance procedures for a period of at least three years.
In June 2012, a collective action complaint was filed in the U.S. District Court for the U.S. District Court for the Western District of Arkansas against us and certain of our subsidiaries.  The complaint alleges that the defendants violated the Fair Labor Standards Act (FLSA) and seeks unpaid overtime wages as well as liquidated damages.  The Court conditionally certified a nationwide class of all of the Company's hourly employees.  The Company will defend the lawsuit vigorously.
In January 2009, a purported class action complaint was filed in the Circuit Court of Garland County, Arkansas against the Company and certain of its subsidiaries and Garland Nursing & Rehabilitation Center (the “Facility”). The complaint alleges that the defendants breached their statutory and contractual obligations to the patients of the Facility over the five-year period prior to the filing of the complaints. The lawsuit remains in its early stages and has not yet been certified by the court as a class action. The Company intends to defend the lawsuit vigorously.
We cannot currently predict with certainty the ultimate impact of any of the above cases on our financial condition, cash flows or results of operations. Our reserve for professional liability expenses does not include any amounts for the collective actions, the purported class action against the Facility or the lawsuit filed against our directors. An unfavorable outcome in any of these lawsuits or any of our professional liability actions, any regulatory action, any investigation or lawsuit alleging violations of fraud and abuse laws or of elderly abuse laws or any state or Federal False Claims Act case could subject us to fines, penalties and damages, including exclusion from the Medicare or Medicaid programs, and could have a material adverse impact on our financial condition, cash flows or results of operations.
ITEM 5. OTHER INFORMATION
On May 7, 2014, the Company entered into a fourth amendment (the “Fourth Amendment”) to the Amended and Restated Rights Agreement, dated as of December 7, 1998, as amended March 19, 2005, August 15, 2008, and August 14, 2009 between the Company (formerly Advocat Inc.) and ComputerShare Trust Company, N.A., as successor to SunTrust Bank, as Rights Agent. In the Fourth Amendment, the Company changed the Expiration Date of the preferred share purchase rights (the “Rights”) under the Rights Agreement from August 2, 2018 to May 15, 2014. As a result of the Fourth Amendment, the Rights Agreement terminated by its terms and be of no further force and effect and the Rights expired at the close of business on

38



May 15, 2014. Shareholders do not have to take any action as a result of this termination and this action had no effect on the Company’s common stock.

ITEM 6. EXHIBITS
The exhibits filed as part of this report on Form 10-Q are listed in the Exhibit Index immediately following the signature page.

39



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
 
Diversicare Healthcare Services, Inc.
 
 
 
August 7, 2014
 
 
 
 
 
 
 
By:
 
/s/ Kelly J. Gill
 
 
 
Kelly J. Gill
 
 
 
President and Chief Executive Officer, Principal Executive Officer and
 
 
 
An Officer Duly Authorized to Sign on Behalf of the Registrant
 
 
 
 
By:
 
/s/ James R. McKnight, Jr.
 
 
 
James R. McKnight, Jr.
 
 
 
Executive Vice President and Chief Financial Officer and
 
 
 
An Officer Duly Authorized to Sign on Behalf of the Registrant

40



 
 
 
Exhibit
Number
  
Description of Exhibits
3.1

  
Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement No. 33-76150 on Form S-1).
 
 
3.2

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.5 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2006).
 
 
3.3

  
Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement No. 33-76150 on Form S-1).
 
 
3.4

  
Bylaw Amendment adopted November 5, 2007 (incorporated by reference to Exhibit 3.4 to the Company’s annual report on Form 10-K for the year ended December 31, 2007).
 
 
3.5

  
Amendment to Certificate of Incorporation dated March 23, 1995 (incorporated by reference to Exhibit A of Exhibit 1 to the Company’s Form 8-A filed March 30, 1995).
 
 
3.6

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.4 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2001).
 
 
4.1

  
Form of Common Stock Certificate (incorporated by reference to Exhibit 4 to the Company’s Registration Statement No. 33-76150 on Form S-1).
 
 
4.2

  
Amended and Restated Rights Agreement dated as of December 7, 1998 (incorporated by reference to Exhibit 1 to Form 8-A/A filed December 7, 1998).
 
 
4.3

  
Amendment No. 1 to the Amended and Restated Rights Agreement, dated March 19, 2005, by and between the Company and SunTrust Bank, as Rights Agent (incorporated by reference to Exhibit 2 to Form 8-A/A filed on March 24, 2005).
 
 
4.4

  
Second Amendment to the Amended and Restated Rights Agreement, dated August 15, 2008, by and between the Company and ComputerShare Trust Company, N.A., as successor to SunTrust Bank (incorporated by reference to Exhibit 3 to Form 8-A/A filed on August 18, 2008).
 
 
4.5

  
Third Amendment to Amended and Restated Rights Agreement, dated August 14, 2009, between the Company and Computershare Trust Company, N.A, as successor to SunTrust Bank, (incorporated by reference to Exhibit 4 to the Company’s Registration Statement on Form 8-A/A filed on August 14, 2009).
 
 
 
4.6

  
Fourth Amendment to Amended and Restated Rights Agreement, dated May 7, 2014, between the Company and Computershare Trust Company, N.A, as successor to SunTrust Bank, as Rights Agent (incorporated by reference to Exhibit 5 to the Company's Registration Statement on Form 8-A/A filed on May 8, 2014).
 
 
 
10.1

 
Third Amendment to Amended and Restated Term Loan And Security Agreement dated as of July 1, 2014, by and among the Company and a syndicate of financial institutions and banks, including The PrivateBank as the Administering Agent.
 
 
 
10.2

 
Third Amendment and Consent to Amended And Restated Revolving Loan and Security Agreement dated as of July 1, 2014 by and among the Company and a syndicate of financial institutions and banks, including The PrivateBank as the Administering Agent.
 
 
 
10.3

 
Fifteenth Amendment to Consolidated Amended and Restated Master Lease dated as of June 30, 2014 by and between the Company and Sterling Acquisition Corp.
 
 
 
10.4

 
Asset Purchase Agreement dated April 3, 2014 by and between Diversicare Rose Terrace, LLC, and Rose Terrace Acq., LLC. (incorporated by reference to exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2014).
 
 
 
31.1

  
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
 
 
31.2

  
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
 
 
32

  
Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).
 
 
101.INS

  
XBRL Instance Document
 
 
101.SCH

  
XBRL Taxonomy Extension Schema Document
 
 

41



101.CAL

  
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
101.LAB

  
XBRL Taxonomy Extension Labels Linkbase Document
 
 
101.PRE

  
XBRL Taxonomy Extension Presentation Linkbase Document
 
 


42
EX-10.1 2 ex101-thirdamendmenttoamen.htm EXHIBIT EX10.1 - Third Amendment to Amended and Restated Term Loan

THIRD AMENDMENT TO
AMENDED AND RESTATED TERM LOAN AND SECURITY AGREEMENT
THIS THIRD AMENDMENT TO AMENDED AND RESTATED TERM LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of July 1, 2014, by and among THE PRIVATEBANK AND TRUST COMPANY, an Illinois banking corporation (“Administrative Agent”) in its capacity as administrative agent for the Lenders (as defined below), the Lenders and DIVERSICARE AFTON OAKS, LLC, DIVERSICARE BRIARCLIFF, LLC, DIVERSICARE CHISOLM, LLC, DIVERSICARE HARTFORD, LLC, DIVERSICARE OF CHANUTE, LLC, DIVERSICARE OF COUNCIL GROVE, LLC, DIVERSICARE OF HAYSVILLE, LLC, DIVERSICARE OF SEDGWICK, LLC, DIVERSICARE OF LARNED, LLC, DIVERSICARE WINDSOR HOUSE, LLC, DIVERSICARE HILLCREST, LLC, DIVERSICARE LAMPASAS, LLC, DIVERSICARE HOLDING COMPANY, LLC, DIVERSICARE KANSAS, LLC, and DIVERSICARE YORKTOWN, LLC, each a Delaware limited liability company (individually and collectively, (“Borrower”).
WHEREAS, Borrower, Administrative Agent, and the financial institutions thereto (the “Lenders”) are parties to that certain Amended and Restated Term Loan and Security Agreement dated as of April 30, 2013, as amended by that certain First Amendment to Amended and Restated Term Loan and Security Agreement dated as of November 1, 2013 and that certain Second Amendment to Amended and Restated Term Loan and Security Agreement dated as of March 31, 2014 (as the same may be further amended or modified from time to time, the “Loan Agreement”); and
WHEREAS, Borrower, Administrative Agent and Lenders desire to amend the Loan Agreement as provided in and subject to the terms and conditions of this Amendment.
NOW, THEREFORE, in consideration of the premises and mutual agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto (intending to be legally bound) hereby agree as follows:
1.Defined Terms. Unless otherwise defined herein, capitalized terms used herein shall have the meanings assigned to such terms in the Loan Agreement.
2.    Amendments. Subject to the terms and conditions contained herein, Borrower, Administrative Agent and Lenders hereby amend the Loan Agreement as follows:
(a)    The definition of “Affiliated Revolving Borrowers” in Section 1.1 of the Loan Agreement is hereby amended and restated in its entirety as follows:




Affiliated Revolving Borrowers” means each of the entities identified on Schedule 1 attached hereto.
3.    Continuing Effect; No Waiver. Except as expressly set forth in Section 2 of this Amendment, nothing in this Amendment shall constitute a modification or alteration of the terms, conditions or covenants of the Loan Agreement or any other Financing Agreement, or a waiver of any other terms or provisions thereof, and the Loan Agreement and the other Financing Agreements shall remain unchanged and shall continue in full force and effect, in each case as modified hereby. Administrative Agent’s and Lender’s failure, at any time or times hereafter, to require strict performance by Borrower of any provision or term of the Loan Agreement, this Amendment or the Financing Agreements shall not waive, affect or diminish any right of Administrative Agent or any Lender hereafter to demand strict compliance and performance herewith or therewith. Any suspension or waiver by Administrative Agent and a Lender of a breach of this Amendment or any Event of Default under the Loan Agreement shall not, except as expressly set forth herein, suspend, waive or affect any other breach of this Amendment or any Event of Default under the Loan Agreement, whether the same is prior or subsequent thereto and whether of the same or of a different kind or character. None of the undertakings, agreements, warranties, covenants and representations of Borrower contained in this Amendment, shall be deemed to have been suspended or waived by Administrative Agent and Lenders unless such suspension or waiver is (i) in writing and signed by Administrative Agent and Lenders and (ii) delivered to Borrower. In no event shall Administrative Agent’s and Lenders’ execution and delivery of this Amendment establish a course of dealing among Administrative Agent, Lenders, Borrower or any other obligor, or in any other way obligate Administrative Agent and Lenders to hereafter provide any amendments or waivers with respect to the Loan Agreement. The terms and provisions of this Amendment shall be limited precisely as written and shall not be deemed (i) to be a consent to an amendment or a modification of any other term or condition of the Loan Agreement or of any of the Financing Agreements (except as expressly provided herein); or (ii) to prejudice any right or remedy which Administrative Agent and Lenders may now have under or in connection with the Loan Agreement or any of the Financing Agreements. In the event any ambiguity or question of intent or interpretation arises, this Amendment shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Amendment.
4.    Reaffirmation and Confirmation. Borrower hereby ratifies, affirms, acknowledges and agrees that the Loan Agreement and the other Financing Agreements represent the valid, enforceable and collectible obligations of Borrower, and further acknowledges that there are no existing claims, defenses, personal or otherwise, or rights of setoff whatsoever with respect to the Loan Agreement or any other Financing Agreement. Borrower hereby agrees that this Amendment in no way acts as a release or relinquishment of the Liens and rights securing payments of the Liabilities. The Liens and rights securing payment of the Liabilities are hereby ratified and confirmed

2



by Borrower in all respects. Upon the effectiveness of this Amendment, each reference in the Loan Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the Loan Agreement, as amended by this Amendment.
5.    Representations and Warranties. In order to induce Administrative Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Administrative Agent and Lenders (which representations and warranties shall survive the execution and delivery hereof), both before and after giving effect to this Amendment that:
(a)    This Amendment has been duly authorized, validly executed and delivered by one or more Duly Authorized Officers of Borrower, and each of this Amendment, the Loan Agreement as amended hereby, and each of the other Financing Agreements to which Borrower is a party, constitutes the legal, valid and binding obligations of Borrower, enforceable against Borrower in accordance with their respective terms, subject to bankruptcy, insolvency or other similar laws affecting the enforcement of creditor’s rights and remedies generally;
(b)    The execution and delivery of this Amendment and performance by Borrower under this Amendment, the Loan Agreement and each of the other Financing Agreements to which Borrower is a party do not and will not require the consent or approval of any regulatory authority or governmental authority or agency having jurisdiction over Borrower that has not already been obtained, nor be in contravention of or in conflict with the organizational documents of Borrower or any provision of any statute, judgment, order, indenture, instrument, agreement, or undertaking, to which Borrower is party or by which Borrower’s respective assets or properties are bound;
(c)    Each of the representations and warranties of each Borrower contained in the Loan Agreement and the other Financing Agreements to which Borrower is a party are true and correct in all material respects (without duplication of any materiality carve out already provided therein) on and as of the date hereof, in each case as if made on and as of such date, other than representations and warranties that expressly relate solely to an earlier date (in which case such representations and warranties were true and correct on and as of such earlier date); and
(d)    No Default or Event of Default will result after giving effect to this Amendment, and no event has occurred that has had or could reasonably be expected to have a Material Adverse Effect after giving effect to this Amendment.
6.    Conditions to Effectiveness of Consent. This Amendment shall become effective as of the date first written above upon the satisfaction of the following conditions precedent:
(a)    Each party hereto shall have executed and delivered this Amendment to Administrative Agent;

3



(b)    Borrower shall have delivered (or caused its Affiliates to deliver) to Administrative Agent the fully executed First Amendment and Consent to Amended and Restated Revolving Loan and Security Agreement contemplated to be delivered in connection with this Amendment; and
(c)    Borrower shall have delivered to Administrative Agent resolutions of the Borrower’s governing body authorizing the execution and delivery of this Amendment.
7.    Release.
(a)    In consideration of, among other things, the consent and amendments provided for herein, and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, Borrower (on behalf of themselves and their respective subsidiaries, Affiliates, successors and assigns), and, to the extent permitted by applicable law, and the same is claimed by right of, through or under the above, for their past, present and future employees, directors, members, managers, partners, agents, representatives, officers, directors, and equity holders (all collectively, with Borrower, the “Releasing Parties”), do hereby unconditionally, irrevocably, fully, and forever remise, satisfy, acquit, release and discharge Administrative Agent and Lenders and each of Administrative Agent’s and Lender’s past, present and future officers, directors, agents, employees, attorneys, parent, shareholders, successors, assigns, subsidiaries and Affiliates and all other persons and entities to whom Administrative Agent or Lenders would be liable if such persons or entities were found in any way to be liable to any of the Releasing Parties (collectively, the “Lender Parties”), of and from any and all manner of action and actions, cause and causes of action, claims, cross-claims, charges, demands, counterclaims, suits, proceedings, disputes, debts, dues, sums of money, accounts, bonds, covenants, contracts, controversies, damages, judgments, liabilities, damages, costs, expenses, executions, liens, claims of liens, claims of costs, penalties, attorneys’ fees, or any other compensation, recovery or relief on account of any liability, obligation, demand, proceedings or cause of action of whatever nature, whether in law, equity or otherwise (including, without limitation, those arising under 11 U.S.C. §§ 541-550 and interest or other carrying costs, penalties, legal, accounting and other professional fees and expenses, and incidental, consequential and punitive damages payable to third parties), whether known or unknown, fixed or contingent, joint and/or several, secured or unsecured, due or not due, primary or secondary, liquidated or unliquidated, contractual or tortious, direct, indirect, or derivative, asserted or unasserted, foreseen or unforeseen, suspected or unsuspected, now existing, heretofore existing or which may have heretofore accrued against any or all of Lender Parties, whether held in a personal or representative capacity, that the Releasing Parties (or any of them) have or may have against the Lender Parties or any of them (whether directly or indirectly) and which are based on any act, fact, event, action or omission or any other matter, condition, cause or thing occurring at or from any time prior to and including the date hereof in any way, directly or indirectly arising out of, connected with or relating to this Amendment, the Loan Agreement or any other Financing

4



Agreement and the transactions contemplated hereby and thereby, the Collateral or the Liabilities, and all other agreements, certificates, instruments and other documents and statements (whether written or oral) related to any of the foregoing, other than any applicable good faith claim as to which a final determination is made in a judicial proceeding (in which Administrative Agent and any of the Released Parties have had an opportunity to be heard) which determination includes a specific finding that Administrative Agent acted in a grossly negligent manner or with actual willful misconduct or illegal activity. Borrower acknowledges that Administrative Agent and Lenders are specifically relying upon the representations, warranties and agreements contained herein and that such representations, warranties and agreements constitute a material inducement to Administrative Agent and Lenders in entering into this Amendment.
(b)    Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.
(c)    To the furthest extent permitted by law, Borrower hereby knowingly, voluntarily, intentionally and expressly waives and relinquishes any and all rights and benefits that it respectively may have as against Lender Parties under any law, rule or regulation of any jurisdiction that would or could have the effect of limiting the extent to which a general release extends to claims which a Lender Party or Releasing Party does not know or suspect to exist as of the date hereof. Borrower hereby acknowledges that the waiver set forth in the prior sentence was separately bargained for and that such waiver is an essential term and condition of this Amendment.
8.    Miscellaneous.
(a)    Costs and Expenses. Borrower, jointly and severally, agrees to pay on demand all costs and expenses of Administrative Agent (including, without limitation, the reasonable fees and expenses of outside counsel for Administrative Agent) in connection with the preparation, negotiation, execution, delivery and administration of this Amendment and all other instruments or documents provided for herein or delivered or to be delivered hereunder or in connection herewith. All obligations provided herein shall survive any termination of this Amendment and the Loan Agreement as amended hereby.
(b)    Financing Agreement. This Amendment shall constitute a Financing Agreement.
(c)    Titles. Titles and section headings herein shall be without substantive meaning and are provided solely for the convenience of the parties.

5



(d)    Severability; Etc. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Amendment shall be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Amendment. The parties hereto have participated jointly in the negotiation and drafting of this Amendment. In the event an ambiguity or question of intent or interpretation arises, this Amendment shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Amendment.
(e)    Successors and Assigns. This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns; provided, however, no Borrower may assign any of its respective rights or obligations under this Amendment without the prior written consent of Administrative Agent.
9.    Further Assurances. Borrower shall, at its own cost and expense, cause to be promptly and duly taken, executed, acknowledged and delivered all such further acts, certificates, instruments, reaffirmations, amendments, documents and assurances as may from time to time be necessary or as Administrative Agent may from time to time reasonably request in order to more fully carry out the intent and purposes of this Amendment and the other documents entered into in connection herewith.
10.    Governing Law. This Amendment shall be a contract made under and governed by, and construed and enforced in accordance with, the internal laws of the State of Illinois without regard to conflicts of law principles.
11.    Counterparts; Fax Signatures. This Amendment may be executed in any number of counterparts, and by the parties hereto on the same or separate counterparts, and each such counterpart, when executed and delivered, shall be deemed to be an original, but all such counterparts shall together constitute but one and the same Consent. A signature hereto sent or delivered by facsimile or other electronic transmission shall be as legally valid, effective and enforceable as a signed original for all purposes.
[Signature pages follow]


6



IN WITNESS WHEREOF, the parties hereto have duly executed this Third Amendment to Amended and Restated Term Loan and Security Agreement as of the day and year first above written.
BORROWER:
DIVERSICARE AFTON OAKS, LLC
DIVERSICARE BRIARCLIFF, LLC
DIVERSICARE CHISOLM, LLC
DIVERSICARE HARTFORD, LLC
BY:
DIVERSICARE LEASING CORP., its sole member
 
By:
/s/James R. McKnight, Jr.
 
Name: James R. McKnight, Jr.
 
Its: Executive Vice President &
Chief Financial Officer
DIVERSICARE OF CHANUTE, LLC
DIVERSICARE OF COUNCIL GROVE, LLC
DIVERSICARE OF HAYSVILLE, LLC
DIVERSICARE OF SEDGWICK, LLC
DIVERSICARE OF LARNED, LLC
BY:

Diversicare Kansas, LLC,
its sole member

 
By:
/s/James R. McKnight, Jr.
 
Name: James R. McKnight, Jr.
 
Its: Executive Vice President &
Chief Financial Officer
DIVERSICARE WINDSOR HOUSE, LLC
DIVERSICARE HILLCREST, LLC
DIVERSICARE LAMPASAS, LLC
DIVERSICARE YORKTOWN, LLC

Signature Page to Third Amendment to
Amended and Restated Term Loan and Security Agreement


BY:
DIVERSICARE LEASING CORP., its sole member
 
By:
/s/James R. McKnight, Jr.
 
Name: James R. McKnight, Jr.
 
Its: Executive Vice President &
Chief Financial Officer


DIVERSICARE HOLDING COMPANY, LLC

By:/s/James R. McKnight, Jr.        
Name: James R. McKnight, Jr.
Its:     Executive Vice President &
Chief Financial Officer


DIVERSICARE KANSAS, LLC

By:/s/James R. McKnight, Jr.        
Name: James R. McKnight, Jr.
Its:     Executive Vice President &
     Chief Financial Officer
                
                
                
                

Signature Page to Third Amendment to
Amended and Restated Term Loan and Security Agreement


ADMINISTRATIVE AGENT:

THE PRIVATEBANK AND TRUST COMPANY, in its capacity as administrative agent

By:/s/Adam D. Panos                
Name: Adam D. Panos
Its: Managing Director


Signature Page to Third Amendment to
Amended and Restated Term Loan and Security Agreement


LENDER:

THE PRIVATEBANK AND TRUST COMPANY

By:/s/Adam D. Panos                
Name: Adam D. Panos
Its: Managing Director


Signature Page to Third Amendment to
Amended and Restated Term Loan and Security Agreement


LENDER:

BANKERS TRUST COMPANY

By:/s/Jon M. Doll                
Name: Jon M. Doll
Its: Vice President


Signature Page to Third Amendment to
Amended and Restated Term Loan and Security Agreement



LENDER:

BOKF, NA D/B/A BANK OF OKLAHOMA

By:/s/Ryan Kirk                
Name: Ryan Kirk
Its: Vice President



Signature Page to Third Amendment to
Amended and Restated Term Loan and Security Agreement


LENDER:

CIT FINANCE LLC

By:/s/Barbara Perich                
Name: Barbara Perich
Its: Director


SCHEDULE 1
(AFFILIATED REVOLVING BORROWERS)
Name
State of Incorporation or Formation
Principal Place of Business and Chief Executive Office
Advocat Ancillary Services, Inc.
Tennessee corporation
1621 Galleria Blvd., Brentwood, TN 37027
Advocat Finance, Inc.
Delaware corporation
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Management Services Co.
Tennessee corporation
1621 Galleria Blvd., Brentwood, TN 37027
Advocat Distribution Services, Inc.
Tennessee corporation
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Assisted Living Services, Inc.
Tennessee corporation
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Assisted Living Services NC, LLC
Tennessee limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Leasing Corp.
Tennessee corporation
1621 Galleria Blvd., Brentwood, TN 37027
Sterling Health Care Management, Inc.
Kentucky corporation
1621 Galleria Blvd., Brentwood, TN 37027
Senior Care Cedar Hills, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Senior Care Golfcrest, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Senior Care Golfview, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Senior Care Florida Leasing, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Senior Care Southern Pines, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Afton Oaks, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Assisted Living Services NC I, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Assisted Living Services NC II, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Briarcliff, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Chisolm, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Hartford, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Hillcrest, LLC,
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Lampasas, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Pinedale, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Windsor House, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Yorktown, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Ballinger, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Doctors, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Estates, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Humble, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Katy, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Normandy Terrace, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Texas I, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Treemont, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Rose Terrace, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Paris, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Therapy Services, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Chanute, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Council Grove, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Haysville, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Sedgwick, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Larned, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Highlands, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Holding Company, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Kansas, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare Leasing Company II, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Seneca Place, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Bradford Place, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Providence, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Siena Woods, LLC
Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of St. Theresa, LLC

Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Big Springs, LLC

Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Nicholasville, LLC

Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Avon, LLC

Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Mansfield, LLC

Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Riverside, LLC

Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of Chateau, LLC

Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027
Diversicare of St. Joseph, LLC

Delaware limited liability company
1621 Galleria Blvd., Brentwood, TN 37027

CONSENT AND REAFFIRMATION
The undersigned (“Guarantor”) hereby (i) confirms and agrees with The PrivateBank and Trust Company, an Illinois banking corporation in its capacity as administrative agent (together with its successors and assigns, “Administrative Agent”) that Guarantor’s Amended and Restated Guaranty dated as of April 30, 2013 made in favor of Administrative Agent (as amended or modified, “Guaranty”), remains in full force and effect and is hereby ratified and confirmed in all respects, including with regard to the Amended and Restated Term Loan and Security Agreement dated as of April 30, 2013, as amended by that certain First Amendment to Amended and Restated Term Loan and Security Agreement dated as of November 1, 2013, and that certain Second Amendment to Amended and Restated Term Loan and Security Agreement dated as of March 31, 2014, and as further amended by the foregoing Third Amendment to Amended and Restated Term Loan and Security Agreement (“Amendment”), and each reference to the term “Borrower” in the Guaranty shall also include New Borrower and each reference to the “Loan Agreement” shall refer to the Loan Agreement as amended by the Amendment; (ii) represents and warrants to Administrative Agent, which representations and warranties shall survive the execution and delivery hereof, that Guarantor’s representations and warranties contained in the Guaranty are true and correct as of the date hereof, with the same effect as though made on the date hereof, except to the extent that such representations expressly related solely to an earlier date, in which case such representations were true and correct on and as of such earlier date (and except for the representations in Section 10(b) thereof which were true and correct on and as of the date when made); (iii) agrees and acknowledges that such ratification and confirmation is not a condition to the continued effectiveness of the Amendment or the Guaranty; and (iv) agrees that neither such ratification and confirmation, nor Administrative Agent’s solicitation of such ratification and confirmation, constitutes a course of dealing giving rise to any obligation or condition requiring a similar or any other ratification or confirmation from the undersigned with respect to subsequent amendments or modifications, if any, to the Loan Agreement, as amended by the Amendment or any other Financing Agreement (as defined in the Loan Agreement, as amended by the Amendment). The execution, delivery and effectiveness of this instrument shall not operate as a waiver of any right, power or remedy of Administrative Agent under or pursuant to the Guaranty. Guarantor acknowledges and agrees that Guarantor has received and reviewed a fully-executed copy of the Amendment (and any other instrument, document or agreement executed or delivered in connection therewith) and understands the contents thereof. A signature hereto sent or delivered by facsimile or other electronic transmission shall be as legally binding and enforceable as a signed original for all purposes. This instrument shall be governed by and construed and enforced in accordance with the internal laws of the State of Illinois, without regard to conflict of law principles.

Dated: July 1, 2014
DIVERSICARE HEALTHCARE SERVICES, INC. (F/K/A ADVOCAT INC.)

By:/s/Kelly J. Gill            
Name:    Kelly J. Gill
Its:    President and Chief Executive Officer


Signature Page to Third Amendment to
Amended and Restated Term Loan and Security Agreement
EX-10.2 3 ex102-conformedthirdamendm.htm EXHIBIT EX 10.2 - ConformedThirdAmendmenttoARRLSAdocx


THIRD AMENDMENT AND CONSENT TO
AMENDED AND RESTATED REVOLVING LOAN AND SECURITY AGREEMENT


THIS THIRD AMENDMENT AND CONSENT TO AMENDED AND RESTATED REVOLVING LOAN AND SECURITY AGREEMENT (this “Amendment”) dated as of July 1, 2014 is by and among THE PRIVATEBANK AND TRUST COMPANY, an Illinois banking corporation (together with its successors and assigns, “Administrative Agent”) in its capacity as administrative agent for the Lenders (as defined below), the Lenders, DIVERSICARE MANAGEMENT SERVICES CO., a Tennessee corporation, and certain of its affiliates parties hereto identified on the signature pages as “Original Borrower” (individually and collectively, “Original Borrower”), and DIVERSICARE OF NICHOLASVILLE, LLC, DIVERSICARE OF RIVERSIDE, LLC, DIVERSICARE OF CHATEAU, LLC, DIVERSICARE OF ST. JOSEPH, LLC, DIVERSICARE OF AVON, LLC, and DIVERSICARE OF MANSFIELD, LLC, each a Delaware limited liability company (individually and collectively, “New Borrower”). New Borrower and Original Borrower are hereinafter referred to individually and collectively as, “Borrower”.
RECITALS:
WHEREAS, Original Borrower, Administrative Agent, and the financial institutions signatories thereto (the “Lenders”) are parties to that certain Amended and Restated Revolving Loan and Security Agreement dated as of April 30, 2013, as amended by that certain First Amendment and Consent to Amended and Restated Revolving Loan and Security Agreement dated as of November 1, 2013, and that certain Second Amendment and Consent to Amended and Restated Revolving Loan and Security Agreement dated as of March 31, 2014 (as the same may be further amended or modified from time to time, the “Loan Agreement”); all capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Loan Agreement; and
WHEREAS, Borrower, Administrative Agent and Lenders desire to amend the Loan Agreement as provided in and subject to the terms and conditions of this Amendment.
NOW, THEREFORE, for and in consideration of the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto (intending to be legally bound) hereby agree as follows:
1.Consents. Subject to the satisfaction of the conditions set forth in Section 7 below and in reliance upon the representations and warranties set forth in Section 6 below, Administrative Agent and the Lenders (as the Required Lenders pursuant to the Loan Agreement) hereby consent to each of the following:
(a) the formation by Diversicare Leasing Company II, LLC (“DLC II”), of New Borrower, each a wholly-owned subsidiary of DLC II, for the purpose of entering into the leases identified on Exhibit A attached hereto and made a part hereof (“Exhibit A”); and
(b) the entering into by Diversicare of Providence, LLC, which is the current lessee and operator of the Providence facility (“Providence”), of that certain Indiana Inter-Governmental Transfer program (the “IGT Arrangement”) with an Indiana county hospital (the “Indiana Hospital”) to be designated by Providence (subject to the approval of the Administrative Agent, which approval will not be unreasonably withheld), with respect to such facility’s Medicaid reimbursement. In connection with the IGT Arrangement, Providence will enter into a sublease agreement with the Indiana Hospital and the Indiana Hospital will become the new licensed operator of the Providence facility and the owner of the Accounts generated therefrom. Diversicare Management Services Co. will enter into a new management agreement with Indiana Hospital to operate the Providence facility on behalf of Indiana Hospital’s behalf and receive a management fee.
2.    Joinder and Assumption. From and after the date hereof, New Borrower hereby absolutely and unconditionally (i) joins as and becomes a party to the Loan Agreement as a Borrower thereunder and to each Financing Agreement to which Original Borrower is a party, (ii) assumes, as a joint and several obligor thereunder, all of the obligations, liabilities and indemnities of a Borrower under the Loan Agreement and all other Financing Agreements, (iii) covenants and agrees to be bound by and adhere to all of the terms, covenants, waivers, releases, agreements and conditions of or respecting a Borrower with respect to the Loan Agreement and the other Financing Agreements and all of the representations and warranties contained in the Loan Agreement and the other Financing Agreements with respect to New Borrower, and (iv) collaterally assigns and transfers to Administrative Agent (for the benefit of Lenders and itself) and hereby grants to Administrative Agent (for the benefit of Lenders and itself) a continuing first-priority security interest in all of New Borrower’s now owned and existing and hereafter acquired and arising Collateral, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all of the Liabilities, subject to any applicable Intercreditor Agreements. New Borrower hereby authorizes Administrative Agent to file at any time uniform commercial code financing statements in such jurisdictions and offices as Administrative Agent deems necessary in connection with the perfection of a security interest in all of New Borrower’s now owned or hereafter arising or acquired Collateral, including, without limitation, Accounts and Deposit Accounts of New Borrower, and all proceeds and products thereof. From and after the date hereof, any reference to the term “Borrower” in the Loan Agreement and the Financing Agreements shall also include New Borrower.
3.    Supplementation of Certain Disclosure Schedules. In connection with the joinder of New Borrower to the Loan Agreement, Schedule 1 (Borrowers), Schedule 1.1(a) (Facilities), Schedule 7.8 (Names), Schedule 7.12 (Organizational Chart), Schedule 7.33 (Capitalization) and Schedule 7.36 (Commercial Leases) of the Loan Agreement shall be supplemented from and after the date of this Amendment as set forth on the applicable and respective schedules attached hereto and made a part hereof so that such schedules shall reflect the matters intended to be shown thereon as of the date of this Amendment, including the termination of the Omega Master Lease Agreement with respect to the Boone Health Care Center and Laurel Nursing & Rehab Center Facilities in West Virginia and the sale of the Rose Terrace Facility occurring contemporaneously herewith.
4.    Amendments to Loan Agreement. Subject to the terms and conditions contained herein, Borrower, Administrative Agent and Lenders hereby amend the Loan Agreement as follows:
(a)    The following definitions shall be inserted in correct alphabetical order into Section 1.1 of the Loan Agreement:
(i)    Aviv Third Amendment Intercreditor Agreements” means each Subordination and Intercreditor Agreement in favor of Administrative Agent identified on Exhibit B attached hereto and made a part hereof (as amended or modified from time to time, collectively, the “Aviv Third Amendment Intercreditor Agreements”).
(ii)    Aviv Third Amendment Lease Documents” means each real estate lease identified on Exhibit A attached hereto and made a part hereof for the Nicholasville Facility, the St. Joseph Facilities, the Avon Facility and the Mansfield Facility identified therein, together with the security agreements, documents, instruments and agreements executed in connection therewith, in each case as the same may be amended or modified in conformity with Section 9.16 of the Loan Agreement (collectively, the “Aviv Third Amendment Lease Documents”).
(iii)    Aviv Third Amendment Lessors” means Nicholasville Property, L.L.C., St. Joseph Missouri Property, L.L.C., Avon Ohio, L.L.C. and Mansfield Aviv, L.L.C., each a Delaware limited liability company and the Lessors under their respective Aviv Third Amendment Lease Documents.
(b)    The definition of “Financing Agreements” in Section 1.1 of the Loan Agreement shall hereafter be deemed to also include this Amendment and each of the documents identified in Sections 7(c), (d), (e), and (n) in this Amendment.
(c)    The definition of “Maximum Revolving Facility” in Section 1.1 of the Loan Agreement is hereby amended and restated in its entirety as follows:
Maximum Revolving Facility” means an amount equal to Twenty-Seven Million Five Hundred Thousand and No/100 Dollars ($27,500,000.00).
(d)    The definition of “Intercreditor Agreements” in Section 1.1 of the Loan Agreement is hereby modified by also inserting a reference to the Aviv Third Amendment Intercreditor Agreements.
(e)    The definition of “Restricted Agreements” in Section 1.1 of the Loan Agreement shall hereafter be deemed to also include the Aviv Third Amendment Lease Documents.
(f)    The definition of “Revolving Loan Commitment” in Section 1.1 of the Loan Agreement is hereby amended and restated in its entirety as follows:
Revolving Loan Commitment” means, as to any Lender, such Lender’s commitment to make Loans, and to issue or participate in Letters of Credit, under this Agreement. The amount of each Lender’s Revolving Loan Commitment is set forth on Annex A attached hereto and made a part hereof (as amended, modified or supplemented from time to time in accordance with the terms hereof).
(g)    The definition of “Eligible Accounts” in Section 1.1 of the Loan Agreement is hereby amended by inserting the following new subsection (ii) at the end of subsection (h) thereof:
(ii)    notwithstanding the ninety (90) day periods prescribed by subsection (a) above (and subsection (i) after the proviso immediately below), (1) solely for the six (6) month period from June 1, 2014 through and including November 30, 2014 and solely with respect to the Accounts of Borrower generated by the operations of the Nicholasville Facility, (2) solely for the six (6) month period from July 1, 2014 through and including December 31, 2014, and solely with respect to Accounts of Borrower generated by the operations of the St. Joseph Facilities, and (3) solely for the six (6) month period from August 1, 2014 through and including January 31, 2015 with respect to the Accounts of Borrower generated by the operations of the Avon Facility and the Mansfield Facility, Accounts that are to be paid pursuant to a Medicare Provider Agreement or a Medicaid Provider Agreement, Private Insurance Managed Care Accounts, or any otherwise Eligible Accounts, which do not remain unpaid more than one hundred eighty (180) days from the invoice date, shall be Eligible Accounts; provided, however, Private Pay Accounts and Medicaid pending Accounts shall not be considered Eligible Accounts; and, provided further, one hundred percent (100%) of all credit amounts in any of the foregoing Eligible Account categories shall be deducted from the “current” Accounts as reasonably determined by the Administrative Agent in its reasonable credit judgment.
(h)    Section 9.1 of the Loan Agreement shall be amended by inserting the following at the end thereof: “ , and (xii) Liens in favor of the Aviv Third Amendment Lessors in accordance with the Aviv Third Amendment Lease Documents, subject in all cases to the provisions of the Aviv Third Amendment Intercreditor Agreements, respectively.
(i)    Section 9.10(a) of the Loan Agreement is hereby amended and restated in its entirety as follows:
“Borrower shall not make any payment, directly or indirectly, to the Aviv Lessor, Aviv CHP, Aviv Third Amendment Lessors, Aviv Twinbrook, or Omega (or any Affiliate or Subsidiary thereof) in contravention of any of the Intercreditor Agreements.”
(j)    Each of the amounts identified in the “Dollar Allocation” designations set forth in Annex A to the Loan Agreement are hereby respectively amended and restated in their entirety as follows:
(i)    The PrivateBank and Trust Company - $12,903,846.15;
(ii)    Bankers Trust Company –$5,288,461.54;
(iii)    CIT Finance LLC - $5,923,076.92; and
(iv)    BOKF, NA d/b/a Bank of Oklahoma - $3,384,615.39.
5.    No Other Amendments. Borrower acknowledges and expressly agrees that this Amendment is limited to the extent expressly set forth herein and shall not constitute a modification or amendment of the Loan Agreement or any other Financing Agreements or a course of dealing at variance with the terms or conditions of the Loan Agreement or any other Financing Agreements (other than as expressly set forth in this Amendment, the Second Note Modifications, the First Pledge Amendment (each as defined below) and the signed Reaffirmation attached hereto).
6.    Representations and Warranties. Borrower hereby represents and warrants to and in favor of Administrative Agent and Lenders, which representations and warranties shall survive the execution and delivery hereof, as follows:
(a)    Each of the representations and warranties of each Borrower (including Original Borrower and New Borrower) contained in the Loan Agreement and the other Financing Agreements to which Borrower is a party are true and correct in all material respects (without duplication of any materiality carve out already provided therein) on and as of the date hereof, in each case as if made on and as of such date, other than representations and warranties that expressly relate solely to an earlier date (in which case such representations and warranties were true and correct on and as of such earlier date); the principal place of business and chief executive office for New Borrower is as set forth on Schedule 1 (as revised pursuant to Section 3 hereof);
(b)    New Borrower has the limited liability company power and authority (i) to enter into the Loan Agreement as amended by this Amendment and (ii) to do all acts and things as are required or contemplated hereunder to be done, observed and performed by New Borrower;
(c)    This Amendment has been duly authorized, validly executed and delivered by one or more Duly Authorized Officers of Borrower, and each of this Amendment, the Loan Agreement as amended hereby, and each of the other Financing Agreements to which Borrower is a party, constitutes the legal, valid and binding obligations of Borrower, enforceable against Borrower in accordance with their respective terms, subject to bankruptcy, insolvency or other similar laws affecting the enforcement of creditor’s rights and remedies generally;
(d)    The execution and delivery of this Amendment and performance by Borrower under this Amendment, the Loan Agreement and each of the other Financing Agreements to which Borrower is a party do not and will not require the consent or approval of any regulatory authority or governmental authority or agency having jurisdiction over Borrower that has not already been obtained, nor be in contravention of or in conflict with the organizational documents of Borrower, or any provision of any statute, judgment, order, indenture, instrument, agreement, or undertaking, to which Borrower is party or by which Borrower’s respective assets or properties are bound; and
(e)    No Default or Event of Default will result after giving effect to this Amendment, and no event has occurred that has had or could reasonably be expected to have a Material Adverse Effect after giving effect to this Amendment.
7.    Conditions Precedent to Effectiveness of this Amendment. The consents set forth in Section 1 hereof and the amendments contained in Section 4 of this Amendment shall become effective on the date hereof as long as each of the following conditions precedent is satisfied as determined by Administrative Agent:
(a)    all of the representations and warranties of Borrower under Section 6 hereof, which are made as of the date hereof, are true and correct;
(b)    receipt by Administrative Agent of duly executed signature pages to this Amendment from Borrower;
(c)    receipt by Administrative Agent of duly executed signature pages to (collectively, the “Third Note Modifications”) the Third Modifications to Amended and Restated Revolving Credit Notes dated as of the date hereof from Borrower (to, respectively, PrivateBank and Bankers Trust Company) and to the Third Modifications to Revolving Credit Notes dated as of the date hereof from Borrower (to, respectively, Bank of Oklahoma and CIT Finance LLC);
(d)    receipt by Administrative Agent of a duly executed signature page to the Reaffirmation of Amended and Restated Guaranty from Guarantor, as provided in the attachment hereto (“Guaranty Reaffirmation”);
(e)    receipt by Administrative Agent of duly executed signature pages to the Second Amendment to Pledge Agreement dated as of the date hereof, among DLC II, New Borrower, Borrower Agent and Administrative Agent (the “Second Pledge Amendment”);
(f)    receipt by Administrative Agent of copies of resolutions of the governing body of New Borrower authorizing the execution, delivery and performance by New Borrower of the Loan Agreement, as amended by this Amendment, and each of the other instruments, agreements and documents entered into in connection with this Amendment to which New Borrower is a party (including with respect to the security interest and equity pledge provided in favor of Administrative Agent), certified by a Duly Authorized Officer of New Borrower;
(g)    receipt by Administrative Agent of copies of resolutions of the governing body of Original Borrower authorizing the execution, delivery and performance by Original Borrower of this Amendment and each of the other instruments, agreements and documents entered into in connection with this Amendment to which Original Borrower is a party, certified by a Duly Authorized Officer of Original Borrower;
(h)    receipt by Administrative Agent of UCC tax, lien, pending suit, bankruptcy and judgment searches on New Borrower (and each of its trade names and assumed names), each as of a recent date, the results of which must be in form and substance acceptable to Administrative Agent;
(i)    receipt by Administrative Agent of good standing certificates for New Borrower from the Delaware Secretary of State and certificates of authorization for New Borrower from the Secretary of State of the State of Kentucky, Missouri and Ohio, as applicable (as of a recent date);
(j)    receipt by Administrative Agent of an opinion of Harwell Howard Hyne Gabbert & Manner, the legal counsel to Borrower and Guarantor, in form and substance reasonably satisfactory to Administrative Agent;
(k)    receipt by Administrative Agent of a certified copy of New Borrower’s certificate of formation, certified by the Delaware Secretary of State (as of a recent date);
(l)    receipt by Administrative Agent of a true, correct and complete copy of the operating agreement of New Borrower, certified by a Duly Authorized Officer of New Borrower;
(m)    UCC Financing Statements, as requested by Administrative Agent, naming New Borrower as debtor and Administrative Agent as secured party with respect to the Collateral, together with such UCC termination statements necessary to release all Liens (other than Permitted Liens) in any of the Collateral except Administrative Agent, and other documents as Administrative Agent deems necessary or appropriate, shall have been filed in all jurisdictions that Administrative Agent deems necessary or advisable;
(n)    receipt of a Third Amendment to the Blocked Account Agreement, in form and substance reasonably acceptable to Administrative Agent;
(o)    receipt of certificates from Borrower’s insurance carriers evidencing Administrative Agent as additional insured with respect to New Borrower’s general liability insurance;
(p)    receipt by Administrative Agent of a true, correct and complete copy of the Management Agreements between New Borrower and Manager available as of the date hereof, certified by a Duly Authorized Officer of New Borrower;
(q)    receipt by Administrative Agent of a true, correct and complete copy of each of the Aviv Third Amendment Lease Documents available as of the date hereof, certified by a Duly Authorized Officer of New Borrower;
(r)    receipt by Administrative Agent of a duly signed and completed Perfection Certificate with respect to New Borrower;
(s)    UCC Amendment Statement naming DLC II as debtor and Administrative Agent as secured party with respect to the equity of New Borrower pledged pursuant to the Second Pledge Amendment shall have been filed in all jurisdictions that Administrative Agent deems necessary or advisable (including the Tennessee Secretary of State);
(t)    receipt by Administrative Agent of copies of resolutions of the governing body of DLC II authorizing the execution, delivery and performance by DLC II of the Second Pledge Amendment, certified by a Duly Authorized Officer of DLC II;
(u)    receipt by Administrative Agent of copies of resolutions of the governing body of Guarantor authorizing the execution, delivery and performance by Guarantor of the Guaranty Reaffirmation, certified by a Duly Authorized Officer of Guarantor;
(v)    receipt by Administrative Agent of copies of the supplemented Schedule 1 (Borrowers), Schedule 1.1(a) (Facilities), Schedule 7.8 (Names), Schedule 7.12 (Organizational Chart), Schedule 7.33 (Capitalization) and Schedule 7.36 (Commercial Leases) of the Loan Agreement;
(w)    receipt by Administrative Agent of a Third Amendment to the Term Loan Agreement dated of even date herewith by and among the Affiliated Term Borrowers, the Lenders and the Administrative Agent, and the Reaffirmation and Consent thereto from Guarantor as provided in the attachment thereto;
(x)    receipt of any applicable Letter of Credit Document (including an amendment to the Master Letter of Credit Agreement or an entirely new Master Letter of Credit Agreement) as Administrative Agent may require in connection with this Amendment;
(y)    receipt of a fully completed Borrowing Base Certificate, signed on behalf of Borrower by a Duly Authorized Officer; and
(z)    receipt by Administrative Agent of such other certificates, schedules, exhibits, documents, opinions, instruments, reaffirmations, amendments or consents Administrative Agent may reasonably require, if any.
8.    Reaffirmation; References to Loan Agreement; Etc.
(a)    Borrower acknowledges and agrees that all of Borrower’s obligations and Liabilities under the Loan Agreement and the other Financing Agreements, as amended hereby, are and shall be valid and enforceable and shall not be impaired or limited by the execution or effectiveness of this Amendment. The first priority perfected security interests and Liens and rights in the Collateral securing payment of the Liabilities are hereby ratified and confirmed by Borrower in all respects.
(b)    Upon the effectiveness of this Amendment, each reference in the Loan Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the Loan Agreement, as amended by this Amendment.
(c)    The failure by Administrative Agent, at any time or times hereafter, to require strict performance by any Borrower of any provision or term of the Loan Agreement, this Amendment or any of the Financing Agreements shall not waive, affect or diminish any right of Administrative Agent hereafter to demand strict compliance and performance herewith or therewith. Any suspension or waiver by Administrative Agent of a breach of this Amendment or any Event of Default under or pursuant to the Loan Agreement shall not, except as expressly set forth in a writing signed by Administrative Agent, suspend, waive or affect any other breach of this Amendment or any Event of Default under or pursuant to the Loan Agreement, whether the same is prior or subsequent thereto and whether of the same or of a different kind or character. None of the undertakings, agreements, warranties, covenants and representations of any Borrower contained in this Amendment, shall be deemed to have been suspended or waived by Administrative Agent unless such suspension or waiver is (i) in writing and signed by Administrative Agent (and, if applicable, the Required Lenders) and (ii) delivered to Borrower by Administrative Agent or its counsel.
(d)    In no event shall Administrative Agent’s execution and delivery of this Amendment establish a course of dealing among Administrative Agent, any Borrower, pledgor or Guarantor or any other obligor, or in any other way obligate Administrative Agent to hereafter provide any amendments or modifications or, if at any time applicable, consents or waivers with respect to the Loan Agreement or any other Financing Agreement. The terms and provisions of this Amendment shall be limited precisely as written and shall not be deemed (x) to be a consent to any amendment or modification of any other term or condition of the Loan Agreement or of any of the Financing Agreements (except as expressly provided herein or in the other documents entered into in connection herewith, including the Third Note Modifications, the Second Pledge Amendment, and the Guaranty Reaffirmation); or (y) to prejudice any right or remedy which Administrative Agent may now have under or in connection with the Loan Agreement or any of the other Financing Agreements. In the event an ambiguity or question of intent or interpretation arises, this Amendment shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Amendment.
(e)    Except as expressly provided herein (or in the other documents entered into in connection herewith, including the Third Note Modifications, the Second Pledge Amendment, and the Guaranty Reaffirmation), the Loan Agreement and all of the other Financing Agreements shall remain unaltered, and the Loan Agreement and all of the other Financing Agreements shall remain in full force and effect and are hereby ratified and confirmed in all respects.
(f)    Borrower shall deliver to Administrative Agent when available a true, correct and complete copy of the applicable nursing home license for New Borrower.
9.    Release.
(a)    In consideration of, among other things, the consent and amendments provided for herein, and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, Borrower (on behalf of themselves and their respective subsidiaries, Affiliates, successors and assigns), and, to the extent permitted by applicable law and the same is claimed by right of, through or under the above, for their past, present and future employees, directors, members, managers, partners, agents, representatives, officers, directors, and equity holders (all collectively, with Borrower, the “Releasing Parties”), do hereby unconditionally, irrevocably, fully, and forever remise, satisfy, acquit, release and discharge Administrative Agent, Issuing Lender, and Lenders and each of Administrative Agent’s, Issuing Lender’s and Lender’s past, present and future officers, directors, agents, employees, attorneys, parent, shareholders, successors, assigns, subsidiaries and Affiliates and all other persons and entities to whom Administrative Agent or Lenders would be liable if such persons or entities were found in any way to be liable to any of the Releasing Parties (collectively, the “Lender Parties”), of and from any and all manner of action and actions, cause and causes of action, claims, cross-claims, charges, demands, counterclaims, suits, proceedings, disputes, debts, dues, sums of money, accounts, bonds, covenants, contracts, controversies, damages, judgments, liabilities, damages, costs, expenses, executions, liens, claims of liens, claims of costs, penalties, attorneys’ fees, or any other compensation, recovery or relief on account of any liability, obligation, demand, proceedings or cause of action of whatever nature, whether in law, equity or otherwise (including, without limitation, those arising under 11 U.S.C. §§ 541-550 and interest or other carrying costs, penalties, legal, accounting and other professional fees and expenses, and incidental, consequential and punitive damages payable to third parties), whether known or unknown, fixed or contingent, joint and/or several, secured or unsecured, due or not due, primary or secondary, liquidated or unliquidated, contractual or tortious, direct, indirect, or derivative, asserted or unasserted, foreseen or unforeseen, suspected or unsuspected, now existing, heretofore existing or which may have heretofore accrued against any or all of Lender Parties, whether held in a personal or representative capacity, that the Releasing Parties (or any of them) have or may have against the Lender Parties or any of them (whether directly or indirectly) and which are based on any act, fact, event, action or omission or any other matter, condition, cause or thing occurring at or from any time prior to and including the date hereof in any way, directly or indirectly arising out of, connected with or relating to this Amendment, the Loan Agreement or any other Financing Agreement and the transactions contemplated hereby and thereby, the Collateral or the Liabilities, and all other agreements, certificates, instruments and other documents and statements (whether written or oral) related to any of the foregoing, other than any applicable good faith claim as to which a final determination is made in a judicial proceeding (in which Administrative Agent and any of the Released Parties have had an opportunity to be heard) which determination includes a specific finding that Administrative Agent acted in a grossly negligent manner or with actual willful misconduct or illegal activity. Borrower acknowledges that Administrative Agent and Lenders are specifically relying upon the representations, warranties and agreements contained herein and that such representations, warranties and agreements constitute a material inducement to Administrative Agent and Lenders in entering into this Amendment.
(b)    Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.
(c)    To the furthest extent permitted by law, Borrower hereby knowingly, voluntarily, intentionally and expressly waives and relinquishes any and all rights and benefits that it respectively may have as against Lender Parties under any law, rule or regulation of any jurisdiction that would or could have the effect of limiting the extent to which a general release extends to claims which a Lender Party or Releasing Party does not know or suspect to exist as of the date hereof. Borrower hereby acknowledges that the waiver set forth in the prior sentence was separately bargained for and that such waiver is an essential term and condition of this Amendment (and without which the consent in Section 1 and the amendments in Section 4 hereof would not have been agreed to by Administrative Agent and Lenders).
10.    Costs and Expenses. Without limiting the obligation of Borrower to reimburse Administrative Agent for all costs, fees, disbursements and expenses incurred by Administrative Agent as specified in the Loan Agreement, Borrower agrees to and shall pay on demand all reasonable costs, fees, disbursements and expenses of Administrative Agent in connection with the preparation, negotiation, revision, execution and delivery of this Amendment and the other agreements, amendments, modifications, reaffirmations, instruments and documents contemplated hereby, including, without limitation, reasonable attorneys’ fees and out-of-pocket expenses.
11.    Post-Closing Covenants. Borrower shall deliver to Administrative Agent as soon as available, true, correct and complete, fully-signed copies of each of the following, which must be in form and substance reasonably satisfactory to Administrative Agent:
(a)    any of the Aviv Third Amendment Lease Documents (i.e., Ohio) not furnished pursuant to Section 7(q) hereof;
(b)    any of the insurance certificates (i.e., Ohio) not furnished pursuant to Section 7(o) hereof;
(c)    any of the Management Agreements (i.e., Ohio) not furnished pursuant to Section 7(p) hereof; and
(d)    all of the sublease agreement, operations transfer agreement, management agreement, intangible property license agreement, assignment and assumption of admission agreement, loan agreement, security agreement and other instruments, agreements and documents regarding or otherwise relating to the IGT Arrangement (including any such instruments, agreements and documents reasonably requested by Administrative Agent).
12.    Financing Agreement. This Amendment shall constitute a Financing Agreement.
13.    Titles. Titles and section headings herein shall be without substantive meaning and are provided solely for the convenience of the parties.
14.    Severability; Etc. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Amendment shall be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Amendment. The parties hereto have participated jointly in the negotiation and drafting of this Amendment. In the event an ambiguity or question of intent or interpretation arises, this Amendment shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Amendment.
15.    Successors and Assigns. This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns; provided, however, no Borrower may assign any of its respective rights or obligations under this Amendment without the prior written consent of Administrative Agent.
16.    Further Assurances. Borrower shall, at its own cost and expense, cause to be promptly and duly taken, executed, acknowledged and delivered all such further acts, certificates, instruments, reaffirmations, amendments, documents and assurances as may from time to time be necessary or as Administrative Agent may from time to time reasonably request in order to more fully carry out the intent and purposes of this Amendment and the other documents entered into in connection herewith, including, without limitation, the Second Note Modifications, the First Pledge Amendment, and the Guaranty Reaffirmation.
17.    Counterparts; Faxes. This Amendment may be executed in multiple counterparts, each of which shall be deemed to be an original and all of which when taken together shall constitute one and the same agreement. A signature hereto sent or delivered by facsimile or other electronic transmission shall be as legally binding and enforceable as a signed original for all purposes.
18.    Governing Law. This Amendment shall be governed by and construed and enforced in accordance with the internal laws of the State of Illinois, without regard to conflict of law principles.
[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have duly executed this Third Amendment and Consent to Amended and Restated Revolving Loan and Security Agreement as of the day and year first above written.
ORIGINAL BORROWER:

BORROWER:
DIVERSICARE MANAGEMENT SERVICES CO.
ADVOCAT ANCILLARY SERVICES, INC.
ADVOCAT FINANCE, INC.
DIVERSICARE MANAGEMENT SERVICES CO.
ADVOCAT DISTRIBUTION SERVICES, INC.
DIVERSICARE ASSISTED LIVING SERVICES, INC.
DIVERSICARE ASSISTED LIVING SERVICES NC, LLC
DIVERSICARE LEASING CORP.
STERLING HEALTH CARE MANAGEMENT, INC.

By:
/s/James R. McKnight, Jr.
Name:
James R. McKnight, Jr.
Its:
Executive Vice President & Chief Financial Officer

SENIOR CARE CEDAR HILLS, LLC
SENIOR CARE GOLFCREST, LLC
SENIOR CARE GOLFVIEW, LLC
SENIOR CARE SOUTHERN PINES, LLC
BY:
SENIOR CARE FLORIDA LEASING, LLC, its sole member
 
BY:
DIVERSICARE LEASING CORP., its sole member
 
By:
/s/James R. McKnight, Jr.
 
Name:
James R. McKnight, Jr.
 
Its:
Executive Vice President & Chief Financial Officer


SENIOR CARE FLORIDA LEASING, LLC
DIVERSICARE AFTON OAKS, LLC
DIVERSICARE BRIARCLIFF, LLC
DIVERSICARE CHISOLM, LLC
DIVERSICARE HARTFORD, LLC
DIVERSICARE HILLCREST, LLC
DIVERSICARE LAMPASAS, LLC
DIVERSICARE PINEDALE, LLC
DIVERSICARE WINDSOR HOUSE, LLC
DIVERSICARE YORKTOWN, LLC
DIVERSICARE ROSE TERRACE, LLC
DIVERSICARE THERAPY SERVICES, LLC
DIVERSICARE HIGHLANDS, LLC
BY:
DIVERSICARE LEASING CORP., its sole member
 
By:
/s/James R. McKnight, Jr.
 
Name:
James R. McKnight, Jr.
 
Its:
Executive Vice President & Chief Financial Officer
DIVERSICARE ASSISTED LIVING SERVICES NC I, LLC
DIVERSICARE ASSISTED LIVING SERVICES NC II, LLC
BY:
DIVERSICARE ASSISTED LIVING SERVICES NC, LLC, its sole member
 
By:
/s/James R. McKnight, Jr.
 
Name:
James R. McKnight, Jr.
 
Its:
Executive Vice President & Chief Financial Officer

DIVERSICARE BALLINGER, LLC
DIVERSICARE DOCTORS, LLC
DIVERSICARE ESTATES, LLC
DIVERSICARE HUMBLE, LLC
DIVERSICARE KATY, LLC
DIVERSICARE NORMANDY TERRACE, LLC
DIVERSICARE TREEMONT, LLC
DIVERSICARE PARIS, LLC
BY:
DIVERSICARE TEXAS I, LLC, its sole member
 
By:
/s/James R. McKnight, Jr.
 
Name:
James R. McKnight, Jr.
 
Its:
Executive Vice President & Chief Financial Officer

DIVERSICARE TEXAS I, LLC
By:
/s/James R. McKnight, Jr.
Name:
James R. McKnight, Jr.
Its:
Executive Vice President & Chief Financial Officer
DIVERSICARE OF CHANUTE, LLC
DIVERSICARE OF COUNCIL GROVE, LLC
DIVERSICARE OF HAYSVILLE, LLC
DIVERSICARE OF SEDGWICK, LLC
DIVERSICARE OF LARNED, LLC
BY:
Diversicare Kansas, LLC
its sole member
 
 
 
By:
/s/James R. McKnight, Jr.
 
Name:
James R. McKnight, Jr.
 
Its:
Executive Vice President & Chief Financial Officer



DIVERSICARE HOLDING COMPANY, LLC

By: /s/James R. McKnight, Jr            
Name:
James R. McKnight, Jr.
Its:
Executive Vice President & Chief Financial Officer


DIVERSICARE KANSAS, LLC


By: /s/James R. McKnight, Jr            
Name:
James R. McKnight, Jr.
Its:
Executive Vice President & Chief Financial Officer


DIVERSICARE LEASING COMPANY II, LLC


By: /s/James R. McKnight, Jr            
Name:
James R. McKnight, Jr.
Its:
Executive Vice President and
Chief Financial Officer


DIVERSICARE OF SENECA PLACE, LLC
DIVERSICARE OF BRADFORD PLACE, LLC
DIVERSICARE OF PROVIDENCE, LLC
DIVERSICARE OF SIENA WOODS, LLC
DIVERSICARE OF ST. THERESA, LLC

By:
DIVERSICARE LEASING COMPANY II, LLC, its sole member


By: /s/James R. McKnight, Jr            
Name:
James R. McKnight, Jr.
Its:
Executive Vice President & Chief Financial Officer




DIVERSICARE OF BIG SPRINGS, LLC

By:
DIVERSICARE LEASING COMPANY II, LLC, its sole member

By: /s/James R. McKnight, Jr            
Name:
James R. McKnight, Jr.
Its:
Executive Vice President & Chief Financial Officer


NEW BORROWER:

DIVERSICARE OF NICHOLASVILLE, LLC
DIVERSICARE OF AVON, LLC
DIVERSICARE OF MANSFIELD, LLC
DIVERSICARE OF RIVERSIDE, LLC
DIVERSICARE OF CHATEAU, LLC
DIVERSICARE OF ST. JOSEPH, LLC

By:
DIVERSICARE LEASING COMPANY II, LLC, its sole member

By: /s/James R. McKnight, Jr            
Name:
James R. McKnight, Jr.
Its:
Executive Vice President & Chief Financial Officer



Acknowledged and Agreed:
DIVERSICARE HEALTHCARE SERVICES, INC. (F/K/A ADVOCAT INC.)
/s/Kelly J. Gill
 
Name:
Kelly J. Gill
 
Its:
President and Chief Executive Officer
 


ADMINISTRATIVE AGENT:

THE PRIVATEBANK AND TRUST COMPANY, in its capacity as administrative agent

By:/s/Adam D. Panos                
Name: Adam D. Panos
Its: Managing Director


LENDER:

THE PRIVATEBANK AND TRUST COMPANY

By:/s/Adam D. Panos                
Name: Adam D. Panos
Its: Managing Director


LENDER:
BANKERS TRUST COMPANY
By: /s/Jon M. Doll            
 
Name:
Jon M. Doll
 
Its:
Vice President
 


LENDER:
BOKF, NA D/B/A BANK OF OKLAHOMA
By: /s/Ryan Kirk            
 
Name:
Ryan Kirk
 
Its:
Vice President
 


LENDER:
CIT FINANCE LLC
By: /s/Barbara Perich            
 
Name:
Barbara Perich
 
Its:
Director
 



REAFFIRMATION OF AMENDED AND RESTATED GUARANTY

The undersigned (“Guarantor”) hereby (i) confirms and agrees with The PrivateBank and Trust Company, an Illinois banking corporation in its capacity as administrative agent (together with its successors and assigns, “Administrative Agent”) that Guarantor’s Amended and Restated Guaranty dated as of April 30, 2013 made in favor of Administrative Agent (as amended or modified, “Guaranty”), remains in full force and effect and is hereby ratified and confirmed in all respects, including with regard to the Amended and Restated Revolving Loan and Security Agreement dated as of April 30, 2013, as amended by that certain First Amendment and Consent to Amended and Restated Revolving Loan and Security Agreement and that certain Second Amendment and Consent to Amended and Restated Revolving Loan and Security Agreement dated as of March 31, 2014, and as further amended by the foregoing Third Amendment and Consent to Amended and Restated Revolving Loan and Security Agreement (“Amendment”), and each reference to the term “Borrower” in the Guaranty shall also include New Borrower and each reference to the “Loan Agreement” shall refer to the Loan Agreement as amended by the Amendment; (ii) represents and warrants to Administrative Agent, which representations and warranties shall survive the execution and delivery hereof, that Guarantor’s representations and warranties contained in the Guaranty are true and correct as of the date hereof, with the same effect as though made on the date hereof, except to the extent that such representations expressly related solely to an earlier date, in which case such representations were true and correct on and as of such earlier date (and except for the representations in Section 10(b) thereof which were true and correct on and as of the date when made); (iii) agrees and acknowledges that such ratification and confirmation is not a condition to the continued effectiveness of the Amendment or the Guaranty; and (iv) agrees that neither such ratification and confirmation, nor Administrative Agent’s solicitation of such ratification and confirmation, constitutes a course of dealing giving rise to any obligation or condition requiring a similar or any other ratification or confirmation from the undersigned with respect to subsequent amendments or modifications, if any, to the Loan Agreement, as amended by the Amendment or any other Financing Agreement (as defined in the Loan Agreement, as amended by the Amendment). The execution, delivery and effectiveness of this instrument shall not operate as a waiver of any right, power or remedy of Administrative Agent under or pursuant to the Guaranty. Guarantor acknowledges and agrees that Guarantor has received and reviewed a fully-executed copy of the Amendment (and any other instrument, document or agreement executed or delivered in connection therewith) and understands the contents thereof. A signature hereto sent or delivered by facsimile or other electronic transmission shall be as legally binding and enforceable as a signed original for all purposes. This instrument shall be governed by and construed and enforced in accordance with the internal laws of the State of Illinois, without regard to conflict of law principles.
Dated as of: July __, 2014
DIVERSICARE HEALTHCARE SERVICES, INC. (F/K/A ADVOCAT INC.)

By:/s/Kelly J. Gill                
Name:    Kelly J. Gill
Its:    President and Chief Executive Officer

EXHIBIT A

1.    Lease by and between Nicholasville Property, L.L.C., a Delaware limited liability company (“Lessor”) and Diversicare of Nicholasville, LLC, a Delaware limited liability company (“Lessee”), dated as of May 28, 2014 and commencing June 1, 2014, for the lease of a nursing home facility formerly known as Royal Manor Health Care, having an address of 100 Sparks Ave., Nicholasville, Kentucky, now known and operated by the Lessee as Diversicare of Nicholasville (the “Nicholasville Facility”).

2.    Master Lease by and between St. Joseph Missouri Property, L.L.C., a Delaware limited liability company (“Lessor”) and Diversicare of Chateau, LLC, a Delaware limited liability company, Diversicare of Riverside, LLC, a Delaware limited liability company, and Diversicare of St. Joseph, LLC, a Delaware limited liability company (collectively , “Lessee”), dated as of June __, 2014 and commencing July 1, 2014, for the lease by each Lessee, respectively, of: (i) a nursing home facility known as Saxton Care Chateau having an address of 811 N. 9th Street, St. Joseph, Missouri, to be known and operated by the Lessee as St. Joseph Chateau; (ii) a nursing home facility known as Saxton Riverside Care Center and an assisted living facility known as Saxton’s Country Villa having an address of 1616 Weisenborn Road, St. Joseph, Missouri, to be known and operated by the Lessee as Riverside Place; and (iii) a nursing home facility and independent living facility known as Saxton Health Care Inn having an address of 3002 N. 18th Street, St. Joseph, Missouri, to be known and operated by Lessee as Diversicare of St. Joseph (collectively, the “St. Joseph Facilities”).

3.     Lease to be executed by and between Avon Ohio, L.L.C. (“Lessor”) and Diversicare of Avon, LLC, a Delaware limited liability company (“Lessee”), having an anticipated commencement date of August 1, 2014, for the lease of a nursing home facility known as Good Samaritan Nursing Home having an address of 32900 Detroit Road, Avon, Ohio, to be known and operated by Lessee as Diversicare of Avon (the “Avon Facility”).

4.    Lease to be executed by and between Mansfield Aviv, L.L.C., a Delaware limited liability company (“Lessor”), and Diversicare of Mansfield, L.L.C., a Delaware limited liability company, having an anticipated commencement date of August 1, 2014, for the lease of a residential care facility known as Ontario Commons having an address of 2124 Park Avenue West, Ontario, Ohio, to be known and operated by Lessee as Diversicare of Mansfield (the “Mansfield Facility”).



EXHIBIT B

AVIV THIRD AMENDMENT INTERCREDITOR AGREEMENTS

1.    Subordination and Intercreditor Agreement (Aviv-Nicholasville) dated as of July 1, 2014, made by and among The PrivateBank and Trust Company, an Illinois banking corporation in its capacity as Administrative Agent for the Lenders described therein (together with its successors and assigns “PrivateBank”), Diversicare of Nicholasville, LLC, a Delaware limited liability company (“Borrower”) and Nicholasville Kentucky Property, L.L.C. a Delaware limited liability company (“Lessor”).

2.    Subordination and Intercreditor Agreement (Aviv-Missouri Facilities) dated as of July 1, 2014 made by and among (i)The PrivateBank and Trust Company, an Illinois banking corporation in its capacity as Administrative Agent for the Lenders described therein (together with its successors and assigns, “PrivateBank”), (ii) Diversicare of Riverside , LLC, Diversicare of Chateau, LLC, and Diversicare of St. Joseph, LLC, each a Delaware limited liability company (referred to individually and collectively as, “Borrower”), and (iii) St. Joseph Missouri Property, L.L.C., a Delaware limited liability company (“Lessor”).

3.    Subordination and Intercreditor Agreement) to be made by and among The PrivateBank and Trust Company, an Illinois banking corporation in its capacity as Administrative Agent for the Lenders described therein (together with its successors and assigns, “PrivateBank”), Diversicare of Avon, LLC, a Delaware limited liability company (“Borrower”) and Avon Ohio L.L.C. a Delaware limited liability company (“Lessor”), to be executed in connection with the Lease to be made by and between Lessor and Borrower , as Lessee, having an anticipated commencement date of August 1, 2014, for the lease of a nursing home facility known as Good Samaritan Nursing Home having an address of 32900 Detroit Road, Avon, Ohio, to be known and operated by Lessee as Diversicare of Avon (the “Avon Facility’).

4.    Subordination and Intercreditor Agreement) to be made by and among The PrivateBank and Trust Company, an Illinois banking corporation in its capacity as Administrative Agent for the Lenders described therein (together with its successors and assigns, “PrivateBank”), Diversicare of Mansfield, LLC, a Delaware limited liability company (“Borrower”) and Avon Ohio L.L.C. a Delaware limited liability company (“Lessor”), to be executed in connection the Lease to be made by and between Lessor and Borrower, as Lessee, having an anticipated commencement date of August 1, 2014, for the lease of a residential care facility known as Ontario Commons having an address of 2124 Park Avenue West, Ontario, Ohio, to be known and operated by Lessee as Diversicare of Mansfield (the “Mansfield Facility”).




EX-10.3 4 ex103-15thamendtomasterlea.htm EXHIBIT EX10.3 - 15thAmendtoMasterLease

FIFTEENTH AMENDMENT TO CONSOLIDATED
AMENDED AND RESTATED MASTER LEASE

This Fifteenth Amendment to Consolidated Amended and Restated Master Lease (this “Amendment”) is executed and delivered as of June 30, 2014 by and between STERLING ACQUISITION CORP., a Kentucky corporation (“Lessor”), the address of which is 200 International Circle, Suite 3500, Hunt Valley, MD 21030, and DIVERSICARE LEASING CORP., a Tennessee corporation, the address of which is 1621 Galleria Boulevard, Brentwood, TN 37027.
RECITALS:

A.    Lessee has executed and delivered to Lessor a Consolidated Amended and Restated Master Lease dated as of November 8, 2000, but effective as of October 1, 2000, as amended by a First Amendment to Consolidated Amended and Restated Master Lease dated as of September 30, 2001, a Second Amendment to Consolidated Amended and Restated Master Lease dated as of June 15, 2005, a Third Amendment to Consolidated Amended and Restated Master Lease dated as of October 20, 2006, a Fourth Amendment to Consolidated Amended and Restated Master Lease dated as of April 1, 2007, a Fifth Amendment to Consolidated Amended and Restated Master Lease dated as of August 10, 2007, a Sixth Amendment to Consolidated Amended and Restated Master Lease dated as of March 14, 2008, a Seventh Amendment to Consolidated Amended and Restated Master Lease dated as of October 24, 2008, an Eighth Amendment to Consolidated Amended and Restated Master Lease dated as of March 31, 2009, a Ninth Amendment to Consolidated Amended and Restated Master Lease dated as of May 5, 2009, a Tenth Amendment to Consolidated Amended and Restated Master Lease dated as of September 8, 2009, and a Eleventh Amendment to Consolidated Amended and Restated Master Lease dated as of April 18, 2011, a Twelfth Amendment to Consolidated Amended and Restated Master Lease dated as of January 22, 2013 (the “Twelfth Amendment”), a Thirteenth Amendment to Consolidated Amended and Restated Master Lease dated as of August 1, 2013, and a Fourteenth Amendment to Consolidated Amended and Restated Master Lease dated as of January 31, 2014 (collectively, the “Existing Master Lease”) pursuant to which Lessee leases from Lessor certain healthcare facilities.
B.    Lessor, certain Affiliates of Lessor listed on Exhibit A (the “New Lessor Entities”), and parties listed on Exhibit B (the “New Tenant Entities”) to this Amendment have entered into an Agreement to Enter into Master Lease dated as of April 2, 2014, pursuant to which certain of the New Tenant Entities shall execute and deliver to the New Lessor Entities a Master Lease (the “New Master Lease”) covering the two (2) Facilities located in West Virginia and listed on Exhibit C to this Amendment (the “West Virginia Facilities”).
C.    Lessor and Lessee desire to terminate the Existing Master Lease as to the West Virginia Facilities, and, effective as of such termination, to reduce the Non-Texas Base Rent by One Million Nine Hundred Thousand Dollars ($1,900,000), all on the terms and conditions of this Amendment.
D.     In addition, Lessor and Lessee desire to extend the draw period for the Tenant improvement allowance provided for in the Twelfth Amendment until September 30, 2014.
NOW THEREFORE, the parties agree as follows:
1.Definitions. Any capitalized term used but not defined in this Amendment will have the meaning assigned to such term in the Master Lease. From and after the date of this Amendment, each reference in the Existing Master Lease or the other Transaction Documents to the “Lease” or “Master Lease” means, as applicable, the Existing Master Lease as modified by this Amendment.
2.    Termination as to West Virginia Facilities. Effective as of, and conditioned upon, the occurrence of the “Commencement Date” under the New Master Lease (the “New Lease Commencement”), (a) the Master Lease is terminated as to the West Virginia Facilities, and only as to the West Virginia Facilities; and (b) Exhibits A-27 and A-28 of the Master Lease are amended and restated in its entirety as follows:

Exhibit A-27 and A-28

Intentionally Omitted.

Effective as of, and conditioned upon, the occurrence of the New Lease Commencement, Lessee shall be and hereby is released from any further obligations first arising under the Master Lease from and after the New Lease Commencement Date as to the West Virginia Facilities. Notwithstanding the foregoing, the obligations of Lessee under the Master Lease with respect to matters first arising prior to the New Lease Commencement shall survive the termination of the Master Lease as to the West Virginia Facilities. Lessee acknowledges and agrees that the New Lessors, as successors in interest to Lessor, are also indemnified parties under Section 21.1 of the Master Lease; subject, however, to the exclusions for the gross negligence or willful misconduct, and the indemnity obligations, of the Lessor under Section 21.1 of the Master Lease.

3.    Non-Texas Base Rent Reduction. Effective as of, and conditioned upon, the New Lease Commencement, the definition of Non-Texas Base Rent is hereby amended and restated in its entirety as follows:
Non-Texas Base Rent:

(A)     During the Initial Term, the Non-Texas Base Rent shall be:
(1)    For period prior to the New Lease Commencement, the Non-Texas Base Rent as set forth in the Existing Master Lease;
(2)    For the period from the New Lease Commencement thru September 30, 2014, the monthly sum of Nine Hundred Eighty Three Thousand Four Hundred Eighty Eight and 81/100 Dollars ($983,488.81), which on an annual basis would be Eleven Million Eight Hundred One Thousand Eight Hundred Sixty Five and 75/100 Dollars ($11,801,865.75) (the “2014 Annual NTBR”);
(3)     For the Lease Year commencing on October 1, 2014, the product of the 2014 Annual NTBR and One Hundred Three Percent (103%);
(4)    For each of the each of the remaining Lease Years of the first Renewal Term, the product of the Non-Texas Base Rent during the previous Lease Year and and One Hundred Three Percent (103%).
Under no circumstances will the Non-Texas Base Rent in any Lease Year be less than the Non-Texas Base Rent during the preceding Lease Year.
(B)    During the second Renewal Term, the Non-Texas Base Rent shall be:
(1)    For the first Lease Year of the second Renewal Term, the greater of (a) the product of the Non-Texas Base Rent during the last Lease Year of the Initial Term and One hundred Three percent (103%), and (b) the Fair Market Rent for the Facilities other than the Texas Facilities on the first day of such Renewal Term as agreed upon by Lessor and Lessee, or, if prior to the commencement of the Renewal Term they are unable to agree, as determined by an appraisal pursuant to Article XXXII of this Lease; provided, however, that the Non-Texas Base Rent for the first Lease Year of the second Renewal Term shall not exceed one hundred ten percent (110%) of the Non-Texas Base Rent for the Lease Year immediately preceding the commencement of the second Renewal Term; and
(2)    For each of the second (2nd) through the twelfth (12th) Lease Years during the second Renewal Term, the lesser of (i) the Non-Texas Base Rent for the first (1st) Lease Year of the second Renewal Term, increased by a percentage equal to two (2) times the percentage increase in the CPI (if positive) from the commencement date of the second Renewal Term to the Adjustment Date in each of the second (2nd) through twelfth (12th) Lease Years, as applicable (the “Adjustment Date”), and (ii) the product of the Non-Texas Base Rent during the first (1st) Lease Year of the second Renewal Term and the following factor:
Lease Year During
Second Renewal Term

Applicable Factor
2
1.030
3
1.061
4
1.093
5
1.126
6
1.159
7
1.194
8
1.230
9
1.267
10
1.305
11
1.344
12
1.384

Under no circumstances will the Non-Texas Base Rent in any Lease Year during the Renewal Term be less than the Non-Texas Base Rent during the preceding Lease Year.
4.    Proceeds to Lessor; OTA; No Prorations with Lessor. All proceeds from the lease of the West Virginia Facilities shall be paid to Lessor. Lessee shall enter into an operations transfer agreement in form and substance reasonably acceptable to Lessee with the new operators of the West Virginia Facilities providing for the proration of revenues and expenses. The operations transfer agreement shall also include such indemnities from and in favor of Lessee as may be customarily included in transactions of this type in form and substance reasonably acceptable to Lessee. Lessee shall prorate all Impositions pursuant to the operations transfer agreement and such proration shall be in full satisfaction of the Lessee’s and Lessor’s obligation to prorate such Impositions pursuant to Section 4.3 of the Master Lease.
5.    Schedule 1 to Amended and Restated Security Agreement. Effective as of, and conditioned upon, the New Lease Commencement, Schedule 1 to the Amended and Restated Security Agreement between Lessee, as debtor, and Lessor, as secured party, is hereby amended and restated by Schedule 1 to this Amendment. After the occurrence of the New Lease Commencement, Lessor will file or record any UCC-3 termination statements necessary to terminate, release or amend, as applicable, any UCC-1 financing statements to extent such financing statements cover the West Virginia Facilities.
6.    Tenant Improvement Allowance. Section 3 of the Twelfth Amendment is hereby amended and restated in its entirety as follows:
3.    Tenant Improvement Allowance. Pursuant to the Second Amendment, Lessor made available to Lessee an Improvement Allowance of Five Million Dollars ($5,000,000). Pursuant to the Third Amendment, Lessor made an additional Improvement Allowance of Five Million Dollars ($5,000,000) available to Lessee. Pursuant to the Ninth Amendment, Lessor made an additional Improvement Allowance of Five Million Dollars ($5,000,000) available to Lessee. Pursuant to the Eleventh Amendment, Lessor made an additional Improvement Allowance of Five Million Dollars ($5,000,000) available to Lessee. Lessor hereby makes available to Lessee an additional improvement allowance equal to Five Million Dollars ($5,000,000) to be used for certain capital improvements to the Facilities. Such additional improvement allowance shall be used only for completion of capital improvements to the Facilities listed on Exhibit B to this Amendment, which shall be approved and constructed in accordance with the terms and provisions of Paragraph 2 of the Second Amendment. The term “Capital Improvements” as and where used in Paragraph 2 of the Second Amendment shall be deemed to include such capital improvements. The additional improvement allowance shall be requested and disbursed in accordance with the provisions of Paragraph 3 of the Second Amendment. The term “Improvement Allowance”, as and where used in Paragraph 3 of the Second Amendment, shall be deemed to include and refer to the additional improvement allowance provided for in this paragraph, except that such additional improvement allowance shall be available for Capital Improvements completed on or before August 31, 2014 and the final request for disbursement shall be no later than October 31, 2014. The annual Base Rent payable under the Existing Master Lease shall be increased by the Improvement Allowance Adjustment Amount for each disbursement of such additional improvement allowance as provided in Paragraph 4 of the Second Amendment. In the event Lessor fails to pay Lessee any installment request for the additional improvement allowance as provided in Paragraph 3 of the Second Amendment, Lessee shall have the rights and remedies provided in Paragraph 4 of the Second Amendment and the provisions of Paragraph 4 of the Second Amendment shall apply to Lessee’s exercise of such rights and remedies
7.    Representations and Warranties of Lessee. Lessee hereby represents and warrants to Lessor that (i) it has the right and power and is duly authorized to enter into this Amendment; and (ii) the execution of this Amendment does not and will not constitute a breach of any provision contained in any agreement or instrument to which Lessee is or may become a party or by which Lessee is or may be bound or affected.
8.    Expenses of Lender. Lessee shall pay all reasonable expenses of Lessor incurred in connection with this Amendment, including reasonable attorneys fees and expenses.
9.    Execution and Counterparts. This Amendment may be executed in any number of counterparts, each of which, when so executed and delivered, shall be deemed to be an original, but when taken together shall constitute one and the same Amendment.
10.    Headings. Section headings used in this Amendment are for reference only and shall not affect the construction of the Amendment.
11.    Enforceability. Except as expressly and specifically set forth herein, the Existing Master Lease remains unmodified and in full force and effect. In the event of any discrepancy between the Existing Master Lease and this Amendment, the terms and conditions of this Amendment will control and the Existing Master Lease is deemed amended to conform hereto.
[SIGNATURE PAGES AND ACKNOWLEDGEMENTS FOLLOW]

LESSOR:

STERLING ACQUISITION CORP.,
a Kentucky corporation


By: /s/ Daniel J. Booth        
Name: Daniel J. Booth
Title:    Chief Operating Officer


STATE OF MARYLAND    )
COUNTY OF BALTIMORE    )

This instrument was acknowledged before me on the _10th__ day of June, 2014, by Daniel J. Booth, the COO of STERLING ACQUISITION CORP., a Kentucky corporation, on behalf of said company.

/s/ Judith A. Jacobs                                            Notary Public, Baltimore County, MD
My commission expires:             


LESSEE:

DIVERSICARE LEASING CORP.,
a Tennessee corporation


By:    /s/ James R. McKnight, Jr._______
Name:    James R. McKnight, Jr.
Title:
Executive Vice President and Chief Financial Officer
    

STATE OF TENNESSEE        )
                        
COUNTY OF WILLIAMSON    )

This instrument was acknowledged before me on the 20th day of June, 2014, by James R. McKnight, Jr., the Executive Vice President and Chief Financial Officer of DIVERSICARE LEASING CORP., a Tennessee corporation, on behalf of said company


/s/ Jacqueline S. Reed            
Notary Public, Tenn. County, Williamson
My commission expires:             

 


The undersigned hereby consent to the transactions contemplated by this Amendment to ratify and affirm their respective Guaranties, Pledge Agreements, Security Agreements, Subordination Agreements and other Transaction Documents, and acknowledge and agree that the performance of the Master Lease and obligations described therein are secured by their Guaranties, Pledge Agreements, Security Agreement, Subordination Agreement and other Transaction Documents on the same terms and conditions in effect prior to this Amendment.
DIVERSICARE HEALTHCARE SERVICES, INC., a Delaware corporation f/k/a Advocat, Inc.


By:    /s/ James r. McKnight, Jr.        
Name:    James R. McKnight, Jr.
Title:
Executive Vice President and Chief Financial Officer
    

STATE OF TENNESSEE         )

COUNTY OF WILLIAMSON    )

The foregoing instrument was acknowledged before me this 20th day of June, 2014, by James R. McKnight, Jr., the Executive Vice President and Chief Financial Officer of Diversicare Healthcare Services, INC., a Delaware corporation f/k/a Advocat, Inc, on behalf of the corporation, who acknowledged the same to be his or her free act and deed and the free act and deed of the corporation.


/s/ Jacqueline S. Reed                
Notary Public, Tenn. County, Williamson
My Commission Expires:                 

 

 

DIVERSICARE MANAGEMENT SERVICES CO.,
a Tennessee corporation


By:    /s/ James r. McKnight, Jr.        
Name:    James R. McKnight, Jr.
Title:
Executive Vice President and Chief Financial Officer
    


STATE OF TENNESSEE         )

COUNTY OF WILLIAMSON    )

The foregoing instrument was acknowledged before me this 20th day of June, 2014, by James R. McKnight, Jr., the Executive Vice President and Chief Financial Officer of DIVERSICARE MANAGEMENT SERVICES CO., a Tennessee corporation, on behalf of the corporation, who acknowledged the same to be his or her free act and deed and the free act and deed of the corporation.


/s/ Jacqueline S. Reed                    
Notary Public, Tenn. County, Williamson
My Commission Expires:                 


 
 
 

ADVOCAT FINANCE INC.,
a Delaware corporation


By:    /s/ James r. McKnight, Jr.        
Name:    James R. McKnight, Jr.
Title:
Executive Vice President and Chief Financial Officer
    
STATE OF TENNESSEE         )

COUNTY OF WILLIAMSON    )

The foregoing instrument was acknowledged before me this 20th day of June, 2014, by James R. McKnight, Jr., the Executive Vice President and Chief Financial Officer of ADVOCAT FINANCE INC., a Delaware corporation, on behalf of the corporation, who acknowledged the same to be his or her free act and deed and the free act and deed of the corporation.


/s/ Jacqueline S. Reed            
Notary Public, Tenn. County, Williamson
My Commission Expires:                 

 

 
 

STERLING HEALTH CARE
MANAGEMENT, INC., a Kentucky corporation


By:    /s/ James r. McKnight, Jr.        _
Name:    James R. McKnight, Jr.
Title:
Executive Vice President and Chief Financial Officer
    

STATE OF TENNESSEE         )

COUNTY OF WILLIAMSON    )

The foregoing instrument was acknowledged before me this 20th day of June, 2014, by James R. McKnight, Jr., the Executive Vice President and Chief Financial Officer of STERLING HEALTH CARE MANAGEMENT, INC., a Kentucky corporation, on behalf of the corporation, who acknowledged the same to be his or her free act and deed and the free act and deed of the corporation.


/s/ Jacqueline S. Reed                
Notary Public, Tenn. County, Williamson
My Commission Expires:                 


 
 

DIVERSICARE TEXAS I, LLC


By:    /s/ James r. McKnight, Jr.        
Name:    James R. McKnight, Jr.
Title:
Executive Vice President and Chief Financial Officer
    
DIVERSICARE BALLINGER, LLC
DIVERSICARE DOCTORS, LLC
DIVERSICARE ESTATES, LLC
DIVERSICARE HUMBLE, LLC
DIVERSICARE KATY, LLC
DIVERSICARE NORMANDY TERRACE, LLC
DIVERSICARE TREEMONT, LLC

BY:    DIVERSICARE TEXAS I, LLC,
its sole member

By:    /s/ James r. McKnight, Jr.        
Name:    James R. McKnight, Jr.
Title:
Executive Vice President and Chief Financial Officer
    
STATE OF TENNESSEE         )

COUNTY OF WILLIAMSON     )

The foregoing instrument was acknowledged before me this 20th day of June, 2014, by James R. McKnight, Jr., the Executive Vice President and Chief Financial Officer of DIVERSICARE TEXAS I, LLC, on behalf of itself and as the sole member of each of DIVERSICARE BALLINGER, LLC, DIVERSICARE DOCTORS, LLC, DIVERSICARE ESTATES, LLC, DIVERSICARE HUMBLE, LLC, DIVERSICARE KATY, LLC, DIVERSICARE NORMANDY TERRACE, LLC, and DIVERSICARE TREEMONT, LLC, each a Delaware limited liability company, on behalf of the limited liability companies, who acknowledged the same to be his or her free act and deed and the free act and deed of the limited liability companies.


/s/ Jacqueline S. Reed                
Notary Public, Tenn. County, Williamson
My Commission Expires:                 
  

New Lessor Entities

To be formed subsidiaries of Omega Healthcare Investors, Inc. expected to be named as follows:

OHI Asset (WV) Danville, LLC
OHI Asset (WV) Ivydale, LLC
Each a Delaware limited liability company



New Tenant Entities


AMFM, LLC,
a West Virginia limited liability company

SOUTHERN INVESTMENT AND LEASING COMPANY, LLC,
a West Virginia limited liability company

HILLCREST HEALTH CARE CENTER, LLC,
a West Virginia limited liability company

CLAY HEALTH CARE CENTER, LLC,
a West Virginia limited liability company



West Virginia Facilities

1.    
Boone Health Care Center, Inc.
Lick Creek Road, P.O. Box 605
Danville
Boone
WV
25053
2.    
Laurel Nursing & Rehab Center
HC 75, Box 153, Clinic Road
Ivydale
Clay
WV
25113



1.    
Best Care, Inc.
2159 Dogwood Ridge
Wheelersburg
Scioto
OH
45694
2.    
Boyd Nursing and Rehab Center
12800 Princeland Drive
Ashland
Boyd
KY
41102
3.    
Canterbury Health Center
1720 Knowles Road
Phoenix City
Russell
AL
36867
4.    
Carter Nursing & Rehab Center
250 McDavid Boulevard, P.O. Box 904
Grayson
Carter
KY
41143
5.    
Elliott Nursing & Rehab Center
Howard Creek Road, P.O. Box 694, Route 32 East
Sandy Hook
Elliott
KY
41171
6.    
Hardee Manor Care Center
401 Orange Place
Wauchula
Hardee
FL
33873
7.    
Laurel Manor Health Center
902 Buchanan Road, P.O. Box 505
New Tazewell
Claiborne
TN
37825
8.    
Lynwood Nursing Home
4164 Halls Mill Road
Mobile
Mobile
AL
36693
9.    
Manor House of Dover
537 Spring Street, P.O. Box 399
Dover
Stewart
TN
37058
10.    
Mayfield Rehab and Special Care Center
200 Mayfield Drive
Smyrna
Rutherford
TN
37167
11.    
Northside Health Care
700 Hutchins Ave
Gadsden
Etowah
AL
35901
12.    
South Shore Nursing & Rehab Center
James Hannah Drive, P.O. box 489
South Shore
Greenup
KY
41175
13.    
West Liberty Nursing & Rehab Center
774 Liberty Road, P.O. Box 219, Route 5 Wells Hill
West Liberty
Morgan
KY
41472
14.    
Westside Health Care Center
4320 Judith Lane
Huntsville
Madison
AL
35805
15.    
Wurtland Nursing & Rehab Center
100 Wurtland Avenue, P.O. Box 677
Wurtland
Greenup
KY
41144


Derwent – 6.18.14    1
EX-31.1 5 dvcr-ex311x63014certificat.htm CEO CERTIFICATION DVCR-EX31.1 - 6.30.14 Certification of CEO


Exhibit 31.1
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(i) CERTIFICATION
I, Kelly J. Gill, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 7, 2014
 
 
/s/ Kelly J. Gill
Kelly J. Gill
Chief Executive Officer



EX-31.2 6 dvcr-ex312x63014certificat.htm CFO CERTIFICATION DVCR-EX31.2 - 6.30.14 Certification of CFO


Exhibit 31.2
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(ii) CERTIFICATION
I, James Reed McKnight, Jr., certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:  August 7, 2014
 
/s/ James Reed McKnight, Jr.
James Reed McKnight, Jr.
Executive Vice President and Chief Financial Officer



EX-32 7 dvcr-ex32x63014certificati.htm CERTIFICATION DVCR-EX32 - 6.30.14 Certification


Exhibit 32
CERTIFICATION OF QUARTERLY REPORT ON FORM 10-Q
OF DIVERSICARE HEALTHCARE SERVICES, INC.
FOR THE QUARTER ENDED JUNE 30, 2014
The undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the undersigned’s best knowledge and belief, the Quarterly Report on Form 10-Q for Diversicare Healthcare Services, Inc. (the “Company”) for the period ending June 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”):
(a)
fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(b)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
This Certification is executed as of August 7, 2014.

 
 
/s/ Kelly J. Gill
Kelly J. Gill
Chief Executive Officer
 
/s/ James Reed McKnight, Jr.
James Reed McKnight, Jr.
Executive Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



EX-101.INS 8 avca-20140630.xml XBRL INSTANCE DOCUMENT 0000919956 avca:SkilledNursingCenterMember stpr:KS 2013-05-01 2013-05-01 0000919956 avca:LouisvilleKentuckyMember 2013-08-01 2013-08-01 0000919956 2013-10-01 2013-10-01 0000919956 avca:HuntsvilleAlabamaMember 2014-03-01 2014-03-01 0000919956 avca:RoseTerraceNursingCenterMember 2014-03-27 2014-03-27 0000919956 avca:NicholasvilleKentuckyMember 2014-06-01 2014-06-01 0000919956 2014-05-01 2014-05-01 0000919956 avca:SkilledNursingCenterMember stpr:KS 2014-05-01 2014-05-01 0000919956 avca:CreditAgreementMember 2014-05-01 2014-05-01 0000919956 stpr:OH us-gaap:ScenarioForecastMember us-gaap:SubsequentEventMember 2014-08-01 2014-08-01 0000919956 stpr:OH us-gaap:SubsequentEventMember 2014-08-01 2014-08-01 0000919956 avca:RoseTerraceNoteMember avca:RoseTerraceNursingCenterMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2014-07-01 2014-07-01 0000919956 stpr:MO us-gaap:ScenarioForecastMember us-gaap:SubsequentEventMember 2014-07-01 2014-07-01 0000919956 stpr:MO us-gaap:SubsequentEventMember 2014-07-01 2014-07-01 0000919956 2013-04-01 2013-06-30 0000919956 2013-01-01 2013-06-30 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2013-01-01 2013-06-30 0000919956 us-gaap:RestrictedStockMember 2013-01-01 2013-06-30 0000919956 avca:LeasedSkilledNursingCentersMember 2013-01-01 2013-06-30 0000919956 2014-04-01 2014-06-30 0000919956 2014-01-01 2014-06-30 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2014-01-01 2014-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2014-01-01 2014-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2014-01-01 2014-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2014-01-01 2014-06-30 0000919956 us-gaap:EmployeeStockMember 2014-01-01 2014-06-30 0000919956 us-gaap:RestrictedStockMember 2014-01-01 2014-06-30 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2014-01-01 2014-06-30 0000919956 us-gaap:StockCompensationPlanMember 2014-01-01 2014-06-30 0000919956 avca:SHCRiskCarriersIncMember us-gaap:ProfessionalMalpracticeLiabilityMember 2014-01-01 2014-06-30 0000919956 avca:UnaffiliatedEntitiesMember us-gaap:ProfessionalMalpracticeLiabilityMember 2014-01-01 2014-06-30 0000919956 avca:CreditAgreementMember 2014-01-01 2014-06-30 0000919956 avca:LeasedSkilledNursingCentersMember 2014-01-01 2014-06-30 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2014-01-01 2014-06-30 0000919956 avca:TwoThousandAndFiveLongTermIncentivePlanMember 2014-01-01 2014-06-30 0000919956 us-gaap:MaximumMember 2014-01-01 2014-06-30 0000919956 us-gaap:MinimumMember 2014-01-01 2014-06-30 0000919956 avca:PrefundedDeductiblePolicyMember 2014-01-01 2014-06-30 0000919956 2012-12-31 0000919956 2013-06-30 0000919956 2013-12-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2013-12-31 0000919956 us-gaap:EmployeeStockMember 2013-12-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2013-12-31 0000919956 avca:RevolvingCreditFacilityInterestAtFourPointFivePercentAboveLiborMember us-gaap:RevolvingCreditFacilityMember 2013-12-31 0000919956 us-gaap:RevolvingCreditFacilityMember us-gaap:MaximumMember 2014-03-31 0000919956 2014-06-30 0000919956 avca:TrialOrArbitrationScheduleTimeframeMember 2014-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2014-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2014-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2014-06-30 0000919956 us-gaap:EmployeeStockMember 2014-06-30 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2014-06-30 0000919956 us-gaap:StockAppreciationRightsSARSMember avca:TwoThousandAndTenLongTermIncentivePlanMember 2014-06-30 0000919956 avca:UnaffiliatedEntitiesMember us-gaap:ProfessionalMalpracticeLiabilityMember 2014-06-30 0000919956 avca:LondonInterbankOfferedRateMember 2014-06-30 0000919956 us-gaap:LoansPayableMember 2014-06-30 0000919956 us-gaap:RevolvingCreditFacilityMember 2014-06-30 0000919956 avca:RevolvingCreditFacilityInterestAtFourPointFivePercentAboveLiborMember us-gaap:LetterOfCreditMember 2014-06-30 0000919956 avca:RevolvingCreditFacilityInterestAtFourPointFivePercentAboveLiborMember us-gaap:RevolvingCreditFacilityMember 2014-06-30 0000919956 us-gaap:InterestRateSwapMember 2014-06-30 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2014-06-30 0000919956 avca:TwoThousandAndFiveLongTermIncentivePlanMember 2014-06-30 0000919956 us-gaap:ProfessionalMalpracticeLiabilityMember 2014-06-30 0000919956 avca:OmegaHealthcareInvestorsInc.Member 2013-01-22 0000919956 avca:OmegaHealthcareInvestorsInc.Member stpr:AR 2013-01-22 0000919956 avca:ChanuteHealthcareCenterMember avca:SkilledNursingCenterMember stpr:KS 2013-05-01 0000919956 avca:CouncilGroveHealthcareCenterMember avca:SkilledNursingCenterMember stpr:KS 2013-05-01 0000919956 avca:HaysvilleHealthcareCenterMember avca:SkilledNursingCenterMember stpr:KS 2013-05-01 0000919956 avca:LarnedHealthcareCenterMember avca:SkilledNursingCenterMember stpr:KS 2013-05-01 0000919956 avca:SedgwickHealthcareCenterMember avca:SkilledNursingCenterMember stpr:KS 2013-05-01 0000919956 stpr:KS 2013-05-01 0000919956 avca:SkilledNursingCenterMember stpr:KS 2013-05-01 0000919956 us-gaap:RevolvingCreditFacilityMember 2013-05-01 0000919956 avca:CreditAgreementMember 2013-05-01 0000919956 avca:LouisvilleKentuckyMember 2013-08-01 0000919956 avca:LouisvilleKentuckyMember 2013-08-01 0000919956 avca:OmegaHealthcareInvestorsInc.Member stpr:AR 2013-09-01 0000919956 avca:CullodenWestVirginiaMember us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2011-12-28 0000919956 2013-10-01 0000919956 avca:OhioandIndianaMember 2013-10-01 0000919956 stpr:IN 2013-10-01 0000919956 stpr:OH 2013-10-01 0000919956 avca:SkilledNursingCenterMember 2013-10-01 0000919956 avca:SkilledNursingCenterMember stpr:IN 2013-10-01 0000919956 avca:SkilledNursingCenterMember stpr:OH 2013-10-01 0000919956 avca:HuntsvilleAlabamaMember 2014-03-01 0000919956 avca:RoseTerraceNoteMember us-gaap:LoansPayableMember 2014-03-27 0000919956 us-gaap:RevolvingCreditFacilityMember 2014-03-30 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2014-04-03 0000919956 avca:NicholasvilleKentuckyMember 2014-06-01 0000919956 avca:NicholasvilleKentuckyMember 2014-06-01 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2014-05-31 0000919956 2014-07-31 0000919956 avca:AvonPlaceMember stpr:OH us-gaap:SubsequentEventMember 2014-08-01 0000919956 avca:OntarioCommonsMember stpr:OH us-gaap:SubsequentEventMember 2014-08-01 0000919956 stpr:OH us-gaap:SubsequentEventMember 2014-08-01 0000919956 avca:CullodenWestVirginiaMember avca:RoseTerraceNursingCenterMember us-gaap:SubsequentEventMember 2014-07-01 0000919956 avca:DanvilleandIvydaleWestVirginiaMember avca:RoseTerraceNursingCenterMember us-gaap:SubsequentEventMember 2014-07-01 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember us-gaap:SubsequentEventMember 2014-07-01 0000919956 stpr:MO us-gaap:SubsequentEventMember 2014-07-01 avca:Bed avca:Center avca:Entity avca:Facility avca:Insurance_Policy avca:Lawsuit avca:Letter_Of_Credit avca:Option avca:State xbrli:pure xbrli:shares iso4217:USD iso4217:USD xbrli:shares 7177000 9356000 32658000 42678000 48516000 51678000 -569000 -594000 594000 19883000 19570000 3879000 4582000 326000 326000 137744000 145635000 60187000 50211000 2913000 2870000 969000 1251000 338000 7693000 15500000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">VARIABLE INTEREST ENTITY</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounting guidance requires that a variable interest entity (&#8220;VIE&#8221;) must be consolidated by the primary beneficiary in accordance with the provisions set forth in FASB ASC 810, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Consolidation</font><font style="font-family:inherit;font-size:10pt;">, as mentioned in Note 2 above. The primary beneficiary is the party that has both the power to direct activities of a VIE that most significantly impact the entity's economic performance and the obligation to absorb losses of the entity or the right to receive benefits from the entity that could potentially be significant to the VIE. We perform an ongoing qualitative analysis to determine if we are the primary beneficiary of a VIE. The Company had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> variable interest entity related to a nursing center in West Virginia that was dissolved in the first quarter of 2014 as a result of the asset purchase of the Rose Terrace nursing center, and is no longer consolidated into the interim consolidated financial statements of the Company. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rose Terrace Health and Rehabilitation Center</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;28, 2011, the Company completed construction of Rose Terrace Health and Rehabilitation Center (&#8220;Rose Terrace&#8221;), its third health care center in West Virginia. The </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center is located in Culloden, West Virginia, along the Huntington-Charleston corridor, and offers 24-hour skilled nursing care designed to meet the care needs of both short and long-term nursing patients. The Rose Terrace nursing center utilizes a Certificate of Need the Company obtained in June 2009, when the Company completed the acquisition of certain assets of a skilled nursing center in West Virginia. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company initially entered into a lease agreement with the real estate developer that constructed, furnished, and equipped Rose Terrace. The agreement included the right to purchase the center and all associated assets beginning at the end of the first year of the initial term of the lease and continuing through the fifth year for a purchase price ranging from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">110%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">120%</font><font style="font-family:inherit;font-size:10pt;"> of the total project cost. On March 27, 2014, the Company exercised this purchase option and acquired the land, building, and all other assets of the Rose Terrace nursing center from the real estate developer for the contractually agreed upon price of </font><font style="font-family:inherit;font-size:10pt;">$7,693,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the exercise of the purchase option, the Company had determined it was the primary beneficiary of the VIE based on the ownership of the Certificate of Need, the fixed price purchase option described above, the Company&#8217;s ability to direct the activities that most significantly impact the economic performance of the VIE, and the right to receive potentially significant benefits from the VIE. Accordingly, as the primary beneficiary, the Company consolidated the balance sheet and results of operations of the VIE for periods prior to the exercise of the purchase option. However, after the exercise of the purchase option, the previous owners paid the outstanding debt related to the entity in full. Subsequently, as further disclosed in Note 11, the Company sold the Rose Terrace facility and all assets associated with the facility. As a result of these events, the entity is no longer considered a VIE as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> 12127000 1200000 43000 2130000 758000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. Any variable interest entities (&#8220;VIEs&#8221;) in which the Company has an interest are consolidated when the Company identifies that it is the primary beneficiary. The Company had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> variable interest entity related to a nursing center in West Virginia that was dissolved in the first quarter of 2014 as a result of the asset purchase of the Rose Terrace nursing center as further described in Note 8, and is no longer consolidated into the interim consolidated financial statements of the Company. The investment in an unconsolidated affiliate (a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50 percent</font><font style="font-family:inherit;font-size:10pt;">-owned joint venture partnership) is accounted for using the equity method and is described in Note&#160;9.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements for the three and six month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, and the results of operations for the three month and six month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, and cash flows for the six month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s balance sheet information at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, was derived from its audited consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> 4071000 3781000 5928000 3949000 -1979000 290000 2048000 -100000 -546000 -5000 -491000 5056000 0.055 0.055 0.11 0.11 0.01 0.01 20000000 20000000 6388000 6307000 6156000 6075000 63000 63000 1056000 -2163000 57000 -3128000 -2147000 1056000 -3094000 32000 50316000 64687000 97828000 127511000 64153000 79580000 124375000 157281000 8000000 0.0465 10524000 1341000 1914000 1860000 36000 -4214000 6666000 6579000 15804000 15912000 1496000 1705000 2938000 3440000 959000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview of Plans</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2005, the Compensation Committee of the Board of Directors adopted the 2005 Long-Term Incentive Plan (&#8220;2005 Plan&#8221;). The 2005 Plan allows the Company to issue stock options and other share and cash based awards. Under the 2005 Plan, </font><font style="font-family:inherit;font-size:10pt;">700,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted thereunder. All grants under this plan expire </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the date the grants were authorized by the Board of Directors.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (&#8220;Stock Purchase Plan&#8221;). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers and </font><font style="font-family:inherit;font-size:10pt;">150,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock has been reserved for issuance under the Stock Purchase Plan. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (&#8220;RSU's&#8221;) at </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. No grants can be made under the Stock Purchase Plan after April 25, 2018. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (&#8220;2010 Plan&#8221;), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. Under the 2010 Plan, </font><font style="font-family:inherit;font-size:10pt;">380,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Grants and Valuations</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors approved grants totaling approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">68,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">69,000</font><font style="font-family:inherit;font-size:10pt;"> shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares are determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed. In addition to the shares of restricted common stock granted in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors also approved grants of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">55,000</font><font style="font-family:inherit;font-size:10pt;"> unrestricted shares of common stock to certain employees. These shares were granted without restrictions and considered fully vested upon the date of the grant.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="240px" rowspan="1" colspan="1"></td><td width="108px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="99px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.58</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, June 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.71</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="240px" rowspan="1" colspan="1"></td><td width="108px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="99px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding June 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="50%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding June 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (&#8220;SOSARs&#8221;) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date, and expire </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the grant date. The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation using the Black-Scholes-Merton equity grant valuation model.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While no SOSARs or Options were granted during </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, previously granted SOSARs and Options remain outstanding as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.28125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.40 to $11.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.37 to $6.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">529,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">306,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$295,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$357,000</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="240px" rowspan="1" colspan="1"></td><td width="108px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="99px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.58</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, June 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.71</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> 128000 242000 -484000 569000 142000 419000 348000 -334000 8987000 8502000 10989000 0 31880000 10222000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">DISCONTINUED OPERATIONS</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">West Virginia Disposition</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective April 3, 2014, the Company entered into an asset purchase agreement with Rose Terrace Acq., LLC (&#8220;Purchaser&#8221;) to sell its skilled nursing facility in Culloden, West Virginia. The original asset purchase agreement was subject to a number of conditions including an amendment to the Master Lease with Omega Health Investors, Inc. ("Omega") to terminate the lease only with respect to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> other skilled nursing facilities in West Virginia, state licensure and regulatory approval. The Company concurrently entered into an operations transfer agreement with respect to the </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> other skilled nursing facilities located in Danville and Ivydale, West Virginia. Effective May 31, 2014, the Company determined that these </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> centers, based on the progress of the underlying contingencies and conditions associated with the asset purchase agreement, met the requirements for classification as discontinued operations. As a result, the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> facilities are reflected as discontinued operations for all periods in the accompanying financial statements. The Company finalized the transaction on July 1, 2014, and is disclosed as a subsequent event in Note 12. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These centers contributed revenues of </font><font style="font-family:inherit;font-size:10pt;">$10,989,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$10,222,000</font><font style="font-family:inherit;font-size:10pt;"> and net income of </font><font style="font-family:inherit;font-size:10pt;">$660,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$906,000</font><font style="font-family:inherit;font-size:10pt;"> during the six months ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160; The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense or any allocation of corporate interest expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Arkansas Lease Termination</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective September 1, 2013, the Company entered into an agreement with Omega Healthcare Investors, Inc. ("Omega") to terminate its lease with respect to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">eleven</font><font style="font-family:inherit;font-size:10pt;"> nursing centers and </font><font style="font-family:inherit;font-size:10pt;">1,181</font><font style="font-family:inherit;font-size:10pt;"> licensed beds located in Arkansas and concurrently entered into operation transfer agreements to transfer the operations of each of those </font><font style="font-family:inherit;font-size:10pt;">eleven</font><font style="font-family:inherit;font-size:10pt;"> centers to an operator selected by Omega. Upon the completion of the transaction, the Company no longer operates any skilled nursing centers in the State of Arkansas. In connection with the closing of this transaction, the Company and Omega entered into the Thirteenth Amendment to Consolidated Amended and Restated Master Lease ("Master Lease") most recently amended on January 22, 2013. This amendment effectively modifies the terms of the Master Lease to terminate the terms surrounding the </font><font style="font-family:inherit;font-size:10pt;">eleven</font><font style="font-family:inherit;font-size:10pt;"> nursing centers in Arkansas, and only as to those </font><font style="font-family:inherit;font-size:10pt;">eleven</font><font style="font-family:inherit;font-size:10pt;"> centers, and effectively reduces the annual rent payable under the Master Lease by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of this transaction, the Company has reclassified the operations of these centers as discontinued operations for all periods presented in the accompanying interim consolidated financial statements. These centers contributed revenues of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$31,880,000</font><font style="font-family:inherit;font-size:10pt;"> and net loss of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$739,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$87,000</font><font style="font-family:inherit;font-size:10pt;"> during the six months ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160; The net loss in 2014 primarily relates to professional liability expense incurred during the first quarter of 2014. The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense or any allocation of corporate interest expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The discontinued assets and liabilities of the disposed skilled nursing centers have been reclassified and are segregated in the interim consolidated balance sheets as assets and liabilities of discontinued operations. The current asset amounts, which are primarily composed of net accounts receivable of </font><font style="font-family:inherit;font-size:10pt;">$2,913,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,870,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, respectively. The current liabilities are primarily composed of outstanding short-term debt on the Rose Terrace facility, trade payables, and various accrued expenses of </font><font style="font-family:inherit;font-size:10pt;">$8,823,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,359,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company expects to collect the balance of the accounts receivable and pay the remaining trade payables and accrued expenses in the ordinary course of business. The short-term debt related to the Rose Terrace facility was paid in full in conjunction with the sale of the facility on July 1, 2014. The Company did not transfer the accounts receivable or liabilities to the new owners or operators of the facilities. Further, in accordance with Company accounting policy, the reserve for professional liability and workers' compensation will remain in the consolidated liability accounts as future payment of these liabilities will be paid through the Company's future operating cash flows.</font></div></div> 86000 86000 172000 172000 -0.39 0.17 -0.57 -0.01 -0.39 0.16 -0.01 -0.57 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EARNINGS (LOSS) PER COMMON SHARE</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net earnings (loss) per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended <br clear="none"/>June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator: Income (loss) amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">973</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,421</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,695</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: income (loss) attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">973</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,437</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,729</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock dividends</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">887</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,523</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">393</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,901</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(484</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">569</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to Diversicare Healthcare Services, Inc. common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,332</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended <br clear="none"/>June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss), net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss), net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator: Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,874</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,861</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,874</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,861</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effects of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">326,000</font><font style="font-family:inherit;font-size:10pt;"> SOSARs and options outstanding were excluded from the computation of diluted earnings per common share for the three-month and six-month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, because these securities would have been anti-dilutive due to the net loss. The weighted average common shares for basic and diluted earnings for common shares were the same due to the year-to-date loss in these periods.</font></div></div> 13203000 12255000 0.50 487000 428000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EQUITY METHOD INVESTMENT</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The investment in unconsolidated affiliate reflected on the interim consolidated balance sheet relates to a pharmacy joint venture partnership in which the Company owns </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;">. The joint venture was initially funded by the Company and its partner and began operations during 2012. This investment in unconsolidated affiliate is accounted for using the equity method as the Company exerts significant influence, but does not control or otherwise consolidate the entity. The investment in unconsolidated affiliate balance at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$428,000</font><font style="font-family:inherit;font-size:10pt;"> as compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$487,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">. Additionally, the Company's share of the net profits and losses of the unconsolidated affiliate are reported in equity in net earnings or losses of unconsolidated affiliate in our statement of operations. The Company's equity in the net losses of unconsolidated affiliate for the six month period ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;">$59,000</font><font style="font-family:inherit;font-size:10pt;"> as compared to </font><font style="font-family:inherit;font-size:10pt;">$215,000</font><font style="font-family:inherit;font-size:10pt;"> for the six month period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> 8000000 0 -320000 5381000 5779000 10495000 10763000 82313000 61488000 160112000 119927000 973000 -2421000 540000 -3695000 1728000 -3708000 931000 -6268000 565000 -2437000 -3729000 973000 -0.43 0.15 0.07 -0.67 0.14 -0.43 0.07 -0.67 242000 128000 -484000 569000 906000 660000 -739000 -87000 -484000 569000 128000 242000 0.04 0.02 -0.08 0.10 0.02 0.04 0.10 -0.08 22000 -56000 -215000 -59000 -1287000 755000 -2573000 391000 45000 33000 747000 763000 3447000 974000 -1929000 146000 13166000 5640000 4641000 -35000 771000 827000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">INSURANCE MATTERS</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Professional Liability and Other Liability Insurance</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, consolidated offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (&#8220;SHC&#8221;) which has issued a policy insuring claims made against all of the Company's nursing centers in Florida, Tennessee, and West Virginia as well as the Company&#8217;s formerly operated Arkansas facilities. Several of the Company&#8217;s nursing centers in Alabama, Kentucky, Ohio, and Texas</font><font style="font-family:inherit;font-size:10pt;color:#1f497d;"> </font><font style="font-family:inherit;font-size:10pt;">are also covered under this policy. The SHC policy provides coverage limits of either </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> per medical incident with a sublimit per center of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> and total annual aggregate policy limits of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;">. The remaining nursing centers are covered by one of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> claims made professional liability insurance policies purchased from entities unaffiliated with the Company. These policies provide coverage limits of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> per claim and have sublimits of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;"> per center, with varying aggregate policy limits.&#160; </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reserve for Estimated Self-Insured Professional Liability Claims</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the Company&#8217;s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company&#8217;s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$27,695,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of the current portion of this reserve. Merlinos&#160;&amp; Associates, Inc. (&#8220;Merlinos&#8221;) assisted management in the preparation of an estimate of the appropriate accrual for the current claims period and for incurred, but not reported, general and professional liability claims based on data furnished as of May 31, 2014.&#160; The Company used this estimate from Merlinos in the preparation of its estimate of liability for incurred, but unreported professional liability claims as of as of June 30, 2014.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company&#8217;s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator&#8217;s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company&#8217;s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company is engaged in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">53</font><font style="font-family:inherit;font-size:10pt;"> professional liability lawsuits. </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Nine</font><font style="font-family:inherit;font-size:10pt;"> lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company&#8217;s cash expenditures for self-insured professional liability costs from continuing operations were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,225,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,134,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows current accounting guidance set forth in FASB ASU 2010-24, &#8220;Presentation of Insurance Claims and Related Insurance Recoveries,&#8221; that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim, and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the Company has recorded assets and equal liabilities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$70,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$440,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company&#8217;s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company&#8217;s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company&#8217;s reported earnings and financial position for the period in which the change in accrual is made.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Insurance</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to workers&#8217; compensation insurance, substantially all of the Company&#8217;s employees became covered under either an indemnity insurance plan or state-sponsored programs in May 1997. The Company is completely self-insured for workers&#8217; compensation exposures prior to May 1997. The Company has been and remains a non-subscriber to the Texas workers&#8217; compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June&#160;30, 2003 until June&#160;30, 2007, the Company&#8217;s workers&#8217; compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July&#160;1, 2008 through </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> per claim, subject to an aggregate maximum of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;">. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers&#8217; compensation claims is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$328,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. The Company has a non-current receivable for workers&#8217; compensation policies covering previous years of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,130,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. The non-current receivable is a function of payments paid to the Company&#8217;s insurance carrier in excess of the estimated level of claims expected to be incurred.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$175,000</font><font style="font-family:inherit;font-size:10pt;"> per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$900,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. The differences between actual settlements and reserves are included in expense in the period finalized.</font></div></div> 440000 70000 949000 745000 1841000 1285000 1076000 1652000 P5Y P5Y P5Y P5Y P15Y P10Y P15Y P15Y P15Y P10Y 137744000 145635000 42167000 59322000 73750000 81093000 8823000 1359000 5952000 0 900000 20000000 22500000 27500000 20000000 65000000 3000000 7712000 9000000 43120000 43552000 4549000 10334000 0.0687 0.0687 0.045 0.045 5000000 500000 500000 1000000 27695000 1758000 1556000 3265000 3617000 1437000 0 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diversicare Healthcare Services, Inc. (together with its subsidiaries, &#8220;Diversicare Healthcare Services&#8221; or the &#8220;Company&#8221;) provides long-term care services to nursing center patients in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">eight</font><font style="font-family:inherit;font-size:10pt;"> states, primarily in the Southeast, Midwest, and Southwest. The Company&#8217;s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. In addition to the nursing, personal care and social services usually provided in long-term care centers, the Company&#8217;s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Ohio, Tennessee, and Texas. The Company's operating results also include the results of certain discontinued operations that have been reclassified on the face of the financial statements to reflect the discontinued status of these operations. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s continuing operations consist of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">46</font><font style="font-family:inherit;font-size:10pt;"> nursing centers with </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,282</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds. The Company owns </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">13</font><font style="font-family:inherit;font-size:10pt;"> and leases </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33</font><font style="font-family:inherit;font-size:10pt;"> of its nursing centers. The nursing center and licensed bed count includes the following recent business development activity:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">73</font><font style="font-family:inherit;font-size:10pt;">-bed facility in Nicholasville, Kentucky, for which the Company entered into a lease agreement and assumed operations effective June 1, 2014. The Medicaid and Medicare certification processes for this facility are currently underway, and are expected to be completed in the fourth quarter of 2014. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">135</font><font style="font-family:inherit;font-size:10pt;">-bed facility in Huntsville, Alabama, for which the Company entered into a lease agreement and assumed operations effective March 1, 2014. The Medicaid and Medicare certification processes for this facility are currently underway, and are expected to be completed in the third quarter of 2014. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">442</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds at the </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> recently leased skilled nursing centers, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> in Ohio and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> in Indiana, which we have operated since October 1, 2013. The Medicaid and Medicare certification processes were completed for these </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> leased facilities in the first quarter of 2014. In addition to the licensed nursing beds, these </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> centers also include </font><font style="font-family:inherit;font-size:10pt;">270</font><font style="font-family:inherit;font-size:10pt;"> licensed assisted living beds which are not included in the licensed nursing bed count. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">107</font><font style="font-family:inherit;font-size:10pt;">-bed facility in Louisville, Kentucky, for which the Company entered into a lease agreement in August 2013. The Medicare certification processes for this facility was completed in the first quarter of 2014. The Medicaid certification process was completed in the second quarter of 2014. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Kansas centers acquired in May 2013, which comprise </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> skilled nursing centers and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">418</font><font style="font-family:inherit;font-size:10pt;"> licensed beds. The Medicaid certification process was completed for these facilities during the second quarter of 2013, and the Medicare certification process was completed for these facilities during the third quarter of 2013.</font></div></td></tr></table></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS DEVELOPMENT</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 6, 2013, the Company entered into an asset purchase agreement ("the Agreement") with Cumberland &amp; Ohio Co. of Texas, as receiver of the assets of SeniorTrust of Florida, Inc. to acquire certain land, improvements, furniture, fixtures and equipment, and personal property of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> facilities, all located in Kansas, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15,500,000</font><font style="font-family:inherit;font-size:10pt;">. The purchase of the Kansas facilities was completed on May 1, 2013. The Company also incurred </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$338,000</font><font style="font-family:inherit;font-size:10pt;"> in acquisition-related expenses associated with this transaction. The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> facilities acquired under the Agreement include the following:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">77</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility known as Chanute HealthCare Center</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">119</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility known as Haysville HealthCare Center</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">80</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility known as Larned HealthCare Center</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">62</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility known as Sedgwick HealthCare Center</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-transform:default;">80</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility known as Council Grove HealthCare Center</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the consummation of the Agreement, the Company allocated the purchase price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15,500,000</font><font style="font-family:inherit;font-size:10pt;"> between the assets associated with the transaction based on the fair value of the acquired net assets. In addition to the assets acquired in the transaction, the Company also assumed liabilities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$758,000</font><font style="font-family:inherit;font-size:10pt;"> which resulted in total cash outlay of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$14,742,000</font><font style="font-family:inherit;font-size:10pt;">. The allocation of the purchase price was determined with the assistance of HealthTrust LLC, a third-party real estate valuation firm. The allocation for the net assets acquired is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:52.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="63%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="35%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of May 1, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,130,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,127,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, fixtures, and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Liabilities assumed</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">758,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash paid</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,742,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lease Agreements</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2014, the Company assumed operations at Diversicare of Nicholasville, an existing </font><font style="font-family:inherit;font-size:10pt;">73</font><font style="font-family:inherit;font-size:10pt;">-bed facility in Nicholasville, Kentucky. The nursing center is owned by a real estate investment trust ("REIT"), and the lease provides for an initial </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;">-year lease term with a </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 1, 2014, the Company assumed operations at Diversicare of Big Springs, an existing </font><font style="font-family:inherit;font-size:10pt;">135</font><font style="font-family:inherit;font-size:10pt;">-bed facility in Huntsville, Alabama. The nursing center is owned by an unrelated third-party and the lease provides for an initial </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">-year lease term with </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> additional </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">-year renewal options. The additional skilled nursing center increases the Company's footprint in Alabama to </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> centers, and the third center in the Huntsville market. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 1, 2013, the Company assumed operations at </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> existing nursing centers, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> in Ohio and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> in Indiana. The nursing centers are owned by a REIT and the lease of these centers provides for an initial </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;">-year lease term with a </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">-year renewal option. This transaction represents an increase in the Company's footprint in the Midwest, expanding into one new state, Indiana, and increasing our presence in Ohio to </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> nursing centers. All </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> of the centers were operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 1, 2013, the Company assumed operations at Seneca Place, an existing </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">107</font><font style="font-family:inherit;font-size:10pt;">-bed facility in Louisville, Kentucky.&#160; The nursing center is owned by a REIT, and the lease provides for an initial </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15</font><font style="font-family:inherit;font-size:10pt;">-year lease term with a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5</font><font style="font-family:inherit;font-size:10pt;">-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.</font></div></div> 19900000 4823000 2775000 20000000 -1839000 -22345000 -21799000 -1834000 -2694000 466000 -4590000 -2203000 -2195000 1101000 81000 -3160000 0 16000 34000 -25000 1015000 -2281000 -91000 -3332000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">RECENT ACCOUNTING GUIDANCE</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2013, the FASB issued Accounting Standards Update ("ASU") 2013-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income</font><font style="font-family:inherit;font-size:10pt;">. The amendments in this update require an entity to provide information about the amounts reclassified from accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the income statement or in the notes, significant amounts reclassified from accumulated other comprehensive income by the net income line item. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the FASB issued ASU 2014-08,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity</font><font style="font-family:inherit;font-size:10pt;">&#160;changing the criteria for reporting discontinued operations. The ASU states that only those disposed components (or components held-for-sale) representing a strategic shift that have a significant effect on operations and financial results will be reported in discontinued operations. The ASU also required expanded disclosures about discontinued operations in the financial statement notes. The ASU is effective for disposals (or classifications as held-for-sale) that occur within annual periods beginning on or after December&#160;15, 2014 and interim periods within those annual periods. Early application is permitted, but only for those disposals that have not been reported in financial statements previously issued or available for issuance. We have chosen to early adopt this ASU and have applied the new criteria in determining the accounting treatment for the nursing centers exited during 2014. The adoption of this guidance did not have a material impact on the Company's consolidated financial results.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No.&#160;2014-09,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January&#160;1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.</font></div></div> -1005000 -1043000 -1820000 -1900000 8 2733000 -2665000 -4448000 2831000 4804000 6251000 12218000 9581000 33314000 33490000 32000 -45000 -24000 32000 129000 78000 78000 248000 84000 110000 224000 110000 4829000 5116000 15214000 14484000 124000 315000 0 43000 323000 662000 172000 172000 1341000 114000 298000 288000 14742000 14742000 14742000 0 1826000 2416000 104000 1410000 0.1 0.10 200000 200000 0 0 0 0 0 0 1925000 2442000 9765000 45000000 33000 78000 -2179000 1101000 -3126000 56000 95310000 93572000 54043000 52134000 1830000 2780000 1118000 1187000 4412000 22805000 -8435000 -9207000 17000000 9000000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net earnings (loss) per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended <br clear="none"/>June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator: Income (loss) amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">973</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,421</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,695</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: income (loss) attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">973</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,437</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,729</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock dividends</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">887</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,523</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">393</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,901</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(484</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">569</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to Diversicare Healthcare Services, Inc. common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,332</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended <br clear="none"/>June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss), net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss), net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator: Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,874</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,861</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,874</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,861</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allocation for the net assets acquired is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:52.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="63%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="35%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of May 1, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,130,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,127,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, fixtures, and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Liabilities assumed</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">758,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash paid</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,742,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.28125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.40 to $11.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.37 to $6.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">529,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">306,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="240px" rowspan="1" colspan="1"></td><td width="108px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="99px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding June 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="50%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding June 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> 12777000 11711000 16375000 16146000 295000 357000 1000 0 5.42 0.00 68000 55000 68000 69000 25000 5.51 5.51 118000 147000 46000 41000 2000 1000 40000 21000 5.47 5.70 150000 380000 700000 2.37 10.4 6.21 11.59 7645000 8129000 9566000 7645000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">SUBSEQUENT EVENTS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective July 1, 2014, subsequent to the end of the second quarter, the Company completed the transaction with Rose Terrace Acq., LLC to sell Rose Terrace, a </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility in Culloden, West Virginia for a sales price of </font><font style="font-family:inherit;font-size:10pt;">$16.5 million</font><font style="font-family:inherit;font-size:10pt;">. The Company also agreed to an amendment to the Master Lease with Omega Health Investors, Inc. to terminate the lease only with respect to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> other skilled nursing facilities in West Virginia, and concurrently entered into an operations transfer agreement with American Health Care Management, LLC, an affiliate of the purchaser with respect to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> other skilled nursing facilities located in Danville and Ivydale, West Virginia. Upon completion of the transaction, Diversicare no longer operates any skilled nursing centers in the state of West Virginia. In conjunction with the closing of the sale, the Company paid the balance of the </font><font style="font-family:inherit;font-size:10pt;">$8,000,000</font><font style="font-family:inherit;font-size:10pt;"> mortgage loan outstanding on the Rose Terrace facility. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In a separate and unrelated transaction, the Company also completed a transaction to enter the state of Missouri through the assumption of operations of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> facilities totaling </font><font style="font-family:inherit;font-size:10pt;">339</font><font style="font-family:inherit;font-size:10pt;"> skilled nursing beds effective July 1, 2014. This portfolio is expected to contribute in excess of </font><font style="font-family:inherit;font-size:10pt;">$17 million</font><font style="font-family:inherit;font-size:10pt;"> in annual revenues with initial lease terms of </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> years. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also effective July 1, 2014, the Company entered into the Third Amendment to the Amended and Restated Revolver ("Third Amendment"). The Third Amendment makes the previously temporary increase to the Amended Revolver capacity from the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000,000</font><font style="font-family:inherit;font-size:10pt;"> in the original Amended Revolver to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$27,500,000</font><font style="font-family:inherit;font-size:10pt;"> as defined in the Second Amendment, a permanent change to the borrowing capacity as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective August 1, 2014, the Company completed a transaction to assume operations of </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> facilities in Ohio. The facilities included in this transaction are Avon Place, a </font><font style="font-family:inherit;font-size:10pt;">142</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility, and Ontario Commons, a </font><font style="font-family:inherit;font-size:10pt;">42</font><font style="font-family:inherit;font-size:10pt;">-bed assisted living facility. The assumption of operations at Ontario Commons represents the Company's first and only all-assisted living facility in the current portfolio. These facilities are expected to contribute in excess of </font><font style="font-family:inherit;font-size:10pt;">$9 million</font><font style="font-family:inherit;font-size:10pt;"> in annual revenues with initial lease terms of </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div></div> 4918000 4918000 5000 5000 5000 5000 5000 5000 232000 232000 2500000 2500000 5874000 6181000 5861000 5995000 5874000 6015000 5861000 5995000 328000 320000 0 0 320000 8036000 8228000 13 P5Y 16500000 175000 393000 -2523000 887000 -3901000 0.10 -0.08 0.02 0.04 0.10 0.02 -0.08 0.04 -59000 36000 1.10 1.20 5000000 11 11 0.03 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">LONG-TERM DEBT AND INTEREST RATE SWAP</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company&#8217;s revolving credit agreement ("Original Revolver"). On May 1, 2013, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated February 28, 2011. The Credit Agreement increases the Company's borrowing capacity to </font><font style="font-family:inherit;font-size:10pt;">$65,000,000</font><font style="font-family:inherit;font-size:10pt;"> allocated between a </font><font style="font-family:inherit;font-size:10pt;">$45,000,000</font><font style="font-family:inherit;font-size:10pt;"> Mortgage Loan ("Amended Mortgage Loan") and a </font><font style="font-family:inherit;font-size:10pt;">$20,000,000</font><font style="font-family:inherit;font-size:10pt;"> Revolver ("Amended Revolver"). Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1,341,000</font><font style="font-family:inherit;font-size:10pt;"> and are being amortized over the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;">-year term of the agreements.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45,000,000</font><font style="font-family:inherit;font-size:10pt;"> with a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;">-year maturity through April 30, 2018, and a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000,000</font><font style="font-family:inherit;font-size:10pt;"> Amended Revolver through April 30, 2018. The Amended Mortgage Loan has a term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> years, with principal and interest payable monthly based on a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25</font><font style="font-family:inherit;font-size:10pt;">-year amortization. Interest is based on LIBOR plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">4.5%</font><font style="font-family:inherit;font-size:10pt;">. A portion of the Amended Mortgage Loan is effectively fixed at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.87%</font><font style="font-family:inherit;font-size:10pt;"> pursuant to an interest rate swap with a notional amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21,973,000</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the interest rate related to the Amended Mortgage Loan was </font><font style="font-family:inherit;font-size:10pt;">4.65%</font><font style="font-family:inherit;font-size:10pt;">. The Amended Mortgage Loan is secured by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">thirteen</font><font style="font-family:inherit;font-size:10pt;"> owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized. The Company&#8217;s Amended Revolver has an interest rate of LIBOR plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">4.5%</font><font style="font-family:inherit;font-size:10pt;"> and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective March 31, 2014, the Company entered into the Second Amendment to the Amended and Restated Revolver ("Second Amendment"). The Second Amendment temporarily increased the Amended Revolver capacity from the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000,000</font><font style="font-family:inherit;font-size:10pt;"> in the original Amended Revolver to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$27,500,000</font><font style="font-family:inherit;font-size:10pt;"> through September 30, 2014, as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process. The Second Amendment also provided for a permanent increase in the Amended Revolver capacity to </font><font style="font-family:inherit;font-size:10pt;">$22,500,000</font><font style="font-family:inherit;font-size:10pt;"> beginning October 1, 2014 through the original maturity date of April 30, 2018, to reflect the expansion of the Company's business through new facility acquisitions. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$9,000,000</font><font style="font-family:inherit;font-size:10pt;"> borrowings outstanding under the revolving credit facility compared to </font><font style="font-family:inherit;font-size:10pt;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">. The outstanding borrowings on the revolver primarily reflect the Company's approach to accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under this Revolver are </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3.00%</font><font style="font-family:inherit;font-size:10pt;"> of the amount outstanding. The Company has </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;"> letters of credit with a total value of </font><font style="font-family:inherit;font-size:10pt;">$7,712,000</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. Considering the balance of eligible accounts receivable, the letter of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$27,500,000</font><font style="font-family:inherit;font-size:10pt;">, the balance available for borrowing under the revolving credit center is </font><font style="font-family:inherit;font-size:10pt;">$10,524,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective March 27, 2014, the Company executed its purchase option to acquire all assets associated with the Rose Terrace nursing center in Culloden, West Virginia from Milton Holdings, LLC which was considered a variable interest entity ("VIE") by the Company and consolidated prior to the date of this transaction. See Note 8 for further information on the VIE considerations. In conjunction with the purchase of the assets, the Company entered into an interest-only </font><font style="font-family:inherit;font-size:10pt;">$8,000,000</font><font style="font-family:inherit;font-size:10pt;"> term loan ("Rose Terrace Note") with a maturity date of March 27, 2015. The structure of the Rose Terrace Note reflected the Company's intent to sell the property and transfer operations to an unrelated third-party operator as further disclosed in Note 12. This transaction closed on July 1, 2014. As such, the Rose Terrace Note is classified as a Current Liability of Discontinued Operations on the Interim Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s debt agreements contain various financial covenants, the most restrictive of which relate to minimum cash deposits, cash flow and debt service coverage ratios. The Company is in compliance with all such covenants at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Rate Swap Transaction</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the debt agreements entered into in March 2011, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the amendment to the credit facility, the Company retained the previously agreed upon interest rate swap terms, and redesignated the interest rate swap as a cash flow hedge. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21,973,000</font><font style="font-family:inherit;font-size:10pt;"> at an annual fixed rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.87%</font><font style="font-family:inherit;font-size:10pt;"> while the bank is obligated to make payments to the Company based on LIBOR on the same notional amounts. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that the interest rate swap was effective. The interest rate swap valuation model indicated a net liability of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$959,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the interest rate swap is included in &#8220;other noncurrent liabilities&#8221; on the Company&#8217;s interim consolidated balance sheet. The balance of accumulated other comprehensive loss at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$594,000</font><font style="font-family:inherit;font-size:10pt;"> and reflects the liability related to the interest rate swap, net of the income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$364,000</font><font style="font-family:inherit;font-size:10pt;">. As the Company&#8217;s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> P5Y 45000000 45000000 3000000 1000000 3000000 2225000 2134000 2 P25Y -364000 270 442 418 5282 107 73 135 90 80 73 77 107 62 119 80 1181 339 42 90 142 5 4 1 46 3 4 3 7 1 2 3 3 2 2 2 33 13 9 53 3 1 8 6217000 5698000 0.1 0.10 0 450000 262000 6.71 1000 27000 7.49 0 0 529000 305000 333000 5.32 11.13 6.64 6.58 5.41 5.45 5.30 5.35 0.85 0.33 2.37 0.00 P10Y 262000 63000 199000 306000 63000 243000 6.86 6.86 P2Y 1130000 false --12-31 Q2 2014 2014-06-30 10-Q 0000919956 6156428 Smaller Reporting Company Diversicare Healthcare Services, Inc. 21973000 EX-101.SCH 9 avca-20140630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Business (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Business Development link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Business Development (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Business Development (Schedule of Assets Acquired) (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Business Development (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Consolidation and Basis of Presentation of Financial Statements link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Consolidation and Basis of Presentation of Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Earnings (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Earnings (Loss) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Earnings (Loss) Per Common Share (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Earnings (Loss) Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Equity Method Investment link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - Equity Method Investment (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Insurance Matters link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Insurance Matters (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Interim Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Interim Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Interim Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Interim Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Interim Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - Interim Consolidated Statements of Operations (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Long-Term Debt and Interest Rate Swap link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Long-Term Debt and Interest Rate Swap (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Recent Accounting Guidance link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable) (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Variable Interest Entity link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Variable Interest Entity (Details Textual) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 avca-20140630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 avca-20140630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 avca-20140630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Combinations [Abstract] VARIABLE INTEREST ENTITY Business Combination Disclosure [Text Block] Document and Entity Information [Abstract] Document and entity information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Earnings Per Share [Abstract] Basic and diluted net income (loss) per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Income (loss) from continuing operations Income (Loss) from Continuing Operations Attributable to Parent Adjustments to reconcile loss from continuing operations to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Provision for doubtful accounts Provision for Doubtful Accounts Deferred income tax benefit Deferred Income Tax Expense (Benefit) Provision for self-insured professional liability, net of cash payments Increase (Decrease) in Self Insurance Reserve Stock-based compensation Share-based Compensation Equity in net losses of unconsolidated affiliate, net of investment Income (Loss) from Equity Method Investments, Net of Contributions Paid Income (Loss) from Equity Method Investments, Net of Contributions Paid Debt retirement costs Gains (Losses) on Extinguishment of Debt Other Other Noncash Income (Expense) Changes in assets and liabilities affecting operating activities: Increase (Decrease) in Operating Capital [Abstract] Receivables, net Increase (Decrease) in Receivables Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Trade accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Net cash provided by (used in) continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Acquisition of property and equipment through business combination Payments to Acquire Businesses, Net of Cash Acquired Change in restricted cash Increase (Decrease) in Restricted Cash Deposits and other deferred balances Payments for (Proceeds from) Other Investing Activities Net cash used in continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Repayment of debt obligations Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Proceeds from issuance of debt Proceeds from Issuance of Long-term Debt and Capital Securities, Net Financing costs Payments of Financing Costs Issuance and redemption of employee equity awards Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Payment of common stock dividends Payments of Ordinary Dividends, Common Stock Payment of preferred stock dividends Payments of Ordinary Dividends, Preferred Stock and Preference Stock Distributions to noncontrolling interest Payments to Noncontrolling Interests Payment for preferred stock restructuring Payments of Stock Issuance Costs Net cash provided by continuing operations Net Cash Provided by (Used in) Financing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Financing Activities, Discontinued Operations Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, beginning of period Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL INFORMATION: Supplemental Cash Flow Information [Abstract] Cash payments of interest, net of amounts capitalized Interest Paid, Net Cash payments of income taxes Income Taxes Paid, Net Debt Disclosure [Abstract] LONG-TERM DEBT AND INTEREST RATE SWAP Long Term Debt And Derivative Instruments [Text Block] Long Term Debt And Derivative Instruments [Text Block] Insurance [Abstract] Schedule of Malpractice Insurance [Table] Schedule of Malpractice Insurance [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] SHC Risk Carriers, Inc SHC Risk Carriers, Inc [Member] SHC Risk Carriers, Inc [Member] Unaffiliated Entities Unaffiliated Entities [Member] Unaffiliated Entities [Member] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Professional malpractice liability insurance Professional Malpractice Liability Insurance [Member] Prefunded deductible policy Prefunded Deductible Policy [Member] Prefunded deductible policy. Trial or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Trial or Arbitration Schedule Timeframe [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months Scheduled for trial or arbitration over next 12 months Trial Or Arbitration Schedule Timeframe [Member] Trial Or Arbitration Schedule Timeframe [Member] Malpractice Insurance [Line Items] Malpractice Insurance [Line Items] Insurance policy coverage limits per claim Malpractice Insurance, Maximum Coverage Per Incident Annual sublimit per center Malpractice Insurance Annual Sublimit Per Center Malpractice Insurance Annual Sublimit Per Center Maximum annual coverage Malpractice Insurance, Annual Coverage Limit Number of types of professional liability insurance policies Number Of Types Of Professional Liability Insurance Policies Number Of Types Of Professional Liability Insurance Policies Liability for reported and estimated future claims Malpractice Loss Contingency, Accrual, Undiscounted Number of professional liability lawsuits Number Of Professional Liability Lawsuits Number Of Professional Liability Lawsuits Cash expenditures for self-insured professional liability costs Malpractice Insurance Self Insured Costs Paid During Period Malpractice Insurance Self Insured Costs Paid During Period Non-current receivables for workers' compensation policy Insurance Receivable for Malpractice Other Insurance Industry Disclosures [Abstract] Other Insurance Industry Disclosures [Abstract] Professional liability insurance, annual coverage limit per facility Malpractice Insurance Annual Coverage Limit Per Facility Malpractice Insurance Annual Coverage Limit Per Facility Liability for workers compensation claims Workers' Compensation Liability Workers compensation insurance, non current receivable for excess premiums paid Workers Compensation Receivable For Excess Premiums Paid Workers Compensation Receivable For Excess Premiums Paid Health insurance, maximum self-insured annual amount per individual Employee Health Insurance Maximum Payable Per Individual Annually Employee Health Insurance Maximum Payable Per Individual Annually Liability for reported claims and estimates for incurred but unreported claims Liability for Future Policy Benefits Organization, Consolidation and Presentation of Financial Statements [Abstract] BUSINESS DEVELOPMENT Nature of Operations [Text Block] Statement of Comprehensive Income [Abstract] NET INCOME (LOSS) OTHER COMPREHENSIVE INCOME (LOSS): Other Comprehensive Income (Loss), Net of Tax [Abstract] Change in fair value of cash flow hedge, net of tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Less: reclassification adjustment for amounts recognized in net income Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Less: comprehensive (income) loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Earnings (Loss) Per Common Share (Textual) [Abstract] Earnings Loss Per Common Share (Textual) [Abstract] Earnings loss per common share. Antidilutive shares excluded from computation of diluted earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Entity Location [Table] Entity Location [Table] Entity by Location [Axis] Entity by Location [Axis] Location [Domain] Location [Domain] Nicholasville, Kentucky Nicholasville, Kentucky [Member] Nicholasville, Kentucky [Member] Huntsville, Alabama Huntsville, Alabama [Member] Huntsville, Alabama [Member] Ohio and Indiana Ohio and Indiana [Member] Ohio and Indiana [Member] Ohio OHIO Indiana INDIANA Louisville, KY Louisville Kentucky [Member] Louisville Kentucky [Member] Kansas KANSAS Entity Location [Line Items] Entity Location [Line Items] Number of states in which entity operates Number of States in which Entity Operates Number of nursing centers Number Of Nursing Center Facilities Number Of Nursing Center Facilities Number of licensed nursing beds Number of Licensed Nursing Beds Number of licensed nursing beds. Number of nursing center facilities owned Number Of Nursing Center Facilities Owned Number Of Nursing Center Facilities Owned Number of nursing center facilities leased Number Of Nursing Center Facilities Leased Number Of Nursing Center Facilities Leased Number of beds not included in recently leased skilled nursing center Number of Beds Not Included In Recently Leased Skilled Nursing Center Number of beds not included in recently leased skilled nursing center. Line of Credit Facility [Table] Line of Credit Facility [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Revolving credit facility Revolving Credit Facility [Member] Loans Payable Loans Payable [Member] Letter of Credit Letter of Credit [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Maximum Maximum [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Revolving Credit Facility Interest at 4.5% Percent Above LIBOR Revolving Credit Facility Interest At Four Point Five Percent Above LIBOR [Member] Revolving Credit Facility Interest At Four Point Five Percent Above LIBOR [Member] Rose Terrace Note Rose Terrace Note [Member] Rose Terrace Note [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] LIBOR London Interbank Offered Rate [Member] London interbank offered rate. Interest rate swap Interest Rate Swap [Member] Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Long-Term Debt and Interest Rate Swap (Textual) [Abstract] Long-Term Debt and Interest Rate Swap (Textual) [Abstract] Long-term debt and interest rate swap. Revolving credit facility and the maximum loan Line of Credit Facility, Maximum Borrowing Capacity Long-term debt for syndicate of banks mortgage debt Long-Term Debt for Syndicate of Banks Mortgage Debt Long-term debt for syndicate of banks mortgage debt . Long-term debt revolving credit facility Line of Credit Facility, Amount Outstanding Loan acquisition costs Debt Issuance Cost Term of debt agreement Debt Instrument, Term of Debt Agreement Debt Instrument, Term of Debt Agreement Long-term debt five year maturity Long Term Debt Five Year Maturity Long-term debt five year maturity. Mortgage loan with principal and interest payable monthly based Mortgage Loan With Principal and Interest Payable Monthly Based Mortgage loan with principal and interest payable monthly based. Long-term debt interest based on LIBOR Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate Long-term debt fixed based on the interest rate swap Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate Notional Amount of interest rate derivatives Derivative, Notional Amount Debt interest rate at period end Debt Instrument, Interest Rate at Period End Number of owned nursing centers secured Debt Instrument Collateral Number Of Owned Nursing Centers Debt Instrument Collateral Number Of Owned Nursing Centers Borrowings outstanding Long-term Debt Letters of credit issued under Revolver outstanding Letters of Credit Issued Under Revolver Outstanding Letters of credit issued under this revolver outstanding. Number of letters of credit Number of Letters of Credit Number of Letters of Credit Borrowing under the revolving credit facility Debt Instrument, Unused Borrowing Capacity, Amount Amount of term loan Debt Instrument, Face Amount Liability at fair value Derivative Liability, Fair Value, Gross Liability Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Net income tax benefit Net Income Tax Benefit Net income tax benefit. INSURANCE MATTERS Insurance Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock Options and Stock Appreciation Rights (SARs) Stock Options and Stock Appreciation Rights (SARs) [Member] Stock Options and Stock Appreciation Rights (SARs) [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, December 31, 2013 Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number Granted Share-based Compensation Arrangement by Share-based Payment Award, Awards, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Awards, Grants in Period, Gross Exercised Share-based Compensation Arrangement By Share Based Payment Award Awards Exercises In Period Share-based Compensation Arrangement By Share Based Payment Award Awards Exercises In Period Expired or cancelled Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Outstanding, June 30, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, December 31, 2013 Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Granted Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Exercised Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Expired or cancelled Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Outstanding, June 30, 2014 Exercisable, shares Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Number Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Number Exercisable, Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Geographical [Axis] Geographical [Axis] Segment, Geographical [Domain] Geographical [Domain] Skilled Nursing Facility Name [Axis] Skilled Nursing Facility Name [Axis] Skilled Nursing Facility Name [Axis] Skilled Nursing Facility Name [Domain] Skilled Nursing Facility Name [Domain] [Domain] for Skilled Nursing Facility Name [Axis] Chanute HealthCare Center Chanute HealthCare Center [Member] Chanute HealthCare Center [Member] Council Grove HealthCare Center Council Grove HealthCare Center [Member] Council Grove HealthCare Center [Member] Haysville HealthCare Center Haysville HealthCare Center [Member] Haysville HealthCare Center [Member] Larned HealthCare Center Larned HealthCare Center [Member] Larned HealthCare Center [Member] Sedgwick HealthCare Center Sedgwick HealthCare Center [Member] Sedgwick HealthCare Center [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Skilled Nursing Center Skilled Nursing Center [Member] Skilled Nursing Center [Member] Purchase Price Business Combination, Consideration Transferred Acquisition-related expenses Business Combination, Acquisition Related Costs Less: Liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Total cash outlay Payments to Acquire Businesses, Gross Lease agreement term Lessee Leasing Arrangements, Operating Leases, Term of Contract Lease renewal period Lessee Leasing Arrangements, Operating Leases, Renewal Term Maximum number of capital lease renewal periods Maximum Number Of Lease Renewal Periods Maximum Number Of Lease Renewal Periods Subsequent Events [Abstract] SUBSEQUENT EVENTS Subsequent Events [Text Block] Discontinued Operations and Disposal Groups [Abstract] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] West Virginia WEST VIRGINIA Omega Healthcare Investors, Inc. Omega Healthcare Investors, Inc. [Member] Omega Healthcare Investors, Inc. [Member] Arkansas ARKANSAS Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Groups, Including Discontinued Operations, Name [Domain] Disposal Groups, Including Discontinued Operations, Name [Domain] Rose Terrace Nursing Center Rose Terrace Nursing Center [Member] Rose Terrace Nursing Center [Member] Leased Skilled Nursing Centers Leased Skilled Nursing Centers [Member] Leased Skilled Nursing Centers [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Revenue from discontinued operations Disposal Group, Including Discontinued Operation, Revenue Income (loss) from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Number of nursing centers under lease terminated Lease Termination, Number of Nursing Centers under Lease Terminated Lease Termination, Number of Nursing Centers under Lease Terminated Annual decrease in rent payable, amount Lease Termination, Annual Decrease in Rent Payable, Amount Lease Termination, Annual Decrease in Rent Payable, Amount Current assets of discontinued operations Assets of Disposal Group, Including Discontinued Operation, Current Current liabilities of discontinued operations Liabilities of Disposal Group, Including Discontinued Operation, Current Statement of Financial Position [Abstract] CURRENT ASSETS: Assets, Current [Abstract] Cash and cash equivalents Receivables, less allowance for doubtful accounts of $4,582 and $3,879, respectively Accounts Receivable, Net, Current Other receivables Receivables, Net, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Income tax refundable Income Taxes Receivable, Current Deferred income taxes Deferred Tax Assets, Net of Valuation Allowance, Current Total current assets Assets, Current PROPERTY AND EQUIPMENT, at cost Property, Plant and Equipment, Gross Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Discontinued operations, net Disposal Group, Including Discontinued Operation, Property, Plant, and Equipment, Net Property and equipment, net Property, Plant and Equipment, Net OTHER ASSETS: Other Assets, Noncurrent [Abstract] Deferred income taxes Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred financing and other costs, net Deferred Costs Investment in unconsolidated affiliate Equity Method Investments Other noncurrent assets Other Noncurrent Assets Other assets. Acquired leasehold interest, net Acquired Leasehold Interest, Net Noncurrent Acquired leasehold interest, net. Noncurrent assets of discontinued operations Assets of Disposal Group, Including Discontinued Operation, Noncurrent Total other assets Other Assets, Noncurrent Total assets Assets CURRENT LIABILITIES: Liabilities, Current [Abstract] Current portion of long-term debt and capitalized lease obligations Long-term Debt and Capital Lease Obligations, Current Trade accounts payable Accounts Payable, Trade, Current Accrued expenses: Accrued Liabilities, Current [Abstract] Payroll and employee benefits Employee-related Liabilities, Current Self-insurance reserves, current portion Self Insurance Reserve, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current NONCURRENT LIABILITIES: Liabilities, Noncurrent [Abstract] Long-term debt and capitalized lease obligations, less current portion Long-term Debt and Capital Lease Obligations Self-insurance reserves, noncurrent portion Self Insurance Reserve, Noncurrent Noncurrent liabilities of discontinued operations Liabilities of Disposal Group, Including Discontinued Operation, Noncurrent Other noncurrent liabilities Other Liabilities, Noncurrent Total noncurrent liabilities Liabilities, Noncurrent COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Series C redeemable preferred stock, $.10 par value, 5,000 shares authorized, issued and outstanding Temporary Equity, Carrying Amount, Attributable to Parent SHAREHOLDERS’ EQUITY: Stockholders' Equity Attributable to Parent [Abstract] Series A preferred stock, authorized 200,000 shares, $.10 par value, none issued and outstanding Preferred Stock, Value, Issued Common stock, authorized 20,000,000 shares, $.01 par value, 6,388,000 and 6,307,000 shares issued, and 6,156,000 and 6,075,000 shares outstanding, respectively Common Stock, Value, Issued Treasury stock at cost, 232,000 shares of common stock Treasury Stock, Value Paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Total shareholders’ equity of Diversicare Healthcare Services, Inc. Stockholders' Equity Attributable to Parent Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Total shareholders’ equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total liabilities and shareholder's equity Liabilities and Equity Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Business Acquisition [Line Items] Land Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Buildings Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Buildings Furniture, fixtures, and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Total cash paid Accounting Changes and Error Corrections [Abstract] RECENT ACCOUNTING GUIDANCE New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Disclosure of Share-based Compensation Arrangements by Share-based Payment Award Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] BUSINESS EARNINGS (LOSS) PER COMMON SHARE Earnings Per Share [Text Block] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Employee Stock Employee Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding, December 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Dividend Equivalents Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Cancelled Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Outstanding June 30, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Outstanding, December 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Grant Date Fair Value Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Dividend Equivalents Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cancelled Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Outstanding June 30, 2014 Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2005 Long Term Incentive Plan Two Thousand And Five Long Term Incentive Plan [Member] Two Thousand And Five Long Term Incentive Plan [Member] 2008 Stock Purchase Plan Two Thousand And Eight Stock Purchase Plan [Member] Two Thousand And Eight Stock Purchase Plan [Member] 2010 Long Term Incentive Plan Two Thousand And Ten Long Term Incentive Plan [Member] Two Thousand And Ten Long Term Incentive Plan [Member] Stock Only Stock Appreciation Rights (SOSARS) Stock Appreciation Rights (SARs) [Member] Restricted Stock Restricted Stock [Member] Stock Compensation Plan Stock Compensation Plan [Member] Number of shares reserved for future issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Expiration period Share Based Compensation Arrangements By Share Based Payment Award Option Expiration Period Share Based Compensation Arrangements By Share Based Payment Award Option Expiration Period Percentage of quoted market price offering rate Share Based Compensation Arrangement By Share Based Payment Award Market Price Offering Date Share Based Compensation Arrangement By Share Based Payment Award Market Price Offering Date Restriction period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Grant of restricted common stock (shares) Vest of restricted stock on each year (percentage) Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage Equity Method Investments and Joint Ventures [Abstract] EQUITY METHOD INVESTMENT Equity Method Investments and Joint Ventures Disclosure [Text Block] Per common share – basic and diluted Earnings Per Share, Basic and Diluted [Abstract] Numerator: Income (loss) amounts attributable to Diversicare Healthcare Services, Inc. common shareholders: Income Amounts Attributable to Parent, Disclosures [Abstract] Income (loss) from continuing operations Less: (income) loss attributable to noncontrolling interests Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest PREFERRED STOCK DIVIDENDS Dividends, Preferred Stock Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders Income (Loss) from Continuing Operations Attributable to parent Shareholders income loss from continuing operations attributable to parent shareholders. Income (loss) from discontinued operations, net of income taxes NET INCOME (LOSS) FOR DIVERSICARE HEALTHCARE SERVICES, INC. COMMON SHAREHOLDERS Net Income (Loss) Available to Common Stockholders, Basic Per common share – basic Earnings Per Share, Basic [Abstract] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Income from discontinued operations Operating income (loss), net of taxes (in dollars per share) Income Loss from Discontinued Operations Operating Income Loss Net of Taxes Basic Income (loss) from discontinued operations Operating income (loss), net of taxes, basic. Discontinued operations, net of taxes (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Net income (loss) (in dollars per share) Earnings Per Share, Basic Per common share – diluted Earnings Per Share, Diluted [Abstract] Income (loss) from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Income (loss) from discontinued operations Operating income (loss), net of taxes (in dollars per share) Income Loss from Discontinued Operations Operating Income Loss Net of Taxes Diluted Income (loss) from discontinued operations Operating income (loss), net of taxes, diluted. Discontinued operations, net of taxes (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Net income (loss) (in dollars per share) Earnings Per Share, Diluted Denominator: Weighted Average Common Shares Outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic ( in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Schedule of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Variable Interest Entities [Axis] Variable Interest Entities [Axis] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Culloden, WV Culloden West Virginia [Member] Culloden West Virginia [Member] Minimum Minimum [Member] Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Variable Interest Entity, Not Primary Beneficiary [Abstract] Variable Interest Entity, Not Primary Beneficiary, Disclosures [Abstract] Number of variable interest entity Number of Variable Interest Entities Number of variable interest entities. Agreement provides company right to purchase Lease Agreement Provides Company Right to Purchase Lease agreement provides company right to purchase. Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Missouri MISSOURI Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Forecast Scenario, Forecast [Member] Danville and Ivydale, West Virginia Danville and Ivydale, West Virginia [Member] Danville and Ivydale, West Virginia [Member] Avon Place Avon Place [Member] Avon Place [Member] Ontario Commons Ontario Commons [Member] Ontario Commons [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Purchase price Disposal Group, Including Discontinued Operation, Consideration Disposal Group, Including Discontinued Operation, Consideration Payment of balance of mortgage loan outstanding Extinguishment of Debt, Amount Expected annual revenues Revenues CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Business Description and Basis of Presentation [Text Block] Income Statement [Abstract] PATIENT REVENUES, net Health Care Organization, Revenue Net of Patient Service Revenue Provisions EXPENSES: Costs and Expenses [Abstract] Operating Cost of Services Lease and rent expense Operating Leases, Rent Expense, Net Professional liability Malpractice Loss Contingency, Premium Costs General and administrative General and Administrative Expense Total expenses Costs and Expenses OPERATING INCOME (LOSS) Operating Income (Loss) OTHER INCOME (EXPENSE): Nonoperating Income (Expense) [Abstract] Equity in net income (loss) of unconsolidated affiliate Income (Loss) from Equity Method Investments Interest expense, net Interest Expense Debt retirement costs Write off of Deferred Debt Issuance Cost Total other expense Nonoperating Income (Expense) INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest BENEFIT (PROVISION) FOR INCOME TAXES Income Tax Expense (Benefit) INCOME FROM DISCONTINUED OPERATIONS: Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent [Abstract] Operating income, net of tax Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Income from discontinued operations NET INCOME (LOSS) NET INCOME (LOSS) ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC. Net Income (Loss) Attributable to Parent Discontinued operations (in dollars per share) Continuing operations (in dollars per share) Discontinued operations (in dollars per share) COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK Common Stock, Dividends, Per Share, Declared WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: DISCONTINUED OPERATIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Tax effect on operating income Discontinued Operation, Tax Effect of Discontinued Operation Consolidation and Basis of Presentation of Financial Statements (Textual) [Abstract] Consolidation and Basis of Presentation of Financial Statements (Textual) [Abstract] Consolidation and basis of presentation of financial statements. Percentage of owned joint venture Investment in nonconsolidated affiliate Equity Method Investment, Ownership Percentage Allowance for doubtful accounts receivable Allowance for Doubtful Accounts Receivable, Current Redeemable preferred stock, par value (dollars per share) Redeemable Preferred Stock Par or Stated Value Per Share Redeemable preferred stock, par value. Redeemable preferred stock, shares authorized (shares) Temporary Equity, Shares Authorized Redeemable preferred stock, shares issued (shares) Temporary Equity, Shares Issued Redeemable preferred stock, shares outstanding (shares) Temporary Equity, Shares Outstanding Preferred stock, par value (dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (shares) Preferred Stock, Shares Outstanding Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (shares) Common Stock, Shares Authorized Common stock, shares issued (shares) Common Stock, Shares, Issued Common stock, shares outstanding (shares) Common Stock, Shares, Outstanding Treasury stock, shares (shares) Treasury Stock, Shares Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $10.40 to $11.59 Stock Options Exercise Price Range One [Member] Stock Options Exercise Price Range One [Member] $2.37 to $6.21 Stock Options Exercise Price Range Two [Member] Stock Options Exercise Price Range Two [Member] Range of Exercise Prices, Maximum Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Range of Exercise Prices, Maximum Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Weighted Average Exercise Prices Grants Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Intrinsic Value-Grants Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Grants Exercisable Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Intrinsic Value- Grants Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] EX-101.PRE 13 avca-20140630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#FQ),IZ@$``%48```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F=%.VS`8A>^1]@Z1;Z?& MM3T8FYIRL;%+0((]@!?_;:(FMF4;:-\>)P6$4%=4K=+.3:,V]G^^^.*3\+SO.A]-:`T5-SJD*]UG#+[N^*,+JS_.KOOH`&]G[^/(Y>]-<#[F&CS0X:?PTG,/NR<^#Z*06GIMNGP"3N'[6-HR1`]_:$`X)*8]O1 M]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL M7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&7 M4"T\U<%J"`=[!ZH^^CSYLK$SO+=N5#9@NIS]NHFD++ M28,5\YS3$$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A`.>YA;+V`0``6!<` M`!H`"`%X;"]?FE!^1 MLD%(;+GW[]M-\>I# M7'=M:6@R-85OJZY>MZO2_'VZ/[LT14RNK=VF:WUI=CZ:V\7IR:Q!1/NSZ_^N?#N^5R7?F[KGK9^C9]\0[[UH7GV'B?\J$NK'PJ MS;`5[?X)R20S&_L-3JZ'+LXEPN&Y,@[/$8YI<*--<(!A6AF$$0]I:(J@ESE:LZC0\1=7A4:4] M2"C_QF]\F*\0SFQ4D!W\YG.-5'VN;,#G"(:T:0CBL/98 MSG`L9^VQG.%8+MH>+-B$1Q72;_()CA*D/4H0'"5$.Z($1I1V0L&`TKXI>%&D M71J"M6'M\&88WJP=W@S#6[0]1Z#GB'9\"HQ/[;C"::4\Y\`D)VU5$505::N* MH*I8NXT9MK%H3X$">T>T926#KNS1_^&+#P```/__`P!02P,$%``&``@````A M`/M5*+B5`P``&0P```\```!X;"]W;W)K8F]O:RYX;6R4EE%3VD`4A=\[T_^0 MR7L-28"J(SA5:5KGCEK*A43?.3Z)SW7H3P6">.KD?MG_OW+J>LH37A",L'IR'VCRKT2'$LP,"7(W<5.OBW/-4G-*KVAEQ/&W5KA7!ZB(99+%M,;$97UB/!&;ZJ-@[5MS"J&`C;GTQ!*=PO5> MK]>\]Y.R5:JW;X*\A_2-@_`]YM7AIKVM(Q%,*IIPS?1;-.6U^TS`""O7I]"9 M[SKRG,$_%89:J5(Q3I=#G^WBTI]T;WD<*23&47!'%5"26T;VD6`9::5PXZ\H\T!BL MC[[%L2B!,KZ*?I3`"?"!):"-1L+O=35N!5_-JB"ML?:Q MS@Y:52D-FG=$`[@M,_`L?8O0F1;Q,Q@`>%^+'%:5,AL$]X"GZ%MH3HCDT+V* M;H52T3V5E4X.SLY2TK83C]&WX'PDDI%%1B<$%E01U>7`ELX'K)`-'=$#!$\R MK-/JZV!X9W%*DQ+I#'$`PR/AQ3],(0XB'(Y*`23(3*5ZB`AQ+.'0$=JWU.K9 M(YUAJR`+YWVKS=()<2KAT*D'!:I9<#LX'+:ZLE#>J5(/"_8WZBK$(85#IYH] M"_-?04AGB)=6://TQ!X(``#:(@``&````'AL+W=OFIW3=GM7@_-<40G?;.O1XA_>&E/P^SML/N(NT/=?WT]>;ON M<`(7#^V^'7],3M>KP^[FM^=CU]^#]783U;O8]_>&X/[2[OANZIW$#[K88 MJ,LYVV9;\'1_^]@"`[7MJ[YYNEM_%C=5Z*^W][?3!OW;-F^#]?MJ>.G>?NG; MQ]_;8P.[#7E2&7CHNJ\*^MNCN@2+M\[J+U,&_NQ7C\U3_;H?_^K>?FW:YY<1 MTAVI);MN#W>"GZM#JVH`J-??I__?VL?QY6X=Q)LH\0,AH_7JH1G&+ZU:NU[M M7H>Q._R'(*%=H1.IG<`*[43`I5E`5<*OA5*L:$S?@ M4$>N;W_F`ENZ4^C/"CXM@B@'N/KM/@MOM]]@;W8:DB,D6:\,)*:08H:H#5)N MR_F"62/HDFI&J#1`Z.?X@3F//_#/X2HK"S>BCG,7(BFB1527$(0'!&)E9N:AKMZM83=, M=62,!T+2J;I2&8B`V@O;'HLP9?M0VG81^T+P7!"`R#)ITDD80#\L,%!7:2:$ M[],0<\3`?2JN(LJKB.H2@A")%XFHJS05PF=MER,FGG(1AW%J=FIJW,*V M1S#&6*>7MEW()!+L!I4-R))4FF02!C!.%E*AKG(&+-DY8C0#&;'[%[8Y3'TV MS$K;+*04)KR)?V7;LR@UWDGT2N?-D)U;05WET;-:SQ&#T8LH8MM;$',2L>A* MVQS$@B6O(F89FQ(EP6>+P:NK/'BV>3EB,/@HL#8':X>8DX2-@=(V"S_,3'BX M]=2>Q&;K2/@"U'QA\Z?+G`"[1:Y!>OL3G]D+:@\SEIZ2V(,P9&.B(G:9!29_ ME((2/[=^!&JB/4N%ST+(-0@I)%"B+(:"`.)01&8?IWTN"4!$B>2)K"A"AD%B M-HH242JX0`3%D1)AQ9JK,PY4'!*12<#"+(C=D[%5SIH'<9`&IE>QGJB#,`S? MRX92P`42*(SP\SSSA6]<3/?(Q27UG"#%=4AY'5)=A-"<*#4T=*83H'6"$BB6 M-#>L57,-"B>9\)PI1B26+V(^:ZH68KW2DN)H:$QSU@XA3MS2K`6R#5( MAY^%+(2"VI/0A*`K"V^"I>F)-'1*BP)D:CS07"@U7""!(DERP(4T%PA"$HQA M08Q>()F])'9FK(B1+*;!*RU<"!XED@;/:B`7MHYZ<)XR&Z2[@@%"UOXE\Y#Q M(UG%`*FU!Y2&4D5#P^D'%$U*AP63"UM9!4Q,>CPLB-T+$CXG2@W`9&;NJ++] M>[&,S0TH%Z61%[B@A%(N7,0%@G1S))&3&:+#DI\02[H^R)S>L-?+*#%[2:A( M*N,\+9.9R;DU*G#Z:I#>5>M.6&/:K-M8AI*%6I+UD:/F='T06R<62H7*N4,% M99T("3]7YQ)!ESYA7(>4UR'510BE!75D%=L\@:6ZS#/#Q5V#,#/"Z1=BAL30 M=BJ)V0M35L(5L4>Q&>\T?J7-IEG.\:-DTR8Q_:8K:]9U]41D(7[;O!"_;5Z* MW[:_'S\5\G/\"P(NS!;H^!&$I2^%,YA70,P@?P`4-'E\+#+G%)I M"JB(.YVQ(.;6&-=4$(21,"DKU%,V*$8T>KRK2F*6;-)5Q.H%ILHH!ZKA$X

55 M2'410NC`1PR;#F_URR<6T MD159`!YC(V24W66)#U"]B:98,Q&3ID$S.Y_%4G`[2WI)[!`K/V16!`#;=^XQ M2F59UH,%6;>>HVH*")HI\`=0A7:"=@@Q8+I4<@!_/EEQ`*@C^6?*G))2BNHV M4X!"2YN):[T&76JFZY#R.J2Z"*%TE#P;.DXSH7K3!'8\,7>L@$?ZBU[P:7>NGQ(")8."4Q^<@V:R;J]A4[.=J>W;/MB;]F`]WN+ MGA7F(UNP=$8PDT;G"T%SB/PL4V@G:%_L+=N!XL!27'$/'^TM>FIPBG'I],#Z M/@\0A,%'F\B9Q,551$D0D`*'GGT/8J>]M7"&`!DXYPKEGXR,P)RG=*X0!`7^ MKOX&5R'E=4AU$4)I*3$W(^-,!S6>C`K^^"$/$(3'4_B"C8V2@MBC-'&ZQUX? M9?ST6K'ULW9P.\<'"J MGYL_ZOZY/0ZK??,$+OU-`B.IQW<3\(^Q.TW?C3]T([QJ,/WZ`N^0-/"%O+\! M\%/7C?,?ZFOW\ULI]_\#``#__P,`4$L#!!0`!@`(````(0`#GHK-5P,``*`+ M```9````>&PO=V]R:W-H965T\45([18Z=;$U#5<1#0FQ6&E__X5/LQUC7%4Q"BC!5[I[YCIC^O/GY8G6KVP M%&.N`4/!5GK*>;DP#!:E.$=L0DM*P.!BLKC.+:*<\,VS2G1HY( MH4N&174/!TT2$N&`1L<<%UR25#A#'.)G*2E9RY9']]#EJ'HYE@\1S4N@V)., M\/>:5-?R:/%\*&B%]AGH?K-<%+7<]<.`/B=111E-^`3H#!GH4+-O^`8PK9BMOIY( MS-.5[DPGWLQT+-O3M3UF/"3"5]>B(^,T_RM!5D,E2>R&!*X-B06W=SH[C3-< M&V?[XQ&X#0G$_/$(IHTS7!OG^W-@R'S6=0@01^ME14\:]#9DC)5(3(JU`&)1 M`,>$/HC$XI-8K3%@9F!]77NVN31>H:11@]D,,78?L1TB7$?!!$.,@MB-(L(A MPK.=+A8#%'>RH>XW9(O5OFS;ZWCJS&R&$,=7,-LAQK.M/D]P#:,J'V)<1ZE" M.,1XMMN]JZ<=.OA">UMJ816:Q>R)VF]:@];5WK6F'6.-V;:8UBE0#3O5$+:& M,ZUWD=Q>H#`M5P(5UEZ@JF&K&@+5L%,-86LX1W59SEY4,+L74:D3(U9AA/0S MD6;]!ME( MC%MO'4KK;]NUL[^2AF`4L1M%A+<0/9&SJR*%516I"-E(S+39'^?*^&[E\HUR M!Z.(W2@B;!%BD_;/NT-/HC@U_7^S%ZM]J9X]4^HI,3>T;$<1@43XEFR*B67V M?DIR=PI:26YXZW4][7Y/>]O#PMK7;)OJN$K,+R2.6?."TK#]R>\KA MQ%3?IG`2QK#YFQ,`)Y3R]D$5^@Z6]Q,GD'`3830PHAVIE:JJE[5QG,0BCB/;P,S;]]@&!$1%;"#. M^?WY/Q=G_OPN&[3GV@C5YCB)8HQXRU0AVBK'OW^MGR88&4O;@C:JY3G^X`8_ M+SY_FA^4WIJ:"J:54:6-`$>"T7[.4S(E0%K, M"P$9N+(CS^`3\T*GA)=XW]J0Y?N:AJ"]W.W!:F&C@)?I$4;@0@<_KN_P^B ML'6.AZ,H&\?#9)!AM.'&KH7;BQ';&:ODWR!*CJ@`&1PA0[!YC&=1.LC&DP:"+R[J-?#:P-O](DO&<[*' MHK"C9MG73$?7DE5?DIP5!(R,/+OF1ZXW=U5W+E!NIQ MQXV+0K$PNJC-Y,9.T*27FFO%ZI[BR@Q`;LVDV;E1+IIC2.W"S/3ZJ&70I+Z- MP\%MC_X7#2;"'0B3T]&*?Z>Z$JU!#2_AQ#@:PQSK<`/"PJK.MVJC+`RT?ZSA M0\5AJN((Q*52]K1P=^S\Z5O\`P``__\#`%!+`P04``8`"````"$`WX".RIT% M``"R%0``&0```'AL+W=OWDF&-LH!BP@R0AL3FGBCI= MU56=WG[Y45RTMZQN\JK?V_:Z,-O5G?%3'8YYF496^%EG9HI,ZNR0MQ-^<\VLS M>"O2S[@KDOKE]6JD57$%%\_Y)6]_=DYUK4@WWTYE52?/%]#]0RR3=/#=?9FY M+_*TKIKJV"[`G8F!SC7[IF^"I_WVD(,"N>Q:G1UW^E>QB6U'-_?;;H'^S;/W M1OFL->?J_;FG_ MJMY_S_+3N85TN](DK2[P)OBM%;FL`9">_.C^ON>']KS3'6_AKBQ'V*ZN/6=- M^Y1+6UU+7YNV*OY#DNA=H1.[=P(6O1,!C^X;FQA()R!*VF2_K:MW#:H"7M5< M$UEC8@,.^\C[UX]:8$E3R?XJZ9T11-G`T[>]*^RM^0:+D_:<`#DK71LYODM810W'4^J#B(#- M<4>$1)D(F[TH0,ZR$\&P4,4,P;9+I*(V6YM8!0UG*@42O3>/7JDIB=+HG5GT MR,'HYRE`U.NT00HE.7DBB5X-@LR``Y*&&]9NL;(CJLOVNS M+1*IUH[/T)A8.[XU;2`BPI^+4%JM1+F(*9%=FP^0@R*$O1[3W*&ABL(VIFBD MHL9R/15Z9QRKL.M-+R8*!(QVG@=E'W0PU2#X4@8]"9N1L'BO"@ENV/9Z6LU^ MULD@=CHZ,'P&Q]3><9QI(:@6.1&GFAJV@\!!"I*/+78Q3PTZ0=RP%DNV$2+B M8+6PZ,\J-J9<8-41`_#H31N3JI/#DJE3"P]GJ3H$7<&""P22!G46BR7D.$MZ M1'"(U6+[+R8$:S$5)I4B!R:3HB8*YRF5PD()!))N2V$XLX^(_8=2J(-;4N3L MG*2,6PA'JBI!V%-BN\P'<+Z7!3E($`P/"0XA.E-+ZMN`ZD!JF(+L:XL1H*N1 MGZGZ:7[D-/U`%`Y9VA=8!01BF--W^L)#2O382WR70N7(`3O)F?4%G+]JKER^ M[P.!I#%72[JOV<*'A`Z9F;<)U=^GVH1J`!YOM@DYB9E8M4W@H*9B^4%!(&D0 M.V\3#)_M+167=A+TVIO'B,>4Z#$EODLA96=#12EE-^9*/F:YG]5`(]*XP2YF<$H9P->PE(ZB4(?O8,X19, MK@/B'TD@^`<2"#Z7@%=D>,-49/4I"[/+I='2ZK6$$K'A8#8^Q:NY0&S@-@@N M==CS"*[LNN?F",!%VC4Y97\D]2DO&^V2'<&EM5C!F*SQS@V_M-6UN_)YKEJX M0NL^GN%N-(-[)FL!Y&-5M<,7>9LTWK;N_P<``/__`P!02P,$%``&``@````A M`%N]&]N<`P``NPL``!D```!X;"]W;W)K&ULE%;; MCJ,X$'U?:?X!\3Z`N>6B)*TFI'='VI56J[D\.\1)K`:,L-/I^?LMVUP=)NEY M":'J^+A.5=G4ZNF]R*TW4G/*RK6-',^V2)FQ`RU/:_O;UY?/<]OB`I<'G+.2 MK.V?A-M/FT]_K*ZL?N5G0H0%#"5?VV543?%"+BMSU/2]V"TQ+6S,LZX]PL..19B1EV:4@I=`D-@^QV%.&NYUM?A)[.`LH= MR249RV$G^+4**GL`I.-W];S2@SBO[2!VHID7(#^RK3WAXH7*M;:57;A@Q0\- M0@V5)O$;$G@V)`C^?G!QT"R&9[?8\><1BN+?""%L6.#9LGP\?D"J),"S7>P[ M\R@*X_GL(8NK,ZHJD6*!-ZN:72UH;\@9K[`\+&@)++($P`:YE\YGZ548,'.P MOFTB+UJY;U#4K,$D&C.SK0[CCQ';"40\AJ2W&QDDNWL(%\1TBJ"HIJ+`ZQ1) M[UC1PA2D(3/5/#(+6].0WI($7CA6M)O"]#N-(H:F,B,.^QI(+S3\(+_AW!MO MEF@,M%57@WXK5@=M.(XO;1'ROHO-X(=./^R]H]CE MA-+?JNT!D%8S=J.RB<;5U7W3>G^=^A8QF?JA$RU^$3L,+%.Y5V8S^O[R_QB2-I#I M_(^<8=3G3Q=`STKZ"UV0^D2V),^YE;%+";>F#R7MK'I&2]`R\>6GRK!OT1*^ M6W+ZZAPP457X1/[!]8F6W,K)$2@]1PX/M1Z^](M@E?I"[IF`64K]/<.03.!3 MZ#D`/C(FVA>Y03=V;_X'``#__P,`4$L#!!0`!@`(````(0`2!4NF*00``((/ M```9````>&PO=V]R:W-H965T^UK,#9FFY?)<#F7/**]ZP??B#=>&GPZ^_ M[.Z\?>VNC(D`&)IN'UZ%N&WCN"NNK,Z[B-]8`W?.O*US`9?M)>YN+N9ZN+1^CJO'U] MNST5O+X!Q;&L2O%#D89!76R_7AK>YL<*\OX@:5[TW.IB0E^71W.Y",% MKT`)_@9U*6<`4L\_U.^]/(GK/EPLHVR5+`C-PN#(.O%2RF?#H'CK!*^_(XAH M*B2AF@1^-0G)HI1FJ_4#+#&N2&7R)1?Y8=?R>P#C`9K=+9?#1K;`+%-(,RAE M(6]^EG<5!L(=1-\/69+LXG1=:/*8)C%K12G$ M/"`%(S*2ZK.143L;NG*S04RJ&D?(VI_)TDLOHRZ]FP%BD'XYP[[RLLNHP[Y. MA^5A?1"#[$;9ZK/<2,WP]I6149?<'27$(/E3:D;:HM]XZ674I5\Y:T>,IC== ML=@)[#>>U:NPRV^*B[71(!0@J9&W%3SFWAC'$72N/:4+)Q,->F!,B>WOOALJ M[.0S&50-VN`6$Z5S)9/VG#:C"^"!@F3I2WA]S>9&CQ+W-U#@QZ96]OFZA4XVLH)>MEVB:F)KEEO^-&[ MQ=]\ZG>]"O^?2S0(73_G$6J;OK>A"KL";AH:A`)TIBO4[W,5=@0F#M$@O6_- M5,AO5V$W`]<=&H0*,^\-^5'GV4-4V.5WK:%! MR)_.["#4MK<:V='&KFZ[GQ_NQJY!#QB$^IVNPDXZDXU=@WJG+TS#+*=3O]-5 MV)68#"UN![W$W,9.;9L/OD#G_GQC5\_N0Y28W]CA:];7=Q5VLIA,K@;U69BQ ML^JT\)M;A5T%0X'>T*"U>L?.3"ZK8O4A:9><,,\!2%9X]; M?F%_YNVE;+J@8F?X'D\BV'*#%L]0>"'X39T'CES`D4C]>X6S+H-S21(!^,RY MZ"_D*6TX/1_^`P``__\#`%!+`P04``8`"````"$`,H^,9$`#``"]"0``&0`` M`'AL+W=O`%B'Y]SS_V(6=^^5:7WREK) M19V3R`^)Q^I"['A]R,G/'X\W2^))1>L=+47-RW;Y^0N6MU'*0DV:Y.@7YR=Y."W)X_B]*GENR^\9I!MJ).NP%:(9PU]VNDE M.!Q,3C^:"GQKO1W;TY=2?1>GSXP?C@K*/=='"E&"$GQZ%=<]`-;IF_D^\9TZ MYF2V\.=I.(OB.?&V3*I'KL\2KWB12E2_$11U5$@2=R3PW9%$8J$<$(--K`?]8:Q;V4GK7ES0F0#4R- MI1"3##`6X4@!9&QJ84WI7:CV@";)%GW,Z`HQ5TA!KPRDSB72JZZ;.+4%0`G$ M)*:`L]FL#\!QLKA(KU?']#;K2(\8I`\ODZ<7R?7JF'S<7HA!\AMKS`E=OU%M M%Y\SHU?'[&D?'H:.F(X]MKL.?7:17J^.Z;,1/6*ZQ(?OM%`$;YY!^&8(T\$, MZNUQ$]E(T8?AR,D5712Y(W].EED>V['I[E1PUC/32`M_86OEY"MR)[V7P/D= M#EZ" MI>@D$(02J9_8IG`E+L\SW"#_[ZL.="[$?-GWG2MQ>::CZ5`GF:7H7`RG.E[8 M.KD*[F";WAV\U.'Z'9M),IN/3@E!9S.#MQ=*X06,UU9##^PK;0^\EE[)]O`& M#WV8%:_%ZQ&PO=V]R:W-H965T M2;$ M25`#1IAT>OY^RRZ'V,9#YR7=N([+QU7'![S]_-[4SAOI647;G1LL?-N?_\_?(I<1TV%.VQJ&E+=NX/PMS/^U]_V=YH_\HNA`P.9&C9SKT,0[?Q M/%9>2%.P!>U("Y$3[9MB@,?^[+&N)\513&IJ+_3]E=<45>MBADW_3`YZ.E4E M^4K+:T/:`9/TI"X&X,\N5NT\E;3I(<:CJ:O@ADKI.4VZ^ MG5O:%X<:]OT>Q$5YSRT>)NF;JNPIHZ=A`>D\)#K=<^JE'F3:;X\5[("7W>G) M:>=^"39Y&+G>?BL*]&]%;DSYWV$7>ONMKXY_5"V!:D.?>`<.E+YRZ+)S7:>\LH$V_R$HD*DP22B31$!3QF%H?K*'1,0& MOA9#L=_V].:`*F`IUA5<8\$&$DKF/:/*JOO4[TQ-D4$NJ(?(I(UR-$ M(P/5,,G$RY$,CT+WE$W&B3\F$L7*$!,KF*6.R.<0&AE(HI"Y=X./[ES8TJ/2 M2V/#&6(2T:LP-0FHT6CYDTJ`-"V+\U%]\3@Q&ITA!A89"9H$YA!:!58:"2%4 MI1T\^E$[$#-'9@ZAD0%Q*Q419!2A\JA9&;,MB%F)MJP2WS>TDVOQ5(UK1/@; MQ#B^"A$>-8E$N@0SQ*2!8.(O(B.>8]Q>-8U*JE&Y2Y2/FA1B@P)B[$N(DY3/ M(302`7BW61!%)B+\D4XD:([/+$0G9#%8I4,!6J%ZA./$U(H$H5B62U4,6!X) ML#/6Z7#_>PCFWJ4`;5&G81S53(+LJT@BF,<.T8EPZWL0,<]S@,X(OZ-S3/U5 M@NRK24)/.VP`:4Q":J-XV!3RRA"RR+%SL5%KZ-/D6$N$G;)>(+OKPF?%E,?# MM\6N,PE25XD3XUV96T"/CNM4=.\=18-VJ8MF\C$PYZFR1W,0G8C%=]73C:;Y M@6@0I-;FL6U):`ZB$YKWW\!FP!/1(`A%$_#3;;X+9!H[99V/;L+FBRFPN'%J MK)9)T/A&2";E>=J-0]V-[\(1P\992LU/!PE2-QVGAC/F%M"#K5:9T.+#BG1$ MV*1DO`HS"5(I/59#ZD"2'%`$78J%!B M:EF"4,L1_ZPQU,6O8=R_[)2Q0'C-PEM*0_HSR4E=,Z>DUQ9>!OQ#91S%ZUT& MUSMQ1?+&`%RZNN),OA?]N6J94Y,33/47:W#/'N]G^##03EPI#G2`ZY;X]P+W M:`)W'7\!X!.EP_V!WU;&F_G^?P```/__`P!02P,$%``&``@````A`.%2Z&ULC)E=;Z,X%(;O M5]K_@+B?$"`D391D5+"Z.]*.M%KMQS4E3H(:(`+:SOS[/?9Q",?00V_:QGY] M_/CXXW6=[=ON=8R/>A&Q<4+YO.E5Z1YZ6*$3?V9&-7QF&=25-EK(D]ONM3M"_ MN7QO>G\[S;EZ_ZW.#W_DI81LPSRI&7BNJA^_R_QT;F&Z(]4DJR[0$_QTBERM`1AZ^D/_?L\/[7GGALM9M)J'?A"Y MSK-LVJ=K1]7N7$ATA[)8 MSBE,C)J%7EM12"N36^4]@#46P2D(Z9(E5;4VJ;6*8]0\:-(@"*+YW!I+0A1^ MN!@H!"K&)X?@PI9C$JMJ;5QK"\2H66K<%9#8L%@_CH*[M!]AH09S#T%8E3E: M9TIO$:A::\TNK7F.4<.P)),*P2D([IK%5;5V:A=T6<:HP=2&P4,_,;C-4<", M1W`*0NN#Q]G9743=%M/5-J^U26(C0F#?#\E4(K&1<,BLA#*K\_WC%>'C\4_/ MA?O9JX%B(S+,JY'=9A0L,O8T+J'(R@XLY'Z:T2THLN4HL8\B1%ZK)-\WC,DR M*L9YM$28(.,2BJR\PT+N[3L?K84B6WX4&]%X;X89XS`2P4:AS!"FQWQS>%\5 M6X?$P-B,B`%)IB6"E5!6Y2U,?M%Z:'ZM"8_A;JD&AO9F.77257YL;ZR$TBIK M86C1>2BM!13[G#V9U3`I$6P4RJP.IH,"+N:)B6"%9"67F#"T8,;F7?SXP(%X-:"`.W,`IF M5(*54&28[=Y2L-=OH*JM-`^N:4;$`"73$L%**#/O<,&(PZWLJZ4189KUS6>8 MYVF',U'&1TZ90&VZ]:8E@)929.EVW]="\^'-8O45H MA_O0Q))IB6`EE)7WN6#$YX9;#T7#:KQ_:/CV^DQ<=T?$4N9'V2B;Q<&B>K7DMXUU,]=Z7=(_ZC M?L.WRF-_D^@W7ZL\"3;)F%X$\&6`?L[O&L`3_34]R>]I?&ULC%;;;J,P$'U?:?_!\GO")2$W):F:$'8K=:75:B_/#IA@ M%3"RG:;]^QW;@0"IDKYPF3ES\)D9CUD^O!4Y>J5",EZNL#=T,:)ES!-6'E;X MS^]H,,-(*E(F).%W*O'#^NN7Y8F+%YE1JA`PE'*%,Z6JA>/(.*,%D4-> MT1(\*1<%4?`J#HZL!"6)"2IRQW?=B5,05F++L!"?X>!IRF(:\OA8T%)9$D%S MHF#],F.5K-F*^#-T!1$OQVH0\Z("BCW+F7HWI!@5\>+I4')!]CGH?O/&)*ZY MS68EA61#F70!]IR_:.A3HDT0[%Q%1Z8`/P5*:$J.N?K%3]\I M.V0*JAWHD)CG\"6XHH+I%@#EY,W<3RQ1V0J/)L-@ZHX\/\!H3Z6*F([%*#Y* MQ8M_%N2=J2R)?R:!B#.)!Z9/!D_.P7!O@H?^+/""R?TE.%:.24-(%%DO!3\A M:"U8L*R(;E1O`-V078VH0R)K,`EV0$RC"#+:5S1R&P':VQ7@!]TO M;3Z`=!';:\1\VH6$UQ"_B]A=(_HDT37$OV2R(WIT4[3V0L.V*C*:]):SL9AQ M"]/+R_8N(KR+V-U%1+<0'HCP-L'N+D%T"]$1"Q.C);;>C=K:$]DOJX7,C,1Q?ZMNK?>6Q)OQ MN[OQ42=^=MDE'74P>%KJS!!J;5GM[:KTW'XI+<;*'`2736*FR[;M]7L9"MO. M0=`CWG6\OM?K`#B:]-H^3J"5:(\>.W,+*@YT2_-`(0AVIW'``561`_U!Q(&5$N4T!4IW.(6D"WN6V1?%*S/S]ES! MT60>,_CEH#!YH>TQ2CE7]8O^0/,3L_X/``#__P,`4$L#!!0`!@`(````(0`" M?Q+2:P@```0S```9````>&PO=V]R:W-H965TP,&FR65I*L)&)M],3//A#@)U8`I['2Z__U(%C+6M?!QYJ6; M''VZEG2/9'F[__[[L"_]\L_A+C@^E(U*K5SRC]O@97=\>RBO/?M;NUP*H\WQ M9;,/COY#^8\?EK\__OW7_6=P_AF^^WY48A&.X4/Y/8I.=]5JN'WW#YNP$IS\ M(RMY#]ZS?OPUSLY6QXS\RX0^[[3D(@]>HPL)514.S?>Y4.U46Z?'^9<=Z MP(>]=/9?'\H_C+NUT2Q7'^_C`?IGYW^&J=^E\#WX')QW+^/=T6>CS?+$,_`< M!#\YZKYPB56N9FK;<0;FY]*+_[KYV$?+X-/Q=V_O$4NWQ:ML@ST[$ONW=-AQ M#["N;W['_W_N7J+WAW*C6;%:M891M\JE9S^,[!VO6RYM/\(H./PK(.,22@2I M7X*P_R]!#*MBUJU6^RM1&I*#:,A1Y#\N81JU2MNRS&;[*W'D.!KLAVQ.LU)O M6X;5_$)2#98'88UK0NIFQ3!K7XHB$\/,KW-M'F\?X9"8/_>;MI",K)I2RGD5%I)1E;RA-"*UUT^V.N44&5&2-S`9D7& M#8U:DGQ>K":_;JEY[0HD/=Z-3DMEGC1A5**7)3)1^EG&K-74.'8!9I!E,L=R M!-/A(_'KT31:37(@EP"-#AF7(0)&"!@C8(*`*0)F")@+@+DGL6RCTU;'?%&` M6689LT9&;%6`\;),)G?K?$:Q/SOII>TOUSPN<]O+^=05PG4^/4DB/2ZD/ST= M8ZICU\\R9HVLG'8!9I!EK`:)XV09LT9FJEN`&19@1@68<0%F4H"9%F!F!9AY MEFETR)EN48!99AFV"U+SOBK`>#JFH<99ZYBKQQ2OLXV9SNM<5KPNA)37)9'V M^O48XF0N&3EC^E*X5K(:9`VULTRC0P(/"C!.ELF8WRW`#`LP(QU35Y,RUC$D M<1,=0_H^U3%DD9GI&&*VN61D\%%9946%'!D\*UWYGYO\YG%+>PJSZ=6[BLN$4(*;=0 MHD>%OA32+25.L"4C1V1`!8<*+A6&5!A)(>?`XP+,I``S+<#,"C!SR)-9YA.)T?K<]=>-&7JMP M^:',KGD2%YL&V6AU!9/G=$G$E[MD_]!3"M6]3E^670]/)I$M"1Z:7&X,TF7D M[.O(LIN174@,(3&"Q!@2$TA,(3&#Q!P2"T@L(;&"A"<)GD^RJUVGRZZ7GXJ- MV;U0G8VYK-JX3B^:NH+)LS$D>I#H0\*&Q``2#B1<0;3C.U"&9=%;74,8802) M,20FD)A"8@:).206D%A"8@4)#Q+K/$+QN<%NV^N,'NNJTZT&61>[%RC/ZACI M8:2/$1LC`XPX&'$3)%Y9&F2[-DR*;YX01A@98V2"D2E&9AB98V2!D25&5ACQ M,++.153O\\<-FKT*?_A)5GG3N)XGXEM)W0N4ZWT1IWEY'-4F-V!Z.$0?(W:" M<#\:#;*O&23%-_WH8,3%R!`CHP2)-UED-1DKI6VR.9PHI89![GA.E6):>::4 M-DD>YDGIS2%:)$C<A->-\A@=/F3>F;^7%]#I(>C]#%B8V2`$0`21]KY%S]U=_G8)\CY$>CA* M'R,V1@88<2[(97MNMDPRW5T$#/%!1A@98V2"D2E&9AB98V2!D25&5ACQ,++. M153OLT5;ZWVNT[T\.8%V^:M1U/LF.0D_Z2#U3DL/(WT-8K;)@FIKH,S61M-D MM34.CN)B9(B1$4;&&)E@9(J1&4;F.H1F>Z&#U/%=ZA`:9Z6#U#@>1M:YB#H/ M^-,8W3E`/*51S@%F9E\O(&:MZYU*"CWQ%__H9%%[U,-(7X.8]%"V!LK,`]@: M!T=Q,3+$R`@C8XQ,,#+%R`PC<%ND'H7J#T?""-?L)(#R/]!.$;;+)-L9/"ZZPDK1A@ MQ,&(BY$A1D88&6-D@I$I1F88F6-D@9$E1E88\3#"/S*XO?J*&2`^(A!O%!_\ M\YO_Y._W86D;?!S9LFZR.S*)*CY><(P[]KXM>Q9,]*%QQ]Z0S>H>_]A!HW?K M=]WX&XAJ$HA]FG#:O/F3S?EM=PQ+>_^5-:%6X:^_G\57#.*/*#CQ%P!*ST'$ M/DJ(?[ZSKTU\]F)LK<+@UR"(Y!^L0=7D^Y7'_P```/__`P!02P,$%``&``@` M```A`,CYE^%+`P``:0H``!D```!X;"]W;W)K&UL MC)9=;YLP%(;O)^T_(.X;,(%\*4E5@KI5VJ1IVL>U`R98!8QL)VG__8XQD)AD MT)LV'%Z_?LZQ\?'Z\:W(K1/A@K)R8Z.):UNDC%E"R\/&_OWK^6%A6T+B,L$Y M*\G&?B?"?MQ^_K0^,_XJ,D*D!0ZEV-B9E-7*<42\WY"/X]:[?KBQ+VC,F6"I MG("=HT%O,@G+':@A M,SB;!W)TB+["M/1'RF:JQMA4?A63%7RVJ MT3L3KS'Q`5._7TZ\18""V;B)HX'J1"(L\7;-V=F"W0%3B@JKO8968-QDT&!T M.4%I8Z5^4O)Z$-`*B)ZV@3]=.RML2HW MH'5\D'2?;^IV..JMB>,%YDRAEBS5F-/61_.9:PIV/<%TV7.(!@0&ZM1`;2NF MHAL;/+IJ!+YO(H1:`^6_:$S%;E01#2D,3)CFJJ(MIHK"KKQ&\'N%"+5F"'-4 M$0TI#$SX+NY@JJA93<^=F;4*M68(4RL6]99`0>#VMD0TY&!`SNY"JF@?TS]DZ[4&N&&$<5 M4:NHC['+D6L0(NA@=\I8A_N,7K<0NHZ-:`AR7!)U$H4Y#RZ[WN14I_WM?^[U$=HW+?P7J1J"FN9^IYM0=7S?*@O`#V9$\%U;,CB4< MT0B^N"ZJ;QHA6D%/4\VK>P']O\('\AWS`RV%E9,4AKJ3.1PN7%\5](-D5=W" M]DQ"YZ]_9G"E(]`5W0F(4\9D^Z`FZ"Z)VW\```#__P,`4$L#!!0`!@`(```` M(0#@X-]PFP<``+4>```8````>&PO=V]R:W-H965T&ULC%E; M;^.V$GXOT/]@Z#VQ>-,E2+*H5&Q;H`6*HN><9\51$F%MRY"4S?;?E]2,1?OAWVFZ_M,';]\2$1MVFR:8^[_KD[OCXD__G[\TV1 M;,:I.3XW^_[8/B3_M&/RZ?'''^X_^N'+^-:VT\9Z.(X/R=LTG>ZVVW'WUAZ: M\;8_M4=K>>F'0S/9K\/K=CP-;?,\/W38;V6:9MM#TQT3\'`W?(^/_N6EV[4_ M][OW0WN3_=[/K#R;IXZO;=],_L--D< M=G>_O1[[H7G:VW5_$[K9G7W/7R+WAVXW]&/_,MU:=UL@&J^YW)9;Z^GQ_KFS M*W!AWPSMRT/RD[BKC4RVC_=S@/[;M1]C\'DSOO4?OPS=\^_=L;71MGER&7CJ M^R\.^MNS&[(/;Z.G/\\9^'/8/+SN3_7]S MZ%P-V*4WW^:_']WS]/:0J.S6Y*D2TB2;IW:Q^G_O`_``ET!4XD M.K%_T8FP'[_S884/V[_+P[>R,,)D_Y_"%I8SA^'G9FH>[X?^8V-KRQ(>3XVK M5'%G/;OUJ]3F8>>,/SGKC+'#HQW]^BCU_?:K#>@.(15`\F3C(111KR"R!;*U M/!8R-AA7R#@K(V,6/S/?"B#Y''2W@#H8(#/9I08SG9?K1NWZP[7D;`:`Z`#" M.-37$(2#=;+"P8T^)):WCV?!.`"DF/.ATUQ0)PSX4;I_"IE\P,$YA>B8(FJJ5E< MF-W6+8]"4/[.RECX:$+%`019E)(70VB66LME#20&;C?Q37B.@1MEL_OG87:` MZ#D'N>8A(-9,K<]=DKFY`#@KX^#]``>`0`1D*9BY)N8B]UDD$1!6N5=",`^S M^2,!DR!`O<)^5"S)%6)PAC2N10(P MJ12^BB@')U=Q(;A-@F>!K;)"#'`HC1(^T!@&<((`97)?2Y2#TR_/@1>$`'DC M\6!U5R$&IKHQ(M8&BM!V$_/KH6S615+$*JE\AT-=(@98%#;JO"[`!]K+0$`H M`RJ42UW$"JE\92`*-%(J5;FU/&KYTC4ZU;Q[*85TD!6B5"Y7&*QHI-LJ94(E5"8(F6`F@%*X?-%.:R+I8C54OLNPWP` M!C(NBHS%JD8?:"^%IT@94,E5AO/(C@[,L7M[#T,UWE(<]WH?GFW/#SL-4NPQ;:848+`LE M4P:H*4!*XS6'Q$)1_>19FL8(& MJT$.@`$.NI`^\T@AM!MQZ8RGG,SY$^?"`-3/^O`G%]8%U?SH^>QO2B59Z=0$ MH*4]BBZG0)H1IY4K'-PP%2_C/6`4`+->>AB(:Q#*@XIH5!D@E"0F7$P58#`K M]OT4DY::`4S0;Y3+=2%5L9`&O8^Q(4*:";X'UN@$RSA3^:6.H4H:Q2565'ZZ MJQ1@8+^/8A+*K2DOAH3*Z5*JL8QF_KR`H2`RJ77!.KI6!&!_+G@`3MYH;TJ9LEVPIH!"![\C:!RH M@G(AU[&2!B^J,!Z`@_+*C3*B.1DQB/\9^8-;$7 M(C@@$29F74WG85J?.5MKA9CU3D4C;JY:^9S1Z:F$GLO"Q-(9[,Z0"L3@AA(' M@-A+$P@?94"EDZ?"7@#R1LWY21`Q<"DBUG[(4L3:#UFX)83KL4,[O+9UN]^/ MFUW_?K1'4&G?LB^C<#M9B;MJOIQDX[6]M9S'MXO!WB6>FM?VCV9X[8[C9M^^ M6)?IK17%S0#7CO!EZD_S'==3/]E;Q/GCF[T>;NUE5GIKP2]]/YV_N(O-Y<+Y M\5\```#__P,`4$L#!!0`!@`(````(0#1$*.MGP,``(T,```8````>&PO=V]R M:W-H965T&ULC%==;YLP%'V?M/^`>&^`?`%1DJJAZE9IDZ9I M'\\.F&`5,+*=IOWWN[8)Q::POI3@OE2E\XP9)[3>N<',=QU< MIS0C]6GG_O[UHSE!):[QS7S%W;_>?/VTOE#WQ`F/A0(2:[]Q"B&;C M>3PM<(7XC#:X!B2GK$("7MG)XPW#*%.3JM*;^_[:JQ"I71UAPSX2@^8Y2?$] M3<\5KH4.PG")!.CG!6GX-5J5?B1/IYHR M="QAWR_!$J77V.IE$+XB*:.OF*R:D0<-PK.26E):P$?YV*R!J`K:,7];R03!0[=[&>K4)_ M$9MT'@V08)X.<')R_:R?#L)L_FT2I8 MK?\OP=/;46FX1P+MMXQ>'*@M$,P;)"LUV$!DN?^%#^>02O!.HHH#PQQ&G_=A MN/6>(:%I2SEH2N@Z'65N,I)W&.N.XH&.3@PD8T*,1"TQ41='Z3UHBJH7-9#T M!HR58*L3*TD4\M#;4QA;*VG*LD=9F8QDBF%H@2`36B2Z]8APWE4P;9S!TSM@RA$/+Z=?%P#2F.:8BTT2[ MVABZ9VSM^0!-ASP[K62]B*)W2M2D^&&?8NJ8-M)@Z*2Q[:0MI]4#/49_,?UM M-2E^:!BNJ<>TU"XO0R^-;2^%YN\M+_.%O+OVQ9E@:!6Z^]-M3X79"2>X++F3 MTG,-']4Y7,=N5'>=AV`#K00T@=9X`MVH&OI&POQ*9K+S((F^:ACS$@8\0,'7\Q0U;])/,M^_UMX[(B,CJ61127?7N%%HB!D1 M^[#V.I_V-W_[Z;*7?2B&H^Z@_^V#C;7U!UG1;P\ZW?[YMP_>G[Q=??D@&XWS M?B?O#?K%MP^NB]&#O]WZ[__MF]%HG/%M?_3M@XOQ^.IW7W\]:E\4E_EH;7!5 M]'ER-AA>YF/^')Y_/;H:%GEG=%$4X\O>UT_6UY]_?9EW^P^R]F#2'W_[X,FS M]>,_/7OQY,'6-Z/NUC?CK3>#]N2RZ(\SUI'M]L?=\76VU_<) M6/C\3!OC_^Y/NQ7]1_")HZ+\ZX^86L'^651?^NK-UT[FG8^+++O MB[PWOK!_MHKAAVZ[&*T`A?9:_:LP]@X`&^8]7ND4G[(?BNOZ>U^M\[]7&Z]> M/7M>?Y1V>G)]-;NJC?75OY_[Q5$Q[`YT2IWL33Z>^7B;<^S86;[MY>?U4;XZ MRWNCF6_2:MYV1VUV](]%/LS>@A.CF>^;SK3^>5AA\P!__Z0^YLYD.`24677R M>;O[:G5UX\GJYD9]C'`D;[N]8ICM`);SP7#V/%J7>4\O'!=7@^$8"LQV!I=7 M>7_FS7C"@\O+03]KC0?MGU:RU@58,LH.)V.C5SZOKV*O/^9P+AFU/QKTNAW6 MTY[V\WR[X'.(<98_>M]YD#Q_/?IJ=7`PF(P@0K)OT>\5HE`W&%\7P8W=4 M9*.KHMT]Z\X2VYNBG>AILS[HSOOCX]V#DVR[U=H]:?UNYG$^NC"*;^L?Q1\G MW0]YCY.8.?7CHEWP[)1%K62V,N`X^&C;@DEDG<'D='PVZ65YV_@-*S_+'CY= M>?;RB8W_<'/EY8M7*QG@8Q]C:*XW`_)#[94WTDSUU1X-BZN\V\F*3["_$08CV&%,Z._*3==,TQ)/M_OW[ MO:-WG-U*EH]AXJ-Q?<'[0A#@/;F<]`S/.L45T.O:*@TV^:60_%_LA_K7;YHW MMY+UBYF9CH;:/1)!`!>67(F]-+YZ>/+][O$\=$N0.NOV01V17^4(V2+(U3#] M7O]#,1H;1^OVH0P.I22N_.RLVV//,^?IZ-0?]&\&^G:;_>CT>D4^*BX&/9TC M1,R,C8LYJ`]X"TQQ)'",;<94?Z/Y6:3E_;WMUWO[>R=[NPT$'>C`N!N,"RQ& MJ3A?94.76:SJ^ZH&/W7^*VL\%IKWO>C-XGP[Q3E'1]E5_?1#TY"GHN3T':[/1211851'^?5PT(.]"`$OKWJ#ZZ+(3HM^<=:=)?=6T3M; M[?9'$Z0^;)>C1)B+<45,"-"IDX1C3'RILI/ZB]/$?,.+!X<'BYS:_BV/*+#@ MN-(YVYD+A@I-S/FT@N25W=WB0&>(KS),,S0KB[KAW9W#=^_V3L066\8E=PX/ M3O8.OML]V($:Z@-_]9K!:WOMX]WOS_$$*P?"OO8%1]&(,;'YI#HUK`>1GS961X(CU`@X1!888?TQ[*@B5,^Z M[>Z,2*R^X@R=^<"C"S03M!NX[FB.#F!8)#F#19B004(5^NA*"6'0U&2"RH8+YYN?T9=;=46^LP M/+Z!SR06DSWJ<';Y<)2A:#FCF3$0;AIHAC5EC_RG7S-*8&IW&*%"SG,7?V?:\SQ;9ZS23O=5&IS]=?)>-WWUFBXW?++*_::Z\$B7E M/`QJ9`Z)-DUQ/$SFUJW8PA'4TY*8OC5KV%S8H[59I_!@7J8-W,!&CK91V['' MCW=_W#UXO]MJ-#%V_^%H]Z#5H-T'H,RZ'?9ENQAO-C]*4*/KZ\2,.\-FA-'! M\R)3G^'2X0MH#K[+]@[0 M\7:S1_N'K=8,\W+K,KX2X/1X1H?:=6F*@,>:C&;Y(XGDQQ*QBUJ0AJ;8@=$L M:3RL-S*JAHBPH0L66>IS)+_K"7,.)V[*]IV]/3Y\E[ER^UY0"?`Y/&AEKW?? M'A[O1CB=;/_#K.+[>O=@]^W>2?8(C\*/>ZV]PX/'&1_=^$U`X@"EL^'@$@W* MG!_2*.9[/\*Z;<%O]EIAS;MO*DN>.9^$Q^%L#+`Z&3PT=B0.=@] MB5MM1B-Y3GZ7/7)_S6/3U=`DQ\/NZ61L!L%XD,D>:5"I9HYV9K)L^^3D>._U M^Y/MU_N[VW]D^_MGZW=XQ_W=L0"`.&,A_GH>/?M M+KZ[-UGKY'#G!PVR]V;WX$VK#I_9^772"\T)@KU[=WB05G>:C;KO^^DX3R@C2>`@_I]_,\4@M^/7!#*4O-NO\#7:ZO0GNVYDM M!J!-'TOV9G=GGQ-^D\')'*+9X=L$8;U<'^CWNWO??7_"%]O@Q_9WN^EE68NM M[/#]2>L$3R#D/T-`KP7[[!'D$T3M#*=\XXN?JWW=4@0OIJF?X&`MSLYP\&;R M/;D(-WL$%)H1'PLL`87DJK2I(HO:-T8^QXU>2F'X2>/W\Y5\%R]0!=3W/2(8 MPIUF)#,'L7.1]\\QM?O96=X-[@(Q,O.GG^$ASRZ*SCD>!`FB9@;GS`C[H8?; M#P]_._AO.W^8!*>G'.RXXB%O.;^YX9J=[=;WV=O]P]^W7%B7 M&LSVS@G,NM$].\.DZGN?PP/KKVTGY!AER"HA!>YT/%G2<;+YPELO"Q,-/:^& M@P]=HK?9Z77V:#+B']T^^E&B6J*LW0_FR9U!>S3)#UTIDEEC\*>^W.3W#[BG M0$QPWM9?G1YYE#RYK([U-JBOB;1\3_FUS/L9*6T!O%5$%N,(9?'2-$9%IC5' M0=/]V/-4QC1[-\4HZCLR5VC]1^<;(S&.$&^2NAUUOT^7>P8^[ M+;,L;J#+H\FP?0%RF.D)GD$#]6A7?1Z+&P6W$8R]^:-L?#$<3,XOLM/)J-M7 MO`[D.\7O)&]3?<12EBCX-.RV%3L6'.LO8G?)856-?W:B`_O48\TS!)#@&0A] M,>5^YBM'Y07U[]!-[N'6SCG\>*N>$$",@[Z4I*6J#JAI`43*)=%)W` MZ>34L$!/^+*^GN#G@WX:;;.]^+DH4$&!RROS!3):BC0%]VS^,1]V9D!+;"JZ M%#G=Y',F?"SV2C2_OJ#*!\C.:N1A_C<(!K=/0!SC^7/LDWESB4_7)S,TF[3' MDR$'6O\P'3V8G<3$KR?=4L`L@D+!J#G>W6[A"D"UMG\]1AG+#+L4(+=_*$K^ MX_8^+I56?0-S7UQ!]IQW^WWCK5"N9=/!QY4'^1P M>)ZC41I/6JEDKDB\BR:.%$#MXSG7#ZRK])LG77MT@\OK]?O6WL%NJW8^0Y+. ME-SVN]%5WB;I#=RT*.V#K84"(-FC\>"\L(21C]WQ129N.)JH4S%V;DEA6J&2PDR-FI#0 M)YX":+"1KP"/%`])=`GW[[X.U; M)8BMV\_#M]C._MY>GTR8[E@O?VT#C+>*[OE%"$)]9F#VK/?_HW MI)T!AZ"&`S3+,T+RV$M@$2.1:X=\PU=;A2M38$@E<#I3YEP-N.,+U>?II?$E7# M^AF2P*8$2(BJSS]^R-&:P8P?.(M)^Z?KE>SPHCM8R4Z*OG2;(L#^I/A$BFH5 M%YB_5-T@]$E/RHO@$,]2YQ$?@!QM]*^G!5Z9VHJO38QKLPC/.MA]8C>M9*Z4SHL M!#F'EVW;&,O@!Z38%K_\/)UCNUS&,(O9S3C%KR.4%<%^&1M_&C)IE[O9&:HU M*;.,_3Q;>?(R),0N>4L]1!=IDYVTMU-4Z"DZS08?42Z7L^O.?_L//+U4`-"L/)TSW8G-5"X'_ M*@_0M(>#;IN$EWSTH4OR=55^R"KY>,%36VB0FE1'*/]2[B@D=>X'FN7G0]*U MM'P=,CZ+R26OE(PY.)Z5>R/>F&UX@8%#[5W1P:]*ZK"^]3]0.R1E2H4?<0]24D*V'5H`"<0D9>?(/UL*SQ33,W.=!9_R*J*\5\A\1X;Y M$4R&*#M_G.1#*8L)?CVOG+P@9P:]B9APQ3A#>?RIX^?8*[L(&A*R4NHEP@>%#6 MF&(G&_TD"BPE0-#[)-JA+F&K-#I#:\L@[)?*GY/IQ\+5+J<[1L(&0L\Z;(\' MIR"V$]WFKR&ZCY!\A7"1?&A._BOY!@^W).9$R<=0IQ!,Z+$=%:'Q5B6Z M,II^-I\V#H7_$O;/3?5CH]IDLU(9PF[950C\5-3+1P_TV794-Q\\SLSVVYE< M(N$HY.MD_R._O/J?+BEW!FO2YLSE8;X9J=C0A>EX&B=$]WBG5?2[@^')4+R* M/RONE?::G!&YTW'R?6@J"@QP"@T^F.*+Y^5L,NQW\=>C1)]U/^D?'@12?"+4 M9&F!R2'&M_S;_4L+H?1?*@LH!3]0QOO5&Y`FX?IU]$H)07/.]9R3HY2)JHYX MMG@RT5&`^3)`\'#CV)6>\,/=E9)% M%_I]?NTZ[<)+?;G^G[/2_7S8!_V]V\'G(?K\"[LG%P5HB\RYC]WV3XLL=+SU M:9;$,B1;1D#S?DTLZ\5SG%(&:*X%0S*FV4:.KT MR3#R(1LC>W&V^#HR09]79JJ?!J$H/C*78C4):UDZPXMG]R<0W7'CF`IP!0OO M1:#<`4*Z/12#9>USX^G*BZ=6F/F%.9U+Z4!%%7*K49+L\`Z.V"%E+*7`-W3$ MCQ.3AIP1NF:^O[^#A@FZX*);I5`+W9F*TUY&>%LZI>J!G;[/NL/+F54$(\ER M+&>0$(8AW[*<\:,&*8O18]'"BJ+F0(N\:+QU%#7:(VFT]::AF58VWWLZ:%FXI)MNB/I3:,N"AG^VRXIG!^Y5.`(&VZB-XDK*G"N*= MKS_VJJ;$0>M+;G:.8@56_?\U0I\-&^`NK>:)0`FU:`4V1?$);)&_;_'8AJ-& M+5I#2`&M!D0DXU;"H\2K,GT4+B4+\=&#X]V]DP>/_0S$O/9ZK5Z]OA;PGA7;_,L/*`PK/C(BP/+;O/EN<_Y?+_%0CPNGN>M1#%4(G`7Q[_QN:S14(9GS][=3&) MEDF5U1C,/W_6Z\UG/?Z(%`M)+IQTX\&/?'&5UYJA+>.`PUCMC`QO8(YEKL8Z`:$$.E]&?C`RCGXJ0./0;Q<9: M;&01?+201V(ZTTP$V'XN6-.$?P@?Z+/"?<1>G,83OKD:B[^[0B,!6>2_2K@FE+H!V_0H99YAT$,M8E3&4!2N@L%Y]EHE9TD4%5!9[RJ6 MY#/C$6(V"W>!O0;Q&J#70.^>/W'()+A8K.H_G5,J.-9,O!#YM"R=;\;`+D/\ M)#B'%L'/%K*DG6='/7*LICFD3RN[^P;3^Y9^DXV_H"C5VB\_FW]H&E7H=%(G MK47E]E(`=C]!_3GZQC)V](4WM.7R\Z]?)4JP3CZP\=8.7@AO/2B[2/Q/U:)F M6APYSTT.BJ9,;A^RM#DHZ&X=[N^]L2SV3(GWK[=;>Y2GOLV.*%-5HKORV_5W M*/0@\9W"U1-+@F]-#S>?#YW`VV'DI#U;W7G9W^VL*7>SZKD,?)A=VV9IB.>5 MDO#LJF+O1IZE&[=B&K<)!T30=.:XX@L?R5?J7:^:O'0Y,.I2=JGJ3--\6*AB MJR2,XV(-$VJTBHP;51)4BUX7"]2C9?BLHEMN[@TZ>6K93FD-U+5G%5L&:63JUNDM+NE%+- M?Z[HH=JADUWCO%%O-1SEPVM7)V*XX")?3I```9ZP^2;A@1)PE_C)/$C+S._9 M`:$-Y+7<.VD*OQ=D?^P.J1SIRC\`U,R[0/71H/S'878N365A3.'K'@XJE"E1`NWFED=FC?"EAE&=T9H/ZH(\OBR]; M3NW9'P8`B'[-Y+BC,]Q!%KXAIH@5.9@_U M3KAMLWQ".0O%+U3!4/Y(TI][58:37D@*(`RNQK!H`2;\-4BK((O5Q8K08_<3 M5:^JQX'"+V%DO+I&=,UK+[IE]V\#M`S_OCB-*B6HC+;D@[XZD*LR)FV$332* M[+0?<0U$YK!C[E>+P0:B$BW)M=#N7FD/YX@@&A$Q.,_I^68\S&#Q'J<7?[7D MDK6];5^"WE@D)?A@?90,632!7(S+[E@?5&$UFI`IT@@L"RD(6H,K>#TZ%&SP MD@*8<\O"B,&>P!3=7-(&3!L(]NB":@S%GU9_(HW#(:GFATHTUCAYI<@?>XO< M9`EFCAE0RG2VEA-`IX(=5G15@M_*A$T+'/]&2+XTJSR@8:=?T0"G6:"SOO]B MA+^ZZO#^&*$.R0(!:IKBWFWA]7\)L/:OJ1:]KW.;,@V,^83^`[0EHM<]4@&" M#`%Q%.:%9.HM937M[PMEYE$,%SQ8"\T"L9G+ER0:G%9JI22KB.I5G^34CN(]:_.$TB@]B=.450Q]&TJEIM7.00%TT&WW M?DE?_6Y"N3C50,[42@]BY15O<>..NMWA$`38&9!V:B=V4P^)X]T='(WTC]DY M?&\-W[/OWN.2/-C9G9YL/L?9XWR*TR$%>+%"0@?T=KOU.K0IK^X$PX([0FCU MDKV_4GB;:/QVZSV9X"*TU?4G*[.,NTNWA:8V#PO+&0!JS?@!)&2T'=J]`>70 M%@ZI5[N367,ILP[)UP)Y=0^*``2#Z;TF5&2[^8U@U.9='J1&+3$Y"BW+C)5VRLU)3]AKYVF,NR MQ7`G]HDK<^PQU.V!*E\&2PQKPV6;#*J5K,"V5NZ^>TM)1DT\#4Z@QBI)@JMS M"`Q'2S:60<_CBH/X2^S"AC8=RF:FL3N\D>[E`>@=3^1PGLM^S@/U89X;%W-; M.,=RE5,=1D4E`1G.<6\[;J]Z9XB;O>WS1/L6P-W&7N]9,:L;PE,$U7IO3U;7 M7Z[$>Q@J^'AWBCER._C&<$;VZ`0SOLU"GCTV-\91*(E84?A2E]B8(R363\37 M-Y^O/_Y=X.WB;;1?0K:0"J/;'@X]1R9&'/0L^D,@3_[$[B:K7D+HM=919ZOLN_B,;1UY4=C;@S&):6(EDMM MK(+NF>B<"!/$R)[>6N;T3%N-+#"@\5FM099YZ5N@!E*49]AM]1IXH?AR%Q)'*^TP.O M9;OY4#ZWJROJTYRVV`U?NA.-[ED20T(/[@ MXD.7F\\84KW<.!+MYT/>I14-/2TUC7Z7;K%&',91AXX".,'$O=$=M5XQ1);# M6H7+HFI',>V#(9V=?BR)0Q@34D,CX2!B%#NT/Y7Y9NT&?)?U8`SG^\E,O5!O MAV9`/?^))-BR.7.@@0:M3.J/N'(H`WW:S),/!F0Q:+VKZZ^6PYB/E0LVX>34 M17P'GJ,;&RF45J>N';(;D:3<=!$X\_/UYZ%[<44XW$V5BN6O@=:E;U84$%0+ M;Z%K..&B6KP:++15@U(>8R4JZHT="(U:7P=38E0_'W'"PKWJY,3GU-KA0^?A M^4"!%I!V%./,?,U-BK[MDD<8#X-5*HN&*`U1PY3R%9<2EFH&31+P(.[[M=9: M]MWV]I&'=EGH*9NZQ'))7,?G"2E1ILTJ?)4>IRT$10"*SOZ.2AOTXU]^=D?* MBSFL0(2=V(%/`Q_T*?QW#R5/X"W`)>A4HC]LJN$@7@`H"`6-3DPR,'^#J">6 M>BS-)XBKU!9"#G80=O$[R101?D!LD`T)81R`GML/`L*J8JBN6PY]YD+/\:CM*R% MF/P;F`/ZP#5)?:J,$>JE'#PZ'7>+Q*+?O MXM-]'F"H"0H";IC,7),0%9%Z@9;,5OQT4S6_:21XE^+YPP>/U[+#J;+)Z+(3PDX55->LQ>0(LOY/M^"0I?9V6A2SH0?UGU1=;!YQ+;@36_9ZV M;FW25$9]D]8VMDD\AD1=TM7[Y?OP!`RXXS&`G]* M"?JC!O8SG]3?JTG2+"[GD502Y3M9-="]"M])5'*"B*6+ M>]G]5&81\BCAMAQ?V0@%/++R_D`@$@F8AU^P6NAX;JD9/'RRL?+JQ:94DX6& MOZ.@XO1-6UUHKEMNY?[S"ETCF3[#:!=BRDLE;\9MY00\77O^[&]N8NX0`(V9 MR)ZSU+YE0$PU=V,\;PN-?<>3#W4OTYG*,/P(KU0];#R?9IYT29>O04`,[C:[ MU(BF228$G'?@.5!T$2_139",1EX\C"1QI8BW\32,5LF>Z4&"I!%*&_?!JC;A MS*NL$S*)^(VS:)>\4!C:=@LEGWIJ<_@$'A[Q?*F#`B1).[C+_U+V<7%:8 MF`SR4$Q`B81<\T3TS+4A>VB2C(%A,*]+`5C:EI*)(([??0*7Y/`3"B^05++K M-^;@2_("X)`/%+R@T>U@:`7M0=Y.RN3$JBV?80+&B>VV2N)31GU"L4?+^ZS-5>R;5I*5E9.6A;[LQ-EQ`DMW*;U?=2/HK-%?@4F"7E3&SAP, MMU3HT_D:Z*=3RTUH MD6Q$2[F`Y]9M1(:/&=-:AP7P[!(R%QK1V4=,^S1>MQ3A4@$DH:+26W1+%O/; MTW(B6U19U\-7TA?-G968,BS_!CY><::FSEUM919(NQ$VF`9J(U:'@1@XLC)6 M&3,W'3VK;U;7X=B7!(A7JBD#K8H483_@``',X2`GR9]U5'-'4NM6,?;4`K-* M@%@C^K,_5E@Q]A`*^Q,9LGSP#UE5^&$C^) M_.@.G`;XF'.!$(RU-5)TR(('#U^LO-BPWD-3*.RXMPR8W;^A0K$.6A(^4JL7 M$2/VZ0C:;\>J0-$C\-O;0:@CFW%0HBZ*R0UKQ@`JPE5KAKBG6[[J] M,9;,]P-OA;62T?4K1.%DPBM2+**"G?L-30V5V5R9^H"J;")6T_5Y9F!I`"_P M9@CD%%R=C8D^HVIC>2H6,XY=1UOTWS^P0EZ3`K'0MUI!$8POIDU+-,\B2LR> MY3[_@5K3G$KX>;':`U@[$W)+!(LI+VW?5DGP>6JAFB*Y"'8Y9MQ,(_[> M,[`B?$O*X#<'D.D`\YHN>2J? M`O0I8Z^2=1@084\'1[\$"8&$;J_]`M"LI0*<$+&+N=CSHW4GG$`@4(N5VPV< M9>1/^&872$-A'./HF4^'QTC);'DFQXKPF('0A[L5..:0V:B>M&W4;A>,AJ&$U MGFF!R_(RWS^CM8-7("'E=V0G91=-UVT^?^8@J:K;HSE:/W*PT5B@.4H`<*!B MD@<68Q\ZJ^#[3HB46(2;QT'W4YI')?$#>A`F62I>,=02:RTH**LGU]IL9,D0 M\0-A7'5"D50J)_0[V)TW,##Y@KK[4WP^)+!&$,S%UWZ!:@ZH0TR'GY-;T<@SB,[0);3^YP$B,U/.?,),LQF/H MD"X\#?+0CKZ=]]JJ5'=.JH6%Y%-IK_W?9,!$O`A1&U)O*P""))Q^OVRFR/U% MPF#VG)H.TAW4!4?X7:>W/$>IK;Q-1HG9I2 M*P6L!@X@=3G!<"Z?*+OFDN164(H2F6\KXJ>DG=\,1OAYGN7U-MP->&`ZF-TF8!HS+:M<+NJ6\J#9QD/&@V8W+[L[+U"E M*9TV;KW_5S2WK:#<5Q1_@ERKCKTF28Q^CBJPG,KS9>I]S21JGH-GKX+;P"2Z M-1!QL1L!/-7*JIEN5XSL@OH52MO&^2<\]NKZ92KAP\WG-H\9,QIEYJ2F52XP M`%$MZT@I>\8O:21&']E8%KJER8,1IX&+&2N?U[=9.]I(\ MVU*01J9X]\J\M^(9/YHG]AU-A#'SI>9^6>[;[(/:XPH&3"&LP'>Y^=%]TF@- MJ3PFOO!/VZ>J3&N/_WGFG8/6^V-5%V?OMD_(=:]U,:01^W!PAA+AF3S[H=&Y M>Q\.`?NP8L:G^:8GD2F^=5*2E94*X,8HARW)N9N6G.Q@!0JDJM3R+DQ64Z%% M(-UH$+*@03OY]#WA5)>4:L,DA]+G7 M;Z]9"T6>60=%=T9888;7FA'JQ'G25@LKQC1OK8/J$DY&C0!&%[:E6C0%?AD8 M(9ZH.O2AJG2M5^U2].GV@6A-\1)W`;?*6CE9JJ.`O[NEV//V\"?=3H33)=WR MMD:6@3PB]369&&U85;ICM;QMT:]N%Y^SR\L6HLV09[#Q]NFK%V_45&CX%K^0 M./:W#_;ZX'UWK%^_MD2%.24@L^SF3K5>S8)2&&I!;2,88%B)G?EINR8AA`FG M#^TIVUQ>@>!KBBDOJ83I-C`BD,K_/@NCK8?W>'<8&1B+0?^V^216`B$7\4(0 M`N/OI%_#P+)+`J/B:O`=#@T<#+YGN($=F](70@J9R':A=?UE[]H\VQ;A#$Z# MRD5WSK]*?%W*=E,MST*CW_&0G3Q1&^"^8LEUGB8"C[1-`$;=WXT[ZQ;C(*J, M?7]6HAKU*Z@?(R6AFQ,XY7T2)_W\[(R;S$VS,RRK<&Q;)N*H',6Y2!,360AL M?]DX:$0EX8BN'U,'`.N:DA?%I8 M\D2I/8[L!B]>WTV60:OHG:WN2<]`)LU1(G=,^_`QH]HJ;;%9TKVF$;\*;2M( M:4H`:JTLGE*)E,:8ZHMU?%+TZ+1I>#V'3/1:Z,)9&2G0EQ78!OT1$Z]@1_5% M1*VMU-:B<)W6!Z6-D7&#]:)!C,G%A8LTM72O@>6QUC1C:H4E+8O3$[I\_LKX M7SKJ:"LM07E1D&%).UFFRV(KFN'M-FV63#3W)E*HXFG9KN*Y>O>(:#983XD^ M[H-TS'ZB=.0)M-/P<7I7#2ETGPY!4'7CBY_62$"85$FMQ!8>]\PL'80:4YF)-+/ME).Z0@X6,I=-3GV95U==E==S^IA5U;X&L!7&$[Q1959Q#OB#->LS9+NA;.C MP3V`W8A)J*]CTP*FLS6`&,$M.E4TQ=)`8PF.-5(3A_1\&HQ^^=GOF]Z.23#@ MZUZT:N-+9MH2V6!*(%WI5ASFOX)8<@N>VP+`N$A8<3V6+DFN"O)`GJ2$&5I] M7&LX#S]I0U#A3L0&[PQ3I>*5)#W$M><(F3!H\EF0-:*N@,1HW3]@-*:.)C&? M/][!$JQF^>DD>H!=VI-G^00`QC.HP4#ND_0!AU+BQ.RFQ%UT4$QT\RZ<=?O_ MB]FF#/!:)L8<:7[8&&:JHM_@U-'/UV.P44#+EA8@*5CW\H^CB<>R[/"\]`5^ M%+Z+'5("+_(ZZ^E,IN"2EZY"-JH&G4;Y.%M'Z1S6XFDP-/>-)8I4\Y;@NN"_ MI^QH+X$QRX5$AVX,=;5OM!;BYD-R6\YXBLTA>5CUEDS1775V6W'U2&VRBIKC MJH4X=<1ZFR`(KNJ2C1`_=(N/G/@T6"I1P(#4H4C=$[R<$5PC1RH<9$U7L#`2 MU%\Y2U]NZ?@-C"%`Q[=>79,??0&+U2"5"1(:FQ:EZ^^PB`ED32A9)DNC?>Z@ M@`5!BF/3B?A'/CSM$FPQ(JE@?;_X-,ZX)AK%W2\J0;D1]["JATJ002D(54X" M.U7+()3J4['"\?1D%Z1XP9+)]]- MO3>](J1DBN=5.(-UBUD(\+"4VMOC!3WU(1>VQ6 MU[MN,#GG>^5.P+QHGH0;OY,1A6X0FTPV!^8M9A]:V:VO4B22D4YS)+6('&QC MH.ACYD2T./=.U*K4>ZQG[KSRX7%R!*PHZ<;"MZAAP\K=;]R:4^0]<@+L;CRY M$LBC#ZW5^[ADE*!ES-%F*ST+96@4./F\\WBG5NA\/>62E85!4(EKAA4+K.SL M7DD0B>X/18A5GI%@T;0ZU#Q+AX!+URWX*6^CC">T/,D<^0A*CZG<16ODNI`CKF(E>YJ+^\AJ'K)@ MSD8KML$5QCUKU=R<&UEW1: M]53%6Q',92,QN+H>(PN!PY35V#2I6+B(DJS?;#*`T; M5%-=O.5EDP9!KCJI`!`HQ0R<#C5RXMPL0Q'TNM]RR_/;DH;A?.;S[HK?"[N#/B7`?1R0&SHD M$_C?Y'>2(]!1*;3<"RW=-;I3>X5NW\*9%0"@5B5H!G_(3FPX;D MG>*2>P-#GIQAV.KPN]JEBERSUU=(K,@G[GPYQL.6`DS_/&JUMSM,SW!Q8JH*;1Y?^&;-TW66G@8AQ">=>E5@L;M? M4U&I)7#-G7-T34S`(_:J6>"T*6=BF_+5SM]!A"L@^,-$@23G3Y43%$OWF4LK M>"U[*_Y2M2O6-^&`8RZ)F/J1RF"A7="1[23GP2QA1'DLG(\[76,XV'#8.Z@BT0< M(T9"2!%IPKLRX[D>U=,<1)](H"^#&'#0>%IZ[*A;60DN%T)3%K-FZ3@88X33 MEU@J63>Q^LB-EM/6\^'F$ZO+7XB(V.1=&,1OIWYF&L5,IS.1&N/;*%JQ#^%- M1YNR_3S)`MT:!+5R7-=2E^8WV%C9H*/8?>79HH(LB6\M4\A9&I+J1?NK#<<* MQU!R06B3P?92*:J%02%W<82J6E*J'_C'5%0@I5#Y;E1'\+U>C\888?<:IYG' M1Q+9IHS!^;[$WW2@;T8_"+[($NJA),T%0;"DLZB=F=`F= M)$\"]1>,L3W<>'%_`1FI&2J81>.5?S)F)4WSLJ`1F[&N]"&'A)"SC.,+7:N] MU:9@'WW`P9E,M"VDC2&JNV"UI9LA"CV5:DQ^T@F#3XO"9(D&V:>SB;3A"XJ" MU/+]*DDU2Q:6K[RKW4*H`,S^?Q.6@67*P22G%:P-I8>@+$Z9D(Q2(I%3G((1 MAF7NZRH+?Z.&!H\4\D4;2CXC:\";CB`QOO%6:SQH_[3J&3+BO-$7X.]&U\)X MJW)=#9A@M7VR=WA07\`A?CCE!(F0='G@J/["7C^+GEAN65GG!C8!86JE_&%)-JGO MT>N!9:WHWD#Y>0;*M=(-8J(X/M8PW''2/U\]4?>E/4X':YIHN19@A6WVAOY2 M#J"39?I)96NZ3CTN0]XV>*(U%,3K`=P)82NDY,?J%=0C0<\8JX7+/3$O5T+- M:"V+)E]8F>9=R5Z$KI'V91*+VC<34B?79M/X<7U"\TF&B^$,BSQ3(-[PYHU, M:!(V;)/6(U"KM8A,)<.RI6%AA@!.0?(`['>8?L4T$(1`2-U`NK$> M5+/D^#/_I^`2/K3X?3[!ASVTBUNP?O5T]GCJ'K'FE!9005J.SH_;+:KPKY[N M=N?#@,N./)]3KV9&#-G1A*I>/+A^RM)%?RBNLR,<9KK@N.<%C79\4V^6&-`T M3)(1&B_MW-P@7'ZFWHH@"J9:G'NAT^0#=U`:XL+P*=GL(J8=H3:>>3O1A89* M/J_`7>IX$4Z6#LNS.W>\;W@0*<#3QRAW$"M@T79SE_XQP3?%@:,6*M;K-S!5 MP&D`9]V_^M,B\IB#)ADB$,8,R0D(5#=,_@KHR M7A\1[#UNO?]*31(>R_1Z^>QO1`4ZL#].R/66$]KJZG$AMHU`6+J1;'AK#MU! M@!HC^OWC,3ODXF*4PQ:8=J2D1GC+3Q1"-HJK?!PTDA<+BM,8/PF)/Z7;.4"C MO*M-*RQ1T>TQUBSEI\#?L))=##ZJ\M5)*JX:F#@$I!]RA+H_+*0']8E@H[;0 M=02F*=\N1ZY)[/T+&@"B74E/2;_!K3AF_XJ"`B6TDU9]WN=3.^MP%RI;JZ0Q MQ864X%NC:UQD+:$ANA6DW0Q5O\33^QZ3\Z.KNE[&-+%2$,);PBOKM)&TI>O, M$^KQQRUE#.SQ,S*&-Z*,6<&3([$"1.0BO!)?03$-#+/$O@J(S9,>^.'&>A12 M857V'^E6SSY:W8%-+WSO*K+D6V=EW* M?2?QYLQ3_1-LQS4]8[ZI^`9//=X(5TMD[WRYM$)=J[C0N)SBW?1GB'&AB6[I M&O[R"4+-@O_7TJ.1$205U!%+5==A&GUQVP(L#4Z[#,@\OT=/XI(.]_G]=7<* M(@O^'YD^A]:N*KCP+LFA'!MHVD]Q:5T/DWX\JUK6,L[,Q*ZT>YF>,RQ$NGHE M20JGG?CH'$U!CTP"]:RF-2Y;V@,\9VR?1@5![QHR3FL([#;,/+[F8G4,#`+L MJ#)+0B<]>Z5DI=Q[,`4/!\;15L<_A[N96. M__^Q=^Z[<1W)&7^5@<&%:8!B>)%LR4`$4!2]9D*1"H?68K$(%D-R*$W$6SBD MM0+R1]XA>8!]EGV4/$E^7U5WG^X^Y\R,3%'>!0PLO.*9<_I:79>OJJL,NH3: ML@#IADKC'INPM"21HW9KE=;Q['+)D=5$'XI3+]0[ M&W_\K#ZE1MH\9-T>@JG^O8N;\RFW1RN9`V$_O+1Y\N604[L37!M>7&6:QZR- MI&7V.5\T9""22PQ"C63EU(A8BU&ID-09N<>=*?*''3D=KS9?3737@&'=.L7P M[@*;SV`)`#F,(>"0P(4".,*<&OW_&N`#C1NG/*/D##(*<[A^'RB]L23^8"45 MQJ<^DN;Y%MR."SCUXZ$M2/UT)V(UKV60UK\>-!4=5AIT+%;\J-_^O:,[]>/_ M^^__K1_%7EMC7[9L-/7KH<1\,\4=`X;,J,,^.R&3>'L9EKGXG[QMS:?%E,RJ MB75^ZE[#()4^;L7QH+XW#Q,:4+=A2S)XB?Y7_])D6:M_>1D,YH&L"HPS`:#U M.V],8M5/E_-@V&;*VWU+E*W%[`G.H.%F[H[<(DZ%A$28J@O5D1]/;QB\^7T] M":-3;Z7^:9G"B*TM[;>H(&G)[H=Q(_V#R@C?CX-+>)S_+-KFS66)4ZYW0TC)2C>?%^0COU/`$K'`\?42^!54."5+75U+KY,B493<. MR`X\I1'K9)TT=!BP&=57S69FG0P`F?JXX:I,'=.E?O469E?!;W M8]19N4R5ZF"3<,2IO?YNZC0'TK);3@9WOW@@U<]7YZR1Q;S; M'2!6D`1]MA19DLKL+<^X(H+0=7WV"1D6H6G[.*KZ0P1&?#S6)S&! MBJ0GY)Q\;A78V"_N_F#)VR^O(E-%]D6>6FC!`?IVX2J4\3>@,6:]?/[YI3JW M;]#D8[T'HQ3X`CXAE'EK2U6O0TFJ^B'W&=;Z36D\['%U2[N7JK'X>-.J6 M+OQ[P\WKM]](A#WJ_BVVQ`T:9$=+/>Y^FJF[=5^A/:UE_1/5OE8?KXEA+:VO MKSYYUOI]8W7S._OYV]6-]?+7_L-J^E2(5"JL/Q3221.A'&"HW$&UAZ<]2D55&L06P0=A!B_6$V\:$SSV3F$LJ#O\Q\ M<"(?&C9W:3'`/-8NWAU-4&DI2)+FX0+<:'#6G.G/U^_S)!) M;#[)[-DY"X3LNIG\[X080?*)9T*#A1YS7\ MV^<[L:+3\AXI]KY1H(R,2.D_!@64'#5[7R\Z6-"?#'YGZW!_=__WP\'RWL%P M2.,[AXH2>W6P3[[QK<.=NO'=3'B:&12&+_X.KYR<&"\^G9S?"9C3[?IT<<\+ M1HGBDOHFQ*T#RI,NJNNV4[@U41&*1[XV]=A!RQ8B9W^W>D*Q\1M_:]HIBN4(C#+&(`*6GX;R:D:#0E@S4`F\*5 M@N>(B?UHF0?LGT/%UB&'0W([6DKN``_3F+8FM;RQ\K@6E[?/ES>5K+.>QA[Q MVM]+_.4CK$:F8B6LT`VHDM2B:":T5(/E]6_KYI/RM6PN#.USLU1-=[< MF<.8^`4+5/>FM=C\KO5T<^6[C9:Z\1HK8ZQL_<$B3P9%Z_.G[8FN?[=1O_:P M,RV.0B"%>@3,_LG&9NOIYLJSM4J=4@&(G`9L7RSWIFT-:]+L3*J2$LB&"BEM M/7'Y\=/6UN];RHR\FU^TQPO.?.-I:X[+S]J/-E<^!+%2SVV!83["\VPBJ?[VY?CR MBA2/SN*CPV@0/$2%F)T.,O.H13$O/B%W;]1QI0K\[:_!4[5)G$&38UQ>T3&PD^?& M_W!U!SC6!'0KL^,C&X^LQE-/D2`0[!*&J(NB;MM]"%['PW5X\,J+2+JFZ5,(LPXTZP]@V^5M-6=O&= MHKW=HC$I*U)-O"^$U^H>V/;5Q;%.B#F#^S7)-UN'NULO]G8&N_L4%=H9'@UV M]H]VC_Y8MMM/_5L=F:.RPIL@BK/*5>.0H7*T115?W#&G8^5*R`H'A_A-D'0@ M>"&**@5&S"7_9M5T'[66I'U1TRLI+*3RU=4CO7UYJ.XV; M%6^U_P`IV14$3,T1J`"XQ&)&]E6J>V,P.@:G=JKN7#A'N!5\KNL$[)`%N1/Q M8O1Z31"M>1<]A)Q%QLCQH\7!'@U4Z=N^,@Q<4<@&K%A:F0F7*T[J> MA>*6X-4GHFY#\/!KVTG7X0AE.`7*H(6/CDEU<1Q3DM.;7O&&+%J)ORQ"1^\* M?->!;J[BQ20RX0,;(Y>_808I&[F!TGG6%;6D3IC4*D79XQ@9'R%.;Z\DPN43 MF(BST5FJYL9G*;YM,#GCM%O&2375M>1QX4H8Z=WH82`5R.%+T)]2V#A+BD9) MW*L(GVE+JRHI.K9EV2G;)Y7L1.$-R?*=(8:4#*P_B:0!^?[804(8H)(. M!1(!W(.7IZC^\+0H<5[6:G'_H$&14!N@KKAWQG:8D-.%S:RN_MBDL;$<+7Z3 M*W0*U[W&\Q7CX^&;F<.M&)&;F782#L?O//>2R\]M*'A\XUN8HAVZ@W`.FLM= M?_LKM^^U1%4I;$EFI83Q:""K<*_CQG@_:3A^!T1ESHXPTT8G8S%MBA3@U;%L MSD7"/OG%6--ZKYW\GZT].I:9]YY,J?Q_N3."%4J3>^8"C`)65$3+4[%H]4[3>$&JUJ"(^8YT6:PS4;R-2# M2E&L;S7-<,-'@/=VZ9!NG\&W?ZQC\:T?%)L,%G7H9^G:M),5^7>`H&PWYUT/-/FO5AF_\X!PG M)L-+5;H-CM*(\6Z>RT'.WK,9X&JR=Y@A`DJ'TRA7B<93&G[?6[F]KZ]I/U]N MI[2F$XQE5UBM(T6#B/,GCJ&G@6:UL8KL9*&N=+F#AL.:'8_?3HBY120$-^G8 M*,OVP+/'2+6+/"G,W\I[QF=AZGS&A"+H$A/W:`QGDS,HS)J11DG.L7CO#:F" MV,2?Q!C>>J:PA7C\)QH:Z^MKOUNH749[+R2>U5^HGT\=_\87&G]@]^X`0N>T MW"U*XK\Z@">_4@'4`8%Z)K+*F(@8]Z`0$)A=VF$WMHRQV-FU>V'0!'&3$/WQ MW>3\E*UWFA>!>H1RC-CH'`1K]AC;9D)RC$BSH) M,O$E51ZR+#^=ELKK&)ZFYN)LXQ&HIELNC12BI%:AT9*V![U`S?0H5?I)^JB[ M^^!T>D"B?9C]N\EU[+.#P7J_7N+>YU4-3.+`$IIQ_*5.%P.UU&`Q6R*4'#1E M=9YIRXLHR5VZ<2`MYN6;K69;:F^NTF8Z>(9O*D0:?BNFMG1%;1D&>A162N6T-TX''G^BKW,4XW1\K/B=$/8>N"A#E<3B]2<6,U_U>C?'B MG.(Y4L/4OF$VW@S<,ZP[R&/1##SO_]A-`P^#5SM&/!R_!']Z` M/KP"?7#!$+N;K6Y,TB"U<>30R=7X5"21K;80)I8C,(E.Q;ZD;RWD=O0?W.)."IE$.'#)-MZ\F4$G2M2Y:3%E!OU+F3B M*V_:&HG+-@@+9'^C0,FNAAT$5"I$;&&S;*@?*'C![>3-D(N-'16+:8(4I0YR M&BZ@7)7G)+2AH:3C?A#B9I/RCQ0T9= M=KS]Z/D:+3CT2&/HD`^A`)4G?*$>X&GW4>6P1%CEA7KZ1&5NZ?&7S"=GT8F0 M*Q3U0,KITN.G7R[4Y8'H*Z:2`8H'9_C\D17=,`=2\/34;%E=[2RT%!#&J<4C M!+5)J#[Z^)F8CQOI5M\P_-HK((0`I%11(U:H*6!01W"@7?^S@> M$44\!8OX@$U!3+V";,Y&%Q-,`@*^__FK]:RD^O-?B^WD!GG=:6\G?\](ADRY]K?`B'R3Y MZT02]2S/9>6X!!34O&;'B";($@U`\WO2#%_/TNI>[@ZW#W`A[?]$YJH#`I,L M;=6P[JS`\XB_4?-VPJL7NQG"COE;!S@):@AS@UC[*R!4DR0S3\UAA.,K%Z7V7MH-DK M_,U>)-&.@Q$]JZ'[Z:Q'L>/*E**VSX&UK/2T41EQW133(VZK2>%2<$O-O+E? M4.]OPV+3Q?8:9\R'#;-5CJ"Y0\_@Z)>CRY^%6MM@=W_^>,HMQ@J:)I5^HDVE M48\%0DO2S%`.@PG@_*B7Y@L/0"1[4J`:R#0@TR:_YYTR3\6,"8:`H\1JI27T M,@*!OB*.F8S+/II;D=IL4BAX<$5+[ONN(JBA35G!B5LT2U\8K#YIGU8X&C9$ M$[;1(NMORSBXL*Z((`09*=W?W"R&A4*DS)RCU'AC2J*QZA!VOTH"UG(>"*81 M,*Z$:)"TJS*P#RT>QH7FYA8^@P,H3TB`&]ZBYGVS^[%;2GXUTUJ5!6%$*X&% M>:$(1%@M@,68T@UFH1.5O_+L:9!K#$9_;VQL*/K#!B?U($1^P0B6OOW6DP1I MW$O/UBQ*),\!E41?#*/PT4IY.38)6S&+)SP9@V@SZ]?KG[^A+W"D?H M:V`ZQV!NKDP6Q2MS=NLC,"1\)7Z3#[$E?UGDNV(<8@;I&(9IZUDMQ>*11:9* MY.>L+E%:YN3=NGE/I@/XADO=HR!&Z<#?COI6/Z=H!,B0`&K+SQ,XU&8I16H! M6&DTN:PW1Z8C>G/EO6;I\KX6]6F^8B!]"NTL[M%QLE2'>1S69@Y?8G?N@U14 M'A$7E:0O?[H>U!!($,]TX8!.NQG$:H_VD8BB0_,P!#%FVC&J2V\;R[>BTF:? MRKONRY'D!$27,#.,3Q1/OU<*W&;;&Y+2."V;_S>CY$S4E83#9NUVSG":[^P;6KGT'W'IWC?,JUW^:O\3U3;[.JN'%QJF@:D M"8PN"37Y.$#:&K`A-B6@,77N09X8'7S'K6JEY73O%#HV=7ELLMQGR'N7'E[H MT?[JE#NRE*600\\((FQZFY>GI7;5Q/1O6(NI]VUJ\9?R88)FW2EULA8T7-BC!1.:%FF_%L.&NNY]U#]%45@R@_WSA[AVFA3C]U3M]M?KF,A`^V,5\00@_N*1W`W^RHSZ3M_?IVE/![&4?""T-+9HJAJ7G3 MOT_;K5\S.&*+"^%M")H;$)%`I`P&%9!70;.AD#Z%NKF=4J@08IIR1$W'0'UO M,;Z3`M`I\Z,KV<)Q&(S^1R!TY["*T3?VAY-H,&H"%AWNR"K"=$(4FP;DX5;&I,590=W/"F"\4R5?RTM+'R;-U"Q$PUY\^G7E]:L9/W%FZ?HEI^>>>4 MS?B+SO'7<F>A=P9B]H>9/ MM&*F;O?H.@*7ST62-\H1%OBUG\-_:`S_/L5XZQC(7F(%/`)6L>=CHD)L\ MJ+\EU'C"L?3K1UJ;#`ATI;`@^<;K3A_F8\]_ALL/>NX.1<$@ZNIQN[LO455S MV#L/^6;T2^O?KCX9$-=RCK9?G@TR`8*]ZIH*C@E#81LD,"Q!@9D9^)E#[BWW MNKXJP,#/[U3708"^@QA&7S-]V_1(GT.C^C6'OG(;@*ERV034.=Q0VY8`?\75 MQ[<6S&1A$9*X@R:\-M!!C*&GUGA56?U!'.V6CCW05Q_JG2=V^66HM\7HON&+VEO4&I1?ZWV2K MCN'+^;D@;:?S^MH7?=M]Q'?9.4X7\5)R[XEBE'+TW,R-['R6Q]A.0W.61\5) MAK2,SFQ6:;U>Z3XG)C)/O32YYHR%Z_*SFY#_]2=>;*K>@WZ;D4T6/. MK;DRM*/)%W(X)GTI&0T&RU]5GWT5ZO)5C\EU^QX.J0:OPTT*V`A>2+F#46U` M/Y2&%%;N.D#L-75T,KJ&'@G!3A>.[FT+=>'+&W92/K_+H/O,B!RT)"ELJS5M MEN-AYOG=RI,O62D4+P4I%L)U4TUYJ`O\&;E)#!./0U`HA#DX>6WA&@D.*`-/&@QYD^Z1I,B^L9 M-X,J4DBE:40$E65,C.$3@2Y;/Z.[4]],5Q-&@_7' M&YW7IB/SET3&EWIY*RM88R>EB@SC0?B.H4ZL&@PUY[1!\3L?5R];!JZIVF2; MKMT_Y5PB+)/4W5'+RC"NQ@^1C7ADHMZW'$&TE0=^R8HXX7+]2 MHM]F:W?FI&?LW6)+&64K&I,<90A_3[+$>AN[@K9[.\QWXK!)#;]+6@35E623 M66O!OIA/=]25]6B(O9!;WE+9(TUE^ M.297P?FT=2ZV38EI+4-[3!9C4K]W<,*UZK7BODFSD0"\Z<=VTCL0;)*\3RUJ M=X6"M5S;.WG?(G;N:_>WH003L8&M\]'QZ&+4&B`,WDABEY@.+*6NW^MG/:\B MB=)0-NMO]J[(Z1#G\L?ZUW^UN+/ZZ8Y?#]V+P7U_VD.Z#W;1Z*;_7K]+WLQC M=$58EVGQYB=S+P`+)YW.)5T[X6#S817#TM^#1WY#K?$+*?3]K\>W/"8IEP\2 M]BU&V3>@_$-3X6=\:1;&)?`8"HMGCP@*B^4Z\J];9HF/KY['=L*<9*A*1(J- M&%+VVH5IBKS\(<4SVUEP&=%[L'QW/WMW1^._W&+[?#,#7VI66,"[11,U@9Y& M+?6H7H]OM#JR:V7[:=NJZ[0>H*@I2T'PU*<-5I?PAKKAO52*_*7N=6MY=^WN M!^K(H8S`=;PK*T MMO7OQOWB/87VC]3YO+NH'S?##:W_$`'GM`ZHCH]7G_Q.B8^U[8,MY5$8=([0 M1A#39;2Z4J#;D2<=LK#[^@7?&=%4]\XL2!X+T'PSZY-RDXSF9#15[,KI%[$VS`)$_/LSWB$]"_SBBH3L:Q3_*U:,KGB(X: M[?;+N8.O7H$#=OHFFSLZ,K`,J&-C5\^Z>MKL:]9QZ0\D8'=RT5J./US=O-?. MG>1&NBV$-I:\S2AM[?G9F@7T&$CD8G)'%+C0_7I:P9&2-1C%!$ZN9L5#@+;' MW^BDPRQ.53013:QNLIQJNKGNTS/FB;D?*GAI,6"K'K3&E3/#^X6XL,O=ZQ%- M3D^N`6P`0Z:1T^:`7AU2DYPJ"/YV@M(5_,IU9[MQ%.%WZ"`D`3Z?7.@V MC/;"5JK^LIABQ[2$RID3H6S1&HP(7-WF\,?MP:'J@N%XH[9SN)T[^"]J`F4G M\A/7<\N'@1O7IN0S0BMKY9E\_BIH,-7`ZU'^=)G4\5-/12RG^/T&V8@(RGC3 M&N*RAPLENO$=H^MZ?`9,=4)W$:/H,P/Z<#7N8B34;B9H-YC%LFL8KAZWU872 MS&'*$:^#+5G="K[XC$^;)>[D,[8J1Z6++D'(PPEKVCV-Y M.90H^+DE/3?6UIX,I!U)*;^`6ZL]*7M=+S=;ZL/6M!3-X9PE'.!8D[%>BQV5 MPW5VXWI/_<+7ZP&YK7]@C$\#-ADO[W<.[W5:#2U==X%Z4H=*PY:25W<3-U-& M?<\(-]PO6'])]/%:[R)RC`*N.J>>J>5J'[8WTG!G$`:6N=C.Y7O3]DJLO0?6 M"\'1@5@R&Y7@>3WFK4:7#&^PTI.IM/AO<@4IS#.OWV9$VUF^595;R3G;;;U_ M>DOUGGS.Q%&; M19X&8S?U6A6OS.FI_M9VJI,UQ_/$H'T[15RMAZ7CHB"G;M+H:6'Y]`FZ=HH3E<49IK5K6CF(8(^8L%H[?=PU:6TADL@Q:?PF1'V'#(8>=9 M+;$H([(C8\DO:BN,/?C[;`JA;>D*64#`8D/K:*[GQL9G79&%]Q!5SQT"->', M;R%^.8,Q;*$_I@HM+F\4E965F&'KYY:7L0_K\;V)O@E.S?A&*O*.>[(B2)-F MUF<.%*%V^W=4B6.#M[M-)X+#.K!RPN%7!S$Y_Z(#E'BX%7.Y4-35BZ;P2=U` M%N_ZIOZM;_:]C<_:I.@^D$T&*(%]IEU1XH^4G3@&@-;C",*FE5@VUP2[17=R M+6?IS>9_Y2*V'L4PI#>8O8G;R&C2\H3H5PM^[=[M;2!=`B]AE?)K.,8SX_4? M1Q_==3O_U3UB$U"!YC8Y')^^_3#!Q)O[IH4&./3_*(99&?Q'*L-ZF8X4=>FA MZL"YYZ,6;K]79?#G8+7\0U_'@,BZ=?^8)`3C#_32;31%".(RN:,))Z,&"[ORZ]8$NFDFUR*J@(E"A>RF$F('S+O>:WUTTA:&7+=3/@TQVYB9L$$ANPY8 M-C.+%\&:M6*HTYWC:RT=.3!@52$!1KUU>7#["1@$IC]^"[*UH?T@P-K14^/K M_E"&F$.D[B3Z$>OG1?1U_2-)`.EITY,`UC\&V9J\Z2OXWCV/^?"=ZGQ(<6S2 MBQ90,Z%9+'R>^-!FBF"2$.C;D]GPC^7ZFJGTU!-HC(/:I^/>%S\4.H66KZ\% M/P?L[W2,ZT:1NQ;%@#-7`*,T[57?;OFP292;GI9M;>W5O\=X M\?KY$'Q)08TK,J&I^C9M.4[RF)E6MTT89=UP%=A8_[Q`LK_ZDWK)9A[I!$SA M]&P#X#'.#ILGNR>0G,/F,H4]$Z=C:63JD21$)L"XN,\LQUSSWC]-I[?/_U\` M````__\#`%!+`P04``8`"````"$`1@]^YBT-```1?@``#0```'AL+W-T>6QE M"UQ8-4)]>E"5=+`=GV6P/N+I!SD4+-$5!293- M'!\*15WL%/W?.[-\S8HBN2176O<1(V>1%F>^^>:QN\/7U3?/GJM]L<.=$_AS M??"VKVNVOPK6CO\XU__\8%Y,=6T76?[:<@/?GNLO]D[_YOJ7O[C:12^N_>G) MMB,-1/B[N?X41=MWO=YN]61[UNYML+5]^,LF"#TK@LWPL;?;AK:UWN%!GML; M]ON7/<]R?#V6\,Y;B0CQK/#S?GNQ"KRM%3E+QW6B%R9+U[S5NP^/?A!:2Q>@ M/@\,:Y7*9AL%\9ZS"H-=L(G>@KA>L-DX*[N("*6R/;WEV_(V%Y3K+T,&O;2S/<5_BW4/-RKILFE(M!OX^T4H>=2-ELT0=]9U-V.3Z;92-S9$ZD M6L;%8M%OJ'!DRJ2R1J'Y?G)[-CKE*RNS+BG#Y\H`3#BY+#J0NA7Y/3'QYQQQ M8U*YHL]2+Z^-#XYG[[1[^R?MN\"S?"26#FKLV]R8O*?^J17_P7^R M0R="L9R4S,-2)61C0#$HRX!PX285S/'X>0\S!_>0938=XOA9GHSEA*.!:-G"1->'E0[RT8N_5_/MQ]!Z&0S9=$_L@%W@.FM$ M\;A@T^O$VL7EG;FX8WH),E$4)4)-WX M:_O9QL6P-)J*",:`8#::SBZ'`*1O3)FJLR(8`8#)>#P=#V9#`_YG%>_T"&1S M.M95>Y4@4.15@D"15]F*3$;I2S(%^E"*2*_!$N5<)`D5> M)0@4>95-=B7F*O1W%>R]HG69[J.Q`C0BM_6&$P[]3$D2#GF3 ML8=>2-PG>`1S-?.TX`$0$VE("!XAP\:\X2YJ(SE"S$9R@*"-Y`A1&R%UCB57 MRN0ZV,-YWD,'F^:TWX][FZ)ZJ@42X$TQ36Z&^%'+C M9H@_;,9ZQ-*:(XIVUAQPQ,J:(T1MY.,F]2XG/&LG8'D^@N2`;^[K[6"`HOC` M%,]!$4SJ$[:WX[,NPN7NN+FUXHG5(*'C<'7`EVQC:L5W,4;8(42)\#%5P9+, M"V":L;)=]Q,._'_=9',-:*E=7SUOR&4@<&T.7CR!5YG@1^A;)Q_C>46\`;XL M.VA8>I!F;;?NR_W>6]JAR2[882K87NR/YULW;$*4;[]WG4??LUE34(_%?!L& MD;V*V`5%K*E?AF=4@F>0"!+!TT6_4:(?>!+FHXM^:#H==2+PHE0_!)>P?IGQ M@)=.)4$-+J!!785')@)H+:0(P`DJ$."E7@D'$)XJ$,"2+44``9HC`#@54=$E M#^#47Z828B!7"?I/I1)J3&HEI_*$5I:57]!?8:7)E=].-)-Z"X&>TPP;%0`Z MJ2PKL:I*#'$[9%I.`6Q44&#"J"MGR(,&0A9WP$$.0!DAI.AR@*`,5#$B+RI) MS06=HHS<2)R'D*#`4J0:`L!1`H$X8J!H_!U0#(I&8!H-BH9@"H$;@ZNKA-2< MH)[@1DA%&`"/DJS(Z_6`&S'.2`.!H*I"DF@8JBJ1%(.J&IF[8JBJ1!((JBHD M]82J$DDQJ*J1Q!6J2B2!`(PHJ9#4$ZI*),6@JD;FKABI*I$$@JH*23PQ.G&) M[-&V:=Q$)?W3V:A5_U1[WM0V4@=EBR;P>WIXO'J*5X[@"[:6(DOI`8"STMZI M]A2$SL^PR,0[[U;03+5#'6_*C)P5W?-3:&T?[&=8BL;GMYXWY;U>0)+V-PZ# MD4=8BBG7#WUO76NB7#H_';!T)Z+6$:OPJAR;KR MM?@:L46PG"CFF\!16['_YR.'1G8\Q#1Q'AU(^+B&IXU4IAX?V*T241`NF4:7 MPRT4BN.3>7X4X&TH7791BMDU=0)++R'018Z;HV[%O*@56&F2J7D#ZEN1_*JC MMBTX*>6YK7(^GPL)TLI+-!6*Z:MR!ML-64FZ5OM/)%G/450XE,4IDPA,%56D M!C8?G\(`VV8+AP8VJB9U0DXMI@=D MQ683-$A3G;B*GG+"3`!2<"I=,._C\*`Z9(O,.]6%99P4?F"WQ-BG2Y0V= M(L52P-$<%XP(K))'9G1GX9+"E5F2!A#F535)N`1(KS= M@I.O][*6&Q+YY`$6EG%\KI_-X;(GRY2P'_:[R-F\"+3M@9MC!8>C##:J\E=H M3M$.$;F03SJB;D'/YV@-0_S@)L17C*[#2K!\M%,`MF6?G">Y;J;&L]PJCUO$ MQ.L-42YC!K`@K$IB8;H:#<)EUZA*0T.+7JMU,I"T$>H-\:.$G!R6DA;_.>G, M!60-;.%XI!$@<]8J"U^C?`&E;:*Q%5DM:EU+>)*3A;WK0_B\$F!>2NV.U([, M65;'#_,3/0%V5E?L1F*.R MP.2FLG(_XAW1.5\C,+FIK-R/@)#(,D!)4UFY'\$+5!:$6U-9F1\-GONQ(/>7 M1_W(QRK>0BR"B\K*_'%96/^*%@Q,=2UWM77CA M;H"OZV6WR./5&<0@O#5/2-*3O?JL+>")IYD@/A]P&!41=/>\=2W?BH+P1G`B>&QZ8CN?PPA+!,=#`(^JR$0<5!1!&7^Q M0A^SA4O=@Q@ML2A_\`?,_M?/^3.3&>\1OOZ;/4TY6P\`46M[8^W=Z"'[XUS/ M/_^1O9``@BGYUK?.ER!B(N9Z_ODCOND!LACZ2%!N/N[@[0'P6]N'SES_Y]W- M9'9[9PXOIOV;Z84QLL<7L_'-[<786-S+=SX8WE86)L`OY3OF^NDXT8/NN"`6RX/2`UHK?+WN5^_6\```#_ M_P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE M;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)` MTDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B M?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K> MG$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[ MGM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\ MTG7I@O%TS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM M9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV M[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S M*EAX.(N#UO5D"53,+2L?VW9`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`E>\,`U!!7?4 MYK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@R ML6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N M?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3A MG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28& M80-1?F#R`Y+< M!P``T2T``!D```!X;"]W;W)K&ULI)I;DZHX$,?? MMVJ_@\7[JB!XJW&VCA>\XEWWF5$WCJ:7JUK)NQV"HW][[VB[K?U74RM%L7L[NI?@YG6T M?[U(^_OUSS]>/H/P9W3VO+A$+-RBCG:.XWN[4HD.9^_J1N7@[MU(R2D(KVY, M?H;OE>@>>NXQN>AZJ1C5:KUR=?V;QBRT0Q4;P>GD'[Q^K>8&0F]BQL3 M_Z.S?X^XM>M!Q=S5#7]^W/\Z!-<[,?'F7_SXW\2H5KH>VN/W6Q"Z;Q=2[]^Z MZ1ZX[>1'SOS5/X1!%)SB,C%788[FZ]RJM"K$TNO+T2"KU31_NAM_>Z MJ55>7Y(&VOO>9_3TO12=@\]AZ!]G_LTCK4WZB?;`6Q#\I.CX2"5R<25WM9WT MP#(L';V3^W&)U\'GR//?SS'I;HM><@@NY$[DLW3U:0R0JKN_D_^?_C$^=[1: MO6PUJC7=L+32FQ?%MD^OU4J'CR@.KO\P2$]-,2-&:H3\3XWH5MDTK$;S.U9J MJ17S88485'2!.)O4@P1PZH)AE'6S6O]&-5J\+6ASLWH:WV\,/6O2AR]ZHVPT M+=WZCC!10 MF48!KUR7"P^3M58#=#ECGF]KB$0_3^2L#/(,L&+G"=.HBW<:,J9532+8U&LM M2P1&,B,@SL?`2*-5%8U,\D8LRQ29J82I`SLS!<918.8R!OBS4&"6"LQ*@5DK M,!L9`]IGJ\#L%)A],2,D!GE6RA*#RD)B0*''A.'QA#)K8!P9 MYQG+JHDY-5%@IA*F#IY2,P7&46#F><:L`I\7"LQ2@5DI,&L%9I-G)DV>L.@BS.6>XX047G@T#CY=YQJJ#FZ]D#)C1K64,<'`C M8>`S(H[*`R@8$-A"(41 M%,90F$!A"H49%PHZWN$,CY8Y%!906'+AV2R,%05FS1E^ZPT7"@QO\XQE@4%] MI\#L\XQI/))""`RRPI0-2%0FVT1/ZS>KWA0?4UW&D,$O6^.!ANJA1!\E!BAA MH\00)48H,4:)"4I,46*&$@Y*S%%B@1)+E%BAQ!HE-BBQ18D=2NR+""$7Z,;X MTT85WXF@ZC"G*!4;4V7Z6T01IW4<-#%#"1HDA2HQ08HP2 M$Y28HL2,$W3[KU8#VR(.+WUT"1AZYBBQ0(DE)Z@/N@EZ;/5<"@O7O/!+!S>< MH,;AKLZ6%WYY^0XE]D6$$/9D#UH6]E06P]ZJ@W[H,J8H[%&BCQ(#E+!18H@2 M(Y08H\0$):8H,4,)!R7F*+%`B25*K%!BC1(;1C2385&O6U7Z)\XSMJB1'4KL MBP@A&73R(D:6#8DNIH.I`T^[*524#QE"\]X$*XR^6"JVPR`K_')4L'%DB",C M'!EG2#(^BXY.A$(P;$ZSPB]K,3)Y!C_`64X6^OY&L$73V7N=YD6`UX"(AA0I3A-DI0/JXE0&. MV#@RQ)$1CHQQ9((C4QR9X8B3(JR?]0;HZ&2PF^-F%CBRQ)$5CJQ3A/G;DKF[ MP:UL<62'(_M"1,P1^DY'EB/L7<]SCI@UN*FD,Z@@`7HXTL>108JPF:=AR&:> MMLBP]G\,#$F\#!68D<@T9/<:ITQ!Q2#Q%E;'T<&.&+CR!!' M1C@RQI$)CDQE"&R\F0P2&\_!D;D$,9M@S%M((+"=M<21%8ZL<62#(UL$( M/1F;B^"L?5FBL).O["SAU0O?O9YWN42E0_!Q(UNQ%EF?9&IVXO9'G9X8`[JC MM\EAN;R^T-LKF;[1V^1(6Y[O&NUN8K^2W8"^1<8K5,X%,0Q/P'N7$E.XS]^A\` M``#__P,`4$L#!!0`!@`(````(0!Y3*0DX`8``!&PO=V]R:W-H M965T+^VX%Q5.U/34J)Q6A=NW# M-:W84J-B`=T]\_9[A1`D"V4Q-]/CGR\K8>5/"(&7;S_/I\YGF*11?)DIZG-/ MZ8277;R/+N\SY9^_S:>QTDFSX+(/3O$EG"F_PE3Y]OKG'R]?5SJ>NUNL-N^<@ MNB@\PC1I$R,^'*)=N(QW'^?PDO$@27@*,NA_>HRNJ8AVWK4)=PZ2'Q_7IUU\ MOD*(M^@49;_RH$KGO)LZ[Y7_817`%+>R<)#S/ENSKU55WIOK[D"?HW"K_2RO\[Z3'^LI)H MOXDN(60;QHF-P%L<_V"HLV<25.[6:IOY"/A)9Q\>@H]3]E?\98?1^S&#X<[; MV\4G:`G^[9PCY@&X].!G_O]*'?^_TP?1'FEA"M]9!T^?#FME@&6?#Z MDL1?'9AK,(#I-6`S5YVJ$+DP1#&JI47`J3N&?V=\7@L&/P7U\U4?#%^ZG^"Y M7<',.0,9+YD)0A8"86YA<9="N-51Y:B&($05DPO<<2R&A05;5'D8U!&$"+K" M,=98V&#!%3$>MK(5A&C%PS'\BM"%D2F'!RQ3&YY^KQP-5BR/AJ;+:9O?061B MP0EIN$8RLB2#&'00LXYHR!96O9W^!/7%KC.:W%NG3N`@JSJB#\9RF/4=1N_) MS.8.@^.X=09U>%LG<(<]CDS8T'^^#M31!/7$K\?0]4'96\E4L))4326F-I.9 MF81+YT*X&;L_N87,Y^V",Z.RTK)%)0-7,K%@M8ABUQE]@,SBM&!6]YA)F;G\ M,M\P&HJS;<%X+1B_F9%&$?8D]^8U MDZ51Q,*""Y4APX2!"1,+%JYB8\'!P@H+:R%4QP>ME9L6C"L8X94M%CPAW%JJ M+6U^,R-E'C9.]S+/9"GS6%APH9)Y3!B8,+%@X2HV%APLK+"P%D(U'VAB;P0C MLNIB88L%#PM^19`2"+N/:@+S;>CPML]AQ?`$4ME1ZCKJWIPS,%W*72)439/?H"H/XGFY[)Y^'_5W7D!\B5$U]+RYD(JU M`;J:I53\-!BC)S%#*M>'J'&S+'ZX1E@T8I<(FWM/(WR)CEP^1H]CJ[+X82?6 M-+*A$;=$6#^'0^3?K50\Z:%I[I7%#[OI-R*R==C93N6>5+,./_NIWIQT'25N MKG*H:>6AD26-BTHA%(S:-.#2RHI%UB3`KJ.@Q;=-8ZI:E#XVPI1&/1OQ& M1+83.^BIV$EL<=C).KI_#?#5S@MHF"_ZNC9&:\RB*&^PV9((8=`A3!JQ:,2F M$8=&5C2R+A">-%4=URS$,]^0-)=N94LC'HWXC8CL(W8\5/%1;5GBQT?RLH1N M67.50PV7OJ"1)8T8-&+2B$4C-HTX-+(JD&*>]7KH_K.F0VQHQ*61+8UX-.(W M(K*KP`J-KF+E>)\D/\S,5<[PY&D3%6WQ%T5Y@^F61`B##F'*(<8C-(06'<*F M$8=&5C2RII$-C;@TLJ41CT;\1D2V$SN#:UJD^!F=M$BAY7D.K[>9Y?B#SGBL MU>S$RQOMU!S"*)IH"&%*O5#[.MJ>6W0(FT8<&EG1R)I&-C3BTLB61CP:8=]+ ML`&^GWUN)_X]!'_Q?0Z3]W`1GDYI9Q=_7.!$:`3;H5+EWV',U2F\HX:33J0O MU2F\B*[KMCJ%=\EUW56G\/:WKB^T*9S]UG5#F\*);UTWM2D<_(+>+3L$7VM< M@_?0#9+WZ))V3N$!+@6^*X!L)/S##OXCBZ_L#+KS%F?PG4;^WR-\@!/"&_/> M,\"'.,[$#]9`^4G/Z_\```#__P,`4$L#!!0`!@`(````(0#(-J%<9P,``'`* M```8````>&PO=V]R:W-H965T&ULC)9=;YLP%(;O)^T_(-\W M8/(=A52%JENE39KV>>V`"58!,]MIVG^_8TP(&#+E)H'#ZW,>'[_8;._?BMQY MI4(R7@8(3SSDT#+F"2L/`?KU\^ENA1RI2)F0G)CM5=S(L*4NQ9SM1[ MG10Y1;QY/I1D7VG+_HH<\0\J"(K`6ZB/Q[+O/@ZRIN6Z9[?2[Y5"_;-^$D-"7'7'WG MI\^4'3(%E>9Z>,QST,*O4S!M'.@7>3,8+%%9@*:+R7SI3;$_1\Z>2O7$]%CD MQ$>I>/''B'"3RB3QFR3P?VJ2S&X>/&T&PW\S&./)S)\O5S<@N&8Z=4L>B2*[ MK>`G!PP)P+(BVMYX,X5^QCKXH*,!6L(2!$A"]'7G;=U7Z&/<*$*C@-]6@?N* MZ*S02P'%VHHP^9&*.JHKZLYKA-`$N@5\J\!0,6T5O8K0L4Y%1Z_Q5'O'S%4_ MA4!G)K,VC4$Q"EBI=J[SOB+ZGZ*'`DDZ*&<$'0T0S*=Z%O$*@3Y[ANZ>C%L'%U\:01M*M@"W/ M1D/)%8CU*(2.6A"7\0;"2'H0EFNCH>22I.=)#+O]2"OJL(5A^3YL-#T.R[K1 MB.8:B-ZUAFN"S6;6?4.QY?ZPT71!!M88T5P#T;O;"(C9]+H@OO4&A-AH>B"6 MAZ,1S340O;==0.S=$TYTVRF^;==&TP6Z%*O-I#\,=)I%_5(M\'PQ\R^+:*QB MSG-S>!54'&A$\UPZ,3^6L&UB&-E&VP^.YDN@?0`G>D4.]"L1!U9*)Z0Q!J5 ME#J3V=]^=].@]H+=?[/S$)/EST5#+QIHU,<_?N^VO5_%X;@I]T]];3#J]XK] MNGS9[-^>^O_]CWUWW^\=3ZO]RVI;[HNG_I_%L?_'\[__]?A9'GXG_OOI]/$P'![7[\5N=1R4'\6>/?-:'G:K$_OW\#8\?AR*U4OUHMUVJ(]& MT^%NM=GW18:'PRTYRM?7S;HPR_7/7;$_B22'8KLZL?8?WSUUG@_G0Y;I^?%EP]:`;_;>H7A]ZG_3'G)]TA\^/U8;Z'^; MXO-X]7?O^%Y^.H?-2[C9%VQKLW[B/?"]+']PZKWP$'OQL/5JN^J!]-![*5Y7 M/[>GO/QTB\W;^XEU=[6\=;EE2V*_>[L-KP&VZJO?U>/GYN7T_M0?3P>3V6BL ML>;UOA?'D[WAK^WWUC^/IW+W?X$TOO1S$KU.PA[K)-ID8.B3V?U7LHSK+.RQ MR3*]N0E&_6+VV+Q8'^CW$VTR_<**L%6NM@9[;++,OIZ%M;K*PAZ;+.,O;]-9 MG61^3J+K`\T8?65U-%8WHG=Y`=4]QSKIQF[5SL5QU26L7;>^O.D3[=(I_V`= MFC[1+IOS'Y2HUFQ/_D>S*69?+U*-C9!BD[(_ZCRW-V*#ZS:`UL$V[=X]!L//_59B]DN>&317\^&/GH<_F)[_KHV"V'8 M[RNCR6;9-D28C>"[-5^T)0*S:C_G`9L&'!IP:0Z/!GP:")J`HO%AVY#&1XUH M&A_30$(#*0UD-)!?!8:LE\Y=Q?:?KJ[B8=Y531L6(C#71;=ILRGIN*4`;#'G MCM/E;C.;G%=B*A,+)K&A<*!PV\+024L\8>:C>GW'\XG<5+^=A*QO0%*T-ED( M4T0D1:L5<3N%H<_EEB9M0UJ:=@BR/;(V,<8D3=XV%R$5'1N`NXJ.AZ6B$P%6 M=$T9+D7DNLH,_;*0:E\W:1JKZT5C>2/97<:0C=-E2%FX-QCO!N-WF9G'Q'.=&6-R4%T(HZI%*$PH+"AL*!PH7"@\*'PH`BA"*"(A^&7) MK^?I9%3]R,-?#),D4*109%#D*B$5([NH4A4C?YH6(SF;6`@S%2>\G9MEB8DI MB**D+2AL*!PH7"@\*'PH`BA"*"(H8B@2*%(H,BARE9"JD<^[=ES_\S"M0G*^ MNA!&43]+*$PH+"AL*!PAQ/ZBZV*'D8<15R)BH"'GS!XF/FQ*`$4(101%+$2] MPK.N%4Y@DA2*#(I<):0Z9+.-777(P[0.R47S0AA5'4)A0F%!84/A0.%"X4'A M0Q$((;8%C52%J;(2Q,;$P<3%Q,/$Q\3`),0DPB M3&),$DQ23#),)CXF`28A)A$F,28))BDF&2:YDL@%RB>?504J)J?E`B55 ML]`$4A:H('--7),/C+GT&%2 MJU[N[4EMW%('$Q<3#Q,?DP"3$),(DQB3!),4DPR37$GDXN6S\ZJ15\S>RR,O MG>AD[QR#Q0N)B;-8-:EG3+3Y;-RZ)K9Q&@<3%Q,/$Q^3`),0DPB3&),$DQ23 M#)-<2>3ZY!/V5_79W&/F[_9J#:ITZK-&RD%5=4-`W(?&62Q,[)J<#[O326N\ M=G`:%Q,/$Q^3`),0DPB3&),$DQ23#)-<2>2ZY%/W5W79NJ024_ORN$FG1/E[ M#=%!OR'\WII&KLE,G,#"Q,;$P<3%Q,/$QR3`),0DPB3&),$DQ23#)%<2N3+Y M9/Y599Y'3#')+U7DI#4]JKH34`V'2_X.5W71FIA8F-B8.)BXF'B8^)@$F(28 M1)C$F"0U$>=)$&YE&4VT]C'."Y9Y++D\_M79=D: M,,7\OUR>9.IXH:EN$M3E*4A]G!T-1JTQ$^:P\&)L3!Q,7$P\3'Q,`DQ"3"), M8DP23%),,DQR)9&*4_^;6TI5G%RZ3\@4T:)&JK/,,^%'<7*6:IZ?O+RQB4QM M69C8F#B8N)AXF/B8!)B$F$28Q)@DF*289)CD2B(7)+F51$=+O>.6TH2,=(L: M*0NS?4N)U)Z)LUB8V)@X-:GO=X\FNG%],*E&=Q>G\3#Q,0DP"3&),(DQ23!) M,'C5GK;-,810CXE(71-359-X^?)JRF+8+SY+$75<2NR:* MECB8N)AXF/B8!)B$F$28Q)@DF*289)CD2B+7)KD!=!XR.V[\3.A=2_[1>?5< MT!(3$Q.K)N(C!N-IN[1MG,3!Q,7$P\3'),`DQ"3"),8DP23%),.$?Z/%WY>+ MJ$KQC17BL^^[XO!6+(OM]MA;ES_W[&,_!GO?QCEZ_J:,;P;_."N)6]H#^P1Z M.[[0'Q9=WM0?S"H^/"=BWX/QL7HKHM7A;;,_]K;%*VO":#!C:W$07YDA_CF5 M']4G]+^7)_8-&-6?[^RK30KVJ?C1@.'7LCPU_[`&#?E7=50?\7_^"P``__\# M`%!+`P04``8`"````"$`(BQGG+$$``!&%```&0```'AL+W=O^?_K`YX*I(&GBMCEI]KE"R;PL5N3;5];E6)%FIT@C+:DP,?#AD*7)Q M>BE0V=`@%$-F5"AW6 MZKNQC`U#U3:K5J!_,G2M>_^5^H2O097M_\A*!&I#GD@&=AA_$#3:$Q,4UAY* M^VT&_JJ4/3HDE[SY@:\ARHZG!M(](T52G$--\*L4&1D#T/7DJWU>LWUS6JOF M?#);Z*8QG:G*#M6-GY&RJI)>Z@87_U*H;7H79'H+8D(S;WXPC2QLW0K#\U9X M.KXPM+%M/CQ9S?;HFN>WPO!DA><3P]+G_Z/KBUL,F#@LQOC60U/;UL.S*SQ9 M&+IM+L:+;\#@H"DDHX3*;T^F;S-C-J(C&AT/[3ARDR;9K"I\56!R0L;K>1,.T%S[A# MS!O/>(^,I>L\XS\R#W4%(YAP!!,],I8^X]L34\8FDGYN+,.T[X`&VG<)@&$T ME`!B)@D@4YED9$L-$+53V[0MODYGB+E7V\9QAQB;C^,],I9N\(P_Q`CY#X88 M812%0XS0KVB(F?/MB8>8^UCC)(?U:TAR8N8DIP9>7&EA",:`]"?-UAWR=LDA'S/8T<,X)$ MO@\?3E#RL39P1"-F45"A_BUEYNWPG4W?A/W9H>X7*XO+B%8V8>OV^D[#O+>> MJMKW6I90=<"\3Y4)I43$"-(X0Q>R&O>]EG&?O)RV<"3O:RLN$<0M:BST9$L9 M.F@-02*'.9]VTY42GI3PI40@)4(I$4F)^!7!R4X^9E[IWOI%X05MMS>(*F\* M7J?S/I=>CGARQ)XKT/P2:E/`#Y@W+`7.`IKW0W@YC\```#__P,`4$L# M!!0`!@`(````(0!%C"2!4`,``+,)```9````>&PO=V]R:W-H965TF%2<='DF`011JPI1,F;78Y__WJZN<5( M:=J4M!(-R_$;4_AN_?'#ZBCDL]HSIA$P-"K'>ZW;91BJ8L]JJ@+1L@:>;(6L MJ89;N0M5*QDMNY?J*HRC*`MKRAML&9;R/1QBN^4%>Q3%H6:-MB22552#_VK/ M6W5BJXOWT-54/A_:FT+4+5!L>,7U6T>*45TLO^X:(>FF@KA?24*+$W=WOW>^1EWJ?XS@*2!)E<8K1ABG]Q,VK&!4'I47] MU]J0GLERQ#T'_/8/?7*+$*^H2>8RYOENSL1S)T[X;@Q\>HN,?)]/TR\FZ!>) M\]T\]LDM,O+]=IK<5.?">3(/SHGO+'R!'HK]["RN*(#56&$VBX>U-:Z.8N@A M/X@TNB+A#VI7`9+.@OD@"CND,`*N/4D_MUX4Z96C@/BS:R7F"R^*?DB'$A8: M17'E="#^[-HFC3(O"C?(YR@L-)(XGQ]>IYJ&&]3B-%L=/"IQ/[S>=*7G(\.G MG9C>)%H$YP$CE^/;0R/'K\POK,*AXS;]&2P1-P:=Q2B&J2%.QT-L5Z1=+363 M._:)595"A3@TYA`"`8>ZU7P?FS8:X\GRWJ[LT#V!3=K2'?M.Y8XW"E5L"YR1 M*2F2=NG:&RW:;J-MA(8EVOW=P\<1@_4209!H*X0^W8!RZ#ZWUO\```#__P,` M4$L#!!0`!@`(````(0#@7D@>^@(``%@(```9````>&PO=V]R:W-H965TLE#6/Z3O7]'[[^=/F*-6++C@W!!1J'=/"F&;MNCHI>,6T(QM>PR^9 M5!4S\*AR5S>*L[0]5)5NX'ESMV*BIE9AK3ZB(;-,)/Q1)H>*U\:**%XR`_'K M0C3ZK%8E'Y&KF'HY-'>)K!J0V(M2F/=6E)(J63_GM51L7T+>;W[$DK-V^W`E M7XE$22TSXX"<:P.]SGGEKEQ0VFY2`1E@V8GB64QW_OK!CZB[W;0%^BOX4?>^ M$UW(XU,W+O+" M0+MG>"21)3C!)ZD$S@"DSMYB&H"#2$T1TW#NS!9>Z`!9RE)#MK( MZI\E^:V[U6IC>&2&;3=*'@DT%MBZ83@F_CJ`Y!,$=XC&=$$)Z&E`7[=!Z&W< M5T@C.7$>+`<^.X[?,5Q0[RP@W@D+1-$"\T3/!POT]8)IO7!2#U&H2"^<(+P$ M9"TL)^IQ9M,60)D(&=&81E#L+N4@O`1I/4ZD'N>&!\CT/`BV/9@[T,IS$Y#0 MVG4ELH@/(S89P*#J\PGYI=_71\90WR+^H`=A.%TB&(YQ^.$R[.LC8ZAOD9%^ M-*V/Z^TRF+8\LYFSN-0'&4-]BXST;Y1_=:T?>O.^/C*&^A89Z<^GX\4-^^N+Z]J+"->CF\@3!UNH/ MYNJ&[/#^VLX.)],_7=2^A86&D4>7G328?5C75X4)9XM^R#D4V[NO?2P*)OOQ;P!N>P1ST'R)F4YOP`SF[WGV#[ M'P``__\#`%!+`P04``8`"````"$`MU+[WHP"```4!@``&0```'AL+W=OF/9KU^>\P&'];SI_5!FR=;"^$0$%J;X]JY;D6(Y;50 MS":Z$RW\*;51S,&GJ8CMC&!%6*0:0M-T3A23+8Z$E?D(0Y>EY.).\[T2K8L0 M(QKF('];R\X>:8I_!*>8>=IW5URK#A`[V4CW&J`8*;YZJ%IMV*Z!NE^R*>-' M=OAXAU>2&VUUZ1+`D9CH^YJOR34!TF9=2*C`MQT94>9XFZUNEYALUJ$_?Z0X MV,$[LK4^?#6R^"Y;`^25<-Q`)GDA)?P2@T_6.PC0^Q"0[X407O4A?)T^YFT4ACQZF3<9\9#OUR3M M4_=_01BD1>FL!\50T3,=>$Z.4>I@N9"Z5W,\A:;WI5,Z/XOQ9AIX_A,#,!=B M>#7$Z/L3E0S.U\6HH[SG(V9H$9VD"9R3XPY[QY@?E6RT`7315S7BP\D8Y!SX MTW29+$Y\[QCSHW+&7U[F^ZOM="IC_LMLF+]WC/E1.>-?G_'C%,8)4,)4XHMH M&HNXWK?053\`O=H/_Y;Z0WJN3U?;<"F0_@?,:L&PO=V]R:W-H965T&ULC)1=;]L@%(;O)^T_(.X;;.<[BE.EJ[I5VJ1IVL,M4(=HJQW]^/]PL,#*6M@5M M5,MS_,H-OMU\_K0^*/UD:LXM`D)K:T\)MD0[(DF1%)18L#8:4_PE!E*1B_5VPO>6L#1/.&6LC?U*(S)YID'\%) MJI_VW0U3L@/$3C3"OGHH1I*M'JM6:;IKH.Z7=$+9B>T_+O!2,*V,*NT(<"0D M>EGSDBP)D#;K0D`%KNU(\S+'VW1UM\!DL_;]^2OXP?3^(U.KPUNBU,->`$OT@* M=P2@9.ER39ZA/G;4 MW`4-_$9-&A4$;*,W^/6\3Q8NZBQ<`YSG70CT>=EUWGC`\[5,IC%UMPHMZZ>U MF$50L`J:24\SC8I!ZB"YDKJ+YA@\WTK/LB02@L=1U-.\XP&8GH[3>9_O%$-^ MB)SQWQFU>_O.C^TDC-`8QM6^AI1G@ M8S0^#=O,G=3S^&2U]4\&B0MPDSM:\1]45Z(UJ.$E(!/7$:3#I0\?5G7^5NZ4 MA3OL_];P-G.X")+`)```N*0``&````'AL+W=OJJ^O6IXLT;W_Z?CI.OG67X="?[Z;Y33:==.==_W0XO]Q-?__MRX_+Z608 MM^>G[;$_=W?3/[MA^M/]OWZX?>\O7X=]UXT36#@/=]/].+ZN9[-AM^].V^&F M?^W.D#SWE]-VQ*^7E]GP>NFV3VK1Z3@KLFP^.VT/YZFVL+[\'1O]\_-AU[7] M[NW4G4=MY-(=MR/\'_:'U\%:.^W^CKG3]O+U[?7'77]ZA8G'P_$P_JF,3B>G MW?KGEW-_V3X>$??WO-KNK&WU"S-_.NPN_=`_CS[Z8/^5K,L^GL_E8EZ(]#]SX$_YX,^_[]WY?#TW\/YP[91IUD!1[[ M_JM4_?E)0E@\8ZN_J`K\K27;O1Q@+>_R+RS6K8)6T,B``@ MOJ&>L6]5[3(GI>@ODKDYW7NC=2K4U*4W2F[C5)Q_#!$A0CR$X=A#G(L/BRW5 M[Z:(P;N3+Q>1ST;I,Y^=BO.9(2)$B,_8/?#9]J%$E6O6Y,8@\\^<;9R27=8R M1(0(\02F`T_T42D6-]#7YXV?%KF">JF1$I3F*IPOES2EC5-R7C)$A`CQ$FKB(OG9+SDB$B1(B7\JKUM&.K*E'JB4;RPIW@)D2( MR14QJ[\23&UK9$Z4B`*]L"5#"'%>#42"TUH:HF8E M67FSY@(J7=ED"%'=#'0M.+TPI\&5'U1.TH_WP@4GX:AR&B+!A1`-3G*)-\LK M9[@FK)R&K@5GM+!ST+O5!\%)KO!>N.`TA9"VT1`)+H1H[,ZN+RZ6?@[ M+]?GGVRAH6OQ&2T:G[\+J2-I,LDYFU@(,05IBV[AQFO9\]1R2!"(^D.9R.6; M,U!N($0;^!/=L(W7\OZXA1821(OX4U!:4H5:8.+\^-Y2*VC?&XC>":OXYO): MUJ^60X)`U%5*=39U!6KFHM& MIZF*;"T$&;<^B,UIA='B03G-<(6G*N^&BT^Q%-M<0B2Z$:'22A[S91'12 M(3HI&KK"<(71P@^7@R+[8+`HT@RGX&CS<#Q2SU:-T=(!T^@H426BXY15:.A: M=$:+1O?!9"$Y)4BRK9V":70&"FM'(!)=2;F$1Z<4H@TTT5R)SBPDHT61?3!: ME&E647"TN2&:RE.:U?)0RR%!()J#!/=\3OTE)R,#R4P'K>J'#=UF7LM1/X<$ M@:BK:7XJ.3]9:!7DR6AYJ.5:@D!T<\IBK@4Y=Y4:`MW;,!L.M1P2!**;I[FK MY-QE(-+_(7?IERE<2Q"(;BYY*&*XO)9#W&3<'W9?-SUJGKN[JM2T%1*J@?`P MX3.BM>3]%'2,']^,GT[++A3&%A8"HGZF*;#D0YZ!Y"T6;!X/>59+QFE?9159 M-'JU5FN!!.!55UUG\C]W!:DXA%52S4>=I@3KVHK3:JDA.&UST7"HM=#<:0D+ MJ3F(;%ZE:57!E'@,%%;00#CSUI^60X)`='-*OC;RB@]R!I*<&A0B'BR-5E34 MN%Q6:Z[*5>1EHEI6)Y&P-%-7?/XS$'RVV6D,%!2PM5!0+0LE-J=,[1+&Z;C2 MD"3](&%^ZM-T;+7DDS0ZM\B+!>O2QXAR7FOM^'H*"R6*1[E;36*?W#$5YW0#D8[26KC3?X/^VYGZ1UP9): M[#:S6KJLBWK)ZBJL"B]BG69T!4&NINS.G/JM?PV' M4*4>]9RY"#P;-%;+0RV'!(%HIM*,7G-&MQ!8TQG6O-X>#T:*&K%:#1OO);WU=P)_E0+HD5]E4P<^?KYM MN9NX:NB<4E\\R)N%03NV'!($HJ[2>T"E=;GZ]`]F-;\C#!2E-9I/&Z_ETZIM M!>X+HD5\Q4<3+*U76D`MH6?%0)&O\<3MM9RO')*?<:AI2W6%]E5_EJ$_,CAU MEY>NZ8['8;+KW\XX':#3^UL'Z^]!-O5B+9L)&S')$A(U\##)"A)%.+%DGMG/ M2V))@0]/\/XWL4]9K.5KE)2DA$115FRMK"!1[!)+ZAJ^J9>:0J&0Q"02I M_;$@J8^4)3.6(V/XVT0BDAP9PU\)$I("&=,W(_.J7&_`VWQ-4Y=KR?M[L!C5,.80)#X)DLNH, M*4DYU4#2)"4M)'+@X?MCX$)*4I*F1HPX+7S-IJK7&SP,<`D>:];RR8%+!"3R M`8)+-M4"UE(-TT#2)B68]6$MO0;QX+5`:I\<^Z3B::I\+9^?^9H6$OD8S24" M$I&4;"JT+!XD^9H&DC8IP5,OK*76;$KD#:_N$M9*Y$#/CO&A*9?K#=[+I-8L MU_*]#I?@3=-:OM[A$KQ>PCY*,G,;X2.VU^U+][_MY>5P'B;'[AG4FJE9X**_ M=]._C'IPFCSV(SY?4U][[?%=8H=OKC+Y!\#GOA_M+]AZYKYTO/\+``#__P,` M4$L#!!0`!@`(````(0!#]&J)+0<``(8<```8````>&PO=V]R:W-H965T&ULC%G;;N,V$'TOT'\0])Y8I*A;$&>QTF+;`BU0%+T\*[8<"VM; MAJ1L=O^^I&8DGGGQ[?NO[+<&R:,=`>+L,V/([C M]6&S&7;'YEP/]]VUN6C+H>O/]:B_]B^;X=HW]7Y:=#YM9!2EFW/=7D+P\-#_ MB(_N<&AWS:=N]WIN+B,XZ9M3/6K^P[&]#K.W\^Y'W)WK_LOK]6[7G:_:Q7-[ M:L?OD],P..\>?GNY='W]?-+[_B94O9M]3U]6[L_MKN^&[C#>:W<;(+K><[$I M-MK3T^.^U3LP:0_ZYK`-/XJ'2N7AYNEQ2M"_;?,V.)^#X=B]_=*W^]_;2Z.S MK>MD*O#<=5\,]+>]N:07;U:K/T\5^+,/]LVA?CV-?W5OOS;MRW'4Y4[,DEUW MTI'TW^#I]D42QD$@;/S3!^;LW:,-B]#F-W_@]` M`EV!$XE.8DT3[?K2[<4;(#)MX%,]UD^/??<6Z*[0H89K;7I,/&B'R!S#+WO1 M*=T9]$<#GQ9IEH.^^O5)*/6X^:J3LT-,"9@L#"R&(JH987*J>2QD]#8XF3A: M8ALKC2T3ZKCT0"BB6B.*;($0,CH;-\@8JZZ>NTG%V0!&.1B&J&XA"!GMQ"$S M5\-F)[JYRJ/;7$)TP*@I MNLI9IU2N]2Y)BX4ZB9Z2Z%.+.EUAK(R%8&DN`0,L$A4M82:.%5C3B>-=G!9V M-:&A&]I)PD0CM4B8B%* MP,!N8[5*AFN616RW0,(7WO#F*@NO;$VA(0`#X666\UJX9I''UDS""ZW0GNU/ MEQF!Q+H``@B"9HAMPT,!T(K-H*2P+4L9>'33:4H!"D8"]<<)Y8?)6`TS!+@XRE`XBB1F!.9 M==#<4!+6,A6Z`)IZ0)?%E(?1,LMC'@D!$D?B"YM+[`D`0036,!5Z`&,LK9F& M]VND?@I8S41B>PK#$QV,N7Q5Z`03(*1=3RG<%DH!.J=3O2@,J1DO`[4RD`A(,H8I':NF-[$D22.E)&6?BU4GC$TNEQK`R`YLSS MFVN%3H"E**1M74J!ZN5J1CS"F5CE12JN-&KAMN.(Z0`[4"VR=WI$4N7D3"8S M5U"[*6""("R-E!$;YXH"5%*\,S.2BNC<']-E1H)OMT005D85;*0KM`/))'+Z MBU1&&HVSJK'*AS$S*JG=#>8#0',^TL+F'DHS!=F&P%4YC4RIW!92"1I)QC=E MNRX1=&M\;T(H(:.*-C=+>4`LR?BF_-8B`80Y$;GS9(DY(0"IA!UO2H+JZJI` M'GU-63^6YK>5KB+DGU6O0N/,5&7*[H4RH?*ZI`-DE::#=4`I`00,8B:Z%5J1 M@DJ5+2MEX-=3Z='3E,4H$33/"TM11Q.6)@.?D)H02,BJX5HL8Q)&. M!]MUB:!Y`)2P(XAI`2]S=\C<^5E#65`1G;LC!O$D+#+;YM"C"((@1<9'J")V ME421=4`Y&&GS9`(4CW*PDXX<`(1C*IR?'Y@(L,\-%+\G%?%MV9S,K%DSEO02 M0<`E8\U3$6ML]82FPJ^9L4]4""?9%97=Q,$(8=(V>U"9="^5.8]"D;;K%RLTF',/!TL5*D`!%14[LP" M4G'MHBC>30>5SQ47GXQR,5<`@FU+Y]D?J8!Y;N@BL^MI9:B*KJAXU)2_32J5 MJY9QEC.UK8@]*:1-*Z5R6TR5YQF4ARH1A!6*G-+SK!0K]/7J[",52ICZ&FHYS-8M"'0]?ZI?FC[E_:RQ"&MUGNAMZ M.$>"+V-WG8X^GKM1'PM-'X_ZO*_19S+1O08?NFZ4$\>E_````__\# M`%!+`P04``8`"````"$`&L>0([`#``#<"P``&````'AL+W=O0S!@;1)' ML5FV?]]Q'((]:=F^[!*?,^,Y,V-[UN]>JM)YIJU@O-ZX9.J[#JT+OF?U<>/^ M^/XX>7`=(?-ZGY>\IAOW-Q7NN^W;-^L+;Y_$B5+I@(=:;-R3E,W*\T1QHE4N MIKRA-2`'WE:YA,_VZ(FFI?F^,ZI*+_#]N5?EK':UAU7[/S[XX<`*FO+B7-%: M:B7'UW7V,W%>L:+G@!SD%=YX.=*QYZ2T]\+1=[QDH4&EW6GK8N._)*B/$ M];;K+D$_&;T(X[/E!U/$LH]4R8%+V$G^.M43/4`2,]?NO\7MI>GC1O.I[.%'Y)@ MYCH[*N0C4[:N4YR%Y-4O3>I"'YP$O1.PZ)T06+IO[.E`.@%I+O/MNN47![H" MMA)-KGJ,K,!A'WF__:`%4EHH]GM%[XP@2@&KSUL2SM;>,R2GZ#FQYBQ<9^`L MYS8EN5)4AI3?]+IPLR&V279EJ#I`[(,`D(X%A/X0KT+M>`,<[E\H]M;)F+%< MV)1T3`EL1C9F&$XL1>%=10J%MC&R2T*4WEAS(H.#1">O,M)7&=D]AB4(`C%* M=&TEM;IQ(2U#FQ"RM),6:\Z#;C3BHYY(3'@2D`4R3TU\AI*4F>`$#N`-MX*' M0V$$WQT0H[\4BJN!>B/6'-AN$(JK\2HC?961W6-8@N9W!2D4525\0%71G*BK MRD-D@XD)$N+;:&JB08!L,Q,U;:WXX6*Y4Q"%XOA16\2:H^.?D`#!B04OD/C4 M0H,(P9D%&\:6!/7NHTO7Z"F%(@D1RF.L.;V$"/>3B8;H(DI-<#(J@8D:IE;X M2RO\ZWE6JSAL=&!CS9GK\^SC(YF8,)SG")VD5.-:M1%<]X1DEG'H+V_-905/ MX'6_D_P.QC)0"N.>I`-!I4DL<$)NUTK_TJG]-ZZVQ8]19AN'_]*@'D/40-%L M>/1@U!F7(K1/8MR3^KMU7`L+AV+,D8/4(LQ0J=2XI6+0[M7U>CLHNAQZF-*S M2$7;(TUH60JGX.<:[LD`Q`RK>HB+R0KF!GC^T7JJAKMN/!L`&+F:_$B_Y.V1 MU<(IZ0%<^M,%W)&MGL[TA^1--QSLN(1AJ_MY@BF:PD3B3X%\X%Q>/]3<,&PO=V]R M:W-H965T&ULC%7?;]HP$'Z?M/_!\GM)3$(IB%`50K=*G31- M^_%L'">Q&L>1;4K[W^\T+X+OOOKOO?#Y6MR^R0L]<&Z'J!)-)B!&O MF"\93Q0Z2 MU]:3:%Y1"_6;4C2F8Y/L(W22ZJ=#<\64;(!B+RIA7UM2C"1;/A2UTG1?@>X7 M$E/6<;>'"WHIF%9&Y78"=($O]%+S(E@$P+1>90(4N+8CS?,$WY'E+L;!>M7V MY[?@1S/XC4RICE^TR!Y%S:'9<$WN`O9*/3GH0^9,$!Q<1-^W%_!=HXSG]%#9 M'^KXE8NBM'#;,Q?"5`69X!-)X48`E-.7]OLH,ELF.+J>S.9A1*8SC/;0,ZW;=Q'INXC=6XB1#BAD<#.= M#F=-,'2CGPX2Q6="/.:FG:^8+,;>[=!+XK,^IT-O%)^U"):`R^Z9KZ)!8E^Y M?^'^@4BN"[[E56404X<:RIU"0;W5+Y8-6<(PPTR>V5-8.*T]Z!VP!QI:\&]4 M%Z(VJ.(Y4(:3.;PZ[5>&/UC5M!.[5Q8V0/NSA,W.X9F$$P#G2MGNX!Y#_U^Q M_@L``/__`P!02P,$%``&``@````A`*20YT!>`@``004``!D```!X;"]W;W)K M&ULC%1=;]L@%'V?M/^`>&\(B=,TD>TJ7=6MTB9- MTSZ>"<8VJ@$+2-/^^UT@86E:37VQS>7<<^ZY7%Q>/ZD!/0KKI-$5II,I1D)S MTTC=5?C7S[N+*XR<9[IA@]&BPL_"X>OZXX=R;^R#ZX7P"!BTJW#O_;@FQ/%> M*.8F9A0:=EIC%?.PM!UQHQ6LB4EJ(+/I])(H)C5.#&O['@[3MI*+6\-W2FB? M2*P8F(?Z72]'=V13_#UTBMF'W7C!C1J!8BL'Z9\C*4:*K^\[;2S;#N#[B1:, M'[GCXA6]DMP:9UH_`3J2"GWM>456!)CJLI'@(+0=6=%6>$/7-PM,ZC+VY[<4 M>W?RC5QO]I^M;+Y*+:#9<$SA`+;&/`3H?1-"D$Q>9=_%`_AN42-:MAO\#[/_ M(F37>SCMJ,?-`$KP1$J&$0#G["F^][+Q?87GEY/%3<1!KE M-`E*V$Y\$L/@$#<['>>O+G,TWZ#-+%Z"O`&#/;).?&.VD]JA0;20.ITL0=JF M.Y`6WHQQSK;&PTC'SQY^50+.%@K#J#7&'Q?AEN6?7_T7``#__P,`4$L#!!0` M!@`(````(0"75K`T4!H``&J"```9````>&PO=V]R:W-H965TZ)91Y[)C=G=:[5,VXJV1(>D'L^\ M_?P@D`02?\IMW[3:7QXJ<2@@@:H"W_W]7X]?+_YY>'YY.#Z]O^Q=W5Q>')[N MCQ\?GCZ_O_S??S1_FUY>O+S>/7V\^WI\.KR__/?AY?+O'_[[O]Y]/S[_\?+E M<'B]@(>GE_>77UY?OQ77UR_W7PZ/=R]7QV^')T@^'9\?[U[QS^?/UR_?G@]W M'T]&CU^O^SG2^^A>/X9'\=/GQ[N#]7Q_L_'P].K=_)\^'KWBOA? MOCQ\>Q%OC_<_X^[Q[OF//[_][?[X^`TN?G_X^O#Z[Y/3RXO'^V+^^>GX?/?[ M5Y3[7[WAW;WX/OV#W#\^W#\?7XZ?7J_@[MH'RF6^O;Z]AJ M#Y_>7_[6*_:WO#JAMM)-K@=^/ MQS^Y?I[_?'SZ^?GE_.1A?C28W@UY_='GQ^^'EM7EPMI<7]W^^O!X? M_]\KG4(_.^D')_AK./F!X2`8XF\P[/>N)KV;V\$$5_^!X3`8XF\P[$VN>L.; ML8OZ!W:0GHJ+OW+!\55_.NJ-_LIR'"SQ-UB.?BK22;##7[GBSQ41M^(IU-MH M^).A]M!=?*.Z?N,;["?KM7?N#[$M^S][66G-WB\W9T_:$WWT'/'/7E9:IA>; MYF=+*XW32UKGQY>]]O?/Z;ZK[E[O/KQ[/GZ_P&"&BGOY=N>&QE[AW(4[+G3& M\SV(H>#>J?_F]-]?0A%WUPOH/S_T1Y-WU__$37T?=&:LT],:I6BX&]NYK7)0 MYZ#)09N#+@?S'"QRL,S!*@?K'&QRL,W!+@?[!%RCVL]UC[[Z2W7O]%W=2ZW- M!"2-D56T:(A)E8,Z!TT.VAQT.9CG8)ZY6.5CG8).#;0YV.=@G0%4T;FRJ MZ.'HW*>=&!.(ZM-379$SKS/$#7_N^".M4IY5SI5-I";2$&F)=$3F1!9$ED16 M1-9$-D2V1'9$]BE158\*HZIWHZ6?['A\FP MKD]/QFB8V&7'-WK@*,]*YRY+I";2$&F)=$3F1!9$ED161-9$-D2V1'9$]BE1 M5>P6SWD*V!]=H2;?&J2=A:Y]3\9HQJ3V\ZSOK'2N?2(UD89(2Z0C,B>R(+(D MLB*R)K(ALB6R([)/B:I]K).H]@?3J[@@Y#G2F>CJ]R2K_G[6^<]*Y^HG4A-I MB+1$.B)S(@LB2R(K(FLB&R);(CLB^Y2HZG>+3JK_'_?^DXFN_X"R!AAD#1"U MSBW`J&;4,&H9=8SFC!:,EHQ6C-:,-HRVC':,]@KI]G"+I60TDAS%K?"S3B\H MF4(958QJ1@VCEE'':,YHP6C):,5HS6C#:,MHQVBOD*YAMTJR:MBOGI!Z2^^< M]3S*)M5AWJW/6F)814-!-:.&4[4?E7=ZC`0:M9)[-%Z+!$%I2^Q6CFE'#J&74,9HS6C!:,EHQ M6C/:,-HRVC':*Z0;Q"V2D@8YCS-A\93>!1YEE3[.[X*S5JQT0K7;,42;)DW3 M,&H9=8SFC!:,EHQ6C-:,-HRVC':,]@KI2G?+)JO2PW(JK72/^OUS'R[=M@'J M+D$5HYI1PZAEU"FDPW:K$ROLL&I)P_8(`X'T@M+M[R+L!%6,:D8-HY91IY`. MVV7\$O;TO-OE=GGS8<4CS!DQ:H^2CEH%PP35`26&34`C/41E6\1MU)(K=@KI M@KCDV2B(SZG5A.51$D_9\RB)NF)4!Y08-@%E!;"F?M:H">I3$6?8\ZF-J2.:$;,NLBEH29QU0 MXJN)6HFO2;:*;J.6^.H44F7NIPEV[(4GK)/H@/H8(F-!)ODB4K0FIXIK)) MR3F3[7N$DDN%EH+&9U0)BF6H&36"HJ\VH%&\O3O1.OG24:?I81(U9X<8B$]S M&<:W6(&3?-49M$:J>TZRI5$EOF+*4C-J?LI7&[6D-COE2Q?7953QEI0TP-U- MV2`9T""V2!D0RB97JD0K+8CWE8Q`#1NVC#KE2T?MT@@C:I]=I`.&NYO#6@N\Q'J7IH"-SHH2X/,`KO MTP-5>(]P>6F?TNVKH#Z2*U4!)5JUH+0,9-BRKTX9ZB9S:8`1M<\.5-0>H:.E MC9%56=GW6ME]E4U/5=#*?%&3A2O&3MM$]Z[))E?#;$)IHX+4;2<7XXFOKU.1 MOYKX3NK9Y!#RD?3N\V@46[<*AJ.8D=4!J;N/#%LQC+XZ,3SYTDWI)GBC*?V\ MKYK2(]?_DR$RJ\JR'[3"E'8S,J:TH)).:0&E?30@=-5X.9[2O-9Y2AMEG::3 M>(PI[=<2F#XG,`$E-UL9T"@V;24H/NNNQ3`MKG<_BJ@5PUA/G:"3+]6.Z!-I M.U*O_,?Q6YJ.G=1UKPPH2:'*@,;Q7JH8U6S8L%;+J%-(E\9.-P:<;@2D>^4T MRZ)*T1J?,I_^&*_"92J5J,0&J!DU@M1-0+TR:&%@=@/.&"\IZ05V)VY.%],E MURD+M6.65@\XE0DH[94!I;U24-(KQ3#60"-:$;6"DEXIR.B5:4;B%D7^E9RX M2LB[):TS%A6V1\E>1#D@ M5#&J&36,6D:=0CILEW188?MD1(7MD1IF*66I7)*#U`XCI+1)'5!BV`24+>NS M[*J-6N*K4TB7Q.435DE\GJ%*XE$24#GP*`F[8E0'E!@V`64ER2;S-FK%DO@K M&AL4`Y<:6"7Q*8,JB4=)0.7)&KFUVOJ99N-X%;4DH#J@Q%<3M9)49IHM+MNH M);XZA70SI9+Z:*G"5%:=,Z(AAZE\[^@)"L5%`M1,VH$Q:5$ M&U"RZ.Q$Z^1+AYUF,VG8G+8,/7(C4ZQ"VH$1K8'/K*P&"WZ2D5.,(FH"PHK3 M96AX021KBC8JG#NFG[:9IOO8A62+.-N\E[QJ),2E^+341-0.?T>9JM\=NH M(&XZY4:7TB4%QCR`"8!*Z9&Z=0**[54%0U6(H)46PJ/D/FF#88(ZY4N'[3(` M*VR?&K#%IZDR6OVLKT-@UQK''?\J:(WCBJ46P_0.),-6#*.O+B"DEBBA*H[+_:P^>.(ZW0A( M3U[3+'TMQ?#F-.GTAA,>($4E*9GX3NXU06B).%=2NA&TQC+'#;-NTZF+Z:)G MZ0:MV[/TTO7/;,8(*)WH1"O6?B4HWJFU&*;E]>Z1&4HO;(/6.&8FG?*EBY.E M(52<;!L"&1H5)Z!XO5*T(JH8U8P:1BVCCM&3]!*4,6H9M0P:AEU"NFPWTC4L-M*87N4+KF#5I*$5(SJ@!+#)B`WAL)0&5`:F2A*0K#N4U&S8!927))L\V M:L62>/*1*XI$.B/9^\*C&M:^_^NG+SSJ@Q%<3M9)F MHKV?J!4+E[K7A?O%-&O$:59`2:!E0'KOYS9_2A*U)-":?351*RUTOO<3M<17 MIY`J-)Y!F2UZXCH9"TAGUK3W(UI^[V?8XUQ,-&+640M*LDQ!&)'B?4BY6-#" M1.D3[4&>BXD;WOI!XFN7G'.ND^KI!0FIT5)0,E\*BH6H&36"8G;3!H0\2]QW MHG7RI1LLR[ED3P1)>SXL!J2S9]KZ$2V?SO:-!\NBD0PWC)J`,'V^L?43%6(Q M?=!^;-/%?"/!0=9-Q?0HS8B#%A[CR*4J06DA@F%$3=!"(<2P9=0I7SKL-U($ MY-,4=D@1\"=V<-KZ"89X;<+5JG4W!3=IKR/4!#?H8L[-^"K?GVBC@A2\DTL; M??"-C,)]!)!EGP&E"T]!Z:WC#9,E="U:L5Q-0,E]TC+JE*%NG#Z3G MIVE6:>4XS/\8Y6.;T;N&04MUR.`^[9`_XZN-5XS-E/K2Y?W%)&3,24A`ZI;S M6IA5)(0J:/G]&9]FB6%:0C)L@U;BJU.^5'$F;Z07)Z[3BX#T;4)[/6+H]WJ& M8TXO1",NO6IQG?1+06B(V`THO0A:&.]#>I&];Z*NI0N>91>T-9+M]$PXZP@H MO0U%*VE'0?'.K,4P+:YWG^[T!"V,\M(G.N5+%R?+.J@XV4[/A+,10?%Z):.* M4T8[172->^2%&,`G/CD)1T`!:4U'+0B MJEBK9M0P:AEUC.:,%HR6C%:,UHPVC+:,=HSV"ND:=NE24L.GOOWCSWLG/L-2 ME>^1FY/C@'*;[?N7P1!:)Y:JQWN4]?AL-Z*MB"K6JADUC%I&':,YHP6C):,5HS6C#:,MHQVC MO4*ZAEW"G?1XV369^$1<=6N/LFZ=OY(1#-5`?C:4GEZS5L.H9=0QFC-:,%HR M6C%:,]HPVC+:,=HKI"L]6\N<*YW7+!./DHT8[152-3Q]8WEUXGIY%5#R'*=D5#&J&36,6D8=HSFC!:,EHQ6C M-:,-HRVC':.]0KJ&LW6<].$IK]<"2C?_&54!Z8<@^?.E.FK)6-*PKS:@Y-%0 MQVC.A@O66C):L>&:M3:,MFRX8ZV]0KK2L]7FN=)Y53GU2%4ZH2IH996>/0JK MHU:L=/+5!BU5Z5XK07..:Q'=IRN$[('%,FI)$"OVM0XHN>*&T98-=P'IFKC- M@MA'+02AF^:-Y>B4EZ,!N:_?DQ51]LI;*5K)ED9`68S91EX=M:2B&O;51JTT MB*SENZ@EON;L:Q&U4E_9FQ3+J"6^5NQK';527UEU4E]97/NH M!5^Z3:T%<`]G0&/!99TY,.75;T#N$_]S6^.K>[U=5HI6VM;>EWH\.KC)MM#K M8`@MJ8>&?;51*PTB6X)W44M\S=G7(FK]P-0?)8_Y%(=.-**?N:#H9Q&0>YOJ7)!^ON6_%,/H:R4H^EH+>C.F MC6A$/UM!T<\NH!_'M!?#DR_=CFX-;2QHIGYMG2YH`DJ?!PB*`54!)0_7:M9J M&+6"XI96)RBZGS-:!)1<<70QNLDFU%*VX+5\%='["-\@&JYIM&D:MH/`(?VC=*3[J)&&8BU6,9R$H M/._HW]+CE:6H1*L5H[4@[ZAWRXXVHA(=;1GM!'E'0_=V0C:K[$7EY$@WH5N1 M)S<)/;7('L),_0I>W3P>I0]A@E92E55`R2/-FK4:1JV@N'?3"8H?(LP%Q:I: M"(HSXE)0U%HQ6@N*5]P(BE?<"HJ^=H+B%?>"C)I_8^D_Y:5_0,FCUI)1Q:AF MU#!J!?D!>W##3PP[48DC]EQ0'$\6C):,5HS6@GP$UD?R&U&)$6P%Q0AVC/8* MJ;Y_FVT-_%7?/^GK+8.`TI9A5#&J&36,VH#PWJ0D/)V@^/7\G`T7C):,5HS6 M`257W`B*5]RRX8[17B%=\]F6`=5\]JP4/Y:3/]<("$-,S%C0=;-T.FI)!5:, M:D8-HY91QVC.:,%HR6C%:,UHPVC+:,?(_=Z0JT(_)/O&\+\?Y'_'Y/'P_/E0 M'KY^?;FX/_[YA"2PCV_./[P[<__+1;/)N'"[]*A-DDP@.?41DDPA.=VDN>3V M_$-(N:0W*-RQD\9U>D-(3D-S;C.`C7^?+9>,^H7[4L#P-H*-GY-RFPEL\,S9 ML'$%M3B*:9<2O_9DZ?=N4)+3Q)!?NX=Z\?LU)$%4?H,RDV`T+-Q]R?%B4$0` ME@2_0_6;64)W>OLSH=YJ7" MC8A\!4Q/A1L868)9JG"#(4LP,Q5N3&0))JC"#8TLP;Q4N!&2)4CP"I=*L`1Y M7>$R"I8@O2M<8L$29'F%RR]8@N0._Q!`E$X:8J2S(I7`+'D@Y1NSR.)4BZ"Y?.L02Y=^&R.I8@Y2Y<28(6*]K$D,\0V,V/#0J@H30G6 M0X7+I;D\6`@5+J5F"=9#AUC2:KI$.6Q1@GL8B$V2X(]*5S'DF"'"6UJ2;!?A/:Q)#/$-C-C M*R$I30EV=M`^5GFPHX/R6!)L[*!]+`EVY6%C#;G88T<=6!)LHJ,.+`FVQ%$' ME@1[WJ@#2U)-!XC`&MRQ;XP(+`EV@1&!)<&>+B*P)-BA1026I)O<%.ZU.^Z] MLPDF-CSY8PD>(2%JRP8/A!"U)<$3'T1M2?!(!U%;$CRS0=269#9!>?!"%<2X*1`CO*EN2FF)EU4*)V2E-205*9$KSL6;@W(/DZ#22-*6DA:4W) M;#PM9GB]E;WA1>*B-"45).[U6K:I(:E-20.)>[.6;3I(W`NV+)F-QXC-2M9* M2$I3@I?1$9ME4T/B7N#FZS20N)>V6=)!XM[=9LEL/$1L5FN7D)2FI(*D,B4U M).Z#`+X./FQ`;)8$GR\@-EN">\Z_OIREF;-Q'U%;_;J$I#0E%23NXQ*.K8:D M-B7X5@916S8=).[S$O96CM"K\#T;2_`M7-&9$GQ\!ANK[^!3,MA8DMD8=Z-9 M.R4D[KLGCJ""I#(E^+(+=6#9-)"XCZ'86PN)^R:*)?BR'E%;DMD(K8U/8-FF M'*''^Q5_UMKXU!,VULR$;RYA8_5K?%0)&TLR0VPS,S:<3U"4IJ2"Q'VJSU'7 MD+@O]EG20-*8DA82]_T^V\R&&,5P(`-+U&XLR!8TD'BCH1@"4Y906Q6C>)D%<1F27":"F*S)#A!!;%9$ARD@M@L"8Y+ M06R69#8<(C9K#"DA*4U)!8D[RH9+BB-Y$)LEPD@<:<@L0T./"O<<68LP?%EA3N) MC"6S(>X?G'C%$APGAO)8D@J2RI3@,#&4Q[+!F6*%.W^+K]-"XH[A8@D.$$-) M+",V2U)#XHZX9F\XP1L16!*< MTXT>8DEF?8R)>">`O>&$>,1F27`J/&*S)#@)'K%9$AP(C]@L20>).T2=(\`/ M+4!BWJ?]/J(VQRI(W"'][`T_.("H+0E^=P!16Q+\_`"BMB3X?0'$9DEFB'IF M1EU"XG[EP8H-]ZDIP<]8(#;+!K]F@9YH25I(W"]`\'5F/>R4X%=O6%+V,%;A MZ$&6X.==8&-)\$,KL+%&)/R2"FPL"7Z[!#;678)?(H'-27)]'BY?/KS[=O?Y ML+Y[_OSP]'+Q]?`)N_TWIU>9GA\^NV.2_3]>_;G=%[\?7U^/C^X([XLOA[N/ M!_S0^(W[6&UL MC)5;;YLP%,??)^T[6'XOYA+(12%5NJI;I4V:IEV>'6."58R1[33MM]\Q3@BD M2.T+E\/?O__Q\;%9W[[(&CUS;81JV): MS6G1#9(UB<,P(Y**!GO"2G^$HOD5F"GU).3/A8N!(/)F]$/W0K\U*C@)3W4]I08#>6T"^$Q8NZBQ?$T+YGDN2C4 M=9!.DLYZ@+?PFME`D_:*4CQX6R8OE.,^3X2C=-?3/,AB7?X3C'F^\@5 M?SG-=XMT;7!5_TXR=CB%QA99>&7A3R&_=R77>_Z%U[5!3!T:6&6W=?MH?_IM M8[>]KN.SU18LX0/IO\!AU=(]_T'U7C0&U;P$9N@*C[0_U_R+56UW9.R4A5.J M>ZS@_\-A_X8!B$NE[/G%&?1_M,U_````__\#`%!+`P04``8`"````"$`6N%! M*%`&``"J%@``&0```'AL+W=OUU?W`[% MI;E5._][U?D?]S__M'UMVN?N7%6]!P^W;N>?^_Z^"8*N/%?7HILU]^J&D6/3 M7HL>?[:GH+NW57$8)ETO012&R^!:U#>?>]BT/^*C.1[KLLJ:\N5:W7KNI*TN M10_^W;F^=]+;M?P1=]>B?7ZY?RB;ZQTNGNI+W7\?G/K>M=Q\/MV:MGBZ8-W? MV+PHI>_A#\O]M2[;IFN._0SN`D[47O,Z6`?PM-\>:JR`TNZUU7'G/[)-'JW\ M8+\=$O1W7;UVRN]>=VY>?VGKPV_UK4*V42>JP%/3/)/IYP-!F!Q8LS\-%?BC M]0[5L7BY]'\VK[]6]>G\]55W_J::YOE>^='US_8<;,>&*.XF$$_R43O#K#TZ.Q63\%),Q]XU@ MA3,V#Y?O$P[XXH>D945?[+=M\^JA$[&\[EY07[,-EBVR)5B,^4,9 M2[)^)/.=O_(]9*8#^G4?K\-M\!4%*85-8MLPW2*5%E04@FZ6@R\K.07$4TAG!L,L36^,]BD_G.QQHF.O':J&4BC-[B/)J,G"TD M5Q&-,Z(KG&4?$CI0DRX3CL30BS%W\=HL[F@DIV46DJN(QF3I9$*HSD0@Z['K M4@O)+"17$2TL-ILC`83J83D215-8"\DL)%<1+2R=AY,PR+P3JH?E"%/"6DAF M(;F*:&'76EBA1[,5BM*?Z_(Y:09)EG3(6J?#$<95FK0EY4B$33$V1A0:VRH; MC61CY"JB,61H,4=F!ECG(J!(W1M1:&SZ5%K1$J6H1N%*W_>9M%H-HLL6BY#^ MZ4:Y-!I:3R=-@FJ7$WDR$R@@D):I2&THD]!RM,HE]$"0'IP4TQ&<"RGT149* MT$;$!ZXDE`H(&UM"F0WE&J0')S5T!!N1&+5E;G9G0,H?!Q/*XCEQ"_[JF7`$9:Z6`H)%1-#X?` M<$J/@*9(V>#/""ZL',%),1W!N9!JZ>&0WD_,V+,I$PK,.X7AM>#(SF@CEY'+ M:8[ZD;8Z"'+)U0AR2&L>#D53IV3,@G().8*3;#J"4:I`=W:S.N$>;!(*`8.V/:[(H(NFFW6-TPAN7`0&!\I0O;J5`F;2:%"&7D",XZ>84_-T.XC*K M-CZ='."I%9%#\?10R825`N4:I!>1U',B)6]']"PT,R)T5B]BK.^I5$R,L?.G M4MM%%.Y#+NSSU9S$2W>52PZ#`NND26(GTN]FDBNREDD.*;5,(5RTY%C=#F+B M=$3FPFH^5%PG14K[!JDOS9W>S&@G_@&"OZ6O57NJTNIRZ;RR>;DA9TC=?CO" M_,M'LMC@<8&I)K[GC:GQSG\NP(G\PW>??8$B!HBN$-'2(DK2!I% M2(EK),,([7$[#C0&<5PC:01J_`9E+IZM-@G./]L;3O(-'9;V"`YK9-(UDK`U MUC.HC!$')Q]8NT9RC-!I8L?!71EQG*5A,5@[O#F&DF0MD$2S=P@`<,&-_"$A8CNZAL\LK!*UP@> M5N#E&L%K"KR&D6`,A`^(]^)4_5ZTI_K6>9?JB,T>#N_3EG]KY'_T7">\IZ;' MI\/A,]L9WX0K/$C#&73SV#2]_`,I"<:OS/M_`0``__\#`%!+`P04``8`"``` M`"$`,>5U#NP:```\@0``&0```'AL+W=O=&+8GNJI(%LDB6=R8W;U6R[*M:$MR2.KIF;>? M'T5D)8`_5;+[HDO^,I$`$P<"21#\\/=_/7P_^N?=\\O]T^/'X\G)V?'1W>/M MT^?[QZ\?C__W'\7?KHZ/7EYO'C_??']ZO/MX_.^[E^._?_KO__KPU]/S'R_? M[NY>CV#A\>7C\;?7UQ_9Z>G+[;>[AYN7DZ?\;&TY M4?Z7;_<_7L3:P^W/F'NX>?[CSQ]_NWUZ^`$3O]]_OW_]]\[H\='#;59]?7QZ MOOG].Z[[7Y/YS:W8WOV#S#_3V!N=.QH'S-UZ?7I[#TZUR! M<_O1\]V7C\>_3;+A_/KX]-.'G8/^[_[NKY?@[Z.7;T]_E<_WGS?WCW?P-NK) MU<#O3T]_.-7JLT-(?$JIBUT-;)^//M]]N?GS^^O_//VUOKO_^NT5U7WNDMP^ M?4=.^/_1P[UK`[CTFW]]/)XBA_O/K]\^'L\N3LXOSV:3Z?GQT>]W+Z_%O4M[ M?'3[Y\OKT\/_CTH3;VHT,O-&\.N-3$\F\[,+9^)`LKE/AE^?[.)D>G4^.7\O M('S_3BY*;3A^>GOXXP:J)R7G['TGQ@];KW.@G4FL<92--P(XLRN4I"GH$A!F8)U"JH4 MU"EH4K!)09N"+@5]"K8I&`)P"K?O?8_V_4N^=_K.]^*UA0"MC&GB:-&0)*L4 MY"DH4E"F8)V"*@5U"IH4;%+0IJ!+09^";0J&`$2.QG#P2XYV^KAUA8W\+&WD MH\XWKAE0Y5QEYE7QE$I,J;G)\#C1(O'?Y=B5QWBQL5(9I@A:`5-SN(*6NZ5)-F* M2$ZD(%(261.IB-1$&B(;(BV1CDA/9$MD"$GD?=SV0^_++=;AV,4CN;K:C_Q+ M(BLB.9&"2$ED3:0B4A-IB&R(M$0Z(CV1+9$A))$_,2NQ_.EP[,^13*?J3R(K M(CF1@DA)9$VD(E(3:8ALB+1$.B(]D2V1(221/]WR/9@;2OMT./;G2#!QE]Z] M)+(BDA,IB)1$UD0J(C61ALB&2$ND(](3V1(90A+Y$\LORY\.Q_X6X+';S MX^5(SN-!-IE5K_9*4@TYD8)(261-I")2CP2CON35['7"^\`LO@]L]DJ2K"72 M$>F);(D,(8F\[M:NH=O]$N?$K9E?O]W?_K%XPHUKHBLU16#&J=:"H&]62HK:,.D8]HRVC(4)Q M_;CE43#,O%L_XW(*,T(IZ,*%&%!E^!&T].A2QZ05HYQ1P:ADM&94,:H]PH^4 MJV&M#:.64><1?L16SUI;1D.$8L^[]=*O>'Y<7T6>']&%+DJ7+GZ#RKB<[:(# MT[/)/!X#5JH@5Y(S*CP*KK=4+1=W@.5D=%FK@EBN&-5LN5$M;SDI\T85Q'++ MJ&/+O6K99=ZJ@E@>(A37F%M6I34VNSI!:%3NSB[VE0Y?([K`C2D8JY)+7/J$ MTUTZ=/)FF(P,4;45LSS&GW6M.SR[3'C%KG8Y>Z MODS:?2Y6]$H+1J6@@WFMO1;RTA+-TG)7IJW+B[CD-K: MLJTATHH]C#HU/>QX,GD;T6ZZMX]93Y(NMG0Q>"0\QTQ".V+:T5:JI?4P)ISJ MXKSP6@$J-:&:GTV2F.):M<1\);;"860:M+O=0%V+EA:B45N[&T\R\&Q4+%FU M;*1CU&O"\$J2@-Q6M<3\(+;>NI*X?MVB-.A![TX*QT5LU+-&A'J7(BS=`PY4 M\H7.H5:,A-=MJ1$O+M6'4>A24JV-;/2?<,AH$ M[

]XM7U//3V=NBO%F4'`R+GDC[X\HNOW-ILDXOO0)+]ZXL:U4+G682U[J MT<*C8,U3:L*@E4Z3!?-:M<1\);;"N9+1W\:K"W)LU-;NEG5!'6Y,@DN5O%J? M9*Z7TDGV.GKV:CB\E&2EN54M,3^(K;J)0TF]^@RC#)1 MVR^\%GXD8:FVPG(E.:Y52Q)6'AW.L?9:^)&$C=H*C/'N)&X2$;0#7?WO7=&W^D8_0B[J$?)Z)O,:9=>RX^^ M5U?)G&BE!?54,"HYX9I1)0EU+*P%A97B(T&JM?%:P8#<"@I&7[;5BY;: MVC(:!!FCKPME!!UK[^$QQ!%UGA'%"X9I,L-=NLCON&!P+6XR39K$2N72)'*/ M@EEDP:C4A+N)^SRYTZ]5+H8KME(S:C1AT)1GR91LHUIBOA5;;\W<=[VR$RU= M@_1J:YP3)3[Y1,/4N M/`HJL^2$:T85VZK95L,)-XQ:03H<=VRK%RU=7FP9#1Z-UQA[W@4D4L]/IX>V M";C50NK\$<7WI%DR)5_ZA+-HV*2`F)@_V\68)V=I?"H7!75,(99U@"H%'D31'7%$,XWSKB2A=H)D>='%&Y,\5H!6C'*&16,2D9K1A6CFE'#:,.H9=0QZAEM M&0T1BCV/7A9Z?C\7<3RY8XT(\QJY0RYQQW%:`5HQRAD5C$I&:T85HYI1PVC# MJ&74,>H9;1D-$8H][((/0=O>>W@,2D1M>$1XYJ8>)K3"(S#G]$`K9U0P*AFM M&56,:D8-HPVCEE''J&>T931$*/(P1DC3PSL>MV&/PMT3'KVSGT6UI&IR1@6C MDM&:4<6H]@@_DF.C6L'=/WWRO%$M2=@RZACUC+:,A@C%]6`%#`["X_>WF.A"G*].:/"HW"/A6KM5I^\QT(5 MQ'+%J&;+C6IYR\F\<:,*8KEEU+'E7K7L,F]502P/$8IKS"WLC7O';%SPA_<. MC^*-%;,D"KGT6AA+)?<5HYQ1(4A;>RE(;:T958QJ06JK$:2V-HQ:1IT@M=4+ M4EM;1D.$8J_1)>[(.C;-TMBFUPI&BA6CG%'A4=0GQD($MM:< ML&)4LZV&M3:,6D8=V^I9:\MHB%#L]&1=OW:$%:.:;36LM6'4,NK85L]:6T9#A&+WO[%$=W') M9(GNT54T5TYWK"V]UG[0.TMZ_$H5M`?XE;ZVM,)K8>4K6J4F'(?3LV1>M58% M25.QF9I1HPF#@6.>1&PWJB7F6[$5C4O!6#(^,!`MO99>;?E;0[RA<*MRR6N( MK,1UZ-;LP43NW:GWN,:/)G@C0MU*?DO$%%T+"!\8,,H]0@.3A(5'4=61K37; MJMA6S;8:3KAAU`K2T;AC6[UHZ6B\931X-%YCY/GY&\&!'8^#`QY=A4UEEC[S M6GHM_Z3Z[(1ZCRJ(OW/)3"^U\"@8K4I-^$;O406Q7+'EFBTWFO!0[U$M,=^* M+?1^G451[Q&M8!*NMNS>HW+):_!H?`@>U^$O!A;F'%CP"'4K^2T].E>T8I1[ MA"F))"P$Z>66G'#-J)*$:JL6I+8:3KAAU`I26QW;ZD5+KW'+:)"$.UNQYY.0 M@=SP44GIO<>C:%H^FR=/A99>RSV7T09%S]2\UOE4IN7))#D7,[K&*P3I$%X* M.IC96C/3(LWFR9VK,FVE/:$6+2U$(^A@(39V(9+E>VO:2@O1B986HA=TL!!; MNQ#).,3+;6U M%J2V*D&J5;.MAK4V@M16*TAM=6RK9ZVM(+4U"-K9BCV/V]C!*4?R3,T='Y%, M)SV*PQOSI"\NO=:%#F$K1CFCPJ-P#L]::T85HYIM-:RU8=0RZMA6SUI;1D.$ MXLI`QPLK8S^..I[,0D84C:,P;!*T0[35C"8C-$.T=)R-8(.%F*CA7#3D)^)=HA=S:ICU`LZ MF/M6K@1I+8V;*L5+4W8,>H%J:TMVQHBK=C#[T8[YASM\.CJ<+3#:P5S M_A6CG%'A4312*W]&,CKM=%RU`-&%/4`0B593N:,:U60M4/E46"Y9M1HPF#@H&B':HGY5FQ% MXU(PEHS1#M'2CM2KK3?6:^2D(;(2UZ&+)?Q"M&,^QAXP$,J%+#P*HQT>A=$. M1KE'8;3#H\#G)2=<,ZK85LVV&DZX8=0*TA!`Q[9ZT0JB'8P&CXQHA]O%$'I> MYAD['L\S/'HGVN&UWHYVJ(+472Z9Z:46'@4C7ZD)WXAVJ()8KMARS98;37BH M]ZB6F&_%%MJZ+DZI]XB6SG=[M67W'I5+7H-'6$P!1;T'`U%4A^\MF7;Z2=V. M`9`PVN&UPF@'H]RC,-HA2"^WY(1K1I4DU%Y="U);#2?<,&H%J:V.;?6B%=SZ M&0V2D*,=B#=$GM_W'HYV[%1WCY*TJB79X+?SXUI.LN',QH^N^ M0I`.X:4@K`RT]::AE;77MK2"U-0C:V8H] MCQE/>./;#9I3G+KLVH`[62F)=F`<),^/Z`IC9]`>TB>6/F$8[6"4,RH\"N?P MK+5F5#&JV5;#6AM&+:..;?6LM64T1"BN##@]K(S]..IX6:42/( M6[Z^3H:WC2J(Y5:06NX8]8*DS!=)&&>K"F)Y$&3TG"2B\.YT@R,-YR-")4I^ M2X_P(VC%*!<4CED^1*$N*$5+;:T958+45NU1,/XUHJ6V-HQ:06JK8UN]:*FM M+:-!T,Y6W$VL2$.X7S8=LSCN<#ZB*S@MZ#Y)>UB*UN78?297B<)*%:2VC*6S:Z#UENV7+'EOO$\A5W'[(\1);C M2G0+XU]8Z^(N3F/@B%")XJ.E:.DZ<,4H%Z1;`@J/HCKR.:JMM2145`E26S7; M:D1+$VX8M8+45L>V>M%26UM&@Z"=K=CS[T49?/>!4\>O28R'S3_E?9,.NY:3ZTTN4:#?J)!)TM\Q5+N>-7I>Y M"F4)^E;FZI4EZ&*9JUZ6H*=EKDI9@OZ$B[$D"T@6I@2C6.8Z`5O#6)6YOL`2 M#%F9ZQ(L*2%QW8`E&)\RUQM8@KL\_&;Y&C=[^,V2X)8.OUD2W-GA-TN"&SS\ M9DEP&X??+,D"DH4IP>0)?K/28(H$OUD2S)3@-TN""1/\9DDP+8+?+`F6:+A2 MJQ-@I9:YJ3_[&JLS^,"28$4&'UB2Y?D")DARNU)(C)X4HM20>) M"P*Q#Q".0]NQ)(BZH4XMR0*2A2E90K(R)0ATPCN6-<0[X1U+@K`GVHXE07`3 M;<>2X`E!Y@+/?*5X4)"Y8#-+\"0@*22N4@]2_#@%E=JC4AX?INY M!X6-228,\)\K$DV+&&=F"5`+O4D(\EP6!)O2T`XL"3:BH=269`')PI1@ZQ_:@95F!8G;O\7>P3X_>-22 M8+L?VH$EP:X_M`-+@IVQ\($UPF*#+*[4DF`'+*[4DG20N"V77.H>$K?-DB78 MXXHZM20+2!:F!!N.X1TK#;85PSN6!+N+X1U+@DW&:#N6!%N)T78L"?;C9VZ; M-U\/MN5G;FLW2[#O/G,[O%G20>(V>K,$6^XSM[F;)=A9CU64)5E`LC`E>,TA M6YF2'!*W*Y[SP3L-F=LD((/+`G>BH(/+`G>HL'U6'>,$A+WQ@OG@S=<4#^6!.^K(!]+@A?8X`.K M!'AI#?E8DAH2]WZ350+_%Z(>=30N)>B&0) M7H"$-4N"UQGA`TNR0`D6;Y0`]SE3LD(:]U89ER"'Q+UO!RAG$4KQESFA(2]](T2_"2-+QC2?"2,_*Q)'B_&/E88R_> M%D8^E@3O_B(?2X(W>9&/)<&Q09D[AX9+C=.#,G<<#4MP8E#F3J5A"4X)0J3$ MDBRF&'?&\'$20UG,,%Z_X6N,HV/\+4FS1/VXDP2X!#CL`;W$DN#,!_A@][P\ ML8:SH#)W^@];P_E/F3L$B"4U).XL();@Z*?,'0G$$ASWE+F3@5B"(YXR=T`0 M2Q:0+$P)#M7*EJ9D!8D[&8FMX02MS!V0Q!(2U-,)_&;U>IQX";]9$AQL";]9D@Z2 MSI3@F$OXS4J#OC-FN_@W'KXS9+@?'KX MS9+@F'KXS9+@M'KXS9+@.'KXS9+@2Q*P9D7]\4&)S'VY@*\''Y%`/I8$'XY` M/I9D@1(LS!+@8P2H'ZML.23N?'HN`3XZ@/JQ)/CV`.K'DN#C`J@?2X*O@""- M5>H*DLJ4X&L?J%,K#3[ZD;FO1W"I\:$/U+8EP2<^4-N6!!^J@0^L&0H^.X.R M61)\1`;6+`D^"8/ZL20+E&#Q1@GFF?M*!U_/"FG0CR7!)Y.0 MCR7!)X^0CR598)%CM;;%-1QM#?W+ZPR?GN-+64XPW3-3U-=H@Y:IYCH;+%,- M3+F/DR&3T_UD#Y^T_W'S]:Z]>?YZ__AR]/WN"YY8GNW.I'R^_^H^D3W^XW4\ M(?'H]Z=7?,S>'99X].WNYO,=OMAWYDY'_?+T]"K_&PO=V]R:W-H M965TV)'^%E>342"(IDN+7 MUMG=:X_C)*Z)XY3MF%B%8#>-MR,ABO MV\>GNX=O[X]G;TZ/CVZ_W3Q\O/OV^?WQ__ZK^,?5\='3\_6WC]=?'[[=OC_^ M]^W3\3\__/=_O?OQ\/C'TY?;V^;S]>OV,\C]]N?O^)-;N;W[&W/WUXQ]_?O_'S[KW?._=T:/C^YOLNKSMX?'Z]^_XKK_GIU=WXCMW3_(_/W=S>/#T\.GYS

+BS?S MJ_/9^<7\_/CH]]NGY^+.)3X^NOGSZ?GA_O\GK9FW-5F9>ROX52OGEZ>+V2\8 M67@C^/5&+@]F>N;U\>OUYZ=O+F>G;Q>7*/F!TD*ZNV;\^H3G;_:%/9#NPJ?# MKUPE\CZ0`.7?983?G[HB]+Z=/G[EBN8_=45O?4+\_M(5S="PINIW+MP?_@4LZLW5^?G9Q=7KU353!J%^^/7+DV:QTS;Q^*52Y.& M@9XBF1UN@C-I$NX/7[SYSU793!J'^^-GKNQDZKF['K^^?K[^\.[QX<<1AE'4 MP]/W:S@2$&9@DT*JA34*6A2L$U!FX(N M!7T*AA2,`8@[_2XYV^KB718W\*O;L#2M#!GF'=SX7 M7RT]P8WJY5I8[94DV9I(3J0@4A+9$*F(U$0:(ELB+9&.2$]D(#*&)'(Q7&:Y MV.'8Q1-98"ZE+IZ=Q@U]M5?:NYA(3J0@4A+9$*F(U$0:(ELB+9&.2$]D(#*& M)'(Q9B.6BQV.73R1JZO]'71%9$TD)U(0*8ELB%1$:B(-D2V1EDA'I".#.:&,"@['_IS(?*[^)+(FDA,IB)1$-D0J(C61ALB62$ND(](3&8B, M(8G\B865Y4^'8W].!"L=Z=TK(FLB.9&"2$ED0Z0B4A-IB&R)M$0Z(CV1@<@8 MDLB?;N%I.73'8X]Z=#E%'-Q28^71>3S0)BN4M6I)7>2,"D8EHPVCBE'M$6X` MDF.C6N$]81'?$[:J)0E;1AVCGM'`:(Q07`]N81,,%'[Q^,8MRY^_W-W\L7S` MK6RF:\=I(82YG!1TZ0("Z`11_4QHCAED<"-,%C9KGQ!:8BMG5#`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`K6/*4F#%KI/%D^;U1+S%=B"[4;C`/)W:`6+1WD&K6UNV5=4(?; M7ZKDU?HDP:5T;+A7PUJBQ3Q9:0ZJ)>9'L?72I435/G\A6K'C\2W+H_"6Y5%P M?UHSRCT*ZJE@5'+"#:-*$NH-I!845(I'EZJU9=0*T@[?L:U>M-36P&@4M!N) M8P^[97C:L6;G+\8AYM.R/>Q4'EV@*>T;YV*>S`97HA7>RA;S9+J_5BUI,+E' MEV',B>XUA=?"A4K"4FV%Y4IRW*B6)*Q^*L>:I2,OLDHMO):?O2]NDKF1&N5R\7D MDEC+AGM-&%Y*,G$;5$O,CV+KI4N)JSV)Q,BZTH47DP6#1]'H.VE%HR^AW"<, MZJE@5'H4V-HPJB2ACH6UH+!2ID)$HR^AUB>\#$??22LH:B]:FN/`:!1DC+XN M+!*,OGL/.Y[,6D$Z''=LJQQSN`!U8$!3? MDQ;)E'SEM1;1L$D!,3%_.G6^TS0^E8N".J80RSI`E8(.9K;Q6KA-:O-?+))N M69FV:*$N6EJ(1M#!0FSM0B2WN=:TE1:B$RTM1"_H8"$&NQ#)/&\T;06%B-N6 M"Y_\2J^>PBW1K'A"T1UQ0@N-\Z[G/J%V@ER01M4*CX([3RE(;6T\NM"@7<5: MM2!U_]?#]_"Y*$8Z&D\G%+ZJ MXK4"M&:4,RH8E8PVC"I&-:.&T991RZACU#,:&(T1BCWO0@%!F]_/1:800=2V M)X3)I-PA5WA`X^HA0&M&.:."4D>P\S6C/*&16,2D8;1A6CFE'#:,NH9=0QZAD-C,8(Q1Y.HAG2 MAA<;E$MJ9J<4<&H9+1A5#&J/<)E2XZ-:@5W__3)\U:U)&'+ MJ&/4,QH8C1&*Z\$*&!R(*BTX6.!15#^3EEM.[6?\V.@4/]Y;^X30DHO.&16, M2D8;1A6CVJ.H?GZFJ%NVU3+J&/6,!D9CA.+Z<4O98*Q_;=6RF):^X3W`H_`= M"X]>?L="%;1J)LM((ZCP6N$[%IIPM_KD=RQ40J()9; M1AU;[E7++O.@"F)YC%!<8VYA']38?F2;%OQ1S4PH?K%BD40A5VY+EKMAZT1M MS2AG5`C2T:@4I+8VC"I&M2"UU0A26UM&+:-.D-KJ!:FM@=$8H=CIR>)^[W1> MQ"_\(A[3(!V;%FELTVL%(\6:4T$%;?@*@^W>Z?PVB]=R,9R]%K_-XK5\Y.ST#2W> MQ8Q&D@I&I:"#F6TT,RW28I&$HBO35K!DG>+.HJ7E:@0=+,16"^$&J,LWI_%_ ME_D_DEMK*W8UJXY1+^A@[H/F'KH@B5>.IJW`!7'+<8MI:XSTBVQ]YKY$/,FW M'!E[5QZAF0A:>X0V(2@7+75!P:@4I+8V;*MBK5J0FF\$J:TMVVI%2Q-VC'I! M:FM@6V.D%7O86IW/L8E[_Z*?"Y$E\4V/KL('>(M%$G5=>:U@.%LSRAD5'D5# MXU2(P-:&$U:,:K;5L-:64+;*N!3XOO:!(PH:MHKIR^ ML;9"*,K5UG[0.TUZ_%H5M`=,:1!($%1XK0"5FM`-+J=O3I-YU485Q$S%9FI& MC28,!HZS)&*[52TQWXJM:%P*QI+=<-J)EEY>K[:F:TGR&E0N>8V1E:@.SY(@ MP&M3[YU^'!SP"'4K^:T\"A\8,,H]0O^6A(5'8=5QP@VCBFW5;*OAA%M&K2"- M=G1LJQ:V\EG]2C3:>]AY5$'_G MDIE>:N%1,%J5FO"%WJ,*8KEBRS5;;C3AH=ZC6F*^%5L86G461;U'M())N-JR M>X_*):_1H^DA>%R';ET=C("O]IYI'1Z.C+"ZN_7K/7#ET;FB-:/<(\QSX)&(4B'\%+0PD$'"S'8A4B6 MLZ-I*RA$W(`PF/Y2UW7ZR8UO0FA8T@-7[A`)-X/1*UP+TA:1"PIO?%/"Z,9' MMC:24&U5@C3'VJ/`5L-:6T%JJQ6DMCJVU;/6($AMC8)VMF+/HZX/>CYYIH;1 MDCP_H4O,_?:==7&6],653SB=K[6;3JT9Y8P*C\(Y/&MM&%6,:K;5L-:64..,PQL>1>,HAS>\UBOA#:^UG^G/SN+5?C*GS<6JMLR" M42D('6??+"BTLM&\58NC'::M8#"9HAVBI>5J!!TLQ%8+X:8A/Q/M$+N:5<>H M%W0P]T%S#UV01CM,6X$+XH;T0K3CC*,='D7CYJ051CN\5ACM\"@8V`I&I2"= M6FS85L5:M2#U<"-(;6W95BM:FK!CU`M26P/;&B.MV,.O1CO..-KAT2O1#J\5 MS/G7C')&A4?12,G1#DY8,:K95L-:6T8MHXYM]:PU,!HC%+O?!1J"N?Y^QCD% M(##$RBQ@>3:A5Z(=7FL_!O)Z;3(3]8`)13V`4$F6DSGC1A6DS)5'@>6:4:,) M@X&#HAVJ)>9;L16-2\%8,D4[1$L[4J^V7EBOD9/&R$I4A^Y9>EB'KZW7=OKQ MI,^C,-KA41CM8)1[%$8[/`I\7G+"#:.*;=5LJ^&$6T:M()W%=FRK%ZT@VL%H M],B(=J`11YZ7WK/CB8>G`,@KT0Z?\.5HARI((\PE,[W4PJ-@Y"LUX0O1#E40 MRQ5;KMERHPD/]1[5$O.MV#H<[1`M7;+W:LON/2J7O$:/L/0&BGO/+T8[L$I. M)^X>H6XEOY5'8;2#4>Y1&.T0I)=;@% M'2S$8!4+AK!U]-HUV"-(6D0L*HAT>13<^ MLK61A&JK$J0^K=E6PUI;06JK%:2V.K;5L]8@2&V-@G:V8L^[4$4P;=Q-.>8X M6]NU`7>R4A+M.'?ZB>%=!C'\`B5*#Y:B9:N`]>,UM9&$BBI!:JMF6XUH M:<(MHU:0VNK85B]::FM@-`K:V8H\CZ;)GM^]ED2'@YA3@%WZ>`K@$;P7=J?D M`?]*M:2^UHQR1@6CDM&&4<6H9M0PVC)J&76,>D8#(_=-%3?\3*UMJISI&RG3 M%Q/N;Q\_WZYNOWY].KIY^/,;1J@YEJ0?WNWY]'66Y<6I?)XED>"[+;_M%L@) M7^)[+KMFD_)Y-IKZBVS<-:!$_[>S[#=<`ZHQ$2S/LG&WBDSY>3;N[G(IO\`5 M6'8NLW$W\*?Z\RN4='>/2R08"S/7\[A,&!(SU]M8@H$O%&DKF!BB6XGV1NO&))"8D;HUB"FT?F MABJ68`H&OUF^QDP,?K,DF&_!;Y8$TR[XS9)@]@6_61+,L>`W2[*$9&E*,+.% MWZPTF+_";Y8$TUCXS9)@-@N_61+,6>$W2X+U,Z[4:NM81F=N7<:^QM(9/K`D M6"[#!Y9D=7Z.Z['Z3@F)6^1P/EC4H'XL"98HR,>2(,`!'U@E0%`#^5@2!#+0 M=BP)XAF96^=RV1##0*NR)"TD;M7+:9:0+$T)(D79RI2L(5F;$H2%X%$K'T2' MT$(L"8)$66E*$$B%#ZS!$_%47*DE0<`45VI).DA@JQ,!O5AH\(8/?+,D*DK4IR2%Q#U&X!`4DA2G! MDS#XS4J#YUWPFR7!4_7,/;[E?/!P/7-/<5F"!^J9>YC+DA$2]TR7):LSW'_P MN)$E)23N`2E+\$`T:&5$,[L"1X.0WU8TGPFA)*;=TQ2DC< M*T5<-KQ"!(]:$KP0A'PL"5XG1#NP2H!7")&/)<%K@V@'E@1O#Z(=6!*\,8AV M8$GPEB!*;4F6D"Q-"=[+1#NPTJPA<2_7L7?P$B8\:DGP+B;:@27!*YEH!Y8$ MKRW#!]8(B[>7<:66!*\GXTHM20>)>Q^62]U#XMZ!90E>0$:=6I(E)$M3@K?! MX1TK#=[YAG`W2X)M#_";)5E"LC0EV(,"OUEI? M):L%QE'L`6=)"8G;TO^!KC*,XP8+S6:%^W#$/+,%)'.@EE@0';9>[T*I;@E+/,'6+%$AQVEKFSK%B"LP+A`ZMOX\A`7*DEP9F`N%)+ M@G,`T1(M"8X#1'NS)#CU#ZW*DBPA69H2',`([UAI<,XBO&-)<-PBO&-)<.HB MVHXEP>&*:#N6I)[/X3>KU^,X4OC-DN#44?C-DG20=*8$9Y#";U8:'#(*OUD2 M'`(,[UB]!(?UXDHM"0[51:DM"0Z_10DLR1(E6+Y0@CE*8)4-A\BB?BQ)`8D[ ME)3;*(Z41:DM" MP!)\$2)SWQ!@"3X,D;GO!K`$7W[(W.<#6()/M""-5>H*$O?T4'-61)\0`>EMB3XC@YJSI+@SKZ>OL)3SI/=X?I/]Y]=M^'G_[Q/!UB>?3[P_/SP_WN M2_)?;J\_WN(;BZ?N`-M/#P_/\@^7P8^'QS]VWY__\!\!````__\#`%!+`P04 M``8`"````"$`"`/YN)P6``#@:```&0```'AL+W=O8]RVB0.T`SC' M9_[]O"HI2TJ]";9OACE/IK)22GVDU%7RNW_^_7!_\-?NZ?EN__C^<'1T[S=?[Y[_/K^\'__U?SC[/#@^>7F\?/-_?YQ]_[PW[OGPW]^^.__>O=C__3' M\[?=[N4`%AZ?WQ]^>WGY7AP?/]]^VSW(?FR?WJX><%_/GT]?O[^ MM+OYW!=ZN#\>GYS,CQ]N[AX/O87BZ5=L[+]\N;O=5?O;/Q]VCR_>R-/N_N8% M_C]_N_O^+-8>;G_%W,/-TQ]_?O_'[?[A.TQ\NKN_>_EW;_3PX.&V6'Y]W#_= M?+I'O?\>36]NQ7;_'V3^X>[V:?^\__)R!'/'WE&N\_GQ^3$L?7CW^0XU<,U^ M\+3[\O[PXZC8GLX/CS^\ZQOH_^YV/YZ3_W_P_&W_HWVZ^[RZ>]RAM1$G%X%/ M^_T?3G7YV2$4/J;231^!S=/!Y]V7FS_O7_YG_Z/;W7W]]H)PSUR1V_T]GH3_ M/7BXST9#(:SPX//NV>7YH[5_;PX/;/YY?] MP_][I5$PY8V,@Q'\#4;&9T=GL]ET?G;ZZU8FP0K^!BNGT9,WGCX-Y?`WE)N_ MZ2VD?97Q5[Q]4_\TZ./O;_DU0M1\V[KP^7;[M1J-I"G<__F]DE*Y4:S=F\\\ M]OVA[T?5SK'*QS<)6#ZQQL6FTA(`9CG#6T:$B1*@=U M#IH0<- M6K-Q_[CYT3Q;3CLQTS],5]UE5%;5?::%95K:;X&YP;4&JBZH%-1O@$.>'[1B M)6K1BJ@1%&VU`90,KZ\BE2RQ=F#"^DC!E>7H5M#); M6793BU;:+0?S;M\[/IK02!L4I"4[94;7WJW*5NW]:JUJ'Q;P.!Y*M_'W595' M50$E([`6E%:""K9LJU,%M=MN>;;<]LNV6]DB506MS!8% M+3PQ[:2#>1>TTZ-IMJZT\?G2DIT\S!^^I5OVD5O;D]K_=`'TN8!J%8_4"`P9 M0XQOU3\(73D.W3J@9%`VHA4+MHPZ*=C;TL%T*WU2G6'=]AF`R?^\-(V_LU4IM?7J4Q` MR8`K`YK%Z;42%,]M:BF8U%>T(FH%Q8;J!/6V5"3'69)"'?-?^^_NM$\BW.MG MU?%I";(!&0AET)K'\50QJ@-*"C:LU3+J%-+5>27QP'[)319IQPQ(=\RS+*$J M16O>)T'C.7ZHR%0J48DAJ!DU@K`\%9U\H[I M\PQ$.+;OY"Q;PQ, MKAEM&&T5TM%Q&4L2G6%Z\)F,&F<>H>-*5@;M:2A.H5T3;(\:.@WG.^,/4H<*@-2-?%:":JY8!-0 M5I,L5VRC5JR)-X^"0+HF+H6P8N)3"Q43CU1-0@*BCHC.L@U_-1ZTQ*$ZH,16 M$[7BS#<^R[:B;=026YU"JG)H3E6YGZTEO;Y>7@-*'"T#^LEY3=021VNVU42M MM-+9SKJ-6F*K4TA7.DN%I&].?'Z31C0@-S_&Q3Q?JTO1\DGM:'3&N8.HQ"6Q M%A07SD80ILWX.$IJ@U9(:F='TZP[=6*&D]K)*VE3S[.XAI.8N'4H@Q;F+VGE M2E"L1,VH$11MM0&EYS6BU=O2$7/9@S$&)SZK4!'S*-L'9H.D#`7QIT^_K(`% M.S&SK:501$U`.!IQ=F9'LRP4;520)NN4&5U-E[18U0S)3-SK+28>I9M$0UU MA)I@9LBQS[+3@#8JQ."D9G0M709@U=)G!JJ6'F'6$+NEZX\N$TJ'3D!I)0@U MH6`R3EI&G9@WALXK*<6$4XJ`G*TX^^29=1FT]%%GWK25:>LT"T`M6K%_-M&\ M'U'3/`V)"M*XG3*C@^:6=2MH?KE700L)1HQ0.0E)03JB2*L.6EAOQ*&&"[:, M.E50N^WR`_F93T^GKQ"B@=@0'-X^E%)2BF_K443"HG6K%@RZ@+ M"%T1-53!G+Z2;O0\<]MG(-D(S-+74@J>](O.:'K*$Z2HI#4+MI-N&K13OGT)B`TB?2<4K1B0"I!<:364C"MKS>/ MGB>VVJ`UCU-UIVSIZF1I"%4G.ZJ8:8?H9*)_!GYFBK-H'5!BJXE:R4)" M)Q-1*U9N<`)(A\EE&4GE:*[-3KFG/BM1E?8H<;0,6OIDXCP_Z(]:XF@=4&*K MB5III?.3B:@EMCJ%5*5=,-)*R\E$S_6<%E"6JV7;SU*T_,G$=,29@FC$-;$6 ME.1`@C`CO9$I!*WA8&*29PIBA@\FL+^Q:^ZSEC2LO:I^D4103!(J0;$2-:-& M4%S^VX#P9PB8:'&JBJK:;G,BTZNZSRK2)J07243+)UMCX^=1T4A&)*,FH-VZ@@ M9CIE1M?RE8P"KP;D&45`Z;9(4(Q7)2AZ7#-J`DK&238C5D%+VZ(]KFBEG=$[`?-^CYLG(?'Q,6;!;V-`N44] M6=V&`>47>S7=A?0B!JBP<8CYD([%Y M)_FBLQ`M+&%#$+($KHPZ,GHJ1C6CAE'+J&.T9'3!Z)+1BM&:T16C:T8;1EN% M='1<(F-,DNBWU*D\4J=!$SJ\#06A%1M]*"BH9JV&4B2T8K1 MFM$5HVM&&T9;A70+OY)FSCG-#"@YI2H958QJ1@VCEE'':,GH@M$EHQ6C-:,K M1M>,-HRV"ND6=NFB-7'X-#+-KMR,@;PI.8XH&54!N5WW,*./YUD.5DY28JO1?:JL&MTCU>B$ MJKE'6:-GF5,=M6*CDZTV:*E&]UH)6@:MQ*^+:#Z)_'FVFE]&+7%BQ;;6`25/ MO&)TS04W`>F6R)W81BTXH4/C\G(K-#Y?5Z'QR+W('GOZ>?9S_D M)#L@J$-!:$D[-&RKC5JI$]G/WEW4$EM+MG41M=ZP=1FUQ-:*;:VC5FHKVRE= M12VQ=ZZWFP&Y%WJ3F.:?;XE6W!)7`>$TTYW* MC$9'HZRNM12*!]R-H&BG%>0/RN?\Q64G&M'.4E"TK3E6A$.]>"HIU-0&_[M)6"O2T=QVSW+(=5I[Q+#B@][1`4':H" M2HX.:]9J&+6"XDZH$Q3-+QE=!)0\\9*U5HS6@N(3KP3%)UXSV@24/'&KM'0+ M9QOZH86'C;N,T\6I1^I@9G*2K>RE:,5#ARJ@X?QRDDU6-9=I&+6"P@\44VND M!!?CPY=2*J(+0>$\=7Q.AT>7HA)+K1BM!7E#HW,V="4JT=`UHXT@;VCJ?GO) M5I6MJ/2&=`BS73^=R62_5Y[R:4!`Z1&3H.AX%1#B*'VB9JV&42LH_M;5"8J_ MWB\%Q2=>"(I/O!04M5:,UH+B$Z\$Q2=>"XJV-H+B$[>">BW=\J]L_4]YZQ]0 M`%HTM&*T;K@)(G7@F*3[SF@AM&6X5TRV='!M3RX238I6;)W6X/NZ>ONW)W M?_]\<+O_\Q&9RAB?6GYX-W!_.R&^HBO%Z*DLP312NP[($ZRW*6/7',HLRE@2K+<)H2;#H%FZZY^=@K46`+N+F"GX.)O'!3!DLPGQ=NYK`D8T@LWSIX[995+H,<")&S M)$B%"K?(2GB8TF0GA8NM>$V0%Z*R%D2I*>(G"7!=@[QL7S#-@[QL238 MS2$^E@2;.L3'DF`CA_A8$NSG$!]+4LW/"W?(P#7%H4+AC@Q8@B."PAT`L`0; M_L)MYUF"[3LF54NR@&\+T[<2DM*48*.-^%CUP08;\;$DV&&!)<"@'#RP) MCMC@@27!@1D\L"3XN1K/L5IG,<="@A]B.*8XT8?7?1)#7L]AS9+@`!Y>6Q*< ML,-K2X(C='A@21;P>F%ZC93N.4U^HXIJ5'&_4#.91I(&E/20M*:DL7L MK%C@[0>VAO=,BM*4X-V2HC(E-23N)0RVAC=-"O?B!4LZ2-S[%RQ9S.;PS>J) M)23NC1XN@W>5X)LEJ2%Q[_=PF082]TX/2SI(W*L]+%G,L)[B12V6E)"4IJ2" MQ+THQF7PPAM\LR1X[PV^61*\W0;?;`E&B3]$R7K\8H95QN^",TD)B7OID'VK M(''O'K*DAJ0V)7B5$EY;93I(W-N';*V6X%7IHC,E>#<99:R^@S>- M4<:2+&88C6;KX,U?M($ULBI(W-NQ[!M>_$4;6)(&$O>N+)=I(7&OS+($GP7! M:S.QGB+:^$*"RY13]'B\NL\2?`F`,I:DG)ZBC-6O\KR$I30F^W(-O M5ID:$O=1&S\''^W!`TN"3_/0;I9D,3DM%OAD-"45))4IP8?H\,VRAN_1X9LEP5?G\,V2X+8& M/,>*-NY>0!E+LIA@_.!S?:XI[D)`?2Q)!8F[+H#+X"8$U,>2X$*$PET>P&5: M2-P=`BS![0?PVI(LQH@/?F+B,K@ZI7!WI;`$=Z.@C"7!)24H8_5$W$*",I:D M'&.(ZUSN'^JZ(V);@&JW!70W%-6TC<#5$LP9U7\-J2+-`&"[L-('&7JK&U"A)W MMQI+:DC<%6LL:2!I3$D+B;MPC(!2W!S85&:$MQ66+@;_+A,#8F[ MR(\E#23N\CZ6X#K"PMWAQY+%"',BKFID":["A&^6!-=?PC=+@BLOX9LE:2!Q MMT3RBC_A6Q;)U;C#!;XE90ME9"XJXC90GN5H77E@17K,)K2X*; M5N&U)<%5JO#-DBQ&F/E,KTM(W(VVEF\8IZ8$=_;"-ZL,KNXMW#6W;*V%Q-UV MRY*%VP(:O,1$9?6.!M.4Q4L,''..PD1D\7*$%037([-'N&T9[=A+CH<@XY^= M^7[S=;>^>?IZ]_A\<+_[@O/GD_Z*Z"?_+]3X_WCQ%Q(>?-J_X!^&PO=V]R:W-H965T0$H54Z:INE39IFG9Y=L"`5<#(=IKVV^_8;ER@1.H+ M@K^/?^?BX\/VYKEKT1,5DO$^QZ$78$3[@I>LKW/\Y_?]U35&4I&^)"WO:8Y? MJ,0WN\^?MB_+HJ$=D1X?:`\K%1<=4?`I:E\.@I+2 M;.I:/PJ"U.\(Z[$E;,1'&+RJ6$'O>''L:*\L1-"6*(A?-FR09UI7?`37$?%X M'*X*W@V`.+"6J1<#Q:@K-@]USP4YM)#WE#J278[+_;?6].X*=`):W(L56_^.D;976CX+A7>DO!6_`$3]0Q MW0.0.GG.<00>6*F:',>IMUH'<1BM,#I0J>Z9WHM1<92*=_^L46B\6Y:)X8XH MLML*?D)PL&`M!Z+;)-Q$D'RAQ;U6<[S&"'@2U*==G*9;_PG2*%YM;JT-/)U- MZ"Q\H#L7$.^""ZUJ%SI/[?/6"F->M,R+)SRDZQ4'+G2]"L(HK#A=.Y!U96V2 MDC48V%WP`9L&'5HT/5Q^KA-!?BUXG M<:>+3*U.F5:!;ALS,Y?)A`G=,(K3EOTZ]J#WSEVC+:9\JT3C0XW7P3)?S[.W M3C3\,'MK2;T\A5ME!K_0@]D$?@Y8JU.F5:8%65_H0WT4\XCC.!I7Q)A,/;Q* ML[#CY9J$^I+-BA)EB:NX69_Q]1:XS=.:)Q?XT[MIBIX$F9>^>;#7$IK=-2(, M0^UAEL&\N^V\L[.FHZ*F7VC;2E3P8P_]J\_5J6[.[LV8G>O)9F_GK^]68"P. MI*8_B*A9+U%+*V`&WAH:6=@):C\4'\R(.W`%`]&\-O"GHS!O`@^,*\[5^0/R M\]V_<_&PO M=V]R:W-H965T[P>+A)%MTX,8*K0J<1#%& M7#%="E47^-?/S=TGC*RCJJ2M5KS`+]SBA^7'#XNC-CO;<.X0*"A;X,:Y;DZ( M90V7U$:ZXPIV*FTD=;`T-;&=X;3L#\F6I'&<$TF%PD%A;MZCH:M*,/ZHV5YR MY8*(X2UU$+]M1&?/:I*]1TY2L]MW=TS+#B2VHA7NI1?%2++Y4ZVTH=L6\CXE M$\K.VOWB2EX*9K35E8M`CH1`KW.^)_<$E):+4D`&ONS(\*K`JV2^SC%9+OKZ M_!;\:$?_R#;Z^,6(\IM0'(H-;?(-V&J]\]2GTD-PF%R=WO0-^&Y0R2NZ;]T/ M??S*1=TXZ/;4'V&Z!2?X(BG\"$#F]%3@%!Q$Z9H"9WDTG<59DDXQVG+K-L*? MQ8CMK=/R3R`EO7O0ZF-XI(XN%T8?$?05V+:C?DJ2>0JY,P^N/%K@&4:@9P$] M++,\69`#I,%>.>O`@>_`>6,04!\L(-X;%A[U%CY/[[D.P%@O'1PO]+(+/>3K ME<5#Z'X7@%%86?XF%*P"9S+B3&];`>5&Z!XM\`2*/J2>Y=F@$#Q>22/.?SQ` MYH:'1WN/H3X!26"^;KI>E"B_T`PERM((YN3<8<^XU`](.FY`ED^&K()^F.(P M09*;FG_F;6L1TWL%4?D!&M#A\JQ2W^1_\TYL_4U$)9U/(* M).-H!HF;<"W"PNFNG]NM=C#E_6\#KQ>'(8HC(%=:N_,"C,GP'B[_`@``__\# M`%!+`P04``8`"````"$`R&'GV+4)```N*0``&0```'AL+W=OGJJOKUJ>+-&]_^GXZ3KYUE^'0G^^F^4TVG73G M7?]T.+_<37__[-$U@X M#W?3_3B^KF>S8;?O3MOAIG_MSI`\]Y?3=L2OEY?9\'KIMD]JT>DX*[)L/CMM M#^>IMK"^_!T;_?/S8=>U_>[MU)U';>32';WU MQUU_>H6)Q\/Q,/ZIC$XGI]WZYY=S?]D^'A'W][S:[JQM]0LS?SKL+OW0/X\W M,#?3CO*85[/5#);N;Y\.B$"F?7+IGN^F#_E:S+/I[/Y6)>B/0_<^!/^>#/O^ M_=^7P]-_#^<.V4:=9`4>^_ZK5/WY24)8/&.KOZ@*_'*9/'7/V[?C^&O__I_N M\+(?4>Y:+MGU1^R$_T].!]D#"'W[7?U\/SR-^[MI.;^I%UF9%_5T\M@-XY># M7#N=[-Z&L3_]7ROEQI0V4A@C^&F-X)^?+"C-`ORT"_[YKI4Q@I_&2)[=Y%4V MEY[SS6M;.I\C94F5<:"2QYJN)/:#U+];KJ8 M3I"6`>BW^W)>W\Z^H1H[H[/A.CG5:*R&K(@TV\:`"(`9/'7N(K/_Q%VI+MVU M&VTLX/TO(M^LAEW2QH`(`.(;ZAG[5M4N*+F- M4W'^,42$"/$0AF,/<2X^++94OYLB!N].OHI]-DJ?^>Q4G,\,$2%"?,;N@<^V M#R6J7+,F-P:9A\XN%S3!C5.RRUJ&B!`AGL!TX(D^*L7B!OKZO/'3(E=0+S52 M@M)V9`@ASJN!2'!:2T/4K"0K;]9<0*4KFPPAJIN!K@6G%^8TN-*5EWHA MZ<=[X8*3<%0Y#9'@0HB:E5SBS?+*&:X)*Z>A:\$9+>P<]&[U07"2*[P7+CA- M(:1M-$2""R$:G#SM%'CN\EJT?;Q]S1U0[*4/ZYN MX1$M-$2B"R%J5C*1-ZN:BT:GJ8IL8-@+009MSZ(S6F%T>)!.#(OM@L"C2#*?@:/-P M/%+/5HW1T@'3Z"A1):+CE%5HZ%IT1HM&]\%D(3DE2+*MG8)I=`8*:T<@$EU) MN81'IQ2B#3317(G.+"2C19%],%J4:591<+2Y(9K*4YK5\E#+(4$@FH,$]WQ. M_24G(P/)3`>MZH<-W69>RU$_AP2!J*MI?BHY/UEH%>3):'FHY5J"0'1SRF*N M!3EWE1H"W=LP&PZU'!($HINGN:ODW&4@TO\A=^F7*5Q+$(AN+GDH8KB\ED/< M9-P?=E\W/6J>N[NJU+05$JJ!\##A,Z*UY/T4=(P?WXR?3LLN%,86%@*B?J8I ML.1#GH'D+19L'@]Y5DO&:5]E%5DT>K56:X$$?+O/ZSJ3_[DK2,4AK))J/NHT M)5C75IQ62PW!:9N+AD.MA>9.2UA(S4%D\RI-JPJFQ&.@L((&PIFW_K0<$@2B MFU/RM9%7?)`SD.34H!#Q8&FTHJ+&Y;):V7LG& M(2RDW["'KU[E:\F`*9R'G*"5)MYU!AQI(76P]?'GD+!08G-)NYZFW.::C4,Z MPK_E1$;[*8_.;&.T,#;J],A&B71:K^.SHXUCI`)$&SY-XA4G<0.1YM%:\,;N MU!JM`!(62FQ.2=QEAY-UI2':/+D?.TWS&"W=/)4\1I3S6FO'UU-8*%$\RMUJ M$OODCJDXIQN(=)36PIWN<\8@81>J-RRT8&ENKC@W&PA/K7:GQD+!O,$A02"R M>9WF9@53;C:0O,#]:<_])*T+EM1BMYG5TF5=U$M65V%5>!'K-*,K.')9DSQ< M=ODR6@'46BCH(`LE-J?4?*V#:D[9!@J+:"#,'-;/ED."0+2(:9%-.8SS5S5HL)#<70\A?5!,3!UFK+XU4QR=J\U%-2RL5!P M'`R$V]8F5UB(#W:CDD"$0SE6;TFC.Z MA<":OG!Y_(#DM6Q&6@X)`E%_)"G[*U`E:5ZJ2?VCOS_5FL?#Z]%`42M&HWGC MM;ROYD[PIUH0+>JK9.+(U\^?.VO-W<150^>4^N)!WBP,VK'ED"`0=97>`RJM MR]6G?S"K^1UAH"BMT7S:>"V?5FTK<%\0+>(K/II@:;W2`FH)/2L&BGR-)VZO MY7SED/R,0TU;JBNTK_JS#/V1P:F[O'1-=SP.DUW_=L;I`)W>WSI8?P^RJ1=K MV4S8B$F6D*B!ATE6D"C"B27SS'Y>$DL*?'B"][^)?@/>YFN:NEQ+WN>2%I(V*<&UA"!3:_!%T$,R^RA8LEXH5U)?%BOA MTT.U?D"KX&&`2_!8LY9/#EPB()$/$%RRJ1:PEFJ8!I(V*<&L#VOI-8@'KP52 M^^38)Q5/4^5K^?S,U[20R,=H+A&0B*1D4Z%E\2#)US20M$D)GGIA+;5F4R)O M>'67L%8B!WIVC`]-N5QO\%XFM6:YEN]UN`1OFM;R]0Z7X/42]E&2F=L('[&] M;E^Z_VTO+X?S,#EVSZ#63,T"%_V]F_YEU(/3Y+$?\?F:^MIKC^\2.WQSE&PO=V]R:W-H965T?V8X"D*,>,M4(=HJQ[]^WE]=8V0L;0O:J);G^(4;?+/]^&%S5/K1 MU)Q;!(36Y+BVMEL38EC-)36!ZG@+7TJE);7PJBMB.LUIT0^2#8G#<$4D%2WV MA+5^#T.5I6#\3K&#Y*WU$,T;:B%_4XO.G&F2O0]$(^])# M,9)L_5"U2M-]`_-^CA:4G=G]RRN\%$PKHTH;`([X1%_/.2,9`=)V4PB8@2L[ MTKS,\2Y:WV:8;#=]?7X+?C2C9V1J=?RL1?%5M!R*#C[?@&^:U3PDAX:^T,=OW!1U196>^F&,-5`)+@B*5P+P,SIH!3MY;KT'KH,G&AP$ MZ$,(R'/,]+9GE.S3%Y>"8I`R6 MF92=FN,%K-@HQO5`\#%.II'GC1B`F8GAU#[&4!>O1-":\F3.3Z,8FR M8#DLK#-,\5Z)QW5/TFR8U`0/#3%*N<='T7*$=X8IWBM3_'4XCW>GXK]>]/@T M"V"+G/O2.:9\KUSPWVC$[+]\YYCRO7+!OVQ,?T#X?26YKO@GWC0&,75H807< MMAK4X5S:Q:[U+_7%>M>?5V3X`,=(1RO^C>I*M`8UO`1D&*30%MJ?./[%JJ[? MS7MEX0#I'VOX,7#86B&L$"J5LN<7"$R&7\WV+P```/__`P!02P,$%``&``@` M```A`-+8,)LV`0``0`(``!$`"`%D;V-0DG.]-G7R" M1]W8BN09(PE8V2AMMQ5Y7BW2&4DP"*M$W5BHR`&0S/GU52E=(1L/C[YQX(,& M3"+)8B%=178AN()2E#LP`K/HL%'<--Z($*]^2YV0[V(+=,38A!H(0HD@Z!&8 MNH%(>J22`])]^+H#*$FA!@,V(,VSG'Y[`WB#?PYTRH73Z'!P<:<^[B5;R9,X MN/>H!V/;MED[[F+$_#E=+Q^>NE53;8]=22#\V$\M,"QCE1L-ZO;`]V^^3A!W M)?VME4IVZ0KI001027RO.*4[*R_CN_O5@O`1RV]2-DO9=#5B13SCR6M)SZY^ MG@]`TP?X%W%Z03P#>)?[YY_S+P```/__`P!02P,$%``&``@````A`(3L!)_Y M`@``"PH``!``"`%D;V-0&UL(*($`2B@``$````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````G%9=3^,P$'P_Z?Y#E7=(H>B$4!H$;>]` M`E'1PCU:KK-M+1([>)T([M>S3JYM"DYTUY?(L7?6XYWQ1W3YEJ6]$@Q*K8;! MR7$_Z($2.I%J-0R>YC^/SH,>6JX2GFH%P^`=,+B,OW^+ID;G8*P$[%$*A<-@ M;6U^$88HUI!Q/*9A12-+;3)NZ=>L0KU<2@%C+8H,E`U/^_T?(;Q94`DD1_DV M85!GO"CMH4D3+1P_?)Z_YT0XCJ[R/)6"6UIE?"^%T:B7MC=Y$Y!&87,P(G8S M$(61]CWN1V'S-YH)GL*($L=+GB)$X:XCN@'NBC;ETF`R@-2?L>Y8E$SK@EM5&3D#391ENK%;E6M MMM1-YMLUW"H+1F9LI!7J5";<0L*N>P1!96!70NB"9%,K M]JL@+4@#;_B=5JLYF(R-86&K&2H9`2U[Y&W5Q,)4HMYS2Y+[J<^L%B_$ECPP MTAD=%EAM3R^)"3>*F"*[TXAL"L9!,EKQ;,U;EOGL]M4B!3(E47!T:Y/Z\[\6 MSK_W8-WMF^%77,TXBV7J9](MU7]1+K-Y\?TZ/9(/C/ROR`SNEZ3P@OIEMI_(G5C!MYYVK96730O M9-*RP3H@#5-MMUFGE%Y`72XZ!KRT6G9HI_J?-ZJ/T]ZM^^F>O9/J!9_RN1[3 MC;1Y2.QW1I7%$KIB-^.[CNB&WA`F=4E&:ZY6D&QBO@ZX9\]S_;:+3\Z.^X,^ MO6@:?5&X>\7%'P```/__`P!02P$"+0`4``8`"````"$`YL23*>H!``!5&``` M$P``````````````````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0` M!@`(````(0"U53`C]0```$P"```+`````````````````",$``!?TQ!X(``#:(@``&`````````````````!! M#@``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``.> MBLU7`P``H`L``!D`````````````````E18``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%N]&]N<`P``NPL``!D` M````````````````9R(``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/\%?3!%!```W@\``!D````````````````` M$2X``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A``)_$M)K"```!#,``!D`````````````````M3L``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$89FD>&70``"'P!`!0````````````````` M?U,``'AL+W-H87)E9%-T&UL4$L!`BT`%``&``@````A`$8/?N8M M#0``$7X```T`````````````````-[$``'AL+W-T>6QE&PO=&AE M;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0`FK6*RG@<``-$M```9```` M`````````````%3%``!X;"]W;W)K&UL4$L!`BT` M%``&``@````A`'E,I"3@!@``%R0``!D`````````````````*&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`.!>2![Z`@``6`@``!D`````````````````).H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`*20YT!>`@``004``!D`````````````````W@H!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%KA02A0!@``JA8` M`!D`````````````````\"H!`'AL+W=O5U#NP:```\@0``&0````````````````!W,0$` M>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``@#^;B<%@``X&@``!D````````````` M````*&@!`'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`,AAY]BU"0``+BD``!D`````````````````J(0!`'AL+W=O M&PO=V]R:W-H965T&UL4$L%!@`````O -`"\`NPP```Z8`0`````` ` end XML 15 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
Variable Interest Entity (Details Textual) (USD $)
In Thousands, unless otherwise specified
0 Months Ended 6 Months Ended
Jun. 30, 2014
Bed
Entity
Mar. 27, 2014
Rose Terrace Nursing Center
Jun. 30, 2014
Minimum
Jun. 30, 2014
Maximum
Dec. 28, 2011
Variable Interest Entity, Not Primary Beneficiary
Culloden, WV
Bed
Variable Interest Entity, Not Primary Beneficiary [Abstract]          
Number of variable interest entity 1        
Number of licensed nursing beds 5,282       90
Agreement provides company right to purchase     110.00% 120.00%  
Purchase Price   $ 7,693      

XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Long-Term Debt and Interest Rate Swap (Details) (USD $)
0 Months Ended 6 Months Ended 0 Months Ended 6 Months Ended
May 01, 2014
Jun. 30, 2014
Letter_Of_Credit
Center
Dec. 31, 2013
Jun. 30, 2014
Interest rate swap
Jun. 30, 2014
Loans Payable
Jun. 30, 2014
Revolving credit facility
Mar. 30, 2014
Revolving credit facility
May 01, 2013
Revolving credit facility
Jun. 30, 2014
LIBOR
May 01, 2014
Credit Agreement
Jun. 30, 2014
Credit Agreement
May 01, 2013
Credit Agreement
Mar. 31, 2014
Maximum
Revolving credit facility
Jun. 30, 2014
Revolving credit facility
Revolving Credit Facility Interest at 4.5% Percent Above LIBOR
Dec. 31, 2013
Revolving credit facility
Revolving Credit Facility Interest at 4.5% Percent Above LIBOR
Mar. 27, 2014
Loans Payable
Rose Terrace Note
Jun. 30, 2014
Letter of Credit
Revolving Credit Facility Interest at 4.5% Percent Above LIBOR
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]                                  
Revolving credit facility and the maximum loan                       $ 65,000,000          
Long-term debt for syndicate of banks mortgage debt 45,000,000 45,000,000                              
Long-term debt revolving credit facility           22,500,000 20,000,000 20,000,000         27,500,000        
Loan acquisition costs                   1,341,000              
Term of debt agreement                     5 years            
Long-term debt five year maturity   5 years                              
Mortgage loan with principal and interest payable monthly based   25 years                              
Long-term debt interest based on LIBOR   4.50%             4.50%                
Long-term debt fixed based on the interest rate swap   6.87%   6.87%                          
Notional Amount of interest rate derivatives       21,973,000                          
Debt interest rate at period end         4.65%                        
Number of owned nursing centers secured   13                              
Borrowings outstanding                           9,000,000 3,000,000   7,712,000
Letters of credit issued under Revolver outstanding   3.00%                              
Number of letters of credit   8                              
Borrowing under the revolving credit facility           10,524,000                      
Amount of term loan                               8,000,000  
Liability at fair value       (959,000)                          
Accumulated other comprehensive loss   594,000 569,000 (594,000)                          
Net income tax benefit       $ 364,000                          
XML 18 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
Discontinued Operations (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended 6 Months Ended 6 Months Ended
Jun. 30, 2014
Center
Bed
Jun. 30, 2013
Jun. 30, 2014
Center
Bed
Jun. 30, 2013
Dec. 31, 2013
Oct. 01, 2013
Center
Jun. 30, 2014
Leased Skilled Nursing Centers
Jun. 30, 2013
Leased Skilled Nursing Centers
Jan. 22, 2013
Omega Healthcare Investors, Inc.
Sep. 01, 2013
Omega Healthcare Investors, Inc.
Arkansas
Facility
Bed
Jan. 22, 2013
Omega Healthcare Investors, Inc.
Arkansas
Facility
Jun. 30, 2014
West Virginia
Rose Terrace Nursing Center
Jun. 30, 2013
West Virginia
Rose Terrace Nursing Center
May 31, 2014
West Virginia
Rose Terrace Nursing Center
Center
Apr. 03, 2014
West Virginia
Rose Terrace Nursing Center
Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                              
Number of nursing centers 46   46     4               3 2
Revenue from discontinued operations             $ 0 $ 31,880       $ 10,989 $ 10,222    
Income (loss) from discontinued operations 128 242 (484) 569     (739) (87)       660 906    
Number of nursing centers under lease terminated                   11 11        
Number of licensed nursing beds 5,282   5,282             1,181          
Annual decrease in rent payable, amount                 5,000            
Current assets of discontinued operations 2,913   2,913   2,870                    
Current liabilities of discontinued operations $ 8,823   $ 8,823   $ 1,359                    
XML 19 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidation and Basis of Presentation of Financial Statements
6 Months Ended
Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. Any variable interest entities (“VIEs”) in which the Company has an interest are consolidated when the Company identifies that it is the primary beneficiary. The Company had one variable interest entity related to a nursing center in West Virginia that was dissolved in the first quarter of 2014 as a result of the asset purchase of the Rose Terrace nursing center as further described in Note 8, and is no longer consolidated into the interim consolidated financial statements of the Company. The investment in an unconsolidated affiliate (a 50 percent-owned joint venture partnership) is accounted for using the equity method and is described in Note 9.
The interim consolidated financial statements for the three and six month periods ended June 30, 2014 and 2013, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at June 30, 2014, and the results of operations for the three month and six month periods ended June 30, 2014 and 2013, and cash flows for the six month periods ended June 30, 2014 and 2013. The Company’s balance sheet information at December 31, 2013, was derived from its audited consolidated financial statements as of December 31, 2013.
The results of operations for the periods ended June 30, 2014 and 2013 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013.
EXCEL 20 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Y.3EE,&%E.%]E-F%D7S0Q.#=?.64P-U]F.68V M-V%F,#DP,C@B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=&5R:6U?0V]N#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D)U#I%>&-E M;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U8G-E<75E;G1?179E;G1S/"]X.DYA;64^#0H@("`@/'@Z M5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D)U#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D)U#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN#I7;W)K#I7;W)K#I7;W)K#I7;W)K M#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E9A5]$971A:3PO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D5Q=6ET>5]-971H;V1?26YV97-T M;65N=%]$971A:3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D)U#I7;W)K#I7;W)K#I7;W)K#I%>&-E M;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I% M>&-E;%=O7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO2!296=I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)V9A;'-E/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)U$R/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^ M)RTM,3(M,S$\'0^ M)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y.3EE,&%E.%]E M-F%D7S0Q.#=?.64P-U]F.68V-V%F,#DP,C@-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO.3DY93!A93A?939A9%\T,3@W7SEE,#=?9CEF-C=A9C`Y M,#(X+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPO2!A;F0@97%U:7!M96YT+"!N970\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO&5S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PX,#0\F5D(&QE87-E(&]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ,"PS,S0\'0^)SQS<&%N/CPO7)O;&P@86YD(&5M<&QO>65E(&)E M;F5F:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPR,#,\ M'0^)SQS<&%N/CPO MF5D+"!I'0^)SQS<&%N/CPOF5D(#(P,"PP,#`@F5D(#(P+#`P,"PP,#`@2!S=&]C:R!A="!C;W-T+"`R,S(L,#`P('-H87)E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPOF5D M("AS:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P M,#QS<&%N/CPOF5D("AS:&%R97,I/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`L,#`P/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y.3EE,&%E.%]E-F%D7S0Q M.#=?.64P-U]F.68V-V%F,#DP,C@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.3DY93!A93A?939A9%\T,3@W7SEE,#=?9CEF-C=A9C`Y,#(X+U=O M'0O:'1M M;#L@8VAA'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!I;B!N970@:6YC;VUE("AL;W-S*2!O9B!U;F-O;G-O M;&ED871E9"!A9F9I;&EA=&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Y.3EE,&%E.%]E-F%D7S0Q.#=?.64P-U]F.68V-V%F M,#DP,C@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3DY93!A93A? M939A9%\T,3@W7SEE,#=?9CEF-C=A9C`Y,#(X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#0T,#QS<&%N/CPO M'0^)SQS<&%N/CPO'!E;G-E6%B;&4@ M86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S(&]F M(&EN8V]M92!T87AE'10 M87)T7SDY.64P864X7V4V861?-#$X-U\Y93`W7V8Y9C8W868P.3`R.`T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y.3EE,&%E.%]E-F%D7S0Q.#=? M.64P-U]F.68V-V%F,#DP,C@O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`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`P,#`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`Z.'!X.V9O;G0M6QE/3-$ M;&EN92UH96EG:'0Z,3(P)3MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE2!E;G1E6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A M=&EO;CIN;VYE.SXD,34L-3`P+#`P,#PO9F]N=#X\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BX@5&AE('!U2`Q+"`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`P,#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BX@(%1H92!A;&QO8V%T:6]N(&]F M('1H92!P=7)C:&%S92!P2!R M96%L(&5S=&%T92!V86QU871I;VX@9FER;2X@(%1H92!A;&QO8V%T:6]N(&9O M6QE/3-$;&EN92UH96EG:'0Z,3(P)3MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E#MP M861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE2`Q+"`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`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T M6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG M#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG6QE/3-$=&5X="UA;&EG;CIR:6=H M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV M/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^,2PR,#`L,#`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT M.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.R<@'0M M86QI9VXZ6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-#,L,#`P/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D M:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$ M=&5X="UA;&EG;CIL969T.V9O;G0M#L@'0M86QI9VXZF4Z,3!P=#L^-S4X+#`P,#PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1'9E'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D M:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ M<'@@6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0MF4Z,3!P=#MF;VYT+7-T>6QE.FET86QI8SL^3&5A M6QE/3-$;&EN92UH M96EG:'0Z,3(P)3MP861D:6YG+71O<#HQ,W!X.W1E>'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M&ES=&EN9R`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^+7EE87(@;&5A6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-3PO9F]N M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.C$P<'0[/BUY96%R(')E;F5W86P@;W!T:6]N+B`@5&AE(&-E;G1E2!O<&5R871I;F<@86YD('1R96%T:6YG('!A=&EE;G1S(&]N('1H M92!T#MT M97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^3VX@36%R8V@@ M,2P@,C`Q-"P@=&AE($-O;7!A;GD@87-S=6UE9"!O<&5R871I;VYS(&%T($1I M=F5R&ES=&EN9R`\+V9O;G0^ M/&9O;G0@3II;FAE3II;FAE M6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,3`\+V9O;G0^/&9O;G0@ M3II;FAE65A6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^='=O/"]F;VYT/CQF M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^(&%D9&ET:6]N86P@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-3PO9F]N=#X\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BUY96%R M(')E;F5W86P@;W!T:6]N6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^3II;FAE2!O<&5R871I;F<@ M86YD('1R96%T:6YG('!A=&EE;G1S(&]N('1H92!T#MT97AT+6%L:6=N.FQE9G0[9F]N M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^3VX@3V-T;V)E2!A6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^9F]U&ES=&EN9R!N=7)S:6YG(&-E;G1E6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&EN($]H:6\@86YD(#PO9F]N=#X\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[ M/F]N93PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.C$P<'0[/B!I;B!);F1I86YA+B`@5&AE(&YU3II;FAE3II;FAE M65A'!A;F1I;F<@ M:6YT;R!O;F4@;F5W('-T871E+"!);F1I86YA+"!A;F0@:6YC3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^(&YU3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^(&]F('1H92!C96YT97)S('=E2!A&ES=&EN9R`\+V9O;G0^/&9O;G0@3II;FAE M2!A(%)%250L(&%N9"!T:&4@;&5A6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C M;W)A=&EO;CIN;VYE.SXQ-3PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BUY96%R(&QE87-E('1E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M2UO=VYE9"X@06QL M('-I9VYI9FEC86YT(&EN=&5R8V]M<&%N>2!A8V-O=6YT2!V87)I86)L92!I;G1E2!H87,@86X@:6YT97)E2!B96YE9FEC:6%R>2X@5&AE($-O;7!A M;GD@:&%D(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I M;VXZ;F]N93L^;VYE/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('9A2!R96QA=&5D('1O(&$@;G5R6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.SXU,"!P97)C96YT/"]F M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^+6]W;F5D(&IO:6YT('9E;G1U2!M971H;V0@86YD(&ES M(&1E6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M M9&5C;W)A=&EO;CIN;VYE.SY*=6YE)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O M;G0@3II;FAE2!T:&4@0V]M<&%N>2P@=VET:&]U="!A=61I M="P@<'5R6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^+"!A;F0@=&AE(')E3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC M;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXR,#$S/"]F;VYT M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^+"!A;F0@8V%S:"!F;&]W"!M;VYT:"!P97)I M;V1S(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R M871I;VXZ;F]N93L^2G5N928C,38P.S,P+"`R,#$T/"]F;VYT/CQF;VYT('-T M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N M9"`\+V9O;G0^/&9O;G0@3II;FAE3II;FAE M3II;FAE3II;FAEF4Z,3!P=#L^5&AE(')E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.SY*=6YE)B,Q-C`[,S`L M(#(P,30\+V9O;G0^/&9O;G0@3II;FAE65A28C.#(Q-SMS($%N M;G5A;"!297!O6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO M;CIN;VYE.SY$96-E;6)E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+CPO M9F]N=#X\+V1I=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3I4:6UE#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE2`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`[8VAA;F=I;F<@=&AE M(&-R:71E2!T:&]S92!D:7-P;W-E9"!C M;VUP;VYE;G1S("AO2!I&ET960@9'5R:6YG(#(P,30N("!4:&4@ M861O<'1I;VX@;V8@=&AI3II;FAE2!T M;R!R96-O9VYI>F4@=&AE(&%M;W5N="!O9B!R979E;G5E('1O('=H:6-H(&ET M(&5X<&5C=',@=&\@8F4@96YT:71L960@9F]R('1H92!T2!A<'!L M:6-A=&EO;B!I65T('-E;&5C=&5D(&$@=')A;G-I=&EO;B!M971H;V0@;F]R(&AA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD M:78@6QE M/3-$;&EN92UH96EG:'0Z,3(P)3MP861D:6YG+71O<#HV<'@[9F]N="US:7IE M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^5&AE($-O;7!A;GD@:&%S(&%G6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#8U M+#`P,"PP,#`\+V9O;G0^/&9O;G0@3II;FAE M3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)#(P+#`P,"PP,#`\+V9O;G0^/&9O;G0@3II M;FAEF5D(&EN('1H92!A;6]U;G0@;V8@ M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)#$L,S0Q+#`P,#PO9F]N=#X\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@87)E(&)E M:6YG(&%M;W)T:7IE9"!O=F5R('1H92`\+V9O;G0^/&9O;G0@3II;FAE3II;FAE65A M6QE/3-$;&EN92UH96EG:'0Z,3(P)3MP861D:6YG+71O<#HV<'@[9F]N="US M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^56YD97(@=&AE('1E6YD:6-A=&4@;V8@8F%N:W,@<')O=FED960@ M=&AE($%M96YD960@36]R=&=A9V4@3&]A;B!W:71H(&%N(&]R:6=I;F%L(&)A M;&%N8V4@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A M=&EO;CIN;VYE.SXD-#4L,#`P+#`P,#PO9F]N=#X\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!W:71H(&$@/"]F M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SYF M:79E/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^+7EE87(@;6%T=7)I='D@=&AR;W5G:"!!<')I;"`S M,"P@,C`Q."P@86YD(&$@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M M9&5C;W)A=&EO;CIN;VYE.SXD,C`L,#`P+#`P,#PO9F]N=#X\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!!;65N M9&5D(%)E=F]L=F5R('1H3II;FAE3II;FAE65A3II;FAE6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+7EE87(@ M86UOF%T:6]N+B!);G1E&5D(&%T(#PO9F]N M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^-BXX M-R4\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.SXD,C$L.36QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^+"!T:&4@:6YT97)E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^+B`@5&AE($%M96YD960@36]R=&=A9V4@3&]A;B!I6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN M;VYE.SXT+C4E/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"!I2!F3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&EN('1H92!O3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#(R M+#4P,"PP,#`\+V9O;G0^/&9O;G0@3II;FAE M2!D871E(&]F($%P'!A;G-I;VX@;V8@=&AE($-O M;7!A;GDG2!A8W%U:7-I M=&EO;G,N("`\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT M.C$R,"4[<&%D9&EN9RUT;W`Z-G!X.V9O;G0M6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!T:&4@0V]M M<&%N>2!H860@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#DL,#`P+#`P,#PO9F]N=#X\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!B M;W)R;W=I;F=S(&]U='-T86YD:6YG('5N9&5R('1H92!R979O;'9I;F<@8W)E M9&ET(&9A8VEL:71Y(&-O;7!A3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M1&5C96UB97(F(S$V,#LS,2P@,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BX@5&AE(&]U='-T M86YD:6YG(&)O2!R M969L96-T('1H92!#;VUP86YY)W,@87!P6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.SXS+C`P)3PO9F]N=#X\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P M<'0[/B!O9B!T:&4@86UO=6YT(&]U='-T86YD:6YG+B!4:&4@0V]M<&%N>2!H M87,@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^96EG:'0\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY*=6YE)B,Q M-C`[,S`L(#(P,30\+V9O;G0^/&9O;G0@3II M;FAE6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M M9&5C;W)A=&EO;CIN;VYE.SXD,C6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^(&%T(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT M97AT+61E8V]R871I;VXZ;F]N93L^2G5N928C,38P.S,P+"`R,#$T/"]F;VYT M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z M,3(P)3MP861D:6YG+71O<#HV<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^169F M96-T:79E($UA2!E>&5C=71E9"!I M=',@<'5R8VAA6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#@L,#`P+#`P,#PO9F]N M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.C$P<'0[/B!T97)M(&QO86X@*")2;W-E(%1E2!D871E(&]F($UA2!O M<&5R871O2`Q+"`R,#$T+B`@07,@2!O9B!$:7-C;VYT:6YU960@3W!E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY* M=6YE)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O;G0@3II;FAEF4Z,3!P=#MF;VYT+7-T>6QE.FET86QI8SL^26YT97)E M#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE2!R971A M:6YE9"!T:&4@<')E=FEO=7-L>2!A9W)E960@=7!O;B!I;G1E6UE;G1S('1O('1H92!B86YK(&-A;&-U;&%T960@ M;VX@=&AE(&%P<&QI8V%B;&4@;F]T:6]N86P@86UO=6YT(&]F(#PO9F]N=#X\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P M<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#(Q+#DW M,RPP,#`\+V9O;G0^/&9O;G0@3II;FAE&5D(')A=&4@;V8@ M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE M.SXV+C@W)3PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.C$P<'0[/B!W:&EL92!T:&4@8F%N:R!I2!B87-E9"!O;B!, M24)/4B!O;B!T:&4@#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE2!A6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.SY*=6YE)B,Q-C`[,S`L M(#(P,30\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD.34Y+#`P,#PO9F]N=#X\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A="`\ M+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY*=6YE)B,Q-C`[,S`L(#(P,30\+V9O M;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#4Y-"PP,#`\+V9O;G0^/&9O;G0@ M3II;FAE7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#$L,#`P+#`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`S,"P@,C`Q M-"X\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[ M<&%D9&EN9RUT;W`Z-G!X.V9O;G0M2!O8G1A:6YS(')E<&]R=',@;V8@ M87-S97)T960@8VQA:6US(&%N9"!L87=S=6ET2!S96UI+6%N;G5A;&QY+B!"87-E9"!O;B!T:&4@0V]M<&%N>28C M.#(Q-SMS(&5V86QU871I;VX@;V8@=&AE(&%C='5A;"!C;&%I;2!I;F9O2!A8W1U87)Y+"!T:&4@86UO=6YT M2!B92!R979I2!B87-I#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE3II;FAE3II;FAE M6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('!R;V9E28C.#(Q-SMS(&-A2!C;W-T6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD,BPQ,S0L,#`P/"]F;VYT M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^(&9O6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M M9&5C;W)A=&EO;CIN;VYE.SYS:7@\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^ M/&9O;G0@3II;FAE3II;FAE2X\+V9O;G0^/"]D:78^/&1I=B!S M='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z-G!X.V9O;G0M M2!S:&]U;&0@8F4@9&5T97)M M:6YE9"!W:71H;W5T(&-O;G-I9&5R871I;VX@;V8@:6YS=7)A;F-E(')E8V]V M97)I97,N("!!8V-O2P@=&AE($-O;7!A;GD@:&%S(')E8V]R9&5D M(&%S6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC M;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD-S`L,#`P/"]F M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^(&%T(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E M8V]R871I;VXZ;F]N93L^2G5N928C,38P.S,P+"`R,#$T/"]F;VYT/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(&%N9"`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%T(#PO9F]N=#X\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L M;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^1&5C96UB97(F(S$V M,#LS,2P@,C`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`R,#`S('5N=&EL($IU;F4F M(S$V,#LS,"P@,C`P-RP@=&AE($-O;7!A;GDF(S@R,3<[28C,38P.S$L(#(P,#@@=&AR;W5G:"`\+V9O M;G0^/&9O;G0@3II;FAE2!A('!R969U;F1E9"!D961U8W1I8FQE('!O;&EC>2X@56YD M97(@=&AI3II;FAE2!F;W(@8VQA:6US M(&)E;&]W('1H92!D961U8W1I8FQE+B!4:&4@0V]M<&%N>2!A8V-O=6YT'!E;G-E('5N9&5R('1H:7,@<&]L:6-Y(&)A2!D961U8W1I8FQE'!E8W1E9"!T;R!B92!I;F-U M2!F;W(@=V]R:V5R3II;FAE6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%T(#PO M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US M:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^ M2G5N928C,38P.S,P+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+B!4:&4@0V]M<&%N>2!H M87,@82!N;VXM8W5R65A M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO M;CIN;VYE.SXD,2PQ,S`L,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%S(&]F(#PO9F]N=#X\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P M<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^2G5N928C M,38P.S,P+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+B!4:&4@;F]N+6-U6UE;G1S('!A:60@=&\@=&AE M($-O;7!A;GDF(S@R,3<[&-E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^07,@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A M=&EO;CIN;VYE.SY*=6YE)B,Q-C`[,S`L(#(P,30\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD,32X@5&AE($-O;7!A;GD@<')O=FED97,@ M6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C M;W)A=&EO;CIN;VYE.SXD.3`P+#`P,#PO9F]N=#X\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A="`\+V9O;G0^ M/&9O;G0@3II;FAE3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Y.3EE,&%E.%]E-F%D7S0Q.#=?.64P-U]F.68V-V%F,#DP M,C@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3DY93!A93A?939A M9%\T,3@W7SEE,#=?9CEF-C=A9C`Y,#(X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQD:78@F4Z,3!P=#MT97AT+61E8V]R M871I;VXZ=6YD97)L:6YE.SY35$]#2RU"05-%1"!#3TU014Y3051)3TX\+V9O M;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[=&5X="UA M;&EG;CIJ=7-T:69Y.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF M;VYT+7-T>6QE.FET86QI8SL^3W9E#MT97AT+6%L:6=N.FIU6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M26X@1&5C96UB97(@,C`P-2P@=&AE($-O;7!E;G-A=&EO;B!#;VUM:71T964@ M;V8@=&AE($)O87)D(&]F($1I2!T;R!I3II;FAE&5R8VES92!O9B!E<75I='D@87=A3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M,S@P+#`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`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C`Q M-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXR,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!T:&4@0V]M M<&5N6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@3II;FAE6EN9R!C;VUM;VX@3II;FAE M2!N;W0@8F4@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXR M,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^+"!T:&4@0V]M<&5N&EM871E;'D@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXU-2PP,#`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1'9E'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT M.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE&5R8VES960\ M+V9O;G0^/"]D:78^/"]T9#X\=&0@#L@'0M86QI9VXZF4Z,3!P=#L^*#$L,#`P/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P M=#L^/&9O;G0@3II;FAE#L@'0M86QI9VXZ6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,BXS-SPO M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV M/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE'!I#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$ M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E#MP861D:6YG M+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG M+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZF4Z,3!P=#L^,S`U+#`P,#PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A M8VMG"!S;VQI9"`C M,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD M+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZF4Z,3!P=#L^-BXU.#PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O M;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M MF4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE M/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^17AE#MP M861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\ M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$ M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A M8VMG6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P M,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`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`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`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`\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$ M=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$ M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@#L@'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#L@#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\ M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^*#$L,#`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`P.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ;&5F M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q M/CQD:78@6QE/3-$=&5X="UA;&EG M;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^3W5T#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIR M:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`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`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`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`C,#`P,#`P.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P M.V)A8VMG6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`P.V)A8VMG6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV M/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE M9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F]R M9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N M92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE M#MB;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$)W9E6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P M,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE3II;FAE6QE/3-$;&EN92UH M96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ:G5S=&EF>3MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE3II;FAE3II;FAE2=S(&-O;6UO;B!S=&]C:R!O;B!T:&4@9W)A;G0@9&%T92X@ M(%1H92!33U-!4G,@86YD($]P=&EO;G,@=F5S="`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I M;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#L@'0M86QI9VXZ8V5N=&5R M.V9O;G0MF4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@ M3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`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`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`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$)W9E#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#L@'0M M86QI9VXZ6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C0S+#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZF4Z,3!P=#L^-#4P+#`P,#PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1'9E'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG M+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D M:6YG+7)I9VAT.C)P>#L@#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R M+71O<#HQ<'@@"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@"!S;VQI9"`C,#`P,#`P M.R<@'0M M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^ M/&9O;G0@3II;FAE3II;FAE65E6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD,CDU+#`P,#PO9F]N=#X\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P M<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A M=&EO;CIN;VYE.SXD,S4W+#`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`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQD:78@F4Z,3!P=#MT97AT+61E8V]R871I;VXZ=6YD97)L M:6YE.SY%05).24Y'4R`H3$]34RD@4$52($-/34U/3B!32$%213PO9F]N=#X\ M+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MP861D:6YG+71O M<#HV<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^26YF;W)M871I;VX@=VET:"!R M97-P96-T('1O(&)A&-E<'0@<&5R('-H87)E.CPO9F]N=#X\+V1I=CX\9&EV('-T M>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q M-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0W('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q/CQD M:78@F4Z,3!P=#L^ M/&9O;G0@3II;FAE"!-;VYT:',@16YD960@/&)R(&-L M96%R/3-$;F]N92\^2G5N92`S,"P\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$ M,3X\9&EV('-T>6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE M/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.'!T.SX\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P M86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.CEP=#L^,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@ MF4Z.7!T.SX\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^ M,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`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`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`C,#`P M,#`P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.V)A8VMGF4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E M"!S;VQI9"`C M,#`P,#`P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[ M)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#LG(')O=W-P86X],T0Q/CQD M:78@6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P M.V)A8VMG6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$ M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D M:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^.36QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#(L-#,W M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.W!A9&1I;F#MP861D M:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9EF4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0R('-T>6QE/3-$)W9E#MP861D:6YG+6)O='1O M;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R M/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`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`C M,#`P,#`P.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^,SDS/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E M"!S;VQI9"`C,#`P M,#`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`C,#`P,#`P.V)A M8VMG6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)A M8VMG#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O M;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O M6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*3PO9F]N M=#X\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\+V1I=CX\9&EV('-T M>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q M-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0W('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q/CQD M:78@F4Z,3!P=#L^ M/&9O;G0@3II;FAE"!-;VYT:',@16YD960@/&)R(&-L M96%R/3-$;F]N92\^2G5N92`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`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`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`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`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.W!A9&1I;F#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1'9E#L@'0M M86QI9VXZ6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`P.R<@'0M86QI9VXZF4Z,3!P=#L^*#`N,#@\+V9O;G0^/"]D:78^/"]T M9#X\=&0@#MB;W)D97(M=&]P.C%P M>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)O M6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+7)I9VAT M.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K M9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[ M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC M;VQO#MP861D:6YG+6)O='1O;3HR M<'@[8F]R9&5R+71O<#HQ<'@@"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O M=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I M=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R M9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO M#MP861D:6YG+6)O='1O;3HR<'@[ M8F]R9&5R+71O<#HQ<'@@6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D M9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R M+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z M,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C M,#`P,#`P.R<@'0M86QI9VXZ6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#`N-3<\ M+V9O;G0^/"]D:78^/"]T9#X\=&0@#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MB86-K M9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^*#`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`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`C,#`P,#`P.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`N,#@\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@#LG(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^*3PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q/CQD:78@6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M#MP M861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.V)A8VMG"!S M;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$)W9E'0M86QI9VXZ M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,"XQ-CPO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.V)A8VMG"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E'0M86QI9VXZF4Z,3!P=#L^*#`N,SD\+V9O;G0^/"]D:78^/"]T M9#X\=&0@#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG M;CIL969T.V9O;G0M#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD M+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[8F]R M9&5R+71O<#HQ<'@@6QE M/3-$)W9E"!D M;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN M9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE M/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+7)I9VAT.C)P>#L@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#LG(')O=W-P86X],T0Q/CQD M:78@6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#LG(')O=W-P86X],T0Q M/CQD:78@6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$ M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#LG(')O=W-P86X] M,T0Q/CQD:78@6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E#LG(')O=W-P M86X],T0Q/CQD:78@6QE M/3-$)W9E"!D M;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M#LG M(')O=W-P86X],T0Q/CQD:78@6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#LG(')O=W-P86X],T0Q/CQD:78@6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV M/CPO=&0^/"]T6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N M92\^/"]F;VYT/CPO9&EV/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&AE(&5F M9F5C=',@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A M=&EO;CIN;VYE.SXS,C8L,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(%-/4T%23II;FAE3II;FAE65A3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Y.3EE,&%E.%]E-F%D7S0Q.#=?.64P-U]F.68V-V%F,#DP M,C@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3DY93!A93A?939A M9%\T,3@W7SEE,#=?9CEF-C=A9C`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`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`Y,#(X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!- M971H;V0@26YV97-T;65N=#QB2!-971H;V0@26YV97-T;65N=',@ M86YD($IO:6YT(%9E;G1U'0^)SQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MT97AT+61E8V]R871I;VXZ=6YD M97)L:6YE.SY%455)5%D@34542$]$($E.5D535$U%3E0\+V9O;G0^/"]D:78^ M/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z.'!X M.W1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE2!J;VEN="!V96YT=7)E('!A6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXU,"4\+V9O;G0^/&9O;G0@ M3II;FAE2!T M:&4@0V]M<&%N>2!A;F0@:71S('!A2!M971H;V0@87,@=&AE($-O;7!A;GD@97AE3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD-#@W+#`P,#PO9F]N=#X\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A M="`\+V9O;G0^/&9O;G0@3II;FAE3II;FAE6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.R<^2G5N M928C,38P.S,P+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!W87,@/"]F;VYT/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)#4Y+#`P,#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.C$P<'0[/B!A3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A M=&EO;CIN;VYE.SY*=6YE)B,Q-C`[,S`L(#(P,3,\+V9O;G0^/&9O;G0@3II;FAE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`[,S`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`Q M,RX@(%1H92!-961I8V%I9"!A;F0@365D:6-A3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C

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`P,#PO9F]N=#X\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P M<'0[/B!I;B!A8W%U:7-I=&EO;BUR96QA=&5D(&5X<&5N6QE M/3-$;&EN92UH96EG:'0Z,3(P)3MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3I!F4Z,3!P=#L^/&)R(&-L M96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQT86)L92!C96QL<&%D9&EN9STS M1#`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`P+#`P,#PO9F]N=#X\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!B971W M965N('1H92!A2!A;'-O(&%S6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M M9&5C;W)A=&EO;CIN;VYE.SXD-S4X+#`P,#PO9F]N=#X\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!W:&EC:"!R M97-U;'1E9"!I;B!T;W1A;"!C87-H(&]U=&QA>2!O9B`\+V9O;G0^/&9O;G0@ M3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^+B`@5&AE(&%L;&]C871I;VX@;V8@=&AE('!U6QE/3-$ M;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.F-E;G1EF4Z M,3!P=#L^/&1I=B!S='EL93TS1'!A9&1I;F3I4:6UE'0M86QI9VXZ;&5F M=#LG/CQT6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F'0M86QI9VXZ8V5N M=&5R.V9O;G0M#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+6)O='1O;3HR M<'@[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP M861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I M=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R M9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X M.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`P.R<@'0M86QI9VXZ6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,30L-S0R+#`P M,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`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`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`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"!N970@:6YC M;VUE(&]F(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.C$P<'0[/B0V-C`L,#`P/"]F;VYT/CQF;VYT('-T>6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\ M+V9O;G0^/&9O;G0@3II;FAE6QE/3-$)V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.R<^2G5N928C,38P.S,P+"`R,#$T M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@3II;FAE2!A;&QO8V%T:6]N(&]F(&-O'!E;G-E+B`@ M5&AE($-O;7!A;GD@8V]N2!W:&5N(&1E=&5R;6EN:6YG('1H M92!C;VYT6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FET86QI8SL^07)K86YS87,@3&5A#MT M97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^169F96-T:79E M(%-E<'1E;6)E2!E;G1E6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&YU6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^,2PQ.#$\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^96QE=F5N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&-E;G1E2!N;R!L;VYG97(@;W!E2!A;F0@3VUE9V$@96YT M97)E9"!I;G1O('1H92!4:&ER=&5E;G1H($%M96YD;65N="!T;R!#;VYS;VQI M9&%T960@06UE;F1E9"!A;F0@4F5S=&%T960@36%S=&5R($QE87-E("@B36%S M=&5R($QE87-E(BD@;6]S="!R96-E;G1L>2!A;65N9&5D(&]N($IA;G5A3I4:6UE3II;FAE#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M2!H87,@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(&%N9"!N970@;&]S3II;FAE6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\ M+V9O;G0^/&9O;G0@3II;FAE3II;FAE M3I4:6UE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO M;CIN;VYE.SXR,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!R97-P96-T:79E;'DN)B,Q-C`[ M(%1H92!N970@;&]S2!R96QA=&5S('1O('!R M;V9E6QE/3-$;&EN92UH96EG:'0Z,3(P)3MP861D:6YG+71O M<#HV<'@[=&5X="UA;&EG;CIL969T.V9O;G0M3II M;FAE3II;FAE6QE/3-$)V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.R<^2G5N928C,38P.S,P M+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!R97-P96-T:79E;'DN("!4:&4@ M8W5R'!E;G-E3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@3II M;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(&%T(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MC;VQO'0M M9&5C;W)A=&EO;CIN;VYE.R<^1&5C96UB97(F(S$V,#LS,2P@,C`Q,SPO9F]N M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.C$P<'0[/BP@'!E;G-E2!O;B!*=6QY M(#$L(#(P,30N("!4:&4@0V]M<&%N>2!D:60@;F]T('1R86YS9F5R('1H92!A M8V-O=6YT2!A M;F0@=V]R:V5R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78@F4Z,3!P=#MT97AT+61E8V]R871I;VXZ=6YD97)L M:6YE.SY354)315%514Y4($5614Y44SPO9F]N=#X\+V1I=CX\9&EV('-T>6QE M/3-$;&EN92UH96EG:'0Z,3(P)3MP861D:6YG+71O<#HX<'@[=&5X="UA;&EG M;CIL969T.V9O;G0M6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+6)E9"!S:VEL;&5D M(&YU6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#$V+C4@;6EL;&EO M;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.C$P<'0[/BX@5&AE($-O;7!A;GD@86QS;R!A9W)E960@=&\@86X@ M86UE;F1M96YT('1O('1H92!-87-T97(@3&5A2!W:71H(')E6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^='=O/"]F;VYT/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(&]T:&5R('-K:6QL960@;G5R6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^='=O/"]F;VYT M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^(&]T:&5R('-K:6QL960@;G5R61A;&4L(%=E6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#@L,#`P M+#`P,#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.C$P<'0[/B!M;W)T9V%G92!L;V%N(&]U='-T86YD:6YG(&]N M('1H92!2;W-E(%1E'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE3II;FAE M'!E8W1E9"!T;R!C;VYT3II;FAE6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('EE87)S+B`\+V9O;G0^/"]D:78^ M/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[<&%D9&EN9RUT;W`Z.'!X M.W1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE2!T96UP;W)A6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN M;VYE.SXD,C`L,#`P+#`P,#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!I;B!T:&4@;W)I9VEN86P@ M06UE;F1E9"!2979O;'9E3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(&%S(&1E9FEN960@:6X@=&AE(%-E8V]N9"!!;65N9&UE;G0L(&$@<&5R;6%N M96YT(&-H86YG92!T;R!T:&4@8F]R#MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M169F96-T:79E($%U9W5S="`Q+"`R,#$T+"!T:&4@0V]M<&%N>2!C;VUP;&5T M960@82!T3II;FAE3II M;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+6)E9"!A2!I;B!T:&4@8W5R'!E8W1E9"!T;R!C;VYT3II;FAE6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&EN(&%N;G5A;"!R979E M;G5E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M,3`\+V9O;G0^/&9O;G0@3II;FAE65A7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1'9E'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P M>#L@'0M M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE&5R8VES960\+V9O M;G0^/"]D:78^/"]T9#X\=&0@#L@'0M86QI9VXZF4Z,3!P=#L^*#$L,#`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`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#MP861D:6YG+6)O M='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG M;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I M9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZF4Z,3!P=#L^,S`U+#`P,#PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O M;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG M"!S;VQI9"`C,#`P M,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O M;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZF4Z,3!P=#L^-BXU.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS M<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^17AE#MP861D M:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P M,#`[8F%C:V=R;W5N9"UC;VQO#MP M861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\ M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`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`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF M;VYT+7=E:6=H=#IB;VQD.SY!=F5R86=E/"]F;VYT/CPO9&EV/CPO=&0^/"]T M6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG M;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD M.SY297-T6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY'6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG M;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$ M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P M>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG6QE/3-$=&5X="UA;&EG;CIR M:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M-BXX-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9EF4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT M/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR M:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MP861D:6YG+6)O='1O;3HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*3PO9F]N=#X\+V1I M=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`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`C,#`P,#`P M.R<@'0M M86QI9VXZ6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,30W+#`P,#PO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F]R9&5R+71O M<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIR:6=H M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C M,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE3I4:6UE M6QE/3-$;&EN M92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^4W5M;6%R:7IE9"!A8W1I=FET>2!O9B!T:&4@4F5S=')I8W1E M9"!3:&%R92!5;FET'0M:6YD96YT.C!P>#ML M:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A8FQE(&-E M;&QP861D:6YG/3-$,"!C96QL'0M86QI9VXZ;&5F=#LG/CQT M#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`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`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M M#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#L@'0M86QI9VXZ8V5N M=&5R.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!R M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG M;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@ M'0M86QI M9VXZ6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X,C$R.SPO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[ M8F]R9&5R+6)O='1O;3HQ<'@@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.R<@'0M M86QI9VXZ6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X,C$R.SPO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F]R9&5R+6)O='1O;3HQ<'@@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M3W5T#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A M9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P M.R<@'0M M86QI9VXZ6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-2XS,#PO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[ M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F]R9&5R+71O<#HQ M<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T3I4:6UE6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&AE(&9O M;&QO=VEN9R!T86)L92!S=6UM87)I>F5S(&EN9F]R;6%T:6]N(')E9V%R9&EN M9R!S=&]C:R!O<'1I;VYS(&%N9"!33U-!4B!G6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^2G5N928C,38P.S,P+"`R,#$T/"]F;VYT/CQF M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^.CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P M)3MT97AT+6%L:6=N.F-E;G1EF4Z,3!P=#L^/&1I=B!S='EL M93TS1'!A9&1I;F'0M86QI9VXZ;&5F=#LG/CQT#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9EF4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#L@'0M M86QI9VXZ8V5N=&5R.V9O;G0M6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY'#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X M="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H M=#IB;VQD.SY%>&5R8VES92!0#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE M/3-$;W9E#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY0#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R M;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY/=71S=&%N9&EN M9SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9EF4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^,3DY+#`P,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E M'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE M/3-$;W9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$)W9E"!D M;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.V)O6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[ M8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3I4:6UE6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^26YF;W)M871I M;VX@=VET:"!R97-P96-T('1O(&)A&-E<'0@<&5R('-H87)E.CPO9F]N=#X\+V1I M=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MF;VYT+7-I>F4Z.7!T M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.CEP=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0W('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P M86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE"!-;VYT:',@16YD M960@/&)R(&-L96%R/3-$;F]N92\^2G5N92`S,"P\+V9O;G0^/"]D:78^/"]T M9#X\+W1R/CQT#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[)R!R M;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M.'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US M:7IE.CAP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#LG(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.CEP=#L^,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$ M)W9E"!S;VQI M9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X] M,T0Q/CQD:78@F4Z M.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US M:7IE.CEP=#L^,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C M,#`P,#`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`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`C,#`P,#`P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)A8VMG6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$ M;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T M>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)A8VMG#MP861D:6YG+6)O='1O;3HR M<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+6)O M='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#LG(')O=W-P M86X],T0Q/CQD:78@6QE/3-$ M)W9E"!S;VQI M9"`C,#`P,#`P.V)A8VMGF4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^*#(L-#,W/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C M,#`P,#`P.R<@'0M86QI9VXZ M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#,L-S(Y/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.V)O6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^4')E9F5R#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@ M'0M86QI9VXZF4Z,3!P=#L^*#@V/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`C,#`P,#`P.R<@ M'0M86QI9VXZF4Z,3!P=#L^,SDS/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!S M;VQI9"`C,#`P,#`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`C M,#`P,#`P.V)A8VMGF4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE6QE/3-$)W9E M"!S;VQI9"`C M,#`P,#`P.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P M,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O M='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIR:6=H M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ M<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\+V1I M=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MF;VYT+7-I>F4Z.7!T M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.CEP=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0W('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P M86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE"!-;VYT:',@16YD M960@/&)R(&-L96%R/3-$;F]N92\^2G5N92`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`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$ M)W9E"!S;VQI M9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P M.C%P>"!S;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E M9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I M=CX\+W1D/CQT9"!S='EL93TS1'9E#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#`N M-C<\+V9O;G0^/"]D:78^/"]T9#X\=&0@#MP861D:6YG+6)O='1O;3HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^*3PO9F]N=#X\+V1I=CX\+W1D M/CPO='(^/'1R/CQT9"!S='EL93TS1'9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$<&%D9&EN9RUB;W1T;VTZ-'!X.W1E>'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE M/3-$;W9EF4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`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`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`C,#`P M,#`P.V)O6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`P.R<@'0M M86QI9VXZ6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#`N,#@\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@#MB;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.V)O6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE6QE/3-$)W9E M"!S;VQI9"`C M,#`P,#`P.V)O6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M#MP861D M:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C M:V=R;W5N9"UC;VQO#MP861D:6YG M+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R M;W5N9"UC;VQO#MP861D:6YG+6)O M='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C M8V5E9F8[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I M;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X M.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N M9"UC;VQO6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR M<'@[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1'9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D M9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P M>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^*#`N-3<\+V9O;G0^/"]D:78^/"]T9#X\=&0@#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+7)I9VAT.C)P M>#L@'0M M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$ M;W9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O M;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1'9E#L@'0M86QI9VXZF4Z,3!P=#L^*#`N-C<\+V9O;G0^/"]D:78^/"]T M9#X\=&0@#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL M93TS1'9E#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$<&%D M9&EN9RUB;W1T;VTZ-'!X.W1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`C,#`P,#`P.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE6QE/3-$ M)W9E"!S;VQI M9"`C,#`P,#`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`N M,#@\+V9O;G0^/"]D:78^/"]T9#X\=&0@#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*3PO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q/CQD M:78@6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X M.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`P.R<@'0M86QI9VXZ6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,"XQ-CPO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N M9"UC;VQO6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P M,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A M9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P M.R<@'0M M86QI9VXZ6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#`N,SD\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$ M=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+7)I9VAT M.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N M9"UC;VQO#MP861D:6YG+6)O='1O M;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E M9F8[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+7)I M9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#LG(')O=W-P M86X],T0Q/CQD:78@6QE M/3-$)W9E"!D M;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M6QE M/3-$;W9E#LG(')O M=W-P86X],T0Q/CQD:78@6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG M;CIL969T.V9O;G0M6QE/3-$;W9E#LG M(')O=W-P86X],T0Q/CQD:78@6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[ M)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E#LG(')O=W-P86X],T0Q/CQD:78@6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E M9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#LG(')O=W-P86X],T0Q/CQD:78@6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^ M/&9O;G0@3II;FAE#LG(')O=W-P86X],T0Q/CQD:78@ M6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P M,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$ M;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II M;FAE#LG M(')O=W-P86X],T0Q/CQD:78@6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#LG(')O=W-P86X],T0Q/CQD:78@6QE/3-$)W9EF4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F M;VYT/CPO9&EV/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@6QE/3-$;&EN92UH96EG:'0Z,3(P M)3MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@ MF4Z,3!P=#L^/&9O M;G0@3II;FAE2`Q+"`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`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`L,#`P/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE#MP861D M:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-#,L M,#`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`W7V8Y9C8W868P.3`R.`T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y.3EE,&%E.%]E-F%D7S0Q M.#=?.64P-U]F.68V-V%F,#DP,C@O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!O<&5R871E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\Y.3EE,&%E.%]E-F%D7S0Q.#=?.64P-U]F.68V M-V%F,#DP,C@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3DY93!A M93A?939A9%\T,3@W7SEE,#=?9CEF-C=A9C`Y,#(X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`P,2P@,C`Q-#QB6%B;&4\8G(^ M4F]S92!497)R86-E($YO=&4\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@^2G5N+B`S,"P@,C`Q-#QB'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S(U('EE87)S/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@("`\=&%B;&4@8VQA&-E<'0@4VAA6UE;G0@07=A'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!3 M:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO6UE;G0@07=A'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO6UE;G0@07=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S(@>65A'0^)SQS<&%N/CPO6UE;G0@07=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6UE;G0@07=A&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2D@*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO M=7-A;F1S+"!E>&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S6UE;G0@ M07=A2!);G-T'0^)SQS<&%N M/CPO6UE;G0@07=A2!);G-T'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M, M:6YE($ET96US73PO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y M.3EE,&%E.%]E-F%D7S0Q.#=?.64P-U]F.68V-V%F,#DP,C@-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3DY93!A93A?939A9%\T,3@W7SEE,#=? M9CEF-C=A9C`Y,#(X+U=O'0O:'1M;#L@8VAA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO&5S("AI;B!D;VQL87)S('!E'0^)SQS M<&%N/CPO&5S("AI;B!D;VQL87)S('!E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N M/CPO&-L=61E9"!F'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&EM=6T\ M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`R."P@,C`Q M,3QB2!"96YE9FEC:6%R>2!;06)S=')A M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y.3EE,&%E.%]E-F%D M7S0Q.#=?.64P-U]F.68V-V%F,#DP,C@-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO.3DY93!A93A?939A9%\T,3@W7SEE,#=?9CEF-C=A9C`Y,#(X M+U=O'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO2!I;B!N970@:6YC M;VUE("AL;W-S*2!O9B!U;F-O;G-O;&ED871E9"!A9F9I;&EA=&4\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^ M)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2`P,2P@,C`Q-#QB2`P,2P@,C`Q,SQB M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO65A'0^)S$U('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO'0^)S4@>65A'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`P,2P@,C`Q,SQB'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA3QB3QB'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA&EM=6T\ M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%Y(#,Q+"`R,#$T M/&)R/E)O3QB'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@;V8@8F%L86YC92!O9B!M M;W)T9V%G92!L;V%N(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S$P M('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&UL/@T*+2TM+2TM/5].97AT4&%R=%\Y.3EE,&%E.%]E-F%D7S0Q 8.#=?.64P-U]F.68V-V%F,#DP,C@M+0T* ` end XML 21 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
6 Months Ended
Jun. 30, 2014
Restricted Stock Units (RSUs)
 
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, December 31, 2013 118
Granted 68
Dividend Equivalents 2
Vested (40)
Cancelled (1)
Outstanding June 30, 2014 147
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, December 31, 2013 $ 5.41
Granted $ 5.51
Dividend Equivalents $ 6.86
Vested $ 5.47
Cancelled $ 5.42
Outstanding June 30, 2014 $ 5.45
Employee Stock
 
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, December 31, 2013 41
Granted 25
Dividend Equivalents 1
Vested (21)
Cancelled 0
Outstanding June 30, 2014 46
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, December 31, 2013 $ 5.35
Granted $ 5.51
Dividend Equivalents $ 6.86
Vested $ 5.70
Cancelled $ 0.00
Outstanding June 30, 2014 $ 5.30

XML 22 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable) (Details) (Stock Options and Stock Appreciation Rights (SARs), USD $)
In Thousands, except Per Share data, unless otherwise specified
6 Months Ended
Jun. 30, 2014
Stock Options and Stock Appreciation Rights (SARs)
 
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Outstanding, December 31, 2013 333
Granted 0
Exercised (1)
Expired or cancelled (27)
Outstanding, June 30, 2014 305
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]  
Outstanding, December 31, 2013 $ 6.64
Granted $ 0.00
Exercised $ 2.37
Expired or cancelled $ 7.49
Outstanding, June 30, 2014 $ 6.58
Exercisable, shares 262
Exercisable, Weighted Average Exercise Price $ 6.71
XML 23 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) (Stock Options and Stock Appreciation Rights (SARs), USD $)
In Thousands, except Per Share data, unless otherwise specified
6 Months Ended
Jun. 30, 2014
Dec. 31, 2013
Jun. 30, 2014
$10.40 to $11.59
Jun. 30, 2014
$2.37 to $6.21
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Range of Exercise Prices, Maximum     $ 10.4 $ 2.37
Range of Exercise Prices, Maximum     $ 11.59 $ 6.21
Weighted Average Exercise Prices $ 6.58 $ 6.64 $ 11.13 $ 5.32
Grants Outstanding 306   63 243
Intrinsic Value-Grants Outstanding     $ 0 $ 529
Grants Exercisable 262   63 199
Intrinsic Value- Grants Exercisable     $ 0 $ 450
XML 24 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
Earnings (Loss) Per Common Share (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Numerator: Income (loss) amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:        
Income (loss) from continuing operations $ 973 $ (2,421) $ 540 $ (3,695)
Less: (income) loss attributable to noncontrolling interests 0 (16) 25 (34)
Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. 973 (2,437) 565 (3,729)
PREFERRED STOCK DIVIDENDS (86) (86) (172) (172)
Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders 887 (2,523) 393 (3,901)
Income (loss) from discontinued operations, net of income taxes 128 242 (484) 569
NET INCOME (LOSS) FOR DIVERSICARE HEALTHCARE SERVICES, INC. COMMON SHAREHOLDERS $ 1,015 $ (2,281) $ (91) $ (3,332)
Per common share – basic        
Continuing operations (in dollars per share) $ 0.15 $ (0.43) $ 0.07 $ (0.67)
Income from discontinued operations Operating income (loss), net of taxes (in dollars per share) $ 0.02 $ 0.04 $ (0.08) $ 0.10
Discontinued operations, net of taxes (in dollars per share) $ 0.02 $ 0.04 $ (0.08) $ 0.10
Net income (loss) (in dollars per share) $ 0.17 $ (0.39) $ (0.01) $ (0.57)
Per common share – diluted        
Income (loss) from continuing operations (in dollars per share) $ 0.14 $ (0.43) $ 0.07 $ (0.67)
Income (loss) from discontinued operations Operating income (loss), net of taxes (in dollars per share) $ 0.02 $ 0.04 $ (0.08) $ 0.10
Discontinued operations, net of taxes (in dollars per share) $ 0.02 $ 0.04 $ (0.08) $ 0.10
Net income (loss) (in dollars per share) $ 0.16 $ (0.39) $ (0.01) $ (0.57)
Denominator: Weighted Average Common Shares Outstanding:        
Basic ( in shares) 6,015 5,874 5,995 5,861
Diluted (shares) 6,181 5,874 5,995 5,861
XML 25 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business
6 Months Ended
Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare Healthcare Services” or the “Company”) provides long-term care services to nursing center patients in eight states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. In addition to the nursing, personal care and social services usually provided in long-term care centers, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Ohio, Tennessee, and Texas. The Company's operating results also include the results of certain discontinued operations that have been reclassified on the face of the financial statements to reflect the discontinued status of these operations.
As of June 30, 2014, the Company’s continuing operations consist of 46 nursing centers with 5,282 licensed nursing beds. The Company owns 13 and leases 33 of its nursing centers. The nursing center and licensed bed count includes the following recent business development activity:
The 73-bed facility in Nicholasville, Kentucky, for which the Company entered into a lease agreement and assumed operations effective June 1, 2014. The Medicaid and Medicare certification processes for this facility are currently underway, and are expected to be completed in the fourth quarter of 2014.
The 135-bed facility in Huntsville, Alabama, for which the Company entered into a lease agreement and assumed operations effective March 1, 2014. The Medicaid and Medicare certification processes for this facility are currently underway, and are expected to be completed in the third quarter of 2014.
The 442 licensed nursing beds at the four recently leased skilled nursing centers, three in Ohio and one in Indiana, which we have operated since October 1, 2013. The Medicaid and Medicare certification processes were completed for these four leased facilities in the first quarter of 2014. In addition to the licensed nursing beds, these four centers also include 270 licensed assisted living beds which are not included in the licensed nursing bed count.
The 107-bed facility in Louisville, Kentucky, for which the Company entered into a lease agreement in August 2013. The Medicare certification processes for this facility was completed in the first quarter of 2014. The Medicaid certification process was completed in the second quarter of 2014.
The Kansas centers acquired in May 2013, which comprise five skilled nursing centers and 418 licensed beds. The Medicaid certification process was completed for these facilities during the second quarter of 2013, and the Medicare certification process was completed for these facilities during the third quarter of 2013.
BUSINESS DEVELOPMENT
Acquisitions
On March 6, 2013, the Company entered into an asset purchase agreement ("the Agreement") with Cumberland & Ohio Co. of Texas, as receiver of the assets of SeniorTrust of Florida, Inc. to acquire certain land, improvements, furniture, fixtures and equipment, and personal property of five facilities, all located in Kansas, for an aggregate purchase price of $15,500,000. The purchase of the Kansas facilities was completed on May 1, 2013. The Company also incurred $338,000 in acquisition-related expenses associated with this transaction. The five facilities acquired under the Agreement include the following:

77-bed skilled nursing facility known as Chanute HealthCare Center
119-bed skilled nursing facility known as Haysville HealthCare Center
80-bed skilled nursing facility known as Larned HealthCare Center
62-bed skilled nursing facility known as Sedgwick HealthCare Center
80-bed skilled nursing facility known as Council Grove HealthCare Center

As a result of the consummation of the Agreement, the Company allocated the purchase price of $15,500,000 between the assets associated with the transaction based on the fair value of the acquired net assets. In addition to the assets acquired in the transaction, the Company also assumed liabilities of $758,000 which resulted in total cash outlay of $14,742,000. The allocation of the purchase price was determined with the assistance of HealthTrust LLC, a third-party real estate valuation firm. The allocation for the net assets acquired is as follows:

 
As of May 1, 2013
Purchase Price
$
15,500,000

 
 
Land
$
2,130,000

Buildings
12,127,000

Furniture, fixtures, and equipment
1,200,000

Inventory
43,000

 
 
Less: Liabilities assumed
$
758,000

 
 
Total cash paid
$
14,742,000



Lease Agreements
On June 1, 2014, the Company assumed operations at Diversicare of Nicholasville, an existing 73-bed facility in Nicholasville, Kentucky. The nursing center is owned by a real estate investment trust ("REIT"), and the lease provides for an initial 15-year lease term with a 5-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
On March 1, 2014, the Company assumed operations at Diversicare of Big Springs, an existing 135-bed facility in Huntsville, Alabama. The nursing center is owned by an unrelated third-party and the lease provides for an initial 10-year lease term with two additional 5-year renewal options. The additional skilled nursing center increases the Company's footprint in Alabama to seven centers, and the third center in the Huntsville market. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
On October 1, 2013, the Company assumed operations at four existing nursing centers, three in Ohio and one in Indiana. The nursing centers are owned by a REIT and the lease of these centers provides for an initial 15-year lease term with a 5-year renewal option. This transaction represents an increase in the Company's footprint in the Midwest, expanding into one new state, Indiana, and increasing our presence in Ohio to four nursing centers. All four of the centers were operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers.
On August 1, 2013, the Company assumed operations at Seneca Place, an existing 107-bed facility in Louisville, Kentucky.  The nursing center is owned by a REIT, and the lease provides for an initial 15-year lease term with a 5-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
XML 26 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Earnings (Loss) Per Common Share (Details Textual)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2013
Jun. 30, 2013
Earnings (Loss) Per Common Share (Textual) [Abstract]    
Antidilutive shares excluded from computation of diluted earnings per share 326 326
ZIP 27 0000919956-14-000029-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000919956-14-000029-xbrl.zip M4$L#!!0````(`$R!!T5`J,^26MD``&R)"@`1`!P`879C82TR,#$T,#8S,"YX M;6Q55`D``R_=XU,OW>-3=7@+``$$)0X```0Y`0``[%WI;]NZEO\^P/P/FCS, MG1F@;K0OZ?(@2_9M;I,XB=/VO4\%+=$Q45ETM3CQ_>OG4(OC55YBQY&CH@@2 MB2+/\CL+CRCRXS\?^QXWQ$%(J/_I1'C/GW#8=ZA+_/M/)]_:-;-MG9^?_//S M?_['Q_^JU?Y5O[W@;.K$?>Q'G!5@%&&7>R!1C_OAXO`7UPUHG_M!@U]DB-YQ M71KT<>"-N!^XTR0>]!G6:EE7@S.,#=70'%DW,)8=7=!1A^^HHFQTD*8[0N?= MXYDFB4A4L&-(6)`U5=9(&]]"IK> MG&Q*BICUPPCYSIC\QSEV'Z2DM6`8QFER=]PT)(L:0K?"Z;\N+]I.#_=1;3P` M((3C/K(.SL+DUBWN=J]BL#K_W@)3PL$E[G=P,'Z^'8%E,2/[$]/[``UZQ$%>T@/3YL^O M[92M,3W0DD2C[-KX*G'9]2[!`9>PCJ?DEN/#.O]Z\IF'?P;(6E$_GLX^/-MM MB.\9:>/+V0T7R'@<>,0A4V$-1":8OJ"@SB'3WE=H$SN_1JG(RHK3 M`HPD2%W&[Z&0HV^.''UOR)%;3B0<0///%J/`;RS&J4=V*4;Y1KA$@?`3ZJ`^*J?9`9-GBYC,K&T)EPCE%,<^'@Y"H;0RAIT=V"R'QK]C':X?Z M*^+TJ(?>4K0O8/E0`%(W]T'JWGQ0,ODI7\"7-\^XY?UEW'(UAZSFD$>-:!MW MHG,_C(*D?O@$9BO`+HG,^P`G(BUW+)EG,@/F0BXKE`!*UJTT)'ZK]66^9=O! M/H*QDU;CN]G%)@VP@\)HUCW&G1#_CN'IQA!^W(T&>/KQZ?OE!N4J=]7ZLA?G M.*F7D\_CVPL5LU,"%NMV@H1%RCV4+6Y:NY'W5[MYABU6YK0W++5[&$>F[YJNFZ2@R+-)Z'@TC`,J>O-`\[-ZN$]0V=X+: M2SG!%3']LE7EUSM/""Y;57Y=&>/SC+&RI[W94P7GS>' MWGS%A%J3^'V)\=\E%:/PZL2X?,5$XE)_?'^%$[NR^>GEZS42]_SC^QN=3>UK M>=//>5]RO&4N:^\N9HW+\8J]RW MRGV/*O=]G5:V./=-%^:Q5+`U2$7KIYFA.1@$V"&)O&_)?2\*VZCL^ST M&.QTK,C*3E?8:7ZUT1]X=(3Q\=8F%W!8H6--=%2UZPHA&R'DFT^B\+;][2T@ M99K7"C%K(B:1W61:P,+^4>*E@-,*+7-HL6C,*FP#(&ITA?J3R?L7ZY:$ORP4 M!*`X5L6;G38`#MS8PZWN)?(&`7(B2`C/_3`.6(DP48SOWL&SYV/U3T'R.J!= M'(9)^7"BAPN".L0#29<;G8L$FV?32R2[T[G`=LIY,J/UM%-9U`86]B3]N%]NI$R\`LLO3?%5(6$=)!#_ M.)$PR5>%A#DD;%O&2`+1=8"[L>]BUX8^X,F.AZ\I"+;DQ8NM:P=)E%HAE+>. MP7/H6[R12[&*.ST9(&+B$&OP7QI+,+^S$W%(-V+9Q#'SM<2.Q5$Z=$A[18=< MK2(NURKB@R.C6KWTEK1%)N7RXZP4L;*W`0ND],Q]H;+TLWCY#W.XT`< MV?N*@""O%9A!AT3I>\6\PG('F.D&TR\W5C@/ZZH/8(_DP[H7_P"VLK?J0]8W;&\O_B'KP>VM*NF^)2U7 M)=W#E70/J_EE[MN\;<_$T%4+`^^P?X3K`HN^)2P2VRZCWLJUB<6B/V),5Y]4 M[:^B6WU257KKF']9D7Z@0GV7^LFKI0[R?[6Z70PM;U%4\NK`HI<0Z;OLZ>RS2,2G^Z3WFIH<_':>VC_)U^MY>.Y88`Z]@Z<8%CN!>JYN.5&Z( M'(K_3[`N$OY(OK5.];?7R/ MOF#D13T'!2#9(41FFNR(][[H`88#J_ M8Q*2\7E8"X99^/P*H']MEPWHZ3JL0OGFN]X5"7B74%^BHWS-V%(EO:2Y?6T? MQMR4B1T>#FMNX!CA^I\!'58VMS^;6RGERO#>F.%]0:-PR)I55K5C7CTXJQ6PKW>-TPO"H#H5YF"GPKR4PB4SOB_(+;(O7<`1 M)_63K\!`[/PJJ;4OSSBR[UL6LWD8E>M[5OGJ/.*H=+]&9'];(&CC@5"M&:C6 M#.P"IL;>8"K;V!'U%?')BCV/@N9_@.R_D^">^`3-8/,["@C[=BU?G]S(/KBM MCRP/A2%`)NVTU4V'F4IY%SX\NJ+1=4#Z*!C5L8^A`P*_EM,YK@B,R^6[2W!O MHZ*G+'UC'1W`4@2VO:JH[\E26DXDE&TG2ZDF\/OS'4PB*UQ'JT=_E MZS<)@G7GEN7S[65ZVW&L@>:%P%F^B%4FM,-&N(['`3(P5SEX^/Y9O1'-0%)Z2E.?']XE= M4!S:Q^,H7D<>^[B[W<,X,GW7=-TDK4">34+'HV$-6^(JDKX/0PFE?WEMAEFE]SJ<4106#=U19O"0N7 M:"15<;.*FT<6-Y4]',R864QZ(DTKCEBO3$!E>[T-XM'V)I[I97R%-4QSF!S? MX\S6#%86+I]:QIT0_XZA:6,(/^8/P)B^7T['L5[9QLOL:R'D1F;4\B,$@UBTWP>_7-G2\VUID40K@SHF@ZK,H@+F:P'F7[%7 M]!WMNFN)7\_,[&W9SJM8I5RB^=ZQ>@CML!["1GY2KF)K:H+V5W\NN3/;-N%G:;>I&BGM,66W6>NN*BSM,66W6>+\$J MZCYOL]4`XV,J?EY3`$[A0+-MMQKP`CV$,8F*QLF:;-=]>)ZRGJ.VFP5==^O,`GYSUDQ@N_;M5WF+SP+.P[;;)5 M[W&XS$F0D,JBH)U]:]O;]GR-@^1U[)>';$^4[SNQ-\STLOCTBFX["=)?)EPWXFQTK)-W()YR+'=)'7OCII":=Y(XNJNGUAL77)4LT#4E434%6&I+5 M4,RZ://-ALB?<&SPI*\$!)J@:9`$?#Q=@Y)GD"S?B$M);HBFT@#B#*4N\DI3 MYD75RD@694$39DDV)$5]'LFWV,%DR-I>X6@K,?.Z8;$/7U:9A-"U+L*6&)DF\GG$HUA55FN-05X0Y,.V$[I>21I&^);4N MZ:+0-!51;LHZ^`1+RE$JFV9S5AH@BWE][U<:K:B'`XOVH>\>R^/9F9)LNGQ! MPQ"@U>K>H<<-(="PI(:DR77%L!F;35-OY.[$UJ4YIFN*:BSC>1WJ=LQ:D3Y5 M6>!!APU=@4D;W^1%GK6;?&BW%!UR3;JO-C,T2IJ M#6$N%1$,A:4BS^'`\^@#FUTU:6#3N!-U8V\^8FT5\$6C84JZ9*IU"/8-0;-5 M)5>'U>3U.68@"YCQ*IO0ME.VBE`F\L"79HD-0]5MJZYJ`+>,K4;=-)6Y>*GH MXL[8@CF]2[R8.8$V=N(@V>.I\4.`3_S[,IQ<0=^)9 M=NUTY]*;.WLIQYINRDU-%VS!$C6I;C<5VTB=A-YDEC;!<3X'@^1MFN==$/Y2 MLOAW@2R:HBDKO*A`0BB#RVPV!4%3`01\HVE":*D?2!9AB*-P0_.4%$FR)5&H M6V"@,G@7,4 M5%'XN2@$4S154M8D93LC%TRA+M0-`T1C:TI#!C^6I_T@'GN6(I47=&T!08NM MN)BN(J75ZX:JU"'_-F39T"T!\O5\$B6JH"L)F=+6Z4R]2BM^C;"5< M2^<54[4-EFTT)<@H=$7-F!`$46W,,B$:@K2`AVT(W1_#A5H3#9A%-B3;UNN0 ME$@:^(V,8;4I\7-H$O79J'XXAJ^H[VRC9*-NBK:J\R:OU;5&L]F$F57N7@Q3 MGION&[-3BN>0NE>NBS0M-`4>\C8(D[IN63"7M)I&[C=@]F'.>3)1662>.V$[ M7SP,T:3#RFQL[OFTCO@6)UF[1<,9;VT?Y+B%I1FQHBDZWQ!U4=,54S=X74M- M1S*;DBW,5;HD:7HVOKX05@K/HC"K<3.AWP7(#[L8Q.X*<^*;VY2B4'XKOA]; MZD5-75`A"C0T46Z:30/RZ]2+@D?5%',.:IIJ2*M$LY3%'0KG]6!+M&U+$53# ME@5#@Z!D:EGE2X)+JC(73`6%Y1Q[$^'38H8[D%?=FYL]IM!*T].GW,D48!JB M-F0-\CA5-9N:J.0P`&.03S[_X44?7#+DPFCDX4\G7>BRUD5]XHW.[D@?A]P5 M?N!N:1_Y'Y)[(?D;GPG\(/IP\L=]]&'F<0_(KO4PN>]%9X+(__?29]CU16,2 MOXP.AN/N M8^*RN1\78(`[S`^XJ(CF05'"Y]/\[][Q^H/_CP#UT4^0_?SQOC MOX0/_\?U8VC7P0PF(?6@9W!F7&<$?6)ND&[="[?'>_="WQP"6H*4A`<2];*F M=$C8@H"0@^C#=6D`-Z!MTVS7.;-M<;K`O^/F1+VA*-(_6?,S5I(@3BH<:TP[ M$/#<,9(>WW$HY)A'@`Y!'L`(V].&$SG4H4/\GKM;)ITPE0;;J3Q52P\ZZM!< M2O0!!UQ$.1?TYH#.')C!)7,WCG9!@Z"<]*D^A!,N!"0ENR[[D0==]P?0/.DF M5>O_A!Q@G;T`(4Q'>^J(HT'R M5\"@S=H&20D!9YQ!<._"C'+R@81&`*3G`DL1NX@\CTEBDF;6$WL&F'K/_<`Y MC4`?1_U[RJ#\.P8E1DE!$BXC;Q0R`8)X,-OH!^R-(UWN`>X%>"D@<\&]YQ*M ML(DO\D<@=_?9<'.H1X.S?R0>FY]S+S[-/0O\LA/4+;?@(,TR$D5R?AK*.">) M90R<;/$LEZ^>3;7S`+AS20AV,4P!S.37)0$T!*D'[$&0'`L'#.H(1@AC+\J! M@5@.R0WBP`'\XOPJ2S.X+,^8H>)=`CO0GD\!8_X]=#_E48"A%`T)9Z0_?;<+ M\XIRFA):>5)#(ZA;W4(>D\`<331.3G?&X MR]C3\CD;/`)+F=+0(:C\!U%_Q]`CO)M4$FBUS]Y1@4J9?J,@=A+F0)4;B6$J M8DT^.1FZWG',-44]$KA<+^V0'0&QS"Q2I[T3.S7XG713ZX"3?-$A@=L[5$`U_2[""B?LWJHQRB21.I.R;1'>=T"L^O+JZ.P.6WC":J(5W/+HJH(C5+"1N? M"73CNJ2XVPV?T4MTEX#TL7L]B//D9YB'!A7.OB=QEK^B!3"0ZJA?T[Q/I$_" MQL=(FDR6+AZ?]&,>0!KR,9"@@+0*"B'?P#P[GCSB9V06=*J<@E+R7]TD%2#R MDQ%M=$6T7KMY"I$4BXN_,%V^AZP8E`SBT>\QK-#`X#(&L7H,2KXEV?UH)M4. MW&B9Q,CCC$K5[F7EI!1S#*]<#.X6HS$:Z46ABRGN1E<\Q88,J$R2VVWJ06?9 MJ(3P\?E"VJDTEN%@,07*E+;!-W4BPK_Q"]LQ+V#!.GG<53^]W^=LE&9YI9&O M?+Y:2TM?5Q,L$(HZ`QRE2IG75!FZEAGZ6$5$&N*".WJ1[;BL:2 MOXNB@&S4@]5:KUKH->M$68^YLD\`2S_^+NOI%;)=SB`K=0'^X4[=W(&$`[,1 MI$V5*M(FT^(V3G6%T-34`?X9?N'6"@*^Y=]0H;_()YEND'E'!F"$)=F^:M<<,1 MS:-4!C7XIM;XX1([WJ*T'Q?MUZ(0)XR@IB;,\WS'"VE0[O@$Q#`;6ZK4V+Q= M<;C`CKX_7Q.2N")S(@7]\QPTL:CC%FH1V%`61R3UJ^A9U7+T@(7.=QADS;FW]"8NW+$L@\?JK/Z'OQ;#2[>?@, M211\C=K-W65;%H_[.*!^)A5$L,@07-W0,<$I>Z'Q3K9E_9M/MS?W$_^M?MQ<`LOAK_#WVY[V3'_ M8Z>-#MTF4^5"6="H1H4ZU(M)=``E&%B8[,66$X\'MTGV`C6E>C\683,H($9# MJ*Q`32]DPO_U*862[1)+DR&49?!*M7J3A-[K$J+X0ED$XMF#^%Z1\Q3+'<%D M,DC&(WGI3E4B]]7-5W@Z/&3%-A8ZFJ6MZ%EM+QJ>]A4\P]-2G8[$E(^2+?ZJ M3!L=X.(VO2Z'\9+DRNKSZKQK^'J[AK7RMNB!Y.6M.,&FHK)4'!JN.]:H:XM) M[4'QPP-X?6SH_#T^F798!%L8**9N]IJD\0_^2D%4`TSRH%"5QQ1T^^H?*&9M M_"B[-!LL9B.]MX3=?E"GYV3^E`[S-6FL5UF;.SUM%N[FEO.&[?PI2]3^P6ST M;?`,SWTJNDO)!+<1[:=7N8GG90KXC_`:>#OP2 M/OP9W*:,@+[>8QQ-9'>UV'1X2-/Y!/W:L(0<`L\&;\%^:L$(=@+;U+'@I^4$ M5ER>#H,0!Q^=(@^/$.4RM<_C^;X@:JL9@L(U*W"NAI8+-ZD65RPW#XUT+Y=9!S`BG2#&,_[D"JC'SP$(^R M<4T[:LWV\BNGJ=Y"AA#Y#HR]TN)O;:77/9_R>&?_UTO_)[LI\>QI\#!.OY8K M=UZIGJU4K9GZ_E8M:)S.V33/=YE4KEE7>BH+"[Q]CJX<=PFQ4I416)\5 M6^_HN]E&ZHDT^GR2:'U`.#N37C@3V0.!5++(:D8R@1SBJ0/3!3SG2S+%@XGPS1$>-J?D\K="?1\@\8X5 MER=6X6-[E#WWK[?O5]?[W3YD'/`!_`]/Q>!A0ASIN!/\W M!/.\_!XZ#4@3[,GDXK78,-:P89,@,&T>,-]W@';'VX:B=O"X98^L9LQS?(.!]_W.&N^"1"DN31[.`;TSG[YE M.G[@VIS97F`S889,B("PR`BC@(@&](M!6-.P]B;WJ)QO4-V`!DX02FQ!U_-M MGPO?U9R'C(B&@[^DI+G$1^3\6NX"'(/SR"14"(@(MA?ZG#+/<55H,TEH&;0! M5G%I,7LCYUN3>U3.-VB[1TA(N.DRTQ"^"9$Q+/POL2&P-#D_)=\W>7[<.=\, MS-;DMDDA[@21$T*,U^&3N%%+^+QD3C,+V)O'R&A-SS M]8H3WR11(T!9Q-JLZ_MRCDUYU?_%T"#?_IB`NTA6X1R5X4@((FP#Z`\]/S!\ MEPB1HZA11I=/G0R^S4:_3$;C7S_,LT7R8?#S`83()+D2+UP6&.@JB1O8OB%< MX>3(LG;00!':@A"-X19(@-S)L`"%@N@XEOL+6V![77^*:C!0`M0[$%0@<@!S M+,$THE`80%:R%--*H&)R12RKLO);$-<%.VP#.Y0*[I.`DH@:/J3)AJ_Q0HS0 M#4.#]XR=ID%6]B M:S%K-3D'T+U6@PSF6Y$!L3-T/:ALP2V%>8""XBDD1Z;[>C9;[$RSB$SJ>!S" MJD'-T*4!-Z.<9D@2:0O-MBG$>I(5)7N2NU8U1&!3SD+&?=\P>0`5*=?HAD%D M^%$[N81W0&YEXOJNCL63'0'NFS8W;3]D!O=R>W0(=]MHILL9V!IR#B%\O2-A MPO5$Y/M>Z&"8Q2E_,@"B!3<(F7Z[$5 M1I'10'8T5Y'9UC[:2-K:]J-A<&XXS#,#,Q*A:SDE:8[G-6`P=R5M&9FY'7:Z M/-HJSAQ(XCZK4T4]OSA6F$@M@^Y7Y(?"YI%A:48+Q!\Z5)EUO0'9!=P"9^ M1KC]=.+.Y]GH;C&7$R]2A$T$MK)T/(:WY+CINVN5"9FXH(P'MHBBR$=,TURK M()0W6842=.L5VH>#$XMG@ZN(PD@$/+0\2X2A`.G MGB'%0X7,GILC8TXIFQD\JKB_L:O;H#Y>$/0H3KX)@"%F0ZJJ^A2>:T:-N106 M,>FR850)V(VX#4;KNP9$D0#**D/8G%IFE$.#AXX%`:B1B#!;+/NT_8G;8#-^ M"-18-C<"'H4T\#T!R8AGN9P90(9HW"ESN&C$EH,DMXXXP[9\RPP0"1Y6C#,[ M>(%ZN M=@X+&Q9E,UC]!GE5$G8E<(/J6<0G8<2X`SD.-U@0.7G+-'2-EJU$[L@K@QT2 MN$']'#MT&?@CP8R`".):EA78-F2*4`!1A[?#"E`(M1D4.\V0:W%C^1S#6@J#Y&Y>CJ"![VP;IG#=AH-<_V0[!'(Z M3Y;NGWY,)X\(]8*?;@Q]_9C&DWR,61,Q>:E.I8$A/&'[@0M.PX>5L\)BVDTD M&GY-+/=<5G&^3C[5B3SN7&UJAY/V]DO!E1H-F<_8W('AZCX(9\SR/+`0ST=8 M;!M4E>D[J!%4:=4R+9_+2*X(LZU5#*]@91WW?TX6LV3HI5F6?L7[Q?$4>`*. M6J9O[""#+\E+.G[!Y]7>LP$QVR*A%83,L**`6T*X)N):>*'G0<[N!\VI>9"+ M&FS-^J_EK44H,[Q^<9^T0ZZSI4O;JTQ%<>SF,&T;6$;^F,<)BTS/\Q@E>$5> M:;P9@!4TAWPPVN2X2O@R7PK=6OY)CQP`O[$O?'[(N&%SN<].@E`XU+'RQ?]B)? MY;:0UFI_[2E(I]TC!YB$[5#NN:''O<@57N3E9QU"YC;/O]FMU*\@YT#:-\1E M%AG<9S[G-G]9,8*W=F)?'B;PA[8=\`D(PZ'N,Q=$P_5 M1+XEHD+EB>TV)\W`?ZUDMU!R`,GKK-2DCF`1J#>D0(8'12MQ>4XR9$?-\L!: M.L9V$,G[&F?@F%'(*=BEY4#1Y7J!E<\[8H[K-=%S(+%L5Y!V:@ZC?*V\&15@ M@"(P0A:QP&5;!0S9UFY5Q)S`-4;:A`[-*#VQ5T7"Z>.1(CLHZGVJ=7<(J"<6">@ M>H,##`,O#'%VH$F@4"(""_!.^?%9T^"1WQB4Z%C+[G0[SI;D45QDOGG`3AF$NGAY)H[['U/K`)QCW>@1P_?.[TIAI^[RP;WXR3.H/)+)\F'GPL2^T6O^K6! MRG_S@MTQ4(WT88!SDV?=7^$U^MXO:HNZW% MG_`V/MY%KD+RX!TN//D`S*+A*^14==-+P2S+3?WR-K/"V(V_`MFSJ\&?:"TE MI?@EA\^2D<+DA'2&D*QX6(:8^0GK=-Q5UZR7"`MXS2I[T1?P1KI`5DC05(,G-\F\U'%H@Z9&_5#-WA"XY\0/N[DF\= MJ/G/GW-`)6E=J"V_)=\'GY-LAMARG+$_5BSMG[E->;[4&.[YV*#11WHN_-24"A5=5-^ MO3(@BE:)T=,)F_.OZ?%\=(5E:;_#A839*2'[M,Y\'4$\DG&N0)&?56'DA_FQ MZXO!4PZW/G]J:I^I9(A9I[,`;U M*81'1T1U/>!&6@2.2$UD6-'& M)2]\"WC46XI;FGB"X_LZ2#0IV3;1A'9QNZ?P9T+W`T% M;JCD_2_ELE`EL:NCKLGU$C,W4/[WA&`L/S*$S+[.7/I<,'8="N5\)HFUAW_X M-GJ&4-U!+K.M.&S1G=L[Y3+:SC'<=25_6J["\KEWR?-TG'Y/-&;CL^PBS5:O M-Z(I8K6!,7JLT7(1-''P(J\FU+]3$Z*&"!9SE?3Y%F:,C-&>& M:SUIS=%G.#E-@7++D4<(3@HQ`B6$H$Z%;M844B8'^ALO$*_\+UWCUB@I)THW M%:5!QM4*E4#")!KVN%(LQ,_P-:E"QE+5">++R0RNIH$@T1JE"#-:J0W4T[/D M&3TB*.5UR7NM+EEKG'E##P3WPP21\2QM1!(LPE\EAEA6=[YX,6GIH#QL]L;* MHY5=-=D"S34CQRNN:YXZ_I(9XH+L]>I)=L6\ M/5TUU!I6V->>8>]$P_AB-9A`&??+429$*Z#Z;?8.\X?@3.E?2/Z4$<(HJ]^K M7ZO0BNL%/;ZG>+"\1P":,A[K]_SZ@7R0O\_PC*#^??==3Y#TXVBBB(P7\S1_ M03I"]W/J_\*"5BWX^R?3_HG/Z# M>W]R1R97+916Q1?LV4$2IG7C+IW/T^=_UFP#&U=5Q:_^KMY?>TEI)KZRDGT1`LL-ON0('BN!YWL2;M@ESCP\EE]1;D<]:?+?7'[(7^;!\B M]^EG?551\@ZJ%O6@_Y$O),-M!7;V4F7D%)E]L?72II!;;JHCSKNW)@P)Z&W:DP]Q2=E'VGLC-- ML[6=V[60^J(K^+F=#RJ\EI:\L[C0>=SLO;;][61J]19\C7UE-X^0G!W-FZYU MCBG"?ZD-O=?T,+VQG6)TD]&9Q^W+,A\[))\C[W&[E#O45V>[Z'L$Z5'^>DS9 MYD5X9\'E?5:'?ZG(\(76N2O_HI0K]J`'L>'9X:MLSKDQ^KI;.U=+V M(0UOKLM#R_=XI6@\[C"Z':%1WY\@9_!.H]R6LOJQ@]TYIKWNKNRKAC9^Q9Q3 MF5M?+.=7EXY]+X3+3-!RX;I`@^TG[RA*O+\XWH78_ M2!-@V3WF%^O$M-MK@OW;*3K\/'NO9'76JSWTJA_GW/LKJW.=MW'7#F_ZOHLZ MKS=)BF$;_2CE^J)IYVJMIV'UM-5:7]3Q;11DO7%G]A6GKR^QOBA/AV75SQ)E MH_7]6R*'O#IC9UB3,ZS)&=;D#&ORZH5P/QLLKRZ?L_Z\J4;*&=;D?6O9V4N= MO=392YUA37JM9/UP4B=6LB\%]Z4_U-&\D3KGC,9TH@,FG8;IOJSPL:/Q.>B^8R`FZ\KJ+)R\ M%X,XEXEKQI?J@7D#'+SZ$H^ASN^LX_,^B\-NCVB_]XSM#9G9_[-W9;V-(TGZ M?8']#X31C:D&5%K>1_5T`[PTXT%7V5.N[L$^%6@I9;&+(M5,RB[MK]^()"E1 MIV69DD@YWW0PDY&17UQY1+372EU.MB6]:^IJ6*= MEFE]SH_'#)X?Z1*L4.N,C=95:TOMUQ3D\UCI>+QU3YW/[S(#J)JSV;Z6AV_; MP#5(=-MK^2XG_@*3*//XB\=?^[*PHWT)R MJN:)9^/,WF7(8X./K>S+PM9K,/`F-*Z^3IX$XF2$[4KB4.'BGU.:A0=4V7M1\;DUY#$W\\+'F$ MK!S84#KTA:=^WVE>V)+(KG&N8\.N@C:./QP_>^+G3=[[Y%DUN)9J`G\X?KB6 MXEDUF@*R9B@IGE7C@B#U)O46SZK1.-7U)M,<5-;XN&X[O6Y[DYCCJ37J!"A/ MK7$X[]33E+)O"E2P';\^=2'+&(U'&\^LL7SZ0*GO]$'3I_ZUBJ8EL0[/K'&B M2\ZUUA1NR@P?VQISHWO1M\5X9@T>)?+,&D<\\,Y#0QX:-LM*7<[-+IY9@T=# M+V$ASZRQN+`LUVJ9UN?\>,QH[L5C;H4N.E8R^.(!CY5X9HW3BEVNA4Q9DNN+ M(@YE9%.@Q<.L%ABX\XDK%]'VBRB/UG@>CF,>6=%Y&@Z^DW9RXWD9XMC@,RYO M*`V'PM77&TW#406Q#H@].Q=YSI"]Z;U-0\P!D@AK!+ZPM\+M+X2043T@_20- MLC")/R`CBE,_FXXO'T)YAV4N<9/QA,24O06_C,,L(Z1,>^(D03K`+UZ8DGZ6 MI%0((IH(P622@C$>"`]X'HOB$WD*E)LXFA4?;7B&],.\Y\\X(51X5X96LOCS MW M05E+^(#_,L*$09"1KB!\P10M['7L%67GCX1F)YLW1?FQEFDK!S@,4YIU!`KO M@B'AL+)1F.*G.`2S0(,T)+3DU8(;'?8H^3Z!"7WUV/,3`>MVZZ!QS4#BJ3!, MD_'>$_A$8!"/>&4BYT"*C!_`ES#G$0W&B)TX)FD^[JS82 M0DJGN+:)S(K)4X&C,K7/(!P.X37X_SW)G@B)-R`R_PV)Q4[(=Y+V0TJ*62&+ M']CC73:<`KX"8#`XCP1$70QC2L_]*L".Z483#))C8+^ MM_=W_5$2$?K^(_@%\#?Y:XHYC')6(I_R5N-D0*)N4S5JVRS`="%^8C4!AP\O!2+!N1B'TFJ*'6GT*P[B< MH`04,&";`-YH/KGA%%`XWCRTG+0TI"&P*=BO$>UJHUE,<0$B% M^P#)+4;U>_>N*V0I">@TG0FSD$0@3]/T$=L)!.2\GY46!^9M)P.6R!N4Q\CR M+HLNEGC8@7$.(WB\A$%$'DF$?X-ZPB'W`SJ:=T21+%`Z&5C3>X)-)D'(AH%9 MQZKVCHMQ3?3^9Q1"A!0GI9T!];]D9A[RD^?"8)KB?)S0W5M?'SS(OJ(6:*&3 M"D[D8YA,:32;3\$&3R`EXP!D.*DLL0;,^ZF%"ERM7:P/;5VV/:3K7+7D60*9 M:F"Y]FB9B9""9AIB?CZF\%/R`/XX/E8HZ])+C@NFS/WQUO&!)TA\38)$T^S* MIE1G>D1)?V5^1,DZ<=I!23WU"R^>4*TMA+:&HZW:SN'\>>/YKEZ: M^I$#JFV`:AQ_.'XX?CA^.'XX?IK)'XZ?'?SA40@7NC<@=,U.[2`XH"J!5`L&2POT,#A5`^<6.V%]QQ4'%1<1W$X-1-.A^BHPY): MG;X$3[/"G]);%6[QN@R7X#-(\)LL`\7AQN%V0KA5DA)QS'',<IJ5EURW"#V-4[`3\>XQF1B`VR= MH$!L4X0*V_'4RURX3E7A1N'UH[AT<>EJ3^)R+F)`R4=T>L[A,<)G@,E%MIVHBEXF:5B;XBF`3 M5@0OC''[GU,[(1/;P+C&,*MMB'O!:,]J2V*1N!#KR?6C*=;(#:@0L%8P2'@U%JHD,4F#B#T9#,9A M'-(,2_L]DGF'22HD$U9_-'Z8_Y@3,)T453;[44!I.`0(,UJ@8_;^)0)9.DS6B3-;Z]A^"M+!O',LVXP, M_$R&OUSU/)SG?\O_^\6[$L(!_!#TL_>^I#L]5S,D_0]5C']"%6&$?':X:./JB&NHCG^J^M%VJ\LERHK`)W#JR-*)J'-E4/ M;6B=ON'!+5\XR):<)VY60-*\Q'2-XP_'SY[X41J!GX87U^1:BFLIKJ6XEFIT M\2VNI'A:J?I!R%8;>(;0,^BT-PFWY43(1U5]#=HH/.9^:R7_94?P2)^,[TDJ M*!);`CY^ZJE6'[56%)Z`83[.IJ'DPNQ"[7:S\6C[X62P:H.NT;OZ^H8<5S2M MCG6.R4)6EF/_):R+OA)UA$PN39GF8YMD;GF/NTKY@OB*RT73+4B#_-=C\K8, MPFLS+I<9';Z33A($RJ'4H_-1)";]6`'4\.3RU[F(.-1TL\6MK?I$W" ME`SP2'D_B/'@6XW6[0@+]O5&\XK@Z`%?- M..?>7%[Q.._973N\Z7L1<5YCG)3&Y'=J"M)XM-90LWK::*TI<&Q'0-88=:9W MC=JJ5G%=ME=RL'TSAYQ_8#M3W=20G68]]0U0$L93,KC),WTE\77<3\;DMX32 M7IJ,-S[B35.0KML1O.9FFMVRE$J?2'8S_!)\WYC_YM^8_V9`^N$XB.@O5^^5 M2C8JJ5XDGY3=?%)5V^R9LN)9MFZ9AF^* MIH5\,E1)UGU_3>HTW6H"F^`I?S@D?6BP\?\7BY5GJZZG>R!%/=?2])ZG:H7V MZ4FFJ1MKVFNN*P.\>Z(E.I:GZZZAZ+HLVK;CZ;[KK`Y44?>P)V<9Z#,B+-DX M2--5'5O"5'*>9_MLH*[F.9;KKZDZ1=E#U;UXI).$!M$_P,><7+-LHR#>&QO> MIIA,-)O=1@%X)?'`_VL:3M!#`?%?'OLU&[NZ=>"ZZ=JF8:J6(RNV89J^`SJ? M0=E59%=?@[()"FYUX'50?2)6`-ZW@UV4?5^R+,UQ)`61;,F%5+NJ9(MK&#`U M<4U_G945G\DC@1^V2?G7`0F_^M`HFSFSWY(\RZS]/:1?:39)O_[GCZ_%.[_F MMNZ+F6HK9\VRQI^J6JIH>:&+?E41'L]9L MC6B9:TKXA8P]VL2<@^^_$0QL[KZ%>'QTB?/T&=;KHFWIB@M&7;$<3?-LTY7S ME)N.Y7O6FIPTC.=*&WFN^(KI]`Q?=PQ+TS1#DAV34L"3Q>3]-\WS-TB"B9'K)ZFB0[ZIHP2*(L'VPUGI^8Y\:[X-1+DNR: M/4-3)5<155.6+9!WQ[=+]+F2XAX]R6Y-BTFKR9BG\8"D^+*\1^_ZSKWY].7Z MT^^^)]S<^I_M+]U26?SY MMFB:SG^3?OX)4^Y3$D5"F%&!Y@I$I>G( M,_,G:0C?L%#`5B(#Z'YZ_R>,&U\9P#M8CANL!9#$N;XK2Q'@JW'`T'#`&A=E M`3X&%%@B,&.3C_IF3!X"X9\DB.#+=?P(E"4I[<#'?E=X=\7^OF)CA(9CH#`C MK*>(=9'$T2SOI\@SC@^N8>J0"DEKZ$1*@-MTV+R%!CBW/1P=>@:,$X2$Q MJD.6^CTE#],H`-[,A&`R29/'(%HNJ0!ST)^F*3`[6D=>,M>R0I8&,1T"22OP MJS"PCKS_)V9BA+::#5CP@O@1GV-LNWZ<#0+E]('$? M&8=,JH@O2'_2#QDK&2JP[3:-T!'&)"NJ?4",F.9[$\(0+W\MEPL!S3&HV/P* M'+N"8&/-$J!U&F6=&J%7'X1-:` M;7Q;EV]1`R1P]%*UH+7B>'+DF/0EN#63K^A7:9%6/.EB%-J MC&[ULT6W=V22Y:E,BTRFST2XRS%%-;CKH^^T9X"'4(@6,6*-L=V^RH=$Z$G4 MHS17L5Z;#9,ZDKE^QNP@&O-@DU5E&BQ%4W-P%X'"EAAS+K@;XDLFW?.?$3X5 M?0EZ@03]4:X?DKKBJSJGKZ*BYI$T:&5*BBC@?I;CO"O\/J^6".(1D:K>J[CN MRQ(4)P)J8%+68&0AV6RKGBSB"+;NC'V7TP/J\IIM+<?= M5?4K"/T83!#6@LP!%10=8&@3Q-,`[`KXMTSKX%('T+Y83R*EAH)VXV0`H28P MCC$:E,@\ZEUZ^]H24OXH!4#CP&$.;WAF'FW<_6S?37E M!&L%>Z.H06'P_F5EI8YIUAS#8]3%8JU3,M]0&K:0LS?E9HV%??E:1:O7*IC4 M@%9$1H&>#+$**[.D$7,>P0F`F'U(0"FS*#\*@_M\!W!>/SSWX0=5(`S#%#RQ MO\#GRO(=/>R]6$O@"R07O4!R@L7Z92RP[:0\GBS!&9*YRSY@9P/@L6V,&`4P M^?<0C"P['PPA,!^40-CY$%1PGU^7D>@>&"'N2;;R=J^=85C*P+B8IX^: M%!3J?5;N>"\=GRF/O70P?!F0,IXL(M!'>$$RI2A_*NR[@7&"->+;&#G^7QK$PR9O,%'(*A*HX_3$."J=F M2=ARF[PJ8X553E(09ESB@[Y3RMYU/P5##XYK0>2JG.<>[J`\H+11WMDAM4D0 M,N,_G.*A.+8J^N` ME.0I1A\F2>?KR'2%"&@`K^U-4SSQU$'R\0WI@$T(HWZ^7IN_&?D^`;^F/^L4 MLT%)"BX2^NA;(@&3<+Y[D?T)&`:2'H[N6RC=>I7W7P>/48 M\R/$"/&`WD+,0C!VNLNVG4[>=3?/,57=[CFRY#J&HOJ2YYER<;?7MT5_[1*B MJ:^V>KZT?=#=6C[G7S-A=Q+J^I6BVIZB6;?JRH6B:H18W M[KJ:+KAFZJM]GJ*JJN]`@*> M:[&K6`N"-])R$+GKXE4E5U8D49)ZCMBS1=&4),/V_#+!@*>K MTC9RQ:YD'(/:=1PL4>M*6L\R>ZXDJ9+LR0K0K.N2);NV+'JFN8.YVE'(79>Q M*KFZ;(J.I!J:Z8JV:HF2)3J,7+MGV:`A=I`K2J\BUPLCMES_0O#*EFSU3-TR M5,7V-%_L`?7YO1#3Z9;D_3;-N0]9YZ("I>1_)NN5,,$\BU M7%44O9[O:U;/RTEVW)YM2LZ!_W=S=_23<^I\%]^;CQYM/PMT_[<]^([=)KV-PKL?! M(J"H'%"Z9]H5/>Q!`5!O M0T!6G'^OOB;&J8J6SP3B,_..63HI`6O5%,_\L>]T`C%9\?WE4C8.\+)) M3F0PS9+RASQ#'OOE*1QD(W@:&%&D^,(P/)A0\J'\L+8VOZ"[FIESD=E+WYAV M=(_DGHR87ZY4Z\=GDX8MIRXK&DJ'MA-/_4(^0#[`)@ZP);G#M^\6FH<9%/.% M!F5+5F>CV26,GK%O+W1$V->GW,3=)]&@W&Q-"1$^)NQ(AX]'.K#K3?D)R\S% M+V!TPV#8N)RQ'(@+(-Z%WY=@*-2%PY;HR&VYW8VSYW9O.E`;S3F.L@-0]ERU MA6.@;)VO^U>?:1NC.2@Y*)O%Z)88Z:8&,LW`YFL\RM>N+-993N7\&I!KO48A M:_U@%4?6A2#K5?:4*S0.N\N#W=[:[F5.&XRU206DCGF#Y=-TG)_5_"#D65_+ M7=SBLH<09/DUGO]G[UJ?TTB2_/>+N/^!<-SLS45(WGH_O#L34=75O>L)O\;6 M[<9\%)W70CL<)0.P7;41EC':W11 MXU#C4.-0XU#C7H;&K1XZSDN)[$+7'CQ0;'G?\WRH>#'H7TTZ[XXZ>3>FN]TG M^\P*ZQ)A5W:TZ"$=$&IU986HNHQC?M\V3RQ&!X4VX*ALP,_L1+#*C@DNJ_H! MC?]_H9%`(X%&XI'[I"AW:\!``6T`VH"78P-^YB?*2@P45@D4MC:AM9-RQ39% M^"[-LC?3IG[3R:P'DUA@E(O^=/UNMS/MN9IFPU7J%7<,L@UG:2LMMJTP'UL] MCO\T.;B-LNK*N>L*KR[:N.U@`.O="-%57"U5>X?FRW#0"%P$;H5R9)7%Q^A2 M$9F(S"JSU\H6OZ)+K3CG/;+4]KG3[NLMVMR&&3@X-./$-=:CM^@6#PX/^20N MUUB;K3+U0\!L%S!5[5C9PFRGJCJ->P:3Z'H024>'I)_YB69VKW[I(!"($XH; MB_"N%SGW;4^;E&/=9",$&YR*J$<\B@5/!"X"%X&+P#URX%+-$+F(7$0N M(A>1BY.,^YAD?*PS3%VJ77N%N#&5S;+419.P^EL?7WEP>/B9G4A6>3?#X_9= M")C]`J:^TR7<5@:E@YCV0->#2-K:Q*,E^^UJ\6E+HJX;6^*U5"$Y@IR9&+_Q5"$)D(3H5F. MCH7!W5#U*/8@V#6T;VK;:V39^POF69I#0 MO"VIA_VYJ``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`ZA'4([M$[`0RH[4J'V0X\!#QH: M-#1["WC4]BW-RPAX-IP]VTWEY\$#\W?6HP\X%B;K:]2/S.FA_J#^H/Z@_J#^ MU%`^VYI8H^3@5R=]'`=+O6_SR\_O3E#9WM$I1],JFKPFU;7/J7NJBX65&MCX M%X6MZ@Y00&PAMA!;LW4Z4MVA7B^[3H?00^BMMOB(H%L[IAKX-@48EIQRN;?C M+=>:S*OM4;:5YG'+SOPYA(:FVXY'T?0]B$4$8H(Q7IDB<\4W0MN#HY( M1:36(*E$I[F]:$F3PW<02CZ[DX]V62!ZF$3L4<2$M1>V]#0 M/"A&88M7+,BC'4([A"U>,>!!0X.&YK@-#;9XK)T3H(G0K=:L[[!9T[&[U(&KXV*+VN9.1-6[QA2UJ=QH/H^_<+Q3WC;:= M99X(*`34T0.J_KUDZP)#;!>+>#NL'*\NR-E]*O=2=N@]H^GKZ1K]#E;0.NPB M\PV[R%1L(-7^Q7D0:K?MQ`#+UV@BT436ST1BL]=#2?70@J(%10M:2PN*S5[1 M@J(%10N*%G1="XK-7FMA05>KCEZ![>JF>[">6UWJDO;Z5YU>SE@>U[NJH MX2E/C-[2FF*$)\(3X;DI/*U%[XGP1'C6%)Y&U6`F]5C@N>&NU<-/.,/ZA[-M MC,J#`Y\ZH69WX*N+BFS;!:*G>\F8VFTZB)A"3+T$3.TRAT-,(:9>`J9VF7@= M"Z9F\JL_#YO`X6/7[XRP&:%U.[WT]+)8NO2&,O+3G/[17-NJ%./99=J`M#EM M#;.\%5")R!6?.Y,(8OY8S=0)7;/JZXEF-+Q^_N,]9 MH]G+NQL5K8T:_?NU78V;=``\_FAU1^VT/3ZO8`A7]LQ?]07'C\'*0IJ?P_?"R>&?6^3'Y!+=T^NVLD?;R-U7"W&^C7GIO M$#DY:3!"R\>9K?/HD\9YVFJ.LIRC%/[-TM8(KNVD6>.F/^JV&Y?-[RE#AM-X=I\?Y&IS?A8C(&KQ?;@OXDG5'Q*!\7RP#-07=_MM_[UZ[__6Z/QU[O+KJZ[_=LT_9QVX=7M=YWF M>:=;R"P:#08I#$+>:0ON_9Q>_/(J>0N#)7X'EP0@Z%PUN]DOKT[YJT:G#;\U M6\/3B)K(!9V(8(.+G8MMB*-8.L^"2&P4OVJ,>IWQLT99^]6OE#/"`3_B2?H#L=I(3440CB:6F6#$A'XIE2`E^AF37_?;; MWOND@N^Q&(K1 M#++GB0]CXO\X"S,4,T5%(KC3)J;!&R:Y&%/,K7:6T5>_/G#>L[;WK',%-NQ# M>M/XW+]J/ATC+_+]54=,FSB-A]Y\!%YND%,\?GS\^W^_/?NC\3X^^_O'T'C[ MX1_QE[/W\8>S2N*>O,__-J/)W'MU[K0E]R:C'JA'L2&@67BTBPNP2[F[&:07 M70B7\E:*A<^!BX?PW.)$[/OKSYO=9J\%GNLR!18C0`0LS$4OQ^3S]UNS-=+"$ MD&"01W@`75:\J),]=Q3ARF:KU1_U\J_SR&.4Y4_**4@+"]*X*DQ(`TB=)2O] M`6E3!C'?MU[G`M*GXC47W5$*@PT!U6@(^1(,=*\_]J2#?KZU1SN3!T>#4/+Q='UPM!<'7;%R'^`4ZDN\VAF11H! M\6([Q_;NF#"Z0B9VIT8A;:5Y_#2C2K3"C`9@Y,!GY"_-+1:19M-?G\1>_H1!>MT?Y%\#2"?&`O[*'WB7RP#F[Q_X MM!$"8S8:`)?PH4`]7'QOW29&X9[^^W?-IEY+WC'-6B%+;/_"RG42>[+!+`BY"> M#]U5'F;,91OC9(/_-NK>TJ^3>[_FU[[M9AD7YO?6\VOG_L9O&XP M:+;2#_UA^KZPH'=WC4_C_#(U(7X<&WS)PT[7:]^;PWO2,W\+'Z[[6;/[MT%_ M=)W!([JC/-2>;13^\&>>18NG6![^/[WXRVTP<%<0P(90Q+!#C@I%)?[8>^RFIQ/-)Q-E;1.6&&*X M2.(X#M8;$PB-J&-!^5*B/$/T4F(VIITOIMW%+-()U]H)&[*MRD$)VT.P6NGX%207@IYE7*>,?UVDO2Q^5_>\+Z(]=1)-`M?;, M.4,2JT@T+E+$L9.Z1+_DAL[3OYB@#:GGBZFW01+%=$Q%%%D?)Z#Q9$*]BSPM M%12EUG:'U"_1>PJ$ND1Z[W1$I".)$J#NTLF(1\Z2$F0I$5;N5OB+R-?2)HH& M*IF6D3>)3K3+R=>"[P,H*XXN,`\N+._Q7F^G,*MG&4 M?D@!+9_@&X#-EW3PO=-*)[]\&O2_=[(B?5X9&S1629S00"3W@@%2^*34&'NO M7%(RJ8S3>08WIGGK(E@",*,<\"JMUL)K%D<.-'0B@H0K*AZ*`+XRYL!$L`2E MX%)!J;WQ7(*M]X%QI\8H%81*4;*0$,Q1R@Y,!DN@GNM[E'AGN)<<''1$M!A# MG3CK5!GJU%JFMRF#<1R8^\UDT+^*QF$<^,[[.&YEN$M)K:`V$BY(&\YM,)]A@!'VB2M$($XSNG(DE M@!,L\=1Q'T>*&9DP:D*L%(4_>6"1*+E%*<@^QF$1"Y%5E'%PBH[%PD3!TR@9 MLQ`+R24O1X7J@6>OG@F?0MZ;CJ\[RX]`>M_I]2&!O'V;YS20\H$;GG_*LV;! MG@$L8X6W$-_8W))";"P@9)MH9=#>E(!%]8.9L!TR5R.I+L6Z%"%82)9TPB)' MK0_ZSEQ15<8ZUP3%NCPHCZGT(A`&F854$;&!\P*Z@5D&7K#D!?BJ!O08A;K$ M'GH5:Y98S604&1(<]2&,A1I(\+P41IXJI@Y&5^_J29_Z@_P+-QP..N>C8I7= M6?]#OS>9&>O")5-:5E;+H&*J"40G1(7$`/*)TH:P"U%]2@=%=YMBX=]ST#6[=HS3F'-*'9CP1$@`CHGO8CGG](-:[71Y(>@- M>2WX*I*8H[)B%LO#/,NB3(3C%-R]\8H`AQ&1TZ)B,-J%IU@DKZFL$8=_/,TA M53YV2B56;0^85*>MX MCE2FI`M1%),%:JIVRN)DV^]:BFJDM8(JX?,@*O8)>+J\`$N],PD$K_$"114K M\CA+9N5<+K8X4>14H!!ZL\1#*ATSXTW!I?>26Z:KM#A;97,Q)HF4D75YR4EY M)I1F--`))AEP^Z1A70.3VQ[,!5P&PS01L;0)=Y&&0"T0-<&E8I*Y*G'Y7#8? MGP8N2I*01ZQ>,H>87&HN3900'HL0Q]Y/YZ1BYTL1%1-L09"PF+@JV5H2^[@$ MXD&MA9&,,QG#^!$S80MRD%!*0.C"&LY.V5H4_YK(\P1H=4I09Z2C'.)?B.@" M6%7(0V[?JNXJU@I(ZSH.12&BB621$<%9"M*4C MHR3W6I0K2D358BC$\0U%PIQW*H]VC?9Q)#D@/!\*``1DO&54*+5H:F'G0[$/ M2;]+FQDXT7]UNMVT/2?K;(FP30@,;(Z`;,I28P*G+(QWDT`<5XK!P;1J7BL; M=%C2=L:"J6>-R M7I2`>I27Q#B"[:E MB$@4JP5UP36!7AW7F]1#A8BC?.FU,PY"21L[*FQ1*8S`(UJZ@.\-E+R:*M.F M-5(K8\*(5D1'7MDXB1-?E6K MG,"`Q1*4V'I!/&4N`D6?5E.#*\=O;%&TLL:"CZK6P*DX$E8J3KPTL0Z.&^ZF M#IC9Q)=2%;FH"+1-1I8M;8PBYQ/E(V(5,SZRF@M(\G7,7<+<(QM>&%VT$F7+ M0[(P5Q(6\D?B!+?$""&<9#SGQ+G$"(@;RD.R*%=:@1%`TF2'@T][Z45GC24N MTDD!^9V*&$2SVG@:A:DVQ:+<2.<4TIK'TOT2)6N2NVQE=>``6QT'#8&7@,A; M>GD'8N9+%5`M'U.9JHA=HN`ATEZ"WZ0L)$X%Q2)N)FO=O8?$H:S@\M%E'A7* M=A&Y4B3.609NP!H*X8Z(C9EL(K(A*B\UYO:Q]8K/)3;-/C4[;?`'*XM5Z4"Y M--IY*[QQ'`BTX[P3-$+2D@Z()U3@CH+5*5RV[MSQ)'%<.VZU-S;?U">G%)*8 MEBIH_(E17T[AY[25=K[G6?%J'86"2R3S`L(\9IF2PC@U[7U$DYC0$H[$$Z"? M)6$M*A=U:)(D=H8+0XV+.8MBH]DDUXR8<*QD5Q_N"GL>E8.\4AK2\?]O>V[< MW62ZU38OS+9:@]%.O(\MH[$P@,J)[Q::5UYEDJ72JE;8/73(+T&,(7T(AT,TO;$ M1L&C/N8M9ESV_]Q=6V_;R)+^*\*^["Z@&&PVF]W<`0[`ZR;829R-DW.PC[1$ MVYS(I(:4[/C?;U5?R*:HBR^RX@2#F7%BB:RJKJY;5W_5%L\(8404!)G+,@C# MT*!G;I(2S6H(<K)'[&82;L1=#Q!"30#B>9]8U%6RT M&XDW"CQ?@=5^8S^=(TCP4I$%64S=5/C,86E@.!*.2\?79BGQ#_%DT?,BT@^= MRF<"TC;(`("7OS]&U#/==)`LX@ M-!(>UDM3[<&=3$2;927PX+XW"C7V4O12^@^UT'MX!<%QP)T3F@4A)6EBZ$^X M/[J&](Z.0I`7D7]1+*X^5.VZP>-#^&K1W#W]TC6A7A)!],Q='@4TH<+AU+BD M-&.C-AS.#ZW!-K*.P\HARY2`EPE$F'C"3QS'C[(N(G0\-QU%KL(]Y%P?PXK^ M[?,`$N,,DMZ8)22AKAM0%_ZO#UDIWC,(?Q6`Q`/8AA\^77S[$GZ*T\G'\.O7 M],O%44`-_>-A.:L_XL?_JUSEBW*FGO2YJ:^*MI6G\1,392AL/>F;K+_K%.&M ML=;A,VH@K,E-WDKDKHZQ1<=$:9@`U=40Q(AMA!A?E>H=F,Q4\\!D=9.OI@A' MK(`<;\IV53>(ASZ9+?+RMIT4X,:;4N'ZE2V\Y'NQ>$``I\MBTJXO$5Y:`QB" MIY'/4[A<^NOX?(D6AL^1<)'JJV4U0V#;^=EDDDK<;4141B"@B49"FP[Q!EL\ M+"S;&P3UFMS?U/#"=_5]5 MYLW#='+Q/IY\*=OODSAO@,NFG8(&S,XF_Z$`F(3K.G_`9[H_D3_^4T-2HOC+ MMEU+@I;P_IF6NY2N8OXVGQ>3_!J17$`(BX6!58L[++/-Y2BK2;:`!9CGT\G7 MHJI`I`4('C7U7W@SY9]E0<*H=>V27"#U2][A<(`5?+]7VE+C^QV85-]6J!H\&/U5K_-_U=5-<(["A5M!>'4^GAT?E M4>^YIK@%^6HPR.LU*VY3_HG>7:85$&G-3L M1OI@.9=!HN'BWZ^K#L%RKE3;,M%*8JW]&&6EMAFI7U7SY?Y%F[["5"BCB+F#/*6 MA8&+QH`"]M]?W12#','FY]CIHO#P<4B/0L56'X7G5,81UVL4TG7>R'?@'EK6 MJT*FPM9NPSUUA^DSOEEBIJK7@GWJB.L62AH*FR';4`Q%KK=;MVQZ`$"1SPQF ML9)/;KT3WKB6G':CG^P7V_)6DJYZJZ5?-W[+?CSAIYCHUYYJT142[O+%6@VA M0`G,B[_7.(-")K^RO&'$C/HP@5^"9F,.+74!D^7;\IV*P3>`U6&M5YCHP[?@ M2%#*WZ!67)7-K=05,/?MRL"7:WI*-7U+%D[T!**E0GKH2&N4-SV; M?)0EN;JU!@3B3_CO)&S;>H;AXK9"QO"+NIJAR`&UN,TK\`MFZ@)2LL0#G:8C M#K:'44]#:[Z$#;1L%"2\I4TV'UIYE,)(K;0MSG1D MKW+P14VE2T1R_WS,'R8:6-^SXR=;']:M=)]E;Q[5_C"RVB$+C#YM86PWI]/. M)&H+N9\;1;7Z+_J'B7$+Q]MFQ]Q6YUMVR'!+U)=J2RC^-7>@Q;UC43,'\OMV MC1+MBX(JL='?F^J2FS;8F.)LSDD91#W2_LJ4$4W@8#N:M_:PLG4C*XA(*(XP MJ9M;MFD:=K@P+=`.;8+]]0/EH M?UD>0(5EZ-XZ2X$O.C/S7GK2I;&X*XO[\3B9?KGTYE+"M'EL'L`96%;N;!*9 M7;9+X&,CIJ6E1&'3IE0"MX9$VN]?9+F^1AY=VIYJ;%&U\34.3KHL9&E6WT+( M:Z;9V%X-*+-TKJX&+T1';@;?J-EF^FE*VGEWF:]_1K\RVD2H4%C1I8VU952` MFEQ.\2EGZT7>&'MX"S;JLI#KA4)>+^\QI(`/S^O[2OV\U1&%E=0]>*X/OJ3/6"\4[]:X(&/2>HNL_!?&!U)_AH\SK]GU.!T6](\\FQPG13VVP0I_ MEPA_:&71=U77X+NE)IYL,M9Q)E+LN=YT8F7-GU7=IPMONPX17:66:ZKG]EJ__-*5?J96 MOJWL-<2037E5%J8]`LWR`DB9R48)=7^[O9'#IS$SQA%GVVI*?6M!5^_:EV`J M_R'?V(?.@US"^H9^_276C7"($<;L7>$+.RX@;[#2X:T5KPEV^LJX>K-6,J@W MYZJ!5=;S_MZL%)ZRHLR/>6+[6PRE/*W7\[Q?>9SCKV!^PP5:ANOAI-Y\ M_M<:0T(9"EO5P8&1VGO4M2WWE=]X5+%U4,:P2J_#2J=.T4WH#T!8L?K71Y M6(R8/O;EZ$RPV'(G"US]W&*96]$HOJO%&M^) MHXEA<2>X1%(9]5.V,'HV267%\":OKOLRCO52ZQQ/YG3S$MPFTIS+ILF=S'<5 MYVX4JUD^6&YXV+)N9<;8I09&\/;$[9ZLKA2D.EN.8X.(>/4.!-7=^[9[>O^% M6U];>-2B^[KY7C2MM9QR;FI1M;JZ:[B9;O3?CAM,AT7:V^6B?BA@&UP6L_RV MV&A_U%V,TB+,B]MJHU-I@1/']8S>=^T26VYU*>"ZR>5VEL"`I51C M7Q=@,[`&8M<14/<.<5O\6"KH-'A5B;I:[W@/;LK+HJBT>[C5[@&\]#L4TZPI ML:BKC9QL4#WX[O:A716J\4B?;#1REL1T+T=&SB"2O]8R3+_?6&'TAXH">\HQ M7A:?;(OE'#K![&6Q_9=\MP5\M";UR]B="`P:QS=-MF1H"4(NU[?:RZL:^[R0 M=2,L^U3]Q]5Y.W`XM#57BN'%0\^3#)L<`9]J9#3Q&X30HUJMU<.(/JZX6LOJ MACJ>+_%6K6E"_K;9ESQZUDCYY#E$V;2G"WZ/VX[_JVN-O\ M1WD+>O?K-O\-#1>N?ROC-(AU\`^F7M$W?.H#313%,A]$49?%HKY7<5NG/\/' MZX>U.O)6>]:<8HXZW_L3]T5/2[K[U\740"3_& M$_01\>F6W16_9$+ZRLUE0Z>K?*RIM34].,!C%K5K7595(W`<2SP*K=7.]T;_YR?,H`M&E['YQ+Q5PC')`NAIB)2,87:NPL3!>RC1U MK)>XNJ?;_OR(QX5+JU54..P/DC4_>.4! MVVI^MN_A[[Y3O^/V?0]:`;GBQWRQ;("'>$"\]U,@V31&F:^F2$0L-?2+P: M%J?16IX,X49]7S@)3Z/`X4%`(S^DF9DVFR3.>#BVMXF8,WC_$XD[`(<7IPF) M:B)\>`<,8)->:'H]E'G2`R=)`E!Z80`HC(G4&AW+@C1&R'2$%<\0W;/!8W+ MN.-%@4M!)*GGN1X73.]PPD##1I!L!"%PMU&W`Y'M`'4'5C8D!%%)619S0>"_ MJ1L+0YT3N6/9^6P3G70/=7]*3``<"`'A0-@T6*.7QEWCLE;7XR*$3[S&4N,.1$_JVOQDUT4/CQ4$<<)9ZC%,_9$[@ M"(V8%6:AP^)_^\=G]G\]7\\@_?B\@^3446>2(A ME(1>["0T>)M`VCM>2AYS*7 M42J"R`N`]\!@4($W93Q\BU*`C8B1U:/%\*F`WSZ]PJAVZ\A,)(TABBC:,T81%$>R'B,O-$:4$E`3< MU#\^D^=(8\C,*PGD.%8NAD`FY#@BE";@;G!HN1FA@S,UT*EPW"#.-SA4Y.#7K#>O#V/(3QEU@B)`D=@0X:=?G,2BW"PN>!1`O MOF%FO/^E>';VF*65`]D^GO>?7%^VQ=]K^&AZ!__Y^K`LY.=V_'ZD`N`L,\*C MV'4@>O5#"*Y("&D`Y%Q^Z,MM2>^1^D$([?W\TH7F0B?K,X4[L,)JQ($63 MX@M0/T%3B)Y>Q8CTO2]A-;]80>(-%G]>-*U")7]:6AT[$-0EB+7/`R?@+FR7 M5&53"75$,IH01"CGWA`,]A!!+R5_7UX=)HR3.`H@>7$S$H-+(]R0'V7;`$^9 MOX'T^&SR8W,7]BGR%FF4@KR)PS(A7+!-F0%S3XA/R0C/U'.)SW?1JREX.H7[ M1"I"RGTA4@**P%Q/1(XP(F60<8^0&EE`-^8P/(%"''+_'"+]V!<9Q+5@F3CS M4LICHF&G$_QG--N14\Z<743V1#R+SGW+[60\%)R[62;2-$@@^2;,Z">E\4@_ M!7$"^@(ZSZ\&LPCWCR)\EGIX/`91`C]NYC#'A_T7"*/`PA\#PPH<4[B#H>=0 M^\JL[UO,`-)A/\#[`ZD#D7(6NX2:G4$R.JH\$;HQ1.)-L/Y<5";!KR^`?9KOA"ECH2<"<.PD"2*:<:X% M0+F7C6S."5A_R.HFDS>4/\LVC<@=+C3;>(`=M7TI M[NK%'0Y3'7QF/%/UPZ?,KMU&+E@TP5CJ!UR"Q?NZ5D(=-V*C"I^K#H@&@G@$ M:R^5AEG.5Y0$A%$1\3S(`V-\%^2&`G(!FH4>3SW?X^,Y3.PG2H*\6!+]IS`@ M'WSOHVI,.R0QEWDNS4@"\8AP`^:01`^:I)3XJ3,RCB[_*1)3-M[]F#^\7&B[ MA<$#L)(QPO`'61PY&14^,1LI<[.1GWRUC:07+ZJ;IKY'-O(E_&8CQ]@FDZ2X M7'VHVE6SQNRL+Z6HQX?732'3MD."\%CFBS`!,Q(0DB4N98DYLW22,!R=H_GL M,8+8Q=6&/.KJ&M-(9&6KHS_([([5-^<8X2JKU\WGNJQ667E7?"X:A#X,+^N[ MXL_RLFXVMA;2L]+TC/+L1RO:.]\NZ9(,\;D-Z?Q0I^9]3DP.CP0&2>%R292SEQ8QJECJM+?92ZT7B@!H>/ M_8Y">Y[*N2)):!*+P'<(I,6!&_A&Y2A6T+>'2D^67EC-85?CI1=9#SJ_7)37 M&F_A29$==7V>A$F^=,Q9[# M,Y\QG)+"71K&GDGXF4^C457"HVPS_7@U3IZ53)+(%5'F19`\!)1RAT5)8/+H MP'%',9;'-IHLGD3;4=G:6QZ(2<*=S$E2G$OL>)'PNGIB$&\IR#FP<5Z#+VT< M\NLB4O`H6?FCF!M+\@4;X`^8J*:\R_%Z;F^H<*C`P(C8C[NXSY>'(R-"HX"Z MPG%]D%"818&)C-P@(K9T%&"5G-KK"[Y=/(=Y/+I\]H3`GA]E"?%<)X681PC' M)\:Q$'`VR<_D[9]X@?AR43Q^^;=$Q?HPK9K7E7S.95Y]/Y<->G-\WJ&U=U@2 MI&",LSA!&Y9Y>"*MY1.&<;Q=/AY[I'BVL?@:$MK-8!CY+'2RC$1<^&G,DH@: M!7!HZI-79]#JA^L:YD+9HQOKBV]_RO$!.UI_^K674+&-O'[^*;\M^M6_>!^C M#3!S13Y4LXV0XT+#09U?;2-&!B'5_"M\]P-V1B-<2#,P*/;=;^L)787EH)(Y M(N!!)'@:,D%58"_L`*+ M1!"6BC2)`I8&@>`D$5TMDHU;3W_)5?AF38!(]5B(-[8.,:&,<(8E8>%F0%@6CQ7C9W5E-);@?D]MP/9]%PLO/G'= ME+#(3R@QW>$0X?-1Y@)J)![)DDW7<7@YT.D.YL6+(1-+21(DH>>S('8U+X+# MMT>\0/[YTW@YT#_M\LR-A>]YE$8$\4>\4-=_K*J]RKKL'<\= M$#<.(#"..*=W[5'5GN66MKM+GCQ0$+`Q'#YO,B/W)U*D307(K?9+)F].WBPZ?TXLT- MU%3X9B4XX;:4Z(3OY8U#^>-%T=S!GNDF#:SJZT)BR$C<`CQ:[B8M(@JBC:EX MX(DV8**!+NV_O'&76$XQZ&Y2(MK5NY7L%<`]R.%!LLH2%D'?B3@B: M+!?L.)<7)1)/B]!DL(D;^+BYMG=1K^%_>;N:3CZ6\_L"?\!K?_+O\8]GN[%_ M]:@U,T1A#JMH@U#J!:KQH#U]RNEWB9UN+< M6IM_;W<`*1N1;IO'V8T/_0#!7E[AA$XY\W,\J?/_V;O^WT:1)?_[2?<_H&B? MWHZ4S-)?@&;VS4K0P%Y.LY/9F7W]5W8"Q\;?!!*-_,%+N-!TV]DVJ^LK.MTE=+!OGU4=S^; M>11>-JF[!Y3)3'^E0T_Z_74&F$65A3JL>LCJZ0K[XI[;_4#O/#0H?[$Y<8R0!T7S5_#^L;W MZ7!\_8YC[\@CH\COX=G9^R,"A.2C^N^&^O&P=8/-+_ZE]>`%)$#L.L;W1*IY M9<#B6DH>L<.H)8=CT-Y1CGP^1:6:,-G^=77_AAE9+>5TO=#WL)EJ.K[W8G1. M/[9[@B98#597P?C,^Y7M\$LUQFJZK#:3Z=2F&6-5['BG`,VDY96)V M?HG:LM['#\?-2,2Y)DQU5\SI1*1\@AWVJP;."&X5<9MJ8LL0?U'P<\"B`Q;] MH%BT>91D[0:OIB]"'T^WD[O!JC_B`N[XLL!*-9(_8-4!JPY8M=F-.-_E/M2H MQM3T\@@,1/JA56^C`&`4YL&"?T/`',[OV([[H7M\#9#:#^&`X/*"LR55J5W.?Z"2A]ATHY10[29X-QCDV<:^&JVSE-]0,NBGV5_T6RQ>G M9Y5Z5=X-.^36,;7J[MUU4PLRY@OMZOAE\CN39J^SR[W#PWN9H` M;'?7C<6X:\K>" MZ];@[84`R*8SX58#]R,?MBCIQ-8TVMX`:I=4-JP"T66F]7)JXXP@_)_PP]FG M/\*/YRLEM$DMQT4^'N8@Q>OA>N347?>+@65:E8^WC2M.7 MAS:9'M9KW$[@![-!SL]'^+.FW\'1&UT6(=7K6R,%->A)\'^=B)#Y6U1X57:D MZJ/T4!%M!FH.HIX+#)^^)%F:%^?%1->+M$J!U"I.9X-^)S4(\.KJ0]E9QRMVGR,"Y2:&NY3 M.=O7;`S3"*^>?-:"K)FBQJ9P9G5-3)\@[>&PV*6_NL"9;TEI8IO]IC4.=G9(8^S=T@AQ]VEJ_Q4_Z,3IP=@.QO:7,S;13[2^H:U]B(L, M+C@8VL'0_FJ&9O=3?;2AH7U)AE?WZ>#;P=0.IO;#F)HR+I7AN MC,;/X<>P`0Y\9_R.&=L=V-@+SM/L*\_OX:!N_:YNG1'%=S`G-S=Q/;I[)ATV M>PX0C^H4\OCZ1TH5-\-R6R<.W41HTLZ#&A>J-*]Y7SDMC+MX-&GRS$V.,4O& MU2T7U^?5CVN=.L\]:GX-RKRIJQ]-YP3L5?Z.U6-*6A^M:Z6L!)"/U9O]Y35. MO1[%>SU_^8GP8X?3'L\A5,:\LIV6D@SFKX^,3U38,I`B"2]2+\DH?]0,OT^*F2T8]9GRJH2TM1`.H\M_E M_K+?*WUOW[BJ5$#[8ET,LZ2JL'UZG/[,1DX5/`2[;-E8K9C MD-ZBOCG*;^+B*LTTD?%DG-=?%(HL]8T._2SZEG'F6'_[]2(OADEQ`E8RBF_+ MY%W]1UM,>+\E`643N_"9F.81\:`BZ/V1S?[VR%"T^B'9\G?,VLL#'Q<&Z\J$ MN?!UKDRA_;FJ9&A_I=>:;A+:M_0;6^U=@M&_NTZ'H-/]6G#3=.(1P7-#+CM: M+:M*@2M)D-OO1IF/TJ%1(_X.9+E`?IN#RB,EJ#[>:URYR$?#)IX#I]`ZL=XB M2-Y<'2_BP;>K`J+TX4GE30>#)+F\?`8]G4>E/O7T4^V8/Z%C?O)&[PFVO%3@ M+T54/_4EG;6JM4)*6PI#*5ZOTEBQ+>E;+"]%`;:*REZ_6ZP"/&KVW`EJMRYR M/R[PY[T.<#0^^[N#K-I0&/2;LX.KV[.I>/E_B MWN@.W-LC]G,[B!?!B*C3IQ&]E'5^%EOYJWCJJ/L6P_'L:PR[L*Y>-__/:W;' M]+!+.[BN1\KP-+L#R\J+AYT8UPZ2E\]J8YSU:F!KQ/-2=.0EN[U#FF3CDX0] M"O15"?&5).MVFB5)RO*=\:%5=U'58CQGZN2E"*>W#,EK2H0LJX4Y[.`.KNS@ MREZJ$`^N[-?S:97=;9SVYL!F8W4&L?HPGV"9TU/V,M5-5075BXW^^SL@V%2$ M>Y;8#E(QRVLM=R6[5Z%*/7K?Y4V!]D;8JRT1[8DX_1$OG^D"]$&U"&QJ[;?O M!#138,KJHM0=J>99-C-E8JXZO=OP/1X;06O27WXY/Q,CSHSD>UJJ^6(=$6P5 MD>]WEL?BP3QIB7.3L$79@WKE8EJ7G69W\)=J-C)6==P_'WT.3\^/WDS;B^GF MDJEN/^Z&Q3Q*+)$ON07CY;:N- M3;566'H?CV"-A@^M67=J,>!+]:$9;IBWWL_0+W(,85%5HZ!"%_%G^7QI/X97 M^+Y'I1E9W9IYKD5HT^QS<:^^M_T,K]L'0,R,=M@"(?STROARBPWRRAW@PSZ' M9VP`#IDQR>H^3.UW.?8)!CV]Y[<0#'JY]?@^[^4^S?M7?8EN=QA5-[9L4;P8 M&+!G5:%'W;4L[>^H*OD8K6C<&@Z*.-0+R65REV3]K$DS+Z%6>=T1L^%.?3S[7L!$NN"U`^GHP=^,J:E1=XBQ4C^-Z<'CR'2Y! M[-&P![IEP#,-M9MIC9C&5:]NC]>"&1OZR8.D4?"^G$]_(-&=LNJ->E+%_HBL M7]6O9PVCFWIV)X%^#MO?AYZJI#(]PS*6<7G]2:OJT'_X6B;#TRQ*LSC#%_$]/1T;"SYP ME#TLTN?D\OU1%"!H_$G_]SPX,F#5TIMX5+X_.F%'1CJ$?P8??.+XCA^8A/NA MZTC']L+(=45@6G84NL(/K"/8_Z?Z=I-R>/0;<5VE"BWB-R:N/Z;X:J9<;MM^ M*'EDVA9QO,@)I%!)/-,<4'9GGF2P%*:3>"[Z:(_FD^3^-P35N3;S*66 MYTKFFS*T/)^9OG2E.<\G=1QK2SX7T;M;WMR`9 MM3N\:PC;+_.G*IO^-&4.A.58?B!IYT'.:Z/O=E2&5$+&Z%%5,N8[[;88I2QC?2W1ZYZD5/(S,@'HDXC2(6 M"1HRSVTXC5CH=3DECKOM^O6IJ+T@E`BEX_LFLVU)?!D%4@11@U!,!HN4E^^; M^;,ZD'B*E7H^E9Q9=F@#!T3Z'G%J..(NZ5HIM=V-&%U`7'],K=%=UPG!%B6U M7)N`KQ&6%S:Z:]F4=ORH;>^9I5Y,U(ZHYX,Q,D(X,<-(A):L$19`*NJL';?< MC5S)A@3OEODUBNN'G%J6D'9(0\*E8+9?6ZAG!PN8I]3<*%C:EOG3;)#?)!_R MRP2%.$#'!#2$D#!8P`MQ.TYE^OQ'D<97DR9<0I5T M(TD<8ED.(79%FN=&PNG$V6!P_5&VTL@C#L\WG=!UO1`C)\=S;9L(B)E][O#. M#D#T1=8:D%OEH!(IZJJ9+E>-'+SAG(0L#9H-A^93X8&.@F'K!0=Q.9\&7T;T) M<;WSML;.!).6@W&*,*5M0PQJ!WYM9[9'>$>9.V[A^?E;N2EV7!F:N%NT@I"( MT(>5LWW+Q5D M[YV]=?&(:4/\[#,A85$"3L$OF0C[(24BLOT.;IZX+XFY-<#"'4E-&W8&ED]" M84:^'1+%'`M<(&ZB9[F";$*]EV--:EW=ZV1`'$%TEY6G6 MOB;-!NGM*"G/@4U_!'=?OJ#3O9`)VX:0F`)H]VPF>"!TK,,HD=2C1[_-';.T MT\.O9^KG9]@+?3PW/"G/OGX\/_WXN_'[U]/`^RC#7HZ7[)Y?0SG-C"BY*"9Q M\=`Z3(J\+[Z1EN4D&1K3=3>^C.-L&!?#TOAZBUESX^H.#L1.;B:Z,.T,."G4 MN5B17"=9F=XEAK:27DXE]`E$#'8R5+:BSZ#3TIAHV12)'NZ)AVT@OO$#GB!4 MYTIP+7:NUTV-XXL=9^'V>P1/? MMEMW'[?(2,N:MJ$F21VU'QM)JF[<]`"7TH3X$TO0!/U>3=*C:30_3(9)D7,=PN]@` M"2?8]1YGJ@(&U;Q-*PBPDSR^3:%(NM0Y7BQ:JSDM>ZI^ZG$^;VVVWFV1CEK5 MJC,V^^6K^I<34QRO>-&L'^/\I!6H:10>-6+\THC1^/D\OP772$WKC3J8^U2- MJ3W&,^EZB&U8-X.I+V>V^>:=,;7^("T'.EN`]MTZX88?X[^-\E(-R`4JX.-M M7H*SQ0^R-@KU"4PA5*;0"PY,Y3M`5YE6$[('<#WJGCH5+!H.AFT.IF?T6J]Q MV93J855DC.HZ0E/(2U1L9"<93NT;9)H7[8_7R6AX`D\[`:Z3-],B&G46"O>% M1R57(-3R.KTI%`-`JU,$Y#J+-L@D.68:5S<$-7H!`LTSYI0Q!,;[$`^(@@?#I(BFFFD$L M75=>%1RA8MPT-ZENK==Y]@%OC3`N0`?BV]M1/;`=N+K%COMCD/BQ<3&IU$0? M/D]5!;F4ZC'X/:+M6^.?B;[] M`!^LYD,DFEX$:`W-:LV!:ZUJR$ M)#HHP/1O`1(OZ\'KY1A,F+\?34JV:E(I4I=:-.H,%?7W[Y:WQN^=]`DK! M&E,T>0R?6C"HGU.50JI8OHN2[6HR>,)_QQGN#EI@IK#,68)-:%(-/NG'-8_2 MW^N2_XDNLZV"3ORF2,9%7MY6E"!`ZV`1/U5>J56U(!!4(%:_\]+R5K,47,=:`@\0NY;)")X-5\==NN&B M0ET,B]2:H-(BN0J]&]E5=.;958[,M0&HBBT>75_4P[Y_+I,`]ZC/=_1.*]1# MVA^=K",FE0YGPK,DD;:,A&?69S9^P,QN.HN8YERV;ADM6Y.\)@,7^L(6KNTZ M$0LFCLF>4TBD$?2"BPS,IEE.Y%G.9Z4FF23!Y1T"R=(IS)M0Y(G&,*=7:H] M#)C!/Q'\];9!;SSF3\Y/-?%MRD\_1C.'?1ZW32D=A\O(#6C@1YY.@)$@=&D[ MOZX>>O2;:%&]GIQ9^L]F>=SJ>-*B0E)?".EY-.("1"R]6J5!Z!W]H`Z;U>@% M1&Q!Y1K#WA64'IN6[EA=%%95!X+.N%E,\G=H)F2MK07-HLI*Y#N\=')YQSL0,RUQB8;0!>6K=`10P#=) M$$F3B!`\!=B>KT\*.047TBEK(I22):K<.^EKK)"&)L06Q!6@)UYD^9R8;GV( MR\RN%;J6V%[H&-IZ:DP='H!.B@*WL.NEKAGVETG\GP]_C-,/'S=S,*U+,ZP@_U+:`T:<<(@Z+$#!JAM.32, M;*O:@40@MZ"SUR-D04%Y^*?)`DPQ*#'/7K/MYH%0XQ&86=W_^S=VW-;>-8^GVK M]C^PO)VM3)7B!L`KG,E4\=J3WDZU[8]YM2A MEFM;!E&)@SP#>QHMUZ4CLYIU7:X+"%G;Y:T7\V;*R2A=Z'.NGQ$T,-%-VV-Z M)_`#C[T5O=Q);;-W5Q$-E:Q?RWIR]B-]V_92+=#YD`+V#U/Y'B78L@K2+>HY M%709!A%)^I#EL(B.%7E`!6-?S*4I8I:4KOMM*69>N&34Q3 MHSKEHF`9I;CXOAI4Z5UQ-.J2F_/^8]$LUXQDZMN4\FH<$P=FJ%T/&Z5R8B&: M7=F31:CU"LE58O8A>]MX`Y]!7'-5SS2]P&64NU[I;C"S[E2C)FM?LJ^G]C!O MZW)F+"J(TC1*?TE6ZY\%Y9_"'_B/X@%_E-?GM\][=.SO=YMZ.;-AI_RWL[G^Y][G'^)IG=)^'C/Y_OG3TBSQ^2/_[IZ77PP<32#6IZ& MF9/N."K?.)DSR<'45ROO%FNFMEX5O+;X/5FE2<,JZEL^LW'8_$_H_KS$RCQ?,.P3,O`CDG=P+`+UQ8CE\65>RVF M0I[(A6U15B;%U&2@9A+O68:G6L@FY<*0IU<2;NVLJ-Q9D.\K8+;P95-![3*W MZNB^9_HZ55WFZ_KJRS`AAY)J>Q2VB+'Y/;U*F[@U;=/,U/1-P^2;>@T;\<*4 M^CPTZ=X,DWB[,?5?9A$Q;;$^EX[>RU^P'Q?R]159&J&8^/2 MPICJFFH36F_+UY.S'^G;Q,3%*K8=+W`LJCH.L>R@A!5E`6\55MI*PJP6[4NN MX9!#":\INY9O#)@N<5J/`O;9,-JD,CEY!>D M]BR[9^_T_U;U[]9ET``[GFN8S)-PV6NQW*`8^\:6P;S%174O;]&W]Y14@K0/:/\XW1=3C.7(P39U`U2U/U52S(#?0S:5\@6!R M+V=9WLF>[]FIQ6(WL(C-+).C:8Z)'":KB):ZQL'N.FALH7F!ECT)W\ALS]1M M'#@L#J*V;U"?Z(%58IK[%*T1GBN<>BEM;#F>'P0Z,O4`$Q]YR"Y+!LAT2,6_ M?I70_+<;$+>I0N`[E!>[/>P[9N"YQ#2>A8SXQ*R8^IK$\>&N16Z8>2\+;6B- MZD2$!+;)PA65^?2NIF+?4(NBLZOYV*OL`L!T98K*#A0)6,(F?B,46+[)L]58 M8\"UJ6<6O60N(99?`0/15L.3^DMXR0&7L?[E[6_3R=UUE#QXT0WW*]WPD>\A MNXJ&LV1>-6G0N6IIB!JFY^HV>TLJBZMTK)=E!0T%%2Q1TUA]/0U);6W%V]K. M+1LS;6.Z#C:GHXMYH.7DQD= MPZBVZ*D[\$308@[*MVT"Y.DZT:A)J:U3@@/3PFK)-]^CE?TW*\U9W?+M-LX: M[2C1B.\C2DR-Q6Z)02U74IDR;BY-/X*-8]PZP. M[%7Q:HJD&:,VBK;!/%O3H4CS'$R1R9R9?%84<\@T[%5;-?2=*5J?YZ@F3[=Z M"8YF,2>&^5:!@S7',0+5*)Q:EP5Q?F7K!]75U1S`1FKVHWR3YIO6='J8W7$H#H#JM76-H M7UG`[M2)7->VKC`/4ST@NL&W)9A60!%]1KNJ5@LV+/Q;V66_S\*RD,\\\,.$ MCWQ)%R:W>=%M/(SKRH)EZ4[@,L?#L@AQ"-.498,F3!EPHBWXU570`E:E9.Z*\@'BJRK_*J_SL8+I=\M MI=M/E]4KKY@C'R;Q-+_J^7^++YEVC(9AFJU6B&H^7; ME_]_?O<20XW%U*')Q-"EAN/9'M$)0;[E,;W.XCU-!ZB.K4M&RS(0SCGFANH-JFV)=#=F'8UO(]&LS&+]DIT MEC61?"0I4QA>/)XQI%[GHTMK#!;5;=>S;<\B&%.'.:6FBPHM1I'A>D'K@T7; MG<_Y,B@RGX_$`N7'?*3-5+G)I\WRN32C.>ORD8E1P5[E[9CYTW_A0W?XE+@' M]H`\SYP/$)M/AN,GH$7CZ=-\IMITEK)GI?SPQ&'TF$_QF=]QT7BVU M7;:94X6*+?B`'[\K^70YI3PRLPDGURK;];S:8M^:3'%\FINXF^EX M-'_0-3]+7/G$_N\^57P^Q)4_^H;/564NR(,0LOU`/#X"X)Q"OXN]+,%1$X;`G.G(5G*7/:PH.18X/J%)S M#E#6`&7J`5!6Y6OQ*WG\5_D)`"6`$D`IC-$],=*R!C)R8',?CW+?S")/*1^/ M!@2M)Q6R5$#6L2)K+WL*"@U@=WRPVUG;U7/:V%K?WX3#?]TET]EDQ.M6T^3B M/X;#*+J]E(`\0! MXDX#P;:\EK7'85\U,5BZ-3^;;UE[-3#QD5RN)A_R2: M">+7G&-.Z**I*2P1)M*_)#YD/>8I\LV#E)'?"6##2"1:_\!>H]>O_5 M\X1!28"2`"61O=L`]ZJ`X/JX"C4<11:*VAUDJYHDX6_16EZ MH<3+Q:R5(A93RCQ?D4S'8YZPB'EE,DJS.OF*YP62/:NT0I-M->JQXN5XKLHM M@HFX=&Y3YLF"QK:=`A76_`HF57#,>V2A[:YE]V9-FVVH@=Y),Q2N(1_=HEGLG3SP(JYJ0FY69.@' M`M.NP(C:L=)"M=,0'<;ML$@P/2!)1R=);]6!2>A![5(O)!`*BGNS\/E,)W8C M'Q`[*D_!AKS)7A)L02E"#G\4$IX@N""X(+@@N$7(OYF-B'3SC(@L0V[:FD`T%T:S!1Z(=/AD*H@FB":)9]8XU"W9# MR9'L`K)UQ`_LVAT\P2>+HJ%-4"J,I".IC-.G+#S/X]A MC-C.7.K#G#$\0+BE,0IK.",+%B`5WKH[`8H&%,U*[9I8PFH$.[/FM.,=T$,' MT$.]*$5)I:3:X%@+&HQ*KKYZ`3S0;:#;0+=)I]O4@:JV5$$"];8E'_9SG@%: M>_W"WPL+&,>3Z-U]E#,/$_1F@9)]#Y#=40]M(F;3^;;+#%YXRI(RXKF^_"GQ MA.G9^>?%GYE,DX=PO(09S*]Y?O`\I3:,QN/BF@]GZ"S_S&`Q+#^OX8I'V3V[FC&B`"P#XSA\3*.+ M\H_*,60O="]F1E]`;*S-@N^07,V)^7"FT3=;Y6-9O(L;<=/[4-<_"`N$!W[^5`Y!^?YB;N9CH>S1]T?9]$ MD?*)_=]]JOC,(([XH]=EKW^=32)%10.(L,07Q0&([Z_B[TLP5$3A$'1DNR<7 MMP#-*B=%[4ZH('G?B(8@+*S]"C0BP&YWV`G?J0FP`]B!M@/820F[G;5=:YO; MCJ]#\#%*EOK]+EJ!;H?<[8/,2\.LXU66@#A`'"`.$`>(.PW$[;OYP^J[:_=E MQ9%3_K,\%QB_5V["-!ZV@<%3A!H$M8`?P`_@!_`C+7\`/P?(CEE:WWVH78?P M'E)2I=_&+:XW>AOJ^K`I#9T+W/PJ^ZOG]\%8G"-Q":1'&RB:I?T5Z%P3-VT6 MAOR`'@(]!'JHB<.#A!VI(/VK!X<'%`THFH,Y/$;[FN8T')X]JV?=9'Y6'LA_ M4XXYX)"8E%>I'YG1`_P`?@`_@!_`CX3\::NPAE'ONY,NY\[2Y&ZY_?SY!)7V MCDXYFE'1Z!R)&Y\C>Z@+B14)=/Q)R9:X`Q1`MD"V0+86\W1(W*%>IYVG`]$# MT:O7?(3`K!U3#KQ-!GI;3KD\V/&6C8IYTAYE*S2.VW;F3Q\&FK;MCX+M`U'L M(.P#4011!%&4(TKV7#_D>DV\=5[37EH`8T11UN M\MJ+ZP70NSOU9)\&U7X\ MCN+Q+)N?VP8[>6`G6)?5,<`/X`?P`_@!_,C#'R@IPXC77D28QS"(")V+.Q!/ M^E?/[X-B[)&X!-*C#13-2C(*1KQ"0A[T$.@A&/$*#@\H&E`TQZUH8,2K-/4S M&/$*B4E)E?J1&3W`#^`'\`/X`?Q(R!\8\0HC7GLR&DCV4!<2*Q+H^'U'&QR5 M['4W"PAD$V039%/.X4`GGB<$T071%6I6.YP6=.QFM10)`@4"=?0")?\L65G$$,;%@KSU*\:317*Z#^5.98?> M#D-?WS68=U`#=3!%Y@ZFR`A6D,;AV=D+V+4=&$#Z&E0DJ$CY5"0,>^U+J`<: M%#0H:%`I-2@,>P4-"AH4-"AHT*8:%(:]2J%!ZV5''YCN&D<'T)ZMMKI$D^E# M/`DSA@SE?R).7S12;+;T\"Y2W'DZ](JG0U/E`'\`/X`?P`?F3D3UL%9KWWGI53\YC0AHT=35S^WK1\&`.$]<.'2K)`BM\' M5]5T=M7CJ`\MLJ:<8Q!/$$\1S7_&D%*PGB">(IZ3B:1D25%*/13SWW+7: M_X#3:WXXV]Y2V3OA,P;8ZD[X9(%(VR80+-TIRU2WX2#(%,C4*!U['(U$)\]7,6LA6NO7[-WW_]>9:^NPO#QXNKX7TTFHVCRUL_3"8, M$NF7*,F;B_)BF3T9%3',-7_^-6.&,YX.__6W?_\W1?EK]2%?H^'T;L)6.?K( M1"J+;^-H9*=IE*7V\,]9G+!/D]%O<7@3C^,LCE+V?[.'U8?GYS*R#U^CVP]G M@4<0UOZ;_.^U=Z;$(_9%.,S>N:IGJ;9N>NQ_=9,2W]0=U]=M1W6P'FCT[&\K MKW'QE5S'#U&J?(Z>E*_3A_!UP5^X?1Q/HG?W>2_6!2;HC5`87-]'2CAF*\]G M&BFWTT3)V%=\LE&8\TX)"^8I,?L[95>PJY_2S1U?75'?",2;B%N0N"'#4)3L M\H*6-!YZ+$Z/B"<N5F.A[-'V2G?"C=I_"'@@<*,V`['][8 M"(X2E3G:=)>^S)+A?9A&RI7K5I]%#?K=YOX438M".P=4=OZ\@`JV#J.C9U MO5<]):&:'=NVPT9D)$3)%"),M[/HBLG(JE#F;)),YF2310;N/O_(]T MH##KK41_SN+'AXAQMP7I.I[N.SP@$*6!Z:K)PX^3;TRRILF/5H3KV";V:JI0 M`8.9O;W(RLH;^M>J)'3(T%XQL2?)NE:S)%&:7B@+G06\=,Y;"PZ9.I&%.<(R M)'U*A)BZ!1$_/W<#S+.U;SY\Z_J]W(JV/L(=>R-`T'CJNY-M7M>2.OCHF-<>N-O`MH M^>BYKW_2;1'>,PORSE7%:F M2KRRO[JW*7A),L5:8O0Q]Y-_#T5JG`KPFIO\XFT8O!5E'>N%;=/-;D MTI.,/X*=7^.E8'WV<9$D\J7=J!B"J5XB2CC^`GU[A M1W:-U)-`I6,V?@TG=Y$RO06Y!+D4`BC_>Y0,XQ1"%P"4&$#]DC<[`9P`3D+@ MQ+L5HW<`*@`5Z"B`DYQP:J*CFNWGZGXFIUSA3^FMSD=)@@0?0()/&@ M@L3S1QI-HY^K1!0C9!&#MHTU",01"P01>^X'R`3(1.]E0B<49`)D`F1BL3Q& M029`)D`F%N_3=*&'$AZ+3/2]F:5?$@2,D^VHU/H-:M(Q3AIF]0UQ-;HAUYUT M(I*S_3A/1D5&MX?)O,;BDSAE!D0;C(ED.A$0!\9$6#+;Z/AD,C`F(-I@3#IC MG-!#\D2<8[?QC+P;_FQW^O`83=+\,5^C-$OB81;-?\6>C%:^^<1CRW'+$_-L&K1_8MXB`HW'[W!$6W9_H9G:B_D< M[GL\F[GGZ6Q$8]QI>!05LIK>JC6]D79_8^,[:RZR)^U;8`2<AI+J><_X<>H/>`KTE!%+Y?$[% M"S-07;*HKI,<0)1G'V&6Y`'4VDG"+0CC1,DG%+>J]B0J)[59E5N8DCA0O&@8 M/=Q$B:+B@4)0!P.*>MV0B[$%V_3+='ATTV2",[AE`S+*_^B5E_K51[@M:Y M1W=N&2!;$`WMRL+?HQ2"H?E];S6A4P2J[[P]9@B'Q5\@5H)8:9?4FPFQ$L1* MN_+6#2=\QX[.MS'N<`=1;W-[FR@8\_'_VGK2W;23+[POL?R""&>PND'CK M/AHS#13KV,T@5W?#NZ`5/?I>KX?)_\"E]C;7-MC_G48$>6>JDR2O\TF>4)176#"'L>\ M=_3.WVN+_$E,(B7;Q]EXG)5P;9!DS5B+I#A/IA=Y1O)A5IY=9%6>?!AEDV18)5F\8P16M_II(^GOB/.S'4LA M](DD@@O"_WPPPRDX^O/]1B\0>L\OXON^<-_OV\\+GTA>='"!UX$U4AX99=D\>9%$H/.$-.[@7$+O+O/@ MI>TXEV)Y[Y[VMW=_Z*Q_J*%Y(KG.<2[%GEJ$^7$NQ3$/.[1ER^-)Q+T6.Y^#$U/*:&A^6E?IR^J.-:9WGCT>,PVW; M/7JA'SI7DL?%@V.N=)Q+L5^UFULA13#I+XNX+R$/1;2.:=83<'#?3UV/*OKT M5?28K1VG6#QFR8HX#K$X[J3MW7G^&.IXP#4NSVB(!3V:K\,88O&7_YY5KSYG MV>5/'\\N\L%LE+\_KPO"/V55/K#%^#*?5-ET6$QN.F#J`1!F,EBY4E>0FV:6 MQ&D$XA0HEH[@HY___=^2Y"_7;\I'YZ\GU:R,238\)"^_Y'96ECG0[0QPA6_] MFI__]45X'0.&7R!6'^1GPW$VJO[ZXA5]D0P'\%EV-GTE&).:8NMMO%$R+E)D M/3G;07D`S/07=BO,TE%+N=3>!.<$ M2S&CIH$96Z;D&LQ88MP?S.^*R=E]P$;&JC15R%.)L%,ZQ5PV8"/JW#K8@DJ^ M%>P;:!X&^28A(0QKA1P5&&F!M;6I42W!$1,=D&,F[@]YU)UT57>6(79SB/]Q MZFX%FG*0$@'R$&R@)`1A&G)3X``-?!5HHE>(W0G&_4"EFT&U@MF0$H]X$"K% M4F'GYZ!BQ`U6JZ""\/<$JBF!(Y_S,3`AO;JYY4-V%2^9KUDYB*4.TRM@WK2< MQ8O5^RD8X=.+;/+^,CZB"D5YG@_!A+V>?`#K7`QN8]7O#2R_U\\]O;K,S;=A M=7VURQ;^^O&WMW4I_JVTXSS53'.."&?>,<]M:-C,9,#4+="NJD^.!?&\`_$> MA3!/C2-^?#DJKO*\YL<6/F".K;5><*VLH4P;01H^<.T<8QU\>!9,F`&J[1"( MILVZ+DJ-38NQA:?NX'ELC2&+'C]@8;T,AG!*A4#2(MPJC"':+QL;H%F-_XN? MXQ#6/3+L3G3[@7BY1=<6.4@<);5K0\0%*S3UHG$77%'MT&T<1"=[M7L'Q<'Z MS=5W\5`L>&3!304(5!FU4GEW[:&XT*C#,@JU)Q>U3)8GQ8R:!8N0Q2EZ6UBA MD$#,:4II:H35+DC6V#Z.%=:B@Q7\+E'A,V?%BEYL80*A,@U*6$E3B4@JG:>\ M80)$N_RH#[>D#[TR0>I@*4NYI`)"9XC;$$>M)A@75!<3]+-F0N\1L^%I*I5# M$BM(](R@UK?&2(.1ZHJ8R7,R1@<5-6LI,629QF@-SIMP$81NG+@(QN+;HV:. M]\^P`PV[#B!V=LQJ;"D-!GEM"$D);OC(C9/>'?G8"=:[8O*E+AY^-ZL'(W0M M?#Y*\!Q35.P4(PS^&2DL1:P-GJDQ71$;QON*%E:H\]\!PM6 ME^*?'0>VVZ9=..`XX0ZGB(`":.NT):;U()JFKBML8_M:3LS*' M[[I\_G.OBRS:()2"J';54UA$.Y**LF>F-)-G2?)FUWT1%A!&6,0 M;!D3G`[*D=#J"1(X_8X;,]^7(_,NK.^R%(E<$$2`WU:&"\\$49Y?K_T[W+59 MQM">F+),EB?%C)TB._@^+MBX_S(+$I5JO,;'I1S$\SVIC#Q&V6=]EXSHOLRUGV^^G7XO2B MF%799&`F`Q^!KWG2GF_4O3'S^EU8+($A3#"*%6?(,"^XQXRUZ]%(:=T5+?"> M7--M=/BN9-ZPZ64N+TL@X[RD,%*[^FA^_3BG\)W9=)I/WA23SZ=Y.89`"&`= M?KD3HRA+!2;"06RG)<8$$]K6>6!K7=?&`54_,J.V$3H`8>]%:66DI=Y(KJQ( MG8.LAIB&TD3:)>?34EJB`Z#TZG=^FPS`H$;!G5N[B'OEO^7EV1!L`_CD_-<( MSIOB:U[.?QN.A],=G4)-^(675$#YVY0E*ZL597D`(NG5.BK=$*W?!X*R50A( M*A%#6(M`).&8<=EX+HF-(^(VST5.Z-8(I!]&'46B3Y%X/\FWB02$+`H,@I"4 M.:$Q\M2EC4@0Q8R\320P.F%/7B1^N[Q\;B)Q!ROA+$$(.[`,S*5>$,N1:T4" M47)K?"M.R-9=K7X8=12)/5L)ECI%';$N58H;2I!,=2L2X%)N%0F,3[C^+C(1 MOWY1C.!)U3QAVK%)P3I#!$JIPSS$7T/*FR8%EK+U3A8IV$HUQ1H`NP.XJ?_# M^M0(R$)#ZG5P(<;/HNW_"$:O-20H3/0#`81XX M[B:[O9OF)LQ(N;/!*7`D0AHL+/--A5CJG%YUO#J%!+&*9UH7D^3K<'H!7*SR!#+8,CO+$W/VQ\G+ MY,T;&]]1Y:/1TLC43'()R^3_XM:__=A/%1ZF-6'=6=)E8U`DB^C#XMT[`6D/V%Q MPA.X;00$[N6))\GI`C/!.A5)]KG,(SOAMTF2068_&"^(Q=NL`AE(WM2;@36+ MWX_SSUGROWDV@C]>U_O(15F]A%_/3NIOY>5X.,FF>?W]4?W%8@+"5W\;;,\E M2&2\L1>$IE^+7IZ3%'&I]3;^#X&U(`%+?`?YG=1+/DUS(F"8U\9U`+?.J5E` M&%,;DVJN*>?PAIK<-85K>I@Q@'0&]S8$M1`P`=$GV7S=I5:?ES5GSL\!DDC6 M1DLOFU73\JD3%OQ,-JVIEKAL\B7>5Y/V]9>K`2C5BKJ=),EOEW7O9&V(HN5I M"+)@C%XF#FP>O.DLDG-2P#L@F"P;AL`[H_2O@C0_C*EF=&T%IPVQ5U__NF[< M_.=LLF#WXA?.1D7]G-:*UK`OVL[+;#@WFY^R4>QO;>_LQU:H.*FDU'"[) MT7357-XXP&S)_8'>U?*S+#MOAU55S,HA7"V+V>>YH&15-1M?MJ*[8"3Z\AOP MLGS]M*][B<&"GDZ+:19#R'Y@I%3W`^&J&H,;KY*\,^Z)WF\(3AI$^[P`GYK` M'_FW:#;G#K".DV/DG$"_2K/RNKD:=@*$]6^6Z"6[<.2^X\?@+25@^CB MEV.J^D(T(&!V8KE!;75^S;\4(_!9R7^^6/G:B_\"JWK:\;AQ]J^HEC$6``D8 M%K,*()OF8Y#OK(PA:U/#M?+:ZS>=99>@W1#NM&I]=E$/PTB#[:[CV$!;='3GYDO>)7%8E@_P<5�XOEQGJ%=BT+, MI<"-0`8=Y0+"0HAV6K9_*LJR^%H'."V_X8%9#!AGHVD;@UP+"[RAS,_RX9>X M>E`EUTZQ2":0I2^Z@XMLOO0Q!-,3/[\L"XAMJVK)US6PP%.+KQ.(KBZ&E_'& M:%F?2JQPDT.;V><9Q(*=RK\A+JC]??XHCKZO('TYSWE_,2SFF>+2];C*U,K@ ML%K",H;9Y@O\\F'49VJ/&7G\W'Z>R+V?3+,20@+@YQA8U!L*?6(`@C2,!4#) M:/AE$8/&/]P:5X*BKJ`'>@T^HXIK?8M2_!]5JD/1N-7MWVVM8: MM;."KN.J.3S5DOA$"=E?K*5_@%"K)^\Q#[4V3S=;GU!VVX+P\KKQ:1MLS!>B M;5:65R`A9ES,)M/E9>@/V>[SI%2*$4^9Y4J&6.`0C%#76S64Z=6UZ68$S[U[58`3CFR>T9O>SG3"C++&XD:66.HPUA2K`0. M$H=V0IQ#*NVJX^>;L-E<4K0S["MRM@Q[X$Q[$02CB@FL8K][RPG'PE*IQ&/! M_AJ,]\YP$P&2HA'1+&#-D.=AT*_ M4512)*D41(&*QEWE@*AO=Y53K7!7/\&#H(_9Q*R\JG2@_V0UC90>FD[QYD] M#,J.2OAM?@;L6A`ZDM,80377`=/6C1HP&FL3#OE*>>@Z`+L#N,G/4R52(;VU MP5%G4\MQVDZ\Y)X9_&``5RKEVZI5-QS-8J/'9M5J)JO\LF$P(XL6+39Y*D^- M!Q?(;-/#IM(0;.>\("79$@X[PM@S@FPS@DYZS(T28/Z\3!4V3C75W,J`-G8U MA($?Q0>$X);1FI)H)8RG'DOM-0^$2Z)L$!A#].*[HQ>(<@X(P2UC3C%@X3U" M1E.GO$&*(5T!N MB^:Q@"1.4XBI@I4!0BJ.111,%#11SML':-Y^.+<)N6`I5[%9*2`GK?(IXK59 M0#6J/58;__0;U07B*0AY*<>`"?:$YM"8)AR$T?,@U=FWQGZ M+98,<1VA%PQ9*PEDYFV^N(*XH<9@!XAZ0&%3K@.BKGT*SI)3 MR"*LU#0T<8#EU*JUZFY%&J-T/Q1J!EWWZ]IB%'?+RFS4&NGW7R=QR$J]X6"; M^J+=TF",C&7"DY2!-F@)G&%-=Q_%7CNS@-#\!2]^QK1!YQ[0W8I;;$LLSN,U MU&9'J!IQ8L=44;"TQ?;5797GM?[VW M>/GSCCD6?'%96+$HL!)T$M2/,F*8@3B!IYH8Q=V:2<>B3>X?Q+(%KK?]__,* MR^O3)=YFWX;CV?A#=A57R#_DY6N(HKX,![-L9.J]GM'VQI*5!4)*XI(/0MX' M[321<>]B+K:.X-4I$(!J@CB2; MCH*=7;83B`0AG`HIN#^/$5$:G#:&4$IP&]R:T]/T!NF'P_O(R&\)&"7BD)D9 MJT&RM944@4A'Y"%'PT3@M6:.5X23IX3^EF!3A$`18]Z1@,#/2TG:E&`>SZ=`)\M0HL>X=EH9"B=0HDEHA",:$<<9]<_R&TM*(391@ M!TN)9JUW5U-!M4`!2>*PBGOK2,C02H4+'/%]F(H&]+U08[..6"T]98@0K:10 MQOG@=:LC3.E;S46?.K)G:FR0#0>&TV+FG#5(4>$U-;R5#2W4K:.V>S6>^R3' M9K,A(-\/E$OE1;#4QGEDK#4;T;CNPVQLHD8L%I^7`+S-IQ=Q/&9L`:S'E<$# MBG/;%O;5$S1CR].N*072AH?`13SI@$G"4-H>V5M\-)S&&W3:)("4V9D\@;1!"3H`>B$7S]_^Q=;6_; MN);^*T;W[F(&2`N1%"EJ![B`2(K3WMLTG:8[@_TT4&RET=:Q#$!)-F,C6Q!2S(H%?NX1@:SDBZ2]_WD1ZQ MB*885%UJ")(T"H0'X8A#$:ENTG$?I+^ONG5-WQ55]>]#>;+%J8>SIA3<;='1>R#O4@I)5#`>9B@D"K!$!,,S%F$<,`X MUF=A[\(\=77KJNWN@J0%X/%-45]PF1!VH4ICI+`69E9=H'"E/22@X,\Z[!6$ M)Z0F[XB5-2FJT!%M>7\R4OF\>,A,8TX#,?48Y!*ML6)*!X2I@&B:!LP['$A9 M&4??"7+)ZZLWOSY_G[Z['*A4O!\D;]3@U1MXG5Z_'[Q+WJ>#ZS^2M[UT8K'9 MYUX[KYI8%7>F:]I^>7?GV MP$O_OZ_A/Y[];-M=&FTP_Y7=SW[Y#XY1](OIE#$Z:?>(5=<&@D/C&[WFVF;- MJ\G@,O--HF2M2?1S/K1I`:RHLQ'4;8K!ZI3M)_/Q9^MOPZH_@4&Z`TI'Q6WA M`5E\"XIYT4UN3>S&VE=?7@Y&=BTZOYDO32\IYI865'4:;:S1MP^N=Q-U-!_V M!5#Q-T;[[2'-QAZ)XB9??,KS25\M8'\+>UYI6YX_/?-ZU*76?='0=\=NH]]Y MO5G7[B&GJN8\OBRJ,]@2]#(KRZD!VX/':^"-3O)K-=]H!?Z4SW.CCH6!,_C7 MJJDVC*8JT,_.Z&M:_ED&R0LFEH,V_'Z^4[F]_AG68N.QOM4%SGVB:K9O8&7,S9 M>MC[-EF5O_Y&=?0^6RSGUGE5K>W);%Z,!R2P7I%?]&1IOQI\PB9<0B>=KB>\ M6VMM?%9OYF].SJY-]L+I*1`]&18SV'I&KH7'>9RY,@%$7)/%W?@1]F5I[&\? M<<*A].)^\%><5E<^Q/[&BT$-9UF4*\I>OQ)7[P:S\;(\&XGA"_J?/6'=#1+; MD][`".O6W:(!&`1RO2T^&V.^.!O)[`6/^J'9H,*9ZZ*+"L^OUEV+ M$D^F[F)9CV'/X>8+7<01ZP%UHN*C26 MIM@:&"P[HH;LR[=HM?]8?QMPN[^`/5=")FSPDFX>SR:YQ5TQ7T!JU\]F,Y`V M&_B!%[6\9C8]=N'!N("TD#];!8Z-K["N?-UVP.*^96?@/'E+Y[I$X)]:WOQ?!:8Y M-@CDI1?;O3O/:1A-4UKR8$C`M)N\A96XK!.&N>=N[5M7M1'SEL%CLH/'S/E< M3\AH?:<_*R2DRVP^O!N0PV#0UM&J#L5!6_]<#82V^855;SH04)>BMNR/'Z!G MWP;HF<]`KO/9PA[+^"P$M.W)X)=U*J.%":WS?%>.7H&S-1>Z6T%[*Y1BW*]H M;G+0MXDQ7%?#Q=2(IK(#+<[5:EDGSZ/*CZPGST#H/+\=6X-[9U&BP*0V@O9& M.7D)GK8IHH9,'YO5PM[`Y?HVH=]9H+HZG1GUA=S5KXVLG6RYTR\WCG=J=3*( M?MG$R!^30&MZ$XU4E63UF!L9K-M3=E-&D'2V`I[IU; M;UJ(E4'(9F!H,PA%3+H['"[OE\[<7^:F\%JXV,*]F.] MG11%%Q'"3]DN/`%_\V+@^_L,66LH^OD88@V;OVWF=!?5'`HCT)4\+QJJ>;QK M\-FW3P?M_8*O44CK-^B^:/$U>\B*L_OTJ?_6SJ2*T1$6XD3#D=%^X�PT[DO>/@$:!T^&>*#ZSP?O)G" M?W.[VVZ7QY.TKS4U5(%PT)S,\HYZXW,LZ69M$K@S=W!(3Q8,VGC&WWPF8_6 MPD_#*E?/LN.M'!2_`5[V/L)/_6E.`K),;HP;,:C^S^U-U>HQ4S$H:Q48N:;22#51^)5TM[?%C<6R]=:W\%9S"P>`9/TVQMJXJ/\IM%\\*AH3T#"1B+ M,%T:G.P)D&;`GX?3AQS^]MOJWD#'U,7CJ>?K/+8%93Y_,&,%#,_8M"?!I;M93N"+BQJNT6@+RR_G?Z#1AK! MKQ;XP_\U%`GA_C3)O32/_[>]53;T4X8JI_'.R/W:G+Z^7^W8)[D=P%@84^1- MX?HN:/F*8N(-:H#083ZE<0Z]-@@-K+4K\U:_;*Y+-2Y0N71\,&S M%A]<=X`)+;I^T)BVU1:[RTX;(W1O"M)1]M1L]S M8Y4JQ]08`U--]5N:46D=O+#7U]RU)?CV%>LV#Y^WLLZQ?Z=@Y[D-YEJ7@JWY MRS[FU2T+^[%9]NC4RX\L,;(?9N-A5+Z"`JQOG*RG"1IG>0';N#V&LZ-?E[55C[=I1)?82=L2ZP/LZ(>W3"6RT M+)A@N_1WXNL+1I-JT,46*V6ODU6C5]T=LZ+:J-^'\VZ;KU'NQH5:TY,MMMD? MDY?5#-QJ>$Q5SJ5*]Y#\C>$1YSQ,(F?,][@9SI[-7,0T_E'`Z#H"N,V*^:J2 MND7R17OPD`_1>S\(ZX_B%R:#WZG"&UL&O*6I#8S\]>3[;/X1",\_N],J9X,;^Z\H MFY9X::MI6<.>-FXZFW*$#<)'K70U&S^"HZH&;/J7;3G9B4^0^I@PI]4^L3.& MM+-9C1.=WIA%$ZV?*0_P M(NW*"%B?U_D#N!7LU]U@X%T!V3FD0H\7=E;4$';J:)6)FX=U[L$ M:=Q.YW:$U""YE@..8>M^J;IL24.U6:<;RW!IYR18SIXA%5_-E3J^?W=+WZ^& MQ_\7DK5+7]K;W^:+6,23.!2:2!:'@>:A$2&],PPC7`@\/7U@-% M%4&7V2/:,:Q.MX1SU1=)F-9\;<%,.\1M-TI_"R MJJ6]-E<[W^9SO;KQL1O?XWH(F>]R##_<]>46*'4R>@^FX-7('!.`V9BO@`?> M@C$T1V>@]Z,E?-+`>4+0,7S]X M-AS$P^OES;CZG(,CV,N\[9`,UR_ENZ+\:,:7`<<,$L,Z$,-?Y+O__-OY]!:R M+IM`-KZA+F_ODX".B.:QD#%F-,4I1DI5""0D%6A3?]&!$MA@XME9_S^3[/86 M>&"\I<4QAN#YB3&?:BK3D`J*(B6"D-.D-M\JQ'QC"."AZG\L\Z_S\:U]D8\, M%+O%4%)+F_O1@9LDFX^PFN\_V:3!..`:9D@"30*<1Y6%<:;`(5-NA M7]F#<.!$S8-]1#0IKARA:1#Y`^+.M[Z-$3:H/XJHH(XNI[:%4=@(^@"DE`0V MGF"ITL;RQ0HG0OB01"!M`-EQ'4/]Q64T"'F3+QRPV?OLLZA2LRZ`F@;0_&8H M:5Q*RQ#YWS:',>8L9@_L%(Y9:`CFDL8Z0F#T:1VT2+6)YOT<)55>%X-7E774FT@AY=NXG%+=B?#NRC\&JXV!%]P=[C!/X1!J^' M4Z61Q]Y$*404S3$ML![0O:@FXJ\OLX/8U["1)V7]G/G2;<3LV8%F/G5FE&E4 M0*JYUWOC$$4H22*"('I*=9H&W-.?I"T<5DM_&.(U^CM6_I?ILZ'R=OHLLM0_ MKW?$TC1A(B5A1("2B"'XSBH:!.DFK3E>CAK$3T+-`0,9? M/E_D]^H"FW=^/L@7C[(J;;DOO;IU/]/RF)T??@1/\-9>RW]TCFU8P)][]XED M:8"8#"&),I.H*$.8L9!QGF+!-5WG;KSN@_JWP2[W;/DNGP*WDZ37V7R2CU:8 M@9U34T35FI2LFI`:&6Z'ASP.;'"72PA3$>,@HE0$"1+"3,\*?7R)D-QP+IIM>.3N?/O,\^4)>.=]X1"GD4)X$.$P5[!PA/ M@XI6")>C^)S.^VA-NLY''SX5PX]/5Y60QDI&D/?&`0L2&6A(F[Q=XFFZ$:JR MT\?=!W/W9?;H=.GILE=2Q0--("1CE$@(R[C`7GN5##=<*D+QT^&O*4G"^[_. MIP]/F,5<*,IYPB#R376$$RJ11TE&)&S5`$[M69\:@#1A-!!&ZT)%B>:"LE1Z M`&FBDHV$`"&.3AAV5//X#B3L\JJ_:7=KAS41UPQ!2H334(,OC2$E9`RR)4B` M.14;L0F$+Z?D2LM_[MQ(5Y.%N=DNI_?WT\G&&-$(0X@?QZ M(R,Y8;9WU"9('J:3MV/@U5/1_Q!I,TU+QF`^94`#33$W^D\8L)9MIG;H+VZ` MEF[H5<=[__7+B+'4#*8;QZLZ,T'G/"$>0_E,DTBF04X/IH M($U"W$'6NA/OEZS]567.(HU#14*!L,9I3'2M/U(PW+7DD#T145R]W%4M5^;X M4R+X`PD@$BE?+4^%Y&D'7>MEC=.1]86A^`YI8H&"F($P0Q8P@B":U*:4$[.$ M$M5)]?GVU9D2D%U:84:P:Z15JB*AA*2)C"/@#T8L9C)IE=W/IQ4G*L`'J501 M[&;!B$QB1*4*F<]G):08';2NEV.^>5W89:QQDH0\#"/&B4X@^XI(*HPNP%LR MP:QS$OP9=`$GLUVZ8,GZX_!QS1D2@$T@NO4N'R[G([5-V]OUU>V7V>?RF6QZ$[=W<9]/R^R\=4\ MF=\4"[>K_3UR,SCO=MXZL3C@X?W)`XE(K"%RBXAB#-PE]TTS(&;5O(=5K?[9 MW]OUIA'#7^NFZ;(\EP-B!E5_NN:=S7CK**9V"&7; MC:TC%4IQK9)8(S!L`>,4$NJDJI/A0*K6K5?G]3>SQ6TKV5CT]+8:Z3FM1GH> MN584@5,E,41!B2*(,T3\10$2,!4T,W_W0W]>W?[I?NG9W]O76S>6TECLE>G7 M?E,WC"<.7F[?4M"F<81:M+X9T+ M.'Z!Y+=P^[#D5":,Q!@)&:HTT52E<;5`(J@4&\.26

3$IBZ%K M*-[I%.R'ZV#3EX4T[KKR\SN8;/J*3`OMNF2P7 M=].YF7)B!_0U?N,MY":0?53K![Z!6UA-:=]8T>9S5Y..T*.UXU+8^#C5`448 MMAX.XS2JVK@8I0G5ZSO.2_-4(ODA]2^7^OM/TWU#Z9,T,&>`B68))M@(OW*O MC)E.K^Z6YF]1],ZOGESD6SE-)85`1F(A4V[NT\C8-[PP%26L>2&UM'H!R2;# MIV"VX\1)F/R'Q:?*1XEKR6YIY%E9CYN*U[>7-&,1QNE4XOHJ9A2A!*.5>,!9#A$JDQE573'9,4)^DVPQ2]".,S2>D\ MYNK7N8'U];_YJQG[]U6WCJ`@#L[,F5Z*1!`*$M0>(Q"1[M@Z/6V;#D[TQ^:K MU7B(?[-`>'_Z$X6)UI&.`TH5D50*B2IP`Q8BL8GQT).\MXKDA]3/D?Y0)@1* MDR#!"=*ABE024I_TFA[$C3(3CGOSD.<5_==.?S"2">PIPGB4Q$0&D5*U20TY MB3I,*@GH*9C==_IS`)/);^%9F$R`93).3%T<'%?`A/0'`$PIUC)B-9,)^<:8 M_%5SS"=ITIHQI2)1(K$@*%!4RH@I&2COQZC68EM,25\0W+L6G"=Z_*$;.X*< MIFX@E`0Z"A3___:NK+>))`C_E#HNB M6XJ:J^=UBZ$Z"/@BLW9V_NS%9H@DTUF/`1&$8\8,<`VV@D@HZ:SOWN7$G5VZ M!^78-P!AM]3="4*>N!%$)6;!)*<--:K.81/22^CQ`*3PGGM M.(/(J(8ZU@LF",8W`/?X).[WLO9^N8W^>7E9=N/%,;:ZG?&4OIP8F$VRYZ\G M[V:9>/2A(^U5.DO=LQ)_L353FUH.SF!I64.(QCVLCI`!27;).S(N+6M,J-%W M1J6#"8?@[]_8O:`L9XLE-K'CWWX._8Z]94M`144"S,N@A9``(W(I ML7C!1GYGTV9EKOLP<+9G^/*A!K,$`RR2J7B*(&54+*;&@1ZDTJ)+N[`3KG8% MX)"\.B!&RT&;APH0EXQ18Z*-&1RPU%+>^+JC$M9V9^[M[A\\&*,.@D[%M$54 M<\>@_#85CPTUFEX.OXQ1Y/.%MI9?[+@018@L:LI\T%H$H4*CUH$9;-E!R;]W M9N[Z>6YEX4X.J54W4Y-6W4IJJ="]O^!"E-;)R'D$X:(S'"2;.STYY?SS^17 M!>ZUTI1X?+LDF;#(C@(=];IX9-X\']O*:%E=]ZW#*7!&)><-(`( M*M;EQW(BOS`@*_QY?(#&(__+CXI;M[K.;A?LL#-\/+XIQ M>>/[P0AOV=/=^+D>F=V\_/NJF,W^FA;7PW?79:>S_=Y5]B[&)"2S,7(?C/11-PVL@F%LI8\HI;SUCMK^ MU%53NRB&IS;/_P)YD$:#JQW:BR%AVB4CC'4FXV))'=)D#NLFD][999Y>\:2_ M\O#%F+YZ93D-9Z\&(VS;&L<7FP(3[:QUK$)*B)=.$\HC!Y]D,[S4$7IGQ\>4 M'7-:$=`UTH*6,'E5"EEU2P5\RM7I0-_M8Z0^2BK9%0T[@Y, MDDDS14,@DIO$A-=61\]&+`6)96P&(KT\'HEWP@NOVUV*5G<3)X$`/.,PYY MWI!/9O.1.;5Y%:"HFFQ9@ZS&7SO2"B%E=>]2FU6GM=:A:UW!N96;-M1P"$$! M<$-C5BZ>6.FUG?,JKGUK2E*0@NDE^C<0^.EDTG!43'W&]VHRW86GA`O!!63: M4G`8A)>T$7/M@+K>V;,\L?S,H_/B[62*D:FFY7J;Q*5A/Z7IO+@:9HV?-TK< MH78@2A&3)2QQI9(5W+ALJ<6&;<"5Z9WEC3GKX2&6\C]:5/4_>E9,W^ ME%NK3TL]8&M0HRH+9,M4JOF.AN,WIY>3R`L``00E#@``!#D!``#M75ES MXSB2?M^(_0]>S^NJS/OHJ)H)'UVUCJ@:.6Q7];PA0`"T.$V1:AYR>7[]`A1E M':9XB``HNCNBH\NF"2#QX2.0F4@D/O[CYSP\6Y(D#>+HT[GZ03D_(Q&*<1`] M?3K__C"Y?+B^O3W_Q]__^[\^_L]D\J^K^Z]G-S'*YR3*SJX3`C."SYZ#;';V M&R;I[V=^$L_/?HN3WX,E_-\S/T[F)`E?SGXCWN<@I'6FDTE9U=GJ)_KP=P^F MY.QG&OR2HAF9PZ\Q@EDASBS+%K]<7#P_/W_XZ27AASAYNM`41;]X+77P#?;; M9/W:A#V:J-I$5S_\3/'Y&>UTE+:HOWSSEY_LP<[[SWKQMNJZ[D7QU]=7TZ#J M15JM>O&O;U\?BBY.@BC-8(3(.<7@[.QC$H?DGOAG[-_O][<[%4"\+`")T`<4 MSR_8*Q=7>1I$)$UIHZSM7V8)\3^=PR6"M*NJH5BZPCKZM_WWLI<%^72>!O-% M2/MVT:_Q&Y+!(&PMP][KG$59DC!>,%:V%^=-$5$B=0;J4$E1`C)2XCPD4_\R M34F67J(_\B`A^'C!6]8HJD./T`O),7+O%N0BWG4];[Z"=:\DL3M5SZ>I-D*(XHL]R@J<+ MDA2M-_:@OI1`P5HBW*HP'S%+M8$.XZ^TP>SE-F+Z0=%@HY0MRG(1\E>81$Q- M^1JGZ1U)KN/Y/(X>9C`A32(VEQ0L8,L!;UV!''$?R<\LAV%OJ??J$2Q\N_6E M;7D^PM(%-GOY1K)9C&^C)4FS-MI0?2F!@K5E:YO"7,2\C=(\82KY-YAEU!YJ MDNS0^T*$:8E60S%.HM&:@_EF929T50Y9HP\S0IK5EK;EI0A[1[_%*)N1+$#- M<]!1E8GJQD;7F?K7,)U]#N/G8["OK4>*\/%\D9`9B=)@26XC6HRP^;)O5^IK ME=&Q]CIBYXKDBM_W(^E0*Y>.?8VCIT>2S&^(QQ3&0B*Z<-Q3*1Z>X:*I!RV+ MRQ"UY;3?K18N@M\3Q-1QA.*<&0]/7W(ZULR?U2!J4SDNPA4J%C45"6;3`)T# M"L95/[U,Z(+Y5-#SZF7SRAU\*>R-9YA0LZ@@[`\**<',`OFY((C^^!BS1],\ M8ZX\YC`M_D82%*1,O6LY>"TV%, M`E3,J_3O=!CWGGR/`N9ORX(EU9Q[=:I74P(AV#@7B[^7E._](0IH2R`([4S0 M-F7Y")E[*?DCI]/0K\LVWLM#[PL1IBT#ZHMQ$>T'3`*&_GJ17KFSFB2K+R50 ML&Y>FBYU5`I-54&4AP5'O]*7RE>9?)VWQ%;UTS9)A`GFV4(E+<0T=&"+2G!C M0W2PTX:18%FJID>>3?+9N3D%B82/3IOM$_'MB>]FZ_T-GJVVW;*0TV8]R$7# MM.DP1CN+4-E<$;[AP]0K@BWR=/($X>*"+D[Z!0FS=/V$+5?Z1%'+0)"_E8_! MQD/T.8GGU23X)\FF_B/\2:6^"<*J)JNZEB%BF8;NU"%#.LX60]2!59O%VSVI)68Y4_1T^;EM>0D M+06O0()K_0`CW_,LTY\XGH,G"G*M"?)T^JL!;>1J2"70;\)DB[J7"3J+$TR2 M3^?J^=DS"9YF6?'CJ@:8H#>,WHT2*M^X2//YZE.=!'1>7)=GH5`#\2$^#?0I M/C5LY//E4CDW0E\NZ0S"%N_'N)Q8F/DSBT,ZR"E;TU#-U]JQ)F![$)JF+?\+ MO5X-(!VNS0A>9M0N]_)L)?+*MUH0IQ2YW;=Y3,T`NECW-,H&T_#]":4!FNB* MY:UXH9D^MHEZRE^ET'$__"5*PEK&-]C<,?I&F#-OR5V<%(.\T]%_QA&;E.BH MA<46R^LO!H$EFJ:2,5&GR]Z""8/PJ[X1(?D-`C?B[QTL=<45T6]EI;3 M472&(4-G?AZ!NGP%I]^\V;DN8".$%%M!_)FH;9@X^7-14<8HR&#F3;`,,+7. MTSM:*4F2AMX%[9[LF`?:/2T MN_G1T^]2VP;]S&UL:"812LR1VS:G@/JI,?>.)`6@G#V$FSJILN*[OF'T8J8L M_^`ASPO'V@&Q3&Q8FC'Q?5^=6*;B3TS%M5(W&"KWH>5L<8C>6&P3S2^^/>&[9?6A]R);DM"U+M'QDG;'5COR M-W"=)\G6]W"P(^5[0,&::D&JE8_4#7/,L,1\`9&A MF+%C"Y<19O^P"6D)0Q::<)E=PR1YH1/Q#QCF=4I8J_)`=71-T8S1^N1ZC&0L M!R\97"DCSU,6ATXEI\LQ56=:S`LUQ8!B&HJA6@*8(<=(Y,<,SC#)(,1&U+05 M$RK?!Z[C*J:G"G!@Z2.C`"]\9(S]74(6,"B.2$0IH5/:-)N1I*VNT*(TSM:B[9(^.25!#EJ"8Q%31[N0OA*BJ<&EK%V03ZD=3J M)(>+`==0/-W01KN9Q<&=P1F?09E`.9[6.>7J"[+>6M`;7[`;_Z%LRY%C<9/D MU\CG;"C8B:E%0E``5\>2%R$IS_1/?9(A@\F5&?=_"E.'&60$S:!WU6E`**J2N:*B(:6([=SIDD?*&2 M8J[/%V'\0L@]*;9;.BTXC66!H=CT/Q&^/SDF/&=ZB`!,!DD>2.B_'@&Z)RE) MEBWFC9I2`$+DN'Z_8YM#^@$X$X,O5-*VB#K-%@=*`(?%P[N&,]:(4,Y4X`>3 M9+.,ZJMT."73KY6GJ?)]UC='LT5L-$A78H5: MR;T@.QU#N;>%3*T[Q_<]$9%;TDWC8\?T*.OX"."&4F];32?U!9GFYJHF%AO@ M-RJ:<`=L"%6W?4A4-8".J;N*;@E0>*4;Q9QHP16L4U9[NRHIQ^[A6$2W%4L5 M$'HGW;SFM4`-`:H,*CZ2^2).8/*RTO76R0L"GF+8EH\% M6%G2YS+^JK,,.*7H1V]@X9S'FD\#`&($#0\[%P@DA+J@G'`X('A'0SP;51Z)+=H6Q?QTE@8*)9E*2X4$!TE1]?D MS`LAB,G@R3W+9!H1O$Y6NW/TV`]04&>W-!<&4->AK:NCS7?$F2="$).<6*#P M5K)KI!,R(U$:+,G;I-#UX71=:J+?C>9C%0EP%\O9R.8]TPB'3P:=O@51G!1F M6J-S9/]58$/#5Q3!>2/>M['*`5-9]DJP.N/'-E4+Y_03B5!`ZC:Q:TI1+5W5 M"#M.--+E2*B+C"]P6P3AG]V_*3_ZRI\\(UF`1*;XKQ!CID3^'\?,P MZ=JK\S/?48'9Z5G$+!ER0U;_UGU.':H!JJ,2UU5Z?5]BT&!9!6D7[I*879.$ MKUZ^IX3*_WJQQ27*@F7Q8=5@T;X28"//)"8>[?$1<8O`%8F(7^NH;B@)-*BZ#M%&&SDSZ$3$&UI) M^M&.!7,;585FU^M(+2H`%NVD!QT!@:AR_$W#ZDEB$)82D,6N>;RB4F/FGZ?? M0Y.:5%T`0,]V?$L=;7*?`?G##5%I9RR8HY^"M9I)RVFTAC('RP!'=S13U02H M1;:6;`BPSY]TSB#>RP["HO*AKK=Y5 M7MC5B5YM*J3H>*JJ]4M%5LT[]T_(.T&0#T/(O=Q"S.F!4)+OI)'I1,@V%3+U M4G4]6T1DO/+>-3!ID-<3\D#ZUXT?EH%V(+4P12_V&3!%/`9#A,7W5="L;Y4` MV@[6;9;F!D%WHOH:_1]R]57*4T/WD.V@(XFFOMNI;P#494Q^7V`0I:Q#))U& MO_YDX.5!.F,=F?HLQ4#-/-=8%I@0FP:Q!*RQJJ2+=P:E6>` M:X.M^M0+5`="WX6C/50B:8M:-L@#1DVLINR>\3@5E5#\':+:+:^Q.4&J#1V/ MPP?3TV(6GWBA-C*/YQPEE*9O?\*500Q_C\@:$8VY> M;%\)<#Q-]0Q+[('N`50\(2S8WQD7"?-0+N&4&CXH(\7ZT=$KO%V4&N<(N[XN M]J*J=THL`>#*G+L^QPE%#1&"B\BUPH?835WK6!.@BBO&&A)[`]8[)9MXK`=9 M-Z_R-(@(,[^+$VZ%5ES>*=1EY:RIAB*!$#O1+308Z)VS3A#00WE**J#CXBEI M72^UZ!S?,)717A`IR7B0#?*`]NSG(((1ZNDIJ:B$X@\USU1&>V_QT)X2/IB> M%K/X>$I:5LQF`':Z6<0.Q9"376]B',T_3BC+24BR*'6(J5^=5?N!H#QIFN^Z M5`.@JF`36F+SF0^@\0EAPIN,)D*!EG0RY=4^NDW3G(47-W>&8EY_;.6X.H&K M4?W'%W&F95!-3P8798(NT_J=^J_H%=>AM[!T]XL`Q[,\4Q5\%=D[G>,X@CK< M?%;$PZ??(\S\/XAV)UBR`*SJ,'GFZDY?T](4>4:FBR:M3VB[P-4-:!LBS))! MSV@--R\.-S!RY\Z;@`$>X;1=\L/Z@H".@J/HOM@37>]^'N4$[4!$VLWX2[^9 MU0/"T@]U9U=3;107CSB.B$.$UI^1<@+PEKL5LL[>5LS49?JO5IL?506I#N-A M2)68]W983":[N$$K=T(KZ+Y6"-I;%F^+T9[JV-!$Y&0<]KR8W"F*"[!#[9%5 M0,5ECZQUO4!U#1/9(NXE.#7/22^WL6R0MP@I)1'D3@;&ZNRXNP+*RL?X5I86 MZ9)K2@':D.H2LY=B*+VOG.].XMP2P]0R5&.T5^%PX\O;Y+`#XRS)=>8'V?84 M4>WG*E\"KDY,0O31YE@<=%3?>JF.AU5:DH[C$]^W2M?NJ%!W=1&$DG1,Y80( M)0CP(:GV/4H(#(/_$,P.(K*.3*,;J@`M(?/>II=)D%+T;O*$P5Q$O/0@YO&- M`<=`BH%%A*O)F1?Y4Z4]0"-,T\`.T&F;\[WQU7IOM5%Q.KV]W M.M]SCCVR->!H+L)81#22I",/@Y%9+NJ2(N8V7>MIN72NBUK]""FV(C9?KD@F MBC).9$`YI!OCK?-,JN=B?5L577#6N\,!JF%VY?M`]QW#\^U>[CEA!^8:4G+3 MGA2=*+I3T_..-0%+41%4E='F4>5+M2US/?<=SJ4"?% MR'=]PQBM8UPTR\1B*8-O^PC=!&&>U1Z).U""H8I\GYR@3[G5S%!V@\L\O5T7 M'7?7M*B!]5YFZJ/&^YBYNB>*)SA;'\6Q3K52G'2(L2E`+QAFQN;/-M%XRK!HV@.[NE[/6V* M#<2!_9TP+MC+X-3_$1AFLVMJ'$V3)QB5=P?>DR6A%E5A1MW1)Q20!Y(L`W;? M4O&7UVOCZAC8NVY@8E77;%W`H01)\0-]>1`/CZB40'(6Y,Y2*JZNIJB-#=][ M%6BZ:]F.(\#FD[4OSYDD'!"2->93OR1JTXAO7J2]L8ABJ:.U\?H-3\58]\)& MQDA_(1%E>,BN^<#S(`K2+"FB/)KO-FLH"4S/]4PH8GV0%2;)D0O\P9)!CC%= M)RTI<1E/4HSO@NC7Y?`KR\R6WE-MID2B/M5.;3FZH*J>[RH"9@HY:2.XDH(W M5#)H\0V&BP2BC*YS3$-:V7Y/)$(O=PF9!_F\Z>!JNPJ`[=A$,PP!(%>U;E8X#I8!-G8TQ[9'>R)C+*X3GB,@WT_=U\-\&%$5Z[8O M-C6AR(TM/J-:ZQ+FAYT]-0&=S'SK:B.]>$$2&OC#)&/;?Z(1* MIK[/;HE;I9]A^0BWDSW4,*&Y,/"@:ZNJB!A/6?G]A)!#"'+REA>Z')MK'%E+!'3,I M3K99ZY/%(IH#NJ=XYHBSPXNCT;X+\#30_^MP80^FI$LH*WM M"OAZ=GRK2PS-<#-;P#C00T[<2U6I\>N?GJ9)#!Z*EAQ];)YI4SX>/D,$UPFT?Y!02.X]-ZS^R`? M8_:(+K]I!B.6-*?X&TE0D+*O3SBPQ6?WID.RVQNHFYMK.=>?(^"+"U3 M);X,).0#FA&[B6Q(.Z`^8!`R] M5_\FG>&R%]GME=U\I"WE]4O8QPOV)X\R@/[R_U!+`P04````"`!,@0=%;@E^ MJRX\``"]]0(`%0`<`&%V8V$M,C`Q-#`V,S!?9&5F+GAM;%54"0`#+]WC4R_= MXU-U>`L``00E#@``!#D!``#L76USVSB2_GY5]Q]\V:_G&.\`IR:WA=<9UV3B ME).=V6\L1H)M5F322TI.?+_^0%EB[(PE411)T]E+U8PE"@"[GZ<)=`,-\.>_ M?[V>'=WZHDSS[,TK^!J\.O+9))^FV>6;5__X<"P_Z-/35W__G__\CY__Z_CX MG^K\[9'))XMKG\V/=.&3N9\>?4GG5T=_3GWY^>BBR*^/_LR+S^EM\M]'%WEQ M[8O9W=&?_I-+9Z'-\OAXU=31_:=P\?.GI/1'7\OTIW)RY:^3M_DDF2_%N9K/ M;WXZ.?GRYN\N#Q!`."3NM;&$M6WXW6QX^K2,43'&+[^6DY?'06E ML[)!^ZN2/U6_3N=UA8>%ZZ:)D^53`T"D_^ M^?O;#TLTCM.LG"?9Q+\*+F3^[ MD&7IYZ6<_&N1%G[:7O"&+?:ET,?DT\RWD?MQQ4[$TWE6YK-TNNS^9#9529F6 M9Q?O"U^&&RZOGEVX-`O=09K,/H0KOI)DI_2'MONLRC6TK(Z:[T15DY:3/`O7 M%GYZ=N.+Y=UW:K"]5H^"-42X4>5NQ%QY&(%&&VXXOSO-*E=B><.=4C:HVXF0 M-BFRRJ-YFY?E>U_H_/HZSSY<)87?)>+NFCT+V)#PQ@T,(^Y'_W6^2&8'2_U= M.ST+WVQ\:5J_&V'#`#N_^]W/K_+I:7;KRWD3;VA[K1X%:VJM32IW(N9I5BZ* MRB7_/9G/0^BT2[)-Y7L1IB%:.ZIU)%IH.;W^-C+[,"K/JIM^N/)^M]O2M/X@ MPKX/SV(VO_+S=+*[#VK56%]J?/-USBYT4EZY6?ZE#?9;VQE$^/SZIO!7/BO3 M6W^:A6J^ZB\/565[JT,HUMQ'W+NA8<4_]"'9H]5.%'N;9YZ^U;D?7*WC#>^)$4(BY8& M^T>`U$^K".3KC9^$CQ_SZM+98EY-Y55SJ\O??#%)R\J]:TC>*(7MAH9Y/OG\ M%QUVXK&U5H^"->6K2>4>Q3P/-!;I9-FOAM\#C=]=^4>65O-M\_0V>,X'*770 MK7J$X-ODXO+WE06@6@C:IVXV0BT^E_]%3HK)6N[5QX>BURMT M:38_F:;7)ZLR)\GL.]$VK`&NE_6JI4.ZE/A!S2X%"I^KT"//CJ?^(EG,YBW% MV]A.3\+FUTF:'2[KHV8Z%779\O&UO_[DB[9R/M5&ET)>A;:*R>*3/ZXA:2GJ MEI:>%#@821J&Y%#L;2BS*EG)M/>"\GWSX8GUV=1/.[S!DWUJ?9_E7<)]9OGD M*<26:)5^\OHROSV9^C2@!G'UH>J&\#&`JUR`OX5+\7WGL\X["/+ZTQ"&UG>> M)9_\[,VK<*=X2^DX0E1+!\(_JH6+'$.:,T4LXPQ8+/%C1695_;Q8X]6+)LO! MNY$6RY(QI$X3P0QUS&)C,(P,NM>`.JN0VJ7!-\YE,3G*BZDOWKR"ZUHKH]^K MCZ[R23I$/N]2_R!NN+!\#G^:S/+@.+UY-2\6_MO%/`QN7^=VM@S#PB/H+^^G MS'N@7-6JR*_I=LM]7#3F)(+2(09=Q(V6VF#LUDH[X\A`I&_IP+89P9[$_<4` M#@)C:0&=DKD6QCP:%[^C\7&A6#`'I#&0::D(!9@"$:UEAI&E\9,.06]$;G1$ MGJ*Q+?QYQVB\#":'9_"1\.,@\F'R^ M^_V1E_>`J%U58N`B9``V&E&D``:N/.6L+==X+$JVX^W41 MPNWEO67@*+E.MO.VH7BL"146($(<<=CAB-*UI`QP@UPKSM!8.>L&A59\G5VE M>5*M-$S3)-M!UE-E8PF41A$DE%NED&$L4E$M(U:B%5-XK$QU`,'^8UDYORFJ MP0PN/U4DP@>C674M/OOU"=)6O\0$8,PUX8A$"D%K@SMNU_(1@MN-6V2$%+53 MN!="3M]M(N3T70R%M-S[KGCM`9:#"'V;3GQ6^NE*%.6G.\E\HDH,0_/%]^X6 MY#?L@^YE\7_[SN81YP$PR+FE4!"&)$$P"I^PT`X982/K"-QEZB/(`T!.`,J% M"CT30=A8:M1*`^X`E6/-`VB,_*X\@+WT[SD/H'WX7.^F^,7GET5R0%-B\WY0&6+2Y,.]=3V4=.,:],XZ M<1AHF`[Q!K9&6%R08>34JLYS+MWR;7?$$,VJ!5;PU@8A@6+!,48 M,0"U6\NMN6VWQ6#_(6W0*+)[7#KFD-U"RA!FR!&M&8J4$&O98>@Z MQAZM5), M-(077]+)Y_TXW5XK)@$%IT/'(HBS&(/(BGH@T1%I-Z_7>?#: M(ZN=XC/$,LHZ+6%Y.'F9;MEGO:-&',EJ(X\+,213#AA(@\&M=9.TI8^U?S?] M+,NHW6#R7'S?GTN_.7AJ7#?FT(8P`\-JW:%*PG5:V[6^$;5\?`%S9PPVL(@N ML/KQ;60T0?9X3:/S.91&0__&&K%42A.A*10"8(VDYFB=GB28L^U28GM;@.T0 M_\U3)P?@L_^:0]\GJ6C'4!@',0NX:,6Y<+2V="IV)_YUY*P/.K1W!$;W9*Z% MV>?\#<8XT$)PKAV`TC("-:P-F@$SOG'Y1H1L_G)+"+N:QN M3N,01-@(:RY#_P\-V,<1-3N/8#X51;;=DS(9!&YI( M.L&HPS9:9PM$"J@1G8#35>IX#[`,&;/H_/I3FBTQJ,[?3Z>KL_8_%DE67OBB M\%/XA#&T:2;&$;'8XBIKQ"K"'81X_8Q$@J!V$].#[L7=US@&@.F9C.5!,'#N M9]4K&W1>SIO,@^UN)!84@X@I*H&4P'+$(K->BHTXA^UR>@;=Z]NAH70#TABV M<".-<:0)M20$A8QJIWC="QIGVBT[#KK7]Z#!X7!(GNE9/_>3_#)+_]=/3Z=A M9$LOE@=V/WY)I\RF;\/EU8`7?EM<^X=7]NL8NKAC;#!D)M*(0<"JA0.,B:D? M$&O;+9D-NO&XPU[D&1`=PEI7KS$I/^8K)=:J^_*7XL'+FYXPNUU58\<%9,JB MT+UR&'PW47GX*VU=>#Q;V<^@.Y7;VD_'T`QA"&\KZ7RUB;IZO\:W=]Z4J[=' M99?+#=9E]QU2T>E"=$W2?FO0W[@-]#EA"`*1T1`C[#@T MVE*IH+'+BC\UK[>8=/ M)/6(UXM+D4BRI\Y7[^M6,0D/'00($NPDW--U0Q^Z,S/J&Q/2E6:A: MI+-I",:&2N&I[QY]G96X.@-MBVP+\U@3[/; M4#XO[@8RV/I^,948"TF9HT90@H-[I=T:5RA;;M?H[?#$T1ML6V!?FL$^;UZO M@U`X#4@DE$-$*&Q`C2UFLMWN@,[S,E^,T;:']J4G^#(LF-&LRA>S@#F+N#/U MJ")PN]ZO\US-7@VI8XR&3<%:+BELRK0Z_`U$U91$/DNG][MPLJE*RK0\NWA? M^#+GK,=1V<0NX[7V0_D<1S*@H7%3(0`&5MC:(@YN(1K MF<-W-KZ$X"!\@[^/./37D'?_X18QJ@.')_[XB8IMKXX95OQ6$A5[:U"3!(7 M8G'%I*[10#AJ-YSVG"`XUN&T0Z"',)]S?[,H)E=)Z>5EX9=0?B_YSJ2RQFW$ MP$3`6H:ML!1#+)#5T5I_(H`:W_#<#9WYL(#]^QG.:+R!D=O+/G:R86O"V;6_ M3+Z=JEZM3)4![*HW?;U]B\+NFK%UB$H8_A'&#`_?(,7K:+LZ<'\<#D6/O.1] MXO7RMBX(R0VNLG@AY"[\<4ZM1U_!H&RWD-+34?8OQ3/I"NV7E^,NHX@S`2,> M:1@T,]8Y5.NGY0C?(MX8=#XUQS@_1?XB'L_]A;X<7,8P`L44"2P409!(R MC!2#[AOREHWJ"/Z7XI*,DKHA'IJ]=&@44[=L,781",.&#CLUX\NI&-MKQ2*"Q$)H ME(1OI$X:BP4*`9EYD[^SD?2'7BO'EN7W3I\[M*'>\[G17Q3@B%`37 M!!!$8*0-!0JRM?14M9Q6ZFVOXJ"\=PU>*^I[>H>(D5ABP)E6@@L>OMA(U;.E M;0]"Z>UQ'W.66P]P#^ZY;`?GW-_Z;+$M(W/_QF+.0W#$EJ=:`ZT5(0+3-2)* MMCS#N;=^9\P&.!@)PTV=O,W+T@42-O3K?GYV\3'YNG,"I%DSL<0D`E)J[:HS M4;BTRO$U"C`"[5SGWK9`OP13[!'^]OY3=8[U:A_7?7>=/^ZNRT46F'M4U#]U M;,2!+<:&1DP)"*W!SLJ@/;2U+Z*9&6K6[`T^LJ MFZ)I;[2SH1B0:H>_)B%N80XSKABNX6)$MG._>MO?.WI#ZIN`(5RO^VW,9Q=[ M^)%Z413;SP!IWV@MQ@ M;_+)HD(Y('N_4>8TN\B+ZZ6PCX7H<"^W38JL.I*JBL?>^T+GU]=Y]N'J_]B[ MUN:V;6;]C\[@?OF(:T]FDMJ3N.V<3QC%HF--'3$O)3G)^^L/((FT'>L*D13E MMM/))#8)`L\N%KN+O8RJX@R?[#I/?N^7;^+'XME\A@ET7$HA57*:__Q0S._+ M\2I`]GE]KIX^US5YWTVC!$H"ZL-HGNRZWCYTSM(''T8/WU(?MVBE---Z?T"Q M@IWO!4PMPI8AK""3RDC+*5M6'4%"&4+WIA5V%-C85#O?-/O#^PQM?3L8Z!@E M+AK[:?5"62K(>MV2UMU!;Z'2<1'_>7$`".3,&$V0]]#@Y M`2!OH/"9N8"]-1)J@<2'Y/$=!]+;2\?"'%E(A8Y+IU):("4#]?JM4@,.%CN- MG-EY67F`_?,89W`!6P/EEQ;\L)_^UWR2*GM M;P3*M-%`,>$`%NE^DG-4SU<+X(85JM`Q55O#J9H6MED\JNZ)YDJ&WQE/MZY+]X-@'CVVOT6-DAZM2=D[5LFL4WR;'#$Z7O"1&Z9]!KJORKIC- MEMQU^F(*6QC1LC3B(>KM?EP^1V.[$/>2THY+6QSD8M#T(7]XW!O@&&[%8I#AX@2`(,$S@"Z)'#R#ADR)-:Y'LS.W8K%SU1[,CS)PO"/HR/34?Q MA]&/R=?%5U-&G$9?BNNHGDUO)^/=873'#12\P(!"2KF25@FIG5LWO(U(1(-O M8+[S;B[H.X4L2YILFM$JN/G3XO/#Y.MDGF*JC@9 MA4%C#7*)!Y:SUY^T.!VKD]*3*J`9-RJWIV3EC!1\7*8`V$L7)62V\@ZI9(\]L MX=%9PEE/RF?+J/530V(]]X_%;3%Y3&[D:/4_6]R.0V/ONP$;88A20'!M/3.* M&U$[!#21F876.LONZN:@:!NE/KCB:GZ?3.?UQ-]-QXO9O/KY+*M-?8X_B-/? MP1T'CQ%DBJ;RZ<(*4FFPBYI5LRLP9GFR1%X6EW2%5LN.C!?&TG53MFE3H_C, MD0+E!*;\0PB,(MHYZFA]?ZR9XGD1A)WYMCJ@VV$NCI;PZT.:_%56?Q=5Z@W^ MK9C.1JL,L[72M,XZ5=/Q[^7T=F^Z\;%#!693D6RI')8(>@.DX77\K':$Y!4! MZNJ^#I9?%TJ5=O$S?$C!>*T`!8;2A'& M",7=0G6]/@-5GDW3F7.L8W'3.7Y9_.&^?GLH?Q;%JJ?-K\[^=:F0I:]_/'F< MC*-P7(G(AZW'4OZ(P4EE$?#">0(Q(I8CU8C7:,H/K")5Q_S2&XY]%LGX&1G= M+^81G57XDRZFD68;?2>'OAJH4"XUVE#>:FE],OJ9B7+3XG MS7$YNV(V_QAG].G[Z-NYOGO.$A3)&Q`YLRK&DWEMEKT_H`3%SO>"<]I)8[QU MR"(7K3P,N-).&X,,PG9O2%E_:]U7>&+K.P$0(`F4%"MIG/:$`NV6:]3>QM-$ M9AV3+9>;:(E*KP[$=C`9;)&)M%_GZ_VZ#%W?G3NXZ?&`)-=8:6N%9,8PD;*H MU^`J[%1?S=V/BMMN@;"_LLKIT/2B3O\RS;U)6YM?"(0BR#P7UDB!@14DW9+'8[1!J#]5/0N`4Q(^L5:0Y=WO'>F:^^96*?C$J/G_J/XZ:E`M'6>*1$9,/7GXL8C6*\!:H:'JW5GT&$3 M)4_"X3)I.CA-NE]2]D_"]3W97B*^>"Y8XQVD3A@C+2(>*JF:=6"9&7K97>&T M'`J\BK7.7W\?=$S*P;OI;%ZMZI7O/C=?/QP,Y<`9;QP3F&F`J*"TX6YC\RC: M<3V"]@_0DX'IG]2'=2G>\DI@C&@@F*:1GQ&G4CC:Z/<,0S+<,_844NVD^LGH MO#4>&-R9/`32MQ!3M!)<3=7'W5G^&Q\.V!#@I5/<,.\!YD[R9MF.V[XNJP[M M!GPRV&7+B&31;8M/K+[^57-?+JKK,H+D)X\I].@V<>GG\K%X/_E<[FO[W<;@ M`0C)XA;P!)%HR%.Q#&-9HY`VQK#<6.WRQ3D0S..C9WW*R_F>*A\;'P[>B.3W ML8HRC!S4E'M3SY((T5<5J?/0N05$^CBJ7[+AOL8&KQX.2L+4`"DU8)(:)$<[ M;"0:="C/67E\M.>9-?.3@>F?U'LULDV/AVA`6N=\BEP4`B#O+/#UJA0V:+@: M^2DDVDGMDY!Y*W0?G!9^;G)?WN4B-R8U*I:I8@-"*"H7"CT9*7A@-\FG$67_ MU>)Q:%QN_("&4GC%K&6(*157"H&HP_&T!WF5*CK3Q5NE>IO`9*G8[\OIN)PN M5?_/H^G?5W=WT088IP#=W=KVOO>"M)HIY*'T&EB-J<:N9E[#A,BKT]N9XMT* M4;L`II_R`B_#LO=NY\TO!*OCLC@12@A+XW_"@?IP,YQG[N/.LJY:W<>M(-*/ M6[2:/([FRSR,VLY,36WVWH=L?RT`YAA%3!LDG-#$6$]JB](HQ/)""X[/FSK[ MS4AK$/7+"*DJ4LH3.RC^<]=K07C"A,00&DV=@LA'SF_8W;%!WY6T0;RM'-$: M5F^5,P9GNPV/(2Y7+Y!&,^@)T2#5`X:(,LSJE5E">FL,>*@/M@TB':8?'(=, MKH*_*P5OW3Q\1ZF@C%$"!-X2&@]02T%4H6#<%;9>ET=B8-$OFW2!]]G)8MWC MU4^>_6M,UA$^NJRJ\GNR64??XF\VUA7*&29XH1@V"A,EX@9SB'LB&Z2ES[,? MNJF^WA5]#T@X;`F^DX6)+ZM//Z?C2:1"G*..MN[L0UG-OXR^%.G7ATB2/4,$ MA!2'U&NDG2,821E1:\0CYGEE7UIW#/7!$!U#=RZ)HKZFTJM7B_EL/HJ+F7XY M4I2\>C\PB(61E!JFK3!>H?BW!EC&\HHFM^YV.K<,.16WW@*X9K-%*J:Q+-2Y M+W+K^;,!1U&@"%.P'L=/T@6E#_5XRJ#Z/Y MHMI1?7+7.X$9Z+1R&$NM,`0&9/^=:+69]'`S@-JRSZUBI&NJS\ M:S*_OZXFT]O)MU0QK%EP?8>9>@X]_-2CV<::]J<,%X2EC&,A))4""D,0U74N MGF46YT4"M%[7NC>NZ`?&?N('GM!:QQW&=>G(Y5%'^3/^F=;P',.=X05'CA7B MY@$>6RPD8T90`I6KP;<1FSRO1>N%L'O5'3O&\.P\Y2<_BG$;#/5JH!"/6""P M@LHP:ZB#4,-:N[*:HKRCJ_6"V8/AIE,!/)R59L7M_WPI'R-2C_%3*T9:_?U7 M%EK]])E'^/=ROFPGL;*?-O#*GC>"1,(QJ)U00%/HH."N$;G<\,SB2.`2N:)= MJ/I/*7J.AYJO>D>XZ:[^/0>]'ZS'A#G%*)5,4,>\@*9A>XLR6>2BW:!=`->" M.6O*AX]IM;>:3,50P@&K,I9;,.0(H9LXT M$E%YFN?4@)?K$.T>P[X5E`/5CX"(`49"P@2S@D3KCLF&UXUCF8&RE^WGS,QK!(SJUVKR;56C/^81B1709V1`7?ZM8\?)!"B$!<)(.FA\(AYBYM5`95) M]8OT:G:.7A9/K`1/>;>>6+F>V#;J;WD\*$DPQT9%$#11@GO!&R/*89-9`^1R M?9OMX-2_BOC'=#$KQJ]N:K=:#QFCI'1>!(%!0AI.(40*P_KBQGI.,A.<+])% MVCU\_;.0']T61_++TRM!`\=(JO)ODK0S$C@-&@^?QWF1N?`B/:4M8]5O(*8? M3:H_1P^+XNKNZ8=->X:#@C)W#Q&P8$`8I#A)E9L\1!PT^X`3GG>;!B_:^=D1 M=GUPCKJ]77Q=)&MHO&P3LJ4!P^_%_.KN9O1C!P,=.5)P&$9()7740H$)4!3K M&HM4*3./CR[:[=DMA'EZ:C%??3A^;]W-9:N.^OK1P*E@DMEH7G$'D'&*@%I4 M.F`RZ^&@B_1BMH31,RJVW1LG]0:;SB,3IE,N*D"_+2;C%`/R<@(M-OWX=#^J MBN4-X_,699M_JJHJE9Y+1['^^?3(]>CGLG#1]U$UOOJV;)3R9R1:,8X4=#^^ M%;?QKS=E^M$S`V_YNZ*ZGXMDK_7]`0U(3A\\)!:T``#GB.:>`A/9 MDS'@((/>8[W7ONP(M=O[8KQXB(?LWB7.MJUQ7U>3UKX1!'`\U?46`($HJ!W4 MDC884IP7:-AR%Y0^6:48EB2B.I$D@#+SQ' MWG#K:U2)!F:XN9Z9W/&K@!L.J/^R;#OH]L^J>Y)0+YA36S!2/\W+V[_7VG^< MP/*?ZELTG6\GJZ;'DR_W\]FG437;7:KDV'$"0I1&LQM:)5+Y!T*\(?7:G/"9 MU^QM6[?#(&_9']"#$'-[K-1GYNC'\N'!EU7Z91?6W,X/!@@@<)AX[:PF1&%G ME:R198ST99VTQ<(=VBE#P#]//.;.?/G'\XFOKE>WBL^6OQ,@Y@`8[QDT',1- M3Z!N9`N._[T1WFR)0S==A?G]5CUK&]TRHV[X4F`8&FI( M_%]Q2:B3@KF&2E[EW69T5IGN#;'JZ<0X![.NW<]%,_&.6/75=X)/'5LBHISL&F$:^[8C)?5,5L=9\R63>C[YAM]WXWI/YZ MD!@@($)(,<,-T35V"NB^*GG_\]BX;=)*GS>BG`S*QNN&-F>V_W8MJGNK M<-?7@Z4J;GXFJ,302\`U]@V.#(O>:K[W?B"TSFC=V)$M$J^;3;#;^?F+G=') M1FAM!@$8"`D$'D@J@66`6=, MH/'(U)BGYKUOUM@>LF[5)TG/Z")-X5V=7CN]^DZP&@,N$8M'+U&46DN(K[%Q MU.7E0@WOF,@WEX<`^YE9\@PR_,"O!PRI%T!#);S#.B&)>;.UHST30E[J:"U74V]KMI2DJ./TB3VAV^?]0@@0"A!%`,*XBY$QXXX^I#U'J? M9R9U=F&82Y*R)WQ:H+I+9M32;KA>5+?W\?PYEN2[1@B8ZXB,P_&\4EIKPI`& M]7H+8+3`K%OBNG).WSW&"'9W,)3@J3`5'IE.!+UF@"5>='C MG;GQVB=XJ_#T4HLF*_'9$,XATPH*BQ%TU@($ZW482/("/X[?UQ>FCY^"X2!" M]BXABU02;A0Q7G*%`9)<4EFC2C5$PS4.,KFCEW32+%#_9=EVT!VQEHX_.!`D9,W*Z(&@-IW+^4-%IH7.6EA:;WR31M`-J; MU'F.UTX[[X"W@N+<&J+C2G4T,J&AF*MZC?%O>:Z;\P5H]"YI6H%U$"K5-N3J MO@[+W\[48GY?5I/_;NPOU]FW@L/&:RH5AYI;SI3CTM1X(F7ZNBGJ+Q`C^U[R MS-#W'#^]BC-\BM@[,97RR.\$@EGXZ^4[WYIKIPYU]KM?OG8VA<")00KK[UW`DO@XTZ5?(V'$"JS-L*0 M(R?SV/!<@`]:XW3_64SF/Y_Z1>

XML 29 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Interim Consolidated Statements of Comprehensive Income (Loss) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Statement of Comprehensive Income [Abstract]        
NET INCOME (LOSS) $ 1,101 $ (2,179) $ 56 $ (3,126)
OTHER COMPREHENSIVE INCOME (LOSS):        
Change in fair value of cash flow hedge, net of tax 84 110 224 110
Less: reclassification adjustment for amounts recognized in net income (129) (78) (248) (78)
Total other comprehensive income (loss) (45) 32 (24) 32
COMPREHENSIVE INCOME (LOSS) 1,056 (2,147) 32 (3,094)
Less: comprehensive (income) loss attributable to noncontrolling interest 0 (16) 25 (34)
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC. $ 1,056 $ (2,163) $ 57 $ (3,128)
XML 30 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Development (Details) (USD $)
In Thousands, unless otherwise specified
0 Months Ended 0 Months Ended 0 Months Ended 0 Months Ended 0 Months Ended
Oct. 01, 2013
Jun. 30, 2014
Bed
Center
Oct. 01, 2013
Center
Mar. 01, 2014
Huntsville, Alabama
Option
Center
Bed
Mar. 01, 2014
Huntsville, Alabama
Center
Bed
Oct. 01, 2013
Skilled Nursing Center
Center
May 01, 2014
Kansas
Skilled Nursing Center
May 01, 2013
Kansas
Skilled Nursing Center
May 01, 2013
Kansas
Skilled Nursing Center
May 01, 2013
Kansas
Chanute HealthCare Center
Skilled Nursing Center
Bed
May 01, 2013
Kansas
Council Grove HealthCare Center
Skilled Nursing Center
Bed
May 01, 2013
Kansas
Haysville HealthCare Center
Skilled Nursing Center
Bed
May 01, 2013
Kansas
Larned HealthCare Center
Skilled Nursing Center
Bed
May 01, 2013
Kansas
Sedgwick HealthCare Center
Skilled Nursing Center
Bed
Jun. 01, 2014
Nicholasville, Kentucky
Jun. 01, 2014
Nicholasville, Kentucky
Bed
Aug. 01, 2013
Louisville, KY
Aug. 01, 2013
Louisville, KY
Bed
Oct. 01, 2013
Ohio
Skilled Nursing Center
Center
Oct. 01, 2013
Indiana
Skilled Nursing Center
Center
Entity Location [Line Items]                                        
Number of nursing centers   46 4   7 4                         3 1
Purchase Price               $ 15,500                        
Acquisition-related expenses               338                        
Number of licensed nursing beds   5,282     135         77 80 119 80 62   73   107    
Less: Liabilities assumed                 758                      
Total cash outlay             $ 14,742 $ 14,742                        
Lease agreement term 15 years     10 years                     15 years   15 years      
Lease renewal period 5 years     5 years                     5 years   5 years      
Maximum number of capital lease renewal periods       2                                
XML 31 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Development (Tables)
6 Months Ended
Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The allocation for the net assets acquired is as follows:

 
As of May 1, 2013
Purchase Price
$
15,500,000

 
 
Land
$
2,130,000

Buildings
12,127,000

Furniture, fixtures, and equipment
1,200,000

Inventory
43,000

 
 
Less: Liabilities assumed
$
758,000

 
 
Total cash paid
$
14,742,000

XML 32 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Development (Schedule of Assets Acquired) (Details) (Skilled Nursing Center, Kansas, USD $)
In Thousands, unless otherwise specified
0 Months Ended
May 01, 2014
May 01, 2013
May 01, 2013
Skilled Nursing Center | Kansas
     
Business Acquisition [Line Items]      
Purchase Price   $ 15,500  
Land     2,130
Buildings     12,127
Furniture, fixtures, and equipment     1,200
Inventory     43
Less: Liabilities assumed     758
Total cash paid $ 14,742 $ 14,742  
XML 33 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidation and Basis of Presentation of Financial Statements (Details)
Jun. 30, 2014
Entity
Consolidation and Basis of Presentation of Financial Statements (Textual) [Abstract]  
Number of variable interest entity 1
Percentage of owned joint venture Investment in nonconsolidated affiliate 50.00%
XML 34 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 35 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Interim Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ 56 $ (3,126)
Discontinued operations 484 (569)
Income (loss) from continuing operations 540 (3,695)
Adjustments to reconcile loss from continuing operations to net cash provided by (used in) operating activities:    
Depreciation and amortization 3,440 2,938
Provision for doubtful accounts 2,780 1,830
Deferred income tax benefit 36 (4,214)
Provision for self-insured professional liability, net of cash payments 827 771
Stock-based compensation 295 357
Equity in net losses of unconsolidated affiliate, net of investment 59 (36)
Debt retirement costs 0 320
Other (315) (124)
Changes in assets and liabilities affecting operating activities:    
Receivables, net (13,166) (5,640)
Prepaid expenses and other assets (146) 1,929
Trade accounts payable and accrued expenses 3,447 974
Net cash provided by (used in) continuing operations (2,203) (4,590)
Discontinued operations (491) 5,056
Net cash provided by operating activities (2,694) 466
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (1,826) (2,416)
Acquisition of property and equipment through business combination 0 (14,742)
Change in restricted cash 35 (4,641)
Deposits and other deferred balances (43) 0
Net cash used in continuing operations (1,834) (21,799)
Discontinued operations (5) (546)
Net cash used in investing activities (1,839) (22,345)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repayment of debt obligations (4,412) (22,805)
Proceeds from issuance of debt 9,765 45,000
Financing costs (114) (1,341)
Issuance and redemption of employee equity awards 78 33
Payment of common stock dividends (662) (323)
Payment of preferred stock dividends (172) (172)
Distributions to noncontrolling interest (1,410) (104)
Payment for preferred stock restructuring (298) (288)
Net cash provided by continuing operations 2,775 20,000
Discontinued operations 2,048 (100)
Net cash provided by (used in) investing activities 4,823 19,900
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 290 (1,979)
CASH AND CASH EQUIVALENTS, beginning of period 3,781 5,928
CASH AND CASH EQUIVALENTS, end of period 4,071 3,949
SUPPLEMENTAL INFORMATION:    
Cash payments of interest, net of amounts capitalized 1,652 1,076
Cash payments of income taxes $ 33 $ 45
XML 36 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Interim Consolidated Balance Sheets (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Jun. 30, 2014
Dec. 31, 2013
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts receivable $ 4,582 $ 3,879
Redeemable preferred stock, par value (dollars per share) $ 0.1 $ 0.10
Redeemable preferred stock, shares authorized (shares) 5,000 5,000
Redeemable preferred stock, shares issued (shares) 5,000 5,000
Redeemable preferred stock, shares outstanding (shares) 5,000 5,000
Preferred stock, par value (dollars per share) $ 0.1 $ 0.10
Preferred stock, shares authorized (shares) 200,000 200,000
Preferred stock, shares issued (shares) 0 0
Preferred stock, shares outstanding (shares) 0 0
Common stock, par value (dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (shares) 20,000,000 20,000,000
Common stock, shares issued (shares) 6,388,000 6,307,000
Common stock, shares outstanding (shares) 6,156,000 6,075,000
Treasury stock, shares (shares) 232,000 232,000
XML 37 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Development
6 Months Ended
Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS DEVELOPMENT
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare Healthcare Services” or the “Company”) provides long-term care services to nursing center patients in eight states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. In addition to the nursing, personal care and social services usually provided in long-term care centers, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Ohio, Tennessee, and Texas. The Company's operating results also include the results of certain discontinued operations that have been reclassified on the face of the financial statements to reflect the discontinued status of these operations.
As of June 30, 2014, the Company’s continuing operations consist of 46 nursing centers with 5,282 licensed nursing beds. The Company owns 13 and leases 33 of its nursing centers. The nursing center and licensed bed count includes the following recent business development activity:
The 73-bed facility in Nicholasville, Kentucky, for which the Company entered into a lease agreement and assumed operations effective June 1, 2014. The Medicaid and Medicare certification processes for this facility are currently underway, and are expected to be completed in the fourth quarter of 2014.
The 135-bed facility in Huntsville, Alabama, for which the Company entered into a lease agreement and assumed operations effective March 1, 2014. The Medicaid and Medicare certification processes for this facility are currently underway, and are expected to be completed in the third quarter of 2014.
The 442 licensed nursing beds at the four recently leased skilled nursing centers, three in Ohio and one in Indiana, which we have operated since October 1, 2013. The Medicaid and Medicare certification processes were completed for these four leased facilities in the first quarter of 2014. In addition to the licensed nursing beds, these four centers also include 270 licensed assisted living beds which are not included in the licensed nursing bed count.
The 107-bed facility in Louisville, Kentucky, for which the Company entered into a lease agreement in August 2013. The Medicare certification processes for this facility was completed in the first quarter of 2014. The Medicaid certification process was completed in the second quarter of 2014.
The Kansas centers acquired in May 2013, which comprise five skilled nursing centers and 418 licensed beds. The Medicaid certification process was completed for these facilities during the second quarter of 2013, and the Medicare certification process was completed for these facilities during the third quarter of 2013.
BUSINESS DEVELOPMENT
Acquisitions
On March 6, 2013, the Company entered into an asset purchase agreement ("the Agreement") with Cumberland & Ohio Co. of Texas, as receiver of the assets of SeniorTrust of Florida, Inc. to acquire certain land, improvements, furniture, fixtures and equipment, and personal property of five facilities, all located in Kansas, for an aggregate purchase price of $15,500,000. The purchase of the Kansas facilities was completed on May 1, 2013. The Company also incurred $338,000 in acquisition-related expenses associated with this transaction. The five facilities acquired under the Agreement include the following:

77-bed skilled nursing facility known as Chanute HealthCare Center
119-bed skilled nursing facility known as Haysville HealthCare Center
80-bed skilled nursing facility known as Larned HealthCare Center
62-bed skilled nursing facility known as Sedgwick HealthCare Center
80-bed skilled nursing facility known as Council Grove HealthCare Center

As a result of the consummation of the Agreement, the Company allocated the purchase price of $15,500,000 between the assets associated with the transaction based on the fair value of the acquired net assets. In addition to the assets acquired in the transaction, the Company also assumed liabilities of $758,000 which resulted in total cash outlay of $14,742,000. The allocation of the purchase price was determined with the assistance of HealthTrust LLC, a third-party real estate valuation firm. The allocation for the net assets acquired is as follows:

 
As of May 1, 2013
Purchase Price
$
15,500,000

 
 
Land
$
2,130,000

Buildings
12,127,000

Furniture, fixtures, and equipment
1,200,000

Inventory
43,000

 
 
Less: Liabilities assumed
$
758,000

 
 
Total cash paid
$
14,742,000



Lease Agreements
On June 1, 2014, the Company assumed operations at Diversicare of Nicholasville, an existing 73-bed facility in Nicholasville, Kentucky. The nursing center is owned by a real estate investment trust ("REIT"), and the lease provides for an initial 15-year lease term with a 5-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
On March 1, 2014, the Company assumed operations at Diversicare of Big Springs, an existing 135-bed facility in Huntsville, Alabama. The nursing center is owned by an unrelated third-party and the lease provides for an initial 10-year lease term with two additional 5-year renewal options. The additional skilled nursing center increases the Company's footprint in Alabama to seven centers, and the third center in the Huntsville market. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
On October 1, 2013, the Company assumed operations at four existing nursing centers, three in Ohio and one in Indiana. The nursing centers are owned by a REIT and the lease of these centers provides for an initial 15-year lease term with a 5-year renewal option. This transaction represents an increase in the Company's footprint in the Midwest, expanding into one new state, Indiana, and increasing our presence in Ohio to four nursing centers. All four of the centers were operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers.
On August 1, 2013, the Company assumed operations at Seneca Place, an existing 107-bed facility in Louisville, Kentucky.  The nursing center is owned by a REIT, and the lease provides for an initial 15-year lease term with a 5-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
XML 38 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information
6 Months Ended
Jun. 30, 2014
Jul. 31, 2014
Document and Entity Information [Abstract]    
Entity Registrant Name Diversicare Healthcare Services, Inc.  
Entity Central Index Key 0000919956  
Document Type 10-Q  
Document Period End Date Jun. 30, 2014  
Amendment Flag false  
Document Fiscal Year Focus 2014  
Document Fiscal Period Focus Q2  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   6,156,428
XML 39 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
Discontinued Operations
6 Months Ended
Jun. 30, 2014
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS
DISCONTINUED OPERATIONS
West Virginia Disposition
Effective April 3, 2014, the Company entered into an asset purchase agreement with Rose Terrace Acq., LLC (“Purchaser”) to sell its skilled nursing facility in Culloden, West Virginia. The original asset purchase agreement was subject to a number of conditions including an amendment to the Master Lease with Omega Health Investors, Inc. ("Omega") to terminate the lease only with respect to two other skilled nursing facilities in West Virginia, state licensure and regulatory approval. The Company concurrently entered into an operations transfer agreement with respect to the two other skilled nursing facilities located in Danville and Ivydale, West Virginia. Effective May 31, 2014, the Company determined that these three centers, based on the progress of the underlying contingencies and conditions associated with the asset purchase agreement, met the requirements for classification as discontinued operations. As a result, the three facilities are reflected as discontinued operations for all periods in the accompanying financial statements. The Company finalized the transaction on July 1, 2014, and is disclosed as a subsequent event in Note 12.
These centers contributed revenues of $10,989,000 and $10,222,000 and net income of $660,000 and $906,000 during the six months ended June 30, 2014 and 2013, respectively.  The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense or any allocation of corporate interest expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations.
Arkansas Lease Termination
Effective September 1, 2013, the Company entered into an agreement with Omega Healthcare Investors, Inc. ("Omega") to terminate its lease with respect to eleven nursing centers and 1,181 licensed beds located in Arkansas and concurrently entered into operation transfer agreements to transfer the operations of each of those eleven centers to an operator selected by Omega. Upon the completion of the transaction, the Company no longer operates any skilled nursing centers in the State of Arkansas. In connection with the closing of this transaction, the Company and Omega entered into the Thirteenth Amendment to Consolidated Amended and Restated Master Lease ("Master Lease") most recently amended on January 22, 2013. This amendment effectively modifies the terms of the Master Lease to terminate the terms surrounding the eleven nursing centers in Arkansas, and only as to those eleven centers, and effectively reduces the annual rent payable under the Master Lease by $5,000,000.
As a result of this transaction, the Company has reclassified the operations of these centers as discontinued operations for all periods presented in the accompanying interim consolidated financial statements. These centers contributed revenues of $0 and $31,880,000 and net loss of $739,000 and $87,000 during the six months ended June 30, 2014 and 2013, respectively.  The net loss in 2014 primarily relates to professional liability expense incurred during the first quarter of 2014. The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense or any allocation of corporate interest expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations.
The discontinued assets and liabilities of the disposed skilled nursing centers have been reclassified and are segregated in the interim consolidated balance sheets as assets and liabilities of discontinued operations. The current asset amounts, which are primarily composed of net accounts receivable of $2,913,000 and $2,870,000 at June 30, 2014 and December 31, 2013, respectively. The current liabilities are primarily composed of outstanding short-term debt on the Rose Terrace facility, trade payables, and various accrued expenses of $8,823,000 and $1,359,000 at June 30, 2014 and December 31, 2013, respectively. The Company expects to collect the balance of the accounts receivable and pay the remaining trade payables and accrued expenses in the ordinary course of business. The short-term debt related to the Rose Terrace facility was paid in full in conjunction with the sale of the facility on July 1, 2014. The Company did not transfer the accounts receivable or liabilities to the new owners or operators of the facilities. Further, in accordance with Company accounting policy, the reserve for professional liability and workers' compensation will remain in the consolidated liability accounts as future payment of these liabilities will be paid through the Company's future operating cash flows.
XML 40 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Interim Consolidated Statements of Operations (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Income Statement [Abstract]        
PATIENT REVENUES, net $ 82,313 $ 61,488 $ 160,112 $ 119,927
EXPENSES:        
Operating 64,687 50,316 127,511 97,828
Lease and rent expense 6,251 4,804 12,218 9,581
Professional liability 1,556 1,758 3,617 3,265
General and administrative 5,381 5,779 10,495 10,763
Depreciation and amortization 1,705 1,496 3,440 2,938
Total expenses 79,580 64,153 157,281 124,375
OPERATING INCOME (LOSS) 2,733 (2,665) 2,831 (4,448)
OTHER INCOME (EXPENSE):        
Equity in net income (loss) of unconsolidated affiliate (56) 22 (59) (215)
Interest expense, net (949) (745) (1,841) (1,285)
Debt retirement costs 0 (320) 0 (320)
Total other expense (1,005) (1,043) (1,900) (1,820)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 1,728 (3,708) 931 (6,268)
BENEFIT (PROVISION) FOR INCOME TAXES (755) 1,287 (391) 2,573
Income (loss) from continuing operations 973 (2,421) 540 (3,695)
INCOME FROM DISCONTINUED OPERATIONS:        
Operating income, net of tax 128 242 (484) 569
Income from discontinued operations 128 242 (484) 569
NET INCOME (LOSS) 1,101 (2,179) 56 (3,126)
Less: (income) loss attributable to noncontrolling interests 0 (16) 25 (34)
NET INCOME (LOSS) ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC. 1,101 (2,195) 81 (3,160)
PREFERRED STOCK DIVIDENDS (86) (86) (172) (172)
NET INCOME (LOSS) FOR DIVERSICARE HEALTHCARE SERVICES, INC. COMMON SHAREHOLDERS $ 1,015 $ (2,281) $ (91) $ (3,332)
Per common share – basic        
Continuing operations (in dollars per share) $ 0.15 $ (0.43) $ 0.07 $ (0.67)
Discontinued operations (in dollars per share) $ 0.02 $ 0.04 $ (0.08) $ 0.10
Net income (loss) (in dollars per share) $ 0.17 $ (0.39) $ (0.01) $ (0.57)
Per common share – diluted        
Continuing operations (in dollars per share) $ 0.14 $ (0.43) $ 0.07 $ (0.67)
Discontinued operations (in dollars per share) $ 0.02 $ 0.04 $ (0.08) $ 0.10
Net income (loss) (in dollars per share) $ 0.16 $ (0.39) $ (0.01) $ (0.57)
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK $ 0.055 $ 0.055 $ 0.11 $ 0.11
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic ( in shares) 6,015 5,874 5,995 5,861
Diluted (shares) 6,181 5,874 5,995 5,861
XML 41 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Insurance Matters
6 Months Ended
Jun. 30, 2014
Insurance [Abstract]  
INSURANCE MATTERS
INSURANCE MATTERS
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, consolidated offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”) which has issued a policy insuring claims made against all of the Company's nursing centers in Florida, Tennessee, and West Virginia as well as the Company’s formerly operated Arkansas facilities. Several of the Company’s nursing centers in Alabama, Kentucky, Ohio, and Texas are also covered under this policy. The SHC policy provides coverage limits of either $500,000 or $1,000,000 per medical incident with a sublimit per center of $1,000,000 and total annual aggregate policy limits of $5,000,000. The remaining nursing centers are covered by one of three claims made professional liability insurance policies purchased from entities unaffiliated with the Company. These policies provide coverage limits of $1,000,000 per claim and have sublimits of $3,000,000 per center, with varying aggregate policy limits. 
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $27,695,000 as of June 30, 2014. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of the current portion of this reserve. Merlinos & Associates, Inc. (“Merlinos”) assisted management in the preparation of an estimate of the appropriate accrual for the current claims period and for incurred, but not reported, general and professional liability claims based on data furnished as of May 31, 2014.  The Company used this estimate from Merlinos in the preparation of its estimate of liability for incurred, but unreported professional liability claims as of as of June 30, 2014.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of June 30, 2014, the Company is engaged in 53 professional liability lawsuits. Nine lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $2,225,000 and $2,134,000 for the six months ended June 30, 2014 and 2013, respectively.
The Company follows current accounting guidance set forth in FASB ASU 2010-24, “Presentation of Insurance Claims and Related Insurance Recoveries,” that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim, and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the Company has recorded assets and equal liabilities of $70,000 at June 30, 2014 and $440,000 at December 31, 2013, respectively.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.
Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either an indemnity insurance plan or state-sponsored programs in May 1997. The Company is completely self-insured for workers’ compensation exposures prior to May 1997. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2008 through June 30, 2014, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500,000 per claim, subject to an aggregate maximum of $3,000,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $328,000 at June 30, 2014. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,130,000 as of June 30, 2014. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of June 30, 2014, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $175,000 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $900,000 at June 30, 2014. The differences between actual settlements and reserves are included in expense in the period finalized.
XML 42 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Long-Term Debt and Interest Rate Swap
6 Months Ended
Jun. 30, 2014
Debt Disclosure [Abstract]  
LONG-TERM DEBT AND INTEREST RATE SWAP
LONG-TERM DEBT AND INTEREST RATE SWAP
The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On May 1, 2013, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated February 28, 2011. The Credit Agreement increases the Company's borrowing capacity to $65,000,000 allocated between a $45,000,000 Mortgage Loan ("Amended Mortgage Loan") and a $20,000,000 Revolver ("Amended Revolver"). Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $1,341,000 and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of $45,000,000 with a five-year maturity through April 30, 2018, and a $20,000,000 Amended Revolver through April 30, 2018. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest is based on LIBOR plus 4.5%. A portion of the Amended Mortgage Loan is effectively fixed at 6.87% pursuant to an interest rate swap with a notional amount of $21,973,000. As of June 30, 2014, the interest rate related to the Amended Mortgage Loan was 4.65%. The Amended Mortgage Loan is secured by thirteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.5% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective March 31, 2014, the Company entered into the Second Amendment to the Amended and Restated Revolver ("Second Amendment"). The Second Amendment temporarily increased the Amended Revolver capacity from the $20,000,000 in the original Amended Revolver to $27,500,000 through September 30, 2014, as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process. The Second Amendment also provided for a permanent increase in the Amended Revolver capacity to $22,500,000 beginning October 1, 2014 through the original maturity date of April 30, 2018, to reflect the expansion of the Company's business through new facility acquisitions.
As of June 30, 2014, the Company had $9,000,000 borrowings outstanding under the revolving credit facility compared to $3,000,000 outstanding as of December 31, 2013. The outstanding borrowings on the revolver primarily reflect the Company's approach to accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under this Revolver are 3.00% of the amount outstanding. The Company has eight letters of credit with a total value of $7,712,000 outstanding as of June 30, 2014. Considering the balance of eligible accounts receivable, the letter of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $27,500,000, the balance available for borrowing under the revolving credit center is $10,524,000 at June 30, 2014.
Effective March 27, 2014, the Company executed its purchase option to acquire all assets associated with the Rose Terrace nursing center in Culloden, West Virginia from Milton Holdings, LLC which was considered a variable interest entity ("VIE") by the Company and consolidated prior to the date of this transaction. See Note 8 for further information on the VIE considerations. In conjunction with the purchase of the assets, the Company entered into an interest-only $8,000,000 term loan ("Rose Terrace Note") with a maturity date of March 27, 2015. The structure of the Rose Terrace Note reflected the Company's intent to sell the property and transfer operations to an unrelated third-party operator as further disclosed in Note 12. This transaction closed on July 1, 2014. As such, the Rose Terrace Note is classified as a Current Liability of Discontinued Operations on the Interim Consolidated Balance Sheet.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relate to minimum cash deposits, cash flow and debt service coverage ratios. The Company is in compliance with all such covenants at June 30, 2014.
Interest Rate Swap Transaction
As part of the debt agreements entered into in March 2011, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the amendment to the credit facility, the Company retained the previously agreed upon interest rate swap terms, and redesignated the interest rate swap as a cash flow hedge. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount of $21,973,000 at an annual fixed rate of 6.87% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amounts.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at June 30, 2014, the Company determined that the interest rate swap was effective. The interest rate swap valuation model indicated a net liability of $959,000 at June 30, 2014. The fair value of the interest rate swap is included in “other noncurrent liabilities” on the Company’s interim consolidated balance sheet. The balance of accumulated other comprehensive loss at June 30, 2014 is $594,000 and reflects the liability related to the interest rate swap, net of the income tax benefit of $364,000. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.
XML 43 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business (Details)
Jun. 30, 2014
Center
Bed
State
Oct. 01, 2013
Bed
Center
Jun. 01, 2014
Nicholasville, Kentucky
Bed
Mar. 01, 2014
Huntsville, Alabama
Bed
Center
Oct. 01, 2013
Ohio and Indiana
Bed
Oct. 01, 2013
Ohio
Center
Oct. 01, 2013
Indiana
Center
Aug. 01, 2013
Louisville, KY
Bed
May 01, 2013
Kansas
Bed
Center
Entity Location [Line Items]                  
Number of states in which entity operates 8                
Number of nursing centers 46 4   7   3 1   5
Number of licensed nursing beds 5,282   73 135 442     107 418
Number of nursing center facilities owned 13                
Number of nursing center facilities leased 33                
Number of beds not included in recently leased skilled nursing center   270              
XML 44 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Subsequent Events
6 Months Ended
Jun. 30, 2014
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS
Effective July 1, 2014, subsequent to the end of the second quarter, the Company completed the transaction with Rose Terrace Acq., LLC to sell Rose Terrace, a 90-bed skilled nursing facility in Culloden, West Virginia for a sales price of $16.5 million. The Company also agreed to an amendment to the Master Lease with Omega Health Investors, Inc. to terminate the lease only with respect to two other skilled nursing facilities in West Virginia, and concurrently entered into an operations transfer agreement with American Health Care Management, LLC, an affiliate of the purchaser with respect to two other skilled nursing facilities located in Danville and Ivydale, West Virginia. Upon completion of the transaction, Diversicare no longer operates any skilled nursing centers in the state of West Virginia. In conjunction with the closing of the sale, the Company paid the balance of the $8,000,000 mortgage loan outstanding on the Rose Terrace facility.
In a separate and unrelated transaction, the Company also completed a transaction to enter the state of Missouri through the assumption of operations of three facilities totaling 339 skilled nursing beds effective July 1, 2014. This portfolio is expected to contribute in excess of $17 million in annual revenues with initial lease terms of 15 years.
Also effective July 1, 2014, the Company entered into the Third Amendment to the Amended and Restated Revolver ("Third Amendment"). The Third Amendment makes the previously temporary increase to the Amended Revolver capacity from the $20,000,000 in the original Amended Revolver to $27,500,000 as defined in the Second Amendment, a permanent change to the borrowing capacity as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process.
Effective August 1, 2014, the Company completed a transaction to assume operations of two facilities in Ohio. The facilities included in this transaction are Avon Place, a 142-bed skilled nursing facility, and Ontario Commons, a 42-bed assisted living facility. The assumption of operations at Ontario Commons represents the Company's first and only all-assisted living facility in the current portfolio. These facilities are expected to contribute in excess of $9 million in annual revenues with initial lease terms of 10 years.
XML 45 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Variable Interest Entity
6 Months Ended
Jun. 30, 2014
Business Combinations [Abstract]  
VARIABLE INTEREST ENTITY
VARIABLE INTEREST ENTITY
Accounting guidance requires that a variable interest entity (“VIE”) must be consolidated by the primary beneficiary in accordance with the provisions set forth in FASB ASC 810, Consolidation, as mentioned in Note 2 above. The primary beneficiary is the party that has both the power to direct activities of a VIE that most significantly impact the entity's economic performance and the obligation to absorb losses of the entity or the right to receive benefits from the entity that could potentially be significant to the VIE. We perform an ongoing qualitative analysis to determine if we are the primary beneficiary of a VIE. The Company had one variable interest entity related to a nursing center in West Virginia that was dissolved in the first quarter of 2014 as a result of the asset purchase of the Rose Terrace nursing center, and is no longer consolidated into the interim consolidated financial statements of the Company.
Rose Terrace Health and Rehabilitation Center
On December 28, 2011, the Company completed construction of Rose Terrace Health and Rehabilitation Center (“Rose Terrace”), its third health care center in West Virginia. The 90-bed skilled nursing center is located in Culloden, West Virginia, along the Huntington-Charleston corridor, and offers 24-hour skilled nursing care designed to meet the care needs of both short and long-term nursing patients. The Rose Terrace nursing center utilizes a Certificate of Need the Company obtained in June 2009, when the Company completed the acquisition of certain assets of a skilled nursing center in West Virginia.
The Company initially entered into a lease agreement with the real estate developer that constructed, furnished, and equipped Rose Terrace. The agreement included the right to purchase the center and all associated assets beginning at the end of the first year of the initial term of the lease and continuing through the fifth year for a purchase price ranging from 110% to 120% of the total project cost. On March 27, 2014, the Company exercised this purchase option and acquired the land, building, and all other assets of the Rose Terrace nursing center from the real estate developer for the contractually agreed upon price of $7,693,000.
Prior to the exercise of the purchase option, the Company had determined it was the primary beneficiary of the VIE based on the ownership of the Certificate of Need, the fixed price purchase option described above, the Company’s ability to direct the activities that most significantly impact the economic performance of the VIE, and the right to receive potentially significant benefits from the VIE. Accordingly, as the primary beneficiary, the Company consolidated the balance sheet and results of operations of the VIE for periods prior to the exercise of the purchase option. However, after the exercise of the purchase option, the previous owners paid the outstanding debt related to the entity in full. Subsequently, as further disclosed in Note 11, the Company sold the Rose Terrace facility and all assets associated with the facility. As a result of these events, the entity is no longer considered a VIE as of June 30, 2014.
XML 46 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation
6 Months Ended
Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION

Overview of Plans
In December 2005, the Compensation Committee of the Board of Directors adopted the 2005 Long-Term Incentive Plan (“2005 Plan”). The 2005 Plan allows the Company to issue stock options and other share and cash based awards. Under the 2005 Plan, 700,000 shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted thereunder. All grants under this plan expire 10 years from the date the grants were authorized by the Board of Directors.
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers and 150,000 shares of the Company's common stock has been reserved for issuance under the Stock Purchase Plan. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. No grants can be made under the Stock Purchase Plan after April 25, 2018.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. Under the 2010 Plan, 380,000 shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted.

Equity Grants and Valuations
During 2014 and 2013, the Compensation Committee of the Board of Directors approved grants totaling approximately 68,000 and 69,000 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares are determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed. In addition to the shares of restricted common stock granted in 2013, the Compensation Committee of the Board of Directors also approved grants of approximately 55,000 unrestricted shares of common stock to certain employees. These shares were granted without restrictions and considered fully vested upon the date of the grant.
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
 
 
Average
 
Shares
 
Exercise Price
Outstanding, December 31, 2013
333,000

 
$
6.64

Granted

 

Exercised
(1,000
)
 
2.37

Expired or cancelled
(27,000
)
 
7.49

Outstanding, June 30, 2014
305,000

 
$
6.58

 
 
 
 
Exercisable, June 30, 2014
262,000

 
$
6.71


 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2013
118,000

 
$
5.41

Granted
68,000

 
5.51

Dividend Equivalents
2,000

 
6.86

Vested
(40,000
)
 
5.47

Cancelled
(1,000
)
 
5.42

Outstanding June 30, 2014
147,000

 
$
5.45



Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2013
41,000

 
$
5.35

Granted
25,000

 
5.51

Dividend Equivalents
1,000

 
6.86

Vested
(21,000
)
 
5.70

Cancelled

 

Outstanding June 30, 2014
46,000

 
$
5.30




Prior to 2013, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date. The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation using the Black-Scholes-Merton equity grant valuation model.

In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.

While no SOSARs or Options were granted during 2014 and 2013, previously granted SOSARs and Options remain outstanding as of June 30, 2014. The following table summarizes information regarding stock options and SOSAR grants outstanding as of June 30, 2014:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$10.40 to $11.59
 
11.13

 
63,000

 

 
63,000

 

$2.37 to $6.21
 
5.32

 
243,000

 
529,000

 
199,000

 
450,000

 
 
 
 
306,000

 
 
 
262,000

 
 

Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $295,000 and $357,000 in the six month periods ended June 30, 2014 and 2013, respectively.
XML 47 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Earnings (Loss) Per Common Share
6 Months Ended
Jun. 30, 2014
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER COMMON SHARE
EARNINGS (LOSS) PER COMMON SHARE
Information with respect to basic and diluted net earnings (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
 
 
 
 
 
 
2014
 
2013
 
2014
 
2013
Numerator: Income (loss) amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
973

 
$
(2,421
)
 
$
540

 
$
(3,695
)
Less: income (loss) attributable to noncontrolling interests

 
(16
)
 
25

 
(34
)
Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc.
973

 
(2,437
)
 
565

 
(3,729
)
Preferred stock dividends
(86
)
 
(86
)
 
(172
)
 
(172
)
Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders
887

 
(2,523
)
 
393

 
(3,901
)
Income (loss) from discontinued operations, net of income taxes
128

 
242

 
(484
)
 
569

Net income (loss) attributable to Diversicare Healthcare Services, Inc. common shareholders
$
1,015

 
$
(2,281
)
 
$
(91
)
 
$
(3,332
)
 
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2014
 
2013
 
2014
 
2013
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.15

 
$
(0.43
)
 
$
0.07

 
$
(0.67
)
Income (loss) from discontinued operations
 
 
 
 
 
 
 
Operating income (loss), net of taxes
0.02

 
0.04

 
(0.08
)
 
0.10

Discontinued operations, net of taxes
0.02

 
0.04

 
(0.08
)
 
0.10

Net income (loss) per common share – basic
$
0.17

 
$
(0.39
)
 
$
(0.01
)
 
$
(0.57
)
Per common share – diluted
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.14

 
$
(0.43
)
 
$
0.07

 
$
(0.67
)
Income (loss) from discontinued operations
 
 
 
 
 
 
 
Operating income (loss), net of taxes
0.02

 
0.04

 
(0.08
)
 
0.10

Discontinued operations, net of taxes
0.02

 
0.04

 
(0.08
)
 
0.10

Net income (loss) per common share - diluted
$
0.16

 
$
(0.39
)
 
$
(0.01
)
 
$
(0.57
)
Denominator: Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,015

 
5,874

 
5,995

 
5,861

Diluted
6,181

 
5,874

 
5,995

 
5,861


The effects of 326,000 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share for the three-month and six-month periods ended June 30, 2013, because these securities would have been anti-dilutive due to the net loss. The weighted average common shares for basic and diluted earnings for common shares were the same due to the year-to-date loss in these periods.
XML 48 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Equity Method Investment
6 Months Ended
Jun. 30, 2014
Equity Method Investments and Joint Ventures [Abstract]  
EQUITY METHOD INVESTMENT
EQUITY METHOD INVESTMENT
The investment in unconsolidated affiliate reflected on the interim consolidated balance sheet relates to a pharmacy joint venture partnership in which the Company owns 50%. The joint venture was initially funded by the Company and its partner and began operations during 2012. This investment in unconsolidated affiliate is accounted for using the equity method as the Company exerts significant influence, but does not control or otherwise consolidate the entity. The investment in unconsolidated affiliate balance at June 30, 2014, was $428,000 as compared to $487,000 at December 31, 2013. Additionally, the Company's share of the net profits and losses of the unconsolidated affiliate are reported in equity in net earnings or losses of unconsolidated affiliate in our statement of operations. The Company's equity in the net losses of unconsolidated affiliate for the six month period ended June 30, 2014, was $59,000 as compared to $215,000 for the six month period ended June 30, 2013.
XML 49 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
Equity Method Investment (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Dec. 31, 2013
Equity Method Investments and Joint Ventures [Abstract]          
Percentage of owned joint venture Investment in nonconsolidated affiliate 50.00%   50.00%    
Investment in unconsolidated affiliate $ 428   $ 428   $ 487
Equity in net income (loss) of unconsolidated affiliate $ (56) $ 22 $ (59) $ (215)  
XML 50 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Earnings (Loss) Per Common Share (Tables)
6 Months Ended
Jun. 30, 2014
Earnings Per Share [Abstract]  
Basic and diluted net income (loss) per common share
Information with respect to basic and diluted net earnings (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
 
 
 
 
 
 
2014
 
2013
 
2014
 
2013
Numerator: Income (loss) amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
973

 
$
(2,421
)
 
$
540

 
$
(3,695
)
Less: income (loss) attributable to noncontrolling interests

 
(16
)
 
25

 
(34
)
Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc.
973

 
(2,437
)
 
565

 
(3,729
)
Preferred stock dividends
(86
)
 
(86
)
 
(172
)
 
(172
)
Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders
887

 
(2,523
)
 
393

 
(3,901
)
Income (loss) from discontinued operations, net of income taxes
128

 
242

 
(484
)
 
569

Net income (loss) attributable to Diversicare Healthcare Services, Inc. common shareholders
$
1,015

 
$
(2,281
)
 
$
(91
)
 
$
(3,332
)
 
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2014
 
2013
 
2014
 
2013
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.15

 
$
(0.43
)
 
$
0.07

 
$
(0.67
)
Income (loss) from discontinued operations
 
 
 
 
 
 
 
Operating income (loss), net of taxes
0.02

 
0.04

 
(0.08
)
 
0.10

Discontinued operations, net of taxes
0.02

 
0.04

 
(0.08
)
 
0.10

Net income (loss) per common share – basic
$
0.17

 
$
(0.39
)
 
$
(0.01
)
 
$
(0.57
)
Per common share – diluted
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.14

 
$
(0.43
)
 
$
0.07

 
$
(0.67
)
Income (loss) from discontinued operations
 
 
 
 
 
 
 
Operating income (loss), net of taxes
0.02

 
0.04

 
(0.08
)
 
0.10

Discontinued operations, net of taxes
0.02

 
0.04

 
(0.08
)
 
0.10

Net income (loss) per common share - diluted
$
0.16

 
$
(0.39
)
 
$
(0.01
)
 
$
(0.57
)
Denominator: Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,015

 
5,874

 
5,995

 
5,861

Diluted
6,181

 
5,874

 
5,995

 
5,861

XML 51 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
Insurance Matters (Details) (USD $)
6 Months Ended
Jun. 30, 2014
Lawsuit
Jun. 30, 2013
Dec. 31, 2013
Malpractice Insurance [Line Items]      
Number of professional liability lawsuits 53    
Cash expenditures for self-insured professional liability costs $ 2,225,000 $ 2,134,000  
Non-current receivables for workers' compensation policy 70,000   440,000
Other Insurance Industry Disclosures [Abstract]      
Liability for workers compensation claims 328,000    
Workers compensation insurance, non current receivable for excess premiums paid 1,130,000    
Health insurance, maximum self-insured annual amount per individual 175,000    
Liability for reported claims and estimates for incurred but unreported claims 900,000    
Scheduled for trial or arbitration over next 12 months
     
Malpractice Insurance [Line Items]      
Number of professional liability lawsuits 9    
Professional malpractice liability insurance
     
Malpractice Insurance [Line Items]      
Liability for reported and estimated future claims 27,695,000    
Prefunded deductible policy
     
Malpractice Insurance [Line Items]      
Insurance policy coverage limits per claim 500,000    
Other Insurance Industry Disclosures [Abstract]      
Professional liability insurance, annual coverage limit per facility 3,000,000    
SHC Risk Carriers, Inc | Professional malpractice liability insurance
     
Malpractice Insurance [Line Items]      
Insurance policy coverage limits per claim 500,000    
Annual sublimit per center 1,000,000    
Maximum annual coverage 5,000,000    
Unaffiliated Entities | Professional malpractice liability insurance
     
Malpractice Insurance [Line Items]      
Insurance policy coverage limits per claim 1,000,000    
Annual sublimit per center $ 3,000,000    
Number of types of professional liability insurance policies 3    
XML 52 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Interim Consolidated Statements of Operations (Parenthetical) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Income Statement [Abstract]        
Tax effect on operating income $ 419 $ 142 $ 348 $ (334)
XML 53 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Recent Accounting Guidance
6 Months Ended
Jun. 30, 2014
Accounting Changes and Error Corrections [Abstract]  
RECENT ACCOUNTING GUIDANCE
RECENT ACCOUNTING GUIDANCE
In February 2013, the FASB issued Accounting Standards Update ("ASU") 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. The amendments in this update require an entity to provide information about the amounts reclassified from accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the income statement or in the notes, significant amounts reclassified from accumulated other comprehensive income by the net income line item. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.
In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity changing the criteria for reporting discontinued operations. The ASU states that only those disposed components (or components held-for-sale) representing a strategic shift that have a significant effect on operations and financial results will be reported in discontinued operations. The ASU also required expanded disclosures about discontinued operations in the financial statement notes. The ASU is effective for disposals (or classifications as held-for-sale) that occur within annual periods beginning on or after December 15, 2014 and interim periods within those annual periods. Early application is permitted, but only for those disposals that have not been reported in financial statements previously issued or available for issuance. We have chosen to early adopt this ASU and have applied the new criteria in determining the accounting treatment for the nursing centers exited during 2014. The adoption of this guidance did not have a material impact on the Company's consolidated financial results.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
XML 54 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation $ 295 $ 357
Restricted Stock
   
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Grant of restricted common stock (shares) 68,000 69,000
Vest of restricted stock on each year (percentage) 33.00%  
Stock Compensation Plan
   
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Grant of restricted common stock (shares) 55,000  
2005 Long Term Incentive Plan
   
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares reserved for future issuance 700,000  
Expiration period 10 years  
2008 Stock Purchase Plan
   
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares reserved for future issuance 150,000  
Percentage of quoted market price offering rate 85.00%  
Restriction period 2 years  
2010 Long Term Incentive Plan | Stock Only Stock Appreciation Rights (SOSARS)
   
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares reserved for future issuance 380,000  
XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 101 250 1 false 60 0 false 13 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.advocatinc.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 1001000 - Statement - Interim Consolidated Balance Sheets Sheet http://www.advocatinc.com/role/InterimConsolidatedBalanceSheets Interim Consolidated Balance Sheets false false R3.htm 1001501 - Statement - Interim Consolidated Balance Sheets (Parenthetical) Sheet http://www.advocatinc.com/role/InterimConsolidatedBalanceSheetsParenthetical Interim Consolidated Balance Sheets (Parenthetical) false false R4.htm 1002000 - Statement - Interim Consolidated Statements of Operations Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfOperations Interim Consolidated Statements of Operations false false R5.htm 1002501 - Statement - Interim Consolidated Statements of Operations (Parenthetical) Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfOperationsParenthetical Interim Consolidated Statements of Operations (Parenthetical) false false R6.htm 1003000 - Statement - Interim Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfComprehensiveIncomeLoss Interim Consolidated Statements of Comprehensive Income (Loss) false false R7.htm 1004000 - Statement - Interim Consolidated Statements of Cash Flows Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfCashFlows Interim Consolidated Statements of Cash Flows false false R8.htm 2101100 - Disclosure - Business Sheet http://www.advocatinc.com/role/Business Business false false R9.htm 2102100 - Disclosure - Consolidation and Basis of Presentation of Financial Statements Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatements Consolidation and Basis of Presentation of Financial Statements false false R10.htm 2103100 - Disclosure - Recent Accounting Guidance Sheet http://www.advocatinc.com/role/RecentAccountingGuidance Recent Accounting Guidance false false R11.htm 2104100 - Disclosure - Long-Term Debt and Interest Rate Swap Sheet http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwap Long-Term Debt and Interest Rate Swap false false R12.htm 2105100 - Disclosure - Insurance Matters Sheet http://www.advocatinc.com/role/InsuranceMatters Insurance Matters false false R13.htm 2106100 - Disclosure - Stock-Based Compensation Sheet http://www.advocatinc.com/role/StockBasedCompensation Stock-Based Compensation false false R14.htm 2107100 - Disclosure - Earnings (Loss) Per Common Share Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShare Earnings (Loss) Per Common Share false false R15.htm 2108100 - Disclosure - Variable Interest Entity Sheet http://www.advocatinc.com/role/VariableInterestEntity Variable Interest Entity false false R16.htm 2109100 - Disclosure - Equity Method Investment Sheet http://www.advocatinc.com/role/EquityMethodInvestment Equity Method Investment false false R17.htm 2110100 - Disclosure - Business Development Sheet http://www.advocatinc.com/role/BusinessDevelopment Business Development false false R18.htm 2111100 - Disclosure - Discontinued Operations Sheet http://www.advocatinc.com/role/DiscontinuedOperations Discontinued Operations false false R19.htm 2112100 - Disclosure - Subsequent Events Sheet http://www.advocatinc.com/role/SubsequentEvents Subsequent Events false false R20.htm 2306301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.advocatinc.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) false false R21.htm 2307301 - Disclosure - Earnings (Loss) Per Common Share (Tables) Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShareTables Earnings (Loss) Per Common Share (Tables) false false R22.htm 2310301 - Disclosure - Business Development (Tables) Sheet http://www.advocatinc.com/role/BusinessDevelopmentTables Business Development (Tables) false false R23.htm 2401401 - Disclosure - Business (Details) Sheet http://www.advocatinc.com/role/BusinessDetails Business (Details) false false R24.htm 2402401 - Disclosure - Consolidation and Basis of Presentation of Financial Statements (Details) Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsDetails Consolidation and Basis of Presentation of Financial Statements (Details) false false R25.htm 2404401 - Disclosure - Long-Term Debt and Interest Rate Swap (Details) Sheet http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwapDetails Long-Term Debt and Interest Rate Swap (Details) false false R26.htm 2405401 - Disclosure - Insurance Matters (Details) Sheet http://www.advocatinc.com/role/InsuranceMattersDetails Insurance Matters (Details) false false R27.htm 2406402 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) false false R28.htm 2406403 - Disclosure - Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable) (Details) Sheet http://www.advocatinc.com/role/ShareBasedCompensationShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableDetails Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable) (Details) false false R29.htm 2406404 - Disclosure - Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details) false false R30.htm 2406405 - Disclosure - Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) false false R31.htm 2407402 - Disclosure - Earnings (Loss) Per Common Share (Details) Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShareDetails Earnings (Loss) Per Common Share (Details) false false R32.htm 2407403 - Disclosure - Earnings (Loss) Per Common Share (Details Textual) Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShareDetailsTextual Earnings (Loss) Per Common Share (Details Textual) false false R33.htm 2408401 - Disclosure - Variable Interest Entity (Details Textual) Sheet http://www.advocatinc.com/role/VariableInterestEntityDetailsTextual Variable Interest Entity (Details Textual) false false R34.htm 2409401 - Disclosure - Equity Method Investment (Details) Sheet http://www.advocatinc.com/role/EquityMethodInvestmentDetails Equity Method Investment (Details) false false R35.htm 2410402 - Disclosure - Business Development (Details) Sheet http://www.advocatinc.com/role/BusinessDevelopmentDetails Business Development (Details) false false R36.htm 2410403 - Disclosure - Business Development (Schedule of Assets Acquired) (Details) Sheet http://www.advocatinc.com/role/BusinessDevelopmentScheduleOfAssetsAcquiredDetails Business Development (Schedule of Assets Acquired) (Details) false false R37.htm 2411401 - Disclosure - Discontinued Operations (Details) Sheet http://www.advocatinc.com/role/DiscontinuedOperationsDetails Discontinued Operations (Details) false false R38.htm 2412401 - Disclosure - Subsequent Events (Details) Sheet http://www.advocatinc.com/role/SubsequentEventsDetails Subsequent Events (Details) false false All Reports Book All Reports Element us-gaap_LongTermDebt had a mix of decimals attribute values: -6 -3. 'Monetary' elements on report '2405401 - Disclosure - Insurance Matters (Details)' had a mix of different decimal attribute values. 'Shares' elements on report '2406402 - Disclosure - Stock-Based Compensation (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2412401 - Disclosure - Subsequent Events (Details)' had a mix of different decimal attribute values. Process Flow-Through: 1001000 - Statement - Interim Consolidated Balance Sheets Process Flow-Through: Removing column 'Jun. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 1001501 - Statement - Interim Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 1002000 - Statement - Interim Consolidated Statements of Operations Process Flow-Through: 1002501 - Statement - Interim Consolidated Statements of Operations (Parenthetical) Process Flow-Through: 1003000 - Statement - Interim Consolidated Statements of Comprehensive Income (Loss) Process Flow-Through: 1004000 - Statement - Interim Consolidated Statements of Cash Flows avca-20140630.xml avca-20140630.xsd avca-20140630_cal.xml avca-20140630_def.xml avca-20140630_lab.xml avca-20140630_pre.xml true true XML 56 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
Subsequent Events (Details) (USD $)
0 Months Ended 0 Months Ended 0 Months Ended 0 Months Ended 0 Months Ended
Oct. 01, 2013
Jun. 30, 2014
Bed
Center
Oct. 01, 2013
Center
Jun. 30, 2014
Revolving credit facility
Mar. 30, 2014
Revolving credit facility
May 01, 2013
Revolving credit facility
Mar. 31, 2014
Revolving credit facility
Maximum
May 31, 2014
Rose Terrace Nursing Center
West Virginia
Center
Apr. 03, 2014
Rose Terrace Nursing Center
West Virginia
Center
Jul. 01, 2014
Subsequent Event
Missouri
Jul. 01, 2014
Subsequent Event
Missouri
Bed
Center
Jul. 01, 2014
Subsequent Event
Missouri
Scenario, Forecast
Aug. 01, 2014
Subsequent Event
Ohio
Aug. 01, 2014
Subsequent Event
Ohio
Center
Aug. 01, 2014
Subsequent Event
Ohio
Avon Place
Bed
Aug. 01, 2014
Subsequent Event
Ohio
Ontario Commons
Bed
Aug. 01, 2014
Subsequent Event
Ohio
Scenario, Forecast
Jul. 01, 2014
Subsequent Event
Rose Terrace Nursing Center
Culloden, WV
Bed
Jul. 01, 2014
Subsequent Event
Rose Terrace Nursing Center
West Virginia
Facility
Jul. 01, 2014
Subsequent Event
Rose Terrace Nursing Center
Danville and Ivydale, West Virginia
Facility
Jul. 01, 2014
Subsequent Event
Rose Terrace Nursing Center
Rose Terrace Note
Loans Payable
Subsequent Event [Line Items]                                          
Number of licensed nursing beds   5,282                 339       142 42   90      
Purchase price                                   $ 16,500,000      
Number of nursing centers   46 4         3 2   3     2         2 2  
Payment of balance of mortgage loan outstanding                                         8,000,000
Expected annual revenues                       17,000,000         9,000,000        
Long-term debt revolving credit facility       $ 22,500,000 $ 20,000,000 $ 20,000,000 $ 27,500,000                            
Lease agreement term 15 years                 15 years     10 years                
XML 57 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
 
 
Average
 
Shares
 
Exercise Price
Outstanding, December 31, 2013
333,000

 
$
6.64

Granted

 

Exercised
(1,000
)
 
2.37

Expired or cancelled
(27,000
)
 
7.49

Outstanding, June 30, 2014
305,000

 
$
6.58

 
 
 
 
Exercisable, June 30, 2014
262,000

 
$
6.71


Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2013
118,000

 
$
5.41

Granted
68,000

 
5.51

Dividend Equivalents
2,000

 
6.86

Vested
(40,000
)
 
5.47

Cancelled
(1,000
)
 
5.42

Outstanding June 30, 2014
147,000

 
$
5.45

Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2013
41,000

 
$
5.35

Granted
25,000

 
5.51

Dividend Equivalents
1,000

 
6.86

Vested
(21,000
)
 
5.70

Cancelled

 

Outstanding June 30, 2014
46,000

 
$
5.30

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
The following table summarizes information regarding stock options and SOSAR grants outstanding as of June 30, 2014:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$10.40 to $11.59
 
11.13

 
63,000

 

 
63,000

 

$2.37 to $6.21
 
5.32

 
243,000

 
529,000

 
199,000

 
450,000

 
 
 
 
306,000

 
 
 
262,000

 
 

TWCOHDO73;BG2KXZ0:JC'@^.I'6OKVL&K+X3_;^_* MFMO&L?4_NH-]J9H7K#-=E6YW9>M'E&(SB:ILR2/9GO&_OZ!LRJM$"21!4)T7 M1[$)$?B^`YP#X"P2&000K.\\M74:.2::6U!AM4H+/.J]8M'H"_)8@(^W(!^] M?(;Z"(-S9RF1%&F,+%;-X8;`@J0M=KW7-RIVL3L2O^R!#*\.0]7BXM5OOL2W MK54T/N[BBOPK#F&WW`"E&/(4":P9M@!10INL5%$MX=8@Z5]Q"%6P<:XAS3E@ M'ED%$3:V"=]''(E<>8&'CD,X6%0&BT,X#NABXQ#2/)^`%P`C&-5R5-=0`"V] M:.!'%J9M5R<3B7`P]7L]GX[#L(@=Z`3<2'"T"*"CU,D(K>%QAT]Q@ZISG$[% M\^E@Z?: M`>$4;I)B8ZQ08BG42?DA'$SU?N>53L#F$"!W=7VYO*^JPWR=WGDZU.XWCK-Z M9,SI"(Y`]`DIE\M/?8K"TAW.(K1@\BGQ'\O%W::HY<"50I(Z$HSW`!C&H?22 M,&N\<4VV=4QDOF))V4[6DK>])?-R(C-D9ZJH['T(<3TB!!#(/4%(*6R8WHH) M<^94JI<,+)SYYU`2?=.>/N7=37/E(9>2"^:Y-_&S4+!!GRJ>9EJ7YZ1V*I.G M$WO3GCL/0_YM<;ZJ8EM;/?P[RAQZORM!P-K'"RF-C9)"6<]A4PX2JR@_)^)= M=RISJ1<6ISVGOFYH&E4?O>Q"L)(`3@$0<=L*#42(BNWYF@55L57=F_;>#[MV[N-?>!>*X)8PHHY'C'#BM^98'XT6N3+/E M:+-AI+@7-^B@.5M<'X-'1C*-@75:"0B(\K;1!`0QG78:4I[J M*V3F3IW_=`WZ;<]@O]T_/=(^V)NGP=KYW?RB6FP>O)M=UH]TTZ3%]#(H3B"B MGDFH/..<4V^:\RWBXG[H;W=*F4FC3E4"IJU97QY0E:E9C^QC<(#%9=!;!RQQ M"`CCC=_RIW2:33SE,]*):]9A^9_V_'U6?:W,R7M,!P.!G@L:S1\"A#`X+K9D MRQS#)"VAUI3/9B<^8>()089J&'=%D.,M_)Q0FZONS$BAG0=3OS>T\S@,BS!' M)Q`G!S0AG#$!*!#*.\&DAPVJV&DRE=#.@Z4C1\!<&JB_1+8?=`L/[9R4I/9Q M>O[,S(\=V)4;?;9:[R\6=.SW!"^H8,+'P3@),':,6-:,S6.4*Y_"F!%Z!]/[ M)B'@<$"/M\QM?OLLK?"7N(=\N[#U;OV_[<;:H#C=Z]S0/F%AM*4)$*XB% MM8`RW8Q$$U!8]=M1N=QEZO8'[P""\OF_RRZ"LFT>(DJ.2<.L<#&ZWN-PCGI[`!@ZRRT!&`$/B:<2-@>2`G(^M5)_ M_4MSN63T*-2)D[(I#_?<66@SX..$NN^W!^2!Q0891A340&GD)6YP),BV^N%, MQ%%V$*$>F8R15^K?%C>K^6(]/Q\F1K+E?4%2PJF-RP"1&GLCL&2BP0H;C3O!7\[Z^\P],(*Q]-N-B+.)[LXEEQ4J9_WM M2L88Z^^S/F=9?W>^+V!1UPWEE'$>01,>"D\;K+2V:5F(2BYB-,;ZVQ?\V3WE M-U?ANSS?FYYT>.GMMW7UG]L(EKNK;^2SO6A4E_Z7??EPB*/^CB;!.<4<4`)I M(*E7E@A,A/'("E/K[]8,2%E&V.I)_\[C@4`M4#T?M&4PFM&,`/XXLKI&?2X/ MN_U.\9UI>7U^U!V)8KW67X^MW7]]1XM`F1?FX:B`6NJ`4(HU@!@+62;1.,XO MJ1.S+6*2!DR6T_"W/6UW>]C5)D",--)ADH/MWQ;1[JX^WW]7%5_4PT6.:+V^KB+.K;V8-+^'[#(4\'@A,2 M2,`0U4H`91@E6CXBKR$2:5OGH?VC^[1#BL0YAX0?-8:#HI02OS%PP;EF&D1P MI)!62&D;ZK2$7)=K$I4F/,LQ"?DEM,\Q*LYV^YO*:@_GY!^7Z^ISM5K-SJL_ M;E?KV"L3`:Q6^SU)][<*SG*N)$0(&Z4LLBIJKZ;?WKFTR^[!#,'!V5D.A5R6 M5:GZ=O.4=J;%L'O[<+1='/)8,\FMY3K^&X?2C,@0E[:6'._-,YX1UAF3_"P? MIEQV-`EQ>^R$QD3&>:$L-5+H[;Q@<22Z!]#+IGB_6?L_MZ M:6N]AWG[NAWOGSVBLT5/T&2A M_L&7YWE/VZ_8=[4)6%OLN(<,(A__P=H[VHPO"KTH5Z/WP-EK*>@9I=.3AN+T M>TE"D$K^NCK_OQ_+NW^L;ZY7-?%P\ZDF'#XCO/Y=^/WL'5H?_Q(TU11(!;G1 MR#J@D`/;+2;TI+1H]>XX+[N,?Q!^SOZ]BY^S?P?U8KZM-YM9BMYLM#+:CGSP?.&.<6`(9P7&.`<$0TSEV& M09N6;NGXL*`"K*<.L&2A^[%[7Q;KZ^I\_GU>7;3KREUM@@;$"*&T-I1J:P"' M!#;CTY+2"5A.:7R]2=W>+T*G)PGE6DTC"\!XQ/OEJCJ?K0_P4GVW06!*6Y=2E_[_'@N*5*>&8A4WG]J*_KP(/[S'9"8=I]5*XHOG@I'<`8F`-)H[0BERVXMQ MH[`M+%HSB8%E?^,__LKAHIH_4!@_O&8N_BJXQ4U4V_K^PR892D3Q?16YZ]%` M`4!1MQ"/I20D#H53W_0?PL3J+W("FK(G1/IGM.G,SKW,VX<"CR::1@!`@KVW M3"'`GZQ_8PO+B^JQ5_5^N;K?/4C M@C;;[^>^NT5P#%E@,(/&"0H1`\@T]Z$&V'R1CON58!>@ET,`,<@%_%]?=UW` M__4U.&@0AAA0HXE%6`BF&LO-.F72]H6]7\#W0%3:@)-FDITM[N:7E]5LJW._W,[7\_WF*(M+8+FO`Z'KD\M-:$&(?`T-HY4H@8$1_,]WN%-/\B, MQ7K]<56U!QBTM@W.X;@1BT/UVCN-$,2B"92W!N*"_2LZ,WB`1/2!U>G+2#'V MEE M;Z`DT76VN*E=-\SRZFJY:"F&_=ZSP7E,D8A;/$6X(='UYSJXC$#B*YVI\??TR10S#@3!'HJ#9%.>JETTV-/ M>%H$;ZY\>Q^2D_'VC$O:UNEYSIC]*6-,%+'YQ>-_=FZG$K\O6.0XLQ@K93!Q MC@FKFGV[54BD'6`,YYC>JPQD`JW35'^1Y.?QKGY>M4[W'=Q6&7LJ(>=\OU@D\.`=O^+8O@C:JZ?M&*2/6=?;TW9#+Y/55Q"=KK]?+X2$#U]25T M%L?.*J0XPK:17"OB3CD8+$>W-GW5UY[&Y%[5K)I#\4'M0]. M<<@\P3[*+R&U1E*-$>L456E*?+CB1'WS/P1(680C[DRJZD,UJ]71LUHSZT>S M8_&C_ENU_ERMKN+XHE&RFIWO6_K3OC!(S;STD#"-X_I7YZH"#>YUK%^:^`Q7 M(JAW\X%WVL/%2MJO7-P]WLR]?W6&KG_=<]%MSY'%]T.[O< M\?)AI]/['?MP0/F=EI:!8Z2P$AP;8R'@Q`$$A>.0-PXSWT_G/ZN+V M,BY][_8_FK2MA7D.^X80-[TXZE-C'14<,:Q1_/`P?NZDSI4:8&^MGMXX?!/M M-`1&LU*K^.P:I+XWE[/U>OY]_G#1>?;]`>"6J[Z4KPLD+N0$&4,HKIW:/2)Q M`7^$TC(!,HG;<=>`?8O),CN068)V7G5VAS)I#>8YXFN"TY1%6P](2QP%WC/@ M4(,"L;+@-#?#DOXZ'FAX3/^N$E;<5>1T!2N_0+W?W3^6-W^NYE>SU;VN%I&^ M\WG\V.I!?_1W!0>8H\H)21"F6,8MAU);T+G+E@CYP$"U0:@^1!7V"&)YKOH( MM-3;V#FN?%U'WLIM?[73 MA42!=P'Z0._]XX`H+^H[=A=#9KFL2VHR1!B2C1(12/NTV3=TD9B!3PQ2T2DS M:%@1YY""R!I-A!-1.E%CP@D%*2A/4W;@84_TEV'/A#9C(-375@^M"0&7@>"=QA_N0']5$AOG-/8&&8] MD1K)+1K8PC2'^L%<`7OALWI#*3A:"NCDH&T$\JAB_4, M;"#U@]7T`VD$8@)[)*WUTABOD;!;76:(,>6:5IT9/#JB)@VKTY>1XDRU\D2C MA\./08KMJCK,01(G#6;<"PF8V)[[:)8O!V)?$3T'\W!$6=WC,"KL5NI9T6KU M;=WF0]CMBP/R@%L("*GS(1'.61U/]8@4E#C;0G&8-`WE-)05Q$[Q);M,JUV+ M25N[X+DCT`L//'40(BD5V$"FI),4T6QWX5T$H'^BWHM#Z0G"$B()&>:&&V0M ME-0@'W]Z_XB#C,MFVA'`8%O',4GOCEX2WQL/9O4C:LG:B_#/U?)N?E&MS?+J M>K:X_SC_\?/F\_+/V]7YS_C8+@$XYCL"-4QSYPF5<2?MH.=:-3<*]9E9VC(P M6*#9&!(Q()PY]QNQP]_FB[=!DI]7L\7Z>S2IJ@NXQ]PXYFN"DE1C3P`6`L2? MGGO?X"RI$&GY@`:+7\LL5!D0W1_$\,]_U(]^B^(:__/_4$L#!!0````(`$R! M!T7/ZV"59:D``!C_"``5`!P`879C82TR,#$T,#8S,%]L86(N>&UL550)``,O MW>-3+]WC4W5X"P`!!"4.```$.0$``-1=:U/L-K;]?JON?]"<^9)4P<'O1RJ9 M*?FA&>H2H(`D,Y6ZY3+=:O!-8S.VFP/WUX_D5S?0#TN6W)XO"31]O-=>6UK> MDK:D'__Z^K0$+S@ODBS]Z8OZ5?D"<#K+YDGZ\-.77VY/X:U_?O[EKW_Y[__Z M\4^GI__P;BY`D,U63S@M@9_CN,1S\"TI'\%O`/K_7V[.=\)SS^@WSE+\0.-PC?,DF]^6<5Y>Q/=X M27!43WO,\6+[(Y9Y_NX)E"*74J1:E*(_'WAP^?:,?_I2)$_/2\+/V1`'.!"7 MG]%*@U?1<,F#+&8Y3:. MK(R7@AO'IT?N!KVD7[L@/S7?I(_?(\.5]49<-YZ,7TN%^4>3PK(\,)[4"SH>6X,`C<,%2# MT`]-Z*FAXOO(CZIG1C@]_>6VA5!])-#&%Q8J/K.JD>=IEIF*):N5$K6FX8M(B:>PB/KEP2',EFMK:=JS7$2U<9N M\$-";:3E9?R$(X68@8JB.I[FJ:[I^KZEMG8<)4!1V0W]=_8A[H>S=)ERQQ3$ MGO[2"-(:%*"H>BH1/V/[97T4LMA4G)6G/3E4@6=?'[*7,^)EG3Z1'SYF3;L8 MV"(M@\DZLI(,QY\):C7,.N$3AP>`E;#** MP>W`)\D81D4OS6ASFCOR3R+-\[7`=U4;*8YK!X'M^';S_$"U=:6O5#`]5+)" M=+DW!<,@"VS$'%8#:9QP#OSVTR&@YV\ZO*/#G6WBA;$ M)8Y"-7!4A$*H0M4U[%#7#*,UY/N:QMJ]V9X^5C^O40$""U!<'%V>D;7^?5\> M89PBT)LK@7KPCH0#PL!'V(04@M.!+5(QA(I>F@&)E3FUA);Q0V3Z`7*0JP=! MJ$+?""%4M-:``6'05RO8GBI9(SHP@*)A4`9&;@XK@CQ:V)2@+R,"^O\[EW?T M>SY:)M#?.8%G0UL$1TZ`DF(6+_^)XQR13XI(]Q7;<"SD^JX6(NB%"NS2#T4/ M#=:L@/7Y8^4%-2Y`@8$*&4=FP,Q=_]Q`)FV&F;@&8, M=F%+EC",#@X=J=.2VICEJH%KNZ$-#=='R(2!UDY/!,ABGSY@MS"REC3I\S`U M86*054]DD3=,4?KQ)EQ3-LCHI2H\Y$U.5[B?O5*P=[VB^ M:1NF!FW3"@T=^4C3NO&.[9A>7VGA-B!961I<[UZY'#,8_/P=%I91J&/3%3[6 M!.C*+BYVR,I@ZB:@*L-]R`2V)>95490L<>X3$P]9_A9YH>4%R$:>:U@0!8IF MN&8WY:KY/MN:*-NSQUD1K3"!%A3SN@[_S?NPK* MQ]0$=&(0_$\KH$-H8*F9R)Z>LO2VS&9_W#[&I.%,,Y3NDN;#,LJFUT5JJZ&F@8= M/W`AA+KCN9:F6Y82JB;R;=VS>NXMX7Z^Q.[40**3"'4W.M[&N%WT;.E,PAB= MR!:1X7YD@IL:8]>AV_GGJR6^6GRT[,5%,H-D0)(L5W27;'R_W-B58FN:;AJF MZ;FNY1!HCA+X+1S=41RVG7&R4+#T/ZZM8_`R@[;1/17NIO9N+V!5;U+,B:DT])7"S\N'M$R^[;>.NT'JJ.YGJ:X M>J"9GFF$"#E!&`2>95NJ<6BCAQ`;$GMY"XMV7N*2VKO/L)9GCN??V2X'GY^D5>97')>GU<%8F+TF9X#42 MW3(5AZ1FT-54Z/FAKMD=$M?Q-;:$2`(`Z;F0#V__#M#%U6^W`-U<_0RNKL,; M>'=^^3<`_;OS7\_OSL/;'QB3'QF!Z"=[1XX`FQ@2L+4&MG#!_1OXCB(FN>CW MH`,-UJB/)Y3LS.Z13XEAFHBHRO0P&ZW-,PHP@;!(R@LR?HIT75-IN9^GA8KB M.H'I!'IK`;IJKQ)75J0RP+//D?E56@[8R`Y>D(V5I2MF*[K+;O`S M;5WI0SV+'2$E-'0ET$W=\P-;0RYRM`:@XR(/19N'W1WL6^/AZM4U]YS^=[B( M;0,\R#KTC/(U8J#ZJ=_$(L0EGN^$LS[3]EVTUIZ<`"JT9.!,O#GYI*?7,:U* M&5D^A05@C_J.'^2)B/<1',^.W;\&O3K\&AVQNH87:4;@V:J*`C]T==L+351N5O55W4!PF*:?#/-JKDP+(ZBV`A2(TN=--[RB'3QO_0)4>?<(+_TR M76V>T8F_Y\V)OU4[\9=U$W]QYSCK%.QQVD4_B9]\@V![*7QH"9U#X-.T"/WS M?\R$KXPH[7G?'+513.0-=5P.L@GU4L:W8("?B0`G]6&6Z1P^T;''_]=GL(;0 M"DS/\O3`4PS%U%7555N3R#88:YZ&6)+^3MH$5Y7*Q!OP&%\@@RCM]QX8BTLV M.=]$=0+(;TO<\;D)\83.8),7^'PUVT^O%'7>P]T>D17!^$2T4H@KF?@&R;YD M]I+0^[!0E@?9ZKY[,L,3Q/1+^$N?,IVQ))$\N248[C`@>X M_O]Y>HN7B_.T6.7T:LP;7.#\!48H>VMU(U7Q8,*\R5<#`=RW$[\D[!E"4H(,)&ISCKRGU(&__NI)(]B>BD:*]^KR^ M))ZT_OM5FITR>.YG3U2BZQ&QHFEZ8(V2OHD8-Q/R&9&N MB-6>Z%-Z*_.<[@?LD+'N!^3DL)^DC4`>FX15@!K6_%ZLR=G=LY67/>HTD,B) MJ-%0+S[NY1%!2K\K[M9K"]2K\%\KDF+\C,O'C&2)+[A9CKC$9;:@B^Q5B05= M5+V.DWGDDE$O]`T=(2_P2'LP`[.;H5.0KD6?KI7>?S^;3"P=]Q` MA9GF#C1)HPO3N*"YVHI67A?9,IG3!X-XL2"Y'/FQ2^:2SD&6&_2D!F^_$$XC M8*)JBIJXU=C!!OBN`O2=`X!Z,)E`,=R`.)6`\5V,*#UP_>Y/'$#BEA?A:'&9 MPFV+H_B9C=S@&9/[O\5D@']1O1JNTO"5KMNODN*QWKH;X/LRZAF%V@Q=5MR';3C%^.QPZQB9A%31&R1I`6S^I MDLP7ET15F$`#JJO;;'"-O?BTDZ`]@C2KQ2]/XU,"T^#8S$1 MO93AV<$%*$'D#5#4&SS#R0O=85=$T*`60L,T`D/5#025[F0"UP]-@WGC_P!; MTE.Z#3#5C.U@&61BDE?YA%,H4NPVP!U=VS:P,,D9#\&353`N9PZ*%C]%`W3J M.L?/<3)ORYV:S!.F\RHKA57F$_D!Q# M*Y.4"HW39#56K)<'Q5<"J0-4N2V6OX[?Z/N`;O>9S?(54:SU^#,*'1\AW[9A MZ"/'AKKGVQT:!08VRREVDB"PJ`''B7=W>3S'W2X<6N!9'6E1;2ZLP79B/5B; MQ82$5YM'CX80;6Y1@^N-R#3`P0;RHVMT'WJ9-%IHO":KT6*]/*C1$DB5<'SS MU@-6%&0[ON&'JF(%"L'CVUK0HM*M4&,YYTDR%";-9C\#ZG+_\2(BSH.2':M^ M(CZA,+&).C\6-YRGQ0M@.3>NM\3TO;3!R-3 M#Q'4H6.93NC9GJNJ-FQ!:4'HL*3H;5@M)H7O'8B+:*L,S[M28D;RAJEEO M#-A^FIZO(5?1H689'F'5U%Q5\5LD`5(9#UR1`$!^"=F'VZO.+W\-;^7<7C4H M$(/4=*P("%75#O0D#C-E9Y9=:$6$:=J"*\3#?L(KCLS^1_$UAY?<97#VKU62 M8X*)R'_Y=DW:?0G3.=VO]4R_$JF:;9B.90>AX;NJ[MJNT\V$6$'`6*TAT+#\ M"@WR^6/<["-^;G!6BTZX!`:@+/+X)=-;%4F*Z4:OZEH8JNS-7^81 MD6P5&JH1*J87V);C*HK38C`M;:AH#C$M738K)$52'22\4SA!^9AGJX='<-^X M0@^EAT28LJZ1KG?JT]RVA7ML;=W#)(NZB@C(5/55B&^' M%%8<@8,V/I!$.)D1$:+V(Q>:NF'!P-(=Z'C00U[8E6/HIN,/W_O`9$ZZEM;; MQFCQ4]XAJZ93!>R#8".6M]1,!J-B=T-TO/I[>1UM1\0F7XR;(KBHGHC(B?.G MQ]:(`40Q)XPHRTFR.L-X7MV8554`;QGR1XH:!E#3?==1-)*^(E^SNDT:@>%: M?#FC*.O2I2[`SQG)&C?W0E?EAZ2$_`_:X% M6YWO]'VS[6';W.:1,L2>?/9($D5'9B(2*LV]':FB'!HEK")M+?%R74-!R/24 MT(2>'2*/0&Q1N9YO"5B/%P5EK#7ZIFY69MFLL.B(7F:2'ACI2TZ3+IOMR;B0 MI:A!H9R(EH_E+?<2E0"2!Y7-;H&TH_3+-C1/517/AKYF*M!7S;"=K("^@MRA M9;/BD/S'ELT*#$8_79].'-ADG5G2IULVVYMNQK)9\6&4,5$R5IG,ZVUXX9GN$I'EV?(QAT#]F&Z[9( M=%,74S([!,#H);/H_!)>^E)*9@<%8I":CA4!H:K:@9YRR>P>9MF%5D28IBVX M0CSL)[SBR.PMP#>XO?'O:G&1I0]W.'^BYWG#=-X<"WF+9ZN\F?&V=,^Q=4TS M=-5!7@!]9+083$=EK%,0:EKZ0EZ'EE86S>FM`MG],GG@FFL02WH_F1V?;2Z! M7<.D/%.@IR5!6ETM<++Q>WNB[455_'"U#D5=4MO^>>W3R-K+0O<>U942M8GH MK1S?LA&:/6O)Q,9JXGE1K.BB_V$TY!T100]Z.@IT-U0<+[`,WU(Z0(:J0;9< M5QX.Z2GONT5\D#3@6REF+:"0%X^>I123"`1C4<6[")QO1."]2.^0WZHH=^P* M"UZ:]]5:2`_=1-1Y!$<_UE^,1"USJ=O5HDO,?7I]5.0X.O*AI7EN8.BZK>J> MUY;60>1:C&>5 M963^_(-2[$=C>!U5%VE]_^NDUQ?UVP1.>586*7GG5V>0[.:',_Q MTW.[`XS\N,S>,*YV?]&-8-_B?,ZLD<<-]9!T=8HQ%I72UKZ!%74.=-Y5C6#7 MO>C5AEZ2YG9.@LI+T+@YB=174,B8T^.QF\I47D33(*-7FGV<$'&DXD%"I\S3 M>4$`/65I93QR;EE^O)Z)G%2Y05%(S M;]%R)^I\Y+*FZ_)8'9RT7^6D1 MK&^#$8PI>L\M6/&Z-SP2W&(X3@BD*&0'O19*E)#*]1T#Y($UM-=ISVH##JZ MP7C)^$!CTC4V2.@.\OM5E9,P)(XL@K*\%LA_;M3+7A M:X'M0-L(=0\1)34[];04EWN`S&%JM$R1[O[_F"I6Y\VL9N4J)]V/.UWD(9@U M+Y3%[.`$L$[QNMG2XRYN?6:I5Q8W@-R)2=JGC!,*#IMV.1-(',E;@R@-3%!L(WV?$"=S0@QB2,"*04(*@ MTR)`R"9F0O4/A[U&6+Y_RM?R+D:BL"\`/.0K?-R\?Z*WYG-!K-"/PF\('(]%S$9;_N- MHP0A2T9!M0YL6D/I%-S>DT>*GRCX):;-KWYE?P;JNQ#P?=S\@O[OE]O?\!V] MGSXIQ,+Z_"`>^E[%!0J1;G.JB_WB`.D-:+""$Y>07R&L%:7R@RA6NT=&(J=F M;#L1HQHBL*>D8J;TZ_4/)NJ_I99EV$,8EP[`6!AV,+0RL,O/:> MF8A%O=%.%VDAV"N@9U1Y56P!ZM#$C+_=\+$:_@?/4E'^_Z-FJ;!12K-4CC+A M6?JT?7U=9GP;/EUR!,FR_.NV>"[7J[J0U]T'A7F7#(91G$1^$L>A%=!.)*@; M.7+'.'6-*C-/E0YD/GUY>+BCG]F\Q'$>WGG&'5Y^UO=8WH&A>LTQ7Y9;_ MOWES`TK^]Z4W+?70*:9M)IF4T[`6">!0KG'CT#LJ+@B2*FDC$1YE^#^]8M>' M!ID7.,M5-DV_9U4[DF_Y00PC[%J6$]+$IQ2WI_NBD%A03DND?_SP,W)10Y3I&XV,J%OP\WN8_<@0%A-^$QEO MLEB6U7:==3$0C6(,81Q0%@I!S_%]._0(?S#(<;"%J.@3W(H_W=R\J"_UVR.Z M7A9PFID+\Z,GE2.9(WVM*+5^7X)S)7V;I[-W5_?%V3I_2_G%(K<%/X73G)'* MOF^B)3_@"7T8>SB`B>NYT$J"P''<%@'"/A(K:!@8V'A-XVYR_^]_3.GC9Q#3 M:%K7(&_OV>_ITQ0\XBD%3[_C!\%%VP3QEX7KRHS+B1G'":;=7:4,*MAC!0=@ MP1\<+JCQ7A`ZX]PORGG];^I\>ZP^.`)Y-5^\6W0X)WPI\2S?M>J%1)ZE$XN+ M0:JOO."8M*PT_IU*9X1L^>.'V[H5D"#'3Y#MN]BET`LM)\*D&2A$$-FBQ]#E M?[#)E&:'Y7I!VT]T7,QG5*D;2:C6PX"?LIE^5(AO-\U?LL5VF4V>/Z?+5SY2 M/L^ZT:?IUV4V(S;UH4<]F[JQ[X0XAFULR(8.;%>F5*)C/,.UDQ8B+YL<@`0' MLZG&*1H6:*5:<+MI8)8EMYKZ$VQFF^ECUBYM,6GD?"1ZIM6D]UM+VND2;X3A M&RG9^C5=;W[[$5,LX;7(R)<^8F0:@$ZQ?#>^[>?H3(O.: M&ON87M(JP]_66;UQ_G[XN%RE>3%S`R>V81BQL2%"L860;[4`8HR)C-SH&W5X M#6J`R:J01I[%I.DZ%/?6JP_9-?7VF1A9%V1,/^$CT38#AOW\Y)D1ZL2*_D^? MR&->_V)M-C41YAWPT$_(I&% M_9!:;AA@&@6!TPX7A185UN$>8QA6XD-DH(4FHR9]Z!.0XH&8DQ/CDZ0I:7$? M]B34>"`6U?18E4TQ.3YO^CE!UD#6&"19AQFEWF]([X8+^V&X6$S9"G&[X*_P M/+-?U14+R[,#%WLVHI:-$NS&$?);.`1#H?#9-`;#LK[?'^`0ZU.U'"38HU2K M:1ISB9;-FD&\H;JOK.R(:VS@G&-2?5.GMV]&4I0P;J;2`NQH) M]`BB442"D*T&26*1)*3MD(GKQ#*ZVV<-/8@T MHHD76+J@>SJX'8FV:3&EU/_IR3\*_)Q5%F[H!U%;TL5Q[$+IUWUU#"HSVY0ZJ`]Q@M5!2\FR10KR=G61?Z%7 M"^]BFG8%PN7D[8CIP^:=#N)A&X]LNJOM\5L!$B^HGV8OC$0(=5OU\[NR^DD3 MJW;RM\+X6\V+F$65;-2OR^RA7.;S=DSL)!&):1Q&KFU3%CT2-^DD&0:"3YYK M&6H`*=P!!(L.(7BM(;J60W[7FA&N7[B'/ M(G[HLA4Z<:CK$.H0;U_%2X1V134/:7@!W,]B_J[TIET.TX-97/)97/!9;#M@ M]<$,-LJ^GO3+`/&&$C"%DIQ&MO4F8098-YR&:6IJ%.:F1RHF2>X8UB,#5DFF M8TJD"6]LG^H`NLN+[':3K:J9"V.''_YVL>TC3%`EGGSM-Y+A]>7, M10@<'Z@!RG;@].15;+]Z.$KE5HX^;!K9D[Y(U(6M:#T$CV0'6I,QI8EO4(-J M?4Z_YZOMBO`X,/V6/63KVV*>\_Z@61*Z%K0A##"*<8@B2EVW1>'9R)-KR]$\ MN/$]Z?T,;';YP'R'$BSS5;ZI^,LJ8+Y,\Y4&C>OC!771&XA^#2IX`W9800N6 M/^,'6K@CT,7S7$H*I0:GC%@Y=5@G(*7:2!2K09R"@(MBFRZ?ME]KN6`(2,:/ ML\_L&%&4V-2)0\NQ$A1%?MB.ST@6KT+H'-1PG-C``M4.5R.=-3*9[%`JW5DER7<8F*P[685ZLYZ/.`6,U!@IUS50<3!(^A[F#$KM+P MEZDABF\@M,O='<CT\&G/BX%%3_)"\B<20;P1"]NN[14Y5=QZ9 M/->'TBO^BZ/#2J<.*#V,QR,2(?WU/:,6W)OQD%B@K\39N9#?K`/&$/P;MK`< M[&M63PCNRJHB9;')BV]9,?^!Y_,U6XV_%(N\FM?7*2YF#H*V&_E>F#C8@T$0 MH8!V(*"#%3/7;SU3>#+/.7LLUO^>('WO/JDV^JF\]>MYN^'MA=5U? M]LU!S7Z0SAP&=H%Z_L"!@@.D+(UHL-Z`0[372R,^9E(LF=#HD?&E%#J-.Y]8 M:*=0+KTXJ>QWZ5_5-M]4,^0@;/N!%P8(^39R@LCM!#UT+*'[]S4.-UCZ<"9K M6.Z`JD2F/8F6R`V&XU@U%S@38-Y=CUZ%0'\XFOL&]LITRT7Q%PGY*&K7P^:8 MHG1-%IV*RG62I;X!_)0MG^O?9`M25IOZA=]XNV8+V4.VSLO%+&%(0BLBR&$? M31R%";5Q!R2@EL0-#T;&-UZJKQ_\SKZ_9FPUYV%W54?F%0XB;RH)[1L9O,`8,=8E!#KA\;!PUHT*"^OCMZ[C`/ZA:=6\T]W:.^ MZ_P18S+;S]K8'\,B9];`CS:D-5,I_S[I8S;/\C?^'%I2K@\0SEP2$@]C*PRB M./$)#DC8'@"+/!1*[DGW'\_X$G=?%O^8;]=K-M/!ND/9+'1_E>L_61;V7VPU M6[$UL&H.JTA=>Z21>;%RT["4RZU=>T'<@ZN)/H!WK9=DS]%UH8ZDC^J1U(XT M&G3NY5E-5`DKWF3SPEM+=Z/?%HMMM5G_B/-JOBRY_E;=4[B(/U24\$LV;8B( M2TGL=Y+KNKY@L*]_7.,*6$,]"%9:L.``K=!3SZ8=(":`UV%>3@BU46Y$$X49 MO*"-^KTP$HTT8%AI^@/6TRE_U#+$XM0DG=>Y_@P&GNTD"-H6P5Y$*:2PO7PS M\G$@_O:/@;$-5]P?3E<_NNZZ=Q1K)`,Z1D>%Y&0? M9-WSG8S$#UK:[P?QAX$N?"6_].W&/T>6?%-^;]K'6A/199Y8B[XF&H6S@]^; M!)\2X/*+4F:/?$6+)PE4](+>L_=X6HP[![G=#!\X19(F[D"H8\\%( M,@9S]I4#?KNO`]\V@46K%+('1$H@53B MRCY2TMQCR3VH7?.K%QO`H$5<;^Q=VP\2J<25_:&62NCWBU@J(4_6N53"(.UC M2"5,FE<.\_7*+'IT];HL?V39IRQ=;E[>7W+QD/[@<.H[+A;Y6[Y@F4Z3[RQ_ MS"C"L6,E(4T\VW6\.'!PE]E$#K0E>HP,HC">6#28#Y>^U>Z8\%&WT:Z:EJYX M9W%=1[B!*V_=X;BFVG9T1J[I72Y;G^WA`KQPWJ!KG5[YC_!ES[>%L+;^`:W$=L7:BY:2-Z M)#4V??:4AKY(V;ZE];>TR/^N%WQ2%A4;=%'_!A<+ELY4;3`P>4[R@FEUGBZ? MV)]D/$K8-PAX@94XOD4CDO@1Q83I\ZY!P,/$\T5["H?A, M[Z>209(*;V+Z:Y@P.3%MP'"9W,,!?TSY`R41FV%_#BV//Y-S0>MZ,#D2X>IC M0:GMLY*4E$Z\)L^WQ;Q<94SG>,UVG;UD196_9;L_;96-I9`1C%GVF+@)A$X0 M^]`+8QJ3D!*/1DAPWN@>UMRDZI#R>74$$308KQ=^2))X8?*9 M3#Y3\,O=Y.GIUX$GWYZ+"_-*@;"13!D5Y&7OKT7E"-&)"<;'O,_8+)RFWYMC MF^S/UUE:97'6_+>;@@EQD!O"D-A61&/L.\2".V2)'6.H<+;(+"#C$VLR_40? M`9M8#X_T$[U_NOV-'D^T?ZF<,S+L)<%JR;C<(UDJJ4\FG8Q`?N$&_'H#F`T\ M2F%67/F(4B^.+Q5$AG/@2'1X2(M/G78:DNS>NO^E8,,O\[^SQ;_3O.`X)T7, M$+ZQ'.HMJ_`ZK_+BV^%Q_M:.&8VAD\1LA2(HB2!"=N*A%BFF1/)T_14`&E\7 MR`O[70;R`CRG^1J\I2O5V`&[;[TD2V^W8 M?H3LV:;BE.]$:./VM.1G?LMBPTAD/_W;+7_\,*LVLRARV@=:X@25= MLVLNJ/^U/H*1+!17,[\4TL07F2HY2ZVEEJ\31 MPC'2E4&:TTNML,;\,Q)U-VC@^T9:PU3J2!!FT`J@BSW?I]#U4&!3.XZ;(1,K MB&.B*=C_<)SK!>X`3Z>/M]&7*8[N*)A.0,S^RN/3+<&/%'RB^&[ZJ?[E$WW\ M[9;0IQO^S_^I+]S_V`6]0W>M[!L*P]]+ZT/*KS<:3XRM%B\+,S\2==1BBG@< M*TF/X+4KZ;I@JEKQC^RAKLJLRN+IA7U/_#@*/Z7>M0@Q70V)2R&U71IA'AC' M?N11WT]3--";8.:AZ:*R?""&C#X90?Y5_G[W74[X++T79%Y M.17L**^?4!TSX3*WH%R%>,5+3UH'U#G5:[,EPAU0<;P75G/!*TU$J3BQBACB M6;G$_9?+O.-WE6T>^\.),M^%8H7_NV[:G= M%B_#6J/$=:/'C"&*+(HLQ_:\D(%*2!BVX)S0E3P&,`PFXXO4H1G-)*WXW9:U M$4VKQ'QO!@\BZ[_,_E_6SG0^R>M_*!FJ#^14L:!^?-Z46_B.W+@W`-`C5Y)C M5W9BS1?*V@Z6'M26#)P.:&'_0N(PK'='DF(,;'1YS0DEN)XLLGQ&&;#-C[NR M::B9\C1X9L.$>*$?P\2G;AR[-HJ=>I@`)C1R(I$KD%5_ME1!1K[PW4`"+2;P M1XU*-.I5)NRRZ@[!E63B($O3!1VLLOD_OY5O_\VL;"20_>*]\IUAX(2&]>7J MRFK4&WZIYY.15HBH&PA_SZM9X"$;)XYO)RB("2:QZR;M.$F<>'(2(?G#A]&( MKX??/\A%A)!:M#\_ M+E=I7LQ"/[%P'-L^P9$'+1=:(6I'L!&%HCHA^6,-*\3^8V_PR"B#+$$?:X)! M;N340((6#2IP;/:9^:_(S0AFOBKRLO>'(;/I<9_/7\IE6KWERV7V/UFQV<[_ M_/$Y6WW-UC,K04YLN3%QH!-9@16AJ%,7BCU'^"65/H,85H(C:#>@!2=31>]% MH+`'PTRJ7V(7@Q*[#P,Q:3:7H,ZHV*;#1>L/[>]H(.P,6PH M:+&CU/PERXB8N@K`=R[>"V$F$)5IU M`,/RO(=U`W;`9(1%F38!61Z",3E)/D&6DAPKLR8AQ4.PIR;#:BR*2?`9J\_) M;U^2QB"]O6TH-7XU,I([>Q4G-FM MK7E0*1:=J&*365%.XG^_!&^294G&E6126QFO[0BG#XC3C4:ST:%2T0P]MB1D MUCE1:AI[R)&6P.J1I:"NSDG3DU8-\N1T]9B]IT35B)LY**J9`:6MQT122ZOM MM\WBYI\+'V(<,3_R_#CQ$.=>P'C_L;Z/I1*)LI\U@DY*+G=IZ\\KH0O#%77O MGY%U#DU=K\'+ MZU-K4,'Z.:Q!%;BEWB2K[":NRJ?UT6P1P3S&'O2#-*0T2&,$,SJX6Z209-<> MP?E96X_K`OSQ'Y4P69\SB7W%*'2I+?$=)+-TNCYO"EN,4?C3VV;H\2BWTSAE M]JG=AC%-<]AQF!M1VGQR5&*?/VX7E$19%D.4X2"C"#$OK.>T_]@`A]*QC\1G M.=;2/Y9%M92];E/:?HG0Q[+I:KKX![V^I;>N(Y\_7AG?AQ(*QL\A\E&!6^K- ML79]\M6ZR"^W^6.UB.N=#^?7]%C$J:US/ZNJR^+?7]9W7UH,[;7P.>.,QC3P`\^O_PLQV\D8043Q@DD+(ZHL M&KVKI1J0XBVHJH$I6C__$$!!WJZJLH.JVO#'!MWGQ6@JGM7$:4?P[0'!G6S= MO$FPFR8^;[-V1,=<<#Z3]\2LFG38FL) MK^LQ/<]/."8Q#BB!"624,]*/*=Y>EJ_4-!S(<52U6X1%"Q#<-0AE5=Y$D[EH6QQ-X=TE#5; M2@C0UI4*@BZ:Q9U@](>UR`\R9@$:HBX:R*-!/S4$VG<\.>,]6\I MMPEA"A+$L8CCF"&$/-CG*)^X"S-I-*:]D:; M*!P']P-.4`J@%B-*29K-8W3[#%L/U,'--.3:B]GMD^PL<'^+;"OA>S.&9@RO MQN6<7((=@Q2B>1VJK#B)*W'5\&J1012G(4$4)VG`@BC+O+[*#\$`60^Q;KLMM>T5+OKHL/N1")A^>V[%OOXJ*J=4+?(LHAHS0+.8T MY1SY20!Q7ZF*,H0CA4;4+F&,>/HI=NF@*)L[;]M.D>M"W(C;F-!Y&5"U1ARX M(QUQ=#)I"BYIZMG235<)W*`&#GKD]1>@Q]Z))^C0'ZCL;*9)P[--/5VF23&# MU64M=:;!X5L>TN6TS,EO.K7SF#=U3ZQTW=#5NLAO[MDF7ZVWG5]_;ELN0A_& M/HH#3&/&D\P/8,)IPA.69"D.82RS&3,?Q?$>3``3*[B%UD>JSXK]4RV0>=ZY MCD'W@HS"*2LIA@ MF!+?"[S=:"$T41C)(2;1&+4^KZ8DZNF,`_YL*(U)+UA[6G.R2ZPE-F>J-ZI6 MO*$X6J1(:\Z'_'OY\%ULY5[$4=WKG3Y"U,-)&B,?)0C"F`2#T!'D<[6W,LS& M.= M!TQPDIBOL;*3[<[&1Z\\_M6I0I MFLGZUP!^N!O1-%UMI?>;FR3E64A)K1PDK3)'8<4[H$9KS4^35-VCX*UUKTC4G%:^*O1C:U_+?.G5_V[Y<_WX]-@'$RSC M*."$L3CU_`S1F`Z#X)@KGC`*"Y]17+D%K\[7M26?X=CJLW`"QK. M2(`>73,1`4WPI8TG1E$(Q+G,95%M-TU99A-PL"""G&6,AP2'"?0"$@1#P,%2 M)370^'C'DB`0@1TDOY+D8K8N:,/.A MJ.2/6)AE$$<\C@:]XU$J55IO\/&.E:?+ZP^H5-Y,TN3KO,J,1)6:OARRI'6E M@29="J]HN:=-[^4K#?KDWJ@3*TH+3VJ*BHZHFBF$OQHE1> M;>DVJQ^;]^6ZV&;K[_G[?"/>KJ*?RN_YU?I3N>DO)"9Q6$>:F>_Y#/.`^`0/ M*6P1?TJK\#AP7*>E3Q:5]7:`Y1;X?P_^#W06@,8$<'69W'Q0$:V19D_")\QO MXA23YF_/&:V_6?]ST%@!A!G'ID_+^8PTCPK.:G[SJ>?P]/A2<4#.>=-T*!K\ M23J&8Q:?%'HC>F8AW&86E-:>%<54^$NQ;Y+N-$9)FF;,\TB<0/'^`!HV9HA[ M2B6Y&A\_3A)J]V:,SH&:#FMR"6_'A&FEHJ2Y2V`7TS26N;6%!: M>Y:,5*1+FWL)3CG/,`XA(=#+>`JS?BR*F8&.2`XPMI+H':'I<:>C)@YH,]23 M:0[-CK$BK2F*),Y2551M.*LK6H3(7@)>K,JBV8%^6A9?;^[OZZWHZL-R"(KB M-`FIEZ$X2V":X"#!O'\OFX6$J/1S-!Y+9=EHO2*MG$\UIT]B1S@J;VIRTT(# M`S;0@0,"G>9-X::,*MT8/B*SNC>'-PRO!X;+CF%QM9MQ!\.W"#BUF[1&W!PV MEO:,*5T\6XJ!8I]-%"/=_EA^ZZM%DWJHR">4D#2H_Q`.^["411&D:JTN-`=Q M+N!#CEZL#E#5R!1#15WVY(+%$6A3T^^!KT:O!:2IRL"/4W,F9C3D2A8CVZP4#CR50/SJ@/ MH1FIJC+EF$]MF1JHG*PX_31#4C)E0.SL9,K$EI,R94R043MX\;W+;?Y8+3A/ M>,Q8EG(O]7@0^1CV[<:8A]/`M"6\_$B.A>KJ5$_SY@<-1!N]X168E1.K\4A5 M3-$9\3E:H_B!JC.R98?BF>B6)6,DFL;K4B1]@O#Y8]?/E1:KPQWHQ_SG]FGY M0#]5C8PN$,Q2/Z`Q2P/(4XCJP"[M(60>@6KG"39'=G^Z('H9?^Q[&8-EL0)' M\B^_=;A_KS<^'735!+K5^9`[H)AJ(I2/*W[!&5`[T)AJ)K2/-[K^WJM^1M:O ME/GQX"_CC)H&W=H#.X[!3[8*;Q;H]DL.'KNF,0_ELK`0C>O/ M@'YP/@KY5F+U"]#WZ!G`@A[M#$+W4T0J1O+&\S'CP-[<-HDXWQ*!ZF%_5FYN MGXO5NB:^!I4LBZ_5NW*S_;S\G(L?+SR/1BC($B_AW,=>'-=*WH^?XHAHQORF MPXX3\.^"F_MR`ZH><'-WI8`,'CO,S2_IQIG&4Z`8YH_)O5&,+TB_W2>]P0IZ ML,TO34:Z9F0_)OE6PGJ9)Q]8C?+?H$@FQ+?%\MSB>VMVG0KN[1)G%-G3Q_*I MV-X\;:MM';G6/G$1(DQ8'`0L3%+",NK57PW;BC!,U>J@[(PYMB/:6+H)R!+C M^B&\6ZHMQ>XM2+"'<@8Q^ROF%(-U?>9G'*4;&"41GIM2IM9[KZJ>EC41K*RV MU0)%69)X&.$HI8S&293Q07'CJ`Y$5)ON*7VZZP/#)FHC`&!AQKFV=`A=R. M_F5S/A',E?=-KK;O*K5`-("9%S%".(0I#STOQH->U>&<=#\(\Z$<:TJS?ZR= M>7LHH=--SP*;$EOR<8G449N]+IX]J.0(9Y0CG&<4(Q@!.LM M>S=@RB/*I*7>:!3GD>/++)6HZ'RN\8''#J!V8E"93M7TJTLFU?.M8)=O;=JA M"6C@W>@DZJ9379)I)W_ZZLFTFRP]($`J.ZI+VAQTW(XA)_.?9M3(J7>?416[ MWW^OMU_>;];%W?K;\F&OM**_<[0LME\>GI-EE:\6)`W""!,2!S%!A/E>D/37 M!*9ABCV%LSA7$)RG0X?#'U&]`'[4T,&W'OO+$J1OW9V[CRU^\$D8H")HSJ9) MPF',87[4?,DP,4U.1V`&[U],S%"MUU^&W`$'R6PF1L$)S6&"]/R3X0HR]EZ: MS)UR;*XG8@X^S[F-Y8A/MNK1X)YW[MJJUN"2VD>OB\__JO\60/8+$A>UNX89 M3C&)PY"1P$>4]]6':0U*LDS=W?AC'QD.Z[E9OZ`LE'J/.YP'R`SIF$H[`IRM M?^8ORL$7,.608(HH"U,6<(02U!]OI$G@,8OJJS[XZ&6#`N%.=T7U]>M7)&P* ML<9\6%!AMQ-A78(;N+^&_KYB5E=\]:?H5U!>`^M49->4Q#K8NRE`6<0>X2%*.*$P"1!').)#C!VQ*)1)[9N.X3BQWZ/I:Z_*^P/) M7`W`90M%C%D]+Y%C$JIZC-M#N@`'O&J)7)7?_?US^?W_6XM;B6N_/A2W-S@Y MHF*V6)Q8KJR94=I]N(SN@-V7/"ID<5VN>+%:I!GV0T[#((A#$O`P(X@-ZI=Z M4G)D=T3'XI2^V$\WZ:YQ8EX.=X M'N$>V1/4O54/9XWZF01DEHTZ>]VL'KD`5BT8#!(<#6$@S0*I(EUG@[L.V!IH(DXK!3A0 MM.C`70L/U$'#TT;M@,?)%$BT,W)S3UH((,.,^A`3SX7VI5\ MX\^)E=H^*W.C4^XGQ9=<`:!=ZN=PK.;4OM-%@BZ(U,KF+CR?018C/R1A2GP> MT3`>W"?C(5?JD:'RP8Y=TO`:?05*F5>W+#"EGD6U2I))CG3"?*=D-E.:JIF$ MQGK8SV0B%0F0+"+.MV)M]>^ZB;=4\M6?1%*R+<[IW;=8,8/`G(H,>L(34NID$BS)V.?T69 MVA'?O9G;0@5_OB1>ZO56%2\V#KU/`L MC=)GAW8F8R9I$B>FG3U'M$F?IHAFR[N\&R^!//0]DF`F`F460Y[`X8V)#"M> MLZ8YB.,H=E?%U>0;-7H.Z].GHW:.F#.4-H%J#B*V8T=:L30(G:4\Z=AQ5HNT MB=&X/"U;KC?_6CX\Y3?WNV]>K9>?FHAD@4D("?-H5._?.R4F1I6*D%%K<+;!^A?%ZKAR*JB^YKL."[0*M]G9HIS;*"-2:_IM>L M#7"$BM4,-W@OP#\V957M?CC9W6OG*3RKS625.6A7IW=W3 MXY,X@5_=U!NU#2L?OVWR+WE1-3=;WI6/^57];%[GVYO[C\N?"XZ11V`<\"!% M!/N0!CCI8?AIB-3$T?;HSC5R#S`H!6)PMP^YCN@JU8:-UF=`3C.DV_; MD>H!DKS([]?;1120,`Y3Y(<1AQ[CU(=]@,LA0[ZO&@](1N))Y53&,5^:)S)'GR_CX_4CQIX\ MB3'@91:G,";X2TL/B&*D>EE43QO1.#A=5W=UG/6TR<5-:TEMU-=%C,*009:F M/.*Q'[$D#NJ1`YIX?@1])'DQCY6AG)^O7%[?_OF!7C,.WM&/'_F'6\6`TXQ( MN>AR-`;5%'>`!7:XP%\"&6B@C7U_\#F:SL2'5MB=23!HQY;2P>.GFE\2,L)2PF"1QQ&#(LX@% M80@Y"A%/L_"M"I214#A,DNT6I*BOV(,..NQ-G__J`C3P_]:V$>D-D+K@UDWR MS(CP8YY3J^:$QE[9IUX%&L3 M<<:YC#_9,_$S$QA>3KW.5(^$FA'J?T-_KJL%YZD71"1*PLSCI/X[)JP?)$H] MJ?L3]#[9=2U.L\0%FCIXK/&H"K@B39*G,LX84CQSD2?'S5G*/@_G3DJT^)J) M%FF"/SSE,*!`/B+5EJH=O&+UOG[&KI>/>5H^+M?%HMYUQP$E7@(SDD5>QJ(Z M9NZP^@E4DI9)`(ZH4"TBY2!SDFF3C#?G/F-JBLG_^R1*I[K`\`PM)Q^0N1.Q6^WY=W7FV\"756/V/Q?^NW;)K];M^F7]>Y>(5GX7G!8$/*4HI26%&?3]C?@^"DTR^I93UD5WG*@1`T`%N+J1H MO[./&;2@P6^W]$/UN\KYL?UYD#B$GW0*%/,)RNR#OUK0LI[:T30HG/%/.AUZ M!0!.ID6N2$"5K5,5!,Y8GT-Y@3OCRC$>7-M[HU-.]VI=Y)?;_+%:B,J(%$+( MN9]$60`9XW3(Y.!$ZNW]$>&X]GD2F=LW$K?"%M`88WW+9&$V+6V0QIU(1<\Y MTAQ.LX]ZDWF379.]:?U5]D@6+5;=$=DFV[W7Z#S>7J.9#^7#0U9NQ`\7""+( ML9\E/$U\GV*>TKA'&X:^VH'O-!#G[ETN^LCS8K_7%OA+V`@Z(T?S.H9/@V-/ M--Z#,+)W,GP&YN6USLZ2"T]FY['XU;V;)19L>3R;DR*9!=2%VORUC[1M!+1` M.(*095F(6`3K_9V/DB%5B>L_B_9NBMOM;LWLYA33+IG]M,SVR>SH5+,ZB^SI9,:7SK5FB#XTP#*R+[G:QKC/-W&=\O'C!]5!14OLMBIJL2-*CCV_?DE* MI-3M%AO?1'>"!Q<7%X!*@%]!\J#DOL;T03T,5A((]K7<+E9U M.2"=-_D-3AA*<^"3E*99`W#HR0<9!?W='M=VL@AQ@%QJ]?!VD&OQ5*+'93.9 MD`B6^53"4(#,)1(\"\_!*>]-/X^X'6=["839>!M,'[3'W4KB\!W=AM(&^;"^ M@J1!P7F-*8-J"*PD#'FUO2E7NWWS->+-DGV]7VV['W`"W:0W(0P)2*#O^QB1 MF(19#QJ#S+><0*@#MI50-,C:2QFWWJ*]^&.]MII;:(BK^5S#4BRGW>LX<])K MO/3.W)PD&]$P,NQE)W9'R,3;(XHCQ4K^\FQ`#.4S^@;"*\AO-)*A,=_1':*I M>C:R*$?--Y-%%*$8^XC"85L(9UEZ[-E@&Y[K4*VC$^_8Z!V1Z]?X[_VF]`+0 M]6J$?]W=7,ZHO`+M47#>[&ZN4`BFZ(K^M6S/_Y1+_*7<%K=EOSS\L%TMRK:S M[>;8V0;21B:#*(Q9$,4!I#!B:.CO;M:.$W5,ZX+_,KNI9U[OOW1T% M7!?^O9@A9KT->XK1Y42+MIZ!Y7K_-F=X[?1VZQYKKZ_O6SM#YGK"S033]MIC MS(LYC7#S@:(D2@.8IR#.@GR`CH+$GZR+7`GU7[:W7"W65CO.K078@3[T9Z;A MESA6)FE;MS9F'&IFEQX[MNLB8\$Q7RW1,C1>5PU%#R5F*BL:PZ4IGQJ_+NQ1 MD]XH?$`@#"'(01JE@"*`*!E*T0S%H;ZN>GN87V"WO<6`ZDB0A93+JF&TI3YUU:AY2=U$LH6*:R+S,CYC4D8(:8T9F# MF0R>&V@GC6.Y3WJ'<@8C6_=)F/7">)+F]ND.M1'@P,D/ M:\%W^52(0WN2AD><0R=*K(V\EW#:9/)LT&`PISJIHF6`O8A6TB0'`&(?(IQ&43HDP0QF_D1G8I0P__])&=<[0G@C^`JT4#LE$W2$ MB(7+YG5([>/$QV-"-`M`G/HH2D&(HXC2,,P'D!'+;:U^Q9'9V79H`X_KQ;%&G]=U?,TB)(X);[?OD$9P:#Y6Y:0W*<)B].( M[P"-NA731U[.\'B_M8B$+_>0)W`\M;#+G5A"($2;F:LK+K'RA*KJ8]*5BR#4 M'7E\7X,F:OAUI[Q];(Y6=\5J,\]A@$@$<,Q8FM`<)C[U>X,QHESM2^I6#.O. M$=C,>_@E'<`)2Y`\EYP29(5&%0EZEC@S(G2)ES$14N;2%1%2=^2Q"&FBAK.< M]/NJ;>I[M]_6J\UM7BQ6Z]7NV[OBKNQTCU&$6)PG*$VB(/`1@"0_FDQ(S#+^ M,I":'=-"=$#G'>%Y/3ZO!2B6$6EAE:?<8H]0P3*)8UR*E"/L<2I91E#BEG/9 M/TK"Q>6Z'NJ<6&9K0^^FVGK3RO[%9%XOEVY+OZ@S M?.(O11&?_)//Q6:_*W\LB_7N\Z+8EJ09@^7VI^YJP'E(((Q]/V4D!1!D2?,_ MW%L,**/'H=B*G^1/N^W`S8AA5?D M44#>[?$II^TJO/*)^2@#EY1<#VTNR+@F3RKM8TI(P*O]IIDI?MA67RZ9!1A$ M89PE,09ADC(4!3#JS488\'?Y:K!E6LH/"+T.HJ*@:R"61]7M-TR@F\ M!EY%5-XNOY)2K\PSI^`_2\9%U=='HQ/2K]&=RLQH$YD$?BR^U5_:U<,%FTF. M6!)3F&`&,4(D0\E@,XMBKD=4M!@R+/\#/#7I5Z:30_=M,BDF^B,D2@F^,IL" M:F^353FI5V.73^:?8>&2QNLBSP6!U^9+96!TB4C[VV*[*9<7#,(8HXC"E-(\ M0P%-LB2C0T4H0BFWKBM9,2SJ!VQJBJ[&(H><6R-03,LO<2OW MQBD,HQSZ.'([X]D=5;1A6\1Z6=X9+[O"'-(GC$FZ3/S'YEJ+. M2._U!6Z>T"!=;#K2=ZWL1J5WD&G0G?:7V[+O"8DA`Y`$D,6(`H)93@CK#:<1 MXSJ`K\_:!%HT\WJ,LB="-)`LKU#F^%77*B%JK>G6`\8$%4R.;8>U3-(A#E53 MH4JF\_A!&H>SC(0)B6"2@(#XF,1^T)M#.1-X*T7>ANG5\:-F38F5L0)_/*MB M.]0)KHB?9$UN-:Q`GW03L3$:]1P4T;T"ONC[Q=6O.EM.K'PUN'&Y-5B!%N', MDU1WGU:;;E21:E.O&M:Z?[C>%IOZIMQNRR6*S+(QS"`-XQ)`F MH<_57F#$L&$-_]#\_N="\!(>,PR+9:#6R95,1L]PSKP'2+TSJ!,EI3PDU?,D"D"*L@@#C`&+?932_O!> M&L<0*XJDK%G#$GD&ZS^W!UQ>^;6]^8?[1ET37$O+I0V:=8CE>N&Z+G?U ML?2PQ)OEV^:WVU-PJ[)N_JQ9X)S_SIP&$-&4^`@"U&[T!$%(![B,<74_38W1 M=.]4X](_O3-`7G'`J*Z]=D(H+=3.14^'JI^<\LZ]\@YN]>7:I5=LE@^"?G1M M=OZ;TT\$.D(D-FM8'13N3C%V:7A^/IH@+-R3U_$2ROJZ.B+I\9?U#]NJKN=Y MG$"4,;^9,F,(($UB0'J[.4OI_$NY_53QSD/*YD0DZ1P9MS)=5[MB[2V*^K-7 M[7?KXIO@5*).*-^<8)5),7'OH7F[JM=L[X1NYG7X+.OS#3F*M/U3`$X^ES6]TM;K?EX>KMYD?<"[Y1-`! MVL6D\0#8.R)^\(;[S!M`>P?4,Z_%[54W7H_`'F'YR<- MR;`0ZWHUV!3A1@7X"+H38D?%]XQ7#E?67 M("ZP,Y*=*1/J2`JF[L?C9R#T$"/]Y5R77W=9X^'O:4I:>%Y76X MIA:?@2`!]1$GU5'YD7#D&?V1I89;@.BJ;IQM%I#[B>H74](#]8[ MH)TN!1"D<^3;-!481[Y88^Y5=L:WX-?]9K.H[LKA@;VL:(;VHOSXN2QW#1:\ M7'9-B\6ZA;NNZGWS'63?'D)L?L1ZOUQM;I]VZ;IM+9ECA*(\@CC.0:-+D&4, M@!Y^AE*A$RNN8#:<^AS<]`8_9][14Z]SM=.7D[/>F;?>IV^/E6?F#2Y[EP3K MM\YMT=/^\7U;;V]5F57!. M.]PTC$\')A@0D^E?V<=K[Y?<&2VEG72[^<5M]^:_6EU8W8?>K5B_A MF5X>/7U"QT0YF%A?A.%6U\?U?>%J>KT=YLOC1#NMJV`O&/XWEQEOL1 MALU?(4(T;OX)1L?SXH<;+[EW.S78,OP]=PB]$T1OP-BE$?\0V8?3P2S']J9E M4L4DXCD^I:[AT$&LP`:G98+E-C@U$,VWQ?D\&Y>V.#7RZ,(6ITYW*C/#320O MPU?S`/DL!WD.8\?1/<#'"D9)J= M%]-;?/4_^-U'/++'I"<;PU>7LC$!]UW(QD3@5G)1=JZ>>7@8VD\"G`$?(@Q1 MX&<(YB?T#$&WRIE_A./Z0NN!S]S@ZUBH M_S+50#%6K!<#)8(FLC?/#^3L8>L\!4'>_!5%(85AZ/LP9P,[28V.AXFZGF#Q**A.+U@"9ZK"087B\T\)HS!R9(8R[^7WGA05: M^>K'5U5=7I?;;;$HG[IK-$EAR""D&89Q0E,`"!M*%D_?>2YT*$\#JQSB;I=0,7T?YU+N=5%U4D6>&+5*KN0[HZHD<[XV^AP5 ME^1>'XWJTWYIOGI]3Q(84(2$C03%?']A.4X"GL74A9S M-96XB/O5M52WKGN=[^[M M.4F-]3T6V?#);;2,@[DJOY3-;\SC.((8=5=*`D*R,$R"J$>28;'+'`V8-UW2 M.\#PVA'K+<^%K1JBIK*#HBD&$ILG]NE7V3=Y?GYIKQ3K,$^Y7\)%*N]6B=X( M.2+T)CTW)\XO;THW:X+JQFL` MGXOQAVK;O16$=[OMZM-^USTKL:N\=XTB5NMU^Z^]:0L796W[GEV1,#R; MN&N.IB.";,:W)U-G(P0*[&>TET4>7XXXW!U6W3PLK.TW#=D/_M5R.:=1BK($ M0D:#G.$&'&3#?CE!E*M'UC0&P]+\;KCV<7.L)2^.M>0.[?$2R-V`5[A\;R@R MO)LETP=%8A?%.T,]\TXA>ESN/X3HX7_B3HA$MUZF#Y7"GHRID`GLUTCQ-[J1 M8S8BSNSP&';SNZT?&[3*S9UXL]D7:UHNMNT?K)K%TV;WH?C6/;UT5^TWNSD( M`TH)"4.8HCQ`<8:"H7J%0LQ5,S)DVO!,>0#H+8\(O=6FO1MYY]T?0,Z\HH.I MHKX:Z)>8%^TRKSP='N-`S^+0(O8^]''`+L1!8?*S&P]MS*0!8B0*<4SB&/I9@RRA M,(51'H*4"E7E#,(P/+T=8;2/P;;OAC:IJYX2GLQ`[1XIU-CRMK'\8H@]AG1YOE8(%"01^GD8H(7Y.XXS2/#S` M8@#$$19Z%,LP%DMZOCY[\UF;J!N/$Y^RNQ0BP77-PZB\%(U7)'Q$Z&V%TA&U MM^;NXS>XK-+,_X1$WWGU_B9O5A*;Q:I8?ZCJKNMJN%\Z]-,D\],\BW#B8Y2" M*&4XSH(X('F"\^CW""9]HX>!MY`/72KLC7[%>GQX_ MHZ"?,,'5]/&C'XP!!#/0WNY.@@SG$#,?1KTQ/\.9V+/VDV&Z_-2G(+\5Z7\XA"F&2$`I\BF$< M`48!Z(W#F$9B#$KV+* M^`=X0M7,;,W?:J]8KZL_N]-3-]766U;[3[N;_=HKCFZT>?K?PEF4^-UW^[=@ MEL3IS&M,W)>+W>I+N?XFFD0HQ8(SE[`5!,&4HB?UA*MK3YVLJ#U"TUB"H8-= M1T1/CR^/TPU]!'%+W-F7?68L3W(XC/PI]E`>]L900*J9M=RVTC2`$Y0D22IXY,B\YR):="#&6!"[7F2EQ'14>/1$;51=*+2.;0$]>7# MMKPO5DOV];[G80)AXB<9"V(_!M1/_'`061K&8DHG M9\.XMAT/V>V*KTUR=;/?+%M84F<8A>GC4R[SO(EIU9&P#M"#-=XT$O4D/2.B MI$:G(S*DZ,23Y__4*.&_Y**\*9MQLFS,':3M+*N#$-`\24G$L@1G:4)SD/7QO1':Z)';2I_'/DGC5A%3`%B,PH#YJ#>"X@3/ M=]6N6$MLH#_[DX7:#0<0W%_5=?N?J"WH!)F2V#/72I+27OF4&^2\&^/<;#DB M&)+@QS;"!2D0*!6UK;>[;Q^:,=+>,-;N]]VWO3X_;*NZGDM]TI0`$2K$DK&C-?(+IZ_X%=7?^OA]]1C_WKYSL?,6U=B] M(D:HY:T(6>-4M!AT`#;S.FA=,6@`-_,Z>-;K0&-K2YN;7Z_)P#G")[]K[@_[=_?Y%D'.&:!KC9H48 M@@R%.`)QD/?XXCC)YIORMK7"W5I@!Q;7!YP>/N!S#[B_X[==Y\')'6]YYD_W M51=GCH@W&%B*'GCT0_5>O90KNWW.FB) MPGA?A-U`.Z+]]OW^OM]B"N)-W%Y[$5NSEI^#Q&^F.XP12W&WAL33D M>KK$-B:AE;G4,X)/G?B;>9M2-+>V%B7.^J*#`1*L10J?^QN?,;I"IKNWY(Y% M8:RH:3G.CDP:UMV6OV17(^WJ-93.9H:B&,`TSK(P#S)$2)3V-DD0`)$ZJY(A MPV77'ELG`^5)!L2U78U.Q:J);B:UUDSL2ZJD3FJAUQ'QT^,+;ZU$G"!NF3KK MPVDO3GYTP(H1/X_:$]3(]WT0YEG>UFD.1H&?^F*57C5;YKN0KW]D5Y('*Q5I MY-,G>_R)"=3#;KX3M.E.7(XR-2)1>AAV1*,T.5.9&(0:&FM.UN=IEN01"$F0 M4Y_B),8^B'NKB<^@>F^-@+$7VUXC0JA\AXTA)@TWV9Q0.]!G6:8)#3QWY.8P6MU1!4)UH,:&SP["DUG7@)I*OB\1P*)@ZJ8Z)F`:'+NB8 M+JJXI:Q=HNZ^_53N/E?+-YLO9;UKUZOU_[%WM;V-Z\KYKPAHT7LND#T@1>H- M_43QY9P4N\DVR=ZBV`^&DRB[0ATKD)W128F4:&\_K9-UQ)EG MJ&>&PR%G)F`08H0#YB&.L`M1R,/M:A4"I?:Z?<*:;2'Z):B[96H54(-Z.\B-H@#"F%+HY<&%<=].J1!$*2P=.``=#Z-5*HP:NGU^]#>R.\J^0[ M#*L!$1MZ'`S4(-,V/50HE=P4_%U$DE7GA)_9XK;IG_AZ90PIC1"`,8B+=3#@ M$%,,FJ&1($"ZSXZF\0S'>HV4=;^Y4LPBYJOE5%F7:D58@HHG`%>-F[>X;B7< M]NNL\W$R>3=S$"L0^`10]V/T?5-Y,,O+(?$1[6O&T08_H%NES-RT,]_5IB44 M(<0OAB^DX"1RHV(2Q2^U_P2'AAO;*$ABV+N<[0;RD[:W4;&07-;!'N,H>J$-;WI#/*Q`:(8]%V#N@:`8AD5^$`&\'2RB MA*D4,/8;P7#E8GU@/&LM?W54!.W'38Y1S4/6)\?RM@+(AK(?U7(?:1@MX:J! M2LB4]RA"HA@_S@)!(?)<[F(64#?V:8SQ=F_*@T+]UHF]CQR%/09<,[$?$Y70 M2RL+][`,&,KXQTW1G^7Q*XM//IU>G7+F2>`B.I/91)$'M]BS!ON-K/4>B=.2 M=K(VFRI8=A&F$9O8PJ%FE-NE58,0*C?G^3I_+F]7O_%72O/3=>:AE[-E6DFO"D4!4W0K>X+81 MZ\2I!)NZL\X[('6M*S5`:PE_:5'E@[8ZP^%1X:;\,;GM"#^)#S!!,:4B@$&` M:0PYVH:?4:#>/6S@>,9Y:B/BMN.%O6O8AU4QK5#)'[>X?UADSTERD51W9;T58`:$[V%!!6=QP+F/B,^:(VN0 M^I%B!Y_AXQEGL\*7%'^\J&\8V8CK7"?+Y"Y5SKUK@%>.V<;%58W9&MD^Y;5P M[U+KQ[P\;7V1K)+\:1L8 M$B]`@`N/,`(QX'[(\99*.8I#-48;,I)Q+BN%^Y0VTI4]6DOQBK>N*0_;).D4 M:6T0NG*$-A:L:E162N5LQ7(VCQ^EA&HXU?0!KF\=A5;,AM=/3%XTH50L(0V>)80R1(.]Q1&*8/2A MD7=N;XL1"&+7913"@(;,%1PV5^%"$D'%:X>&C65\L75V?J:W7*L/H,I,8QC) M`:1CP[V/G4#)L=$`@.TCIB'*?,Q1@R'27,,UBP4(?4(9P6XQ/*PN:6M&!V%$ M]!=O[1W2\$+LLV*)UDGQJ]5J8!Y)ES4D26]\0RBRGT*IEI456H-+LZ3!MX49 M-6O5JQA+$;1!.?3V$?#0BR-/`,0XA*$(111N:[]@A-'P-+K"8--ETEN7)NE+ MIJO`W#^?;@A?/2GUR<[\=2.EF%CO`;$EU*9+&XGT>F^0^JQ2^YZ&%C@(&0BX M*X`;8H`P]TDC&8Z(4`H)S8MC.%QLK& MPRZW.C=M4TO8?$R-/U[GCP-V[WW7UHB\\$,!H`Q#'T4P0.7M%]L1(4!#MEX5 MAAEE]W7Y+I?_ER>O6%GUU=.N2,.?3\[.KT[`]^ M1D_YI2+K#()4CGO&PE*-@5I2U1L6;;E&YJ$.A#K82`>NEG"2%E4R_=-.D9^N MDON'+)_GSW7K!SK/\^=B4')?GO4DZW6>7C^NJ_.>V=?YYA0!\P/F`0HCZ&'B MDACXC2`XA$2-M?2//\+V1%[F>*B3)[=)4]<=H2.^O,J64>F5J5,>T@7'/VL82& M#2J8C3755?>*2X8IKPM/\E4MR[:2!V(/N$A@X;.(Q7$4L^T)+Q=SIGB`=,!` MYDGX3W+!_SS_S/C%Y;_]2^C"X-\=_I_?3J_^6[4(<`B'A<%M";CHTV=T3U@6.-%U];4*C:NBR06\R(Q$55`C/ MBT%,.(1Q0)J*0Q=&2+&>I<\(8T6)Y&UH^!+].<48K;CP;=2XS):)G@BQEQ7D MZ,TT_&J\MI7&N:SA_D<-Y6F%XLC\]0XT'<0U!$A+&&N0"IF^>=4C2YID\Y_0\UM?!<&K=7"+SD[*,K^'Y&:=/B6+YQX9037SR:P-`$(^FY$BBN-N M!'U/L$@$'@YI,U(8"#I;)C^J^T+D\CWJ`TB]$U']3K1ED<_K;&2JV M\R>.B]Q79'-7_/Z%]50S;#V0E4RA&8*T7XZLP;)--&/GO]X`TI7@ZH^>)20S M1(/=%-50,.1O9KR]3&Y&0D:0SP)$80B1QR(O;*HV M7!%ZGN+5C,,'-!Y4E9)]2I?-82[5FQDU0"K'."-CJ<9`+\(YI71.@>=&OA.G M'02-?3GC7LPZ2$HCX):0EDZ-=N]GU`V6-*E=).MYNDQN^3Q?%DN2%;FY>;Q_ MK&Y38\E=>I.N9P!C6K9>*=:A98VLBR!LVAVX$?,524W#@,9)K263RST8 M\FVI"8[4K_W7.OJHC%?WD+QIB^PL"FG'OQI:!<.N4,20-2QY?XVI]_82:8,P M#B@%F(4\PC$*`8T)@4!$/$*B-1)0J5_O\7B5M[-W\7J5T=G(U6S^)_4.=G7R MKGCM5^E-\1WGSV2^6/^L/EXF^5-Z4R:T"_O\/KA(8#_0?8L#M&)LK"A@\DH` MI0H`:4PMX;$A&NS=\5<$0YJ-OJ3++"^>?[I<)\4D6\_B@`I&:>RZ-,(1(\S% MVXH"W^>!RLD^Y87U]6$*8;L11Y11TR.58QBI8!3ME!\W0O MFD9(9A>U#HKI#;`E!--?_DS33!LD9MI6/"^& MB!(1>H&[E:Y@1#XL/#(BTL0AU>!(R8R=^D97DYMH.'NV+Y/8:&$IH>J!7RG2 M,VI?2\A[;*WW1I0C@-[G6#=9WKX3_2(<(N9Y/`RXSPD,(QAM=P_B&,">)[S[ M#38*N;>O#2H+L5ID_[=5/YH?CK(<@8\*L!HU?]Y!E>_!T?1Y\'?QZ>!.;=!: MPHKZ]/GXP+@.H.1#WIN?R>WC(CF_NTANLA_+LD#S]#99KM.[-+DEJU6R7I&; M0H2\^&G9[OA4_-_C?7)[5?%O\MZ1V"61 M1V.EFW;'ELWP:KY1I\P?OBCDO&CDU"HYC4[5&]]F@(U:JM'RV":6#)LMMJYB M_*S+L,[W2B>G5,JIM!K],)1>HW1%U1.9WQ)',IGZNW'VI&;HX:;BQU6Z3%:U M4*NJBF<5/[=^J@2:A9AP&$#LDR""J/B`8U[)`1F#`H?]_)"FP4=T-(W$3EOD M$^?ZN?V+#>]TD,U(1E'U'!/8H[]KT&0*P[PO!ZD4L6NVCG7,K5N_#ZG9")#2 MW/O.Z)^+7YRND_O53&`H0H9=$#$*D8M$`-EF3!X(!%5X=M!`ACGUO9?7^5Z* MYU3RJ7+G,%#E>'(T/-4X<0"41KBO"Z8.GM."KB67S,#TZ\E5-+N_3I?5 MO<-OX]J2+"4BV\_%*FV&`R0@<"%&0B#`((BYU\C)D8C[\-MHPAGFQ%*&GK0W MGGW4J-)*T_2DUY8N)^_E):I4@V1FXL3I-K918M9E%`DR']W^ECF`\?7_P&E, M9(A)'$W\F"[*C[.$8$XI`(:L?LA!MA!4D8DK7U$\CH?$P?"/(A'Y' MP5SC.Q\SEK+"`TG8WGHWM-5A)%^D/AV.T"'U`,&@5^IKDDE<4[GY_'!?733I M48H!0SP,7((8HPR01EC*H\D60O(2&G9-XC%?INO'/#EQ[M*_R@^K^H*BI)%P M0I^E8,?Q?989$UKAL_A^VUOOL[8ZC.2SU*?#$?JL'B`8]%E]33*)SSI=/A7? MS_+GF4<0"HGG"X^%'D8HQE0TPD(2NU/Y+'D)#?NLK2`3NB8%17)/Z=#A"U]0#!(.NJ:])Y.^6GC]7W5*NLHT9G!@QEV&'6M_\U\]=-YF*>C7W6\!YT.%M`& MK"4OM#Y]=F]$U@N4R@4R99.+=/F#_BQF7%4&S_,\RVF6Y^6=O=ERM;U&WHT0 MAJZ'"T%0)"`.A0MK&6C@,>D67%K'-!<`O(CI;.2LSX*4DCHM4:?KH:`"9,=+ M:L0>EKRP9G1[>V6,*0"E7^2SY)\O8GS-LV7Q\2;9-ARKY3I=MK^3+F_2AT6R M>BDC)H5DF#'`B,^$QP-?!&$C6]DV4>UZJ%%$4GG_>]T9=<$I/[MR"*7GWZK. MALX?WTX9.:-<C MV[[3'SO4;)L.GS35++#$/4VF?F;'R]C[V&$EP/6ND!=)L99*;]:;_E&%D]WY MS;=E6N8OU^E3NG[>.2K)?!%Z$'.7$T88P\7RR]_(7&@3*.4-)Q74L#MKGZ'[ MB.S*_9!&G_KN_BKX?O/+2DVGT;/W><F=GTF3=7A" M*V:*)6[1#BP^//\YN8'Z.LPW'KN2Z_RA2D26S8-J5U_NY-6_VY'2\P(7-MM*I;;6T6!R^*#?."QDWYK-.V['=:X1I#?GYJOJV7G^4.25Q*L9L*- M!<.1*-MC>A&$!*#-2.6F6*!4V][C\:;/3'V[/#WCEY=C;RZ\`:)KJZ`_:I:\ M@T,TV$WC#P5#^EUH^@1]3?+JE7UY^6@1$!(@?(QI"$CQ_A5C^S[@T!,L*`11 MVX#M/X[Q755.+LY.S_ZX='[[?'YY^7?G*[]PZ/F7+^=GSN6?Y$)U;W4`HG*! MSCA0JL4LVVYCA5!UT#+EKN:'"'7PSW!4+:$A#8IDNB><ZK="P%5'!S\3D,HQ MTWAHJK%3)Y#.]UJ^L4FJ$ZP.HM(#LB5DI4F9-TT0]4$D'TG=/RRRYR2IAMP, MY0<1XH%?#NCS&'$>NEXS%.=<:8.GS_,-$U0CTKY>R?KPDHR0#$.E&!N]0FDJ MNGD'DZYH:`""EE#+(!5V(Z#!<,CGS_?MA7^T%=[TR"BH[[':,Z]:1E[]G"\W M"9>S;/E4$&-R>Y$M%B++RS\J(C@!`/4#&(FHK`,6E/-&"QP!JI1?MTMTT_EW MB:J;SJ*;DZ9-64MQI]+<61>JOZ1VM]H7'Q_+N;?-#*^<[R4BS@82Y>M[[3*8 M;*+?+JD-;@0;ZV)D20E%V%MG?5E&;P\\?U:CU?EI<] MG3@LN:DB1P?!$Z?D._N\M:S=K7'4!HQ],#[Z^%QQK=>T7EAQ1OTZ#E@5F/%] M;R_36>!V_R@>L5Z=+K]6;F86$`&#*`I"7P2"%I]#`AOY/:)6BV"-T(87XY4T MZGW1;$%G?AIOB@EM\;/]K7WU/YV!%/;ZG=KU9U&=^>W1ON.DI8#\\#O6W<23SQP MHAV]1QZ*SVB>68LA+?#0_ZB6ZML(@T48!!X`(0T$I-!UO3!LY&<@B&;+Y,>\ M^(,K&QRTHNQ2;!W5;/U&36GFKH6RQB.KVG=J3VS"II9[X%KE(USYOK;E)/ZV MYW0Z>C_;%Y?1_.L@PUG@5T66WR5I6X48<`\SGT<,B-"-O)#'P38/SJ+0*M>J M+OXXWI7.BQ=GL;#(P?8P]-0^UI!Q+7>S6ZV/T-.^L>@DSK;_O#IZ?SL`FM%< M[E#S6>!U=_>>&1>NBP(6,AJ@&)51`VL4H"SFFXHIOKR=VN&J2JY>+]4HV:=: MROF/QV7B(%`52N&CH4T;*UUD#7_TE-D;F,DJ7=1,9Q-=_E>2_OA9_$N>DGS^ M(ZFV'5D1HHMYFI<7@R3M.EJ7>+X7NB3T*',QBS&#>+L+Z2*EBWX/3;=C/,32 M`.1L$*I+,9P2(Z<$J;K+*)'J97$<\W?J]=GT4]?6-9R967NH48O*])@VMC$R MD7^=",@,?./'20:GP=YH:OYT,S>H8VNQM%?+&>8!PSXF-'9Y$``>Q\%6-2I" M+'^0YY"T.IPC/H>$ZIYHY9!4.88(Y=7\:R#YU!FC'..DO,UNJF$J\7ZYR?E* M^V.?I#O1@BH@MLO([4;!%TDG/P8DCWX.$+#MWNZ3S9 M_-O1)-T4)X4%Q_ST3=RC3[09`VZB@X*Z3:^07+ONT.[Z^>4K^[5;OVC7G'EK M'7G;KR()RF;:PH\@$7X0!)Z@S5$,S`7E,L''(>IE[_G#0T13.KUV."H=0SSR MWBP<'I,<_FQ5S;L=CFK'E'\S,WL5$G'6F+TS(6>-E-*3TYK$W`%"]R9!=X`Z MV)*H>WUZ:K^"'/@%20C&``F.M:LV_061!Z;0V2/!1M*;(!" M$80>=GT,PI"B(I3"6^U\A`,[P@ZM*AF..:P]'ZUI0DP=O11AAG4QC[&;<+H!U5D[W*`(B^F/HMH+,H>Y4&\#9T8#F7/ M?A^23@=Q*OS_*T3-3P!K$M$'!)F%%:)JYI9>_GTMWNBS^7U"_DI7,^JZG'&( M64`+!X`C2"*_[F3O^P'QA,HB3.G!AI="I2Q.*8SSO11']=2R&D9RZQ)C\*BM M#N21,1*0MU'H"(M[@65)<-I/]DS#;.G)!"R[GZ?+61##T",@BD(:^1Y`!=&@ M9A0:!*0/%T@^>CPVJ`7Z/_*NM;EM7,G^%51MU5:FRG67(,'7[">``#;>=2RO M[;K1C8>N'L@R MI:8(#DC2UH0W^7&J"NWH$KJ@2-G$E$$5_1%MT")!;AIW^X_R]FNYK42N@E?W MO'C.+\K5E]M\_7@N+%UMQ#=J%-WURV+^B!,/1P&&0#=<3V&B[@YF/"84JT< M;@9DV3#@"*0N9SNFS&M'G0$]8"GN&'I")_2<)DDN^%@B>GKAQY9AQP.05>KD M%V?6$0\_/:WSNZ)Y9*_K.%C=X.N;;N`T))1!ROW(\W&2!EY`T"[V(>0KK9LT M'LUQR&D3O=EJ^;W+^0[!@A8M>')R(YAD:4-A\MG13J<.760=:&XYAFB(B!BZ'%%^I;3HQ&&>0 MM.G%XG^%.;H5(A52HP$XU$F*?J)OU%SH=9+>RH(,J9V(&%DQY;7,QPH][C?> MM5<,S1Z:GU9XN_E:KHO_S>_G+,@X"5,<0Q+3.,(L3K,>J(\SI>6;PZ-S+((M M+E`^@*I!!L1_^?I9I!,/Y1H\;.M=$J"HJFV];6ZH+7/ZKI04U$E[45&&S3>R M[9^!UBZP-^Q7V8EVS#&GI'^TAV`J`6,\`FQM];+D"DN[MJIC,-N-#>S;4[%N MHVA[>2@*(A$^/>IQ%,,@2400W8%,*,S4SE\<$IGCH+3'`Y[>N(9X"FZ2Z*U- MVD,:`0>0DP&G`J2+.-TOOH@XW=YH<.#FMVZ;GH*;;=[8,::[#<[^&]KMEO9% M*K)]K&LXFE>GT%D!X>_>'Q?JO?'.U+N[RV<.#`+CZ4N]V%-E, MA,(DQ2E/T[H$B"G>K>3QO"BQERC81N8X41!.K)O.]4$:8O;R]VU9U\$?&ZS@ MJ08KOMVB!<+KP]PCI>U$&VG$F/ZSGT:<#B>M3:`Q"O16-4>I3-O/0]S\-82_ MW>41]OWN^("%(W1K)Q*NW/I+)!+.C+=R?($=%T@F$G7Y70=DWTKI9#-ND)'AU_Y]EL=I\ M%/^HC_C>446]QMYF$&_3@+$P]%"'N0^N*K!@;D)(XBV<6CMH=U%Q6Z"PI: MJ.``*Z@W;#=H00\7?.H!#[UP7Y'/$_,15YZ9R+3"F7GE,`^XG=>;%M7=LJP$ M@MO\VX8(@OZ:^W&"H$=Y`#&E0>0AED0[!%XH=9&U@V%=KY+\[S_.;_\'?&"W M[V<4G%]^9#>W']CEK>(J?9L\&RFH:XH=BN<>.OA4@P<-^HDHZ2N\JHNHB7.F MK9]&ELE)ISEY\JJY6*]$]E6)]*M/SXH[(=VT6&[K@_1[T182'<,4)@SCA'&" M"<[\A#)*,0M"QJ%:.=C6J,Y+&P+@KGK;-)C^]5\2'\)_!Y]KQ,VK?=]B5E51 M6[Q+2N@(A"OJ9X>PGFNV4](S0'8D=SA'S#KE"#PEE)9=,!65M&W6CQ+IA#9I M?3Q?B=<_QX_EMDYI-YMU\7F[67Q>YK?E=?Y4KNNI*UMMA(KO17N?ZF:0!;&7 M!"&E88*S*$LQZD`A5&_H5E)-MUB<:^GE]C%?UP_K[Z"U!+P3&*O?P**U""P. M3`*;4KST8ASA[5IWW^>+Y>9K\^5-OGXN[NK;\<3'_.V%/'\ME^)QKWY7%&/' M3I:3Z.EX5TVX.U]VP`'^P8E7PBVKS=E!RCMB[<"(XQ/:/HSO)J+X`QE;CO%Z M:$6'"Z%B7-"4E6+\U58`F3WE[:Z1:LZ1SU,"/4BRF+`L13!.^I$)BHE."#`: MT+G.OQ3W^OD1&MT#!>4.Z2CO_BGJWGS!K?`^J;?8CD6OOJH6R9)^'R_SS7[P MER)Q*6@12`1%XN^_G*\V>=VNGD<0D=CG?II&U,<\\CF%/9",0#9?Y5\6(L^4 M>SWMCR_UMJ;MVWH(5?IMO>NO16/S&%1$O=H M*8?)?%-N%DM;\=L)1*7.PLX:ZQ%?;X:G-9D;_BE0F>5-^@'0FOZ]N]C[?F\5 MV)O5^+(U#'26_317?&DPE72V]U1W&>Q%Y=,\ZN MKQD%-[>S[+\`/?]X3MDEO5&,'=HTRHF_4_ZTU'N'Z`SL,+UUB+(3T3U"S0G5 M-"5S(K)G;$9I]QE365K_MD:^U,2V%GQS4*F?9[0^=RTA,`D2C#!.$8IZ6#&, MI9+KH;#\TEGT:WT2E17;0_CZM(I.T6PM_8">FL(:^B'-+<=Y(8Q*:G5GK067 MW^^Q7>:;V0<9X0FGF(4+3)(T9"G>U%IJD*H5[VV,[GDM,_PQ>W[YLL;=OWQ/&,W9_6?_`V( MO_HPNP0W[\7/WL\NJ/@3Q3**=4?)E5?&])':1$`@!2\G`SNX=9+8`@:'B+O% ML*-V7-]D5+K?:L\W$U%O9^:=[+7:IM%PUT"_V,J/?1\*[<\@A8AZ.$C)+A>- MB*>XY,ELK)%W"%C9%2#-JYQ,#D>HFB@>WP$PL57_NFO]52F>B+99,D9J7;\> M1197B`@X#9(&TYR(M#7S0Q0DOA>(.34,`K1/9%.D/VDU']OQU#1[M9SUKEB! M^W*Y7*RK^@S,5O)4[PBV[@5;2R_<.<#5FHI:*EN-;#!/;J7$"T:-ED#H^68B M$NK,/.5%"R8TZC0%7R\C=%_5ZR+Z7^XK"WF7N<9I$":(Q8B3C*(X"C.X6RB1 MADCJ%KXA\0Q3*3Q5(@0[*_HB85M7W)4.FYJAF80/ZF'E=N`DG*LE]1>[-M*A M#8=%*(Q]D9D$?K^9&V$_#/27W-M$ MX;B&3]_H!%H(YP-X2F=N-I:3C&=IQX)W>X1%]516BV7MNB._=W80SZ#=8A'"H(NQZ([AN MO(H7^$469T>@-=DT:`A8)=)2(V`*U7_5JK\TCQ.1+D,C9*K\BI1H2\Z/1P2E M-(TXAG'*PY`2GK*`D7[8($12]V?;&LMQN>AH5]+.:67*S.H)D4M2S25I2 MZ9]%IDOT1#5+VYPWU,N,)KM=R@Y+F\/%22(T%'DP9B@FXDWW?-8!"3/F2Q7+ MW8T^_"+:U]?B#]>\5'..Q?:E,[^X;&#V0CK^-%>"5=,FII:')J*S#@W4:60: M4#E0*[-#.,&:F;*()K/QX=?I:DH[>XB^I@L_ MC]?9I$JSEH'=.61WTX5;I]+?[*:FXW54-MIJGU./= MSA>)"TW#*$@833!,`Q1PDNW68(7BVRY[G4HX_M]V.]6\Y:3?ZUU/+5]//!*IG6&@[3Z#*H=Q>DV9R(F!F;(==-4*1%6H3^S(LO7^MN MQ;-0P2_YY?;Q<[Z>/31#5[/MIMJ(&"WP[+H92-"AW^W';M"#`_BJ%XW8]XF&Y1\SY:+JBH>BKNF@S1[:(\VQ=^*:HX8 MCI"?94BDNP&.N8\RVF.A4>*I2*43`(YU\]3;6^-3E4HW3I#3S='Y5Q-1`^J= MZ*8.?2=$U*DW)J*H;FTL!WR\%;7VQQ%?Q?:=EH^+8C5G)(PBG'HI12ST.(\\ MYO<8$$V5TE&K`X^CK=_/P$LKP*<6KZK6VG6"G,:.QK\5;=6AWHG6JM!X0F.= M>&,BVNK&MG*`Q]E&WOK]LMQY0%B(+S_D=>%ASKR(A9@E*?*# M,$@CGF*\$_68Q<9)J]'HHZFJ``TZU.``MHT,ULP=!NGK8)ZPI:]'G``^M9@G MD=2>(E4UH[7BH(E(KD,#97)9BU3*[0G,MLME>9^O_A0(/A;K+\6J6'3#I1&" M(:=^@F+,(Q0$-.WSYH0P(G7%D>D8CH6T1W8&_ORHLAO+A+732C@D86IZUX," M-2K0PY(0-;OT*6Q/&XA&O0UGVG3*[1H[;OLKZFZ+K2GL[+)A1FGW(5),AC^( M(1ZWC]T@'@T#G(6(1`'E!$&2H+0?)`Z)TC(JM4]VK+T=&,745)$`:.+)28NX M?6OU2XOF),O5&?OUHL,P1YPCT>,@C]-,5>$W=PRM+0#Q,YA;/F(K@7^2+*L=?UGE>/W!7Z_*YN,^KK'Q\ M6JR^7]=["6[+*_'`?16_-@^SB,2,HS#E*&60QP3WE=0TPYF*^%L=UWD@V`$% M3QW2^ISS&BI8UUCKZ].?.K0J$F:7?8GP,!KM:J&B@0GVK/=`08<47/>L7XW. MND(0&8U]O8#2>F&A\.P;AQ<5AHZ%&BOBEM%O5DQ@6!ADHCQ=T@:M.1HR`X MJG1.5'.4S7A#=O1H,5&>;J4^#'SBDS@-,QY%5"11<>#U`X8^-M4>R5'&41^] MO40&7&HKD`,:K6C0.%N"CA*DID.*I$Y7B50->5N+M*C15:-N=53DX32$<9!` M2%$6IA[,@GZP%!.3*9;D"`.KD)GNR+*FI3D."#.=78VSUO%57N1E1I'':4J, MJA&GY46+DC>EI=H\K>/!V=T:^\AZKFC_R&ZL,M]3SLFJ`WRPV307WYBY?+=9%V`[+)IU#3W2)..[<[X4X[LL56ZB^FMLG(KJ M1NQ-):J;&?%C5+=`B<)I?NT8?ZRJI_RN>"CR^VZ&0CR4)0DF)`M#0C,OA@CV M`Y(T5-K;H#_*0+IR!@Z@:9!A4=G(GG0:3E[7V557\*'@]"/T$\P"C.4`2SE"?]0&F2 M274;]#_=L2)VF+HK.I5V+>J1):&-SGE2$\@?*-)223VN%*32.6=Z>JG.G9QH MOF;N,>4THF8*\FEF0&GK*3%;FW6Q._"%,1PQ#R<^\=*08XJ2`/7C)4&F=E.2 M[B`#K]`R.39*GTC):N<0'"K6._7H&V+AUH7$R5#&C$ZEZFELQ^D57+K$2%8^ MB^JIK!;+_UB7VZ?SU=UR6]\35Y\_4JXVQ6J;W\^>\G43SS*AAL5]]X\Y;6Z4 M#P*,LP`Q%B44AST8["=$OAKJ"H%C]>HW1H*G=:$V57;'N4R!=`IT*Q9-.\B@ MP7P&=JC!(6RPPWT&7B"?AFM4:JM3<)%FO=65JR1+L)K,'2W+NO;$%#)G]T:6 M0S[@:D)K6&>@!39P>+U6HKDH=UATM1 M:^0YDE,6)_2HZSR9G9Q3O'M^>P2X$L*"+XYOP$S#JZNV?^U=VW- M;>-(]Z_@81\R59HIWB_[!A!`XMK891':$TZ?!TXUFLSDC5_/Z)^SO].(*7B47\".8L0_))?O93%!H M=+BHFR2-[!LQ\6K!@A.T52-.A9(P1\<,ZA`#UV^%*?UC#)J])$A&JK3 MPGRP#2^HR^RLFM^EAP=Q#G.9;0="Z">.Z\5QZ-AA$B`KP@1C%(8N\;N^(USV MZ_5=OC4B<(`TWMSS5[@YW:?.3:A!AR7ZS7!`D"#\[$N'D'5 M3_)R5[(DC5=UMN7)&RQ8&N8AB*@7L#4"FZ+`;:-,9$'LB(FY]#+:-9K\\YI< MS9K])R1N]Z,&J)B_>W(%6\U"\)ZZ6I%8@K0@ M$742F]I)3"*$(QL'V&T7I5$(Q52BWUK:1:-YNP.+M`4_C:0U-$$%Z9.J-`:A@V1)`4&9/KV(2"\+).J(^IKNKU]N"[2NVQ_5Z55"]N+L>MC2IAB6B0,V=^3=G4?BV8W MBA;57_DJ\G5:\I/K<@,VV?)+MNG^1C[5#'=3LA&H%9.T$X"`(P0G$">@`0DJ ME$._];X3=6IULFNAMV;(2KNVR;\2/C+ON>-L*[ M@($#>S%GJ7OA1.%3"`IMGW,DL70CY/0 M;M>!+B:+7;Y;;N0*WF]^N5#7Y@%'YZMJSO])>Y`4[=449TJNQJV4I+ZU[9$+ MV@*%[,ZT&:(C\OC?*%P+$B%>F:I;,GBVM:`0V:$50!3BT'4P]JWH<*K$/A42 M"YGOUZP7TVMR`^<75^_!Q54RO23@WDM,1TZZ%)8D$27J9\%H129J.SGIRE6_SQZLU"G:X\V;9=H)CCR** M`]^G%G2)TRP<0Q0)GI[ZKZ?_-MG\`[DY:$US4_X7T9OR"HCMIC[#,BJF1:?8 M#G+4P/MEO#OV;U)V1JK4T6V(<"DT*->U,Z5:KKEL4F8N^?]]MGNX3'??\M7% M]GM:[G@/:[D('.QZ!(>.A5S'=:D7H?8L%[MNW&DNK]H5A1(IB M3_:_^G+<\.R`W__>LP^V9;[)5LOJF;KU.MMD[(^"PJ>(_&[B-SSO8@+X*`4# M_.(#C1=JE.`$YBC-\6]0=T8(U5)OB!@J-NK%-GJUE`F((I,,MDA;RHK](`@1 M=D@26%$,R%EILTZ]<"+H*H-BW=[KDXOJ2.P4B<.75@-I"DTS#NS!E M745+`U>2\M20-$XY^PD19\5&CC)C9$42_C,!Z4-#9ZGXON\2.O?FR]_I.5EMLV98CZTB2#C.]!,GT:GYQ]8G?CVSN3$ZO9@`1.KTA M[5V#.?PG$1T.8Q*K4M6WGVU MS,&[ZYOIYXL9BW0L"$YO^H_S@A]H"/L' MNX?#C7=*[3`FH>4G)("![\96WA6=0]*+T#J@Q_N"8;SF+\"9[G?7:9'EJ]:@!26^:]E.$F+? M#I.8^,BB!ZQA0L6BTB@0]7>G'JK/=0-7U=?`96RW_"$8D,;Q8;>89+SSQ,+2 M:V^QZ1RN0&T8J"S[-=_O0&W;:10;.$3I<-&9*#7JCC`D4(W+06[0):KQ!+6@ M,8QQ2%SJVM2/8Y^=W5"#`<8V3N3OE?1<6/?-CEJ,*A5:G:I0?H!JA8HMRA;!B>/%MF6%EN,=.F0AC<)0Y`(5 M^%K-E]\5F7=]PE'+Q79DXLRE)$&7(1>*#/*\]UX1;4I*=R?/_$6N%]@VY1. MZ3G7ER1%HR'2(@G^:?]1#PJT),(L->H%^FX9B.'07H'!+Z?&X%VV!:M\LUD6)6"?@I+#'><6GP2OBM)G.5\9 MDO"X\^5.&` M;E6-P9D7*W;4\$"%;P(.""?\IBBH0+)/&YB##T]\F[DSNJJ4>$,$5*U-SP8O M*B>L^W/R:?;U&]-=R'1C^36]VM]]28OINEJ[G.YWY6ZY7;&\[M",$SN!Y2>1 MA2!U70)QQ'O3:QS(X8NK]V>:*_4\\2W(Y9E+6)M;#+F<]=GW]-EPO42*]+K=Y^5R\[[(]_[[LRUD9_W23E_LB/;Y9.HCC($0)\B!T(,6!A?VD>;-T[+LN%)DTIAV, MT*T?B>$9+S=3B[>N:79)YS8U<[PAW))600L?TT0+P![+/%[9M.18[7/LQ M9[OA\ZJ M/K(#A*7\Q>[BZIG#QB/K5U3=A*;AMZ@5[0I6YBIS5%JGD5WZ>A53^J8>+[_? M+MG9OIU'RU:`VQ6__5E.U]?L4DBWN^K3Z9IFV^7V-EMN9NR3:B!;R:/$?KDY MG`N2A)WY$?00._3'H4^C((GK6&%3Q\8=;U$."FF(NY9'0ZJWC52F<*$X-8;_ M_6`..-H#WC46=1OC/:)OSTN^L4X5+8C^EWASE=_N[]JO_/F\^@A^#^]^:;U[ M_\2[ZX-WRX-!9_HDG\1XSAN/W)X5N%85MU4R^4(8'\51(T?U<6S.1[PR!,]@ M+\]XF?ZY38OR6W9_G;*KA,'\FBYL*W1]R\<))`&VW2`F8=@"")T@$"FLJ5M5 M,1L<#[VK"O M"3C@!$>@`Q^V.A-XYH"EW@F&'*HT&);KWK^"0@HWF_Q//D>7Y@7.]U]VZ_T& MWM[F>Z;E-^EMFGWGSP8D^X(_&+!PH`7M!/O((:$;V7%D!Z@&$<.(^H)/WZM= M6_MQZ``7K/,"K!K`8-D@!L4!LJ!J*O9!-^4HL4M%#!$>L$-&@' MEE`A)L_(J!Z/&"*EFHS+A]C4(O6HFW25IG=\%98JU]/*J\:3ZV4Q+:HT>?5Y MN=FG;?_)PO$BZH88^=@+0V3%T'6=%@3VXHYCMO2LK5U2CXCY*;49[5_6+5OW MRP)\YW#!.Y$&V2%-*HOQ!3VQ`D'K'7?''\>D$E#705:@0KPL7]N7!\( M5'E&]85<.:?3A=&[:"-*S&O5&6T$FU"&T6=%3P/S-.[^[Q8%@_UR:1N MI()[=CXILG^GJT4$$QQ$/H%^Z,:.Y3F10]IE:6`)/N+9=[51`U05B4JP/,`% M[^J/1-\[W9OS;AG_D&2+1:`#LF8P^J0.,"4XHALXIW^#JS-9O"J6#E;'HFBR+<#.[:PR]^N:+=+QI0(#KSMLY()LI954)5*6E>> M>\B9!H(525F-S`09JY&(2I@@LR;+EZ@I7:1+BIY^LG72WKZ(?-^#=D(#3`*' MHL!'T#W();0%G[#OO9P)`I8?\2I5,2':>TB9+KX5Z=D)/!-$[02.J++)$&VR MO$G9TT7CY(D2F.#7Z?`;H-B*@L@E=NC$)*`88:]=W;:\2$SN%"VJ7?2N=91( M53/?3?%&H%Q,]YY40B>RI5!-8Q@EJW6:Z#=$#55;]6RTHP;2))7QV7G9\8EK M^S'UH,<'/?D!\JUVU2"*>RFB\&+#*Z&R6EQ?FF7D3RN_/65O[$+<>:8Z2YPT MQ49*F[PU9R6M)TF]I*PY/P<^MH*$PA"%?D03UZ+(/YR?/21X>Z''0J-)6+^Z M6Q]JY:5+`Z=J9&N4HMOK#`G*E2"M!DN5J"4=9$J*G%X2=7K\)=""D8\C&%*/ M>);MV%;8+INXKM=?IT16&TVL%-38>C,M+UNZ*%:C7>,5V-[@2E#%9%@V6,JD MS.F@9_(TR8SG>_7TFJ#`(B$,["!(2!PFB45AN[03(20]G4]Z1>WBUDR*TU!3 M4T)X-WT;FFDQC7L\C,^D4EH'WL[HG4K6#=$\I2:]/HA/$5TRVO?LF(MC[,8T MHE[@(FR%46QYM%D2A;9'I#5/>*6!M4Y9U:P7N\("IY76/L(V=K'L#$?=1$R: M6?/$2]Z4UT6K)SWR8M4<=BGV/.RY08+X:^/YZU[J2@]-6/8$EETL6L"GD:K^1UCB81H9)AUU2U MDK+E+J)3LJVO,B1VDR3=[(DIT8&V1UHT=$OKEEPM->U=YT M=):6ZMO1LDQ73-CNTVU9/=7[]%CX:TP\#'D1W4Q7X;AP3;B MJ.*#/3>L&8E2FP8JVR;@9:FK+1PP/LEO`NWQ:1#_B\6G45UO6IQ[S3]ZXESO MW?#SQ[G^%*B+4W8]G8 MVLBSPBZ!2^F"FB/1WVSK-\\"NQS\S;9_\V.1N5K*.#T?!T:C4U#83V2Z?%F@ M&4SP1PU4:'J],J(%YI:-0;C;6]:1F!="F!9>39A2IMRF7.-&5!F"NJ.&\YL;5D$C^,VQU4F9 M`*.]8X8>,I7'#`930\P0(%I9S-!#N+:8T8UX%3'C0(Q_&K)`).W6$4IE.?YI2,YN`RLI&\BL[?^;JV1.7#55& MD]TI?\5ZFC07.@MK_1PT3MS[='__"#/R'3=V`N(B*T9QY-I^Y!QBM6,)O:1^ M5*#_S7%/V*DCQ#V=_C0G[E56_E7BWA.7#17W9'?*7S'N27.A,^[UOG`/X)_+HM5]9_3GN3?T^SKMUVZ@M_38ODU?63.PG)M M@D/L6:YC4=NC?FS;+70[#`5N3)F!5W,4;+&!!MS3:-B[HC,(BZ\6A,SRH1'U M),,HR%[CG8[JEN M@^/5K&[OV<[9=9S28ZY/N]S",0/JSYGBU_;RH^")Q:`V^6?<+R)WHLR`/,"- M+./V3Y_\2;6#Q/*GT;:'N?G3>)2\G3^-[*ZA3X<7VUV1;NP!_;4@ M28^;F[T,28*>>D\OEXQ8X6E^PM^1UB17"4(D)-BWW9!&@>>Z,3W<$URCG]@E?#I6A4>O.TVL\)Q8;$J%1V*_C%WAT;MO3*[PB.R?$2L\ MSQPT:(5'?GN8FR.-1XGV"D]?=PU2X3D!^239J\,@C'+C"`W0D34,X4G^)9Q@?CE;B.3%OS!)/CRTP7(EGF*TP>HE';DL, M4N)YU0.:2CS]/6YN^C(D"0I+/*I`RWGZ8X>8!_ZU\&.6+*$@\>T(1IC:04";F896:%F6X&LJ=*,142JI>:>S M^33YQZ\(S@@&R?3RFES-X/QB>B786Z_=*]W:YTURAU@.<43.#[&/0D8#'E3H M)R^%C!+\P6T`E1%#3TWJR?F9%O>AO&E(%_M@YN;C7#3/A/YTHWYD?V(?MA^Q M__`=SC[Y#U!+`P04````"`!,@0=%UYU),LAG``!=+@4`%0`<`&%V8V$M,C`Q M-#`V,S!?<')E+GAM;%54"0`#+]WC4R_=XU-U>`L``00E#@``!#D!``#L75MS MVSBR?C]5YS_X9%^/8]PO4SMG"]<9USAQ*LE,]HW%2(C-BBQZ2Y,-L M?/'KBS_?':MWYO3TQ3_^[[__Z^__?7P\'^KH[J?X M\//'M`Q'7\OLEW)P&:[2LWR03F;D7$XFU[^7)P@`/#) MHM?2%M5OQW6SX^K1,43'&+[\6@Y?'$6FQV6#\>S MORZ:EMEC#>.P\.2?K\[>S5@\SL;E)!T/PHN(P='1WXM\%-Z&3T?5OW^^/?UN M@'1X,P-D/'@YR*].JB8G>EIFXU"6\:75NW^Y+,*G7U^D-X,TL@H)8!A4C/[M M8;O)[77X]46975V/(F\GF[W28? ME_DH&\YLFAH/=5IFY?FG-T4HXPMG3\\_^6P'X=BMG;5W+P=*\>"6N(<*/.W9`Y=QNB&%U\X>3V M=%SY![,7KJ2R0=].B'1I,:[OPN0R'YZ.;T(Y:>(-/=VK M1\*::FN3SIV0>3HNIT7EDK]*)Y,8#ZVB;%G[7HAIB-:*;AV1%D?.KNYGYA!G MY5'UTG>7(:QV6YKVWPJQ;^*W.)Y)X&ZEX]R6]7L5!P^[;(+6AV5]OE$X(?QL&E3L^ M&.33*GBX^&T:95WELU:0NJI?)\3-7*P8*H9A90:B#9AIW.-/51$GS(N9>NK; M^R9OTMM9O/$E+6)8-%/8OR*D85A%(%^OPR#^^#ZO'IU/)U4JKTJ8SOX6BD%6 M5NY=0^'M);'=B&&2#S[_P,-*/)[LU2-A3>75I'./9+Z-8BRRPLX;,;71JWJ$X#ZY./O[7.4W_A![>%>/(#0+09OT[8;(Z<_5(V'I9FG7& M6)OH;U?HY!W-XW!1.9AGZ27$W^:/D_/B(AUG M_YX1_G#1;>5JF_H8O<)TL$@;CRJ&PVT%U`JXZC2 MB`AAH/H>NE$%<5[4PND-N]?I9%J$Q_(TCP#Q8^/$(^TMD5XIKJF$4`%L:JX\ MXGH55]\JG2H&1WDQ#,6O+^"+H_B73Z$HYG/:$_4N,P6<_&`MTF+P@^I^WW'> MXN1ZELTY'EQFHV'=NZH%VJD6Y!U#'YE=?.DG#S_U[@S`HV[G3SOPC08(BBC` MUF`-I20*0XTLT\0Q3J-$,=S$#I1A\/(BOSD9ANP.MOC#0[3BH^3.MZUKU681 MU2-\+VF90.H-$J-7I!E?J:/39; M+&N:<"*A\HA!+[DUREB,?4V_MYX\?[W96'(_:,!&$':O`C4Q-K]*L_$2X7_? M*!',`V4M9$9I$C\$"H2L:8;2T4,2>UMQY1VA][3$?TQZ5$^2U]G@,A^EY4TV M&H4_(I_3P>?;5^'J8R@>D?"J+@GP$MG*WB&*-.!`2[U@VBF"#D/>;<64]X)B M*[G_/HVSU.S=*LHWO4J?EOF2YHDA5#B`"/'$8X\EI36E#'"+?$MYH\.3=S<( MMI+U^666I]7RZC!+QRL$_5C;1`%MD(2$$`(RY(1P1J1%T#E'C:OH(P6TG M:7)0XFT'5B_"/'V]3)BGKQ,HG-,.`D6E1XABS32NZ7/:FI;"I(9%-46RN"QNLK4PKBU,5WZ234)Z./US& M>.^._+LT?GARL65U[X0XXXR2BA**2/P78'.O_P*V=@!THV4X2P;A'$9AG-2=!BN5(1'NB0P3J)*"^0$$HXS*"RA M-<46N`.)UWM1@LWA[,,:G'\9AV%+DS#KFR#HM3:.QV#'1V>)2!P]KCD/WOJV M?L:>Q?C;M`MM<.U#-\Y"527;4CGN.B<>1.^+":BPMM30Z%BC.JD!`85M9XT] M2QIL4SM:`;N1>E2FZG4^.1T/1M-A&)Z.[[:LC&[O2'GWN0J(A]^1NTII6@R9 M<`F,4%XZ99V#1,>(KDZI0`\QWU::XKFXI5L&?&NE0$L.J?E9#O1M01@''E69 M1N.9=LH@8NN",&4(6YFKW<^R0``YB:9-`$=B4.^00$;67`%AVF:Q]BHPW9$> MK"X,7`_\[5N#GS6"JY0!`<6I!A!*0K2`@%FOA?'(QMA#,;1R-6X/:@21%X!R MH:._0Q"VCMH%!Q[0E=7.^U\$LB.)KZH17`OW;61!%\S^%O*+(KV^K/;,+RD= M7-DGD9@*+@U"FGM*(8[_6_`G*3_D&L*FDLW[P7(KNA(N'E*ZM-)P99\D>K[, MT/AA.2>%]5`@BVK^.+,'4'C8H8P?:DU'J.Y@`97$[\%;#(QD!BLD(5C0QRRR M!R3US67T<#UU+>SVH=@4">H\\YAA[3TUP`M.YQ0+Y_D!K)UV+^V.0=UM20R$ M&BO.M++,1K8)!L@L:.6V;:2Y1^LHTIXP@#%0-<0KB2-7V> MB+9%4'NTC-&3@5\;N^U7+AJ*E2(\_F,9$1YS27A-'Q*H;=BX1XL0/Q: M6>WOD\_SE8[;U^E56!+0->B5.,M8=#L$DX)BC!B`QM=T&^[:;B?S0[UH*EP5JC?I%V!RE#F"%/C&%(:B%JVF$T5L_?=>]4@LVTHA6VK?3"7*;C MZ23\'M+1Y'(0<;A;G7K:L7NR4T(,A!PAZ8P$$%2),:UJJN/W<@#!7,?2RWN" MMIU"Y--Q9.6W(K]95RM6]DR``I1P+;@"1$C'*(:+((4J<`#;SOI4C:[Q;;T"",KD\X\8>U2(#I%MYVV&X<67;/!Y/7UXNE=" M(@K>1(,FB'<8`^G$8O(SDK1-&^Y1G-FC1G2*[3:6E>H:A-E%3F7VQ-DE*WHD M4E5[>'T,W)CVP$(:E;7F3='6_N@>32U=+S]V@^2NM.3NYJ_E<6WCO@F'+@9R M&%8+*=7^`6^,J_F5U+6MB=RC2*8SB3?0H$VP[2#GT6@&6MHC45H;(@R%0@!L MD#(YEW;4NMGH@LM9;<\V[$!MGUM"6U_2);Q#$7#BEG$Q6C.A:>+KX0* MLO)XN/WW5;N:83J"L'L5J(E9YY`LQC@P0G!N/(#*,0(-7'P&#!Q`HFMS<2T_ M)&L]]-KE*KHY+$D0X20V7$4C!2WSTHC:W$D4`^O#D'-;\30Y+&D]!/=USS^# MG+LX2<5@21$$9?RIGJ:D\ZW-_!X%H-V;^4U1W*L]VHRYZ*%`*Y47C'KL9+T0 M+S70!W)(WL9R6VN/]EJ0;C.B-/G5QVR\J!#/AO.M&N^+=%S>"0L^HDAMADFP M)`X[7!5S.$VXAQ#7ME8*@MHFO_=H6:1+Q=H"Q#M2M&\BKK=A5%U08/)RTB3G MM7J01%`,)--4`:6`XXA)6R]12\Y7GV7_'--@O2A9-P#OPWD3R&`L#:&.Q*B= M4>,U7UA?ZVW;Y=B]CEL[FM`VAW-'-N9M&.07X^S?87@ZC,!EGV87**FR#)-R MGN:IKO$[BX_GDW3\V_0J?/MD/8/4Q1L3BR&STB`&`:L6)S`F=O%Q.==V.7"O M?>]>K-<.I+$-39]?25F^S^=,U*R'\K?BFXMX'U'955T3SP5DVJ%HUCF,OJJH M(N,YMSY^VBUU[]D'; M,`Y?TE'%3P5$4\VUPLHRSHSSU3$$P:71@^K>R;046R)$<`"A:#AT?M=&'&$6\^.\C`UI1]4 MMW\>R/TUQ=^[CC_/"5EU:H3W1@*MN=<6&^J4!=51]%1I:*V#M-#082VDH11K0HA59!$@X$,ZYK$;9=BD M]&T]K)]=64HZ?NP2C;Y>E9`X#4"`(,'>8V`AT([>H^D/X.2C;6ON-N7QW+1; M3Z.(8MR[K9*KQ?L2!*BF1!-E,(BP,F%%[35Y)6W;X',/_8*]U_.V0GENRN[B MW[Z[>J1G95^\+P'4&`(L=H(CA:TU%M3Y2A\#AK9&?8\*89^-LK<5RG-3]M/Q M36R?%[=;4O;%^Q*J,!:*,D^MH`1'E]#X&E>H6F]CVJ-2VF>C[&V%\MR4?;>U MXQY"X0T@4FB/B-#8@@6VF*FV.U_VZ`;V9Z/P[<7RW(O(&1;,&E95]SG`O$/< MV\5L)G!;J[M'%;V]*F''^&Z_8&Z64OQ9%[>\J@G&V%THJSG`!BIGE')W:2JD MA(%R92*Z[[JX'VU>M'&K+=Y,[N^CI'4D\'.CLKE.WI0PCZC46C`H`;9<4@KI M'$])C?YYFU=;_5M:5;<+N?5LR!["J=,R*\\_K43UIYU;JF?:\3@%"FQDG/&T MX)JPNV5%%*A'!39]7)Q-S%EZP^6..^E18@PZ;!W6C/B?(T* MY'9KQ\@_G\M'&^O1$G>^-^'LJ4GZN3-AE49Q+S3$Q&@B28S*@/'P+KN,8'3; MZ=H[$Y:>,-].@)4^3M/1$W!T.7QBC'!6*Z*9L))3+UA](R_T"-JM^4_/QR(U MUI]\Y^+:Z/2-O])BEN\XK6I10SF9[0UK<*[4LGZ)LJHZ0P\!9:B4$B--X`(X MX+=VP%R?JK8;83]V=$='8MA&0JI:#)G?-[8D_'@]&TJA=XG+GJZ2@OIT6CK-2F0R=,2L9U]`F40LI; M!BPU-6(4XP-*0_6F2_E.1;(3L[++8&UWU@4R8[#5U#EDX\P"%(?S`\0L!VQ7 MJ:&H8?E56,R#.AW%F3&\NPQA$EE1P^%LB2<=W:M:J6_74M)5.\JW1$&B&*.> M0L4]0)Y!IQT`-?Z:R;;GO<3("%PTQ@H;"SED(HN((US?'WMI'< M'JG3YN):?C/!>NCULJGOPU_+-O5]^"OAFB*/'`3.6XL5YP`M6&34'<`TM8E0 M\DW`VD92I[K',T(7$7CR&NZGFB>BR@%(B)@BW@$6PP>S0`-AV7:^V*-4S;[/ M%QV*9QM*]S9<3XO!95H&=5&$&90/*5^YN;SQ&`FP$CC'L!..8H@%9)KWB?7S.R9%*&YQ=:`#A-S'?[S7M>46#*JVE;5[ MN%-MW^?"KF3T_$Y745)R)J#DTL#(F77>HP5_1FVM?&F7IZLTEG'CTU760[67 M0$R]71:(J;<)9LAYX#V$T@&"/58+BRTL`_\O3E=I+*/\/^Q=V78;.9+])>S+ M(]9IS]AE'=O=<^8)AR6F))ZB2`\7ESU?/P#)I"692Q+,!)-T/Y6E2D"(&Q>! MB``0.`>[$A:A>^MZ9(DK,X#@D,!*`P29@@PCS:#_B;QC-_!:Z;6LE[U4>(FI M=I(,C6+3S!Z#ER`N5-Y32BPD!"'HW18;*VZH+%K?R';.KG:V`K,BX4_3>?4E MJG)P7YU0%/1PJR`D)`Y"JQ7D(D9^P+AM5,;0\3+@UT.\SC4[[0KU++:LJOD/ M=Y4MG1\FS-&&01(*XM(""")0&DN!AJP>/=79D6X/L[Y%.=,V\+?AK+YO4%FP MX"@"EE`887`**Q`2SBM*:AU(QW-3ACTL6_%OMS57ZV<=ZV_YM6BKL,*`,Z,% M%SS^X*3>IEWSJS?W<('O)1].>87Z-%45#Y`.@_.I^E;%7S2-C1IU%CB/=H&M M7N0#QFA"!*8U(EIEOS_70T^CS^0MIL!R'LO[Z7SNHQ+V>'+5XN/#E\'WHRY' MLVZ"PD0"I8SQJ;XW5TY[7J,`) M)N;+2=3YJT^K705GS^PQ6"J9%A`ZB[U347KHMI&+8?;?6=ER[D(Q+9[EKK;T M!KP&W%*$,#&,"^<\P7[K^Q!KDA(424D]2(;Q, M>O>P]E^?Z5U^AP\M/`M(&62,A M]T!(;BT79E.[AEG(<>XEQ1ZE7KMEP1E@=J?\NVHVFD9!AS;Z.D=8\.K;X*`5 MT'NGH(*2<(<1(;4$)GHRUY_>+$.'N$E MMM9!98A3"J!ZQ$0I>_WIQFYY<`Z:W=D%'T.'P?A_JL',Q]_LJWRQY^N`#>!$ M,"^-1#&@T0ZHK74#V.4>A>Q1]J^,;3@/UZ[9L;9R-1VB[ M$G)!<[>Q>I1MZI8A+0';53SJ1^-J9N)X'G>_F+;GRZ`=T]9SKR5AREN`B*1; MQQF9W,R[_%UH<3ZFG64HIL_/T\GGQ?3^K\]/$:'YQ^5BOAA,4B;S<+KB0,/T MY+=W,+V8[)4BGF*&:XPL!BPW3$D%TGXGPK2(<<>I9#>83=+3JNE44EP7-P-/ M8SXQD=Q2P>?-<.)05H-H4&1R7Y.@.4%,IV>QM#!:4BL18`PX2'VZB'6A:I)O MA]ND".W>-B$N1U`!SV+8*X"RP$BO:ADYD<52T"6*])^OZ+>%J%N"]6)3]))5 M8MN+:I@A\)X> M`B"&0PF%4THXKY56!M7R4^=SSSY>URQN3((CL[@=D,N="%^?(IJKQ6(V^G.Y M6#V&-OU4?9W.HAEX7/L3+W;.&]#NK'Z#@0YS(#"UE@IEF)&*;'`B1)F;>(RC M,^[L//%=1A/E[S"8]6F)*,.O[R$+&Z M>26X5X@;!^\@M*"$$K3[HUK\'/=KJ/Z83M*AG8A[_*N/]9,V!UAXDQG[&^0E%WKI!^F<7O0["[A&+EP'I&[ M^8/!:8Z=UE)"J[!UVC/!:V2MSSZ]EB,+Y!KO=";66N\'X;#6,D.K^K M];[*AQU@])X6(3I;Q,65AS`'$8GN%XYNV$8V!41NDJ/YV8F;-\#M()]UZ^;X M?'B-PMT*QI6W_C0=1T7NO?5U?L_!6*^I%!JFPNM$*4D(J^7GT2TJ=EKCQHSA M9?33MUO>!V%NO/*?\3>"<3&<18IJJ!A'-GK\JRIE*_R@4+EW%'IT\J1/BWTY M394/RKX-1N/UR%_L?6VFZ2JKTC@D.]I3=/Z=\\):`XBV4DCN"-WZ.E;(8J=A M;LPJE]%'"6[NSNOE)NQK/!%'",8):*"%Q`*%I=ZN-DQGO^IP\L'^6\B,MHET M/\+[*,E*B%>;YUEQ^ZN>@HYVWB!*L$``1P\'8DQ^6OY;*I39$B=.#KC/P;N% MF&>W6[#Y5PKQZX]K3Z':NZ*VV'O@$E-!'(]AG[&$,VK@-J,@*DJM]M)AIVM9,24W5'.O=(QP'M*]B1(V8K02)[SL*W`AXL0B`,8`G&N!($!N M@PN-%+*9D1,KG('Y9:*%S8`[BQE*("&>L4<]-[JZ+%NL5!1 M";<;,9S+OTOJH8=10Y:%/*G78"5E6#@K%)0X%1,TVRB?QE_?<.30C:WL$OT+ M^H.G^X$!.*,CJ'O M$Q&/)45.ZB=(SZ&3S!"I((5,4&SK]"0E7!:[M](]!;NC2"87E!7 M>'\2"<=%5"_F&F+GO#(.,4T<8QYK=ORII8:)B/UX;H`\5AFT<0?!QP5<&.RH MBP)I!2""MI:(2G53%X'.5^NT`,8E%@\5`\AA,BVC;]7GZGXY6]7K==_3>?AJ MN$[)/7]=KM7Z\>$7X/95Y6^U_Y#.V0,G`8*$B(B7-T+4N"&!<[>(>L7-KJCT MMA3Y!11RL45G]>C@]5_6Q]`AI(2Q4BF%A98,X4UM!!/7?7;J8M..A)_OGZKA M)*"TV*;F3V&#A"F)+H_DC)1,1*`&MJ?+``N7<&>F4>VB/)]!*@ M=VT"_GIL-WDV_5?)%*#5UFXN\KI1.9[&G03$!8'`>@R5M9@! MX@3;H@!H;I*NAQF2SOCQ-CG<%?@7,0H7K>!S,=N@*:`@%<\3(+VF0915?.VP M&0\A.SHK2N+Q\>])G#M/HZ]Q(;I/RG\\M"79N(\`B/3`0J>0,P+#.`$:E(<(\I4=Y MW+%,I\4DAYH%"2-'@+'6<2<)3S4R-\\D$`Y(=DV77J8DSM#S+[.R-4@+3\9+ M1A7GS4DC$?,16ZRPHT0`I)59PRHDE?#HX:FNDXL?!N.O::"C^VH[^%4JJE$B M<6_K=%6;4>((=-@R))2E@FSEYC!W\[J'T<`9.M^;*VP+UQ(^FDE;%M4L@K7X MD1Z\4]]'AURR79\'`CDS!I/H<4*/TWO8D&^EBN;M=MC2JHZGK4-;@C"?JJ_+ MV?W38%ZIQUFU>F'U[,^`D[%1:C0470JI8TA#@.U_%:IW-M+ M/:36>>J?E@$XZ\+(YW^83Z/Y7V8PFXTBC#&Z^%"E'4,"EJRZRH4C=4>J`#_4W;1SB+#?^<#!X>1N-1*EVWJA4SJN:'^;"_1:!, M&PT4$PY@P973G*-ZO%J`&[KBTS$C6L.XQ!)T9!6.XU"3X9?(['?#"-/H(?[K MB%N3V6.(H17'BD#I`)1>8:LEJ[$QZGC,?CW\Z]+S*8-^"6;N'.M1=^A`JT") MD4YKPT6'2_GRI-F@6%4O$?9Z.#`:&+L\Y@OP6&\MSW.'IYKZ%- M@G0`;A8MOLQ&@_''F9K].5JLK\76AO?+Z+EZF.W/`9W2/%A.J!<6*(X`(U9S M`^#6*FN7N^_;PUVY+CRC#J'."^$W?WCHI[-?A_4QSL4_JN^++W]7XV_5A^ED M\33?Z_2Y"MJWY:'ORNK-/AY:MQ M!T$28)C`$4"/'(XA+3+DYQ+L;\"S+J3M$VU6%OPE7.Q=YOO]:%*]6U3/AY(' M!]L%3"U*1A\KR*0RTG+Z,SPA].C]A.NY%]]EBJ!-C"_%I0^#[Z/GY;.9KB^O MWD6G_CD>/8\6Z6)7E7+!^U;%$[H(T$HG/73("H"`EUHS44L4 ME92[+O8PI]DN@3H&^E)6:SWZFOKODP@GFJL=/01AK)9*,($\5'$P"H-M],PE M+E:5\K;LU/E(9QFHN@Q#2I?,/SZ\3(%M\U[;,:[R':-J;X(AJ[-`;`R!F"8^ MQC_&6`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`\$2:&1])HJ@123@$JGN,8<&R^4OU"90C6?1]!K+^NXJ#N_#X!! M#9Q#UF"M/%0.05K+AO1M%=%N5]EORQ2W`&^1V@*#^5/TR=-_4A&A;X/QJES1 M(MT[_3&://YK,%X>2DXV:A\@(U`(8P&R"G(*G`6@EAMR>U,W5L[4_-N*`QW@ M6X)7ZGZU&SC_Z:7_42W,T0#^4+/`HBOEK<5:>H>U0TK;[5PDS!>[R7E]+&H1 MUC+U*^IASANQ9N?WP0NO*).,2(\8H@0QCVNYI#&YYTUZ>7ZI7;JT@6>9"Y?5 MUQCJN^\I*9!N@:U\]%=8'&!-@]8APH;3G0W@,066R;CD;^>&=3;7'^IE4-TN MA]I'M\P^;2JKN'H:]>AL7M MLJ8-/(NX-RNITZM6\Z_3^6#\'[/I\FL<_'B9WK3:^;)I`^.NG^VN`NCDX=BH3HFT=@M?MR-!ZL-VY1X^)H29=$ZS@_M%QQN&"@W%GNC MH8&*1^R4E!N\+&"8%;NU=/7)Q59Q+I0-6CXOQVF/P%9161&-!$3\][A:(3(9 MJN?I;#'ZO]7O]\IW.'/4RI\(CEG)5?0R"=",*`HX]C5ZG(OW\A1`=U&@+E&).*BYC6(VUK;%SDJ!2 M"8P"5]N[Y/)EU''1Q?XP/P]+J1GE`$JN-4GOSAI#92VEP3CWK/#IUZTZ=PPO ML\R?CG&Q\^B;8&=[Q*_I&?1][8(SR%,B+&0((4"\]LFK6 M:6P3YDME,QH=`C[<,$@M/`7$8&^158(K!'@MJ4#95<]ZN1?=DLX;Y#:R`2Y) MI=5ML1./E!]M&XRPZ>*^(#%:-T0!;-4VW(JV^*;"VFX)U1;&)3C5WO-['G)! M,.&68H<)@E@XL5W)(<@]'-/70^*MLZ<=7+,.@*\$>B'*2K1]9[MW?AR,B]82 M0F$,1$0BJ*W0]2@]SB[ET\L=YG;UWQJH6:I7]Y%V"=QJ,*^>IN/AZCQL)-\Q M-^6$U@$:(S&`&OP_>=?6W#:.K/\2[I='7/>D:F:=RF2>41J;CG76EGPDV3N9 M7W\`2:3C6)9(B`1I91]V:V8%F/CPH='=Z(N.%R=PD!@"ZG5$,[*<(?7!1,-P M&$_T<;F5*G/6O$$IQ2(B$1BG))+Q,.@7K[(B%U0/8YAKJB3ZHYG[7530,J_I`M9Q,.RF<`H_KQA2YE#IED&9& M$](H^A3F!K),D`\%T@\ZHEDR&VU>=7]0<-Q!$#5[)83%1&.+<>T&A5$# MS(T)GV3IDT$9TQO&15BT7'S[6JT>;/779IL=\3A/QS4I>E=_W<^_;;>S13Q+ MIWF"92HU`F:2(FNE<=S4\1X62@HNJ+=='V3XF5\#0ETRH66?_?MU-;NIVN>S M'!@5L.$V+@L80`WU%&,AZBL?,@-SJXY/TF\X`*'Z@[;PO==SU/"9,X=H5`A! M*;8HZIS&0RI1[:Z'\1\OJ`O,$%*M*/B%Y-PJ?FF6GG9R;%`,$(5U7"K?MC'5 MT.$&9\ESK]!)>CN'D7F]`ESDH61?3.-+M0T%>_OMQYY,3HT-P#-*O/'.:NX< MPXK9EP/$Y$4EK/>X^S\_H?2,-55`=V4;U]7JN85"=F144)1CX#Q55D$" M'!..-.BY**@O22$;CDO](5S,B]E))KTS(CAC-4T'0W*OM`11P*-Z;3A>\)>C M1PW'G7ZP'<>/UZC_P1#)(?5NO/P+,R0 M3N&01\<%C0'7"$7K%G(C+/(.U@'$4$F8^UXRR3*\I?R=9\,\'9?GV;[.H#T0 M3!FK"(I+A]O0O7KE0,C=H\/#%!0+:D'V#H( MA1=>BL:5"R7!EZ15#T.I7@&>LK.S%=W.GSQXPH4%W"$/D"``$\=4C1B1*O>1 M>8*J^D`RKO06C&$)M@]J.3@HN'@L.3"60(8EY#C%[#0KC&IO*5?G1R59;]". MINQW5?*#`%)9232/UBU#)B('ZV,R;:-P&+F4C6H)MICEP\-\%Z6> M5,2FF]KAEHLM1@4#XJ(\%1H*;HERR(DZT`> M66FUEMHV3TZ(Y-=>A).T'`=E5V\@ERE(L-^;[5>?JC]]X-=!2>.-]Y1JH%6T MB357M?J`H,2YFO=$I=+Y6_NV9D);2H9:+5ASY^:=!4B>4%:F"K3'$(X-L M;7PBHUCNO351P=([0<[$LXA>M*IFZZ?5]U;\>/OC@$F$PB$)&?56>DZ),/6* M!,^VQ"9:!*IWAIR-:)%(MYN;[?4:+]K9_.;38N^J_X'=QT+=3@X.2EB%F8V7 M,Q004RNIJ+T4R`N:^\0[R5BW`3C4.\(E./6EVLSFB^K&S5:+J+^O7]5`NYU? MSX^7L3\U.`!"3,KEB?=QW7V=_'X_/[3)3\,`39:@TD@M"D:-0N,;?061N MAL)$:R_U+\$&A7LS?/PYU3W->[:*\]F>K-9+C81U_@IWUHPJI\_$*RG2!G(&1+8J*@X M\B8)!\7#EMO%LG-,W85(J0)[4/A)5RUN.MV$IX9&8UA@2ZD3W#&GH)!0-H:+ MUB"[!F'W")2/7>:@9Z!_H-48'5-W+SMWU69^/;M__647U#[5`L^!Y!1K&L4* M9BC=6MLFME)%<^ND\W4@(^O^?OG?M!5^N;++I[\VMT_W;[OFM4CX[C)/0`HH M:"S5R'$L8,IXUS46PM/<0+2)OE3T28Z?3:T!83]^V;Q3'NY+=5-5#]L^X:^> M4^(9OUIMH;C9^D4_5ZL_[B)^!RB5-4]`1'C,K::6<*Z!5!BC>FV6R-R6/1-] MVQB`4B5@'R$T9/N9:_6TN8MFPS_5S1$9=F)D$,I8)JA+V7PRVIU((%>OU3.0 MZQ::9&/-0:56OT"/1JI/Z_53=T+M1@4*B!-"4,BB:F:QY?$OUVN4WN7*JXF^ MDI0F4Q;(HQ'IZFFSWLP6R7;LRJ8?A@9!*8GW>[1D741/,ZH5;HZ-R@Y+F^@C M26E*Y2-=/GJH@[;5;8+`M`2"">P@1](Q;[4E]**.LD99J">J5,R%QF3;+G9D%FG8GS6(PZJ5N]/R@P:@$SZ8&( M4^$-!E[3YM8G.E=/_[BU,?MD4A;&8[&HG6)U8F1P"BA!K5#<$T<`1!#P>JT& MX]SB71^W]D"??,H'NG"T;89.U6)T,)H!QQ6#C!DGN3'`JP9+H;.C_3]N!E,N MN_I'NS##.NA21T8%*RV67GC"L+:`"PF(WZ]15N>]L,Y:S7@\Q">C'X99Z;^K3?K4SZOE\SSBJK__N:YN/BWV M16P6W]3U9OZ\"SDZO?[NDP7,*!`J_D(-*E*8W#JB4]=:SZ#'LC#F M9;PXR]OY)J4'''78U#\*&".(F"51G`$@A:7"XGH%9]2%G OB&W]VT#]CQ\ M2S#D)8'$1XP.UMMJ4DM>A^!^J1Y39.[BFXL#C@:R]O8W@@>.8&!QO+:-Y#_^[3O&IT.1CQ#U_/[*J+VLIJO MR_Z4PB'^7``(>BVMIXYR#IBS"+^<7YY=4'R2=F)!/D]@KTJ<`%O%78[F]G;W M%S?J(=T-_VS_\0B1CXP*3C%+-=/8:D``36G4L%ZCY]D!,I,T8\8ER7*H32ED MYSS/U_';#@3N'[=\WAT6'!4FGFHM%291K1$`"U:O,KU)7%((_*2HU^.NE!%Z MN\W<014U9/?W8[585[I:5+='*W6<&!DH)0C%`T90!)&85.FFOFT$LY<5(3\I M!O:[,86LG.28KFRU^]]/BT/EWH];.BTF"%`QJ86#D'#NM0;8\091(UANRNDD M]<-)47*0_2F2OI_>2'3\XIM4N"2>HE/JX.$!$3B$+7?.HY2#RQCBR7M6>Q:R MDQPG&8X_*>;ULA]9V8\OJTT0[;('?J\V=\NXTN=J#U!$97F;/`1;KU1R#:1" M7P?X=>Z404;50QF"O==1\4V5PFBC]@*/X%*W7\.2(=3XX-0@F"`>)>2:25&OKRT9QUYI$-E7Z&SA`6\_2>"<&Z\\8](`3PR"'#8( M<")RX\(GF70P*5(.MD?CL/2E"LB)9\/WQP5%TJ(*NL11+W;>A,%8+PTG2+#D MQ`?:4U3KQ5)QE^O*F60LQ2@T'&`7QN%G[7S_//N>#E5Z#GK3N[L3/]M,&)PP MWAO.E3->\-0'G#?(`&5STR8FV%YQ%'8.L`+352CT^O4X\/Q^K[M)PD0<4(%X]81 M(R&6\7PW2@RS-KO(]Q3-]"$)\G.0V5`[,`H']=-ZOJC2H],V32.!N/]_CA9] MZC!-B"!#12!Q@&K+F9``B!H%RM!%N8O&Y&%_>S"6ASPB,K^.6Y0^O:.3_,>A M02J*"5.68:&$5MIKUS@?,!47U3VQ(.-ZQKVDO//+543HNJINMGE!6S_J`8A: MB+R6,P4`G54(&RD`BE>`-X@USPX\SK"5B,EMO%#MIXW<((TA$!S91`% MRD#J:O5&&>!SJ]1\'#_D$-PMN273$KR]"-F@G;.,(H<\CY8?PUQ94".`A,H5 MJ!_'#SFN0.V(_X@,W->:ZL62R0'1$6R<#,&*!M>=$RAH13/%%I865]$/V MAWD)%GZI'O=*]-7M;\O%MZ_5ZB'%%ZO%S3YHX(_J^FEU2A)VF28`AK7@&"&" MH?#:*N/KF@N*"IAKD7\D7V0O)'G33WRP/2B4?-U8<*D@9\I'.[V0B.\Q.SUW MSJ"TTMA;+!T0VC)B&&CP(1#EAI]/\I6F($=+;4A)=U)3'W+QS2S7QRL%O#,D M"(&]40QI:0G&'&*M:V>9\I+E!O-^)"?E('3K!^_QQ-^N-.B?BYODT+J.2YD_ MIQB[P\F4Z#(0QP@2+$`F*8,CU?KAF#46[TY203 MO4<7H^-L6EE1:^<)W,7-^H?BRZT$[J&!07)FB'+`$<<8B;:A1;Q>*:398K>] MF_/2Q6X/J(_$K]=M4>(QVOV+*C7([DZZ4[,%+:6D6@*O@068((>8;_1QJG,% M96Y6^`4SL>>M*!NH\?M\L5S5W0_WW>5;A68<&A@T@QXZYA#6*HIVC:6H_6Y* M8))KY.3F>%\:Z7I!O:SXVYZ`6J-H;\V\'18U;&*0Y4)QXB)V\431YA0Q('.O MUDGF;X\BT,[&?%I.[G[>MUM.'"PB7D;]UEJ'B/+`^B8$2EF1'83;.9%[M.>8 M(;A9=$_&>M\^L)I>WK=;SQN0IY)BP5"*JI<&<(]=X[N@V?7\NC>G&^V!>PCR MEMR3:4G>7J1L,(AC0:BB1FA#C3.2UI4=E)3YCSK=FS[\FB*UXP:4$I];=_[Z M+H7!/\_ND^;RN5K-4\&MU^&C)Z1EVVD"C,L%@D6`N<8$RW@6:\=N5(@D*.5P M')Z%@[QI#XCU>(Q3\0RM5M_C<=GV'>U,M9_&!\P=H$@98*D'@"O"I&O6#4!N M=?O.P9&/VVV)/%AM+H5IYT%].12CUFAE">IM.GQ$)J??AED>A#D M49.-MCEGC"JL:N]E4C2S6Z-/S_CL?7??9%"=@VRAM+Q=X?IJW88H/_\X,,"X MI5IA`)!PGCFGZH<^+4RVHM0YB.H2N'(FN#_098QVLWW=>LGVV:FH(#1-%XPT&-/*>*6T6U@A9GZ/S)@S=(8D&%@4`[JQB*PF^/F(=6%;ME+HF0Q;=E3"+_N8A??C__ MI[I)9=?3$J\6-B[N>98BZ-9J-5]'>]$^K>)_[Q9=0Y!![/P_%IRER-LH&HST MFDH)_W\>L>5IA)XBC=5 M5^;3JX6?<1C.^&L!`\Q%1-4I8IS#"$FE:TR!`6YPL5^Z0<4$CT2Y_1O[3)Q) M\F;57A+L4E$4`*SDBGAO8;UJIF5N_:,)]GF>DJK2$?8B[PAOO[C^VB8J_W/J MEAKW^56O]-2:(W4G6M[';_I6.Y&.O3CT^Y>"UDAQ3AB`"$*CF72LNBI$%<9Y0#11PBA5AS%%,)(<.6KM;HP?UP_ M^-OHT**N[QURS0>UZXUU:$2`2"E%#8J(2XX@-TSORZEPCAT]Z00>9GW_$^WS MS9V)U+U:?9LM]HWFOU3/U>)I1YC/\=_$=?Q1K9[GJ=WM]O]I.H4?\X"?/7=P M5C"/.`%&$*N,0<+O0PVX@)+GZDV3=-^LO$:3]XH]' M;!P=%YSPR$`/C71"6P$MJUO><9&Z.%V22.F=,WU"6X)"O\_N']."(\.3*;?+ MS_I6+:Z_?UY5#_.GAU.YH.TF")!(BZGU+IX@X#B/_VSJE5.;+8@F672N=U(- M@G$)=OVK6L3C<)^:P]T\S!?SA$-Z##C='_K$R*`84DFS2]+8,8`]0JY>*X*L MF"_R0_*I7W!+$,E6<5NNY[OMBI_]D)RB.UO@"(F.C`I2>&(XAM!;"*0@Q'M5 MKY$0ADOE4864N!:#0Z2WTN/R;XK-NW]7T^FD7> MKY:+Y>L/K?LPMZC-?&IL`!`:*XG7WC)*/5#8[5-W>0J*N"@MIF_^](UNN;R* M1/44(I.RTS;??Z\V=RER)Y4NW[X6G/3*GQ@?&+*8.,L1T!AA[(G0M?HF,9:Y M/L$)9NKTR(&#>1?](ETRO^NTA?73+\/_LW>EO6WC6OL?O9?[\I'K8("9IFA[ M9W`_$:ZC),9-[<)+.[V__B4=2UF]T1(ENRT&12>1*/(Y#\G#P[-(RAC7%CG# M@)",>\+)XUA`;GS7,`NT=?YI/:09K] M+P/8F+K',MUDMO/'*VJV=U MVHN@B(/,$F)2A6QO/?>XD:KA(G??'6#%M;9/`,.54M$8[*XI=)`IB+OAX*F8#F-E/6E!#$1[)Y'B0'D` MXQX%%&IF""'EDHINOC"\L?!SH@M M?BMX#[ET'%#CF&(42V`:M9EKDVMX.SQ)\1D;WOJ61I'[QK=&=<#`-T&@=Z-% M=;5:'APSW,7G@G<4`X@,MS0*5SJJ@6]0Y<9G<%S`\8&F!Z^;:T@&\3+CT+4*B[8U@(@*(#60S-2Y;'PB#8#T]HYK[5$5(AX/G92U#->44]RRW<-,JZR!".[P[ZW MK?78+37$+80`J'E$$0(KXA$'U\$V*NJNN=K9`)6S;AC5!JI]L,5.[E?QM)6A MBKUX,\0E.R7'`\XIX2B*9Q[1("?;9->JV&G0#D89VPRC%77L M:5N!,&64YU(P)1T!B!'2*`B8N6(*61\;8#8WC6@W`<"9( MJM$HM2&4T>2MO\&(\>P\@6>AFG7#S"[Q[W'#/7ZC#0Q0A%PZ`TGKC81.P-H3 M4$&M+EA%:XM9[2!;)M*\L>P]VI;K7J=TV?.=%#KD]:`P4$!"CZ0T5+BH]Z+Z M)E])D%]O]^B0]'.TGG6`<)&8K6IR>Y>F4L1\=%N]6WWY7,VO;M;=7ERMEHOE M:)IR!1]P'CBVJ2!1G&=&`*T\3JFT1?)W?T!#`PQRO$O?V M&3".:B=`ZC#Q454%2CDD`(&BGH/:&94;13A`XVUW%,GD8HX`>B3B4T7RZ3". MI^*VE@+""GD:-P-%G"9.:.-)@S@WN9X8@SP>]$W'EH3PA)"]IGM^OP;]KEI. MQJ/[YUT\N]S/U`L,'/3&.&,\H,1((8Q'5C*%!=ZK>19TU4\!63'H52AM(:VR,S/9-'J1MZV1^'.(RWS+B':\'?\RF MMY^J^9<4G[^.*7WP1?P0(?KX??2UEXF?^I*@NY\M5O-#\A6]_4)PVBI*+7<` M2$H08U`0XZC2",5CTO[4G2]'-_HV'J4^$\`P6/\H=WTB@C%JB./688`H\YPCA>F1292>1'.2D/56XLT(H]SM1;;4< M3>[[*=+0UGPUT`'-A)/&2H0-QN1A<%55W=F#@E)DL_ M&D_N)\L?GY(_W(X!;GTG``(D@9)B)8W3GE"@W6:,%C-0;.9V?SP\5!+.QA!G#!/28KT=ED(JGE5RGFP$2 MI07)ON3*Z8#V01,[^S*:[-+PWWXA$(H@\_'L&M56#*P@B*+'D;%B]YA21::)7CRH?HVN_\VF=X^GR-_5LGPL(,N.]\+!$*%L+82$JAAU*($;6`3 MD!0S5);0(4\5]:P[8,LL-*-DT/F1%M6]K'G]<)#$,JA!/!D[[(A7$#.R&5%R M6ROF`%I^@3F1*"=C680=U7*9#)@/9-[/CS<>#Y8AB*DAQ`AL`"7<8%>/"C"0 MFT/G>%^!LV/(Z6@6V8)&T]M]:FSS3`!:8J"!M)08HAQT287;]!\1EYO`8XCK M1>NZ:RZ*Q5BP7^UX?"H0;9UG2D3:"AOW0>,1K,<`=7:QB@&JIAER>TOR6;B5 MD/V?HW\F7U9?]DK_V7/!&N\@=<(8:1'Q4$G5C`-+=T%'DRSIO2J7E(]=D>CO ME,2WL93NV0Y>/QP,Y<`9;QP3F&F`J*"TF1G&EO,H/,-]X60XRQ/DW>C+?IO& MME<"8T0#P32-LP"EX'5'&T69X>P$R@-<.DX1[4Z69*.YFRM;[L$>V*YNY]7Z M=G7K3K']X8`-`5XZQ0WS'F#N)&^&[;B],.OX:8*:M8QFELRW6$*:+,5+/UO- MW\\FTZ6??*O>5_/Q^MY]]JWZ8_)Y-M_-D58:#ZEZ09P^GB`2CU%4$($;=2Q- MJLLYC+3+J3[0S^/@;%%]BG(8C:MWL^7V\\GVAX,W(IW8K:(,(P78<:0'-(N$-SRB\1W%]_7!0$FIKO4%(2`V261\=7PQAS-4 M7$^&LSQ!]BJM;ST>XJG,.N=Q!$,(@+RSP->C4MA<4/6J4T2ZDQU92#[GQ[FB M>.S0N[UI."?'[U9Q+'>UM]V;\#KE78[\^SR:_O?J)J)=722A]!I8C:G&KKZA,$R(W%#A818R;X,27Y60\&F>RLU36D%3S+F.M>^[]^F"S^N]>RN_VU`)AC%*4* M[,()38SUI%;^C4(L]^YO@%E9NK#QM@9L6?JD=![)N_,@+[9=KP7A"1,20V@T M=0HB'^=+,TD M]5YP3CMIC+<.6>0H)QC4FJ]!V-+,>7ET[H9S7-;;1#;W3+$K=B1%O*Q&]SL" M-S):"1!X2VB$RE(0-2<8URU;C\LC4>SJOXA_:3L2WA&JU"[:?:U#&P<'/9O/ M9]_3(7OT-?YF^>/(96E;,\$+Q;!1F,33.#0.<4]D@[3T%Y`YMU-N'+!NM03] MR3Z($8Q]U/)HO_IS-E[>CVRK]^I`U;$\3`2'%(?4::><(1E)& MU.H16M`=U5EN30J?AF;73/+^G3*&]+P:H*/"(&Q$/JL`ZAI#$ M#0YQQ3U_\URQ+:UML$_7B2;?JO]4H_F?H^5J_K96O?>=P`QT6CF,I588`@[B M7KSILW5:#&=!!OQ^=YS2SU.:"\)2QK$0DDH!A2&(ZCJ:R3*+B]57/W>UIJ`02D6_UVAM MO`?CN'2<(U$K^RO^G<;P%,-=^O6Q;:5:B\!CBX5DS`A*H'(U^#9BDVN=&E0= M]:*Z=L<2Z)V1?O)/==T&'5\U%*)J``164!EF#740:EAKE%93E+OE'EV[]Z?@ MXJGP'T[$137^O]O9MW]-IM_BIQYH^/#OEP1\^.F3>ZMWLR3+",7ZM/H&T_:\ M$202CD'MA`*:0@<%=\URSPW/SAYS>.7>BU#CVH6Y?`364SQ4F@N3V;6;[LKD M?M#[P7I,F%.,4LD$=#"S^_O8A_GHOLYQ>_5] M6EV_6\T7R?)?I7Z^99O*;2H80#7F4DOF'`$4,V>:E5AY6J`F\$70JA#^I56R M`Q6N@(@!1D+"!+."Q+,TD\T\,8YE)S8:4#1/7]K4D=CF6;36&5$6M>$^&5^K MZW]/HPP>?+,C>7?>N1S?2"!$(2X20-)#X1'S%C>C`ODY^P?EZEK.[-4A]EF, M>ECR9C>;CLTV'=O&G2V/!R4)YMBH"((F2G`O>'-@==ADYS+Y&6WG[6!<7J'^ M]W2UJ*Y?>3]L/:=EM)+"MA$$!J5Z!!1"I#"L+R2MY_F%+0=5)ZD_];I-\,L3 MT(_&U9%L>WPE:.`804)CD]99(X'3H+$">YSKG']\2:3S7L):QKFLK[X?3>9_ MC>Y7U=7-XP__F(P^K_TC#O+;W]U$P((!89#B)*6_\A!QT,PA3GCN'3,\W+@N M'U@VK6Y3@9,+X%DGR)?@G1J/5U]6Z>QY?;6\J^9F]B7*\*Z:+M:!#W7ES;J^ MY@[Z'=E2H7QL)N!9"GV5?+AP_'[^EJ M6MWLT.I?/QHX%4PR&X^SW`%DG"*@7J8=,-DIIM#A5O(+H4A+"#_A0!*B3AJG5:3->%V#ZX!2 M&L4 MFO4NE8Y7EW7AO[6S3=H8XZZX;N7MGZKY/`TP#5?_>'SD_>C'.@/@]]'\^NKK M&NB_XBI=72<)_/,U8E]=?YJE'SVM9YA^5\W'DT5RL>BU#E!3[>7JYNEH/U1K MI6'M/KL>[.",,%88*;3D!C#GN:&,`0<9=-;O3T+<#5H?QW?5 M]>J^VI2HW,61Q3:2[*M#U-HW@@".I[PG`B`0Y[6#6M88>D]Q;FS"@"Y\2Y-M M-@Q1%3D$KCNWOQ#2L^>"?"_'X(ZD22`,O/$?>\+@>;%`E&EP0GS/9]')% M[%\(64:)C\NHFV[4M]B!]?^JKU%&X\G#1I+*1R\^CN:+W1F]CFTG($0I`0I: M)5*F(D*\(?78G/#9[C/#(UB_U)B5$](@UM9M6/YQ0%:1TQL/R51D`0#.$QI6.?>NP_(*6PX>D!Q<0V:X)MY_>2P_6%V?^]G\_3++DB_\X,!`@@< M)EX[JPE1V%DE:V09(Q=T!BM)P[9F0)NRR],[,V@XB#LB@;K9>''\4XK77]>NUA^7H_ERF.QNB6*SX0BS#Z+_%I];+GZ? M/GC6_S:?+;8ZL;?_I<`P--20^)_BDE`G!7.-E+S*O4D8HC9S.30_79!]$'US M+5`U'>^(YJ^^$WRJ?N:8]``9::6.N#3J)]`%"GT]OU?_](OKY:39!],C7C?5 M9+F:/UQ6_O-U,E\WT#7S]WXWI"JND!@@($)(,<,-T35V"NCN*X?\F@F#D>Y/ MIM5KZED53+35M?I6 MS4>W5;W]O9]/QE42Q4U)<\^!G0E`QI4'4\(=IAQ#"VG4/6OK1MRH?YTBAF4* MZD:N/6\HNP;5_3:SZ^O!4A47#B:HQ-!+P#7V#8X,BV*UN,[0I-0Z5;O9FEH4 M?S?3:/<5Y`N30B=3J;4>!&`@)!!X(*D$-JH"UC1ZKF,\VU'^@K:;H4VDOH3? MRV1Z9;/H8SX=U8E@F'>>:6B,5E8R"H7>&%408![DYAP84)**GVU*=2G_01K5 M>M#_3NI34(81:1!04*;H7&@\,C7FWL'<(C8#2HU]<7-N.'3X==C:AF/RFI/" M`P`5@DQ)2F6SE#F8;>.^?$O?D*=6-\+O\1HT^<5U:@)_]9U@-09<(A;U9J(H MM980WV!#76ZZC4O2\?*M=$,06<]T[F%/./#K`4/J!=!0">^P3DABWNRMT.96 MF[XD56LPU&]1D%W'V";W^E=C_A7L^B3^4$L3=0+H#12*.:L\('@=$XT`5]+L MO1GJ&:VG;#THO/_$E@.5J00',_$`KH3UD#&O:[S2E+RDR/Y2U'J9OJBHB'I9 M@GZ%W;^F"P-*`^'BD0`#ABB*^P9Z$!MCD/6U$IU7V#UT"*9:L0BG@Y4#!"!= M8R@AN:1RZ(7(UEG8_7&B*N$D4\:/D7<;1<0T$5D%(8R2C`\:B`ZY$8SB^@"/-I`MS" M@BSTL@P0G[[//MW-5HO1-"462I7IZO1POT]3AK3X@]2IW='I1S42"(BJ&U`, M*XBY$QXXXS:CXM;[7'/`@#EQK#AGA;!M@3$NF0O6>O#[U7Q\%Q?%8^FRJX6` MN8[(.!P74:6U)@QI4(_'\>PM:(#.)NUSI45@6R#*IVIZ\LJRNXV0[%+"4X*D MP%1Z93@2]9A`/#A>CHF]?;*T"NUP\T@9PCED6D%A,8+.6K!)41C'82#)O9X< MX'K2OTI["O*#B!LXASQ2DG"CB/&2*PR0Y)+*&E6J83'?YM)YI`YF4Y$\4D<) MH0BUMZ0>4A\^;MUO#WXW2*KCX<9ZQ`!20F*`-6ET!Y*]B`Z0=/W2Y25W6Q9, M"2)^J!;+^23EJEWW?B_YWGP^4,"(B5,=46,@C7.?DD;[B*/\F2*<2A*N#6$4 M6^V>XK7S7''`6T%Q;@W1<:0Z'FJ@H9BK>HSQ7[DFB@&>)`9%N/9$,@C]L>=< M>11KR`4W@DJDO6&$N&8W$#0[!>002=S[6:>XN`9-\+JN[/JW"[5:WLWFD_]5 MG<1-;_M6<-AX3:7B4'/+F7)J><$ZTU7I=EKFU-P1*"%9>>^\$EL!'*9=\0P\A5')Q MNVF&MJ=!>"AFC=K#=G\_Y/=/+_UF5\]=&+_\F,TWF66O<_J[<+QK3B$P*#7S MSF'N"#1((6O*K95P2*>&`M7.#.PCN/H18Z*\A!=6J]2$\E%U:A_<&`S%KN&,06W5'8KS4,Z= MI412I#&R6)4GI0(+DJIH:_=UGR@06Z7^(`DJ;^YUU/SJS6_^G.?W*Q5=I\=H M$3[26?8S#)0P"!$LG-?,<@:`Q'"3I(D())5=[3_26;)@HYPAS3E@'ED%$3:V M+"6%.!(3ZE#5%]@Z2V>IQZKQ1O\!+P!&,%KW:/6A`%IZL5E'5-0P=;<^0L@- MP/NCT7_U*#^*K?<91/_AZ%!`1ZF3D;2&>^TI+JGJ'$_=O;F/O_Q9]W@J]?C@E&`,BR=7:,&>.7Y_6^+^6,T)MG5 MYVX;ER9-)!CO`3",0^DE8=9XX\H6:IC(*75$[Q.VO5T.M<#3B4C7P;J2O<\A M1&--"""0>X*04M@PO84)<^:CF6I/\.Y?"I,`<-X".+Z(!ZX\Y%)RP3SW)GX6 MJCRXQ53QU!WS&'W!GUWP&G'^O.5NO>1?YI?++(ZUV?K?0>3O_:D$`8N(1:0T M-DH*93V'IN2&BOCYB#.=C!RV@H#SEL>OSVP:U`Z^GD*PD@!.`1"&>V@@0E1L MC^LMX*G=/R?8]W8J8M@(`.:E<\N$F7ON+;CU=IM79!>*X)8PHHY'C'#BM M^98/QHO>*N%/Z%ZC&SEH)7=G2.R\+?KK@_5Q6O2: M`,-[X+?^43O7FIU1#9232?^[8.6_9WVEP/T[!KS/!0*#G M@D:WBP`A#(Z*FFPYQS!)+;%;NQS,A]0/+_4=`N?C$*ZK@Q3D`)94&V:ET5XC M!;G>JEY+4B^4?][+K)_F"*X><@8ID;*3W%3\?7^517^MEZ[I'S52]LM60,.I M5=@2YKD6TA@AURU:H.6(0?A1(Z7R'0%KPK'UR%N"$%3:.8A*&EHE)E3#NB^P M=58CI1ZKQELCQ2-,/"'(4`TY@9!CM5T'B32>#N0&X/W1&BGU*#^*O>P9U$@! MFA#.F``4".6=8-)O-0-VR:=+(\1S(IKZJ)%2CPGI9:,W?EJU!?$BE3=;C^RY0/OG@OP5-KZ#MP4?E0ND0AO,(6?4"LAX25,WK6X4@WL* MP_-OY#*QO\9$=Z/1VX)V3&F)E!/48RZ%U4R5-)6`])9Q/Y0QZ`F1[4E'2YQL M[++LS^-BGIWNJ1P9'C"QVE*$B%80"VL!9;I?\MO\V(U- MEZ\-`FBG!;,.8B^@EP3A4D<)H&QJX/79N!'=0+)+3[89!\].3OZ\NQM"3MZ\ M-FB*L$3,80VDE@+'#P`8 MNFC\"<`(>$@\E;`\VA60\]2-YQC=J/XE8;R,;%$@$@6Z;"Z]&Z_SO.!Z`M'V MVP/RP&*##",*:J`T\A*7="3(INXKIA3IWHE`#,S(@2W$+_/[93Y?Y9?=1)56 MO"](2CBU4840J;$W`DLF2EIA8WKK^_FS@;YWUHU'[^]$9@Z@]_?>'HS6KF@) M"#'W@A&,I=]NO)Q-SG6H'2K]LXG`P(P<0N_OS+D7O7_P?0$+(1CDE'$>B28\ M%)Z6M-+:IE9]K-V&]&<#?>^L&R1`__G0^2/@?C<&V@JN)`="`,*TT8""38P3 M4D!`/U#`_>ZB&MPQ1-[J.,'_G$B^%MX4HFIFA!)C/3:"&\FX4R4]G=$3ZJ[7 M%_`68V)8+^?;KZ_7]FHFU.O$_*SS3I&$+E\;+/."0N*04U992SR");2;+-6HNI]2B MKC&;W\IR2T3M62R'S.MN4SJE1U$'$THM$R0Z`-1H*(Q'5A@%0'5,0B\KK$RK M?N?Q0*`6J#BAT)9!!34C@)0<""K564"'Q@2(D4;1!-&BI)B% MGG,,RO51I"8,E]HUQM"11M`^D_#*/?F+V1V32^G)E=C.;7V9__,BR>S6_4E=7><&]V&8QC\[G0W9U<97V6\/RU6< ME8D$S);'TR"/CPK.\K@%@PAAHY1%5D4-4L[;.Y<:V#E"X'7.V4575.]%%6;? M[E^J)%:8\_V'H^UQR&/-)+>6Z_AO7$JY(D-J;!JP]BI)D:C:V.HO[BL(.[SX(.J]Q>:1NWYE/E>0JC#AF15&KVH1\^+>;7D;:WQ>I/..1\[_'@ M(%.4(BD<%\PRQH1VY:JB/NV^T_9YVH\6:#D$0BKMQ_L#@D200DX\EP)[#9P$ MAFS%B$RIJFPSQE:@)(F:_>!D-E_]/GLJ9*+R/'/_X>"%1DQ9;N(.SQ$6CPKVQQO9S=_<@O9S=5-VJ'Q@1'J:3>04&= MA,S%3W[KC%F2?/`]QNRN5N_46B)H+X#)KM_.M/I6[="8@+7%CGO((/+Q'QQW MZK1<7Q25U+81(U0N+?#X+6I:HNKIJ%EEE_]WO7C\Q^K^;ED@!CY_*I`"=Y!2 M_"[\>O$.'C9_"9IJ"J2"W&AD'5#(@:V[#3V94O&8YCQ:-*%=)[R]^/W>.,;[HG9Y6YMVO;H'?UQF\]DR7YSJ&NP^ M'SACG%L`&,)1MP'AB"@C!PR#-K4.ZA@S7CMQ"QH0LY^8_?7T_IRO[K++_'N> M756[!(?&!`V($4)I;2C5U@`.21G`9K2D$]IO-.3O7H!\.Q3M$S%^L'1"84E9S+3B*5/,>,R]+8V@HYA.Z:6N!NP?PTHBD?8#%1"[D]WYVF=_D M]T\5!FC_X4#CU)T'%G&%M8E*6+DR=L@0)5./RL>8>MZF]6E,R?ZQ46EUWGL\ M.&ZI$IY92!3SCEFL^%;A:C.AW4@3EAY%1Q(E^\#'Y^QQ!D7%>7+<(?*=4K87U>LQVSY;=$K9NHR>M$=67N!SPG-5%X:%G!I M`4=&(`6*J%3''%;E_`U5J3G@K00B\+]%)%,35> M6U[>)QEAQ81Z?B3P[3W.)]&M#][_.OM??OMP6\G]5\\%([D#$@%I-'>$4N2V M5SRF:$DY,?[7Y=ZB/=K5/]N\RO(U^^.'MUR/OPIN?A^MD7[Z])P*&NG_ON8_ M]&B@`*"H_(C'4A(2E\*I+^@"9,671"QDZNLO[X>NLKZZVMPT"`, M,:!&$XNP$$R5;HUURJ3Z\R.ZRFJ!R6G$2I)@.YL_YC@@Q:4BL]JKU&)6(PJX;TNJ.R!G'RZ]?ECE\VRU4I=_ M/^2K_(B/5S$B:,Z+W*?BC$P3:A`"+VOC2"6;>S`>K'2RV6^'GD-AI?BXS*I# M;2O'!N=PW!?%I7KMG48(8E'FTED#\81N.1MS_`0$-:%MDBE2C\_UHB\K M/!8@P@BHZ.M0R0"UD$AOMT;2TPG%6K?(I45K!$UB]46D]S)?F,7M[6)>T2[^ MO6>#\Y@B$7='BG!#HK40!I(ZI4E`I>18$6SA>2XV!%JBBZK$Z42-$E1E(T"/N67V7R576V2E'5V MN./$D2&!8L:9(-!3:8ATTDNERQE[PE.SM\:/@`2F+3JA:=HF=38L*H\7;$*B=0CJA&:G7;QTQ/!&ZF85_4/ M-K?H>5:I9@X,"T@(((@S#!CB&)5*D)>9QV6=_[E'MZJF';KVX:.X_T4(7T?G M[$<1=WKQO4AU4[>+A_FQ0J*'!P4*%5=`(V&D4)!+IL#6_U8^.0!S_"G&Z\D9JF;W/$G`3;'1"(->TDC MCHN[^/XF@O`9KCL=XX[`XZ3QP2D.F2?81^P34EA15>X/G:(JU6FIG2G21V1= MZ^CI@L2]0"M;K;+L4S8KC.ANDY>-HS6_+OZ6K;YDR]NBY\"\JO)UVA<&J9F7 M'A*F<=2\13494-*]R.9*!=_X`\5;@%X?%-_!8A?EWK_.EOFF_5D6O^9^'>OP M>@H]57LO#]+,XO9;/M^4X*NN^'YL6"#"\2+,FPFI;)%I"*U;MW%SP!A?&9S4 MVTI?JA2>TJ#AM"\(6$9WBBLJ`?>D*/*#XJK7JX?,F=Y.4_HP+.W`X,"U2ZMT M'D2B-VTD`;L%R=M4 MQ^YX,)AZ?/IM'3;(JP<>IMG!Q7 MGA&,K=S.5SL]@2K739AT8II-/2*.+ZT^3A=#9KDLVHPQ1!B2I;X32/M4D1]C M=$+'>ZM4FHXSTUX1YY""R!I-A!,1TZCT;(2"=$)[[@2^'W7C+MH[8Z M*=-^][D`+,7*4*(9MEX7$:-$ENO@5$^H^%<2]]YFVC>@W7BK+5`AO7%.8V.8 M]41J)+?4P!:FIM&,<'?0"@8:T.Z\TO,@]$9I1+DL4@V`-!QM\2T92#T*&V-< M6L<^0SL4/O^$/8&8P!Y):[TTQFLD[-;R&F)2:WN,T-HTYGCMA+UZM$W:EG;2 MZ$\5>022.&DPXUY(P,1V1Z[9E"H'MLC#&BW]ZM%WN,/T3R>D>E6,#!PCA97@ MT1I;"#AQX.5TQZ4G!(\Q:G:(&\1D2H_LBF:GA>L)`2/-OC@@#W@D$2%%)2[" M.2NR-3>4@A+W9O/Z")IJ#37I-S;-6=`HJ>B0-!XRCE7C@N>.0"\\\-1!B*14 MX)ED2CI)$>WM/GHX^+3/YO?2CUIBP!B27AGFAAMD+934(!]_>K^A@XR.0.J9 MS@CW\T,"ICGED[#R'`*NKJ//6(2&_[Y;/WW.KW_.M\1J&&:.T^H]$0ZZ+E6YK__$?Q\+<(]OB?_P=02P,$%`````@`3($'1?^F6HN%$```QZ\``!$`'`!A M=F-A+3(P,30P-C,P+GAS9%54"0`#+]WC4R_=XU-U>`L``00E#@``!#D!``#M M75ESVS@2?M^J_0]8/__^_9__^/BO?O_/T]LK=,XM;T:80F>"8$5L]$C5%'VSB7Q` MCN`S](V+![K`OR"'BQD1[A)](^,+ZH),V>\'HI#_]"3M8VE-R0PCK)2@8T^1 M"V`[)P[V7'72\]AW#[O4H<0&U5RB2TX1)#XK+"9$W>`9D7-LD9/>5*GY\?[^ MX^/C'K87W,**,FO/XK/]-P>';P_>'P%<,`"3QWAAX3KT`.8A1?\T%NX>%Q.@ M/#C:UY_'6)*0G''&O%DV@ZW$OEK.R3X0]8&*"&I%?.5,:09-8*N()ZG5NWW_ M8Y*4%F"@3"K,K`C#TQKFQR-#??CAPX=]\S4BE786(8@]W/_S^NK..+P'_D?( MU``ZFW.A$%OSG(/EV+!ZLC_!>*[]<-0_..P?'?:07V^NC)MT[4UBSF3<)ZZ2 MX9M^+&H/=.BA_9KZ".X2V9)"1M;&&ND*T99&1E8CC8IJ4HX^ZRSZ5S_DZ^M7 M_<,W&ZH1-\IZ:H1\K:CQ81\+2[L;/&>I/GF:NYAAQ<7R`GY74\T5(B7E4RQ$ MZ_A!ZWCX?A,=C6A&)CJ^5]7!6& MJ66ZXL,ZFL1<_F,_%M!0#TFMVEJ$//JA!0W47-17(60R3T5*8,:X,I+,N_#M M?$Z9PX-7\%+WX<=A1WY+'&3RU>.@%RW.:O?G@L^)4!22JT1B;P1,!7%.>GKT MT`^'"']9V-V#/#@D62L@G6*8_@I8+,\U,*YB)4,).GZ?]"38VR4A^!^.RB9. M753`0AGM,B@7C^N"`A;B=A7/7)"Z>(!%PIBZ6=W3$NZ!`E$8\)UZDC(B90_I MUU]N+XL&U*;LB",2&PJ.J\[O;PZA]1\ MS=%/@9"?M]?Z"^+RN9Z-:N*!F+FXYD/5SZ_Y*"%GYP>U08-8DU'<-@X/WAZ\ MJ>*573M)&$//^MF>2X;.0$JBY,#Z[E%![#;\5B:[W)]'U?P9%H2X@_RB4%C6 MSSMO)TQUC\\<6O&2/Y,G]M;_@K M-?<]>5(>=EMT8"BQW(]K(_C*?D1!(3M_1M:O.WPOE50\BC_X-6,47^Z_+1W1 M?_KN02=_3=24VY=FP;K>/'0.?TG7]B&K:S.2D"\*Q;)V'FDT(UTLIB0$?LA( MX//\L[U=V"4#T^A-A==8*2)J.&>-LZ2]O,MH+Y$,%`C9=O/7;B)Y`DH:Q[N, MQK'FC&UN%8"?SN(9-6*?8E?;YFY*2)VYX%))18XZC,:WT32=\9,1B9(R42`4 M^5)W_DI;>03I$5-3HJA5)QNO)[;,D^],DZOI2?13JI!=2R1V/&4]=,ZPG%ZX M_'&S%IDML<2?;RNVS,0,.W>0%H^,_)TGTW;G,\`X)4S2!;EDX"ZBASGM^35' M?HF7CYIY.5D8\DL+AFT[MZ?^:>3<[5V7J6SX]OK;*O++O%RQ MX\WS\K9WP5><3>Z)/F(ZUDLTQG8P;KX%:]T]XGEU]Y8)*AE`OLT80&J1?2T3 M::%FR2<4B[1F+K1?"G.;'@\9[K5T-/Z6._^@H"\XT( MBTH]T5^['7=+[9)P\3YC!*H*2RZ"?_RWC]2P('&B]1DB[`@@R87U`` MYQ?D`_*W#P20D.+F-5#%L`**"-@6;WB]4]QZ6*M#-6IF-G])D'J?$:2,I(PJ MLO.(%ET_9!2**6_":YL)\ORS:SMI$]]"M!'4,B,@^`XA=.7-%U!!#BQ%%U0M M6_)KLT++:\';ZK4@+M`G,D%V[:71`X6*[`+O:I<>'?\PWX.>K<5$HLU2RZO/ MN^K5)WD>Q:\J@1J[CKM&_:F[VZ502LE.E_<9.UWR_;NE.USNO+$DWST`\6E1 M[RS*&F=Q3G68=<8DEH%\(=MN_OH!,T=`<>P[S#KEL>:,[0U>7[&@.AZ$4T;^ M9N_J7LGA+QEU_);10D))\>R5+VOG$14GBK4WPU:25I(^_);1A/*\M54;8#_N MKUX,$[Q)7R!CKH\)[IDT+M87;/P5GO&](M!'3[D;S0G?$'7#F7^3D^J9NW!. M>I6IJ>MJOYSTE/#TM700ZL`OGE;F#\&]^4G/7-)X3!69]9!_%8?_9L89N$XL M+^&+!ME#_ONQOYGBI&>3,57AVSD1E-OWAM^_5$^E+M$)\6(H7V!+A0K%^!>< MC5QLD6LR&Q,1`5U[W021?SGFLY((RDCZB*NAB];/(A,WQDQ+[QA(3V M[+<>&8%LQ-H\J%`0,2&B"'-1GY@#62_BL$(?M*AM@-F%S.*%_6O`AE7,N ML6L*O&26Z^G)HLQ#Q+ISH#8)I08XF_._FL2GZ*CN:@]:D;9[W6/!X:WL7*$. MPXO!C>'-YBY?DJ`_3QP@>*(S;S;"2ZT?P+AD-EU06ZL/L1*[[C+"NXF$5U/7 M/^.E--U/<8I43M;!7OBS!ZFJT7H`NN'92L>;_[D#?6V\>?="<+U94`=7:!GQ MCKU!\*\3M*;WW-^]9YJC'GPFNMY6)#UC?;9,HMJ6I;*OPPB>(+!$Q#`L'SKW M^(E(/>BQLJVU@;1&=0@J$,@VMF^["C6`S01T;T6E1M'KZ#G)W9Q!U%"TX&(:B;FHG1\!(-]2$ZE M7GG#;'E+)U,%L<\3UM1S0;76NPY;PJ@''Y0%4SHZ(SDG4"/@`V6W M&H6?N0QF>H-C"FA-QJ[E.+E6\`>9W$F/+ST&?5N*-`YU&TEXL5%K?@/6.MIW M#SK761EEK[3B"H2=:,KFZ.[0\2>Y+J6$3NB+]L8M67!W041B(T2,K1[3,S;F M9D[DS.;,K"J,,7L8.@X!('H#^8H/R^FZX,+T=OMS$+``-GUJ+9Q$,;/,IRZW M'A+0:C%M@%.%8MH?EI2<-,@9?M?F>ODQ>%+E"_#2?PD6UUAYPBQ@K\/*H.G" ME%E*12[NEA`A+##[T#F%]B6ON5`3/"'Z# M3^[W#@2=:^S.-2QJD6@^Q\]TSCC$?_#(%9U1-2+B`EO435331IPOD2!M:H@[ M;^P&2/R.O]P"62RO"_H=<1WS0^_MD\H,TX.[,SMOQD("^BZ`H8[ MP10;#Z;8TABR/G=OJG0XI5SOQ((!.V8K"\8YWSJX\CVRN8JE!V$2&#Y)-R?Q?*RBQVSK<.)(!#-24BW@WN_S.I2.V`!3\GP$?7`.^YUP,;^1'?SU$)T,F3H/+BP:;^Z*5]6T9R-UBHU27)C8=O[6'Z1O2>*&(/_#6QX`ND0M1ZAMI8 M4MI+Y54MVQ4-5*>?O;\P? MT,XWU>'EMQAO:(`_@$Y%:$%G*5LR;;;D5U]K$]OWGB4/*I+_=\V#$IA;S8.R MY+[V/"B!Z0?$Q^JEO=X\R#]3D=C<::9([Z>8K=^[MF($$^/.L2(7F(IVHD#; MVKQ>OUQC\4"4J5]F>[$^`0S@-K9POMP7/UG1&).^4=??#*85@;JPL96R)';? M/K+FH*25$-IRH:\@IRQ!G$[]?H2-:Y7XF@WL=P+Q0*7FL+.^W"YL."RX;5T. M/#7E@OXO.&63N"]U!*FM3/G^5ILAW.N0F.+QZU"Q$9^AM(ZFHALB3=Y2^_QV MS2JM&W8=%S3#\3(F*4_^5)S\G>M+(`@SA`OL:I)Z*6F7M'JQ.)R_VI.QH75E MI:>(HHOK5RE]PW7Q&\`R>*(R&U4&535DMCJVZ4S_JS8_ZO^8.V;RE5]9F"RG MZ\(R7>8%T!42]O!F]_6DH$V)+Y@.Y%>`Q!WI`Q9/4< M<@.^+K;P!(KU?G+(2#[H8O)7A_7^D=?!FB3O(-;UO1/ASHI[B+&.6`GAUKU)QUP_(U\P74?.OM=`5R'H_.(]6Z\\!CS M)=.31'I[7@GH`Q0````(`$R!!T5`J,^26MD``&R)"@`1`!@```````$```"D@0````!A M=F-A+3(P,30P-C,P+GAM;%54!0`#+]WC4W5X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`$R!!T633:J6[!4``%%``0`5`!@```````$```"D@:79``!A=F-A M+3(P,30P-C,P7V-A;"YX;6Q55`4``R_=XU-U>`L``00E#@``!#D!``!02P$" M'@,4````"`!,@0=%;@E^JRX\``"]]0(`%0`8```````!````I('@[P``879C M82TR,#$T,#8S,%]D968N>&UL550%``,OW>-3=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@`3($'1<_K8)5EJ0``&/\(`!4`&````````0```*2!72P!`&%V M8V$M,C`Q-#`V,S!?;&%B+GAM;%54!0`#+]WC4W5X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(`$R!!T77G4DRR&<``%TN!0`5`!@```````$```"D@1'6`0!A M=F-A+3(P,30P-C,P7W!R92YX;6Q55`4``R_=XU-U>`L``00E#@``!#D!``!0 M2P$"'@,4````"`!,@0=%_Z9:BX40``#'KP``$0`8```````!````I($H/@(` M879C82TR,#$T,#8S,"YX`L``00E#@``!#D!``!02P4& 2``````8`!@`:`@``^$X"```` ` end XML 28 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Interim Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2014
Dec. 31, 2013
CURRENT ASSETS:    
Cash and cash equivalents $ 4,071 $ 3,781
Receivables, less allowance for doubtful accounts of $4,582 and $3,879, respectively 42,678 32,658
Other receivables 1,187 1,118
Prepaid expenses and other current assets 1,925 2,442
Income tax refundable 747 763
Current assets of discontinued operations 2,913 2,870
Deferred income taxes 6,666 6,579
Total current assets 60,187 50,211
PROPERTY AND EQUIPMENT, at cost 95,310 93,572
Less accumulated depreciation and amortization (51,678) (48,516)
Discontinued operations, net 8,502 8,987
Property and equipment, net 52,134 54,043
OTHER ASSETS:    
Deferred income taxes 15,804 15,912
Deferred financing and other costs, net 1,860 1,914
Investment in unconsolidated affiliate 428 487
Other noncurrent assets 6,217 5,698
Acquired leasehold interest, net 8,036 8,228
Noncurrent assets of discontinued operations 969 1,251
Total other assets 33,314 33,490
Total assets 145,635 137,744
CURRENT LIABILITIES:    
Current portion of long-term debt and capitalized lease obligations 10,334 4,549
Trade accounts payable 9,356 7,177
Current liabilities of discontinued operations 8,823 1,359
Accrued expenses:    
Payroll and employee benefits 13,203 12,255
Self-insurance reserves, current portion 12,777 11,711
Other current liabilities 4,829 5,116
Total current liabilities 59,322 42,167
NONCURRENT LIABILITIES:    
Long-term debt and capitalized lease obligations, less current portion 43,120 43,552
Self-insurance reserves, noncurrent portion 16,146 16,375
Noncurrent liabilities of discontinued operations 0 5,952
Other noncurrent liabilities 14,484 15,214
Total noncurrent liabilities 73,750 81,093
COMMITMENTS AND CONTINGENCIES      
Series C redeemable preferred stock, $.10 par value, 5,000 shares authorized, issued and outstanding 4,918 4,918
SHAREHOLDERS’ EQUITY:    
Series A preferred stock, authorized 200,000 shares, $.10 par value, none issued and outstanding 0 0
Common stock, authorized 20,000,000 shares, $.01 par value, 6,388,000 and 6,307,000 shares issued, and 6,156,000 and 6,075,000 shares outstanding, respectively 63 63
Treasury stock at cost, 232,000 shares of common stock (2,500) (2,500)
Paid-in capital 19,883 19,570
Accumulated deficit (9,207) (8,435)
Accumulated other comprehensive loss (594) (569)
Total shareholders’ equity of Diversicare Healthcare Services, Inc. 7,645 8,129
Noncontrolling interest 0 1,437
Total shareholders’ equity 7,645 9,566
Total liabilities and shareholder's equity $ 145,635 $ 137,744